<SEC-DOCUMENT>0001213900-24-041808.txt : 20240510
<SEC-HEADER>0001213900-24-041808.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510170035
ACCESSION NUMBER:		0001213900-24-041808
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		24935844

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0203872-20f_tiziana.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:17 UTC 2024 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:tlsa="http://tizianalifesciences.com/20231231" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-24637">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-24638">&#9746;</ix:nonNumeric>&#160;<b>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-24639"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-24640">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-24641">2023</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-24642">&#9744;</ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-24643">&#9744;</ix:nonNumeric>
<b>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-109"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tiziana
Life Sciences Ltd</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter and translation of Registrant&#8217;s name into English)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-120"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bermuda</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-24644">Clarendon
House</ix:nonNumeric>,</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-134"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
Church Street,</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-24645">Hamilton
HM</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-24646">11</ix:nonNumeric>,</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-24647">Bermuda</ix:nonNumeric>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-150"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Keeren
Shah</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-155"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Financial Officer</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-24648">14-15
Conduit Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-24649">LondonW1S</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-24650">2XJ</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-24651">United Kingdom</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-24652">+44</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-24653">20 7495 2379</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ed
Lukins</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orrick,
Herrington&#160;&amp; Sutcliffe (UK) LLP </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>107
Cheapside</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>London
EC2V 6DN</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
Kingdom</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jeffrey
Fessler</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sheppard,
Mullin, Richter &amp; Hampton LLP</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>30
Rockefeller Plaza</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
York, NY 10112-0015</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(212)
653 8700</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Shares</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act: <b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act: <b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of outstanding shares of each of the issuer&#8217;s
classes of capital or common stock as of December 31, 2023: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24654">103,087,744</ix:nonFraction> common shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;Yes&#160;&#160;&#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-24655">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15 (d) of the Securities Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-24656">Yes</ix:nonNumeric>&#160;&#160;&#9744;&#160;No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;Yes&#160;&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-24657">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;Yes&#160;&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-24658">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting
company, or an emerging growth company. See definitions of &#8220;large accelerated filer, &#8220;accelerated filer&#8221;, &#8220;smaller
reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer &#9744;</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-24659">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td style="text-align: right; white-space: nowrap; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &#9746;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: right; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-24660">&#9744;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-24661">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-24662">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. GAAP &#9744;</span></td> <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-0">International Financial Reporting Standards</span> as issued by the<br/> International Accounting Standards Board &#9746;</span></td> <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;
Item 17&#160;&#160;&#9744;&#160;Item 18</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-24663">&#9746;</ix:nonNumeric>&#160;No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    I</b></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1</span></td>
    <td style="width: 80%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identity of Directors,
    Senior Management and Advisers</span></a></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2</span></td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Statistics and Expected Timetable</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3</span></td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Information</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4</span></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on the Company</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4A</span></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5</span></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and
    Prospects</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6</span></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7</span></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders and Related Party
    Transactions</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8</span></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9</span></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer and Listing</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10</span></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures
    About Market Risk</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Other than
    Equity Securities</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="4" style="text-align: center"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    II</b></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults, Dividend Arrearages and
    Delinquencies</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span>0</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14</span></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Modifications to the Rights
    of Security Holders and Use of Proceeds</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15</span></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>Item 16</td>
    <td><a href="#a_019">[Reserved]</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16A</span></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Financial Expert</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16B</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16C</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16D</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemptions From the Listing Standards
    for Audit Committees</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16E</span></td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases of Equity Securities by
    the Issuer and Affiliated Purchasers</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16F</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#8217;s Certifying
    Accountant</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16G</span></td>
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16H</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16I</span></td>
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions
    that Prevent Inspections&#160;</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16J</span></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policies</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">122</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16K</span></td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">123</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    III</b></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 17</span></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 18</span></td>
    <td><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 19</span></td>
    <td><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Annual Report on the Form 20-F references to &#8220;Tiziana,&#8221; &#8220;Tiziana Life Sciences plc,&#8221; &#8220;the company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Tiziana Life Sciences Ltd, Bermuda and its wholly owned subsidiaries,
Tiziana Life Sciences Ltd (formerly Tiziana Life Sciences plc), Tiziana Therapeutics Inc., Tiziana Pharma Limited and Longevia Genomics
S.r.l.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks and trade names in this registration statement may be referred to without the <sup>&#174;
</sup>and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert,
to the fullest extent under applicable law, their rights thereto. This annual report contains additional trademarks, service marks and
trade names of others, which are the property of their respective owners. We do not intend to use or display other companies&#8217; trademarks,
service marks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report, unless otherwise stated, all references to &#8220;U.S. dollars&#8221; or &#8220;US$&#8221; or &#8220;$&#8221; or
&#8220;cents&#8221; are to the currency of the United States of America, and all references to &#8220;Pounds Sterling&#8221; or &#8220;Sterling&#8221;
or &#8220;&#163;&#8221; or &#8220;pence&#8221; are to the currency of the United Kingdom.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report, any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension
thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include
the feminine or neutral gender.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Presentation
of Financial Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report includes our audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022, which
are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or IASB. None of our financial statements were prepared in accordance with generally accepted accounting principles in the United
States.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial information is presented in United States dollars. For the convenience of the reader, in this prospectus, unless otherwise
indicated, translations from Pounds Sterling into U.S. dollars were made at the rate of &#163;1.00 to $1.2743, which was the noon buying
rate of the Federal Reserve Bank of New York on December 29, 2023. Such U.S. dollar amounts are not necessarily indicative of the amounts
of U.S. dollars that could actually have been purchased upon exchange of Pounds Sterling at the dates indicated.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in
some tables may not be an arithmetic aggregation of the figures that preceded them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements that involve substantial risks and uncertainties. All statements contained in this
Annual Report, other than statements of historical fact, including statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or
other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties
and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained
in this registration statement are based upon information available to us as of the date of this registration statement and, while we
believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
Forward-looking statements include statement as about:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of Foralumab,
    anti-IL6R monoclonal antibody (TZLS-501), Milciclib, and any of our other product candidates, including statements regarding the
    timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work, the period during which
    the results of the trials will become available and our research and development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain regulatory approval of our product candidates, including Foralumab, anti-IL6R monoclonal antibody (TZLS-501), Milciclib,
    in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved
    drug or therapy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to research,
    develop, manufacture and commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of our regulatory
    filings for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and growth potential
    of the markets for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise additional
    capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commercialization,
    marketing and manufacturing capabilities and strategy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding
    our ability to obtain and maintain intellectual property protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract
    and retain qualified employees and key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to contract
    with third-party suppliers and manufacturers and their ability to perform adequately;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding
    future revenue, expenses and needs for additional financing; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments
    in the United States, European Union and foreign countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results
to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure
you that the forward-looking statements in this registration statement will prove to be accurate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in
these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that
we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we have filed as exhibits to this Annual Report completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these
cautionary statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1: IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2: OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3: KEY INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Selected Financial Data</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our consolidated financial data as of the dates and for the periods indicated. The consolidated financial
statement data as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 have been derived from our consolidated
financial statements, as presented at the end of this Annual Report, which have been prepared in accordance with IFRS, as issued by the
IASB, and audited in accordance with the standards of the Public Company Accounting Oversight Board (United States). The consolidated
financial statement data as of December 31, 2020 and 2019 and for the years ended December 31, 2020 and 2019 have been derived from our
consolidated financial statements, which are not presented herein, which have also been prepared in accordance with IFRS as issued by
the IASB.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
functional and presentational currency is the U.S. dollar.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our
historical results are not necessarily indicative of the results that may be expected in the future. The following selected consolidated
financial data should be read in conjunction with our audited consolidated financial statements included at the end of this Annual Report
and the related notes and Item 5, &#8220;Operating and Financial Review and Prospects&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Operations and Comprehensive Loss Data:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended December 31,</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="18" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands except share and per share data)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,113</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,955</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,208</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,993</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,714</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,871</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,631</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,311</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,203</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,207</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization bonus</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(855</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,214</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of asset</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(279</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposal of Intellectual Property</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,663</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,984</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,586</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,374</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,921</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,984</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,586</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,374</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,921</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expense), net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">742</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(811</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(312</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(91</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax provision</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(449</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,240</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,207</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">689</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to ordinary shareholders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,691</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,397</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,417</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,131</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,323</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive loss:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency translation adjustment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,492</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,582</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4, 478)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,474</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total comprehensive loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,199</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,979</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27,895</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,657</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,350</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per ordinary share</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.24</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.16</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheet Data:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center">(in thousands except share and per share data)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,122</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">65,824</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,619</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,846</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total shareholders&#8217; equity/(deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,280</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,514</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
define working capital as current assets less current liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Capitalization and Indebtedness</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Reasons for the Offer and Use of Proceeds</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business has significant risks. You should consider carefully the risks described below, together with the other information contained
in this Annual Report, including our financial statements and the related notes. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. This Annual Report also contains
forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these
forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this Annual Report and
our other SEC filings. See &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; above.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Development of our Product Candidates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter substantial delays in clinical trials of our product candidates, we may be unable to obtain required regulatory approvals,
and therefore will be unable to commercialize our product candidates on a timely basis or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials
to demonstrate the safety and utility of the product candidates. Clinical testing is expensive, time-consuming and uncertain as to outcome.
We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all, as a failure of one or
more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching a consensus
    with the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or other regulatory authorities on trial design;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching agreement
    on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in execution of development due to financial
    instability of our CROs, CMOs and CDMOs</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in opening clinical
    trial sites or obtaining required institutional review board or independent ethics committee approval at each clinical trial site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in recruiting suitable
    patients to participate in our future clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical
    hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or
    clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us, any CROs
    we engage or any other third parties to adhere to clinical trial requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to perform in accordance
    with good clinical practice, or GCP, or applicable regulatory guidelines in Europe and other international markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in the testing,
    validation, manufacturing and delivery of our product candidates to the clinical trial sites, including delays by third parties with
    whom we have contracted to perform certain of those functions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in having patients
    complete participation in a clinical trial or return for post-treatment follow-up;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trial sites or
    patients dropping out of a clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selection of clinical endpoints
    that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of serious adverse
    events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of serious adverse
    events in clinical trials of the same class of agents conducted by other sponsors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements
    and guidance that require amending or submitting new clinical protocols.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing
or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates
to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully
commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may fail to demonstrate the safety and therapeutic utility of our product candidates to the satisfaction of applicable regulatory authorities,
which would prevent or delay regulatory approval and commercialization.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive
preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Most product candidates that commence
clinical trials are never approved as products. If the results of our registrational trial or future pivotal trials for our other product
candidates do not demonstrate therapeutic utility of our product candidates, or if there are safety concerns or serious adverse events
associated with our product candidates, we may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be delayed in obtaining
    marketing approval for our product candidates, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval for indications
    or patient populations that are not as broad as intended or desired;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval with labeling
    that includes significant use or distribution restrictions or safety warnings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to additional
    post-marketing testing requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to changes in
    the way the product is administered;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be required to perform
    additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have regulatory authorities
    withdraw or suspend their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation
    and mitigation strategy, or REMS;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to the addition
    of labeling statements, such as warnings or contraindications; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be sued or experience damage
    to our reputation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Success
in preclinical studies or clinical trials may not be indicative of results in future clinical trials.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise
provide adequate data to demonstrate the effectiveness and safety of our product candidate. Frequently, product candidates that have
shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. To date, some
of our clinical trials have involved small patient populations and because of the small sample size in such trials, the interim results
of these clinical trials may be subject to substantial variability and may not be indicative of either future interim results or final
results. In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in
the design of a clinical trial may not become apparent until the clinical trial is well advanced. &#160;In addition, there is a high
failure rate for drugs and biologic products proceeding through clinical trials. In fact, many companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing
and earlier-stage clinical trials. Moreover, data obtained from preclinical and clinical activities is subject to varying interpretations,
which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of
many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could
negatively impact our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on enrollment of patients in our clinical trials for our product candidates and may find it difficult to enroll patients in our
clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates and could materially
adversely affect our R&amp;D efforts and business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical
trials depends on our ability to recruit patients to participate, and to see those patients through the completion of required follow-up
periods. If, for any reason, patients are unwilling to enroll in our clinical trials, then the timeline for recruiting patients, conducting
studies and obtaining regulatory approvals for our product candidates may be delayed. These delays could result in increased costs, delays
in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials
altogether.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidates are being developed to treat oncology and immune diseases of high unmet medical need. However, we may not
be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical
trials required by the FDA, EMA or other regulatory authorities. As a result, we may not be able to identify, recruit and enroll a sufficient
number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment
can be affected by many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size of the patient population
    and process for identifying patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility and exclusion
    criteria for our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived risks and benefits
    of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity of the disease
    under investigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity and availability
    of clinical trial sites for prospective patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition with other
    clinical trials for product candidates competing in the same therapeutic areas as our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability to obtain and maintain
    patient consent;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient drop-outs prior
    to completion of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient referral practices
    of physicians; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability to monitor patients
    adequately during and after treatment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully initiate, enroll and complete clinical trials in any foreign country is subject to numerous risks unique to conducting
business in foreign countries, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty in establishing
    or managing relationships with CROs and physicians;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different standards for
    the conduct of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">absence in some countries
    of established groups with sufficient regulatory expertise for review of certain treatment protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to locate qualified
    local consultants, physicians and partners; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential burden of
    complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical
    and biotechnology products and treatment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling a sufficient number of patients or finding additional clinical trial sites to conduct our clinical trials
as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which could have an adverse effect on
our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties
that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences
following any potential marketing approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study
doctor. Often, it is not possible to determine whether the product candidate being studied caused these conditions. Regulatory authorities
may draw different conclusions or require additional testing to confirm these determinations. For Milciclib, the most frequent drug-related
side effects reported across studies, at all doses tested, were gastrointestinal, or GI, adverse events (nausea and diarrhea, followed
by less frequent vomiting), neurological effects (mainly tremor, then ataxia, dizziness and dysgeusia), skin disorders and asthenia,
fatigue, headache and anorexia. For Foralumab, the most frequent drug-related side effects reported following intravenous administration
were infusion related reactions, or IRR, including fever, headaches, chills, nausea, vomiting diarrhea and hypotension considered the
result of cytokine release also known as cytokine release syndrome, or CRS. Other adverse events included reactivation of Epstein-Barr
virus (clinically silent); moderate lymphocytopenia, abnormalities in liver function tests. Since most of these changes are related to
the infusion route of administration and dosage level, such systemic toxicities are not anticipated when administered orally or nasally
due to what we assume will be minimal systemic absorption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of
these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse
events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be
reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3
clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical
experience indicates that our product candidates cause serious or life-threatening side effects, the development of our product candidates
may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm
our business, prospects, operating results and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
in the future we are unable to demonstrate that such adverse events were caused by the administration process or related procedures,
the FDA, EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates
for any or all targeted indications. Even if we are able to demonstrate that any serious adverse events are not product-related, such
occurrences could affect patient recruitment or the ability of enrolled patients to complete the clinical trial. Moreover, if we elect
or are required to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such
product candidate may be harmed and our ability to generate product revenues from such product candidate may be delayed or eliminated.
Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and
prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we or others later identify undesirable side effects caused by any of our product candidates, several potentially significant negative
consequences could result, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may suspend or withdraw approvals of such product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require additional warnings on the label;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change
    the way a product candidate is administered or conduct additional clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components
could result in delays in our clinical development or marketing schedules.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the nature of biologics and NCE manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability
to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. In addition,
some of the raw materials required in our manufacturing process are derived from biologic sources and are difficult to procure and may
be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances
in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical
material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Capital</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net losses in every year since our inception. We anticipate that we will continue to incur losses for the foreseeable future
and may never achieve or maintain profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biotechnology company with a limited operating history. Since our inception in May 2013, we have incurred significant
net losses. Our net losses were $17.8 million, $15.4 million and $23.4million for the years ended December 31, 2023, 2022 and 2021, respectively.
As of December 31, 2023, we had an accumulated loss of $134 million. We have devoted substantially all of our efforts to research and
development of our product candidates, including clinical development of our lead product candidates, Foralumab and Milciclib, as well
as to building out our management team and infrastructure. We expect that it could be several years, if ever, before we have a commercialized
product candidate. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. These
net losses will adversely impact our shareholders&#8217; equity and net assets and may fluctuate significantly from quarter to quarter
and year to year. We anticipate that our expenses will increase substantially if, and as, we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue research and development
    of Foralumab, including the initiation of a clinical trial with nasally administered Foralumab in patients with secondary&#160;progressive
    multiple sclerosis (SPMS), develop a program for intranasal administration of Foralumab for the treatment or prevention of Type 1
    Diabetes (TID), investigate intranasal foralumab for the treatment of Long COVID, study intranasal foralumab in patients with mild
    to moderate Alzheimer&#8217;s Disease and potentially study intranasal foralumab in rare Orphan pediatric diseases when funding becomes
    available.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate a Phase 2 trial
    for Milciclib in combination with gemcitabine in patients with KRAS-mutated (mut) non-small cell lung cancer (NSCLC) after failure
    of standard-of-care (SoC) therapy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cGMP manufacturing of anti-IL6R
    mAb drug substance and drug product for treatment Interstitial lung disease associated with systemic sclerosis (SSc-ILD) is complete.
    An IND to conduct a Phase 1 clinical trial was submitted in December 2021</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture our product
    candidates in accordance with current good manufacturing practices, or cGMP, for clinical trials or potential commercial sales;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing
    and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop, maintain, expand
    and protect our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, assess, and acquire
    or in-license other product candidates and technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure, maintain or obtain
    freedom to operate for any in-licensed technologies and products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any competing technological
    and market developments; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our operations in
    the United States and Europe.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large
enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to
raise capital, maintain our R&amp;D efforts, expand our business or continue our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need substantial additional funding to complete the development of our product candidates, which may not be available on acceptable terms,
if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development,
research operations or future commercialization efforts, if any.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing
activities, particularly as we continue the R&amp;D of, initiate further clinical trials of and seek marketing approval for, our product
candidates. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related
to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating
as a public company listed on the Nasdaq in the United States. Our future capital requirements will depend on many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results
    and costs of laboratory testing, manufacturing, preclinical and clinical development for our current and future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of regulatory review of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we
    acquire or in-license and develop other product candidates and technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    and maintain collaborations and license agreements on favorable terms, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of potential future commercialization activities, including manufacturing, marketing, sales and distribution for our product candidates
    for which we receive marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of developing,
    maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sales price and availability
    of adequate third-party coverage and reimbursement for our product candidates, if and when approved.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes
years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, will be derived
from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need
to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to
us on acceptable terms, if at all. To the extent that additional capital is raised through the issuance of equity or equity-linked securities,
the issuance of those securities could result in substantial dilution for our current shareholders and the terms of any future issuance
may include liquidation or other preferences that adversely affect the rights of our current shareholders. Debt financing, if available,
may involve covenants restricting our operations or our ability to incur additional debt. Any debt or additional equity financing that
we raise may contain terms that are not favorable to us or our shareholders. If we raise additional funds through collaboration and licensing
arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our product candidates or grant
licenses on terms that are not favorable to us. Furthermore, the potential issuance of additional securities in the future, whether equity
or debt, by us, or the possibility of such issuance, may cause the market price of our Common shares, to decline and existing shareholders
may not agree with our financing plans or the terms of such financings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain adequate funding on a timely basis, we may be required to significantly curtail, delay or discontinue our R&amp;D
programs of our product candidates or any future commercialization efforts, be unable to expand our operations or be unable to otherwise
capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
limited operating history and no history of commercializing pharmaceutical products may make it difficult to evaluate the success of
our business to date and to assess the prospects for our future viability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have devoted substantially all of our resources to developing Foralumab and Milciclib, and our other product candidates,
building our intellectual property portfolio and providing general and administrative support for these operations. Although our R&amp;D
efforts to date have resulted in a pipeline of product candidates, we have not yet demonstrated our ability to successfully complete
Phase 3 or other pivotal clinical trials, obtain regulatory approvals, or commercialize any of our product candidates. In addition, given
our limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown
factors in achieving our business objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are not profitable and have incurred losses in each year since our inception, and we expect that our financial condition and operating
results may continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are
beyond our control. Consequently, any predictions you make about our future success or viability may not be as accurate as they could
be if we had a longer operating history.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties
do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for
or commercialize our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs,
to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs.
In engaging these third parties, we typically have to, and expect to have to, negotiate budgets and contracts, which may result in delays
to our development timelines and increases costs. Additionally, there is a limited number of qualified third-party service providers
that specialize or have the expertise required to achieve our business objectives, and so it may be challenging to find alternative investigators
or CROs, or do so on commercially reasonable terms. We rely on these parties for execution of our preclinical studies and clinical trials,
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our preclinical studies
and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required
to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States
of the European Economic Area and comparable foreign regulatory authorities for all of our product candidates in clinical development.
Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical
trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable
GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon a regulatory
inspection of us or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority
will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with
product produced under applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials,
which would delay the regulatory approval process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources,
including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote
sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise
the prospects for approval and commercialization of our product candidates. These investigators and CROs may also have relationships
with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development
activities, which could affect their performance on our behalf. In addition, the use of third-party service providers requires us to
disclose our proprietary information to these parties, which increases the risk that a competitor will discover them or that this information
will be misappropriated or disclosed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results
of operations and commercial prospects would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repeating
clinical trials or switching or engaging additional CROs involves additional cost and requires our management&#8217;s time and focus.
In addition, there is a natural transition period when a clinical trial has to be repeated or when a new CRO commences work. As a result,
delays could occur, which could materially impact our ability to meet our desired clinical development timelines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged contract manufacturing organizations, or CMOs, to cGMP manufacture Foralumab (TZLS-401) drug product, Milciclib (TZLS-201)
and anti-Interleukin 6 Receptor monoclonal antibody (anti-IL6R mAb, TZLS-501) drug substance and drug product and to perform quality
testing, and because we collaborate with various organizations and academic institutions for the advancement of our platforms, we must,
at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary
technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets
and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated
into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based,
in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information
or other unauthorized use or disclosure of such technology or information would impair our competitive position and may have an adverse
effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development or publication of information including our trade secrets by third parties. A competitor&#8217;s discovery of
our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
utilize, and expect to continue to utilize, third parties to conduct our product manufacturing for the foreseeable future, and these
third parties may not perform satisfactorily.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on CMOs for the manufacturing of clinical batches and intend to continue to rely on third parties to manufacture our preclinical
study and clinical trial product supplies. If our current CMOs, or any future third-party manufacturers, do not successfully carry out
their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, or
if there are disagreements between us and our CMOs or any future third-party manufacturers, we will not be able to complete, or may be
delayed in completing, the preclinical studies required to support future investigational new drug, or IND, submissions and the clinical
trials required for approval of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our current CMOs, we may rely on additional third parties to manufacture ingredients of our product candidates in the future
and to perform quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured
the product candidates ourselves, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control for certain
    aspects of manufacturing activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination or nonrenewal
    of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions to the operations
    of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the
    bankruptcy of the manufacturer or service provider.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize
any of our product candidates. Some of these events could be the basis for FDA, EMA or other regulatory authority action, including injunction,
recall, seizure or total or partial suspension of product manufacture.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent we rely on a third-party manufacturing facility for commercial supply, that third party will be subject to significant regulatory
oversight with respect to manufacturing our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of therapeutics for clinical trials or commercial sale is subject to extensive regulation. Components of a finished therapeutic
product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP requirements.
These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality
systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes
can lead to the introduction of outside agents or other contaminants, or to inadvertent changes in the properties or stability of a product
candidate that may not be detectable in final product testing. To the extent that we utilize third-party facilities for commercial supply,
the third party&#8217;s facilities and quality systems must pass an inspection for compliance with the applicable regulations as a condition
of regulatory approval. In addition, the regulatory authorities may, at any time, audit or inspect the third-party manufacturing facility
or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If, for example,
these facilities do not pass a plant inspection, the FDA will not approve the applicable NDA or biologics license application, or BLA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not directly control the manufacturing of, and are completely dependent on, our CMOs for compliance with cGMP requirements. If our
CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA,
EMA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.
In addition, we have no direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified
personnel. Furthermore, all of our CMOs are engaged with other companies to supply and/or manufacture materials or products for such
companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet
the regulatory requirements for the production of those materials and products may generally affect the regulatory clearance of our CMOs&#8217;
facilities. Our failure, or the failure of third parties, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our products and product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
potential future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins
and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Product Candidates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no marketing and sales force. If we are unable to establish effective sales, marketing and distribution capabilities or
enter into agreements with third parties to market, sell and distribute our product candidates that may be approved, we may not be successful
in commercializing our product candidates if and when approved, and we may be unable to generate any product revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates. In order
to commercialize any of our product candidates that may be approved, we intend to build, on a territory-by-territory basis, marketing,
sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services.
These efforts will require significant capital expenditures, management resources and time, and we face competition in search for qualified
personnel or third parties to assist with marketing, sales and distribution of any of our product candidates. We may not be successful
in building these capabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks involved with both establishing our own sales, marketing and distribution capabilities and entering into arrangements with
third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could
delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing
and/or distribution capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that may inhibit our efforts to commercialize our product candidates on our own include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to recruit,
    train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability of sales
    personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future product that we may develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of complementary
    treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive
    product lines; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen costs and expenses
    associated with creating an independent sales and marketing organization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability
to us from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves.
In addition, we may not be successful in entering into arrangements with third parties to sell and market &#160;our product candidates
or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them
may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish
sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in
commercializing our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory
approval before us or develop therapies that are more advanced or effective than ours.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong
emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical
and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical
and life sciences industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive.
We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become
available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources,
such as larger R&amp;D, clinical, sales and marketing and manufacturing organizations. These third parties also compete with us in recruiting
and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, the development of our products. In addition, mergers
and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller
number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that
are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidate
that we may develop. Competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly or earlier than
we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter
the market. Additionally, technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we
may not be successful in marketing our product candidates against competitors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the
validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could
limit the demand, and the price we are able to charge, for any product candidate that we may develop and commercialize.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market opportunities for our product candidates may be smaller than we anticipate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
focus our R&amp;D efforts on treatments for cancer and autoimmune disease. Our understanding of both the number of people who have these
diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates,
is based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of
these diseases. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected,
may not be otherwise amenable to treatment with our product candidates or patients may become increasingly difficult to identify and
access, all of which would adversely affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there are several factors that could contribute to making the actual number of patients who receive our potential products, if and when
approved, less than the potentially addressable market. These include, for example, the lack of widespread availability of, and limited
reimbursement for, new therapies in many underdeveloped markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
future commercial success of our product candidates will depend upon the degree of each product candidates&#8217; market acceptance by
physicians, patients, third-party payors and others in the medical community.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are at varying stages of development, and we may never have a product that is commercially successful. To date, we
have no product authorized for marketing. Due to the inherent risk in the development of pharmaceutical products, we may never successfully
complete development and commercialization of any of our product candidates. Even with the requisite approvals from the FDA, EMA and
other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance
of physicians, patients and third-party payors of our product candidates as medically necessary, cost-effective and safe. Any product
that we commercialize may not gain acceptance by physicians, patients, third-party payors and others in the medical community. If these
products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable.
Even if some product candidates achieve market acceptance, the market may not prove to be large enough to allow us to generate significant
revenues. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness and safety
    of our product candidates as demonstrated in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential and perceived
    advantages of our product candidates over alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability and cost
    of treatment relative to alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the standard
    of care for the targeted indications for any product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of physicians
    to prescribe, and the target patient population to try, new therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity
    of any side effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product labeling or product
    insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s
    approved labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of market introduction
    of competitive products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales, distribution and
    marketing support;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity concerning our
    product candidates or competing products and treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential product liability
    claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any restrictions on the
    use of our products together with other medications; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">favorable third-party payor
    coverage and adequate reimbursement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a potential product displays favorable clinical properties and safety profile in preclinical studies and clinical trials, market acceptance
of the product will not be fully known until after it is launched.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for our product candidates, if approved, could limit our ability to market those products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that coverage and adequate reimbursement by government and private payors will be essential for most patients to be able to afford
these treatments. Accordingly, sales of our product candidates will depend substantially, both domestically and abroad, on the extent
to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare
management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors.
Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination
that use of a product is:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a covered benefit under
    our health plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe, effective and medically
    necessary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate for the specific
    patient;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither experimental nor
    investigational.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide
to the payor supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance
with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels,
we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount
may not be adequate to realize a sufficient return on our investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party
payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which
new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private
payors develop their coverage and reimbursement policies. However, no uniform policy of coverage and reimbursement exists among third-party
payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. One payor&#8217;s determination
to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement. It is difficult
to predict what the Centers for Medicare and Medicaid Services, or CMS will decide with respect to coverage and reimbursement for fundamentally
novel products such as ours, as there is no body of established practices and precedents for these types of products. Moreover, reimbursement
agencies in the European Union may be more conservative than the CMS. For example, several cancer drugs have been approved for reimbursement
in the United States and have not been approved for reimbursement in certain European Union, or EU, member states, or Member States.
It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been
a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing
cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement
and requirements for substitution of generic products for branded prescription drugs. For example, in the United States, the Patient
Protection and Affordable Care Act of 2010 (as amended by the Health Care and Education Reconciliation Act of 2010), or the PPACA, contains
provisions that may reduce the profitability of products, including, for example, increased rebates for products sold to Medicaid programs,
extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual
fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Further, there has been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent congressional
inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, contain
the cost of drugs, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, international operations generally are subject to extensive government price controls and other market regulations
and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on
us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems.
In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies
to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes
in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside
the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient
to generate commercially reasonable product revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part
of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing
negotiations may continue after reimbursement has been obtained. Reference pricing used by various Member States and parallel distribution,
or arbitrage between low-priced and high-priced Member States, can further reduce prices. To obtain reimbursement or pricing approval
in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other
available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, our business could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by government and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such
organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or
provide adequate payment for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors
increasingly are considering new metrics as the basis for reimbursement rates, such as average sales price, average manufacturer price
and actual acquisition cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain
states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy
National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. Therefore,
it may be difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover product candidates
that we or our partners are able to commercialize. We expect to experience pricing pressures in connection with the sale of any of our
product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional
legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and
other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as
ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
rights to develop and commercialize our product candidates are subject to the terms and conditions of licenses granted to us by others.
If we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could
lose license rights that are important to the business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily reliant upon licenses and sublicenses from Nerviano, Lonza and Novimmune to certain patent rights and proprietary technology
that are important or necessary to the development of our technology and product candidates, including the patents and know-how relating
to manufacture. These and other licenses may not provide exclusive rights to use such intellectual property and technology or may not
provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which
we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to prevent
competitors from developing and commercializing competitive products, including in territories covered by our licenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain
the patents, covering technology that we license from third parties. If our licensors fail to maintain such patents or patent applications,
or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop
and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition
to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may
own in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licenses
to additional third-party technology and materials that may be required for our development programs, including additional technology
and materials owned by any of our current licensors, may not be available in the future or may not be available on commercially reasonable
terms, or at all, which could have an adverse effect on our business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain patent protection for our current product candidates, any future product candidates we may develop
and our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize
products and technology similar or identical to ours.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to seek, obtain and maintain patent protection in the United States and other countries
with respect to our product candidates and to future innovation related to our manufacturing technology. Our licensors have sought, and
we intend to seek to protect our proprietary position by filing patent applications in the United States, the United Kingdom and elsewhere,
related to certain technologies and our product candidates that are important to our business. Our current patent portfolio contains
a limited number of patent applications, all of which are in-licensed from third parties and relate to either composition of matter,
formulation, method of use or process of manufacturing Foralumab, Milciclib and a fully human anti-interleukin-6 receptor, or IL-6r,
mAb. However, the risks associated with patent rights generally apply to patent rights that we in-license now or in the future, as well
as patent rights that we may own in the future. Moreover, the risks apply with respect to patent rights and other intellectual property
applicable to our product candidates, as well as to any intellectual property rights that we may acquire in the future related to future
product candidates, if any. Tiziana was granted a new patent by USPTO in June 2020 covering lyophilized formulation of Foralumab..</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce or
license all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the work of certain academic researchers in the oncology and immunology fields has entered the public domain, which we believe
precludes our ability to obtain patent protection for certain inventions relating to such work.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequently,
we will not be able to assert any such patents to prevent others from using our technology for, and developing and marketing competing
products to treat, these indications. It is also possible that we will fail to identify patentable aspects of our R&amp;D output before
it is too late to obtain patent protection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing license agreements impose, and we expect that future license agreements will impose, various due diligence, development and
commercialization timelines, insurance, milestone payments, royalties, and other obligations on us. See the description in the section
titled &#8220;Business-Collaboration and License Agreements&#8221; herein. If we fail to comply with our obligations under these agreements,
or we are subject to a bankruptcy, or, in some cases, under other circumstances, the licensor may have the right to terminate the license,
in which event we would not be able to market product candidates covered by the license. In addition, certain of these license agreements
are not assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in
certain transactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of any patent rights are highly uncertain. Our licensed patent applications may not result in patents being issued which protect
our technology or product candidates, effectively prevent others from commercializing competitive technologies and product candidates
or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even assuming patents issue
from patent applications in which we have rights, changes in either the patent laws or interpretation of the patent laws in the United
States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
parties have developed technologies that may be related or competitive to our own and such parties may have filed or may file patent
applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our
own patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to
our current and future product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and
in other jurisdictions are typically not published until 18 months after filing, or, in some cases, not at all. Therefore, we cannot
know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those
patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Similarly, should
we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for
the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our
patent rights cannot be predicted with any certainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases
and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that
any of our licensed patents have, or that any of our pending licensed patent applications that mature into issued patents will include,
claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. In addition, the laws
of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited
lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be
available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. As a result, our licensed patent portfolio may not provide us with adequate and continuing patent protection
sufficient to exclude others from commercializing products similar to our product candidates, including &#8220;highly similar,&#8221;
or biosimilar, versions of such products. In addition, the intellectual property portfolio licensed to us by Nerviano and Novimmune may
be used by them or licensed to third parties, and such third parties may have certain enforcement rights. Thus, patents licensed to us
could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee
or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other
reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we acquire patent protection that we expect should enable us to maintain some competitive advantage, third parties, including competitors,
may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable.
In litigation, a competitor could claim that our patents, if issued, are not valid for several reasons. If a court agrees, we would lose
our rights to those challenged patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and our licensed patents may be challenged
in courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art
to the USPTO challenging the validity of one or more claims of our licensed patents. Such submissions may also be made prior to a patent&#8217;s
issuance, precluding the granting of a patent based on one of our pending licensed patent applications. We may become involved in opposition,
derivation, re-examination, inter partes review, post-grant review or interference proceedings challenging the patent rights of others
from whom we have obtained licenses to such rights. Competitors may claim that they invented the inventions claimed in our licensed issued
patents or patent applications prior to the inventors of such patents or applications. A competitor who can establish an earlier filing
or invention date may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed
under our licensed patents, if issued. Competitors may also contest our licensed patents, if issued, by showing that the invention was
not patent-eligible, was not novel, was obvious or that the patent claims failed any other requirement for patentability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse determination by former employees or consultants asserting ownership rights to our patents may result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our
ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration
of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture
or commercialize our product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection
provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop
or commercialize current or future product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if they are unchallenged, our licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection
or prevent competitors from designing around our patent claims to circumvent our licensed patents by developing similar or alternative
technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapeutic that provides
benefits similar to one or more of our product candidates but that uses a different antibody or molecular active ingredient that falls
outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue
with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize
our product candidates could be negatively affected, which would harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the
scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently depend, and will continue to depend, on our license agreements whereby we obtain rights in certain patents and patent applications
owned by them. Further development and commercialization of our current product candidates may, and development of any future product
candidates will, require us to enter into additional license or collaboration agreements. The agreements under which we currently license
intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple
interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope
of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations
under the relevant agreement, either of which could have an adverse effect on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our licenses or material relationships or any in-licenses upon which our licenses are based are terminated or breached, we may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lose our rights to develop
    and market our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lose patent protection
    for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience significant
    delays in the development or commercialization of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not be able to obtain any
    other licenses on acceptable terms, if at all; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur liability for damages.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a third party may in the future bring claims that our performance under our license agreements, including our sponsoring of
clinical trials, interferes with such third party&#8217;s rights under its agreement with one of our licensors. If any such claim were
successful, it may adversely affect our rights and ability to advance our product candidates as clinical candidates or subject us to
liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks apply to any agreements that we may enter into in the future for our current or any future product candidates. If we experience
any of the foregoing, it could have a negative impact on our business, financial condition, results or operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into license agreements with third parties and may need to obtain additional licenses from one or more of these same third
parties or from others to advance our research or allow commercialization of our product candidates. It is possible that we may be unable
to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant
time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology,
all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize
our product candidates, which would harm our business. We cannot provide any assurances that third-party patents or other intellectual
property rights do not exist which might be enforced against our current product candidates or future product candidates, resulting in
either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties
and/or other forms of compensation to third parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
each of our existing license agreements, and we expect in our future agreements, patent prosecution of our licensed technology is controlled
solely by the licensor, and we may be required to reimburse the licensor for their costs of patent prosecution. If our licensors fail
to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights
to the intellectual property, or our exclusivity with respect to those rights, and our competitors could market competing products using
the intellectual property. Our license agreements with Nerviano and Novimmune also require us to meet development thresholds to maintain
each license, including establishing a set timeline for developing and commercializing product candidates. Disputes may arise regarding
intellectual property subject to a licensing agreement, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted
    under the license agreement and other interpretation-related issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our
    technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent
    and other rights pursuant to our collaborative development relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations
    under the license agreements and what activities satisfy those diligence obligations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship or ownership
    of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the priority of invention
    of patented technology.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have certain rights to the intellectual property, through licenses from third parties, to develop our product candidates. Because
our programs may require the use of additional proprietary rights held by these or other third parties, the growth of our business likely
will depend, in part, on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license
any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for
our product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more
established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive.
These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make
an appropriate return on our investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may collaborate with non-profit and academic institutions to accelerate our preclinical R&amp;D under written agreements with these institutions.
These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting
from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms
that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially
blocking our ability to pursue our program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to successfully obtain rights to required third-party intellectual property or maintain the existing intellectual property
rights we have, we may have to abandon development of our product candidates and our business, financial condition, results of operations
and prospects could suffer. Moreover, to the extent that we seek to develop other product candidates in the future, we will likely require
acquisition or in-license of additional proprietary rights held by third parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of non-compliance with these
requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid
to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications
and any patent rights we may own in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non-U.S.
patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee
payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to
help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect
to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in
accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event,
potential competitors might be able to enter the market and this circumstance could have an adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In
some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the
laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing
our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling
or importing products made using our inventions in and into the United States or other jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and,
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as
that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights
may not be effective or sufficient to prevent them from competing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for
us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary
rights generally. Moreover, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties. Many countries limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our
licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position
may be impaired, and our business and results of operations may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to
enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our trade secrets in court.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less
willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into
confidentiality agreements with our employees, consultants, scientific advisors and contractors. However, we may not be able to prevent
the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, despite the existence
generally of confidentiality agreements and other contractual restrictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitoring
unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies
will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breach
or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we
could lose our trade secrets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary
technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, agreements and security measures, they may still be breached, and we may not have adequate remedies
for any breach.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors could purchase our
product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully
infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that
fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed
by a competitor, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology
or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217;
therapeutics, our competitive position could be adversely affected, as could our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market and sell our
product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third
parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and
other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation
regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings, post
grant review and inter partes review before the USPTO. Our competitors or other third parties may assert infringement claims against
us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Given
the vast number of patents in our field of technology, we cannot be certain or guarantee that we do not infringe existing patents or
that we will not infringe patents that may be granted in the future. Since this area is competitive and of strong interest to pharmaceutical
and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future,
as well as additional R&amp;D programs expected in the future. Furthermore, because patent applications can take many years to issue,
may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which
may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates and we
may or may not be aware of such patents. If a patent holder believes the manufacture, use, sale or importation of one of our product
candidates infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our technology. Moreover,
we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our licensed
patent portfolio may therefore have no deterrent effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before
November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential
until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that
may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among
patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents
or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that
such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents
that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that
a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have
been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates
or the use of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless
of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their
patent or other intellectual property rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction
could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize
our product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome
a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of
any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S.
patent. Similarly, there is no assurance that a court of competent jurisdiction would find that product candidates or our technology
did not infringe a third-party patent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain.
If we are found or believe there is a risk that we may be found, to infringe a third party&#8217;s valid and enforceable intellectual
property rights, we could be required or may choose to obtain a license from such third party to continue developing, manufacturing and
marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third
parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We
could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product
candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are
found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing
and commercializing our product candidates or force us to cease some or all of our business operations, which could harm our business.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact
on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive
and time-consuming. Competitors may infringe our patents or the patents of our licensing partners, should such patents issue, or we may
be required to defend against claims of infringement. To counter infringement or unauthorized use claims or to defend against claims
of infringement can be expensive and time consuming. Even if resolved in our favor, litigation or other legal proceedings relating to
intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from
their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and
if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on us. Such litigation
or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any
future sales, marketing or distribution activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not have sufficient
financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the
costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and
developed intellectual property portfolios.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, despite our efforts,
we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on
our ability to compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims asserting that
our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or
claims asserting ownership of what we regard as our own intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our employees,
consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants
and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these
individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such
technologies or features would harm our business and may prevent us from successfully obtaining necessary regulatory approvals and commercializing
our product candidates. In addition, we may lose personnel as a result of such claims, and any such litigation or the threat thereof may
adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product
could hamper or prevent our ability to obtain necessary regulatory approvals and commercialize our product candidates, which would have
an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a distraction to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while it is our
policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact,
conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual
property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached,
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership
of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre-existing or competing
obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership
of inventions developed by that individual. Disputes about the ownership of intellectual property that we may own may have an adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent patent reform legislation
could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued
patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act
includes several significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted
and also may affect patent litigation. These also include provisions that switched the United States from a &#8220;first-to-invent&#8221;
system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set
forth additional procedures to attack the validity of a patent through various post-grant proceedings administered by the USPTO. Under
a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally
will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed
new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated
with the Leahy-Smith Act, and in particular, the first-to-file provisions, only became effective on March 16, 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, it is not clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents, all of which could have a negative impact effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the U.S. Supreme
Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, the combination of new federal legislation, federal court decisions, and guidance from the USPTO has created uncertainty
with respect to the value of patents, once obtained. Depending on the decisions by the U.S. Congress, federal courts, and the USPTO, the
laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or enforce
our existing patents and patents we might obtain in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
registered trademarks and we have not filed any trademark applications to date. Any trademark applications in the United States, Europe
and in other foreign jurisdictions where we may file may not be allowed or may subsequently be opposed. Once filed and registered, our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties
or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may
not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners
or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our
ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark
infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered
trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary
rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result
in substantial costs and diversion of resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights and regulatory
exclusivity rights do not necessarily address all potential threats</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately
protect our business or permit us to maintain our competitive advantage. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may be able to make products
that are similar to our product candidates but that are not covered by the claims of the patents that we license or may own in the future;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we, or our license partners
or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications
that we license or may own in the future;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we, or our license partners
or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may independently develop
similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property
rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may circumvent our regulatory
exclusivities, such as by pursuing approval of a competitive product candidate via the traditional approval pathway based on their own
clinical data, rather than relying on the abbreviated pathway provided for biosimilar applicants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">it is possible that our pending
licensed patent applications or those that we may own in the future will not lead to issued patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">issued patents that we hold
rights to now or in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may have access to the
same intellectual property rights licensed to us on a non-exclusive basis;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our competitors might conduct
R&amp;D activities in countries where we do not have patent rights and then use the information learned from such activities to develop
competitive products for sale in our major commercial markets;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not develop additional
proprietary technologies that are patentable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the patents or other intellectual
property rights of others may have an adverse effect on our business; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may choose not to file a
patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any of these events
occur, they could significantly harm our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we complete the necessary clinical
trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates and the approval may
be for a narrower indication than we seek.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot commercialize a
product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. The FDA must review and
approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory review and approval
process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed labeling, as well as
the evaluation of the manufacturing process and manufacturers&#8217; facilities, all of which is lengthy, expensive and uncertain. To
obtain approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that the product
candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet the FDA&#8217;s
safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner, or we may not
be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse to file our
application for substantive review or may determine after review of our data that our application is insufficient to allow approval of
our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing validation
studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee or other
regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon
additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the
period of product development, clinical trials and the review process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA, EMA or other regulatory
authorities also may approve a product candidate for more limited indications than requested or may impose significant limitations in
the form of narrow indications, warnings or a REMS. These regulatory authorities may require precautions or contraindications with respect
to conditions of use or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the FDA,
EMA or other regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization
of our product candidates. Any of the foregoing scenarios could harm the commercial prospects for our product candidates and negatively
impact our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delays in obtaining regulatory approval
of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our product development and
commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin to commercially manufacture
our product candidates, whether in a third-party facility or in our own facility, if and when established, we must obtain regulatory approval
from the FDA for our manufacturing process and facility. A manufacturing authorization must also be obtained from the appropriate European
Union regulatory authorities and from other foreign regulatory authorities, as applicable. In order to obtain approval, we will need to
ensure that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories
and suppliers. If any of our vendors, contract laboratories or suppliers are found to be non-compliant with cGMP, we may experience delays
or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement
vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying
with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality assurance to confirm that the
product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible
regulatory action and may not be permitted to sell any product candidate that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our third-party manufacturers
fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing
approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if the supply
of our products from our third-party manufacturers to us is interrupted for any reason, including due to regulatory requirements or actions
(including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contamination,
business interruptions or labor shortages or disputes, there could be a significant disruption in commercial supply of our products. We
do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial sale. An alternative manufacturer
would need to be qualified through a supplement to its regulatory filing, which could result in further delays. The regulatory authorities
also may require additional clinical trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may
involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our competitors are able to obtain orphan
drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able
to have competing products approved by applicable regulatory authorities for a significant period of time. In addition, even if we obtain
orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities in
some jurisdictions, including the United States and the European Union, may designate products for relatively small patient populations
as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat
a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United
States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing
the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In the European
Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that
are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more
than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended for the diagnosis,
prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it
is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug
or biologic product. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific
advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The designation as an orphan
product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate,
nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that
treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, if a product candidate
with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product
is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for
a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances.
If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving
marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and
ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets
the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.
Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain orphan drug
exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different
drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve
another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it
is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, marketing authorization may
be granted to a similar medicinal product for the same orphan indication if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the second applicant can establish
in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective
or otherwise clinically superior;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the holder of the marketing
authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the holder of the marketing
authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval for
a product candidate, our product candidates will remain subject to regulatory oversight.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain regulatory
approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage,
advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may
be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4
clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our product candidates
are classified as biologics in the United States, and therefore, can only be sold if we obtain a BLA from the FDA. The holder of an approved
BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling
or manufacturing process. In addition, the holder of a BLA must comply with the FDA&#8217;s advertising and promotion requirements, such
as those related to the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s
approved labeling (known as &#8220;off-label use&#8221;). Advertising and promotional materials must comply with FDA rules and are subject
to FDA review, in addition to other potentially applicable federal and state laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, product manufacturers
and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we,
or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or
labeling of that product (in addition to our being obligated as holder of a BLA to monitor and report adverse events and any failure of
a product to meet the BLA specifications), a regulatory authority may impose restrictions relative to that product, the manufacturing
facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with
applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.35pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">issue a warning letter asserting
that we are in violation of the law;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek an injunction or impose
administrative, civil or criminal penalties or monetary fines;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">suspend or withdraw regulatory
approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">suspend any ongoing clinical
trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refuse to approve a pending
BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">restrict the marketing or manufacturing
of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seize or detain the product
or otherwise require the withdrawal of the product from the market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refuse to permit the import
or export of the product; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refuse to allow us to enter
into supply contracts, including government contracts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect
our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA&#8217;s
policies, and those of the EMA and other regulatory authorities, may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable
to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would
negatively impact our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain and maintain approval
for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our product candidates
in other major markets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market any products
in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories
regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries,
and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures
vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory
approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional preclinical
studies or clinical trials, which would be costly and time consuming. Regulatory requirements can vary widely from country to country
and could delay or prevent the introduction of our product candidates in those countries. For example, in many jurisdictions outside of
the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In
some cases, the price that we intend to charge for our products would also be subject to approval. Satisfying these and other regulatory
requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval
in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have
any product candidates approved for sale in any jurisdiction, whether in the United States, Europe or any other international markets,
and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements
in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the
full market potential of our product candidates will be compromised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may seek a conditional marketing authorization
in Europe for some or all of our current product candidates, but we may not be able to obtain or maintain such designation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of its marketing authorization
process, the EMA may grant marketing authorizations for certain categories of medicinal products on the basis of less complete data than
is normally required, when doing so may meet unmet medical needs of patients and serve the interest of public health. In such cases, it
is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting of a marketing authorization, subject
to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This may apply to medicinal
products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention, or the
medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A conditional marketing authorization
may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and therapeutic utility of the medicinal
product have not been supplied, all the following requirements are met:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the risk-benefit balance of
the medicinal product is positive;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">it is likely that the applicant
will be in a position to provide the comprehensive clinical data;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">unmet medical needs will be
fulfilled; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the benefit to public health
of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional
data is still required.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The granting of a conditional
marketing authorization is restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete
preclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency
situations in response to public health threats. Conditional marketing authorizations are valid for one year, on a renewable basis. The
holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that the benefit-risk balance is
positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Granting a conditional marketing
authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the case and will ensure that
additional data on a product is generated, submitted, assessed and acted upon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures may
have a negative impact on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and some
foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities
and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical
products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part D program and introduced a new
reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs. In addition, the MMA authorized
Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic class in their formularies.
The MMA&#8217;s cost reduction initiatives and other provisions could decrease the coverage and price that we receive for any approved
products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies may be enacted in international
markets, which could similarly impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2010, the PPACA
(as amended by the Health Care and Education Reconciliation Act of 2010) was passed, which substantially changes the way healthcare
is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA,
among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates
owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid
managed care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv)
expands the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v)
establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition
for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Additionally, in the United States, the Biologics
Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biologic products that are demonstrated to
be biosimilar or &#8220;interchangeable&#8221; with an FDA-approved biologic product. This new pathway could allow competitors to
reference data from biologic products already approved after 12 years from the time of approval. This could expose us to potential
competition by lower-cost biosimilars even if we commercialize a product candidate faster than our competitors. Moreover, the
creation of this abbreviated approval pathway does not preclude or delay a third party from pursuing approval of a competitive
product candidate via the traditional approval pathway based on their own clinical trial data.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional changes that may
affect our business include those governing enrollments in federal healthcare programs, reimbursement changes, rules regarding prescription
drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the PPACA and the
passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives,
and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For each state that does not
choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact the sales, business and
financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage under any of the new options
made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting drug utilization. The U.S. federal
government also has announced delays in the implementation of key provisions of the PPACA. The implications of these delays for our and
our potential partners&#8217; business and financial condition, if any, are not yet clear.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there have been
judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration and Congress will likely
continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions of the PPACA. In January 2017,
President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the PPACA to waive, defer,
grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states,
individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. More recently, the U.S. House
of Representatives passed legislation known as the American Health Care Act of 2017, and Senate Republicans have released a draft bill
known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects of the PPACA if ultimately enacted. The
prospects for enactment of these legislative initiatives remain uncertain. Further, Congress also could consider other legislation to
replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or any future healthcare reform legislation
will impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that additional
state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional
pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to governmental regulation
and other legal obligations related to privacy, data protection and data security. Our actual or perceived failure to comply with such
obligations could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to diverse
laws and regulations relating to data privacy and security in the UK and EU, including the EU and UK GDPR. New global privacy rules are
being enacted and existing ones are being updated and strengthened. We are likely to be required to expend capital and other resources
to ensure ongoing compliance with these laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EU and UK GDPR applies
extraterritorially and implements stringent operational requirements for controllers and processors of personal data. For example, the
EU and UK GDPR: (i) require detailed disclosures to data subjects; (ii) require disclosure of the legal basis on which personal data is
processed; (iii) make it harder to obtain valid consent for processing; (iv) require the appointment of a data protection officers where
sensitive personal data (i.e. health data) is processed on a large scale; (v) provide more robust rights for data subjects; (vi) introduce
mandatory data breach notification through the EU and in the UK; (vii) impose additional obligations when contracting with service providers;
and (viii) require an appropriate privacy governance framework to be implemented including policies, procedures, training and data audit.
The EU GDPR permits Member State derogations for certain issues and, accordingly, we are also subject to EU national laws relating to
the processing of certain data such as genetic data, biometric data and data concerning health. Complying with these numerous, complex
and often changing regulations is expensive and difficult. Failure by us, or our partners or service providers, to comply with the EU
and/or UK GDPR could result in regulatory investigations, enforcement notices and/ or fines of up to the higher of 20,000,000 Euros/17,500,000
GBP or up to 4% of our total worldwide annual turnover. In addition to the foregoing, any breach of privacy laws or data security laws,
particularly those resulting in any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure
of sensitive or confidential patient or consumer information, could have a material adverse effect on our business, reputation and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a data controller, we are
accountable for any third-party data service providers we engage to process personal data on our behalf. We attempt to address the associated
risks by performing security assessments, detailed due diligence and regularly performing privacy and security reviews of its vendors
and requiring all such third-party providers with data access to sign agreements, including business associate agreements, and where required
under EU or UK law, obligating them to only process data according to our instructions and to take sufficient security measures to protect
such data. There is no assurance that these contractual measures and our own privacy and security-related safeguards will protect us from
the risks associated with the third-party processing, storage and transmission of such information. Any violation of data or security
laws by our third-party processors could have a material adverse effect on our business and result in the fines and penalties outlined
above. We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing
the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the
laws of each Member State. The draft e-Privacy Regulation imposes strict opt-in marketing rules with limited exceptions for business-to-business
communications, alters rules on third-party cookies, web beacons and similar technology and significantly increases fining powers to the
same levels as GDPR (i.e. the greater of 20,000,000 Euros or 4% of total global annual revenue). While the e-Privacy Regulation was originally
intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators
do not expect it to be enacted before mid to end 2023 and would not come into force before mid to end 2025. The UK is also updating its
data protection law via the Data Protection and Digital Information Bill that is currently being considered by the UK Parliament. This
is expected to be passed at the end of 2023 and will modify certain aspects of the UK GDPR and Data Protection Act 2018. These proposed
changes will require us to modify certain aspects of our data protection compliance program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to the U.K. Bribery Act,
the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade
and economic sanctions laws and other laws governing our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to anti-corruption laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977,
or the FCPA, the U.S. domestic bribery statute contained in 18 &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply
in countries where we do business. The U.K. Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries
from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value,
to government officials or other persons to obtain or retain business or gain some other business advantage. Under the U.K. Bribery Act,
we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners
operate in a number of jurisdictions that pose a high risk of potential U.K. Bribery Act or FCPA violations, and we participate in collaborations
and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the U.K. Bribery
Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject
or the manner in which existing laws might be administered or interpreted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject to other
laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom
and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and
embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations,
collectively referred to as the Trade Control laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the U.K. Bribery Act, the
FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery Act, the FCPA and other
anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial
measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity.
Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti-corruption laws or Trade Control
laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results
of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with customers, physicians
and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws,
health information privacy and security laws and other healthcare laws and regulations. If we are found in violation of these laws and
regulations, we may be required to pay a penalty or be suspended from participation in federal or state healthcare programs, which may
adversely affect our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for our product candidates and begin commercializing them in the United States, our operations will be directly, or indirectly through
our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without
limitation, the federal Anti-Kickback Statute, the federal civil and criminal laws and Physician Payments Sunshine Act of 2010 and regulations.
These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to
patient privacy laws by both the U.S. federal government and the states in which we conduct our business. The laws that will affect our
operations include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback Statute,
which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration
(including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for either the
referral of an individual, or the purchase, leasing, furnishing or arranging for the purchase, lease or order of a good, facility, item
or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted
to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on
the other. The PPACA amended the intent requirement of the federal Anti-Kickback Statute, such that a person or entity no longer needs
to have actual knowledge of this statute or specific intent to violate it;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">federal civil and criminal false
claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or
causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent.
The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support the view that federal
Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act of
1863;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit, among other things,
a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud any healthcare benefit
program, regardless of the payor (e.g., public or private);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">HIPAA (as amended by the Health
Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations, which impose certain requirements
relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization
by entities subject to the rule, such as health plans, health care clearinghouses and health care providers, and their respective business
associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">federal transparency laws, including
the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for
which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report
annually to the CMS information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals
and (ii) ownership and investment interests held by physicians and their immediate family members;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">federal consumer protection
and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">state and foreign law equivalents
of each of the above federal laws, state and local laws that require drug manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing
the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that our
business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties,
damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such
as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure
our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk of our being found
in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or
the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if
we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from
the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to
comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare
company may run afoul of one or more of the requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur substantial costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use,
storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and
regulations relating to occupational health and safety. We contract with third parties that conduct operations on our behalf that involve
the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors also produce and dispose of
hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination
or injury resulting from our contractors&#8217; use of hazardous materials, we could be held liable for any resulting damages and any
liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We also could incur significant
costs associated with civil or criminal fines and penalties. Our third-party contractors may not carry specific biological or hazardous
waste insurance coverage, and their property, casualty and general liability insurance policies specifically exclude coverage for damages
and fines arising from biological or hazardous waste exposure or contamination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain workers&#8217;
compensation insurance for certain costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous
materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive
materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to
become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts.
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which
could adversely affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may be a greater
commercial opportunity or for which there is a greater likelihood of success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of our business
depends upon our ability to identify, develop and commercialize product candidates. Research programs to identify new product candidates
require substantial technical, financial and human resources. Although a substantial amount of our efforts will focus on the continued
preclinical and clinical testing and potential approval of our product candidates, a key element of our long-term growth strategy is to
develop and market additional products and product candidates. However, we may fail to identify other potential product candidates for
clinical development for several reasons. For example, our research may be unsuccessful in identifying potential product candidates or
our potential product candidates may be shown to have harmful side effects, may be commercially impracticable to manufacture or may have
other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, because we have
limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that
later prove to have greater commercial potential. Our spending on current and future R&amp;D programs may not yield any commercially viable
products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights
to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous
for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources
to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-term growth strategy
to develop and market additional products and product candidates is heavily dependent on precise, accurate and reliable scientific data
to identify, select and develop promising pharmaceutical product candidates and products. Our business decisions may therefore be adversely
influenced by improper or fraudulent scientific data sourced from third parties. Any irregularities in the scientific data used by us
to determine our focus in R&amp;D of product candidates and products could have a material adverse effect on our business, prospects,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these events occur,
we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful
product candidate, which could have a negative impact on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends on our ability
to retain key employees, consultants and advisors and to recruit, retain and motivate qualified personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to compete in
the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel. While we have entered into employment agreements with each of our executive officers, any of them could
leave our employment at any time. We currently do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the
services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recruiting and retaining other
qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to
our success. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical
and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical
studies or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel.
The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of
our research, development and commercialization objectives and have an adverse effect on our business, financial condition, results of
operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to manage expected growth
in the scale and complexity of our operations, our performance may suffer</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2023, we had
3 full-time employees, who were engaged in R&amp;D activities. If we are successful in executing our business strategy, we will need to
expand our managerial, operational, financial and other systems and resources to manage our operations, continue our R&amp;D activities
and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved
for sale. Future growth would impose significant added responsibilities on members of management and, to a potentially significant extent,
divert our management and business development resources away from their current uses. It is likely that our management, finance, development
personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage
our operations, growth and any future product candidates requires that we continue to develop more robust business processes and improve
our systems and procedures in each of these areas, to attract and retain sufficient numbers of talented employees and to expand the group
of contractors we use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to successfully
implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, principal investigators,
consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards
and requirements and insider trading, which could have a material adverse impact on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties
could include intentional failures to: comply with FDA or EMA regulations or the regulations applicable in other jurisdictions, provide
accurate information to the FDA, EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in
the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent
fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct
also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or other
regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Additionally, we are subject
to the risk that a person could allege fraud or other misconduct, even in none occurred. We have adopted a code of conduct applicable
to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect
and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government
investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant
impact on our business, financial condition, results of operations and prospects, including the imposition of significant criminal, civil
and administrative sanctions, such as monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation
in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational
harm, and we may be required to curtail or restructure our operations. We are also subject to the data privacy regime in the EU, which
imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU and includes
the General Data Protection Regulation, or the GDPR, and any national laws implementing or supplementing the GDPR. If we do not comply
with our obligations under the EU privacy regime, we could be exposed to significant fines and we may be the subject of litigation and/or
adverse publicity, which could have a material adverse effect on our reputation and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product liability lawsuits against us could
cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face an inherent risk of
product liability exposure related to the testing of our current and future product candidates in clinical trials and may face an even
greater risk if we commercialize any product candidate that we may develop. For example, we may be sued if our current or future product
candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing
or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of
dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">decreased demand for any product
candidate that we may develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">loss of revenue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards
to trial participants or patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">significant time and costs to
defend the related litigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawal of clinical trial
participants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the inability to commercialize
any product candidates that we may develop; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injury to our reputation and
significant negative media attention.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain product
liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will
need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate.
Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate
to satisfy any liability that may arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A pandemic, epidemic or outbreak of an infectious
disease, such as COVID-19, may materially and adversely affect our business and operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outbreak of COVID-19 originated
in Wuhan, China, in December 2019 and spread to multiple countries, including the United States and several European countries. Disruptions
caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting
or completing our planned and ongoing preclinical studies and clinical trials, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the COVID-19 pandemic may affect the operations of the
FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates.
The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential
delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However,
these effects could have a material impact on our liquidity, capital resources, operations and business and those of the third parties
on which we rely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exchange rate fluctuations may materially
affect our results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Owing to the international
scope of our operations, fluctuations in exchange rates, particularly between Pounds Sterling and the U.S. dollar, may adversely affect
us. Although we are based in the United Kingdom, we may source R&amp;D, manufacturing, consulting and other services from the United States
and the European Union. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result,
our business and the potential value of our Common shares may be affected by fluctuations in foreign exchange rates not only between the
Pounds Sterling and the U.S. dollar, but also the euro, which may have a significant impact on our results of operations and cash flows
from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our internal computer systems, or those
of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption
of our product development programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our internal computer systems
and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any
such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations,
it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade
secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or
future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed,
and the further development and commercialization of our product candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Ownership of Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The prices of our common shares may be volatile
and fluctuate substantially, which could result in substantial losses for holders of our common shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market prices of our common
shares on the Nasdaq Capital Market may be volatile and fluctuate substantially. The stock market in general and the market for smaller
pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating
performance of particular companies. As a result of this volatility, holders our common shares may not be able to sell their common shares
at or above the price at which they were purchased. The market price for the common shares may be influenced by many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the success of competitive products
or technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">results of clinical trials of
Foralumab, anti-IL6R mAb (TZLS-501), Milciclib and any other future product candidate that we develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">results of clinical trials of
product candidates of our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>&#9679;</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">changes or developments in laws
or regulations applicable to Foralumab, anti-IL6R mAb (TZLS-501), Milciclib and any other future product candidates that we develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>&#9679;</b></span></td><td style="text-align: justify"><span style="font-size: 10pt">our entry into, and the success
of, any collaboration agreements with third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">developments or disputes concerning
patent applications, issued patents or other proprietary rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the recruitment or departure
of key personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the level of expenses related
to any of our product candidates or clinical development programs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the results of our efforts to
discover, develop, acquire or in-license additional product candidates, products or technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes
in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">variations in our financial
results or those of companies that are perceived to be similar to us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">market conditions in the biotechnology
and pharmaceutical sectors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general economic, industry and
market conditions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the trading volume of our common
shares on the Nasdaq Capital Market; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the other factors described
in this &#8220;Risk Factors&#8221; section.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our common shares
may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to meet
any of the continued listing standards of The Nasdaq Capital Market, our common shares could be delisted from The Nasdaq Capital Market.
These continued listing standards include specifically enumerated criteria, such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">a $1.00 minimum closing bid
price;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">stockholders&#8217; equity of
$2.5&#160;million;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">500,000 shares of publicly-held
common stock with a market value of at least $1&#160;million;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">300 round-lot stockholders;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">compliance with Nasdaq&#8217;s
corporate governance requirements, as well as additional or more stringent criteria that may be applied in the exercise of Nasdaq&#8217;s
discretionary authority.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2022, we received a written notice (the &#8220;Notice&#8221;)
from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that were not in compliance with Nasdaq Listing Rule 5550(a)(2) (the
&#8220;Rule&#8221;), as the minimum bid price of the Company&#8217;s common shares has been below $1.00 per share for 30 consecutive business
days. On December 13, 2022, Nasdaq notified us that we were eligible for an additional 180 calendar day period, or until June 12, 2023<b>,
</b>to regain compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 21, 2023, we received notice from
Nasdaq that we had regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 19, 2023, we received a written notice from Nasdaq notifying
us that were not in compliance with the Rule, as the minimum bid price of the Company&#8217;s common shares has been below $1.00 per share
for 30 consecutive business days. On January 22, 2024, Nasdaq notified us that we were eligible for an additional 180 calendar day period,
or until July 15, 2024<b>, </b>to regain compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;If we fail to comply
with Nasdaq&#8217;s continued listing standards, we may be delisted and our common shares will trade, if at all, only on the over-the-counter
market, such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker-dealer market makers comply with
quotation requirements. In addition, delisting of our common shares could depress our stock price, substantially limit liquidity of our
common shares and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Finally, delisting of
our common shares could result in our common shares becoming a &#8220;penny stock&#8221; under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Because we are a foreign
corporation, you may not have the same rights as a shareholder in a U.S. corporation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are a Bermuda exempted company. Our Memorandum of Association and&#160;Bye-laws&#160;and the Companies Act 1981 of Bermuda (the &#8220;<span style="text-decoration:underline">Companies
Act</span>&#8221;) govern our affairs Bermudan 1981 While many provisions of the Companies Act resemble provisions of the corporation laws
of a number of states in the United States, Bermuda law may not as clearly establish your rights and the fiduciary responsibilities of
our directors as do statutes and judicial precedent in some U.S. jurisdictions. In addition, apart from three&#160;non-executive&#160;directors,
our directors and officers are not resident in the United States and all or substantially all of our assets are located outside of the
United States. As a result, investors may have more difficulty in protecting their interests and enforcing judgments in the face of actions
by our management, directors or controlling shareholders than would shareholders of a corporation incorporated in a U.S. jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, you should not
assume that courts in the country in which we are incorporated or where our assets are located would enforce judgments of U.S. courts
obtained in actions against us based upon the civil liability provisions of applicable U.S. federal and state securities laws or would
enforce, in original actions, liabilities against us based on those laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders of Bermuda exempted
companies such as the Company also have no general rights under Bermuda law to inspect corporate records and accounts other than rights
to review the Company&#8217;s memorandum of association and bye-laws, financial statements, minutes of the shareholder meetings and the
shareholder register. This could make it more difficult for you to obtain the information needed to establish any facts necessary for
a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
a result of all of the above, public shareholders might have more difficulty in protecting their interests in the face of actions taken
by management, members of the board of directors or controlling shareholders than they would as public shareholders of a U.S. company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. persons who own our securities may
have more difficulty in protecting their interests than U.S. persons who are shareholders of a U.S. corporation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Act, which applies
to the Company, differs in some material respects from laws generally applicable to U.S. corporations and their shareholders. These differences
include, but are not limited to, the manner in which directors must disclose transactions in which they have an interest, the rights of
shareholders to bring class action and derivative lawsuits, the scope of indemnification available to directors and officers and provisions
relating to amalgamations, mergers and acquisitions and takeovers. Holders of our common shares may therefore have more difficulty protecting
their interests than would shareholders of a corporation incorporated in a jurisdiction within the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the duties of directors
and officers of a Bermuda company are owed to the company and not, in the absence of special circumstances, to the shareholders as individuals.
Shareholders of Bermuda companies typically do not have rights to take action against directors or officers of the company and may only
do so in limited circumstances. Class actions and derivative actions are typically not available to shareholders under Bermuda law. The
Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy
a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result
in the violation of the company&#8217;s memorandum of association or bye-laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain Other Bermuda Law Considerations</i>.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Bermuda &#8220;exempted
companies&#8221; are exempt from certain Bermuda laws restricting the percentage of share capital that may be held by non-Bermudians.
However, exempted companies may not participate in certain business transactions, including (1) the acquisition or holding of land in
Bermuda except that required for their business and held by way of lease or tenancy for a term not exceeding 50 years or, with the consent
of the Minister of Economic Development (the &#8220;Minister&#8221;) granted in his discretion by way of lease or tenancy for a term not
exceeding 21 years in order to provide accommodation or recreational facilities for officers and employees of the Company, (2) the taking
of mortgages on land in Bermuda to secure an amount in excess of $50,000 without the consent of the Minister, (3) the acquisition of any
bonds or debentures secured by any land in Bermuda, other than certain types of Bermuda government securities or securities issued by
Bermuda public authorities or (4) the carrying on of business of any kind in Bermuda, except in furtherance of business carried on outside
Bermuda or under license granted by the Minister.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Bermuda companies must
comply with the provisions of the Companies Act regulating the payment of dividends and making distributions from contributed surplus.
A company may not declare or pay a dividend, or make a distribution out of contributed surplus, if there are reasonable grounds for believing
that: (a) the company is, or would after the payment be, unable to pay its liabilities as they become due; or (b) the realizable value
of the company&#8217;s assets would thereby be less than its liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bermuda Exchange Control
Regulation</i>. The permission of the Bermuda Monetary Authority is required, under the provisions of the Exchange Control Act 1972 of
Bermuda and related regulations, for all issuances and transfers of shares (which includes our common shares) of Bermuda companies to
or from a non-resident of Bermuda for exchange control purposes, other than in cases where the Bermuda Monetary Authority has granted
a general permission. The Bermuda Monetary Authority, in its notice to the public dated June 1, 2005, has granted a general permission
for the issue and subsequent transfer of any securities of a Bermuda company from and/or to a non-resident of Bermuda for exchange control
purposes for so long as any &#8220;Equity Securities&#8221; of the company (which include our common shares) are listed on an &#8220;Appointed
Stock Exchange&#8221; (which include Nasdaq). In granting the general permission the Bermuda Monetary Authority accepts no responsibility
for our financial soundness or the correctness of any of the statements made or opinions expressed in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Company is incorporated
in Bermuda, as an exempted company, the Company is classified as a non-resident of Bermuda for exchange control purposes by the Bermuda
Monetary Authority. Other than transferring Bermuda Dollars out of Bermuda, there are no restrictions on the Company&#8217;s ability to
transfer funds into and out of Bermuda or to pay dividends in currency other than Bermuda Dollars to nonresidents of Bermuda who are holders
of our common shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities
and subject us to other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to continue to evaluate
various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies
or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased operating expenses
and cash requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the assumption of additional
indebtedness or contingent liabilities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">assimilation of operations,
intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the diversion of our management&#8217;s
attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">retention of key employees,
the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risks and uncertainties associated
with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory
approvals; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to generate revenue
from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated
acquisition and maintenance costs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><b><i>As an FPI, we are
exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than U.S. public
companies</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an FPI, as defined
in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized
within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate disclosure obligations and
procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the
Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions
of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not
required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly,
there may be less publicly available information concerning our company than there is for U.S. public companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an FPI, we will file an
annual report on Form 20-F within four months of the close of each fiscal year ended December 31 and reports on Form 6-K relating to certain
material events promptly after we publicly announce these events. However, because of the above exemptions for FPIs, our common shareholders
will not be afforded the same protections or information generally available to investors holding shares in public companies organized
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>While we are an FPI, we are not subject
to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are entitled to rely on
a provision in Nasdaq&#8217;s corporate governance rules that allows us to follow our home country corporate law and the Companies Act
with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in
significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, we are exempt
from Nasdaq regulations that require a listed U.S. company to (i) have a majority of the board of directors consist of independent directors,
(ii) require non-management directors to meet on a regular basis without management present and (iii) promptly disclose any waivers of
the code for directors or executive officers that should address certain specified items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with our Nasdaq
listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the
Exchange Act, both of which are also applicable to Nasdaq-listed U.S. companies. Because we are an FPI, however, our audit committee is
not subject to additional Nasdaq requirements applicable to listed U.S. companies, including an affirmative determination that all members
of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as an FPI. Furthermore,
Nasdaq&#8217;s corporate governance rules require listed U.S. companies to, among other things, seek shareholder approval for the implementation
of certain equity compensation plans and issuances of ordinary shares, which we are not required to follow as an FPI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may lose our FPI status, which would
then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting
and other expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an FPI, we are not required
to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers.
In order to maintain our current status as an FPI, either (a) a majority of our Common shares must be either directly or indirectly owned
of record by non-residents of the United States or (b)(i) a majority of our executive officers or directors cannot be U.S. citizens or
residents, (ii) more than 50% of our assets must be located outside the United States and (iii) our business must be administered principally
outside the United States. If we lose our status as an FPI, we would be required to comply with the Exchange Act reporting and other requirements
applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for FPIs. We may also be required to
make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs
to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may
be significantly higher than the cost we would incur as an FPI. As a result, we expect that a loss of FPI status would increase our legal
and financial compliance costs and is likely to make some activities highly time consuming and costly. We also expect that if we were
required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for
us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher
costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members
of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As of December 31, 2023, we were no longer
an emerging growth company within the meaning of the Securities Act of 1933, but still remain a smaller reporting company, and will take
advantage of certain reduced reporting requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
of December 31, 2023, we were no longer an &#8220;emerging growth company&#8221;, as defined in the Jumpstart Our Business Startups
( JOBS) Act. While we were an emerging growth company, we took advantage of exemptions from various reporting requirements that are
applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404. Even though we are no longer an emerging growth company, we
remain exempt from the auditor attestation requirements of Section 404 pursuant to the rules of the SEC, as we remain a
non-accelerated filer. We will cease to be a non-accelerated filer if (a) the aggregate market value of our outstanding Ordinary
Shares held by non-affiliates as of the last business day of our most recently completed second fiscal quarter is $75 million or
more and we reported annual net revenues of greater than $100 million for our most recently completed fiscal year or (b) the
aggregate market value of our outstanding Ordinary Shares held by non-affiliates as of the last business day of our most recently
completed second fiscal quarter is $700 million or more, regardless of annual net revenues. If we cease to be a non-accelerated
filer, we would be subject to the requirement for an annual attestation report by our independent registered public accounting firm
on the effectiveness of our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
remain a &#8220;smaller reporting company&#8221;, as defined in Rule 405 under the Securities Act, which means that we are <span>not
an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a &#8220;smaller reporting
company&#8221; which allows us to take advantage of many of the same exemptions from disclosure requirements, including this Annual Report
on Form 20-F. In addition, we are eligible to remain a smaller reporting company for so long as we have a public float of less than $250
million measured as of the last business day of our most recently completed second fiscal quarter or a public float of less than $700
million as of such date and annual revenues of less than $100 million during the most recently completed fiscal year.</span> We cannot
predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common
shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares
may be more volatile in the event that we decide to make an offering of our common shares.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to establish and maintain proper
internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.05in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 404(a) of the Sarbanes-Oxley
Act, or Section 404(a), requires that beginning with our second annual report following our IPO, management assess and report annually
on the effectiveness of our internal control over financial reporting and identify any material weaknesses in our internal control over
financial reporting. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our independent registered public
accounting firm to issue an annual report that addresses the effectiveness of our internal control over financial reporting, we have opted
to rely on the exemptions provided as a non-accelerated filer, and consequently will not be required to comply with SEC rules that implement
Section 404(b) until such time as we are no longer a non-accelerated filer.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section 404, we
will be required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain
a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify as
a non-accelerated filer, we will be engaged in a process to document and evaluate our internal control over financial reporting, which
is both costly and challenging.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this regard, we will need
to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document
the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control
over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or
at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material
weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We have identified
a material weakness in our internal control over financial reporting. Failure to maintain effective internal controls could cause our
investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective,
we may not be able to accurately report our financial results or prevent fraud.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection
with the preparation of our consolidated financial statements for the year ended December 31, 2023, we concluded that there was a material
weakness in our internal control over financial reporting&#160;<span>related to our failure to timely
develop and communicate an employee handbook for employees to consult in the event an issue arises. </span> A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
we identify additional material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis
and our consolidated financial statements may be materially misstated. Moreover, in the future we may engage in business transactions,
such as acquisitions, reorganizations or implementation of new information systems that could negatively affect our internal control over
financial reporting and result in material weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
independent registered public accounting firm did not perform an evaluation of our internal control over financial reporting during any
period in accordance with the provisions of the Sarbanes-Oxley Act. Had our independent registered public accounting firm performed an
evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control
deficiencies amounting to material weaknesses might have been identified. If we identify new material weaknesses in our internal control
over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner,
if we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting
firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be late with the
filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial reports and the market
price of our common shares could be negatively affected. As a result of such failures, we could also become subject to investigations
by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, and become subject to litigation from
investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from our
core business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our 10% or more
stockholders and management own a significant percentage of our stock and are able to exercise significant influence over matters subject
to stockholder approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this annual report, our executive officers, directors
and 10% or more stockholders, together with their respective affiliates, owned approximately 39% of our outstanding securities. Accordingly,
this group of security holders will be able to exert a significant degree of influence over our management and affairs and over matters
requiring security holder approval, including the election of our Board of Directors, future issuances of our securities, declaration
of dividends and approval of other significant corporate transactions. As a result, if these shareholders were to choose to act together,
they would be able to exert significant influence over matters submitted to our shareholders for approval, as well as our management and
affairs. For example, these persons, if they choose to act together, would exercise sufficient voting power to influence the election
of directors and approve any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership
control may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay, defer or prevent a change in control;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">entrench our management and board of directors; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impede a merger, consolidation, takeover or other business combination involving us that other shareholders may desire.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Claims of U.S. civil liabilities may not
be enforceable against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Bermudan law. The United States and Bermuda do not currently have a treaty providing for recognition and enforcement of judgments in civil
and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely
upon U.S. securities laws, would not automatically be recognized or enforceable in Bermuda. In addition, uncertainty exists as to whether
the courts of Bermuda would entertain original actions brought in Bermuda against us or our directors or senior management predicated
upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite
sum obtained against us in U.S. courts would be treated by the courts of Bermuda as a cause of action in itself and sued upon as a debt
at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. The courts of Bermuda will
not automatically accept that the foreign court had jurisdiction and was properly seized of the matter. For a Bermuda court to enforce
or recognize a foreign judgment either at common law or under the Judgments (Reciprocal Enforcement) Act 1958 of Bermuda, the foreign
court must have had jurisdiction according to Bermuda Conflict of Law principles. Whether these requirements are met in respect of a judgment
based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws
would constitute a penalty, is an issue for the court making such decision. If a Bermuda court gives judgment for the sum payable under
a U.S. judgment, the Bermuda judgment will be enforceable by methods generally available for this purpose. These methods generally permit
the Bermuda court discretion to prescribe the manner of enforcement.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, U.S. investors
may not be able to enforce against us or our senior management, certain of our board of directors or certain experts named herein (who
are residents of countries other than the United States) any judgments obtained in U.S. courts in civil and commercial matters, including
judgments under the U.S. federal securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are a passive foreign investment company,
there could be adverse U.S. federal income tax consequences to U.S. holders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Internal Revenue
Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year in which (1) 75% or more of our gross income consists of
passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production
of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment
property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or
indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets
and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year during which
a U.S. Holder (as defined below under &#8220;Material Income Tax Considerations-Material U.S. Federal Income Tax Considerations for U.S.
Holders&#8221;) holds our shares, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify
as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on
certain taxes treated as deferred, and additional reporting requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we were a
PFIC for our taxable year ended December 31, 2023 but cannot provide any assurances regarding our PFIC status for any past, current or
future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles
and methodologies which in some circumstances are unclear and subject to varying interpretation. In particular, the characterization of
our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In
addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part
by reference to the market price of our common shares from time to time, which may fluctuate considerably. Under the income test, our
status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate
structure. The composition of our income and assets may also be affected by how, and how quickly, we spend the cash we raise in any offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain circumstances,
a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making a qualified electing fund,
or QEF, election to include in income its pro rata share of the corporation&#8217;s income on a current basis. However, a U.S. Holder
may make a QEF election with respect to our common shares only if we agree to furnish such U.S. Holder annually with a PFIC annual information
statement as specified in the applicable U.S. Treasury Regulations. We currently do not intend to prepare or provide the information that
would enable U.S. Holders to make a QEF election if we are treated as a PFIC for any taxable year, and prospective investors should assume
that a QEF election will not be available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For further discussion of
the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this
report entitled &#8220;Material Income Tax Considerations-Material U.S. Federal Income Considerations For U.S. Holders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to use net operating loss
and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U.K. tax legislation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a U.K. tax resident trading entity, we are subject to U.K. corporate
taxation. Due to the nature of our business, we have generated losses since inception. As of December 31, 2023, we had cumulative carryforward
tax losses of $20 million.&#160;&#160;Subject to any relevant restrictions, we expect these to be available to carry forward and offset
against future operating profits. As a company that carries out extensive research and development activities, we benefit from the U.K.
research and development tax credit regime for small and medium-sized companies, whereby we are able to surrender the trading losses that
arise from our qualifying research and development activities for a payable tax credit of up to 33.35% of eligible research and development
expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead
costs incurred as part of research projects. Certain subcontracted qualifying research expenditures are eligible for a cash rebate of
up to 21.67%. The majority of our pipeline research, clinical trials management and manufacturing development activities are eligible
for inclusion within these tax credit cash rebate claims. Our ability to continue to claim payable research and development tax credits
in the future may be limited because we may no longer qualify as a small or medium-sized company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may benefit in the future
from the United Kingdom&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenues from patented products
to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent applications which, if issued, would
cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be taxed at this
tax rate. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term
lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the U.K. research and development tax
credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation,
or we are unable to use net operating loss and tax credit</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes and uncertainties in the tax system
in the countries in which we have operations could materially adversely affect our financial condition and results of operations, and
reduce net returns to our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our tax position could be
adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof
by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being affected by certain changes currently
proposed by the Organization for Economic Co-operation and Development and their action plan on Base Erosion and Profit Shifting. Such
changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends
continue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual effective tax rate
may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including:
(1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues arising from any future tax
audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities; (4) increases in expenses
not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5) changes
in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws, and changes in generally
accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A tax authority may disagree
with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&#8217;s Revenue&amp;
Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of income by tax
jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies,
including methodologies for valuing developed technology and amounts paid with respect to our intellectual property development. Similarly,
a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection,
often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could
increase our expected tax liability in one or more jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A tax authority may take the
position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical
violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation,
in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application
of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable
law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment,
the implications could increase our anticipated effective tax rate, where applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4: INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. History and Development of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were originally incorporated
under the laws of England and Wales on February 11, 1998, with the goal of leveraging the expertise of our management team as well as
Napoleone Ferrara, M.D., Arun Sanyal, M.D., Howard Weiner, M.D. and Kevan Herold, M.D., and to acquire and exploit certain intellectual
property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition
of Tiziana Pharma Limited in April 2014. On August 20, 2021 we announced that we had formally commenced a strategic plan to change our
corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, to become the ultimate parent company of
the Tiziana Group. The reorganization was performed under a scheme of arrangement under Part 26 of the UK Companies Act 2006 and became
effective on October 20, 2021, at which point all shareholders became shareholders in the new Bermuda company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registered office is located
at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda and our telephone number is +44 20 7495 2379.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC maintains an Internet
site that contains reports, proxy and information statements, and other information regarding issuers, such as we, that file electronically,
with the SEC at&#160;www.sec.gov.&#160;Our website address is www.tizianalifesciences.com. The reference to our website is an inactive
textual reference only and the information contained in, or that can be accessed through, our website is not a part of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our agent for service of process
in the United States is Tiziana Therapeutics, Inc, 420 Lexington Ave, Suite 1402, New York, NY 10170.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biotechnology company
that specializes in developing transformative therapies for neurodegenerative and lung diseases. Our clinical pipeline includes drug assets
for Secondary Progressive Multiple Sclerosis, ALS, Alzheimer&#8217;s, and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives
with extensive drug development and commercialization experience. Our mission is to bring breakthrough therapies to patients with the
aim of treating Secondary Progressive Multiple Sclerosis, ALS, Alzheimer&#8217;s, and other CNS indications. Crohn&#8217;s Disease, lung diseases
and optimizing health outcomes. We are developing transformational formulation technologies, enabling&#160;to switch from traditional
routes to alternative routes of immunotherapy to facilitate local site of action. For example, nasal, oral and inhalation administrations
to target neurodegenerative and lung diseases. We believe, if we succeed in these alternative routes of immunotherapies that has the potential
to&#160;change the way immunotherapies are currently conducted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ a lean and virtual
research and development, or R&amp;D, model using highly experienced teams of experts for each business function to maximize value accretion
by focusing resources on the drug discovery and development processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Foralumab,
for which we in-licensed the intellectual property from Novimmune SA, or Novimmune, in December 2014, as a potential treatment for neurodegenerative
diseases such as Secondary Progressive Multiple Sclerosis (SPMS), Crohn&#8217;s disease and delayed onset of Type I Diabetes (T1D). On
November 10, 2022, Tiziana announced a short-term focus on administration of intranasal foralumab for treatment of neurodegenerative diseases,
especially SPMS, based on positive clinical findings of Expanded Access (EA) SPMS patients at Brigham and Women&#8217;s Hospital treated
with intranasal foralumab for up to 1 year. As the only fully human engineered human anti-CD3 mAb in clinical development, Foralumab has
significant potential advantages such as a shorter treatment duration and reduced immunogenicity. We believe that oral or intranasal administration
of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects. To date, Foralumab has been
studied in one Phase 1 and two Phase 2a clinical trials conducted by Novimmune in 68 patients dosed by the intravenous route of administration.
In these trials, Foralumab was observed to be safe and well-tolerated and produced immunologic effects consistent with potential clinical
benefit while demonstrating mild to moderate infusion related reactions, or IRRs. With completion of the intravenous dosing for Phase
2a trial in Crohn&#8217;s Disease, Foralumab&#8217;s ability to modulate T-cell response enables potential extension into a wide range
of other autoimmune and inflammatory diseases, such as Graft versus Host Disease (GvHD), ulcerative colitis (UC), multiple sclerosis(MS),
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis (PSA) and rheumatoid arthritis (RA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foralumab is being developed
as both an immunosuppressive and immunomodulatory agent, with therapeutic benefits of rendering T-cells unable to orchestrate an immune
response and induction of immune tolerance via maintenance of regulatory T-cells. There is further potential for Foralumab to be combined
with the Company&#8217;s TZLS-501, a fully human anti-IL-6R mAB in development to target autoimmune and inflammatory diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2016, Tiziana
announced new data for oral efficacy in humanized mouse models with Foralumab, a major milestone and a potential breakthrough for the
treatment of NASH and autoimmune disease. This unique oral technology stimulates the natural gut immune system and potentially provides
a therapeutic effect in inflammatory and autoimmune diseases with greatly reduced toxicity. Positive therapeutic effects with Foralumab
were consistently demonstrated in animal studies conducted by Prof. Kevan Herold (Yale University) and Prof. Howard Weiner (Harvard University).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 16, 2018, Tiziana
entered into an exclusive license agreement with The Brigham and Women&#8217;s Hospital, Inc. relating to a novel formulation of Foralumab
dosed in a medical device for nasal administration. An investigational new drug application (IND) for the first-in-human evaluation of
the nasal administration of Foralumab in healthy volunteers for progressive multiple sclerosis indication was filed in the second quarter
of 2018. Subsequent to IND approval, a single-site, double-blind, placebo-controlled, dose-ranging Phase 1 trial with nasally administered
Foralumab at 10, 50 and 250 &#181;g per day, consecutively for 5 days to evaluate biomarkers of immunomodulation of clinical responses
was initiated in November 2018. The trial conducted at the Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, in
healthy volunteers. 18 subjects received Foralumab treatment and 9 patients received placebo. The study was completed in September 2019.
Phase 1 clinical data demonstrated that nasally administered Foralumab, was well-tolerated and no drug-related safety issues were reported
at any of the doses. No drug-related changes were observed in vital signs among subjects at predose, during treatment and at discharge.
Nasally administered Foralumab at the 50 &#181;g dose suppressed cytotoxic CD8+ as well as perforin-secreting CD8+ cells, which have
been implicated in neurodegeneration in multiple sclerosis (MS). Treatment at 50 &#181;g stimulated production of anti-inflammatory cytokine
IL-10 and suppressed production of pro-inflammatory cytokine IFN-&#947;. Taken together, the treatment showed significant positive effects
on the biomarkers for activation of mucosal immunity, which are capable of inducing site-targeted immunomodulation to elicit anti-inflammatory
effects. .&#160;Systemic levels of Foralumab were below the lower quantitation limit of 8 ng/mL suggesting that nasally administered Foralumab
appears to exert its effects via nasal epithelium utilizing local and lymphatic immune systems directly. These data support other clinical
and pre-clinical studies showing that this route of administration is capable of inducing site-targeted immunomodulation and anti-inflammatory
effects. Furthermore, these pharmacodynamic data point to a clinical dose range that Tiziana intends to test in further clinical development
among MS patients.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&#160;9, 2019,
the FDA granted approval to initiate the Phase 1 clinical trials to evaluate the safety and pharmacokinetics of a novel enteric-coated
capsule formulation of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. The study was completed in December
2019 at Brigham and Women&#8217;s Hospital (Boston, MA USA). A total of 12 subjects were enrolled; 9 received the single dose of foralumab
and 3 received placebo. The median age (range) for the oral foralumab subjects was 23 (21 &#8211; 55) years, and for the placebo subjects
it was 34 (27 &#8211; 51). Of the foralumab subjects, 6 were male and 3 were female. All 3 of the placebo subjects were female. No subjects
discontinued the study. Formulated Foralumab powder blend encapsulated in enteric-coated capsule was well-tolerated at all doses tested
and there were no drug-related safety issues observed even at the highest dose of 5 mg in this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana initiated a Phase
1b clinical trial in Crohn&#8217;s disease patients to evaluate oral capsules of foralumab, a fully human&#160;anti-CD3 monoclonal antibody.
The revised protocol allowed for the study of a broader patient population and a shorter dosing period. These protocol amendments or revisions
were intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.&#160;This study was the first
multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohn&#8217;s disease. Due to the refocus
of the company after the first six months of 2022, this study was withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A collaborative clinical trial
was initiated on November 2, 2020 in&#160;Brazil&#160;investigating nasally administered Foralumab, either alone or in combination with
orally administered dexamethasone (&#8220;Dexa&#8221;) in COVID-19 patients. The clinical study was completed in collaboration with scientific
teams at the&#160;Harvard Medical School&#160;(Boston, USA), and INTRIALS, a full-service Latin American CRO based in&#160;S&#227;o
Paulo, Brazil.&#160;The objectives of the trial were to assess safety of the treatment and to evaluate if progression of the diseases
is delayed with nasally administered 100mcg/day Foralumab (50mcg/nostril). This study enrolled 39 patients randomized in three cohorts:
cohort 1, control with no treatment (n=16); cohort 2; nasally administered Foralumab plus 3 days of priming with orally administered 6
mg Dexamethasone (n=11) and cohort 3; nasally administered Foralumab (n=12). The Foralumab treatment regimen was once a day dosing for
10 consecutive days. The trial was completed in January 2021. There were no significant differences between cohort 2 and 3. All treatments
were well-tolerated. There were no grade 3 or 4 severe adverse events (&#8220;SAEs&#8221;) in any of the cohorts<i>.</i>&#160;The CT scans
of the lungs showed the improvement was approximately double that shown in patients treated with Foralumab as compared to those in the
control group. &#160; The results of the study were published in the&#160;peer-reviewed journal,&#160;<i>Frontiers in Immunology</i>&#160;entitled
&#8220;Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in
Mild to Moderate COVID-19 Patients: A Pilot Study&#8221; in&#160;August 2021. This program has been temporarily paused to pursue the short
term focus on clinical development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 2, 2021 the Company
and Precision BioSciences Inc announced an exclusive license agreement to explore Foralumab as an agent to induce tolerance of allogeneic
CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Precision&#8217;s approach to manufacturing produces CAR
T cells that are virtually CD3-negative. Foralumab will be used as a lymphodepletion or tolerizing agent, either alone or in combination
with other co-stimulatory molecules, to improve the long-term survival of CAR T cells in cancer treatment. Tiziana has completed manufacturing
of foralumab solution for injection to be used by Precision Biosciences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
May 25, 2021 the Company announced that&#160;the first expanded access (EA) patient with secondary progressive multiple sclerosis (SPMS)
was dosed with nasally administered Foralumab at the&#160;Brigham and Women&#8217;s Hospital&#160;(BWH),&#160;Harvard Medical School,&#160;Boston,
MA.&#160;Nasal Foralumab 50 mcg (25 mcg/nostril) was administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed
by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, was to continue
for six months to evaluate routine safety, tolerability, and neurological behaviors. The study also examined microglial activation, by&#160;positron
emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the dosing regimen</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
March 10, 2022, the Company reported positive clinical data in the first EA SPMS patient following completion of six months of treatment
with intranasally administered foralumab, at the Brigham and Women&#8217;s Hospital (BWH),&#160;Harvard University,&#160;Boston, MA.&#160;In
addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana&#8217;s novel immunotherapy
technology, which, importantly overcame the challenge of effecting immunomodulation in the brain using nasal administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Foralumab
was given to an EA SPMS patient intranasally into each nostril on a regimen of M-W-F for two weeks followed by one week off therapy for
a period of six months. This regimen was well-tolerated with associated beneficial clinical and biomarker changes. Importantly, the PET
imaging data indicated inhibition of microglial cell activation observed at 3 months following treatment initiation and was sustained
at 6 months after treatment start (see Table 1). The reduction in microglial activation was seen in all parts of the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><b>Table 1. Percent
Reduction* in Activated Microglial Cells (AMCs) PET Signal After Starting Intranasal Foralumab as Compared to Baseline, in Whole Brain
and Selected Brain Regions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHOLE<br/> BRAIN</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBRAL<br/> CORTEX</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">THALAMUS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHITE<br/> MATTER</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBELLUM</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-left: 0.75pt">3 MONTHS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-20</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.75pt">6 MONTHS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-36</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Percent reduction is based
on changes from baseline in SUVR-1, a surrogate index for PET binding potential. SUVR=Standardized Uptake Value Ratio, calculated with
reference to a pseudo reference region in cerebral white matter that showed minimal change in PET SUV, across time points.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with clinical and
PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines, including interferon-gamma
(IFN-g), interleukin (IL-18), IL-1&#946; and IL-6, which are associated with multiple sclerosis pathogenesis and progression. Clinical
evaluation showed improvement in Timed 25-Foot Walk Test (T25FW), 9-Hole&#160;Peg Test&#160;(9HPT) and Symbol Digit Modality Test (SDMT).
Other published PET studies have shown an increase in activated microglial cells (AMCs) in patients with secondary progressive MS (SPMS),
and the increase in AMCs associated with higher scores on the Expanded Disability Status Scale (EDSS), a widely-used scale to measure
disability<sup>1,2</sup>. Several FDA-approved drugs, such as TYSABRI<sup>&#174;</sup>, MAYZENT<sup>&#174;</sup>&#160;and ZEPOSIA<sup>&#174;</sup>&#160;have
been shown to suppress microglial activation and exert neuroprotective effects in the central nervous system (CNS) in animal studies but
longitudinal assessment of drug effects on microglial activation in exclusive cohorts of SPMS patients are lacking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to treatment, this patient
had continued to experience worsening disease progression despite several MS therapies, including B cell depletion. The patient&#8217;s
gait and limb strength had been deteriorating over the prior two years. The patient then started on intranasal foralumab, which stabilized
his disease course. Tiziana also received FDA authorization to continue treating this patient for an additional 6 months to determine
if 12 months of consistent treatment maintains clinical stabilization and provides sustained clinical benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2022, FDA approved
enrollment of a second EA SPMS patient for treatment with intranasal foralumab.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These data were presented
in a virtual Key Opinion Leader (KOL) event hosted by Tiziana on&#160;March 14<sup>th</sup>, 2022, entitled &#8220;Foralumab Clinical
Update in Multiple Sclerosis; A Landmark Study with Intranasal Immunotherapy&#8221; featuring four Key Opinion Leaders and a live Q&amp;A
session. The company plans to continue treatment of EA SPMS patients at Brigham and Women&#8217;s Hospital and elsewhere and continue
evaluation of foralumab treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, Tiziana
announced that FDA granted permission to enroll up to eight additional (SPMS) patients in the Intermediate Size Patient Population EAP
with intranasal foralumab. As part of the original treatment plan, the foralumab dose will remain 50 mcg three times a week (MWF), which
is the same dose administered previously to the first two SPMS patients. The dosing regimen in this IND also has a provision for dose
escalation up to 100 mcg three times a week (MWF) as an option to improve clinical benefit, if needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Data from a Secondary Progressive
Multiple Sclerosis patient treated with intranasal foralumab were presented on&#160;June 2, 2022&#160;at the consortium of multiple sclerosis
centers (CMSC) 2022 annual meeting. Dr.&#160;Tanuja Chitnis, MD, Professor of Neurology and the Principal investigator of the clinical
study at the at the Brigham and Women&#8217;s Hospital (BWH),&#160;Boston, MA., presented a poster discussing clinical data from a patient
with SPMS, who was treated with intranasal foralumab for six months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 8, 2022, Tiziana announced
positive clinical results for the second patient (EA2) in the non-active SPMS Expanded Access (EA) Program following three months of dosing
with intranasal foralumab. These results confirm the previously reported data, from the first non-active SPMS patient (EA1) that after
three months of treatment, intranasal foralumab. was well-tolerated and improved clinical and PET imaging analyses. The second patient
was diagnosed with SPMS in 2014. Since then, the disease has been progressive, resulting in an accumulation of disability. Patient EA2
started ocrelizumab in 2018 and stopped this treatment in 2021. During this time EA2&#8217;s non-active SPMS progressed as measured by
EDSS worsening from 3.5 in 2018 to 6.0 in 2021. At this point in time EA2 needed a cane to walk 100 meters. Patient EA2 was subsequently
enrolled in the intranasal foralumab expanded access program. On&#160;September 2022, 8 months after starting treatment with intranasal
foralumab, EA2 was able to walk 100 meters without a cane or need to rest. This improved the EDSS from 6.0 to 5.5. EA2&#8217;s pyramidal
score remained stable during this time. In&#160;December 2022, 11 months after starting treatment with intranasal foralumab, EA2 was able
to walk 200 meters without a cane or need to rest, resulting in further improvement in EDSS from 5.5 to 5.0. EA2&#8217;s pyramidal score
continued to remain stable. Lastly preliminary reading of EA2&#8217;s 11-month PET Scan (December 2022) demonstrated improvement in microglial
activation over baseline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;September 20, 2022,
Tiziana announced that the second patient (&#8220;EA2&#8221;) with non-active secondary progressive multiple sclerosis (SPMS) receiving
intranasal foralumab had shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS), a standard
clinical assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2022, Tiziana
announced that it planned to submit an Investigational New Drug Application (IND) for a Phase 1 Trial of intranasal foralumab in Alzheimer&#8217;s
disease patients after receiving an affirmative written response from the FDA on a Pre-Investigational New Drug Application (PIND). Tiziana
plans on filing the IND for Alzheimer&#8217;s disease by the third quarter of 2023 upon the completion of requested toxicology studies,
then starting its Phase 1 program by the end of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 2, 2022,
Tiziana announced the completion of enrollment of the first patient cohort in its Intermediate Size Patient Population Expanded Access
Program to evaluate foralumab in non-active SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 10, 2022,
Tiziana announced its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS)
such as non-active SPMS, Alzheimer&#8217;s disease and amyotrophic lateral sclerosis (ALS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, Tiziana completed
compatibility, stability and characterization studies of foralumab nasal solution in unit dose devices for nasal administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are evaluating administrations
of Foralumab to delay onset and progression of T1D in at-risk individuals. T1D is characterized as a chronic and progressive autoimmune
disease leading to the destruction of insulin-producing &#946;-cells of the pancreas. Teplizumab (Provention Bio), a humanized Fc-mutated
anti-CD3 monoclonal antibody that alters the function of the T-lymphocytes that mediate the destruction of the insulin-producing &#946;-cell
is seeking FDA approval. The Company believes that Foralumab, a fully human anti-CD3 mAb, would have a better safety profile and clinical
benefit than Teplizumab based on Foralumab&#8217;s fully human protein sequence and binding affinity for CD3e compared to Teplizumab.
cGMP manufacturing of Foralumab solution for subcutaneous injection was initiated in April 2022 and IND submission is anticipated in 2023.
This program has been temporarily paused to pursue the short-term focus on clinical development of intranasal foralumab administration
for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Tiziana initiated
five Good Laboratory Practice (GLP) safety toxicology studies of foralumab administered intranasally and subcutaneously in HuGEMM CD3
transgenic mice. The five studies consisted of three intranasal toxicology studies of 14 days, 13 weeks and 26 weeks dosing duration and
two subcutaneous safety toxicology studies of 14 days and 28 days dosing duration. On&#160;December 15, 2022&#160;the Company announced
that it had successfully completed the 13-week toxicology trial and that intranasal foralumab was well-tolerated. The 26 week toxicology
study was completed on February 15, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on August 18,
2020 the United States Patent and Trademark Office, or USPTO, granted us a patent on use and methods of treatment of Crohn&#8217;s disease
with Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 mAbs.&#160;The CD3 (cluster of differentiation
3) is a protein complex on T-cells, which is important for the regulation of the immune system. The patent was published by the USPTO
on September 1, 2020 as Patent No.&#160;10,759,858.&#160;Recently, we also announced the issuance of the first-ever patent on oral administration
of anti-CD3 mAbs for treatment of human diseases (Patent No.&#160;10,688,186). We believe the grant of this additional composition-of-matter
and use patent further strengthens our intellectual property, consisting of proprietary technologies on oral and nasal administration
of Foralumab and other anti-CD3 mAbs for the treatment of human diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2020, we&#160;announced
that we had submitted a patent application on the potential use of Foralumab, a fully human anti-CD3 mAbs, to improve success of chimeric
antigen receptor T-cell, or CAR-T, therapy for cancer and other human diseases. We accelerated development of a fully human mAb targeting
the IL-6R (TZLS-501) for which the intellectual property was licensed from Novimmune in January 2017. This fully human mAb has a novel
mechanism of action, binding to both the membrane-bound and soluble forms of the IL-6R as well as depleting circulating levels of the
IL-6 in the blood. Excessive production of IL-6 is regarded as a key driver of acute inflammation resulting from infection with viral
agents such as Coronaviruses and of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications
and rheumatoid arthritis, and we believe that TZLS-501 may have potential therapeutic value for these indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, TZLS-501
demonstrated the potential for overcoming the limitations of other IL-6 blocking pathway drugs. Compared to tocilizumab and sarilumab,
while binding to the membrane-bound IL-6R complex, TZLS-501 has been observed to have a higher affinity for the soluble IL-6 receptor
from antibody binding studies conducted in cell culture. TZLS-501 also demonstrated the potential to block or reduce IL-6 signaling in
mouse models of inflammation. The soluble form of IL-6 has been implicated to have a larger role in disease progression compared to the
membrane- bound form (Kallen, K.J. (2002). &#8220;The role of trans-signaling via the agonistic soluble IL-6 receptor in human diseases.&#8221;
Biochimica et Biophysica Acta. 1592 (3): 323&#8211;343.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company initiated development
of TZLS-501 for treatment of Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Tocilizumab (Actemra&#174;, Roche)
a humanized interleukin-6 (IL-6) receptor mAb antagonist. was approved by the FDA as a subcutaneous injection for slowing the rate of
decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating
condition with limited treatment options. Actemra&#174; is the first biologic therapy approved by the FDA for the treatment of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2020 The Company
announced that it had developed investigational new technology to treat COVID-19 infections, consisting of direct delivery of anti-IL-6
receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer for treatment of patients infected
with COVID-19 (SARS-CoV-2)&#160;coronavirus.&#160;On June 29, 2020 the Company announced that it was advancing GMP manufacturing of TZLS-501
with STC Biologics concurrently with the development of inhalation technology using a hand-held nebulizer with Sciarra Laboratories and
safety toxicology studies in Cynomolgus monkeys with ITR Canada Laboratories. GMP batches were initiated in January 2021 and completed
in March 2021. Safety inhalation toxicology studies were initiated in November 2020 and completed in March 2021. Technological assessment
of nebulizers for inhalation treatment of patients was initiated in September 2020 and completed in February 2021. An additional 240L
cGMP batch of TZLS-501 drug substance was manufactured using an improved downstream process to support future development activities.
An IND for a Phase 1 Clinical Trial in Healthy Subjects for treatment of interstitial lung disease associated with systemic sclerosis
(SSc ILD) was filed in December 2021. This program has been temporarily paused to pursue the Company&#8217;s short term focus on clinical
development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Milciclib,
for which we in-licensed the intellectual property from Nerviano Medical Sciences S.r.l., or Nerviano, in January 2015, as a potential
treatment for pan KRAS mutations in NSCLC patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, Milciclib has been
studied in a total of eight completed Phase 1 and 2 clinical trials in 316 patients. In these trials, Milciclib was observed to be well-tolerated
and showed initial signals of anti-tumor action. Prior to in-licensing, Milciclib was granted orphan designation by the European Commission
and by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of malignant thymoma and an aggressive form of thymic
carcinoma in patients previously treated with chemotherapy. In two Phase 2a trials, CDKO-125a-006 and CDKO125a-007, Milciclib showed signs
of slowing disease progression and acceptable safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#160;</td><td style="text-align: justify">&#160;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the first half of 2017,
the Group initiated a Phase 2a trial (CDKO-125a-010) of Milciclib to explore safety, tolerability and antitumor activity of milciclib
as a single therapy in Sorafenib-resistant patients with unresectable or metastatic HCC and good liver function.. Typically, this population
of patients have an advanced form of the disease with poor prognosis and an average overall survival expectancy of 3-5 months. The compound
was administered as home-based treatment at the dose of 100 mg/day for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off
x q4 wks) for a total of 24 weeks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase 2a trial was completed
in June 2019 with clinical safety result reported in July 2019 and efficacy results reported in September 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since overexpression of CDKs
and dysregulation in pRB pathway (regulates transcription factors critical for cell cycle progression) are prominently associated with
tumor cell resistance to certain chemotherapeutic drugs, inhibition of multiple CDKs is an appealing approach to improve clinical responses
in cancer patient&#8217;s refractory to existing treatment options. A Phase 1 dose-escalation&#160;study of Milciclib in combination with
gemcitabine in patients with refractory solid tumors exhibited clinical activity in patients including those refractory to gemcitabine.
Milciclib shows inhibitory effects against multiple cell lines with mutationally active G12D (non-small cell lung carcinoma), G13D (colorectal
cancer), G12V(pancreatic cancer), and G12C (pancreatic cancer<b>&#160;</b>The Company also intends to evaluate milciclib in combination
with gemcitabine for treatment of pan KRAS mutations in NSCLC patients. cGMP manufacturing of milciclib capsules was completed in January
2022 and IND filing was completed on December 15, 2022. This program has been temporarily paused to pursue the short-term focus on clinical
development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Competitive Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our mission is to design and
deliver next generation therapeutics and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding
of disease biology with clinical development expertise. We believe the following strengths will allow us to continue to pursue this mission:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Advanced, novel pipeline</i></b>. We have an advanced pipeline of novel and proprietary drug candidates, including antibodies and small molecules, to address high unmet medical needs in the inflammation, autoimmune and oncology markets with significant commercial potential.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>Proprietary technology</i></b>.
Our proprietary technology enables the development of alternative routes of administration of antibodies, including oral delivery. We
believe that oral and nasal routes of delivery will alleviate the significant time and cost burden associated with other routes of administration,
including intravenous delivery.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>Broad and engaged network
of experts. </i></b>Our strong relationships with key opinion leaders contribute to our clinical development efforts and position us
well to support our products, if approved. Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Kevan Herold, and Dr. Howard Weiner are among
the thought leaders on our scientific advisory committee.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>Specialized expertise
and focus on oncology and inflammation</i></b>. Our management team, including Dr. Matthew Davis, Dr. William Clementi andJules Jacob,
, has considerable experience translating technologies from bench to market, and managing the global administration of clinical trials.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>Strong intellectual property
and know-how</i></b>. We believe our proprietary intellectual property portfolio, in-licensed from Nerviano and Novimmune, provides us
with a substantial competitive advantage for the commercial development of small molecule NCEs, and biologics, as well as expanded possibilities
for new development programs in the future. We have retained the worldwide development and commercialization rights to all of our product
candidates. We have submitted additional patent applications to further strengthen our intellectual property.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><i>Lean research and development
model, designed to maximize value</i></b>. We employ a lean and virtual R&amp;D model using highly experienced teams of experts for each
business function to maximize value accretion by focusing resources on the drug discovery and development processes.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become a leading
biotechnology company focused on developing and delivering therapies and related diagnostics in both oncology and immunology. The key
elements of our strategy to achieve this goal are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Advance the clinical development
of intranasally-administered Foralumab for treatment of neurodegenerative diseases, particularly SPMS, and potentially including Alzheimer&#8217;s
Disease, ALS and intracerebral hemorrhage (hemorrhagic stroke). Tiziana will continue to supply foralumab for intranasal treatment of
up to 10 EA patients at Brigham and Women&#8217;s Hospital and nitiated &#160;a multisite Phase 2 trial for treatment of SPMS patients
in Q3 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following programs have
been paused temporarily to focus Tiziana&#8217;s clinical development efforts on intranasal foralumab for treatment of SPMS and other
neurodegenerative disease.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Development of our product candidate,
TZLS-501, a fully human mAb targeting the IL-6 receptor (a biological mAb which may control the proteins involved in cell signaling relevant
to many inflammatory diseases and cancers), for treatment of inflammatory and oncology indications especially SSc-ILD. Additional cGMP
manufacturing and IND-enabling GLP safety toxicology studies in Cynomolgus monkeys, have been completed evaluation/qualification of hand-held
nebulizers for pulmonary administration of TZLS-501&#160;for SSc-ILD treatment have been completed</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical development and obtain
regulatory approval for our lead oncology product candidate, Milciclib, as a combination therapy for the treatment of refractory solid
tumors (being cancers which are non-responsive or become resistant to treatment), especially NSCLC. An IND was filed on December 15,
2022. The IND was withdrawn in January 2023 to refocus clinical activities on use of foralumab for treatment of neurodegenerative diseases.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following activities will continue to be pursued aggressively:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Continue development of platform
drug delivery technologies that provide competitive advantage over existing approved products, e.g. inhalation delivery and&#160;&#160;nasal
delivery of mAbs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Continue to leverage relationships
with key opinion leaders to promote clinical trial success and enhance future commercialization.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Opportunistically identify and
acquire or in-license complimentary product and technology candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Seek orphan drug, fast track
or breakthrough designation for our product candidates where warranted.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidate pipeline
is set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>DEVELOPMENT PIPELINE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Foralumab (TZLS-401 formerly known as NI-0401)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Foralumab is the
only fully human anti-CD3 mAb in clinical development, in contrast to the previous non-human or humanized anti-CD3 mAbs. Foralumab targets
the CD3 epsilon (CD3&#949;) receptor, which is a recognized approach for modulating T-Cell response and achieving immunosuppression.
We believe Foralumab could have broad application to autoimmune and inflammatory diseases, such as inflammatory bowel disease such as
MS, Crohn&#8217;s disease type-1 diabetes (T1D) psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
In July 2017, we announced publication of a research article in, Clinical Immunology, entitled: &#8220;Oral treatment with Foralumab,
a fully human anti-CD3 mAb, prevents skin xenograft rejection in humanized mice.&#8221; We believe this is the first-ever published report
demonstrating the potential of oral therapy with Foralumab for inflammatory diseases and is based on the landmark discovery by Prof. Howard
Weiner of Harvard University, one of our Scientific Advisory Committee members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 16, 2018, Tiziana
entered into an exclusive license agreement with The Brigham and Women&#8217;s Hospital, Inc. relating to a novel formulation of Foralumab
dosed in a medical device for nasal administration. An investigational new drug application (IND) for the first-in-human evaluation of
the nasal administration of Foralumab in healthy volunteers for progressive multiple sclerosis indication was filed in the second quarter
of 2018. Subsequent to IND approval, a single-site, double-blind, placebo-controlled, dose-ranging Phase 1 trial with nasally administered
Foralumab at 10, 50 and 250 &#181;g per day, consecutively for 5 days to evaluate biomarkers of immunomodulation of clinical responses
was initiated in November 2018. The trial conducted at the Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, in
healthy volunteers. 18 subjects received Foralumab treatment and 9 patients received placebo. The study was completed in September 2019.
Phase 1 clinical data demonstrated that nasally administered Foralumab, was well-tolerated and no drug-related safety issues were reported
at any of the doses. No drug-related changes were observed in vital signs among subjects at predose, during treatment and at discharge.
The mean blood pressure (BP) during the 5 days of treatment were; Cohort A (10 &#181;g/d):124/73, Cohort B (50 &#181;g/d): 119/67 and
Cohort C (250 &#181;g/d):113/65 compared to placebo:118/67). Heart rates, respiratory rates and oral temperatures were unchanged among
the 3 cohorts compared to the placebo. Nasally administered Foralumab at the 50 &#181;g dose suppressed cytotoxic CD8+ as well as perforin
secreting CD8+ cells, which have been implicated in neurodegeneration in multiple sclerosis (MS). Treatment at 50 mg stimulated production
of anti-inflammatory cytokine IL-10 and suppressed production of pro-inflammatory cytokine IFN-&#947;. Taken together, the treatment
showed significant positive effects on the biomarkers for activation of mucosal immunity, which are capable of inducing site-targeted
immunomodulation to elicit anti-inflammatory effects. Based on the results we intend to conduct a Phase 2 trial in secondary progressive
MS (SPMS) patients starting in Q3 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enteric-coated capsule
formulation using a proprietary and novel technology has been developed for oral administration of Foralumab. cGMP manufacturing of clinical
trial materials for a Phase 1 study has been completed and an IND was submitted in March 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&#160;9, 2019,
the FDA granted approval to initiate the Phase 1 clinical trial to evaluate the safety and pharmacokinetics of a novel enteric-coated
capsule formulation of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. The study was completed in December
2019 at Brigham and Women&#8217;s Hospital (Boston, MA USA). A total of 12 subjects were enrolled; 9 received the single dose of foralumab
and 3 received placebo. The median age (range) for the oral foralumab subjects was 23 (21 &#8211; 55) years, and for the placebo subjects
it was 34 (27 &#8211; 51). Of the foralumab subjects, 6 were male and 3 were female. All 3 of the placebo subjects were female. No subjects
discontinued the study. Formulated Foralumab powder blend encapsulated in enteric-coated capsules was well-tolerated at all doses tested
and there were no drug-related safety issues observed even at the highest dose of 5 mg in this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana initiated a Phase
1b clinical trial in Crohn&#8217;s disease patients to evaluate oral capsules of foralumab, a fully human&#160;anti-CD3 monoclonal antibody.
The revised protocol allowed for the study of a broader patient population and a shorter dosing period. These protocol amendments or revisions
were intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.&#160;This study was to be
the first multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohn&#8217;s disease. Due
to the refocus of the company subsequent to the first six months of 2022, this study has been withdrawn to focus on nasal administration
studies for SPMS indication</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A collaborative clinical study
was initiated on November 2, 2020, investigating nasally administered Foralumab either alone or in combination with orally administered
dexamethasone in COVID-19 patients in Brazil. In view of the importance and urgency, scientific teams at the Harvard Medical School, Santa
Casa de Miseric&#243;rdia de Santos Hospital (Jabaquara, Santos, Brazil) and at our company closely collaborated to facilitate initiation
of this study in expedited time frames. The clinical trial was coordinated by the team at INTRIALS, a leading, full-service Latin America
Clinical Research Organization, (CRO) based in Sao Paulo City, Brazil. The trial was completed in January 2021. This trial, the first-ever
trial on nasal administration of Foralumab for treatment of COVID-19, is of enormous significance because the underlying scientific approach
is to modulate immune system, which is dysregulated and crippled to protect against the virus The results of the trial were All treatments
were well-tolerated. There were no grade 3 or 4 severe adverse events (&#8220;SAEs&#8221;) in any of the cohorts<i>.</i>&#160;The CT scans
of the lungs showed the improvement was approximately double that shown in patients treated with Foralumab as compared to those in the
control group. &#160; The results of the study were published in the&#160;peer-reviewed journal,&#160;<i>Frontiers in Immunology</i>&#160;entitled
&#8220;Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in
Mild to Moderate COVID-19 Patients: A Pilot Study&#8221; in&#160;August 2021. The study served as &#8220;proof of concept&#8221; that
nasal administration of foralumab could be used to treat systemic inflammatory response related to COVID infection and could be used for
treatment of other systemic inflammatory diseases. The Company has refocused development of Foralumab for treatment of Crohn&#8217;s disease
(oral treatment) and progressive MS (nasal treatment) utilizing site specific delivery technologies to limit systemic exposure of foralumab
which achieving local delivery to inflamed tissue. Further development has been paused because of the Company&#8217;s refocus on administration
of nasal foralumab for SPMS and other neurodegenerative diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Multiple Sclerosis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MS is an inflammatory-mediated
demyelinating disease of the human central nervous system. The disease develops in young adults with a complex predisposing genetic trait
and most likely involves an environmental insult such as a viral infection to trigger the disease. The activation of CD4+ autoreactive
T cells and their differentiation are crucial initial steps in the progression of this disease. The therapeutic use of monoclonal antibodies
was initially viewed with great skepticism owing to the high rates of sensitization against mouse proteins, their pharmacokinetic properties,
and the difficulties in their production. However, most of these problems have been overcome, and monoclonal antibodies are now among
the most promising therapies for MS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The innate immune system plays
a central role in the chronic central nervous system inflammation that drives neurological disability in progressive forms of multiple
sclerosis, for which there are few effective treatments. The mucosal immune system is a unique tolerogenic organ that provides a physiological
approach for the induction of regulatory T&#160;cells. Nasal administration of CD3-specific antibody ameliorates disease in a progressive
animal model of multiple sclerosis. This effect is IL-10-dependent and is mediated by the induction of regulatory T cells that share a
similar transcriptional profile to Tr1 regulatory cells and that suppress the astrocyte inflammatory transcriptional program. Treatment
results in an attenuated inflammatory milieu in the central nervous system decreased microglia activation, reduced recruitment of peripheral
monocytes, stabilization of the blood-brain barrier, less neurodegeneration, and decreased accumulation of neurologic disability (Mayo,&#160;2016).
Patients with non-active secondary progressive MS, demonstrate increased microglial activation that drives disease progression. These
nonclinical findings suggest foralumab may be a new therapeutic approach for the treatment of progressive forms of multiple sclerosis.
Based on this work, we hypothesize that nasal foralumab will slow disability accumulation and microglial activation measured by PET imaging
in non-active secondary progressive multiple sclerosis. Two patients with non-active SPMS have been treated for 12 or more months with
a suggestion of clinical improvement and no clinically significant adverse events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Binding of foralumab to the
T-cell receptor complex, through the nasal, results in suppression of effector T-cells involved in various inflammatory and autoimmune
diseases along with a reduction in inflammatory cytokines and increase in Tregs anti inflammatory cytokines resulting in site-targeted
immunomodulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Autoimmune and Inflammatory Diseases</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Autoimmune diseases are primarily
due to a malfunction when the immune system attacks certain cells in the body as foreign invaders. This can result in irreparable damage
to critical organs and tissues eventually resulting in autoimmune diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In humans, CD3-epsilon is
encoded by the CD3&#949; gene on Chromosome 11. The CD3&#949; molecule, along with four other membrane-bound polypeptides (CD3-gamma,
-delta, -zeta, and -eta) form the CD3 complex, which is associated with the T-cell receptor. Upon antigen bindings, the CD3 complex sends
signals through the cell membrane to the cytoplasm inside the T-cell. This leads to activation of the T-cell that rapidly divides to produce
new T-cells sensitized to fight the particular antigen to which the TCR was exposed. While T-cell activation is critical for the human
immune system to properly fight bacterial, viral or parasitic infections, abnormal T-cell induction can cause and worsen numerous human
diseases, including T-cell lymphoma and leukemia, human malignancies, autoimmune disorders, cardiovascular disease and transplant rejection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Our Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Foralumab is the
only fully human anti-CD3 mAb in clinical development. Since the discovery of the hybridoma technology, a method to generate large quantities
of a single (monoclonal) antibody, the production and manufacture of mAbs has become widely available showing promise in several autoimmune
and inflammatory disease clinical trials and therapeutic utility in animal models. The first murine anti-CD3 mAb (IgG2a) was developed
and approved by the FDA in 1985 under the name of muromonab, OKT3, (Ortho Kung T3; Orthoclone&#174;) to treat allograft rejection in kidney,
liver and heart transplantation by exerting its potent immunosuppressive effects, mainly due to depletion of T-cells in tissues and thereby
preventing rejection of the allografts. Subsequently, OKT3 was administered in clinical trials to patients with MS, T1D, inflammatory
bowel disease, rheumatoid arthritis and NASH. Although showing promise to alleviate the disease process, the mAb being of murine origin
and extremely immunogenic in humans, was associated with a wide range of side effects that included the typical Cytokine Release Syndrome
(CRS) or flu-like syndrome, limiting its clinical development. The side effect profile of OKT3 is a consequence of T-cell activation resulting
in the release of numerous cytokines into the systemic circulation. These shortcomings of the murine OKT3 led to the development of a
new generation of anti-CD3 mAbs using genetic engineering of the mAb structure, as depicted below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foralumab dosed intravenously
has been observed to alter T-cell function via antigenic modulation, that is, removal of the CD3/TCR complex from the T-cell surface.
Modulation has two therapeutic benefits:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">It transiently renders the T-cells
incapable of recognizing an antigen and thus unable to orchestrate an immune response such as an allograft rejection; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">It has a favorable long-term
effect on generation and maintenance of regulatory T-cells, a specialized subset of T-cells that promote immunological tolerance.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In comparison with the two
other anti-CD3 mAbs evaluated in patients with T1D (otelixizumab and teplizumab), Foralumab, being fully human, was less mitogenic (capable
of causing cell division), therefore allowing re-treatment, and to have a better risk/benefit profile. As such, Foralumab was previously
developed by Novimmune as an intravenous formulation for the treatment of autoimmune indications: Crohn&#8217;s disease and in renal allograft
recipients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, recent data from
studies conducted in the laboratories of our Scientific Advisory Committee members, Prof. Howard Weiner of Harvard University and Prof.
Kevan Herold of Yale University, suggest that oral administration of Foralumab has the potential for therapeutic utility while minimizing
toxicity associated with intravenous administration, such as Cytokine Release Syndrome (CRS). Importantly, recent clinical studies conducted
by Prof. Yaron Ilan with oral administration of anti-CD3 (OKT3; murine mAb) in HCV infected patients (non-respondents) and in NASH patients
suggested that the treatment was well-tolerated and produced immunologic effects consistent with potential clinical benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, increasing appreciation
for the gut-liver cross-talk and of its role in the initiation of NASH-associated inflammation and fibrogenesis has led to the understanding
that systemic inflammatory processes can be alleviated by modulating the gut immune system, without inducing generalized immunosuppression.
This has been achieved in multiple approaches, including oral administration of fatty liver-derived proteins, anti-CD3 antibodies, TNF,
fusion protein, anti-lipopolysaccharide antibodies, glucosylceramide, delayed-release mercaptopurine and soy-derived extracts. Several
of these compounds were shown to be effective in patients with NASH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orally administered OKT3 was
evaluated in a Phase 2 trial in 36 patients with NASH and type 2 diabetes and was found to be well tolerated. Increases in regulatory
T-cell markers consistent with induction of regulatory T-cells was observed as well as increases in other anti-inflammatory markers. Although
not powered sufficiently to evaluate efficacy endpoints, positive trends were observed including lowering of liver enzymes and lowering
of glucose levels (Lalazar et.al, J. Clin. Immunol. (2015) 34 (4):399-407).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More recent animal studies
conducted separately by Prof. Howard Weiner and Prof. Kevan Herold demonstrated therapeutic utility of orally administered Foralumab for
immune-inflammatory diseases. Our strategy is to build on these findings to develop orally administered Foralumab for the treatment of
Crohn&#8217;s disease and other autoimmune diseases. We believe Foralumab may also be combined with our other product candidate, TZLS-501,
a fully human anti-IL-6R mAb, for the treatment of rheumatoid arthritis and other diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enteric-coated capsule
formulation using a proprietary and novel technology has been developed for oral administration of Foralumab. cGMP manufacturing of clinical
trial materials for a Phase 1 study has been completed and an IND was submitted in March 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&#160;9, 2019,
the FDA granted approval to initiate the Phase I clinical trials to evaluate the safety and pharmacokinetics of oral Foralumab at 1.25,
2.5 and 5.0 mg/day as a single ascending dose study. The study was completed in December 2019 at Brigham and Women&#8217;s Hospital (Boston,
MA USA). Formulated Foralumab powder blend encapsulated in enteric-coated capsule was well-tolerated at all doses tested and there were
no drug-related safety issues observed even at the highest dose of 5 mg in this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana initiated a Phase
1b clinical trial in Crohn&#8217;s disease patients to evaluate oral capsules of foralumab, a fully human&#160;anti-CD3 monoclonal antibody.
The revised protocol allowed for the study of a broader patient population and a shorter dosing period. These protocol amendments or revisions
were intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.&#160;This study was the first
multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohn&#8217;s disease. Due to the refocus
of the company subsequent to the first six months of 2022, this study has been withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Development Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase 1a Clinical Trial for Oral Foralumab
in Healthy Volunteers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase 1a trial, conducted
at the Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, USA, was a single-site, double-blind, placebo-controlled,
single ascending dose (&#8220;SAD&#8221;) study in healthy subjects in which Foralumab was orally administered at 1.25, 2.5 and 5.0 mg
per dose as enteric-coated capsules. The primary endpoint of the Phase 1 study is safety and tolerability of Foralumab in humans. Each
cohort comprised of 4 subjects, of whom 3 received Foralumab treatment and 1 received a placebo capsule. All subjects completed the trial
without any safety concerns at any of the doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase 1 Clinical Trial of Nasally-Administered
Foralumab for Treatment of Secondary Progressive Multiple Sclerosis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase 1 trial, conducted
at the Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, was a single-site, double-blind, placebo-controlled, dose-ranging
study with nasally administered Foralumab at 10, 50 and 250 &#181;g per day, consecutively for 5 days in healthy volunteers for the treatment
of progressive multiple sclerosis (pMS). 18 subjects received Foralumab treatment and 9 patients received placebo. All nasal doses were
well tolerated. Biomarker analysis showed significant positive immune effects, that were most prominent in the 50 &#181;g cohort with
minimal immunomodulatory effects at the 10 &#181;g and 250 &#181;g doses. &#160;Prominent results included:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Treatment was well-tolerated
and no drug-related safety issues were reported at any of the doses.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">No drug-related changes were
observed in vital signs among subjects at predose, during treatment and at discharge. The mean blood pressure (BP) during the 5 days
of treatment were; Cohort A (10 &#181;g/d):124/73, Cohort B (50 &#181;g/d): 119/67 and Cohort C (250 &#181;g/d):113/65 compared to
placebo:118/67). Heart rates, respiratory rates and oral temperatures were unchanged among the 3 cohorts compared to the placebo.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Nasally administered Foralumab
at the 50 &#181;g dose suppressed cytotoxic CD8+ as well as perforin secreting CD8+ cells, which have been implicated in neurodegeneration
in multiple sclerosis (MS).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Treatment at 50 <span style="font-family: Symbol">m</span>g
stimulated production of anti-inflammatory cytokine IL-10 and suppressed&#160; production of pro-inflammatory cytokine IFN-&#947;.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Taken together, these results
suggest stimulation of Tregs that are needed to provide clinical benefits</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treatment of Expanded Access SPMS Patients
at Brigham and Women&#8217;s Hospital (Boston) with Nasally-Administered Foralumab </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
May 25, 2021 the Company announced that&#160;the first expanded access (EA) patient with secondary progressive multiple sclerosis (SPMS)
was dosed with nasally administered Foralumab at the&#160;Brigham and Women&#8217;s Hospital&#160;(BWH),&#160;Harvard Medical School,&#160;Boston,
MA.&#160;Nasal Foralumab 50 mcg (25 mcg/nostril) was administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed
by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, was to continue
for six months to evaluate routine safety, tolerability, and neurological behaviors. The study also examined microglial activation, by&#160;positron
emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the dosing regimen</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
March 10, 2022, the Company reported positive clinical data in the first SPMS EA patient following completion of six months of treatment
with intranasally administered foralumab, at the Brigham and Women&#8217;s Hospital (BWH),&#160;Harvard University,&#160;Boston, MA.&#160;In
addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana&#8217;s novel immunotherapy
technology, which, importantly effected immunomodulation in the brain using nasal administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Foralumab
was given to an SPMS patient intranasally into each nostril on a regimen of M-W-F for two weeks followed by one week off therapy for a
period of six months. This regimen was well-tolerated with associated beneficial clinical and biomarker changes. Importantly, the PET
imaging data indicated inhibition of microglial cell activation observed at 3 months following treatment initiation and was sustained
at 6 months after treatment start (see Table 1). The reduction in microglial activation was seen in all parts of brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><b>Table 1. Percent Reduction* in Activated
Microglial Cells (AMCs) PET Signal After Starting Intranasal Foralumab as Compared to Baseline, in Whole Brain and Selected Brain Regions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHOLE<br/> BRAIN</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBRAL<br/> CORTEX</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">THALAMUS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHITE<br/> MATTER</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBELLUM</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; padding-left: 0.75pt">3 MONTHS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-20</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.75pt">6 MONTHS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-36</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Percent reduction is based
on changes from baseline in SUVR-1, a surrogate index for PET binding potential. SUVR=Standardized Uptake Value Ratio, calculated with
reference to a pseudo reference region in cerebral white matter that showed minimal change in PET SUV, across time points.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Consistent
with clinical and PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines,
including interferon-gamma (IFN-g), interleukin (IL-18), IL-1&#946; and IL-6, which are associated with multiple sclerosis pathogenesis
and progression. Clinical evaluation showed improvement in Timed 25-Foot Walk Test (T25FW), 9-Hole&#160;Peg Test&#160;(9HPT) and Symbol
Digit Modality Test (SDMT). Other published PET studies have shown an increase in activated microglial cells (AMCs) in patients with secondary
progressive MS (SPMS), and the increase in AMCs associated with higher scores on the Expanded Disability Status Scale (EDSS), a widely-used
scale to measure disability<sup>1,2</sup>. Several FDA-approved drugs, such as TYSABRI<sup>&#174;</sup>, MAYZENT<sup>&#174;</sup>&#160;and
ZEPOSIA<sup>&#174;</sup>&#160;have been shown to suppress microglial activation and exert neuroprotective effects in the central nervous
system (CNS) in animal studies but longitudinal assessment of drug effects on microglial activation in exclusive cohorts of SPMS patients
are lacking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Prior
to treatment, this patient had continued to experience worsening disease progression despite several MS therapies, including B cell depletion.
The patient&#8217;s gait and limb strength had been deteriorating over the prior two years. The patient then started on intranasal foralumab,
which stabilized his disease course. Tiziana also received FDA authorization to continue treating this patient for an additional 6 months
to determine if 12 months of consistent treatment maintains clinical stabilization and provides sustained clinical benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
January 20, 2022, FDA allowed enrollment of a second EA SPMS patient for treatment with intranasal foralumab.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These data were presented
in a virtual Key Opinion Leader (KOL) event hosted by Tiziana on&#160;March 14<sup>th</sup>, 2022, entitled &#8220;Foralumab Clinical
Update in Multiple Sclerosis; A Landmark Study with Intranasal Immunotherapy&#8221; featuring four Key Opinion Leaders and a live Q&amp;A
session. The company plans to continue treatment of EA SPMS patients at Brigham and Women&#8217;s Hospital and elsewhere and continue
evaluation of foralumab treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, Tiziana
announced that FDA granted permission to enroll up to eight additional (SPMS) Intermediate Size Patient Population EAP with intranasal
foralumab. As part of the original treatment plan, the foralumab dose will remain 50 mcg three times a week (MWF), which is the same dose
administered previously to the first two SPMS patients. The dosing regimen in this IND also has a provision for dose escalation up to
100 mcg three times a week (MWF) as an option to improve clinical benefit, if needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Data from a Secondary Progressive
Multiple Sclerosis patient treated with intranasal foralumab were presented on&#160;June 2, 2022&#160;at the consortium of multiple sclerosis
centers (CMSC) 2022 annual meeting. Dr.&#160;Tanuja Chitnis, MD, Professor of Neurology and the Principal investigator of the clinical
study at the at the Brigham and Women&#8217;s Hospital (BWH),&#160;Boston, MA., presented a poster discussing clinical data from a patient
with SPMS, who was treated with intranasal foralumab for six months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 8, 2022, Tiziana announced
positive clinical results for the second patient (EA2) in the non-active SPMS Expanded Access (EA) Program following three months of dosing
with intranasal foralumab. These results confirm the previously reported data, from the first non-active SPMS patient (EA1) that after
three months of treatment, intranasal foralumab. was well-tolerated and improved clinical and PET imaging analyses. The second patient
was diagnosed with SPMS in 2014. Since then, the disease has been progressive, resulting in an accumulation of disability. Patient EA2
started ocrelizumab in 2018 and stopped this treatment in 2021. During this time EA2&#8217;s non-active SPMS progressed as measured by
EDSS worsening from 3.5 in 2018 to 6.0 in 2021. At this point in time EA2 needed a cane to walk 100 meters. Patient EA2 was subsequently
enrolled in the intranasal foralumab expanded access program. On&#160;September 2022, 8 months after starting treatment with intranasal
foralumab, EA2 was able to walk 100 meters without a cane or need to rest. This improved the EDSS from 6.0 to 5.5. EA2&#8217;s pyramidal
score remained stable during this time. In&#160;December 2022, 11 months after starting treatment with intranasal foralumab, EA2 was able
to walk 200 meters without a cane or need to rest, resulting in further improvement in EDSS from 5.5 to 5.0. EA2&#8217;s pyramidal score
continued to remain stable. Lastly preliminary reading of EA2&#8217;s 11-month PET Scan (December 2022) demonstrated improvement in microglial
activation over baseline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On&#160;September
20, 2022, Tiziana announced that the second patient (&#8220;EA2&#8221;) with non-active secondary progressive multiple sclerosis (SPMS)
receiving intranasal foralumab had shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS),
a standard clinical assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2022, Tiziana
announced that it planned to submit an Investigational New Drug Application (IND) for a Phase 1 Trial of intranasal foralumab in Alzheimer&#8217;s
disease patients after receiving an affirmative written response from the FDA on a Pre-Investigational New Drug Application (PIND). Tiziana
plans on filing the IND for Alzheimer&#8217;s disease by the third quarter of 2023 upon the completion of requested toxicology studies,
then starting its Phase 1 program by the end of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 2, 2022,
Tiziana announced the completion of enrollment of the first patient cohort in its Intermediate Size Patient Population Expanded Access
Program to evaluate foralumab in non-active SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 10, 2022,
Tiziana announced its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS)
such as non-active SPMS, Alzheimer&#8217;s disease and amyotrophic lateral sclerosis (ALS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 23,2022,
Tiziana <span style="background-color: #FEFEFE">announced publication of a scientific article in the peer-reviewed journal&#160;<i>Frontiers
in Immunology</i>&#160;entitled &#8220;<b>Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function
and induces a regulatory response in T cells in human subjects&#8221;</b> . The study was completed by researchers at the Brigham and&#160;</span>Womens
Hospital<span style="background-color: #FEFEFE">&#160;(BWH) and&#160;</span>Harvard Medical School<span style="background-color: #FEFEFE">.
The goal of the study was to assess safety and the immune effects of an entirely human, previously uncharacterized nasal anti-CD3 mAb
(foralumab) in humans and it&#8217;s&#160;<i>in vitro</i>&#160;stimulatory properties. The findings support Tiziana&#8217;s intranasal
foralumab platform as a new modality for the treatment of autoimmune and CNS diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
January 3, 2023, Tiziana announced that the second patient (&#8220;EA2&#8221;) with na-SPMS receiving intranasal foralumab exhibited additional
clinical improvements since their last reported improvement in&#160;</span>September 2022<span style="background-color: #FEFEFE">. The
improvements were measured by EDSS. Before foralumab treatment, EA2&#8217;s non-active SPMS disability had progressed and EDSS worsened
from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy. Ocrelizumab was discontinued in 2021. At this point, EA2 required a cane
to walk 100 meters. EA2 was subsequently enrolled in the intranasal foralumab Expanded Access program in&#160;</span>January 2022<span style="background-color: #FEFEFE">.
In&#160;</span>September 2022<span style="background-color: #FEFEFE">, 8 months after starting treatment with nasal foralumab, EA2 was
able to walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2&#8217;s pyramidal score remained stable during this time.
In&#160;</span>December 2022<span style="background-color: #FEFEFE">, 11 months after starting treatment with intranasal foralumab, EA2
was able to walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to
5.0. EA2&#8217;s pyramidal score continued to remain stable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
March 8, 2023, Tiziana announced a publication in the preeminent<sup>1</sup>&#160;journal,&#160;<i>Proceedings of the&#160;National Academy
of Sciences</i>&#160;(PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
March 28, 2023, Tiziana announced it has received feedback based on the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with na-SPMS. Tiziana plans to accept
the FDA&#8217;s recommendations and intends to start a Phase 2 study in the third quarter of 2023.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
April 4, 2023, Tiziana announced pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral
hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month. The data showed that </span>modulation of
neuroinflammation by induction of FoxP3+ Tregs appeared to have beneficial effect in intracerebral hemorrhage. Dr. Saef Izzy<span style="background-color: #FEFEFE">&#160;presented
this data from the podium on&#160;</span>April 23, 2023 <span style="background-color: #FEFEFE">at the Neurocritical Care Scientific Platform
Session at the prestigious Annual&#160;</span>American Academy of Neurology<span style="background-color: #FEFEFE">&#160;(AAN) conference
in&#160;</span>Boston, MA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 13, 2023, Tiziana
<span style="background-color: #FEFEFE">announced it&#8217;s plans to investigate intranasal foralumab for the treatment of Long COVID.
The work is supported by foralumab&#8217;s well-established role in de-activating microglia cells, a key component in the pathogenesis
of this disease. The company intends to enter into a Phase 2a, placebo-controlled trial following positive feedback from the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 20,2023, Tiziana
<span style="background-color: #FEFEFE">announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate
Alzheimer&#8217;s Disease in Q2 2023. Tiziana is also seeking&#160;</span>$3,000,000<span style="background-color: #FEFEFE">&#160;in non-dilutive
funding from a prestigious Alzheimer&#8217;s foundation to support the Phase 2a trial. It is expected that this funding application will
receive a response in Q3 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
June 5, 2023, Tiziana announced 3-month PET scan results from the </span>first patient cohort in its Intermediate Size Patient Population
Expanded Access Program. Data showed a <span style="background-color: #FEFEFE">reduction in microglial activation in 3 out of 4 patients
confirming that previously reported in the first two EA patients. Overall, 5 of the 6 na-SPMS patients treated with intranasal foralumab
in its Expanded Access program have exhibited a reduction in microglial activation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
June 5, 2023, Tiziana announced 3-month PET scan results from the </span>first patient cohort in its Intermediate Size Patient Population
Expanded Access Program. Data showed a <span style="background-color: #FEFEFE">reduction in microglial activation in 3 out of 4 patients
confirming that previously reported in the first two EA patients. Overall, 5 of the 6 na-SPMS patients treated with intranasal foralumab
in its Expanded Access program have exhibited a reduction in microglial activation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
August 15, 2023, Tiziana announced that the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer&#8217;s disease. The clinical
trial will be overseen by Brigham and Women&#8217;s Hospital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
August 24, 2023, Tiziana announced an oral presentation by Howard Weiner, MD entitled &#8220;Nasal anti-CD3 mAb induces Tregs that dampen
microglial activation and treat neuroinflammatory diseases including MS, AD and ALS&#8221; at the 16<sup>th</sup>&#160;</span>International
Society of Neuroimmunology (ISNI) Congress<span style="background-color: #FEFEFE">&#160;in&#160;</span>Quebec City, Canada<span style="background-color: #FEFEFE">,
held&#160; on </span>August 21-24, 2023<span style="background-color: #FEFEFE">. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
September 6, 2023, Tiziana </span>announced acceptance of a publication entitled, &#8220;Nasal Administration of anti-CD3 monoclonal antibody
(mAb) ameliorates disease in a mouse model of Alzheimer&#8217;s disease&#8221;, in the journal,&#160;<i>Proceedings of the&#160;National
Academy of Sciences</i>&#160;(PNAS), validating foralumab&#8217;s mechanism of action (MOA) as a potential treatment for Alzheimer&#8217;s
disease (AD), a difficult-to-treat neuroinflammatory disease.&#160; This was the second publication pertaining to intranasal administration
of anti-CD3 monoclonal antibody in 2023 to be published in PNAS. This study shows that intranasal anti-CD3 ameliorates disease in a rodent
model of AD by targeting microglial activation in the brain and brain gene expression independent of affecting amyloid beta deposition.
These studies identify a novel approach to treat Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">On September 26, 2023,
Tiziana announced initiation of the Phase 2a multicenter clinical trial for treatment of non-active Secondary Progressive Multiple Sclerosis
(na-SPMS) patients with intranasal foralumab. Tiziana <span style="background-color: #FEFEFE">announced that it held an Investigator&#8217;s
Meeting with principal investigators at Brigham and Women&#8217;s Hospital to begin site initiation for the clinical trial. In total,
six to ten new clinical trial sites will be recruited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
October 11, 2023, Tiziana announced a late breaking poster entitled, &#8220;Treatment Of Six Non-Active Secondary Progressive MS With
Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes&#8221;, that was presented at the 39th&#160;</span>Congress<span style="background-color: #FEFEFE">&#160;of
the&#160;</span>European Committee for Treatment<span style="background-color: #FEFEFE">&#160;and Research of Multiple Sclerosis (ECTRIMS)
held in&#160;</span>Milan, Italy<span style="background-color: #FEFEFE">,&#160;</span>October 11-13, 2023<span style="background-color: #FEFEFE">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
October 13, 2023, Tiziana announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans,
was observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis treated with intranasal foralumab
in its Expanded Access Program (EAP). Activated microglia play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative
diseases including multiple sclerosis, Alzheimer&#8217;s disease, and amyotrophic lateral sclerosis, or ALS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
October 16, 2023, Tizana announced</span> six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale
(MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple
Sclerosis patients participating in an Expanded Access (EA) Program.&#160;&#160; This follows on from previously announced positive six-month
PET scan data which was presented at ECTRIMS 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">The findings, which are summarized in Table
1 below, show broad-based six-month improvements across various key measures for multiple sclerosis. Secondary progressive multiple sclerosis
is hallmarked by an increase of disability over time. The table below shows a stabilization or an improvement in physical function of
the various clinical measures over a six-month period. <span style="background-color: #FEFEFE">Various degrees of improvement were also
observed in the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk Test (T25FW), pyramidal function scores and NeuroQoL Fatigue
scores in a disease state that typically shows a decline in function over time.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><b>Table 1. Six Month Test Scores in Expanded
Access na-SPMS Patients</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">EA Patient</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">EDSS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pyramidal<br/> score</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">T25FW</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">MFIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left">EA1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="width: 9%; font-weight: bold; text-align: center">&#8212;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="width: 9%; font-weight: bold; text-align: center">&#8212;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="width: 9%; font-weight: bold; text-align: center">&#8212;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA2</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EA3</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA4</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EA5</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8595;</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>&#8212;</b></td><td style="text-align: justify">Denotes stabilization</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#8595;</td><td style="text-align: justify">Denotes improvement</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Fatigue, as measured above in MFIS, refers
to an overwhelming sense of physical, mental, and emotional exhaustion that is disproportionate to the level of activity or effort exerted.
It is a major, common, and often debilitating symptom experienced by many individuals with MS. It differs from the typical tiredness that
everyone experiences from time to time. In the context of MS, it is called &#8216;primary fatigue&#8217; and is a direct result of damage
to the central nervous system. This kind of fatigue can significantly impact a person&#8217;s daily life and functioning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">On October 18, 2023,
Tiziana announced that <span style="background-color: #FEFEFE">the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
had allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab. Delivery Device Training materials have
been developed and refined in collaboration with the FDA, and patients trained in the use of the nasal device in accordance with these
materials. Patients in the Expanded Access program that have been exposed to intranasal foralumab for more than</span> 1 year have demonstrated
acceptable tolerability and safety. At-Home Dosing is likely to Improve patient compliance to treatment and outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
November 1, 2023, Tiziana announced that Chief Operating Officer and Chief Medical Officer,&#160;</span>Matthew Davis<span style="background-color: #FEFEFE">,
MD, RPh, will present at BIO-Europe,&#160;</span>Munich, Germany<span style="background-color: #FEFEFE">,&#160;</span>November 6-8, 2023<span style="background-color: #FEFEFE">.
The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, for the treatment of non-active secondary
progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer&#8217;s. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">On November 20, 2023,
Tiziana announced <span style="background-color: #FEFEFE">that the company had successfully enrolled and dosed four new patients with
non-active secondary progressive multiple sclerosis in the Brigham and Women&#8217;s Hospital&#8217;s Expanded Access pgrogam. A total
of ten patients are now being followed in the EA Program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">On December 19, 2023,
Tiziana announced <span style="background-color: #FEFEFE">&#8220;first patient dosed&#8221; in its Phase 2a study comparing two doses
of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis.&#160;&#160; Six investigational
centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint
of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status
Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient&#8217;s
everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images
is an integral component of this study.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">The
Company plans to continue treatment of EA SPMS patients at Brigham and Women&#8217;s Hospital and continue evaluation of foralumab treatment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase 2a Clinical Trial of Nasally-Administered
Foralumab for Treatment of Secondary Progressive Multiple Sclerosis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A multisite Phase 2a study
evaluating intranasal foralumab for treatment of SPMS was initiated on September 26, 2023 by holding the first investigator&#8217;s meeting.
This is a double-blinded, placebo-controlled study of two (2) doses of foralumab nasal solution (50 &#181;g and 100 &#181;g) delivered
intranasally compared to placebo, administered in non-active secondary progressive MS patients who are continuing to deteriorate despite
standard of care therapy. The first patient was dosed on December 19, 2023. Topline results are anticipated by Q4 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><b><i>Earlier Phase
1 and 2 Studies Conducted by Novimmune with Intravenous Administration of Foralumab</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intravenous Foralumab has
been studied in a total of three Phase 1 and Phase 2 clinical trials conducted by Novimmune. A total of 68 patients were exposed to Foralumab:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Study NI-0401-01:</b> a
Phase 1/2a randomized, double-blind, placebo-controlled and dose escalation study NI-0401-01 in subjects with moderate to severe active
CD. The study was completed and 33 subjects were exposed to Foralumab. The study NI-0401-01 was designed to assess tolerability of Foralumab
and was not powered to evaluate efficacy parameters included the proportion of patients achieving, clinical response and change from baseline
of Crohn&#8217;s Disease Endoscopy Index of Severity. A trend, although not statistically significant, was seen when analyzing the clinical
response and endoscopic response. Single and repeat intravenous doses of 0.05, 0.1, 0.5, 1.0, 2.0 and 10.0 mg Foralumab were administered
to subjects and serum pharmacokinetics evaluated for up to five days. Limited pharmacokinetic data was collected, however it was observed
that at doses over 1.0 mg, severe infusion related reactions (IRRs) were observed that led to discontinuation of the 2 and 10 mg groups.
Therefore, the 1.0 mg dose was considered the MTD in this study. CD3 modulation on CD4 positive and CD8 positive T cells was related to
Foralumab dose. There was a dose response for the reduction of peripheral T-cell (CD2 positive) count. The main adverse events were infusion
related reactions related to the route of administration of the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <b>Study NI-0401-02:</b> an open-label, dose titration, multicenter Phase 1 study of Foralumab for the treatment of subjects with biopsy-proven acute cellular renal allograft rejection (BpACR). The study was completed and 11 subjects were exposed to Foralumab. Patients were dosed with 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg of Foralumab daily for five days and most were pre-treated with methylprednisolone. The data from study NI-0401-02 has confirmed the dose response in terms of CD3 modulation and reduction of peripheral T-cell count. A CD3 modulation of up to 90% was achieved at study NI-0401-02 day five with a daily dose of 2.5 mg during the 5 days of treatment period. Although there was no dose-response relationship, treatment with foralumab seems to be globally effective to reverse protocol defined acute cellular rejection and in the mormalization of serum creatinine levels, a primary efficacy objective. The main adverse events were infusion related reactions in patients that were not premedication with prednisolone.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Study NI-0401-03:</b> a
Phase 2a study with an open label dose escalation phase followed by a double-blind phase to assess safety and efficacy of Foralumab in
subjects with moderate to severe active CD. The study NI-0401-03 was completed and 24 subjects were exposed to Foralumab. 74% of patients
had achieved a clinical response at week 2 and 87% of patients at week 4. At weeks 6, 8 and 12 the proportion of patients with a clinical
response decreased to 75%, 70% and 67%, respectively. 30% of patients had achieved clinical remission at week 2, 42% by weeks 4, 38% by
week 6, 43% at week 8 and 46% at week 12. Treatment failures were 12.5%. There was a reduction in the mean Crohn&#8217;s Disease Activity
Index (CDAI) scores in all treatment cohorts and an overall improvement in the Crohn&#8217;s Disease Endoscopic Index of Severity (CDEIS)
scores across all treatment groups following 5 daily doses of Foralumab treatment. Pharmacokinetic evaluations were performed, and no
dose-response relationship was established due to variability between patients. The observed half-life of Foralumab was approximately
180 hours. A rapid and almost complete disappearance of CD45 positive lymphocytes, CD3 positive T-cells, CD3 positive and CD4 positive
helper T-cells and CD3 positive and CD8 positive cytotoxic T-cells from the circulation was observed was observed within 24 hours of infusion
for all dose cohorts. The lowest unit dose in the study NI-0401-03 was equivalent to the 1 mg daily unit dose that was the maximum tolerated
dose in study NI-0401-01. Pre-medication with prednisolone reduced the severity and frequency of infusion related reactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In two Phase 2a trials conducted
by Novimmune, patients with Crohn&#8217;s disease and renal allograft rejection in kidney transplants demonstrated Foralumab&#8217;s immunomodulatory
activity in humans. We have decided not to pursue evaluation of intravenous Foralumab in Crohn&#8217;s Disease because we believe the
market for this disease is saturated by other FDA approved drugs. Further, while intravenous administration of antibodies has been widely
used, side effects from the intravenous administration still are prevalent as well as patient compliant issues come into play. We intend
to move forward with an oral formulation of Foralumab for treatment of Crohn&#8217;s disease at a later date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two of Novimmune&#8217;s clinical
trials were in patients with Crohn&#8217;s disease and the third clinical trial was conducted in patients undergoing kidney transplantation
and suffering with renal allograft rejection. Sixty-eight subjects with active Crohn&#8217;s disease and 11 subjects with acute cellular
renal allograft rejection were treated with Foralumab. The route of administration of Foralumab in these studies was via intravenous administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In these trials, it was observed
that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The short-term tolerability profile of Foralumab was very similar to those reported with other anti CD3 antibodies and no new emerging concerns have been identified.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Total daily doses of up to 1mg
(~ 500 &#181;g/m2) per patient were generally well tolerated without corticosteroid premedication. The most common adverse events following
exposure to Foralumab were IRRs, which occurred in all patients treated with the compound. In the majority of cases, these symptoms were
mild (66%) in intensity and were reported following the first two infusions of the 5-infusion treatment course. The number of affected
patients and the severity of symptoms tended to increase with increasing dose level, or DL.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A clear reduction of CRS and
its associated IRRs were observed with steroid pre-medication. All patients who received pre-medication with steroids had mild or no
IRRs, and CRS was reduced. Only one patient who did not receive steroid pre-medication had significant levels of CRS, in particularly
IL-6.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Usage of steroid pre-medication
allows the administration of higher doses.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Both the magnitude and duration
of CD3 modulation increased in a dose related manner.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">No anti-drug antibodies were
detected.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Prior Clinical Experience</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Oral anti-CD3 antibodies,
as opposed to the narrow therapeutic window of its intravenous counterpart, have been shown to impact the gut immune system and mesenteric
lymph nodes, thereby promoting regulatory T-cells activity, without inducing immunosuppression. The treatment alleviated experimental
autoimmune encephalitis and T1D mellitus, which was associated with regulatory T-cells induction. Orally and nasally administered anti-CD3
suppressed autoantibody production in a mouse lupus model. Oral anti-CD3 yielded reduced pancreatic hyperplasia, hepatic fat accumulation
and muscle inflammation in a leptin-deficient model of NASH and diabetes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Pharmacology Summary (In Vitro Studies)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key conclusions arising
from the non-clinical studies of Foralumab by Novimmune are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Foralumab is a specific anti-CD3
epsilon mAb, as it binds to human T-cells and the recombinant human CD3 epsilon chain, and can be displaced by another specific anti-CD3
epsilon mAb, muromonab CD3.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">When bound to its target, Foralumab
triggers calcium flux into the cell and modulates the CD3/TCR complex causing its&#8217; transient removal from the cell surface.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The combination of the two-point
mutations introduced into the Fc portion (the constant region of the antibody that has limited structural variability and is responsible
for adverse side effects) of Foralumab, resulting in the abrogation of the binding to Fc gamma receptors, and C1q, consequently eliminates
T-cell proliferation and the release of numerous cytokines including TNF, and interferon gamma, or IFN&#947; <i>in vitro</i>.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Foralumab does not cross react
with CD3 molecules expressed by T-cells of other species including baboon, <i>Rhesus </i>monkey, <i>Cynomolgus </i>monkey, rabbit, dog,
rat and mouse. As a consequence, options for the most relevant species selection for pharmacology and toxicology assessment of Foralumab
are limited. Novimmune addressed this limitation by studying LCD3 transgenic mice. This transgenic mouse line expresses the human as
well as the mouse CD3 epsilon chain on the surface of their T-cells.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Using a transgenic line of mice
expressing both human and mouse CD3 molecules (1:1 ratio) at the surface of T-cell (LCD3<i>), </i>following a single intravenous injection,
Foralumab dose dependently:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Modifies human CD3 epsilon expression;
that is, more than 80% of the cell surface protein was removed within 24 hours when given at a saturating dose. This modulation was transient
as receptor expression levels returned to baseline values within 7 days of dosing.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Caused a reduction of 70-80%
in the number of circulating T-cells when given at a saturating dose. The maximal effect was observed at hour 6 post dose. Cell counts
returned to baseline levels within 3.5 days.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Demonstrated a half-life of
1.4 and 1.7 days for doses of 5 and 200 &#181;g per mouse, respectively. This seemingly short half-life is similar to that observed
in vivo for other anti-CD3 mAbs and reflects internalization of Foralumab by the human CD3 molecule on the T-cells of these transgenic
mice. It was therefore expected that Foralumab will be internalized by human T-cells in patients and consequently have a half-life comparable
to other therapeutic anti-CD3 mAbs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Safety Toxicology Studies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana conducted Intranasal
and Subcutaneous Safety Toxicology Studies in HuGEMM Transgenic Mice Expressing human CD3 and mouse CD3 molecules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Study 700656 14 Days Intranasal
Dosing Duration/7 days Recovery</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three times/week intranasal
dosing of 1, 10 and 50 &#181;g foralumab /animal</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">There were no test item related
mortalities during the course of the study.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The three times weekly intranasal
instillation of Foralumab at doses of up to 50 &#181;g of Foralumab/animal were well tolerated. There were no foralumab related changes
in clinical signs, body weights, hematology or clinical pathology.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Intranasal instillation of a
high dose (50 &#181;g) of Foralumab promoted a neat depletion of the mCD3/hCD3 coexpressing T lymphocyte compartment, including the
mCD3<sup>+</sup>hCD3<sup>+</sup>mCD4<sup>+ </sup>and mCD3<sup>+</sup>hCD3<sup>+</sup>mCD8<sup>+</sup> subsets.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Study 700800 13 Weeks Dosing
Duration/8 weeks Recovery</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three times/week intranasal
dosing of 1, 10 and 50 &#181;g foralumab /animal</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">There were no test item related
mortalities during the course of the study.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">There were no Foralumab related
changes in clinical signs, body weights, hematology or clinical pathology.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Intranasal instillation of Foralumab
to mouse three times weekly for 13 weeks was well tolerated at dose levels up to 50 &#956;g/dose and did not produce Foralumab-related
macroscopic or microscopic pathology findings</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The no-observed-adverse-effect
level (NOAEL) is considered to be 50 &#956;g/animal (equivalent to a 10 mg dose administered to a 60 kg adult human).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Study 700657 26 Weeks Dosing
Duration/8 weeks Recovery</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">Three</td><td style="text-align: justify">times/week intranasal dosing of 1, 10 and 50 &#181;g Foralumab
/animal</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no Foralumab related mortalities. All deaths observed were unrelated to the administration of Foralumab.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no Foralumab related clinical sign, change in body weight, body temperature, ophthalmology parameters, clinical pathology parameters (hematology, coagulation, and clinical chemistry), organ weight, or functional observational battery finding.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over the dose range, exposure to Foralumab (based on maximum mean AUC0-Tlast values) on Days 1 and 29 generally increased dose dependently but not consistently in a dose-proportional manner.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Foralumab sex ratios based on maximum mean AUC0-Tlast (male vs female), on Days 1 and 29, ranged between 0.3 and 2.2 and were not consistent with sex-related differences in exposure. Other TK parameter ratios were consistent with no sex-related differences in Foralumab exposures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In animals surviving to scheduled termination, there was no Foralumab-related pathological finding at doses up to 50 &#181;g Foralumab/animal.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal instillation of Foralumab to mice three times weekly for 26 weeks was well tolerated at dose levels up to 50 &#181;g Foralumab/animal and did not produce any signs of toxicity.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Study 700680 14 Days Subcutaneous
Dosing Duration/7 days Recovery</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once daily subcutaneous dosing
of 5, 15 and 50 &#181;g Foralumab /animal</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">There was no evidence of local
(subcutaneous injection site) or systemic toxicity.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The administration at 50 &#181;g/animal
of Foralumab promoted a neat reduction of the mCD45<sup>+</sup>mCD3/hCD3 co-expressing T lymphocyte compartment, especially in the mCD3<sup>+</sup>hCD3<sup>+</sup>mCD8<sup>+
</sup>subset. Meanwhile, the number of mCD45<sup>+</sup>mCD3<sup>+</sup>hCD3<sup>-</sup> cells increased including the mCD3<sup>+</sup>hCD3<sup>-</sup>mCD4<sup>+
</sup>and mCD3<sup>+</sup>hCD3<sup>-</sup>mCD8<sup>+ </sup>subsets</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The no observable adverse effect
level (NOAEL) was determined to be 50 &#181;g/animal based on parameters monitored on the study.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Study 700681 28 Days Subcutaneoous
Dosing Duration/28 days Recovery</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three times/week intranasal
dosing of 1, 10 and 50 &#181;g Foralumab /animal</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The three times weekly (Day
1, 3 and 5 of the week) administration of Foralumab for 4 consecutive weeks by subcutaneous injection at doses of 5, 15 and 50 &#181;g/animal/dose
to HuGEMM mice was well-tolerated.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">There was no evidence of local
(subcutaneous injection site) or systemic toxicity.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The administration of Foralumab
promoted the decrease of mCD3/hCD3 co-expressing T cells and subsets in a dose-independent manner.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The no observable adverse effect
level (NOAEL) was determined to be 50 &#181;g/animal/dose based on parameters monitored on the study.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Milciclib (TZLS-201)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Milciclib is an orally bioavailable,
small molecule broad spectrum inhibitor of CDKs (CDKs): 1, 2, 4, 5 and 7 and Src family kinases. CDKs are a family of highly conserved
enzymes that are involved in regulating the cell cycle, which is a series of events that takes place in cells leading to division and
duplication of its DNA to produce two daughter cells. Src family kinases regulate cell growth and potential transformation of normal cells
to cancer cells. A novel feature of Milciclib is its ability to reduce microRNAs, miR-221 and miR-222, that silence gene expression. miR-221
and miR-222 promote the formation of blood vessels (angiogenesis) that are important for spread of cancer cells (metastasis). Levels of
these microRNAs are consistently increased in HCC patients and may contribute towards resistance to treatment with Sorafenib. As a result,
we are investigating Milciclib both as a monotherapy and plan a combination treatment with Sorafenib. To date, Milciclib has been studied
in a total of eight completed and ongoing Phase 1 and Phase 2 clinical trials in 316 patients. In these trials, Milciclib was observed
to be well-tolerated and showed initial signals of anti-tumor action. A Phase 2a trial (CDKO-125a-010) for Milciclib as a single therapy
in patients with HCC was completed in June 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Hepatocellular Cancer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana plans to conduct a
Phase 2 study combination therapy of milciclib and gemcitabine in Non-Small Cell Lung Cancer (NSCLC) patients with a broad-spectrum of
KRAS mutations (except G12C mutation) after failure of at least one line of standard-of-care (SoC) therapy. NSCLC is the most common type
of lung cancer, occurring in approximately 80% of patients. Due to the asymptomatic nature of early disease, many patients are diagnosed
with later stages of disease, and typically have short overall survival. In the United States, at initial diagnosis of NSCLC, approximately
55% of patients have distant metastases with a 5-year survival rate of 7%, despite the recent development of novel anticancer therapies
and regimens. The results of clinical trials with sotorasib (Lumakras&#8482;) demonstrated that selective targeting of a single KRAS mutation
is a promising therapeutic strategy. Although there is a clear benefit to target KRAS directly, KRAS represents a challenging molecular
target due to the lack of suitable drug pockets where a small molecule can bind. An alternative approach is to target downstream signaling
pathways. The rationale for evaluation of milciclib in combination with gemcitabine is suggested by preclinical studies conducted on a
non-small cell lung xenograft model that demonstrated the efficacy of milciclib in terms of antitumor activity, both as a single agent
and in combination with gemcitabine, at well tolerated doses. Given that gemcitabine is used for treatment of both pancreatic cancer (for
which gemcitabine is the standard therapy) and NSCLC (for which gemcitabine is used in combination with cisplatin), an evaluation of the
feasibility of the combination of milciclib and gemcitabine is considered appropriate in view of future uses in these diseases. In addition,
the 2 compounds showed non-overlapping toxicities when administered as single agents, providing an additional rationale for their evaluation
in combined treatment in the clinical setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, in the Phase
1 CDKO-125a-004 study, 16 patients were treated with milciclib at 3 dose levels administered once daily for 7 days, followed by 7 days
off treatment in a 4-week cycle and with a fixed dose of gemcitabine administered intravenously on Days 1, 8, and 15 in a 4-week cycle1,
Overall, the combination was well tolerated and showed clinical benefit with 1 PR and 10 patients with SD. The PR was documented in a
patient with NSCLC whose disease was refractory to gemcitabine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Data</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Milciclib has been studied
in a total of eight completed Phase 1 and Phase 2 clinical trials in approximately 316 patients. Milciclib was observed to be well tolerated
by patients with thymoma in Phase 1 and Phase 2 clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase 1 Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Milciclib has been investigated
in each of the below, open-label, multi-center, non-randomized, dose-escalation Phase 1 clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 14%"><span style="font-size: 10pt"><b>Trial</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Patient Population</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Treatment&#160;Schedule&#160;/&#160;Dosing</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-size: 10pt"><b>Key Findings</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">CDKO-125a-001</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced/metastatic solid tumors</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">37 patients</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1st Schedule: Orally, once daily</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">for 7 consecutive days every 14 days in a 2-week
    cycle at escalating doses of 50, 100, 150, 200 and 300 mg</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2nd Schedule: Orally, once daily for 4 consecutive
    days a week for 3 weeks in a 4-week cycle at escalating doses of 150, 180 and 200 mg</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacokinetics:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparable plasma pharmacokinetic parameters between
    the two schedules were observed.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exposure to Milciclib increased with the dose
    and there was a 3-fold accumulation in the daily systemic exposure after repeated dosing, in good agreement with expectations on the basis
    of the half-life of the compound (24-43 h).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">No objective responses were
    achieved on 1st schedule; Disease stabilizations, defined as cancer disease that is neither increasing nor decreasing in extent or severity,
    was observed in 6 of 14 evaluable patients (42.9%).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A partial response, or PR, was achieved in 2 out
    of 14 evaluable patients (14.3%) on 2nd schedule; Disease stabilization (no change in extent or severity of disease state) was reported
    in 3 patients (21.4%), all treated at 180 mg/day DL, including a stabilization lasting 31 weeks in a patient with pancreatic cancer and
    stable disease, or SD, lasting 29 weeks in a patient with carcinoid.</p></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">CDKO-125a-002</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recurrent malignant glioma 28 patients (Phase 1)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">34 patients (Phase 2)</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Escalating oral doses of 18, 36, 54 and 72 mg/m2
    once a day for 14 consecutive days followed by 7 days of rest in a 3-week cycle</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">54 mg/m2 (RP2D)</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacokinetics:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results indicated that the pharmacokinetics of
    Milciclib was dose-independent in the dose range 18</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8211; 72 mg/m2.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Systemic exposure values of Milciclib maleate accumulated by a factor of 3</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase 1: No evidence of clinical effect was observed
    in all the 28 treated patients. However 5 patients seemed to have benefitted from therapy with SD observed (no change in extent or severity
    of cancer).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase 2: One out of 34 patients achieved the primary
    endpoint. PFS at 6 months or PFS-6 rate was 2.9%. No complete response, or CR (disappearance of all signs of cancer in response to treatment)
    or PR (decrease in tumor size or extent of cancer in the body) were reported. 4 patients showed SD as best overall response (11.8%). Prolonged
    SD (&#8805; 6 months) was observed in one patient whose SD lasted for 24.9 months.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 14%"><span style="font-size: 10pt"><b>Trial</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Patient Population</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Treatment&#160;Schedule&#160;/&#160;Dosing</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-size: 10pt"><b>Key Findings</b></span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Safety:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">34 patients were enrolled and treated: 29 patients
    of non-Enzyme Inducing Anti-Epileptic Drugs, or non-EIAED, population and 5 of EIAEDs population. The primary clinical endpoint was not
    met. Only one patient (non-EIAEDs) achieved the study primary endpoint out of 34 treated patients. PFS-6 rate evaluated in the treated
    patients was 2.9% (95% CI, 0.07-15.33). No CR or PR was reported; 4 patients in the treated patients showed SD as best overall response
    on treatment (11.8%). Prolonged SDs (&#8805;6 months) was observed in one patient whose SD lasted for 24.9 months. Median OS in treated patients
    was 7.03 months (95% CI, 5.72-10.58). The exploration of the role play by potential prognostic factors, such as Karnofsky&#160;Performance
    Scale&#160;(&#8805;90 vs. &lt;90), age (&lt;40 vs. &#8805;40) and interval between initial diagnosis and current recurrence (&#8805;52 weeks vs.
    &lt;52 weeks) indicated a better survival outcome for patients whose interval between initial diagnosis and current recurrence was (&#8805;52
    weeks). Given the non-comparative nature of the study, it cannot be said whether the treatment played any role in this result.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The influence of other factors cannot be excluded
    but was not apparent in the current sample.</p></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">CDKO-125a-003</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced/metastatic solid tumors</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">30 patients</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1st Schedule: Orally, once daily for 21 consecutive
    days followed by 7 days of rest in a 4-week cycle at escalating doses of 16 and 24 mg/m2</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2nd Schedule: Orally, once daily for 14 consecutive
    days followed by 7 days of rest in a 3-week cycle at escalating doses of 24, 48, 54 and 72 mg/m2</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacokinetics:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No differences in the pharmacokinetics were observed
    between the two schedules after both single and repeated dosing.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The systemic exposure to Milciclib (amount of
    Milciclib available systemically in the patient) increased with dose in terms of both Cmax (maximum concentration of Milciclib in plasma)
    and daily Area Under the Plasma Drug Concentration, or AUC, vs Time Curve, a measure of drug bioavailability without deviations from dose-proportionality
    (plasma concentration changes in a linear relationship to amount of drug dosed).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After repeated administrations, Milciclib Cmax
    and AUC accumulated by a factor of 2-4, independent of the dose-level.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No objective (measurable) responses were achieved.
    SDs were reported in 5 out of 16 evaluable patients (31.3%), starting from the dose of 48 mg/m2/day. One disease stabilization maintained
    for 12 cycles (10.5 months) at 48 mg/m2/day, was achieved in a parotid gland patient.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Phase 2 Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 14%"><span style="font-size: 10pt"><b>Trial</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Patient Population</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Treatment&#160;Schedule&#160;/&#160;Dosing</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-size: 10pt"><b>Key Findings</b></span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">CDKO-125a-004</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced/metastatic solid tumors</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16 patients</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Orally administered at 45, 60 and 80 mg/m2 once daily for 7 days on / 7 days off (Days 1 to 7 and 15 to 21) in a 4-week cycle in combination with fixed dose of IV gemcitabine (1000 mg/m2/day) on Days 1, 8, 15 over 30 minutes every 4 weeks</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacokinetics:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmacokinetic parameters (Cmax, AUC) of Milciclib
    after Milciclib maleate/ gemcitabine combination were consistent with those previously observed after Milciclib maleate administration
    as single agent, suggesting no influence of gemcitabine on the pharmacokinetics of the compound.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One PR in 14 evaluable patients (7.1%) and one
    SD in 10 patients (71.4%).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disease stabilizations lasting z 6 months were
    recorded in 4 cases (28.6%) in thyroid, prostatic, pancreatic carcinoma and peritoneal mesothelioma, in 2 of them lasting 13.4 months
    (peritoneal mesothelioma) and 14.3 months (prostate cancer).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PR and 3 of the 4 long lasting disease stabilizations
    were obtained at the recommended Phase 2 dose (RP2D) of 80 mg/m2/day plus 1000 mg/m2/day gemcitabine, supporting development of combination
    therapies with Milciclib in advanced cancer patients.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results of trial CDKO-125a-004 were published:
    S. Aspeslagh et.al. Cancer Chemother. Pharmacol (2017) 79: 1257-1265</p></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">CDKO-125a-005</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Malignant pleural mesothelioma</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">38 patients</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">150 mg/day orally administered for 7 consecutive days every 14 days in 2-week cycles</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacokinetics:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Plasma levels of Milciclib were comparable to
    those previously obtained in the Phase 1 study CDK0-125a-001 at the same dosage and with the same schedule, confirming the reliability
    of the pharmacokinetic profile of the compound.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No objective responses were reported; prolonged
    SDs were observed in 2 patients, lasting 8.9 months and 8.7 months, respectively.</p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CDKO-125a-006</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trial cutoff: 1/9/2017</p></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Malignant B3 thymoma / thymic carcinoma 72 patients</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Single agent (flat dose)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 mg once daily 7days on/7days off q2wks</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment with Milciclib met the primary endpoint
    of PFS at 3 months (PFS-3). 56 of 72 treated patients had median PFS of 5.78 months with upper and lower 95% confidence limits of 3.48
    months and 7.89 months, respectively. The secondary endpoint, OS, was also met in this trial. 36 of 72 patients (50%) had median OS of
    24.44 months with upper and lower 95% confidence limits of 22.05 and 54.55 months, respectively. Five patients from this study are continuing
    treatment with Milciclib.</p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CDKO-125a-007</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trial cutoff: 1/9/2017</p></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Malignant B3 thymoma / thymic carcinoma 30 patients</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Single agent (flat dose) 150 mg once daily 7days on/7days off q2wks</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Observations:</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment with Milciclib met the primary endpoint
    of PFS-3. 18 of 30 patients had median PFS of 5.65 months with upper and lower 95% confidence limits of 3.94 months and 17.45 months,
    respectively. The secondary endpoint, OS, was met in this trial. 18 of 30 treated patients (54.5%) had OS of 48 months. Upper and lower
    95% confidence limits could not be calculated because the median survival probability was not reached.</p></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Trial</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Patient Population</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Treatment&#160;Schedule&#160;/&#160;Dosing</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Key Findings</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 14%; text-align: justify"><span style="font-size: 10pt">CDKO-125a-010</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 15%"><span style="font-size: 10pt">Recurrent or metastatic unresectable HCC</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 28%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Single agent (flat dose)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 mg once daily</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4days on/3days off x 4 wks q4 wks</p></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 37%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The trial successfully
    met the primary endpoint that oral treatment with Milciclib was well tolerated with manageable toxicities and no recorded drug related
    deaths.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#9679;&#160;&#160;The
    secondary endpoints for clinical activity assessment were based on the independent radiological review using the modified Response Evaluation
    Criteria in Solid Tumors (mRECIST)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#9679;&#160;&#160;Positive
    demonstrated clinical activity included:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">1.&#160;&#160;&#160;50%
    (14 out of 28) evaluable patients completed 6-month duration of the trial.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">2.&#160;&#160;&#160;64%
    (9 out of 14) patients requested and were approved by their respective ethical committees to continue the treatment.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">3.&#160;&#160;&#160;Both
    median time to progression (TTP) and progression free survival (PFS) were 5.9 months (95% Confidence Interval (&#8220;CI&#8221;) 1.5-6.7
    months) out of the 6-months duration of the trial.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">4.&#160;&#160;&#160;Approximately
    57% of evaluable patients showed &#8217;Stable Disease&#8217; (SD; met at least once in an 8-week interval) and 3.6% patients showed &#8216;Partial
    Response&#8217; (PR).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">5.&#160;&#160;&#160;Approximately
    61% of patients showed &#8216;Clinical Benefit Rate&#8217; defined as CBR=CR+PR+SD (with CR representing Complete Remission).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify; text-indent: -0.2in; background-color: #FEFEFE">6.&#160;&#160;&#160;Five
    patients on compassionate use continued the treatment for a total of 9, 9, 11, 13 and 16 months, respectively. Two patients continuing
    the treatment have reached 16 months.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Source: Milciclib Investigators Brochure version 14</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Safety</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Overall, Milciclib has indicated
a similar pattern of toxicity across studies. Consistent with preclinical findings, the safety profile of the compound in humans is characterized
by a dose-limiting neurological toxicity and, to a lesser extent, by GI toxicity. Asthenia (weakness) and fatigue have also been observed,
as well as effects on liver, especially with prolonged schedules of administration. Mild/moderate tremors are a common finding, reported
also at recommended Phase 2 doses (RP2Ds) (only one case of grade 3), whereas ataxia (loss of muscle control and balance) was observed
primarily during the first dose-escalation study (one case of grade 3 ataxia occurred also at the RP2D in the combination study CDKO-125a-004
and one in CDKO-125a-006 trial). Both tremor and ataxia were generally reversible in all cases in up to 7-9 days, upon drug discontinuation
or dose reduction in some cases. Grade 1-2 dizziness was also reported, with only one grade 3 occurrence, overall. Mild dysgeusia (disorder
of sense of taste) is another event that was reported across studies, as well as headache and anorexia (loss of appetite). Grade 3 myasthenia
(muscle weakness) was also reported in two patients. Nausea and/or vomiting and/or diarrhea were mostly of grade 1-2 in severity and were
manageable with appropriate therapy. Diarrhea was occasionally severe, leading to dehydration in several instances. Skin disorders were
also reported across studies; the events were mainly of grade 1-2 in severity except for one case of grade 3 rash maculopapular and one
case grade 3 of erythema multiforme. Hematological toxicity was mainly represented by lymphocytes (white blood cells) decrease and, to
a lesser extent by all the other hematological parameters. Severe thrombocytopenia (decrease in number of platelets in blood) was sporadically
observed, especially at the highest doses tested and in combination with gemcitabine. Effects on liver were dose-dependent and mainly
represented by transient transaminase elevation (with bilirubin slightly less affected). ALT/AST (liver enzymes measured to monitor liver
damage) elevations were usually mild using the 7 days on / 7 days off schedule (even if prolonged transaminases (liver enzymes) were occasionally
observed). The more prolonged administrations were associated with a more frequent and pronounced effect on liver function tests. Asymptomatic
grade 3-4 lipase (a pancreatic enzyme that breaks down fats, measured to monitor pancreatic function) elevations were sometimes reported,
without clinical manifestation. No important effects on renal function were noted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Monitoring of visual function
was performed through visual acuity, funduscopy (ophthalmic examination of the back of the eye) and, in a subset of studies, electroretinography
examinations, or ERG. Overall, no clinically relevant abnormalities for these parameters emerged during treatment across studies, except
for ERG worsening, compared to baseline, observed in three patients, who for this reason discontinued study treatment as per protocol,
and one case of retinal detachment reported as a serious event in one patient (CDKO-125a-006 trial) and assessed as probably related to
Milciclib maleate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our interim review in trial
CDKD-125A-010, as noted above, found Milciclib to be well-tolerated with no drug-related serious adverse events in 6 patients with unresectable
or metastatic HCC who had concluded a first cycle of treatment with Milciclib.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Preclinical Data</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmacokinetics of Milciclib
were investigated in mouse, rat, dog and monkey models after single intravenous and oral administration of the compound. Since the compound
is intended for the oral administration route, the pharmacokinetics were further characterized after single and repeated oral administrations.
These preclinical studies were performed with Milciclib formulated as maleate or mono/di/tri-hydrochloride salt. Following intravenous
administration, Milciclib was characterized by a moderate clearance in mice, rats and monkeys and a high clearance in dogs. The volume
of distribution was higher than the total body water in all tested species, suggesting an extensive tissue distribution. Following oral
administration to rats and monkeys, Milciclib crossed the blood-brain barrier and distributed in the brain. In all species, Milciclib
plasma levels increased largely in direct proportion with the dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical toxicology studies
conducted with Milciclib have shown that the hemolymphopoietic system, the GI tract and the male reproductive organs are the major target
organs considered related to the pharmacological activity of the compound in all species. The effects on the hemolymphopoietic system
and GI tract were reversible after drug withdrawal. Reversibility could not be demonstrated in the male reproductive organs at the end
of the 2-3-week recovery period because of the longtime of maturation of the seminiferous epithelium. Additional toxicities, that are
considered not related to the mechanism of action of the compound, were Central Nervous System, or CNS, ocular and renal toxicities. In
addition, hemorrhages in different organs were observed in dogs and monkeys. Clinical signs of CNS toxicity were observed at high doses
given as single or repeated administrations in all species.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Anti-IL6R Fully Human mAb TZLS-501 (formerly known as NI-1201)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TZLS-501 is a fully human
mAb targeting the IL-6R. We licensed the intellectual property from Novimmune in January 2017. This fully human mAb has a novel mechanism
of action, binding to both the membrane-bound and soluble forms of the IL-6R and depleting circulating levels of the IL-6 in the blood.
An excessive production of IL-6 is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple
myeloma, oncology indications and rheumatoid arthritis, and we believe that TZLS-501 may have potential therapeutic value for these indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, TZLS-501
demonstrated the potential for overcoming the limitations of other IL-6 blocking pathway drugs. Compared to tocilizumab and sarilumab,
while binding to the membrane-bound IL-6R complex, TZLS-501 has been observed to have a higher affinity for the soluble IL-6 receptor
from antibody binding studies conducted in cell culture. TZLS-501 also demonstrated the potential to block or reduce IL-6 signaling in
mouse models of inflammation. The soluble form of IL-6 has been implicated to have a larger role in disease progression compared to the
membrane- bound form (Kallen, K.J. (2002). &#8220;The role of transsignaling via the agonistic soluble IL-6 receptor in human diseases.&#8221;
Biochimica et Biophysica Acta. 1592 (3): 323&#8211;343.).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Originally TZLS-501 clinical
development was intended or treatment of &#8220;cytokine storm&#8221;-induced lung damage in COVID-19 patients by aerosol delivery to
lung, however, with the increasing number of effective therapies and vaccines now available for COVID patients the Company decided to
refocus TZLS-501 development for SSc-ILD indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2020 The Company
announced that it had developed investigational new technology to treat COVID-19 infections, consisting of direct delivery of anti-IL-6
receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer for treatment of patients infected
with COVID-19 (SARS-CoV-2)&#160;coronavirus.&#160;On June 29, 2020 the Company announced that it was advancing GMP manufacturing of TZLS-501
with STC Biologics concurrently with the development of inhalation technology using a hand-held nebulizer with Sciarra Laboratories and
safety toxicology studies in Cynomolgus monkeys with ITR Canada Laboratories. GMP batches were initiated in January 2021 and completed
in March 2021. Safety inhalation toxicology studies were initiated in November 2020 and completed in March 2021. Technological assessment
of nebulizers for inhalation treatment of patients was initiated in September 2020 and completed in February 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional 250L cGMP batch
of TZLS-501 drug substance was manufactured using an improved downstream process to support future development activities. An IND for
a Phase 1 Clinical Trial in Healthy Subjects for treatment of interstitial lung disease associated with systemic sclerosis (SSc ILD) was
filed in December 2021. This program has been temporarily paused to pursue the Company&#8217;s short-term focus on clinical development
of intranasal foralumab administration for treatment of SPMS patients</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><br/>
Competition</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property.
We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies,
academic research institutions, government agencies and public and private research institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are aware of a number of
companies focused on developing therapies in various indications. Any advances made by a competitor may be used to develop therapies that
could compete against any of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For our specific product candidates, the main competitors
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We believe that Foralumab is currently the only fully human anti-CD3 mAb in clinical development for treatment of Crohn&#8217;s disease, progressive MS and other autoimmune and inflammatory diseases.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our potential competitors,
alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger
R&amp;D, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries
may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced
or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects,
are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval
for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market
position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product
candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Intellectual Property</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We strive to protect and enhance
the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining
and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary
position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United
States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the
development and implementation of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 4, 2024, our intellectual
property portfolio was made up as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subject</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cooley Ref.</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Priority</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expires</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td></tr>
  <tr style="vertical-align: top">
    <td rowspan="19" style="padding-top: 2in; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foralumab TZLS-401</b> </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (autoimmune or inflammatory diseases and disorders)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-010</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Issued:</span> Australia, Canada, China, Hong Kong,
    Israel, Japan, Mexico, Norway, Singapore, South Africa, Ukraine, Armenia, Austria, Azerbaijan, Belgium, Belarus, Switzerland, Germany,
    Denmark, Spain, France, United Kingdom, Ireland, Italy, Kyrgyzstan, Kazakhstan, Luxembourg, Moldova, Netherlands, Norway, Portugal,
    Russian Federation, Sweden, Tajikistan, and Turkmenistan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition and methods of use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-011</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued: Australia, Armenia, Azerbaijan, Belarus, Brazil, Canada, China, Austria, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Kazakhstan, Kyrgyzstan, Mexico, Moldova, Netherlands, Norway, Republic of Korea, Russian Federation, Singapore, South Africa, Spain, Switzerland, Tajikistan, Turkmenistan, U.S. United Kingdom, and Ukraine; Pending: US.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (in combination with anti-IL- 6/IL-6R antibodies)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-012</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2011</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Issued:</span> United States</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulations and dosing regimen</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-013</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2037</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Issued:</span> United States, China, Japan, Israel<br/>
    <span style="text-decoration:underline">Pending:</span> Australia, Canada, China, Europe, Hong Kong, Israel, Japan, United States</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (CNS disorders)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-019 (co-owned with The Brigham and Women&#8217;s Hospital, Inc.)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2038</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> Canada, Europe, Japan, United States</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (CAR-T therapies)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-027</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> United States, Australia, Canada, China,
    Europe, Israel, Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (coronavirus)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-028</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> United States, Australia, Canada, China,
    Europe, Israel, Japan, Hong Kong</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of administering Foralumab by subcutaneous injection</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-029</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> United States, Europe</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasal formulations of Foralumab</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-033</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2043</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> PCT</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of suppressing micrglial activation</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-034 (co-owned with The Brigham and Women&#8217;s Hospital, Inc.)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> PCT</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<tr style="vertical-align: top">
    <td rowspan="15" style="padding-top: 2in; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milciclib TZLS-201</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of matter, methods of use, process of manufacturing</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2003</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, Brazil, Eurasia,
    Africa, Algeria, Argentina, Australia, Barbados, Bosnia &amp; Herzegovina, Canada, Colombia, Costa Rica, Croatia, Cuba, Ecuador,
    Georgia, Iceland, India, Indonesia, Israel, Japan, Korea, Kosovo, Malaysia, Mexico, Mongolia, Montenegro, New Zealand, Nicaragua,
    Norway, Pakistan, Philippines, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Thailand, Trinidad &amp; Tobago, Tunisia, Ukraine,
    Uzbekistan, Vietnam<br/>
    <span style="text-decoration:underline">Pending:</span> United States, Egypt, Venezuela</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (multiple indications)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2008; 2009</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029; 2030</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, China, Hong Kong, Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (combination therapies with cytotoxics)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2008; 2009</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029; 2030</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, China, Hong Kong, Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions of related entities (salts and crystal forms), formulations and methods of treatment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, China, Hong Kong, Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods of use (combination therapies with therapeutic antibodies)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, China, Japan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic combinations of Milciclib for use in the treatment of cancer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2038</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Japan <br/>
    <span style="text-decoration:underline">Pending:</span> United States, Europe, Canada, Japan, Hong Kong</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enteric-coated pharmaceutical formulations comprising Milciclib</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2045</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States (provisional)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method of treating KRAS mutated cancers by administering Micliclib and a chemotherapy</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> Australia, Canada, Europe, Israel,
    New Zealand, United States</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<tr style="vertical-align: top">
    <td rowspan="3" style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 10%; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti
    IL-6/IL- 6R Antibody TZLS-501</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of matter and methods
    of use</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-016</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Issued:</span> United States, Austria,
    Australia, Belgium, Canada, China, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Luxembourg, Mexico, Netherlands,
    Spain, Sweden, Switzerland and United Kingdom</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions of IL-6/IL-6R antibodies and methods of
    use thereof (coronavirus includes combinations with dactinomycin)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIZI-022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pending:</span> United States, Europe, Australia, Canada,
    China, Israel, Japan</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinomycin D</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Actinomycin D in the treatment of acute myeloid
leukemia</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Europe, Japan, Australia, Canada</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinomycin D compositions and use of the same in the
treatment of myelodysplactic syndrome and acute myeloid leukemia</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued/Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States, Australia, Japan<br/>
 <span style="text-decoration:underline">Pending:</span> United
    States, Europe, Canada, Japan</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent family that discloses the Milciclib compound,
methods of using the compound, and processes for making the compound licensed from Nerviano Medical Sciences S.R.L. (which is further
described below). This patent family includes six granted U.S. patents, one granted European patent, and one granted Eurasian patent.
This patent family also includes granted patents in Africa (African Intellectual Property Organization, African Regional Intellectual
Property Organization), Algeria, Argentina, Australia, Brazil , Barbados, Bosnia &amp; Herzegovina, Canada, Colombia, Costa Rica, Croatia,
Cuba, Ecuador, Georgia, Iceland, India, Indonesia, Israel, Japan, Korea, Kosovo, Malaysia, Mexico, Mongolia, Montenegro, New Zealand,
Nicaragua, Norway, Pakistan, Philippines, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Thailand, Trinidad &amp; Tobago, Tunisia,
Ukraine, Uzbekistan, and Vietnam. Applications are also pending in the U.S., Egypt, and Venezuela. The patents in this family will expire
in April 2024, excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available
in several other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a patent family which covers related entities,
such as salts and crystal forms, of Milciclib, and methods of using the salts and crystal forms licensed from Nerviano Medical Sciences
S.R.L. This patent family comprises one granted U.S. patent and one granted patent in each of Europe, China, Japan, and Hong Kong. The
patents in this family will expire in April 2030, excluding any patent term adjustment and patent term extension in the U.S. and several
other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have rights to five patent families which cover methods
of using Milciclib in the treatment of multiple indications licensed from Nerviano Medical Sciences S.R.L. These patent families comprise
five granted U.S. patents, and granted patents in Europe, China, Hong Kong, and Japan, and one pending patent application in Europe. The
patents in these families will expire between February 2027 and March 2030, excluding any patent term adjustment and patent term extension
in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among the above five patent families, two families also cover combination
therapies of Milciclib with cytotoxic agents. These families comprise two granted U.S. patents, and granted patents in Europe, China,
Hong Kong, and Japan. The patents in these families will expire between November 2029 and March 2030, excluding any patent term adjustment
and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One family of the above five
patent families also covers combination therapies of Milciclib with therapeutic antibodies. This patent family includes one granted U.S.
patent, and granted patents in Europe, China, and Japan. The patents in this family will expire in February 2027, excluding any patent
term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such
as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have rights
to a patent family which covers methods of using Milciclib together with a second anti-cancer agent in the treatment of cancer. This patent
family includes granted patents in the U.S. and Japan and pending applications in the U.S., Europe, Canada, Japan, and Hong Kong. The
patent and patent applications in this family, if issued as patents, will expire in November 2038, excluding any patent term adjustment
and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a U.S.
provisional application which covers enteric-coated pharmaceutical formulations comprising Milciclib. The patent applications in this
family, if issued as patents, will expire in March 20432045, excluding any patent term adjustment and patent term extension in the U.S.
and similar regulatory extensions available in several other jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a patent
family that discloses method of treating KRAS mutated cancers by administering Milciclib and a chemotherapy. This patent family includes
pending applications in the United States and in Australia, Canada, Europe, Israel, and New Zealand. Any patents issued in this family
will expire in August 2042, excluding any patent term adjustment and patent term extensions available in the U.S and several other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent
family that discloses methods of using Foralumab, licensed from NovImmune S.A. (which is further described below). This patent family
includes one granted European patent and one granted Eurasian patent. This patent family also includes granted patents in Australia, Canada,
China, Hong Kong, Israel, Japan, Mexico, Norway, Singapore, and South Africa, and Ukraine. The patents in this family will expire in April
2025, excluding any patent term extensions available in several jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a patent
family that discloses the Foralumab compound and methods of using the compound also licensed from NovImmune S.A. This patent family comprises
four granted U.S. patents, one granted European patent, and one granted Eurasian patent. This patent family also includes granted patents
in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Mexico, Republic of Korea, Singapore, and South Africa, and Ukraine.
An application is pending in the U.S. The patents in this family will expire in June 2025, excluding any patent term adjustment in the
U.S. and patent term extensions available in the U.S. and several other jurisdictions, such as Europe.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent family that discloses formulations of Foralumab
and dosing regimens for treating various disorders. This patent family has an issued patent in the U.S., issued patents in China, Israel
and Japan, and applications pending in the U.S, Australia, Canada, China, Europe, Israel, Hong Kong, and Japan. The patents in this family
will expire in August 2037, excluding any patent term adjustment and patent term extensions available in the U.S and several other jurisdictions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent
family that discloses methods of using Foralumab for treating central nervous system (CNS) disorders, licensed from Brigham and Women&#8217;s
Hospital, Inc. (which is further described below). This patent family has applications pending in Canada, Europe, Japan, and the United
States that, if issued as patents, will expire in June 2038, excluding any patent term adjustment and patent term extensions available
in the U.S and several other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a PCT application
that discloses methods of using Foralumab for microglial activation, which is co-owned with Brigham and Women&#8217;s Hospital Inc. The
patent applications in this family, if issued as patents, will expire in 2042, excluding any patent term adjustment and patent term extensions
available in the U.S and several other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent
family that discloses methods of using Foralumab for treating gastrointestinal, autoimmune, and inflammatory disorders. This family has
pending applications in the U.S., Europe, Australia, Canada, China, Hong Kong, and Japan. The applications in this family, if issued as
patents, will expire in October 2039, excluding any patent term adjustment and patent term extensions that may be available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a patent
family that discloses methods of using Foralumab in the treatment of coronavirus. This family has pending applications in the U.S., Australia,
Canada, China, Europe, Hong Kong, Israel and Japan. The patent applications in this family, if issued as patents, will expire in 2041,
excluding any patent term adjustment and patent term extensions available in the U.S and several other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a patent
family that discloses methods of using Foralumab to enhance cell adoptive therapies. This family has pending applications in the U.S.,
Australia, Canada, China, Europe, Israel and Japan. The patent applications in this family, if issued as patents, will expire in 2041,
excluding any patent term adjustment and patent term extensions available in the U.S and several other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a PCT
application patent family that discloses methods of administering Foralumab subcutaneously for the treatment of various diseases. This
family has pending applications in the U.S. and Europe. Any patents issued in this family will expire in April 2042, excluding any patent
term adjustment and patent term extensions available in the U.S and several other jurisdictions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to a U.S.
provisional PCT application that discloses nasal formulations of Foralumab for the treatment of various diseases. Any patents issued in
this family will expire in 2043, excluding any patent term adjustment and patent term extensions available in the U.S and several other
jurisdictions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a patent
family that discloses methods of using TZLS-501 to treat various disorders, licensed from NovImmune S.A. This patent family includes five
six granted U.S. patents, one granted European patent, and granted patents in Australia, Canada, China, India, Israel, Japan, and Mexico.
Applications are pending in U.S. and Japan. The patents in this family will expire in May 2029, excluding any patent term extensions available
in several jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have rights to a second
patent family that discloses methods of using TZLS-501 to treat coronavirus alone and in combination with Actinomycin D. This patent family
includes pending applications in the U.S., Australia, Canada, China, Europe, Israel, and Japan. The patent applications in this family,
if issued as patents, will expire in March 2041, excluding any patent term extensions available in several jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have rights to two
patent families related to Actinomycin D (ActD). The first family covers the use of ActD in the treatment of acute myeloid leukemia, and
includes granted patents in the U.S., Australia, Canada, Japan, and Europe. The patents in this family will expire in September 2036,
excluding any patent term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other
jurisdictions, such as Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The second ActD family covers
nanoparticle formulations of ActD and the use of the same in the treatment of acute myeloid leukemia and myelodysplastic syndrome. In
this family, there are granted patents in the U.S., Australia, and Japan and pending applications in the U.S., Europe, Australia, Canada,
and Japan. The patents and patent applications in this family, if issued as patents, will expire in September 2037, excluding any patent
term adjustment and patent term extension in the U.S. and similar regulatory extensions available in several other jurisdictions, such
as Euro</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual patents extend
for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents
in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted
a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended
to recapture a portion of the USPTO delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA
regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent
term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance
with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection
afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of
patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular
country and the validity and enforceability of the patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we rely upon
trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect
our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention
assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators
and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment
agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be
breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently
discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in
their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party
patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or
cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require
to develop or commercialize our future product candidates may have an adverse impact on us. If third parties have prepared and filed patent
applications prior to March 16, 2013 in the United States that also claim technology to which we have rights, we may have to participate
in interference proceedings in the USPTO, to determine priority of invention. For more information, see &#8220;Risk Factors&#8212;Risks
Related to Our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Material Agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Nerviano Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2015, we entered
into an agreement with Nerviano, or the Nerviano Agreement, pursuant to which we obtained a worldwide, exclusive license to patents owned
or controlled by Nerviano, or the Nerviano License to develop and commercialize products and services incorporating Milciclib as an active
ingredient, and any product or service controlled or owned by Nerviano that is used to diagnose or assess responsiveness to Milciclib
therapy or dosage. The Nerviano License confers the right on us grant sub-licenses, and otherwise to employ third party manufacturers
and distributors to produce and sell licensed products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party to the Nerviano
Agreement agreed to a development plan, or the Nerviano Development Plan, approved by a joint development committee, or the JDC. The JDC
is comprised of at least two members of each party, meets at least twice a year and endeavors to make decisions by consensus, save that
where there is a disagreement with respect to any aspect of the licensed products or services we shall have a deciding vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nerviano Development
Plan, we (or, as the case may be, our sub-licensee(s)) are obliged to use commercially reasonable efforts to develop and commercialize
a licensed product or service in at least one therapeutic indication that arises out of the Nerviano Development Plan, and Nerviano is
obliged to use commercially reasonable efforts to manufacture such product(s) or service(s). Pursuant to the Nerviano Development Plan,
we have sole responsibility for costs for further clinical development and Nerviano is obliged to perform Phase 2 studies of licensed
products and services, save that the amounts to be invoiced by Nerviano to us for Phase 2 studies shall be commercially reasonable and
not be greater than a low-double-digit percentage in excess than amounts estimated to be invoiced by another reputable clinical research
organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the term of the Nerviano
Development Plan, or the Nerviano Exclusivity Period, we and our affiliates may not, directly or indirectly, develop, make, use, sell,
offer for sale or import any small molecule compound or other biological or chemical molecule other than Milciclib that directly binds
to, with an affinity indicated by an IC50 of 100nM or less, and modulates the following specified pharmacological targets hit by Milciclib:
Cdk-2, Cdc-4 and Cdc6.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon entry into the Nerviano
Agreement, we paid an upfront, non-refundable initial license fee of $3,500,000 to Nerviano. We issued 4,233,616 of ordinary shares, fully
paid with a nominal value of three pence each, or the Consideration Shares, to Nerviano at an issue price of 50.5 pence (equivalent to
an aggregate value of &#163;2,137,976.08).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nerviano granted us an option,
or the Nerviano Option, to buy-back all the Consideration Shares for a de minimis aggregate consideration exercisable on written notice
at any time after the earlier of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">(i)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an unsuccessful Phase 2 trial for HCC or breast cancer with a licensed product or service and the concomitant decision of the company, our affiliates or sub-licensees to discontinue development of a licensed product or service;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the fifth anniversary of the Nerviano Agreement, (provided that if on such date a Phase 2 trial has commenced but has not been completed our ability to exercise the Nerviano Option shall be delayed until the outcome of the Phase 2 trial has become clear); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(iii)</span></td>
    <td><span style="font-size: 10pt">our abandonment of any licensed product or service for bona fide scientific reasons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nerviano Option cannot
be exercised if any of the following events (each, a Release Event), occurs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a successful completion of a Phase 2 trial for HCC or breast cancer with a licensed product or service, where such successful conclusion renders the licensed product or service eligible for entry into a Phase 3 trial with no further clinical study; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our abandonment of the development of, or failure to exercise commercially reasonable efforts develop any, licensed product or service, save for where we have bona fide scientific reasons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nerviano Option effectively
allows us to recover the Consideration Shares if it transpires that Milciclib proves to be unsuccessful in the indications for which we
licensed it or we fail to see satisfactory results in a period of 5 years from the date of the license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to a Release Event,
Nerviano has agreed to not transfer, dispose of, or grant options or other rights over directly or indirectly any interests in the Consideration
Shares nor to derive any financial benefit from the Shares, but is entitled to exercise all voting rights arising from the Consideration
Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following a Release Event,
Nerviano has agreed to a 12 month lock-up, or the Nerviano Lock-Up, in respect of the Consideration Shares, subject to customary exceptions,
including the prior written consent of the company and our nominated adviser from time to time (which consent may be approved, provided
or provided subject to conditions as each may determine in its absolute discretion), acceptance of takeover bids, share buy-backs by the
company, or where required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the lapse of the
term of the Nerviano Lock-Up, Nerviano has agreed to not directly or indirectly, transfer, sell, mortgage, charge or otherwise dispose
of more than 10% of the Consideration Shares (i.e. 423,362 ordinary shares) per calendar month, and to utilize the company&#8217;s broker
from time to time to execute those transactions in respect of the legal and or beneficial ownership or any other interest in the Consideration
Shares so as to ensure an orderly market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay Nerviano
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$100,000 upon initiation, first patient dosed, or FPD, of the first Phase 3 registration trial in thymic carcinoma.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$4,000,000 upon FPD of the first Phase 3 registration trial in HCC.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -25.3pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$6,000,000 upon FPD of the first Phase 3 registration trial in breast cancer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -24.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Upon the first NDA equivalent in: thymic carcinoma, $900,000; HCC, $9,000,000; breast cancer, $15,000,000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obliged to pay Nerviano
a low-single-digit percentage royalty fee of the annual net sales of licensed products or services, subject to certain royalty off-sets
on a country-by-country basis and, subject to certain exclusions, a low-double-digit percentage of sub-licensing revenues from the sale
of licensed products or services for the life of the licensed patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Nerviano Exclusivity
Period, we have the right to terminate activities and funding to Nerviano after 24 months from the beginning of the Nerviano Exclusivity
Period but not prior thereto. If we exercise our termination right, we are obliged to transfer to Nerviano all relevant data, licensed
products and services and an exclusive license pertaining to the licensed product or services, and Nerviano shall pay us a low-single-digit
percentage royalty on annual net sales of licensed products and services, subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the expiry of the
Nerviano Exclusivity Period, we may terminate the Nerviano Agreement at any time on 90 days&#8217; written notice, and either party may
terminate the Nerviano Agreement for material breach by the other party of any material obligation or condition of the Nerviano Agreement
by written notice, subject to a 45 day cure period for a payment breach, and a 120 day cure period for any other breach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Absent early termination,
the Nerviano Agreement shall remain in force until the later of, in all countries in which licensed products and services are marketed
pursuant to the Nerviano Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents, subject
to certain exceptions, which covers the sale of such licensed products or services, or (b) five years from the date of first commercial
sale of such licensed product or service in such country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Novimmune CD3 Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2014, we entered
into a license and sublicense agreement with Novimmune, or the Novimmune CD3 Agreement, pursuant to which we obtained a worldwide, exclusive
license to certain patents owned or controlled by Novimmune, or the Novimmune CD3 License, together with a sublicense to certain patent
licenses from Bristol-Myers Squibb Company, or BMS, or the BMS CD3 Sublicense, and any associated know-how, biologic materials, clinical
data or other technology relating to CD3 receptor mAbs and their use in order to research, develop and commercialize products and services.
The Novimmune CD3 License and BMS CD3 Sublicense both confer the right to us to grant sublicenses, and otherwise to employ third party
manufacturers and distributors to produce and sell licensed products and services, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Novimmune
CD3 Agreement, Novimmune granted the BMS CD3 Sub-License to us. Novimmune effected such grant pursuant to a research and commercialization
agreement between Novimmune and BMS dated September 20, 2014, or the BMS R&amp;C Agreement, and the agreement for the exclusive commercial
license for the CD3 licensed product (NI-0401) between Novimmune and BMS dated February 2005.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Novimmune CD3 Agreement,
we have full control and authority over the research, development and commercialization of licensed products and services, and are required
to exercise commercially reasonable efforts to commercialize such licensed products and services at all times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon our entry into the Novimmune
CD3 Agreement we paid an upfront fee of $750,000 to Novimmune (to be on paid by Novimmune to BMS pursuant to the terms of the BMS R&amp;C
Agreement), and a further upfront fee of $500,000 to Novimmune. We are required to pay Novimmune installments of $250,000 on each of the
14 month, 26 month and 38 month anniversaries of the date of the Novimmune CD3 Agreement. For the term of the Novimmune Agreement, we
are obligated to pay to Novimmune a royalty of a low-single-digit percentage on net sales of licensed products and services, together
with any amounts owed to BMS incurred pursuant to the BMS CD3 Sub-License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate the Novimmune
CD3 Agreement at any time on 90 days&#8217; written notice, and either party may terminate the Novimmune CD3 Agreement by written notice
for a payment breach or any other breach, subject to 45 day and 120 day cure periods, respectively. Absent early termination, the Novimmune
CD3 Agreement will continue until the later of, in all countries in which licensed products are marketed pursuant to the Novimmune CD3
Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents or a claim that has not been
pending more than five years, subject to certain exceptions, which covers the sale of such licensed product or service, or (b) the end
of any market exclusivity period granted by the relevant governmental authority in a country that prevents another party from marketing
the same licensed product or service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Novimmune IL-6r Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2016, we entered
into a license and sublicense agreement with Novimmune, or the Novimmune IL-6r Agreement, pursuant to which we obtained a worldwide, exclusive
license to certain patents owned or controlled by Novimmune, or the Novimmune IL-6r License, together with a sub-license to certain patent
licenses from BMS, or the BMS IL-6r Sub-License, and any associated know-how, biologic materials, clinical data or other technology relating
to IL-6r mAbs and their use in order to research, develop, commercialize products and services. The Novimmune IL-6r License and BMS IL-6r
Sub-License both confer the right to us to grant sub-licenses, and otherwise to employ third party manufacturers and distributors to produce
and sell licensed products and services, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Novimmune
IL-6r Agreement, Novimmune granted the BMS IL-6r Sub-License. Novimmune effected such grant pursuant to the BMS R&amp;C Agreement and
the agreement for the IL-6r exclusive commercial license for the IL-6r antibody licensed product (NI-1201) between Novimmune and BMS dated
September 20, 2009, or the IL-6r Commercial License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Novimmune IL-6r
Agreement, we have full control and authority over the research, development and commercialization of licensed products and services,
and are required to exercise commercially reasonable efforts to commercialize such licensed products and services at all times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon our entry into the Novimmune
IL-6r Agreement we paid an upfront fee of $100,000 to Novimmune. For the term of the Novimmune IL-6r Agreement, we are obligated to pay
to Novimmune a royalty of a low-single-digit percentage on net sales of licensed products and services, or low-double-digit percentage
of any sub-license royalty revenue which we receive that arises from sales of licensed products and services, together with any amounts
owed to BMS incurred pursuant to the BMS IL-6r Sub-License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BMS R&amp;C Agreement
and the IL-6r Commercial License Agreement were amended pursuant to an agreement between Novimmune and BMS dated December 2016, or the
Novimmune Amendment Agreement. Pursuant to the Novimmune Amendment Agreement, in the event that Novimmune (or, as the case may be, a sublicensee)
commercializes a combination product comprising NI-1201 and NI-0401, then such product shall be subject to a single royalty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate the Novimmune
IL-6r Agreement at any time on 90 days&#8217; written notice, and either party may terminate the Novimmune IL-6r Agreement by written
notice for a payment breach or any other breach, subject to 45 day and 120 day cure periods, respectively. Absent early termination, the
Novimmune IL-6r Agreement will continue until the later of, in all countries in which licensed products are marketed pursuant to the Novimmune
IL-6r Agreement, (a) the expiration of the last claim in an issued, unexpired patent within the licensed patents or a claim that has not
been pending more than five years, subject to certain exceptions, which covers the sale of such licensed product or service, or (b) the
end of any market exclusivity period granted by the relevant governmental authority in a country that prevents another party from marketing
the same licensed product or service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Brigham and Women&#8217;s Hospital License</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 29, 2018, we entered
into a license agreement, or the BWH License, with BWH pursuant to which we obtained a worldwide exclusive license to a patent owned by
BWH for a novel technology discovered by Dr. Howard Weiner. The patent relates to a formulation of Foralumab in a medical device developed
for nasal administration of Foralumab. The BWH License extends to any associated know-how, clinical data and use in order to research,
develop and commercialize products and services. The BWH License confers on us the right to grant sub-licenses, and otherwise to employ
third party manufacturers and distributors to sell licensed products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the BWH License we have
full control and amnesty over the research, development and commercialization of licensed products and services and are required to exercise
commercially reasonable efforts to commercialize such licensed products and services at all times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon our entry into the BWH
License we paid an upfront fee of $10,000 to BWH. We are required to pay annual maintenance fees, all ongoing patent maintenance and prosecution
costs and a low single-digit royalty on annual net sales (and a 12% royalty of non-royalty sub-license revenues for the life of the intellectual
property). We are also obliged to make certain milestone payments of: (a) US$300,000 within 60 days of first patient enrolled in a Phase
1 human clinical trial; (b) US$600,000 within 60 days of first patient enrolled in a Phase 2 human clinical trial; (c) US$1,500,000 within
60 days of first patient enrolled in a Phase 3 clinical trial; and (d) US$3,000,000 within 60 days of first commercial sale of a licensed
product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate the BWH License
at any time on 90 days&#8217; written notice, and either party may terminate the BWH License by written notice for payment or other breach,
subject to a 60 day cure period. Absent early termination the BWH License will remain in effect until the date on which all patents and
filed patent applications have expired or been abandoned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Organizational Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets out details of the Company&#8217;s
significant subsidiaries:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal activity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Registered address</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage <br/> shareholding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Country of <br/> incorporation</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 24%; text-align: left">Tiziana Life Sciences Ltd</td><td style="width: 1%">&#160;</td>
    <td style="width: 24%; text-align: left">Clinical stage biotechnology company</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 24%; text-align: left">107 Cheapside, London EC2V 6DN</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">100</td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%; text-align: center">England &amp; Wales</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left">Tiziana Pharma Limited</td><td>&#160;</td>
    <td style="text-align: left">Clinical stage biotechnology company</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">107 Cheapside, London EC2V 6DN</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">England &amp; Wales</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Tiziana Therapeutics Inc.</td><td>&#160;</td>
    <td style="text-align: left">Clinical stage biotechnology company</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">420 Lexington Ave, Suite 1402<br/>New York , NY 10170</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">USA</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left">Longevia Genomics S.r.l.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Biotechnology discovery company</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Via Constantinopli 42 <br/> 09100- Cagliria (CA)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Italy</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Property, Plant and Equipment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The below table contains information
regarding existing or planned material tangible fixed assets owned or leased by Tiziana and its subsidiaries. We believe that suitable
additional or substitute space will be available as needed to accommodate any future expansion of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; width: 25%"><span style="font-size: 10pt"><b>Location</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Tenure</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Principal Use</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Size</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14-15 Conduit Street</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">London W1S 2XJ, United&#160;Kingdom</p></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">3-year Lease</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Principal Office</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">821 square feet</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">601 New Britain Road <br/>
Building 100, Suite 102<br/>
Doylestown, PA, United States</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Annual lease</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Research &amp; Development Centre</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">408 square feet</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A: UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5: OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should read the following
discussion and analysis of our financial condition and results of operations together with &#8220;Selected Consolidated Financial Data&#8221;
and our consolidated financial statements and the related notes thereto appearing at the end of this Annual Report. We present our consolidated
financial statements in U.S. dollars and in accordance with International Financial Reporting Standards, or IFRS, as issued by the International
Accounting Standards Board, or IASB.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Some information included
in this discussion and analysis, including statements regarding industry outlook, our expectations regarding our future performance, liquidity
and capital resources and other statements regarding our plans and strategy for our business and related financing, are forward-looking
statements. These forward-looking statements are subject to numerous risks and uncertainties. You should read the &#8220;Risk Factors&#8221;
section of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results
described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>We maintain our books and
records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial
results in U.S. dollars.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Introduction to Tiziana</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biotechnology company
that specializes in developing transformative therapies for neurodegenerative and lung diseases . Our clinical pipeline includes drug
assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer&#8217;s, Crohn&#8217;s Disease and KRAS+ NSCLC.. Our lead product candidate in
immunology is Foralumab (TZLS-401), which we believe is the only fully human anti-CD3 monoclonal antibody, or mAb, in clinical development.
MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers
and autoimmune diseases. Generation of antibodies for use in humans developed in animals, leads to strong, immune responses limiting their
effectiveness and potentially leading to severe side effects. A process known as &#8220;humanization&#8221; removes most of the animal
components of the antibody thereby lowering the immune response from the human immune system. The entire omission of other animal material,
as in fully human antibodies, is the optimal goal to avoid incompatibility with the human immune system. Our lead product candidate in
oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin-dependent kinases,
or CDKs, and Src family kinases. CDKs are a highly conserved family of enzymes that phosphorylate a specific group of proteins that are
involved in regulating the cell cycle. The cell cycle is a series of events that takes place in cells leading to division and duplication
of its DNA to produce two daughter cells. Src family kinases are non-receptor tyrosine kinase proteins encoded by the Src gene also involved
in regulating cell growth and potential transformation of normal cells to cancer cells. We are developing a fully human mAb targeting
the IL-6R (TZLS-501) for which the intellectual property was licensed from Novimmune in January 2017. This fully human mAb has a novel
mechanism of action, binding to both the membrane-bound and soluble forms of the IL-6R as well as depleting circulating levels of the
IL-6 in the blood. Excessive production of IL-6 is regarded as a key driver of acute inflammation resulting from infection with viral
agents such as Coronaviruses and of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications
and rheumatoid arthritis, and we believe that TZLS-501 may have potential therapeutic value for these indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ a lean and virtual
research and development, or R&amp;D, model using highly experienced teams of experts for each business function to maximize value accretion
by focusing resources on the drug discovery and development processes. Our mission is to design and deliver next generation therapeutics
and diagnostics for oncology and immune diseases of high unmet medical need by combining deep understanding of disease biology with clinical
development expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Foralumab,
for which we in-licensed the intellectual property from Novimmune SA, or Novimmune, in December 2014, as a potential treatment for neurodegenerative
diseases such as Secondary Progressive Multiple Sclerosis (SPMS), Crohn&#8217;s disease and delayed onset of Type I Diabetes (T1D). On
November 10, 2022, Tiziana announced a short-term focus on administration of intranasal Foralumab for treatment of neurodegenerative diseases,
especially SPMS, based on positive clinical findings of Expanded Access (EA) SPMS patients at Brigham and Women&#8217;s Hospital treated
with intranasal Foralumab for up to 1 year. As the only fully human engineered human anti-CD3 mAb in clinical development, Foralumab has
significant potential advantages such as a shorter treatment duration and reduced immunogenicity. We believe that oral or intranasal administration
of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects. To date, Foralumab has been
studied in one Phase 1 and two Phase 2a clinical trials conducted by Novimmune in 68 patients dosed by the intravenous route of administration.
In these trials, Foralumab was observed to be safe and well-tolerated and produced immunologic effects consistent with potential clinical
benefit while demonstrating mild to moderate infusion related reactions, or IRRs. With completion of the intravenous dosing for Phase
2a trial in Crohn&#8217;s Disease, Foralumab&#8217;s ability to modulate T-cell response enables potential extension into a wide range
of other autoimmune and inflammatory diseases, such as Graft versus Host Disease (GvHD), ulcerative colitis (UC), multiple sclerosis(MS),
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis (PSA) and rheumatoid arthritis (RA).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foralumab is being developed
as both an immunosuppressive and immunomodulatory agent, with therapeutic benefits of rendering T-cells unable to orchestrate an immune
response and induction of immune tolerance via maintenance of regulatory T-cells. There is further potential for Foralumab to be combined
with the Company&#8217;s TZLS-501, a fully human anti-IL-6R mAB in development to target autoimmune and inflammatory diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2016, Tiziana
announced new data for oral efficacy in humanized mouse models with Foralumab, a major milestone and a potential breakthrough for the
treatment of NASH and autoimmune disease. This unique oral technology stimulates the natural gut immune system and potentially provides
a therapeutic effect in inflammatory and autoimmune diseases with greatly reduced toxicity. Positive therapeutic effects with Foralumab
were consistently demonstrated in animal studies conducted by Prof. Kevan Herold (Yale University) and Prof. Howard Weiner (Harvard University).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 16, 2018, Tiziana
entered into an exclusive license agreement with The Brigham and Women&#8217;s Hospital, Inc. relating to a novel formulation of Foralumab
dosed in a medical device for nasal administration. An investigational new drug application (IND) for the first-in-human evaluation of
the nasal administration of Foralumab in healthy volunteers for progressive multiple sclerosis indication was filed in the second quarter
of 2018. Subsequent to IND approval, a single-site, double-blind, placebo-controlled, dose-ranging Phase 1 trial with nasally administered
Foralumab at 10, 50 and 250 &#181;g per day, consecutively for 5 days to evaluate biomarkers of immunomodulation of clinical responses
was initiated in November 2018. The trial conducted at the Brigham and Women&#8217;s Hospital, Harvard Medical School, Boston, MA, in
healthy volunteers. 18 subjects received Foralumab treatment and 9 patients received placebo. The study was completed in September 2019.
Phase 1 clinical data demonstrated that nasally administered Foralumab, was well-tolerated and no drug-related safety issues were reported
at any of the doses. No drug-related changes were observed in vital signs among subjects at predose, during treatment and at discharge.
Nasally administered Foralumab at the 50 &#181;g dose suppressed cytotoxic CD8+ as well as perforin-secreting CD8+ cells, which have
been implicated in neurodegeneration in multiple sclerosis (MS). Treatment at 50 &#181;g stimulated production of anti-inflammatory cytokine
IL-10 and suppressed production of pro-inflammatory cytokine IFN-&#947;. Taken together, the treatment showed significant positive effects
on the biomarkers for activation of mucosal immunity, which are capable of inducing site-targeted immunomodulation to elicit anti-inflammatory
effects. .&#160;Systemic levels of Foralumab were below the lower quantitation limit of 8 ng/mL suggesting that nasally administered Foralumab
appears to exert its effects via nasal epithelium utilizing local and lymphatic immune systems directly. These data support other clinical
and pre-clinical studies showing that this route of administration is capable of inducing site-targeted immunomodulation and anti-inflammatory
effects. Furthermore, these pharmacodynamic data point to a clinical dose range that Tiziana intends to test in further clinical development
among MS patients.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&#160;9, 2019,
the FDA granted approval to initiate the Phase 1 clinical trials to evaluate the safety and pharmacokinetics of a novel enteric-coated
capsule formulation of oral Foralumab at 1.25, 2.5 and 5.0 mg/day as a single ascending dose study. The study was completed in December
2019 at Brigham and Women&#8217;s Hospital (Boston, MA USA). A total of 12 subjects were enrolled; 9 received the single dose of foralumab
and 3 received placebo. The median age (range) for the oral foralumab subjects was 23 (21 &#8211; 55) years, and for the placebo subjects
it was 34 (27 &#8211; 51). Of the foralumab subjects, 6 were male and 3 were female. All 3 of the placebo subjects were female. No subjects
discontinued the study. Formulated Foralumab powder blend encapsulated in enteric-coated capsule was well-tolerated at all doses tested
and there were no drug-related safety issues observed even at the highest dose of 5 mg in this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana initiated a Phase
1b clinical trial in Crohn&#8217;s disease patients to evaluate oral capsules of foralumab, a fully human&#160;anti-CD3 monoclonal antibody.
The revised protocol allowed for the study of a broader patient population and a shorter dosing period. These protocol amendments or revisions
were intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.&#160;This study was the first
multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohn&#8217;s disease. Due to the refocus
of the company after the first six months of 2022, this study has been withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A collaborative clinical trial
was initiated on November 2, 2020 in&#160;Brazil&#160;investigating nasally administered Foralumab, either alone or in combination with
orally administered dexamethasone (&#8220;Dexa&#8221;) in COVID-19 patients. The clinical study was completed in collaboration with scientific
teams at the&#160;Harvard Medical School&#160;(Boston, USA), and INTRIALS, a full-service Latin American CRO based in&#160;S&#227;o
Paulo, Brazil.&#160;The objectives of the trial were to assess safety of the treatment and to evaluate if progression of the diseases
is delayed with nasally administered 100mcg/day Foralumab (50mcg/nostril). This study enrolled 39 patients randomized in three cohorts:
cohort 1, control with no treatment (n=16); cohort 2; nasally administered Foralumab plus 3 days of priming with orally administered 6
mg Dexamethasone (n=11) and cohort 3; nasally administered Foralumab (n=12). The Foralumab treatment regimen was once a day dosing for
10 consecutive days. The trial was completed in January 2021. There were no significant differences between cohort 2 and 3. All treatments
were well-tolerated. There were no grade 3 or 4 severe adverse events (&#8220;SAEs&#8221;) in any of the cohorts<i>.</i>&#160;The CT scans
of the lungs showed the improvement was approximately double that shown in patients treated with Foralumab as compared to those in the
control group. &#160; The results of the study were published in the&#160;peer-reviewed journal,&#160;<i>Frontiers in Immunology</i>&#160;entitled
&#8220;Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in
Mild to Moderate COVID-19 Patients: A Pilot Study&#8221; in&#160;August 2021. This program has been temporarily paused to pursue the short-term
focus on clinical development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 2, 2021 the Company
and Precision BioSciences Inc announced an exclusive license agreement to explore Foralumab as an agent to induce tolerance of allogeneic
CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Precision&#8217;s approach to manufacturing produces CAR
T cells that are virtually CD3-negative. Foralumab will be used as a lymphodepletion or tolerizing agent, either alone or in combination
with other co-stimulatory molecules, to improve the long-term survival of CAR T cells in cancer treatment. Tiziana has completed manufacture
of foralumab solution for injection to be used by Precision Biosciences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
May 25, 2021 the Company announced that&#160;the first expanded access (EA) patient with secondary progressive multiple sclerosis (SPMS)
was dosed with nasally administered Foralumab at the&#160;Brigham and Women&#8217;s Hospital&#160;(BWH),&#160;Harvard Medical School,&#160;Boston,
MA.&#160;Nasal Foralumab 50 mcg (25 mcg/nostril) was administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed
by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, was to continue
for six months to evaluate routine safety, tolerability, and neurological behaviors. The study also examined microglial activation, by&#160;positron
emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the dosing regimen</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
March 10, 2022, the Company reported positive clinical data in the first EA SPMS patient following completion of six months of treatment
with intranasally administered foralumab, at the Brigham and Women&#8217;s Hospital (BWH),&#160;Harvard University,&#160;Boston, MA.&#160;In
addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana&#8217;s novel immunotherapy
technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation
in the brain using nasal administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Foralumab
was given to an EA SPMS patient intranasally into each nostril on a regimen of M-W-F for two weeks followed by one week off therapy for
a period of six months. This regimen was well-tolerated with associated beneficial clinical and biomarker changes. Importantly, the PET
imaging data indicated inhibition of microglial cell activation observed at 3 months following treatment initiation and was sustained
at 6 months after treatment start (see Table 1). The reduction in microglial activation was seen in all parts of the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><b>Table 1. Percent
Reduction* in Activated Microglial Cells (AMCs) PET Signal After Starting Intranasal Foralumab as Compared to Baseline, in Whole Brain
and Selected Brain Regions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHOLE<br/> BRAIN</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBRAL<br/> CORTEX</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">THALAMUS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">WHITE<br/> MATTER</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CEREBELLUM</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-left: 0.75pt">3 MONTHS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-20</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.75pt">6 MONTHS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-36</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-38</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Percent reduction is based on changes from baseline in SUVR-1, a surrogate index for PET binding potential. SUVR=Standardized Uptake Value Ratio, calculated with reference to a pseudo reference region in cerebral white matter that showed minimal change in PET SUV, across time points.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with clinical and
PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines, including interferon-gamma
(IFN-g), interleukin (IL-18), IL-1&#946; and IL-6, which are associated with multiple sclerosis pathogenesis and progression. Clinical
evaluation showed improvement in Timed 25-Foot Walk Test (T25FW), 9-Hole&#160;Peg Test&#160;(9HPT) and Symbol Digit Modality Test (SDMT).
Other published PET studies have shown an increase in activated microglial cells (AMCs) in patients with secondary progressive MS (SPMS),
and the increase in AMCs associated with higher scores on the Expanded Disability Status Scale (EDSS), a widely-used scale to measure
disability<sup>1,2</sup>. Several FDA-approved drugs, such as TYSABRI<sup>&#174;</sup>, MAYZENT<sup>&#174;</sup>&#160;and ZEPOSIA<sup>&#174;</sup>&#160;have
been shown to suppress microglial activation and exert neuroprotective effects in the central nervous system (CNS) in animal studies but
longitudinal assessment of drug effects on microglial activation in exclusive cohorts of SPMS patients are lacking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to treatment, this patient
had continued to experience worsening disease progression despite several MS therapies, including B cell depletion. The patient&#8217;s
gait and limb strength had been deteriorating over the prior two years. The patient then started on intranasal foralumab, which stabilized
his disease course. Tiziana also received FDA authorization to continue treating this patient for an additional 6 months to determine
if 12 months of consistent treatment maintains clinical stabilization and provides sustained clinical benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2022, FDA approved
enrollment of a second EA SPMS patient for treatment with intranasal foralumab.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These data were presented
in a virtual Key Opinion Leader (KOL) event hosted by Tiziana on&#160;March 14<sup>th</sup>, 2022, entitled &#8220;Foralumab Clinical
Update in Multiple Sclerosis; A Landmark Study with Intranasal Immunotherapy&#8221; featuring four Key Opinion Leaders and a live Q&amp;A
session. The company plans to continue treatment of EA SPMS patients at Brigham and Women&#8217;s Hospital and elsewhere and continue
evaluation of foralumab treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, Tiziana
announced that FDA granted permission to enroll up to eight additional (SPMS) patients in Intermediate Size Patient Population in the
EAP with intranasal foralumab. As part of the original treatment plan, the foralumab dose will remain 50 mcg three times a week (MWF),
which is the same dose administered previously to the first two SPMS patients. The dosing regimen in this IND also has a provision for
dose escalation up to 100 mcg three times a week (MWF) as an option to improve clinical benefit, if needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Data from a Secondary Progressive
Multiple Sclerosis patient treated with intranasal foralumab were presented on&#160;June 2, 2022&#160;at the consortium of multiple sclerosis
centers (CMSC) 2022 annual meeting. Dr.&#160;Tanuja Chitnis, MD, Professor of Neurology and the Principal investigator of the clinical
study at the at the Brigham and Women&#8217;s Hospital (BWH),&#160;Boston, MA., presented a poster discussing clinical data from a patient
with SPMS, who was treated with intranasal foralumab for six months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 8, 2022, Tiziana announced
positive clinical results for the second patient (EA2) in the non-active SPMS Expanded Access (EA) Program following three months of dosing
with intranasal foralumab. These results confirm the previously reported data, from the first non-active SPMS patient (EA1) that after
three months of treatment, intranasal foralumab. was well-tolerated and improved clinical and PET imaging analyses. The second patient
was diagnosed with SPMS in 2014. Since then, the disease has been progressive, resulting in an accumulation of disability. Patient EA2
started ocrelizumab in 2018 and stopped this treatment in 2021. During this time EA2&#8217;s non-active SPMS progressed as measured by
EDSS worsening from 3.5 in 2018 to 6.0 in 2021. At this point in time EA2 needed a cane to walk 100 meters. Patient EA2 was subsequently
enrolled in the intranasal foralumab expanded access program. On&#160;September 2022, 8 months after starting treatment with intranasal
foralumab, EA2 was able to walk 100 meters without a cane or need to rest. This improved the EDSS from 6.0 to 5.5. EA2&#8217;s pyramidal
score remained stable during this time. In&#160;December 2022, 11 months after starting treatment with intranasal foralumab, EA2 was able
to walk 200 meters without a cane or need to rest, resulting in further improvement in EDSS from 5.5 to 5.0. EA2&#8217;s pyramidal score
continued to remain stable. Lastly preliminary reading of EA2&#8217;s 11-month PET Scan (December 2022) demonstrated improvement in microglial
activation over baseline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;September 20, 2022,
Tiziana announced that the second patient (&#8220;EA2&#8221;) with non-active secondary progressive multiple sclerosis (SPMS) receiving
intranasal foralumab had shown additional clinical improvements as measured by the Expanded Disability Status Scale (EDSS), a standard
clinical assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2022, Tiziana
announced that it planned to submit an Investigational New Drug Application (IND) for a Phase 1 Trial of intranasal foralumab in Alzheimer&#8217;s
disease patients after receiving an affirmative written response from the FDA on a Pre-Investigational New Drug Application (PIND). Tiziana
plans on filing the IND for Alzheimer&#8217;s disease by the third quarter of 2023 upon the completion of requested toxicology studies,
then starting its Phase 1 program by the end of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 2, 2022,
Tiziana announced the completion of enrollment of the first patient cohort in its Intermediate Size Patient Population Expanded Access
Program to evaluate foralumab in non-active SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On&#160;November 10, 2022,
Tiziana announced its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS)
such as non-active SPMS, Alzheimer&#8217;s disease and amyotrophic lateral sclerosis (ALS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 23,2022,
Tiziana <span style="background-color: #FEFEFE">announced publication of a scientific article in the peer-reviewed journal&#160;<i>Frontiers
in Immunology</i>&#160;entitled &#8220;<b>Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function
and induces a regulatory response in T cells in human subjects&#8221;</b><sup>.</sup> The study was completed by researchers at the Brigham
and&#160;</span>Womens Hospital<span style="background-color: #FEFEFE">&#160;(BWH) and&#160;</span>Harvard Medical School<span style="background-color: #FEFEFE">.
The goal of the study was to assess safety and the immune effects of an entirely human, previously uncharacterized nasal anti-CD3 mAb
(foralumab) in humans and it&#8217;s&#160;<i>in vitro</i>&#160;stimulatory properties. The findings support Tiziana&#8217;s intranasal
foralumab platform as a new modality for the treatment of autoimmune and CNS diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
January 3, 2023, Tiziana announced that the second patient (&#8220;EA2&#8221;) with na-SPMS receiving intranasal foralumab exhibited additional
clinical improvements since their last reported improvement in&#160;</span>September 2022<span style="background-color: #FEFEFE">. The
improvements were measured by EDSS. Before foralumab treatment, EA2&#8217;s non-active SPMS disability had progressed and EDSS worsened
from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy. Ocrelizumab was discontinued in 2021. At this point, EA2 required a cane
to walk 100 meters. EA2 was subsequently enrolled in the intranasal foralumab Expanded Access program in&#160;</span>January 2022<span style="background-color: #FEFEFE">.
In&#160;</span>September 2022<span style="background-color: #FEFEFE">, 8 months after starting treatment with nasal foralumab, EA2 was
able to walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2&#8217;s pyramidal score remained stable during this time.
In&#160;</span>December 2022<span style="background-color: #FEFEFE">, 11 months after starting treatment with intranasal foralumab, EA2
was able to walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to
5.0. EA2&#8217;s pyramidal score continued to remain stable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
March 8, 2023, Tiziana announced a publication in the preeminent<sup>1</sup>&#160;journal,&#160;<i>Proceedings of the&#160;National Academy
of Sciences</i>&#160;(PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
March 28, 2023, Tiziana announced it has received feedback based on the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with na-SPMS. Tiziana plans to accept
the FDA&#8217;s recommendations and intends to start a Phase 2 study in the third quarter of 2023.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
April 4, 2023, Tiziana announced pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral
hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month. The data showed that </span>modulation of
neuroinflammation by induction of FoxP3+ Tregs appeared to have beneficial effect in intracerebral hemorrhage. Dr. Saef Izzy<span style="background-color: #FEFEFE">&#160;presented
this data from the podium on&#160;</span>April 23, 2023 <span style="background-color: #FEFEFE">at the Neurocritical Care Scientific Platform
Session at the prestigious Annual&#160;</span>American Academy of Neurology<span style="background-color: #FEFEFE">&#160;(AAN) conference
in&#160;</span>Boston, MA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 13, 2023, Tiziana
<span style="background-color: #FEFEFE">announced it&#8217;s plans to investigate intranasal foralumab for the treatment of Long COVID.
The work is supported by foralumab&#8217;s well-established role in de-activating microglia cells, a key component in the pathogenesis
of this disease. The company intends to enter into a Phase 2a, placebo-controlled trial following positive feedback from the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 20,2023, Tiziana
<span style="background-color: #FEFEFE">announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate
Alzheimer&#8217;s Disease in Q2 2023. Tiziana is also seeking&#160;</span>$3,000,000<span style="background-color: #FEFEFE">&#160;in non-dilutive
funding from a prestigious Alzheimer&#8217;s foundation to support the Phase 2a trial. It is expected that this funding application will
receive a response in Q3 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
June 5, 2023, Tiziana announced 3-month PET scan results from the </span>first patient cohort in its Intermediate Size Patient Population
Expanded Access Program. Data showed a <span style="background-color: #FEFEFE">reduction in microglial activation in 3 out of 4 patients
confirming that previously reported in the first two EA patients. Overall, 5 of the 6 na-SPMS patients treated with intranasal Foralumab
in its Expanded Access program have exhibited a reduction in microglial activation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
June 5, 2023, Tiziana announced 3-month PET scan results from the </span>first patient cohort in its Intermediate Size Patient Population
Expanded Access Program. Data showed a <span style="background-color: #FEFEFE">reduction in microglial activation in 3 out of 4 patients
confirming that previously reported in the first two EA patients. Overall, 5 of the 6 na-SPMS patients treated with intranasal Foralumab
in its Expanded Access program have exhibited a reduction in microglial activation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
August 15, 2023, Tiziana announced that the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
has cleared the Investigational New Drug (IND) application for intranasal Foralumab to be studied in Alzheimer&#8217;s disease. The clinical
trial will be overseen by Brigham and Women&#8217;s Hospital.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
August 24, 2023, Tiziana announced an oral presentation by Howard Weiner, MD entitled &#8220;Nasal anti-CD3 mAb induces Tregs that dampen
microglial activation and treat neuroinflammatory diseases including MS, AD and ALS&#8221; at the 16<sup>th</sup>&#160;</span>International
Society of Neuroimmunology (ISNI) Congress<span style="background-color: #FEFEFE">&#160;in&#160;</span>Quebec City, Canada<span style="background-color: #FEFEFE">,
held&#160; on </span>August 21-24, 2023<span style="background-color: #FEFEFE">. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
September 6, 2023, Tiziana </span>announced acceptance of a publication entitled, &#8220;Nasal Administration of anti-CD3 monoclonal antibody
(mAb) ameliorates disease in a mouse model of Alzheimer&#8217;s disease&#8221;, in the journal,&#160;<i>Proceedings of the&#160;National
Academy of Sciences</i>&#160;(PNAS), validating foralumab&#8217;s mechanism of action (MOA) as a potential treatment for Alzheimer&#8217;s
disease (AD), a difficult-to-treat neuroinflammatory disease.&#160; This was the second publication pertaining to intranasal administration
of anti-CD3 monoclonal antibody in 2023 to be published in PNAS. This study shows that intranasal anti-CD3 ameliorates disease in a rodent
model of AD by targeting microglial activation in the brain and brain gene expression independent of affecting amyloid beta deposition.
These studies identify a novel approach to treat Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 26, 2023, Tiziana
announced initiation of the Phase 2a multicenter clinical trial for treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
patients with intranasal Foralumab. Tiziana <span style="background-color: #FEFEFE">announced that it held an Investigator&#8217;s Meeting
with principal investigators at Brigham and Women&#8217;s Hospital to begin site initiation for the clinical trial. In total, six to ten
new clinical trial sites will be recruited.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
October 11, 2023, Tiziana announced a late breaking poster entitled, &#8220;Treatment Of Six Non-Active Secondary Progressive MS With
Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes&#8221;, that was presented at the 39th&#160;</span>Congress<span style="background-color: #FEFEFE">&#160;of
the&#160;</span>European Committee for Treatment<span style="background-color: #FEFEFE">&#160;and Research of Multiple Sclerosis (ECTRIMS)
held in&#160;</span>Milan, Italy<span style="background-color: #FEFEFE">,&#160;</span>October 11-13, 2023<span style="background-color: #FEFEFE">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: #FEFEFE">On
October 13, 2023, Tiziana announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans,
was observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis treated with intranasal foralumab
in its Expanded Access Program (EAP). Activated microglia play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative
diseases including multiple sclerosis, Alzheimer&#8217;s disease, and amyotrophic lateral sclerosis, or ALS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
October 16, 2023, Tizana announced </span>announced six-month data showing positive clinical improvements related to Modified Fatigue
Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive
Multiple Sclerosis patients participating in an Expanded Access (EA) Program. This follows on from previously announced positive
six-month PET scan data which was presented at ECTRIMS 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">The findings, which are summarized in Table
1 below, show broad-based six-month improvements across various key measures for multiple sclerosis. Secondary progressive multiple sclerosis
is hallmarked by an increase of disability over time. The table below shows a stabilization or an improvement in physical function of
the various clinical measures over a six-month period. <span style="background-color: #FEFEFE">Various degrees of improvement were also
observed in the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk Test (T25FW), pyramidal function scores and NeuroQoL Fatigue
scores in a disease state that typically shows a decline in function over time.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><b>Table 1. Six Month Test Scores in Expanded
Access na-SPMS Patients</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 55%; text-align: left"><b>EA Patient</b></td>
    <td style="text-align: center; width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>EDSS</b></span></td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td>
    <td style="text-align: center; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Pyramidal<br/> score</b></span></td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td>
    <td style="text-align: center; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>T25FW</b></span></td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td>
    <td style="text-align: center; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>MFIS</b></span></td>
    <td style="width: 1%; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EA1</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EA3</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA4</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EA5</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">EA6</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#8212;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8595;</span></td>
    <td style="text-align: left">&#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#8212;</td><td style="text-align: justify">Denotes stabilization</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#8595;</td><td style="text-align: justify">Denotes improvement</td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">Fatigue, as measured above in MFIS, refers
to an overwhelming sense of physical, mental, and emotional exhaustion that is disproportionate to the level of activity or effort exerted.
It is a major, common, and often debilitating symptom experienced by many individuals with MS. It differs from the typical tiredness that
everyone experiences from time to time. In the context of MS, it is called &#8216;primary fatigue&#8217; and is a direct result of damage
to the central nervous system. This kind of fatigue can significantly impact a person&#8217;s daily life and functioning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">On October 18, 2023,
Tiziana announced that <span style="background-color: #FEFEFE">the&#160;</span>U.S. Food and Drug Administration<span style="background-color: #FEFEFE">&#160;(FDA)
had allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab. Delivery Device Training materials have
been developed and refined in collaboration with the FDA, and patients trained in the use of the nasal device in accordance with these
materials. Patients in the Expanded Access program that have been exposed to intranasal foralumab for more than</span> 1 year have demonstrated
acceptable tolerability and safety. At-Home Dosing is likely to Improve patient compliance to treatment and outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE"><span style="background-color: #FEFEFE">On
November 1, 2023, Tiziana announced that Chief Operating Officer and Chief Medical Officer,&#160;</span>Matthew Davis<span style="background-color: #FEFEFE">,
MD, RPh, will present at BIO-Europe,&#160;</span>Munich, Germany<span style="background-color: #FEFEFE">,&#160;</span>November 6-8, 2023<span style="background-color: #FEFEFE">.
The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, for the treatment of non-active secondary
progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer&#8217;s. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On November 20, 2023,
Tiziana announced <span style="background-color: #FEFEFE">that the company had successfully enrolled and dosed four new patients with
non-active secondary progressive multiple sclerosis in the Brigham and Women&#8217;s Hospital&#8217;s Expanded Access pgrogam. A total
of ten patients are now being followed in the EA Program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">On
December 19, 2023, Tiziana announced <span style="background-color: #FEFEFE">&#8220;first patient dosed&#8221; in its Phase 2a study comparing
two doses of intranasal Foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis. Six investigational
centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint
of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status
Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient&#8217;s
everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images
is an integral component of this study.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: #FEFEFE">During
2022, Tiziana completed compatibility, stability and characterization studies of Foralumab nasal solution in unit dose devices for nasal
administration. Compatibility, stability and characterization studies of Foralumab intranasal solution in multi dose device for intranasal
administration will be completed in Q1 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are evaluating administrations
of Foralumab to delay onset and progression of T1D in at-risk individuals. T1D is characterized as a chronic and progressive autoimmune
disease leading to the destruction of insulin-producing &#946;-cells of the pancreas. Teplizumab (Provention Bio), a humanized Fc-mutated
anti-CD3 monoclonal antibody that alters the function of the T-lymphocytes that mediate the destruction of the insulin-producing &#946;-cell
is seeking FDA approval. The Company believes that Foralumab, a fully human anti-CD3 mAb, would have a better safety profile and clinical
benefit than Teplizumab based on Foralumab&#8217;s fully human protein sequence and binding affinity for CD3e compared to Teplizumab.
cGMP manufacturing of Foralumab solution for subcutaneous injection was initiated in April 2022 and IND submission is anticipated in 2023.
This program has been temporarily paused to pursue the short-term focus on clinical development of intranasal Foralumab administration
for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Tiziana initiated
five Good Laboratory Practice (GLP) safety toxicology studies of Foralumab administered intranasally and subcutaneously in HuGEMM CD3
transgenic mice. The five studies consisted of three intranasal toxicology studies of 14 days, 13 weeks and 26 weeks dosing duration and
two subcutaneous safety toxicology studies of 14 days and 28 days dosing duration. On&#160;December 15, 2022&#160;the Company announced
that it had successfully completed the 13-week toxicology trial and that intranasal Foralumab was well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on August 18,
2020 the United States Patent and Trademark Office, or USPTO, granted us a patent on use and methods of treatment of Crohn&#8217;s disease
with Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 mAbs.&#160;The CD3 (cluster of differentiation
3) is a protein complex on T-cells, which is important for the regulation of the immune system. The patent was published by the USPTO
on September 1, 2020 as Patent No.&#160;10,759,858.&#160;Recently, we also announced the issuance of the first-ever patent on oral administration
of anti-CD3 mAbs for treatment of human diseases (Patent No.&#160;10,688,186). We believe the grant of this additional composition-of-matter
and use patent further strengthens our intellectual property, consisting of proprietary technologies on oral and nasal administration
of Foralumab and other anti-CD3 mAbs for the treatment of human diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2020, we&#160;announced
that we had submitted a patent application on the potential use of Foralumab, a fully human anti-CD3 mAbs, to improve success of chimeric
antigen receptor T-cell, or CAR-T, therapy for cancer and other human diseases. The patent application conveys inventions related lymphodepletion
to improving CAR-T expansion and/or survival using anti-CD-3 mAbs administered either alone or in combination with other co-stimulatory
molecules, such as an anti-IL-6R mAb, an anti-CD28 mAb or specific inhibitors of signaling pathways of phosphatidylinositol 3-kinase (PI3K),
protein kinase B (AKT), or mammalian target of rapamycin (mTOR).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 31, 2020, we announced
that we had submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 mAb, for the
treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies implied that a combination of
anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages of COVID-19 disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing a fully
human mAb targeting the IL-6R (TZLS-501) for which the intellectual property was licensed from Novimmune in January 2017. This fully human
mAb has a novel mechanism of action, binding to both the membrane-bound and soluble forms of the IL-6R as well as depleting circulating
levels of the IL-6 in the blood. Excessive production of IL-6 is regarded as a key driver of acute inflammation resulting from infection
with viral agents such as Coronaviruses and of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology
indications and rheumatoid arthritis, and we believe that TZLS-501 may have potential therapeutic value for these indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, TZLS-501
demonstrated the potential for overcoming the limitations of other IL-6 blocking pathway drugs. Compared to tocilizumab and sarilumab,
while binding to the membrane-bound IL-6R complex, TZLS-501 has been observed to have a higher affinity for the soluble IL-6 receptor
from antibody binding studies conducted in cell culture. TZLS-501 also demonstrated the potential to block or reduce IL-6 signaling in
mouse models of inflammation. The soluble form of IL-6 has been implicated to have a larger role in disease progression compared to the
membrane- bound form (Kallen, K.J. (2002). &#8220;The role of trans-signaling via the agonistic soluble IL-6 receptor in human diseases.&#8221;
Biochimica et Biophysica Acta. 1592 (3): 323&#8211;343.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is developing
TZLS-501 for treatment of SSc-ILD. Tocilizumab (Actemra&#174;, Roche) a humanized interleukin-6 (IL-6) receptor mAb antagonist. was approved
by the FDA as a subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated
interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra&#174; is the first biologic therapy
approved by the FDA for the treatment of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2020 The Company
announced that it had developed investigational new technology to treat COVID-19 infections, consisting of direct delivery of anti-IL-6
receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer for treatment of patients infected
with COVID-19 (SARS-CoV-2)&#160;coronavirus.&#160;On June 29, 2020 the Company announced that it was advancing GMP manufacturing of TZLS-501
with STC Biologics concurrently with the development of inhalation technology using a hand-held nebulizer with Sciarra Laboratories and
safety toxicology studies in Cynomolgus monkeys with ITR Canada Laboratories. GMP batches were initiated in January 2021 and completed
in March 2021. Safety inhalation toxicology studies were initiated in November 2020 and completed in March 2021. Technological assessment
of nebulizers for inhalation treatment of patients was initiated in September 2020 and completed in February 2021. An additional 240L
cGMP batch of TZLS-501 drug substance was manufactured using an improved downstream process to support future development activities in
June 2022. An IND for a Phase 1 Clinical Trial in Healthy Subjects for treatment of interstitial lung disease associated with systemic
sclerosis (SSc ILD) was filed in December 2022. This program has been temporarily paused to pursue the Company&#8217;s short-term focus
on clinical development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Milciclib,
for which we in-licensed the intellectual property from Nerviano Medical Sciences S.r.l., or Nerviano, in January 2015, as a potential
treatment for pan KRAS mutations in NSCLC patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, Milciclib has been
studied in a total of eight completed Phase 1 and 2 clinical trials in 316 patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cumulative Patient Exposure
in Completed Milciclib Clinical Studies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Clinical Study</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Drug</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Indication</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> Patients<br/>
Treated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 32%; vertical-align: top">CDKO-125a-001 Phase 1</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 18%; text-align: center">Milciclib</td><td style="width: 1%">&#160;</td>
    <td style="width: 36%; text-align: center">Solid tumors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left">CDKO-125a-002 Phase 1 / Phase 2</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Milciclib</td><td>&#160;</td>
    <td style="text-align: center">Malignant glioma (Phase 1) <br/> Glioblastoma (Phase 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">CDKO-125a-003 Phase 1</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Milciclib</td><td>&#160;</td>
    <td style="text-align: center">Solid tumors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">CDKO-125a-004 Phase 1</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Milciclib + gemcitabine</td><td>&#160;</td>
    <td style="text-align: center">Solid tumors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">CDKO-125a-005/-0061/-0071 Phase 2</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Milciclib</td><td>&#160;</td>
    <td style="text-align: center">Malignant Pleural <br/> Mesothelioma&#160;(-005) <br/> Thymic carcinoma and malignant thymoma (-0061 and -0071)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; vertical-align: top">CDKO-125a-010 Phase 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Milciclib</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">HCC monotherapy</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Total Patients Exposed</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">316</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Source: Development Safety
Update Report No. 8, February 28, 2019, Tiziana Life Sciences PLC; Investigator Brochure, Version 14, 2019. <b>&#160; </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In these trials, Milciclib
was observed to be well-tolerated and showed initial signals of anti-tumor action. Prior to in-licensing, Milciclib was granted orphan
designation by the European Commission and by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of malignant
thymoma and an aggressive form of thymic carcinoma in patients previously treated with chemotherapy. In two Phase 2a trials, CDKO-125a-006
and CDKO125a-007, Milciclib showed signs of slowing disease progression and acceptable safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the first half of
2017, the Group initiated a Phase 2a trial (CDKO-125a-010) of Milciclib to explore safety, tolerability and antitumor activity of milciclib
as a single therapy in Sorafenib-resistant patients with unresectable or metastatic HCC and good liver function.. Typically, this population
of patients have an advanced form of the disease with poor prognosis and an average overall survival expectancy of 3-5 months. The compound
was administered as home-based treatment at the dose of 100 mg/day for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off
x q4 wks) for a total of 24 weeks. The Phase 2a trial was completed in June 2019 with clinical safety result reported in July 2019 and
efficacy results reported in September 2019. The drug was well tolerated and the trial met clinical endpoints.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in; background-color: #FEFEFE">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since overexpression of CDKs
and dysregulation in pRB pathway (regulates transcription factors critical for cell cycle progression) are prominently associated with
tumor cell resistance to certain chemotherapeutic drugs, inhibition of multiple CDKs is an appealing approach to improve clinical responses
in cancer patient&#8217;s refractory to existing treatment options. A Phase 1 dose-escalation&#160;study of Milciclib in combination with
gemcitabine in patients with refractory solid tumors exhibited clinical activity in patients including those refractory to gemcitabine.
Milciclib shows inhibitory effects against multiple cell lines with mutationally active G12D (non-small cell lung carcinoma), G13D (colorectal
cancer), G12V(pancreatic cancer), and G12C (pancreatic cancer<b>&#160;</b>The Company also intends to evaluate milciclib in combination
with gemcitabine for treatment of pan KRAS mutations in NSCLC patients. cGMP manufacturing of milciclib capsules was completed in January
2022 and IND filing was completed on December 15, 2022. This program has been temporarily paused to pursue the short-term focus on clinical
development of intranasal foralumab administration for treatment of SPMS patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in March
2014, we have devoted substantially all our resources to conducting preclinical studies and clinical trials, organizing and staffing our
company, business planning, raising capital and establishing our intellectual property portfolio. We do not have any products approved
for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the
sale of ordinary shares. Through December 31, 2022, we had received net cash proceeds of $118.5m million from sales of our ordinary shares,
issuance of convertible loans, short term loans and warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
incurred operating losses. Our net loss after taxation was $17.5 million for the year ended December 31, 2023, $15.4 million for the year
ended December 31, 2022 and $26.7m for the year ended December 31, 2021 respectively. As of December 31, 2023, we had cash and cash equivalents
of $1.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant expenses for the foreseeable future as we advance our product candidates through preclinical and clinical development and
seek regulatory approval and pursue commercialization of any approved product candidates. In addition, if we obtain marketing approval
for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing,
sales and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Trend information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent developments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be a party to litigation or subject to claims incident to the ordinary course of business. Although the results of litigation and claims
cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material
adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement
costs, diversion of management resources and other factors. We are not currently a party to any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Foreign currency translations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items included in the financial
statements are measured using the currency of the primary economic environment in which the entity operates (the functional currency).
The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the income statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
overseas subsidiary undertakings are translated into U.S. dollars on the following basis:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Assets and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Profit and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Components of Our Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development
efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product
sales. Any ad hoc sublicensing revenues have been treated as other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">R&amp;D expenses consist primarily
of costs incurred in connection with the R&amp;D of our product candidates and are expensed as incurred. These expenses consist of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">manufacturing scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies and clinical trial materials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in R&amp;D functions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">costs related to compliance with regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">facilities costs, depreciation and other expenses, which include rent and utilities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">fees for maintaining our third-party licensing agreements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize external development
costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our direct R&amp;D expenses
are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside
consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development activities. Our direct
R&amp;D expenses by program also include fees incurred under our license agreements. We do not allocate employee costs or facility expenses,
including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as
such, are not separately classified. We use internal resources primarily to oversee the R&amp;D as well as for managing our preclinical
development, process development, manufacturing and clinical development activities. These employees work across multiple programs and,
therefore, we do not track their costs by program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarizes
our R&amp;D expenses incurred by program:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="14" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Direct research and development expense by program:</td><td>&#160;</td>
    <td colspan="14" style="text-align: center"/><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Foralumab</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,570</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,962</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,372</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,346</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Milciclib</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>TZLS-501</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,785</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>ACT-D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>CAR-T</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">StemPrintER</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total direct research and development expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,993</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Indirect research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total research and development expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,113</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,208</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,993</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">R&amp;D activities are central
to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in
earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product
manufacturing expenses. As a result, we expect that our R&amp;D expenses will increase substantially over the next several years as we
increase personnel costs and prepare for regulatory filings related to our product candidates. We also expect to incur additional expenses
related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements
to acquire the rights related to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The successful development
and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing
and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates
or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks
and uncertainties associated with development and commercialization, including the uncertainty of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishing an appropriate safety profile with IND- and CTA-enabling studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">successful patient enrollment in, and the initiation and completion of, clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significant and changing government regulation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintaining a continued acceptable safety profile of the product candidates following approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may never succeed in achieving
regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue,
delay or modify clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel in executive, finance
and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting and
audit services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that our general
and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and
development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance,
director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Impairment of an asset</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This is an extraordinary expense
item for 2020 and includes the expenses for the impairment of a non-current asset.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Disposal of Intellectual Property</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This is an extraordinary expense
item for 2020 and includes the expenses related to the disposal of intellectual property during the year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Income (Expense)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other expense consists of
interest on a convertible loan note and income received from a partnership agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Taxation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax income for a period
represents the total of current taxation and deferred taxation. The charges in respect of current taxation are based on the estimated
taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted
for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is
calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under UK tax legislation,
small and medium entity R&amp;D relief allows us to claim back up to 14.5% of our surrenderable losses as a tax cash credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations
that follow reflect the historic periods under review and should not be taken as indicative of future performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Years Ended December 31, 2023
and 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables summarizes
our results of operations for the years ended December 31, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Expenses</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,113</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,955</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,842</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,871</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,638</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,233</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization bonus</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,984</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,593</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,391</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,984</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,593</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,391</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income/(expense):</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Income/(expense)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,144</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,151</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>FV Loss on Investment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(402</p></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(869</p></td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">467</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">65</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(65</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other income/(expense)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">742</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(811</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,553</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations before income taxes</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,242</span></td>
    <td style="padding-bottom: 4pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,404</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,838</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax credit</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(449</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(449</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss for the year</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,691</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,404</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,287</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Comprehensive loss:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain/(Loss) on currency translation</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,492</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,582</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,074</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,199</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,986</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,787</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development activities
were $8.1 million for the year ended December 31, 2023 compared to $12.9 million for the year ended December 31, 2022 a decrease of $4.8
million. The decrease in cost is a result of focused expenditure on initiating a Phase 2 trial for foralumab in patients with non-active
secondary progressive multiple sclerosis and developing and initiating the open label expanded access program in the same indication,
offset by the absence of manufacturing costs on TZLS-501.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating expenses were $9.8
million for the year ended December 31, 2023 as compared to $1.6 million for the year ended December 31, 2022, an increase of $8.2 million.
The increase in operating expenses is a result of a increase in in option related expenses of $2m due to a large number of forfeitures
in 2022, an increase in public relation and investor relations expense of $1.0m, an increase in travel expenses of $0.3m, an increase
in directors fees due to additional fees and a bonus to the chairman of $0.2m and a $4.7m net loss due to unfavorable foreign exchange
movements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Income/(expense), net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was finance income during
the year of $0.74m for the year ended December 31, 2023. There was a gain of $0.6m due to the change in fair value of the company&#8217;s
investment in Okyo Pharma Ltd, a related party. The share price for 2.1m shares, on December 31, 2023, was $1.77 compared to the investment
price of $1.50. There were financing fees and interest received for Okyo Pharma Ltd. $1.13m and Rasna Therapeutics Inc, a related party,
$0.02.m. There was a loss of $1m due to a change in fair value of the company&#8217;s investment in Accustem Sciences Inc., a related
party. The share price for 1.3m shares on December 31, 2023, was $0.63 per share compared to the investment price of $2 per share. There
was lease interest paid of $0.01m.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Tax Credit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A R&amp;D tax expense was
recognized for the year ended December 31, 2023 as the provisions for 2021 and 2023 were adjusted in accordance with HMRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Years Ended December 31, 2022
and 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables summarizes
our results of operations for the years ended December 31, 2021 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating Expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12,955</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13,208</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">253</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,638</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13,311</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Realization bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(855</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Impairment of asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Disposal of Intellectual Property</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,593</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other Income/ (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(176</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Income/(Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(844</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,737</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,404</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Comprehensive (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18,986</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(27,895</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,909</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development activities
were $13.0 million for the year ended December 31, 2022 compared to $13.2 million for the year ended December 31, 2021 a decrease of $0.3
million. The decrease in cost is a result of focused expenditure of anti-IL-6R monoclonal antibodies (mAbs) compounds and the manufacturing
of Foralumab and less spending on Milciclib.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating expenses were $1.6
million for the year ended December 31, 2022 as compared $13.3 million for the year ended December 31, 2021, a decrease of $11.7 million.
The decrease in operating expenses is a result of a decrease in option related expenses of $6.3mm due to options forfeitures and a decrease
in options outstanding during the year, a saving of $2.4m in labor costs due to a reduced headcount in 2022, a reduction in legal costs
of $1.5m due to a one off reorganization in 2021, a savings in insurance of $0.5m due to more favorable market conditions for D&amp;O,
$1.3m net gain due to favorable foreign exchange movements and other general savings of $0.3m.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Realization Bonus Expense</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A realization bonus of $13.2
million became payable during the year ended December 31, 2020 to the chairman of the board. This became payable upon the Company raising
funds in excess of $28m (&#163;20m), which it successfully raised in August 2020. As the bonus was not settled until November 2021, interest
of $0.9m was accrued on the amount due in the year to December 31, 2021. No further realization bonus was paid during the year ended December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other income/(expense)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was finance expense
during the year of $0.8 million for the year ended December 31, 2022. This charge related to the change in fair value of the company&#8217;s
investment in Accustem Sciences Inc as the share price as at December 31, 2022 was $1.35 per share compared to the investment price of
$2 per share.. No further charges were incurred in the year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Tax Credit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income tax credits of $3.2
million were recognized for the year ended December 31, 2021. No income tax credit was recognized for the year ended December 31, 2022
as the claim for 2020 is currently under review by HMRC, the company is awaiting the results of this review before proceeding with a claim
for year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have funded our operations
to date primarily with proceeds from the sale of ordinary shares, American Depository Shares, or ADSs, and convertible loan notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had cash and cash equivalents of $1.18 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our cash flows for each of the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,698</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,615</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,762</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in investing activities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,253</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,996</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash (used in) / provided by financing activities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(55</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of exchange rate changes on cash and cash equivalents</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(398</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,983</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (decrease)/increase in cash and cash equivalents</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,911</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,666</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,655</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Net Cash Used in Operating Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our use of cash in each of the years ended December 31, 2023, and 2022,
resulted primarily from our net losses, adjusted for non-cash charges and changes in components of working capital. Net cash used in operating
activities of $15.7 million during the year ended December 31, 2023 decreased by $3.9 million compared to the year ended December 31,
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our use of cash in each of
the years ended December 31, 2022, and 2021, resulted primarily from our net losses, adjusted for non-cash charges and changes in components
of working capital. Net cash used in operating activities of $19.6 million during the year ended December 31, 2022 decreased by $2.1 million
compared to the year ended December 31, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Net Cash Used in Investing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, we used $1.3 million of cash in investing activities. The Company spent $1m investing in a related party, Okyo Pharma Ltd. where
we purchased 2,100,000 shares for $1.5 a share, and $0.3m on a share buyback scheme.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, we used $4 million of cash in investing activities. The Company spent $2.7m investing in a related party, Accustem Sciences
Inc, where we purchased 1,337,970 shares for $2 a share, and $1.3m on a share buyback scheme.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Net Cash (used in)/ Provided by Financing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023 $0.01 million was used in the repayment of lease expenses. There was $.14 million consisting of net proceeds for the exercise
of warrants. During the year ended December 31, 2022, net cash used by financing activities was $0.01 million consisting of repayment
of lease expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022 $0.01 million was used in the repayment of lease expenses. During the year ended December 31, 2021, net cash provided by financing
activities was $0.01 million consisting of net cash proceeds the exercise of warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Funding Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our expenses to
increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities, manufacturing
and clinical trials of our product candidates and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establish a sales, marketing and distribution infrastructure in anticipation of commercializing any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">hire additional clinical, medical and development personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expand our infrastructure and facilities to accommodate our growing employee base; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintain, expand and protect our intellectual property portfolio.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our existing
cash, will enable us to fund our operating expenses and capital expenditure requirements for the immediate future. We have based these
estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we
receive regulatory approval for our other product candidates, we expect to incur significant commercialization expenses related to product
manufacturing, sales, marketing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the numerous risks
and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate
the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly
as a result of many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs and timing of hiring new employees to support our continued growth;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the extent to which we acquire technologies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until such time, if ever,
that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings.
To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted. If we raise additional
funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution
arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates
or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights
to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Research and Development Expenses, Patents and Licenses, etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4.B.&#8212;Intellectual
Property,&#8221; &#8220;Item 4.B.&#8212;Research and Development,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See &#8220;Item 5. Operating and Financial Review
and Prospects&#8212;Trend Information.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have during the periods presented, and
we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Tabular Disclosure of Contractual Obligations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our contractual
commitments and obligations as of December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>As at December 31, 2023</td><td>&#160;</td>
    <td colspan="14">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="14">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <br/> 1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Between 1<br/> and 5</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than<br/> 5 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Borrowings</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$-</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$-</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$-</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$-</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">259</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">259</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>As at December 31, 2022</td><td>&#160;</td>
    <td colspan="14">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="14">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 1 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Between 1<br/> and 5</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/> 5 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Borrowings</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">382</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">139</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">243</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">382</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">139</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">243</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to &#8220;Item
4.B. Business Overview&#8221; and &#8220;Item 10.C. Material Contracts&#8221; for further details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G. Safe Harbor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form&#160;20-F&#160;contains
forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act and as
defined in the Private Securities Litigation Reform Act of 1995.&#160;See the section titled &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6: DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -10.25pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Directors and Senior Management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our directors as of March 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><span style="font-size: 10pt">Gabriele Marco Antonio Cerrone MBA&#160;(2)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">52</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 55%"><span style="font-size: 10pt">Executive Chairman and acting Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Willy Simon&#160;(1,2,3)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">72</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">John Brancaccio (1), (3)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">76</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Non-Executive Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Remuneration Committee member</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Nominating Committee member</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Audit Committee member</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our senior managers as of March 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: black 1.5pt solid; width: 49%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Matthew Davis</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Medical Officer and Chief Operating Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Keeren Shah</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">William Clementi</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Development Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Jules S. Jacob</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Executive Director, CMC &amp; Non-Clinical Development</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gabriele Marco Antonio Cerrone &#8211; <i>Executive
Chairman</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Gabriele Marco Antonio
Cerrone, is the Founder of the company and has been its Executive Chairman since April 2014. Mr. Cerrone has founded ten biotechnology
companies in oncology, infectious diseases and molecular diagnostics, and has listed seven of these companies on Nasdaq two to the Main
Market and AIM Market in London. Mr. Cerrone co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he
was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of
and led the restructuring of Siga Technologies, Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman
of the Board until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn
sale to Bristol Myers Squibb Co in 2012. Mr. Cerrone is the Executive Chairman and Founder of Tiziana Life Sciences Ltd, an oncology focused
therapeutics company; Co-Founder of Rasna Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder
of Hepion Pharmaceuticals, Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused
on oncology using microRNA technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital
Ltd. Mr. Cerrone graduated from New York University&#8217;s Stern School of Business with a master&#8217;s degree in business administration
(MBA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Willy Simon &#8211; <i>Non-Executive Director</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Willy Jules Simon has served
as a Non-Executive Director of the company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before
serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management
from 1999 to 2002. He acted as chairman of Bank Oyens &amp; van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly
24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed company. Willy
Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He
is also a non-executive director of OKYO Pharma Ltd.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>John Brancaccio &#8211; <i>Non-Executive Director</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">John Brancaccio, a retired
CPA, has served as a director of our company since July 2020. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer
of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a director of Callisto Pharmaceuticals,
Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was a director of Tamir Biotechnology, Inc.
(formerly Alfacell Corporation) until 2019, as well as a director of Hepion Pharmaceuticals, Inc. since December 2013, Rasna Therapeutics,
Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd since June 2020. Mr. Brancaccio
served as a director of Synergy from July 2008 until April 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Keeren Shah &#8211; <i>Chief Financial Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Keeren Shah serves as our
Chief Financial Officer. Ms. Shah currently also serves as the CFO of Accustem Sciences Inc, OKYO Pharma Ltd and Rasna Therapeutics Inc.,
having previously served as the Group Financial Controller for these businesses from June 2016 to July 2020. Prior to joining the Company,
Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance team where she was responsible for key financial controller activities,
financial planning and analysis, and core processes as well as leading and participating in key transformation programmes and Visa Inc.&#8217;s
initial public offering. Before joining Visa, Ms. Shah has also held a variety of finance positions at other leading companies including
Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of
Management Accountants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Matthew W Davis - <i>Chief Medical Officer
and Chief Operating Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Davis has extensive
experience in new drug application, or NDA, and biologic license application, or BLA, FDA approvals and device clearances. Notable approved
brands that Dr. Davis has worked on include Lidoderm&#174;, Sculptra&#174;, Colcrys&#174; and most recently QWO&#174;. Dr. Davis previously
served as Chief Scientific Officer and Chief Medical Officer at Endo Pharmaceuticals where he restructured the R&amp;D department and
collaborated to obtain BLA approval for QWO&#174;. Additionally, Dr. Davis was Chief Medical Officer for Lupin Inc. and URL Pharma, Inc.
where he spearheaded three NDA approvals and was the inventor on all 17 Orange Book listed patents for Colcrys&#174;. He also was on the
executive team that sold URL Pharma to Takeda Pharmaceutical Company for approximately $800M combined with over $1B in performance-based
contingent earn out payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Davis matriculated
to the University of Pennsylvania as an undergraduate. He received his Pharmacy Degree from Temple University and his Medical Degree from
the Medical College of Pennsylvania. Dr. Davis undertook his surgical training at Brown University and his Urology training at Washington
Hospital Center.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>William Celementi &#8211; <i>Chief Development
Officer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Clementi has followed
a science-driven career path since completing his NIH Training Fellowship (under John L. McNay M.D. and Thomas M. Ludden Ph.D.) Upon completing
his Fellowship research in drug metabolism and vascular smooth muscle relaxation, Dr. Clementi joined the University of Texas Graduate
School of Biomedical Sciences (UTGBS) faculty and the College of Pharmacy faculty in Austin, Tx, in the Departments of Medicine and Pharmacology
at the Health Sciences Center in San Antonio. His primary responsibilities were interdisciplinary, and he led innovative programs in the
Colleges with teaching, research, and clinical commitments. Dr. Clementi directed the Clinical Pharmacokinetic Consultation Service, providing
novel computer-based drug dosing to the acute care settings at two major teaching hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Clementi continued
his career in the pharmaceutical industry, joining Synthelabo and the U.S. affiliate Lorex Pharmaceuticals, where he held the Worldwide
Director of Market Development position. Lorex and Synthelabo launched three EMA and FDA-approved products (betaxolol, zolpidem, and alfuzosin).was
on the executive team that sold URL Pharma to Takeda Pharmaceutical Company for approximately $800M combined with over $1B in performance-based
contingent earn out payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Jules S. Jacob &#8211; <i>Executive Director,
CMC&#160;&amp; Non-Clinical Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Jules Jacob has served
as Senior Director (2017-2021)_ and Executive Director of CMC and Non-Clinical Development of the company since January 2022. He has over
25 years of drug development experience. Previously, Mr. Jacob was senior director of product development at Aprecia Pharmaceuticals Company,
a drug delivery technology platform company, from March 2009 to July 2017, where he led the development of Spritam&#174;, the first FDA-approved
dosage form manufactured using 3-dimensional printing, and other 505(b)(2) pipeline products. Mr. Jacob was director of formulation development
at Panacos Pharmaceuticals Inc., a drug company focused on human immunodeficiency virus, or HIV, and other major human viral diseases,
from March 2007 to December 2008, where he worked on the development of first-in-class maturation inhibitors for the treatment of HIV.
Mr. Jacob was a founding scientist, director of R&amp;D and director of technology development at Spherics, Inc., a pharmaceutical company
that engaged in developing and manufacturing oral pharmaceutical products for CNS conditions, GI disorders, and cancer, from February
2000 to February 2007. Mr. Jacob worked on the development of bioadhesive dosage forms for treatment of CNS disorders, through the 505(b)(2)
regulatory pathway at Spherics Inc. Mr. Jacob completed his undergraduate degree and graduate education in biological and medical sciences
at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacology, Physiology and Biotechnology
at Brown University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among any of our executive officers or directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Total Compensation for the Executive Chairman and Non-Executive
Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets out the
total remuneration received by the Executive Chairman and the Non-Executive Directors for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees<br/>
earned<br/>
or paid<br/>
in cash<br/>
($000)</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus <br/>
earned<br/>
or paid<br/>
in cash<br/>
($000)<br/>
(2)</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options<br/>
awarded<br/>
($000) <br/>
(1)</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other<br/>
($000)</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
($000)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">717</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">817</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy Simon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non &#8211; Executive Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Brancaccio</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non &#8211; Executive Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the fair value of incentive stock options granted during the year to December 31, 2023 using an appropriate valuation model for computing stock-based compensation expense as of the date of grant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Narrative Disclosure to the Compensation table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Gabriele Cerrone</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 9, 2016 we entered
into an agreement with our Executive Chairman, Gabriele Cerrone. Under the agreement, Mr Cerrone was to hold office as Chairman for &#163;80,000
per annum. The agreement was to expire no earlier than 24 April 2018 and was to continue thereafter until terminated by either party giving
written notice of 12 months. Mr Cerrone was also eligible to receive an annual bonus of up to 50% of his base salary, such bonus amount
to be determined at the discretion of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, Mr Cerrone was
also eligible to receive two realization bonuses as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event that, either: (i) the Group raises, in one or a series of transactions, new equity capital in excess of &#163;20,000,000 (after expenses); or (ii) there is a sale, in one or a series of transactions, of all or substantially all of the assets (calculated on the basis of book values) of the Group Companies (or a license of the same on an exclusive or non-exclusive basis), where the Enterprise Value equals or exceeds &#163;150,000,000; or (iii) there is a change of control where the Enterprise Value equals or exceeds &#163;150,000,000, in which case the Realization Bonus will be the amount equal to the Enterprise Value multiplied by two and a half (2.5) per cent</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that, during
    this Agreement, either: (i) there is a sale, in one or a series of transactions, of all or substantially all of the assets (calculated on the basis of book values) of the Group (or a license of the same on an exclusive or non-exclusive basis), where the
    Enterprise Value equals or exceeds &#163;300,000,000 (Subsequently amended on 22 April 2024 to be expressed as US$372,000); or (ii)
    there is either a change of control where the Enterprise Value equals or exceeds &#163;300,000,000, (Subsequently amended on 22
    April 2024 to be expressed as US$372,000) the Chairman will be entitled to receive an additional Realization Bonus in the amount
    equal to the Enterprise Value multiplied by three and a half (3.5) per cent.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Enterprise Value means:
(i) in the case of a change of control resulting in consideration payable to the Group (for example, on a sale of its assets or licensing
transaction), the total cash and non-cash consideration received by the Group; or (ii) in the case of a change of control resulting in
consideration payable to the shareholders of the ordinary shares in the issued share capital of the Group from time to time, the total
cash and non-cash consideration payable to the Shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first realization bonus
was satisfied on 5 August 2020, and the Chairman was unconditionally entitled to the immediate delivery of 4,763,995 new ordinary shares
credited as fully paid in lieu of a cash payment. The number of shares to be issued was fixed. Due to the delayed delivery of shares,
additional shares were granted in lieu of interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 9, 2020, we entered
into an amended agreement with Mr Cerrone, increasing his base salary to &#163;240,000 per annum. All other terms and conditions remained
the same.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, we entered
into a new agreement which superseded the original consultancy agreement dated June 9, 2016 and the amended agreement dated October 9,
2020. The duration of the consultancy agreement was fixed until December 31, 2028 and the fee remained at &#163;240,000 per annum. All
terms regarding the second realization bonus remained the same.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 22 April 2024, we entered into an agreement comprising of an amendment,
supplement, and restatement of the consultancy agreement, fixing the term of the agreement until 31 December 2030 and increased his compensation
to US$500,000 whilst Mr. Cerrone continues to discharge his function of chief executive officer and executive chairman of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 14 March, 2023, which was
subsequently amended and restated on 22 April 2024, we granted Mr Cerrone a long-term realization bonus on the basis that were the Company
to be sold, during the currency of his directorship or in the period of 6 years,(extended to 10 years pursuant to the amendment and restatement
agreement on 22 April 2024) thereafter, for a price at, or in excess of, US$1,000,000,000 that Mr Cerrone receive a bonus equal to 6.5%
of the enterprise value of the Company (and not just the excess over US$1,000,0000,000), such bonus to be in addition to the current realization
bonus contained in Mr. Cerrone&#8217;s consultancy agreement dated December, 21 2022 (as amended and restated on 22 April 2024) but on
the basis that were the US$1,000,000,000 threshold to be hit, the Company would be entitled to offset any payment due under the realisation
bonus contained in the December, 21 2022 Consultancy Agreement against any amount then due under this new realization bonus. The terms
of the award to make appropriate provision for any &#8220;spin-off&#8221; of assets and for the eventuality that the Company be sold for
non-cash consideration. In addition, it should be a clear condition that Mr Cerrone be responsible for all tax liabilities in connection
with any payment of the award.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr Cerrone was awarded a stock
allocation in 2024 to compensate for (i) additional salary of $424,000 to compensate him for a salary differential with other executive
staff, covering the period from August 1, 2022 to December 31, 2023, and (ii) a one-off 2023 bonus of $100,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Non-Executive Director remuneration</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remuneration of our non-executive
directors is determined by our board as a whole, based on independent compensation reviews. We intend to enter into service contracts
with our directors for their services or amend and restate any prior service contracts in place prior to, or as soon as practicable, following
the filing of this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 103; Options: NewSection; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards at Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding all outstanding equity awards for our directors, executive officers, and non-executive directors, as of December
31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary<br/> Shares<br/> Underlying<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/> Price Per<br/> Ordinary<br/> Share (&#163;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration<br/> Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gabriele Cerrone</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">915,388</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">25/06/2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">25/06/2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,629,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">06/05/2020</td><td>&#160;</td>
    <td style="text-align: center">05/05/2028</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">25/08/2020</td><td>&#160;</td>
    <td style="text-align: center">24/08/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">14/03/2023</td><td>&#160;</td>
    <td style="text-align: center">14/03/2033</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">John Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">25/08/2020</td><td>&#160;</td>
    <td style="text-align: center">24/08/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">John Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">14/03/2023</td><td>&#160;</td>
    <td style="text-align: center">14/03/2033</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Tiziana Life Sciences Ltd (formerly Tiziana
Life Sciences plc) Employee Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Tiziana Life Sciences
Ltd (formerly Tiziana Life Sciences plc) Employee Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan, or the 2016 Plan, was
adopted by the Board on March 23, 2016 and approved by shareholders on June 30, 2016 and allows for the grant of options to eligible service
providers. The material terms of the 2016 Plan are summarized below. This plan closed to new entrants on October 21, 2021 and has been
superseded by the Tiziana Life Sciences Ltd 2021 Equity Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Eligibility and Administration</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to October 21, 2021,
our employees, consultants and directors, and employees and consultants of our subsidiaries were eligible to receive options under the
2016 Plan. The 2016 Plan was administered by our board of directors, which may delegate its duties and responsibilities to one or more
committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to the limitations imposed
under the 2016 Plan, stock exchange rules and other applicable laws. The plan administrator has the authority to take all actions and
make all determinations under the 2016 Plan, to interpret the 2016 Plan and option agreements and to adopt, amend and repeal rules for
the administration of the 2016 Plan as it deems advisable. The plan administrator also had the authority to determine which eligible service
providers receive options, to grant options and to set the terms and conditions of all options granted under the 2016 Plan, including
any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2016 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Options </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2016 Plan provided for
the grant of options. All options granted under the 2016 Plan were set forth in option agreements, which will detail the terms and conditions
of the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Options provide for the purchase
of our ordinary shares in the future at an exercise price set on the grant date. The plan administrator will determine the number of shares
covered by each option, the exercise price of each option and the conditions and limitations applicable to the exercise of each option</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a holder of options dies,
options may be exercised by the personal representative with 12 months following death in respect of all or such proportion of the option
as the plan administrator may specify to take account of the extent to which any exercise conditions have been achieved at the relevant
date. If a holder of options leaves as a good leaver or the plan administrator allows, options may be exercised within 90 days in respect
of all or such proportion of the option as the plan administrator may specify to take account of the extent to which any exercise conditions
have been achieved at the relevant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercise Conditions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The plan administrator may
specify one or more appropriate exercise conditions that must be satisfied before options may be exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Change of Control and Variation of Share Capital</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a change of
control, the plan administrator may specify whether all or a proportion of options will be exercisable to take account of the extent to
which any exercise conditions have been achieved at the relevant date. Alternatively, holders of options may agree to accept an offer
to exchange options for options to acquire shares in an acquiring company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If there is a variation of
our ordinary shares the plan administrator may adjust the number of shares under options and/or the exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Plan Amendment and Termination</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
amend the 2016 Plan at any time; however, the provisions governing eligibility requirements, equity dilution, the basis for determining
the rights of holders of options and the adjustment of options cannot be altered to the advantage of existing or new holders of options
without the prior approval of our shareholders in general meeting. No options may be granted under the 2016 Plan after the tenth anniversary
of the date of adoption by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Transferability </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Options granted under the
2016 Plan are generally non-transferrable, except on death. With regard to tax withholding and exercise price obligations arising in connection
with the exercise of options under the 2016 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or cheque,<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Employee Sub-Plan </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Non-Employee Sub-Plan,
options may be granted to advisers, consultants and non-executive directors on terms comparable to those described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>US Sub-Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The US Sub-Plan permits the
grant of options to employees, directors and consultants who are US residents and US taxpayers, including potentially tax efficient Incentive
Stock Options (as defined in Section 422 of the Internal Revenue Code of 1986, as amended). A maximum of 9,233,392 ordinary shares may
be issued under the US Sub-Plan (which number shall be the maximum number that may be granted as Incentive Stock Options). <i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Tiziana Life Sciences Ltd 2021 Equity Incentive Plan </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&#160;20, 2021,
Tiziana adopted the Tiziana Life Sciences Ltd 2021 Equity Incentive Plan (the &#8220;Plan&#8221;) which operates over common shares in
Tiziana. The purpose of the Plan is to assist the Company and its Subsidiaries in attracting and retaining valued Employees, Consultants
and Non-Employee Directors by offering them a greater stake in the Company&#8217;s success and a closer identity with it, and to encourage
ownership of the Company&#8217;s shares by such Employees, Consultants and Non-Employee Directors. Any employee, director or consultant
of Tiziana Life Sciences Ltd or any of its subsidiaries is eligible to receive Awards under the Plan. The Plan will be administered by
the Compensation Committee of the Board (the &#8220;<span style="text-decoration:underline">Compensation Committee</span>&#8221;). Awards granted to nonemployee members
of the Board will be administered by the full Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan was approved by the
shareholders of the Company, no new awards will be granted under the Tiziana Life Sciences plc Employee Share Option Plan with Non-Employee
Sub-Plan and US Sub-Plan with California Supplement, as amended and/or restated from time to time (collectively, the &#8220;Prior Equity
Plan&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to adjustment as provided
in the Plan, the maximum number of shares that may be issued pursuant to Awards under the Plan is 15,000,000 shares (the &#8220;<span style="text-decoration:underline">Cap</span>&#8221;).
The Cap will be increased by the number of shares corresponding (as determined by the Compensation Committee) to the securities underlying
the portion of an award granted under the 2016 Plan that is cancelled, terminated or forfeited or lapses, in any case, on or after the
effective date of the Plan. No more than 15,000,000 shares issued under the Plan may be issued pursuant to the exercise of incentive stock
options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Plan, awards may
be in the form of options, share appreciation rights, restricted stock, restricted stock units, performance stock, performance stock units,
and other share-based awards. Each Award will be evidenced by an Award agreement containing the terms and conditions applicable to such
Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Change of Control and Variation of Share Capital</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Change in Control shall
not, in and of itself, accelerate the vesting, settlement or exercisability of outstanding awards, unless otherwise specified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<i>Transferability </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transferability of Restricted
Stock shall be prohibited or restricted in the manner and to the extent prescribed in the applicable Award Agreement. Such restrictions
may include, without limitation, rights of repurchase or first refusal in the Company or provisions subjecting the Restricted Stock to
a continuing substantial risk of forfeiture in the hands of any transferee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>UK Supplemental Plan </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The UK Supplemental plan
shall apply to any Award granted to a Participant who is resident in the United Kingdom for tax purposes at the time the Award is granted
or on the occurrence of any taxable event in respect of the Award and to any Participant who is not resident in the United Kingdom at
such time(s) but who is granted the Award in respect of duties performed in the United Kingdom (a &#8220;UK Participant&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Terms for UK Participants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Employer National Insurance
Contributions Indemnity.&#160;</i>In the case of any Award to a UK Participant in the form of Options, Restricted Stock, Restricted Stock
Units, Performance Stock, Performance Stock Units or Other Share-Based Award, if required by the Board, it shall be a condition of such
Award that the UK Participant irrevocably agrees that the Company and/or any applicable Subsidiary may recover from the UK Participant
the whole or any part of any employer National Insurance Contributions, Apprenticeship Levy or other social security contributions for
which the Company and/or any applicable Subsidiary is liable to account in respect of the Award, in each case to the extent permitted
by applicable law, and/or that the UK Participant shall enter into such election (using a form approved by HM Revenue &amp; Customs) as
may be required for the whole or any part of such taxes to be transferred to the UK Participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Date of Termination.&#160;</i>For
the purposes of the Plan (and the corresponding provisions in any Award Agreement) the termination of employment of a UK Participant for
Cause or as the result of the UK Participant&#8217;s resignation shall be deemed to occur on the earlier of (i) the date on which the
UK Participant&#8217;s employment terminates, and (ii) the date on which the UK Participant gives or receives notice of the termination
of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bankruptcy. </i>Unless
otherwise provided in an Award Agreement, the unvested portion of a Participant&#8217;s Award shall be immediately forfeited with no compensation
or other payment due to the Participant upon the Participant (i) being declared bankrupt, (ii) making an application for an interim order
or any proposal for a voluntary arrangement within Part VIII of the Insolvency Act 1988, or (iii) proposing any form of compromise with
his creditors or any class of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tax Election.&#160;</i>In
the case of an Award to a UK Participant in the form of Options, Restricted Stock, Restricted Stock Units, Performance Stock, Performance
Stock Units or Other Share-Based Award, unless the Board determines otherwise, it shall be a condition of the Award that the UK Participant
enters into a joint tax election with his or her employer pursuant to Section 431(1) of the Income Tax (Earnings and Pensions) Act 2003
in respect of any Shares acquired pursuant to such Award, such election to be made no later than 14 days following the date on which such
Shares are acquired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Relationship to Employment
Contract. </i>The rights of a UK Participant under the terms of his or her office or employment with the Company or any Subsidiary shall
not be affected by the Plan, this Supplement or any Award Agreement. The value of any benefit realized by a UK Participant in respect
of an Award shall not be taken into account in determining any pension or similar entitlement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Limitation on Claims</i>.
A UK Participant shall have no right to compensation or damages on account of any loss in respect of an Award where the loss arises (or
is claimed to arise), in whole or in part, from termination of office or employment with, or notice to terminate office or employment
given by or to, the Company or any Subsidiary. This exclusion of liability shall apply however termination of office or employment, or
the giving of notice, is caused, and however compensation or damages are claimed. A UK Participant shall have no right to compensation
or damages from the Company or any Subsidiary on account of any loss in respect of an Award where the loss arises (or is claimed to arise),
in whole or in part, from any Change in Control, any company ceasing to be a Subsidiary or the transfer or any business from the Company
or any Subsidiary to any other person</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Governance Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer,&#8221; as defined by the SEC. As a result, in accordance with Nasdaq listing requirements, we may rely on home country governance
requirements and certain exemptions thereunder rather than complying with NASDAQ corporate governance standards. While we voluntarily
follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Exemption from filing quarterly
reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form 8-K upon the occurrence
of specified significant events.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Exemption from Section 16 rules
requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from
trades in a short period of time, which will provide less data in this regard than shareholders of U.S. companies that are subject to
the Exchange Act.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Exemption from the Nasdaq requirement
requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Exemption from the requirement
that our board have a compensation committee that is composed entirely of independent directors with a written charter addressing the
committee&#8217;s purpose and responsibilities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.2in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Exemption from the requirement
to have independent director oversight of director nominations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the migration
to Bermuda, Tiziana adopted a Code of Business Conduct and Ethics which covers a broad range of matters including the handling of conflicts
of interest, compliance issues and other corporate policies such as insider trading and equal opportunity and non-discrimination standards.
Tiziana&#8217;s Code of Business Conduct and Ethics applies to all directors, executive officers and employees of Tiziana. Tiziana publishes
its Code of Business Conduct and Ethics on its website (www.tizianalifesciences.com).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not follow Nasdaq Rule
5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements are not required under English
law. In accordance with generally accepted business practice, our Bye-laws will provide alternative quorum requirements that are generally
applicable to meetings of shareholders.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not follow Nasdaq Rule
5605(b)(2), which requires that independent directors regularly meet in executive sessions where only independent directors are present.
Our independent directors may choose to meet in executive sessions at their discretion.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we may rely on certain
home country corporate governance practices, we must comply with Nasdaq&#8217;s Notification of Noncompliance requirement (Nasdaq Rule
5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies Nasdaq Rule 5605(c)(3),
which addresses audit committee responsibilities and authority and requires that the audit committee consist of members who meet the independence
requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take all actions
necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley
Act, the rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not have the same protections afforded
to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. For an overview of our corporate
governance principles, see the following section titled &#8220;Description of Bye-laws and Memorandum of Association&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Bye-laws and Memorandum of Association</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
includes a summary of specified provisions of our memorandum of association and our Bye-laws. This description is qualified by reference
to our memorandum of association and our Bye-laws which are incorporated by reference as exhibits to this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preemptive Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bye-laws do not provide
shareholders with pro rata preemptive rights to subscribe for any newly issued common shares. Additionally, the Companies Act does not
provide shareholders with a statutory preemptive right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Repurchase of Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
exercise all of the powers to purchase for cancellation or acquire our shares as treasury shares in accordance with the Companies Act.
On a reacquisition of shares, such shares may be cancelled (in which event, our issued but not our authorized capital will be diminished
accordingly) or held as treasury shares. Such purchases may only be effected out of the capital paid up on the purchased shares or out
of the funds otherwise available for dividend or distribution or out of the proceeds of a fresh issue of shares made for the purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Alteration of Share Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may, if authorized by a
resolution of our shareholders, increase, divide, consolidate, subdivide, change the currency denomination of, diminish or otherwise alter
or reduce the share capital in any manner permitted by the Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Variation of Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time we have more
than one class of shares, the rights attaching to any class, unless otherwise provided for by the terms of issue of the relevant class,
may be varied with the sanction of a resolution passed by a majority of the votes cast at a general meeting of the relevant class of shareholders
at which a quorum consisting of at least two persons holding or representing one-third of the issued shares of the relevant class is present.
Our Amended and Restated Bye-laws specify that the creation or issue of shares ranking equally with existing shares will not, unless expressly
provided by the terms of issue of existing shares, vary the rights attached to existing shares. In addition, the creation or issue of
preference shares ranking prior to common shares will not be deemed to vary the rights attached to common shares or, subject to the terms
of any other series of preference shares, to vary the rights attached to any other series of preference shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer of Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
in its absolute discretion and without assigning any reason refuse to register the transfer of a share which is not fully paid. Our board
of directors may also refuse to recognize an instrument of transfer of a share unless it is accompanied by the relevant share certificate
and such other evidence of the transferor&#8217;s right to make the transfer as our board of directors shall reasonably require. The board
shall refuse to register a transfer unless all applicable consents, authorizations and permissions of any governmental body or agency
in Bermuda have been obtained. Subject to these restrictions, a holder of common shares may transfer the title to all or any of its common
shares by completing a form of transfer in the form set out in our Bye-laws (or as near thereto as circumstances admit) or in such other
common form as the board may accept. The instrument of transfer must be signed by the transferor and transferee, although in the case
of a fully paid share our board of directors may accept the instrument signed only by the transferor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary in the Amended and Restated Bye-laws, our shares may be transferred without a written instrument if transferred by an appointed
agent and in any form or manner which is in accordance with the rules or regulations of an appointed stock exchange (which includes the
Nasdaq Capital Market) on which the shares are listed or admitted to trading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual general meeting
will be held each year in accordance with the requirements of the Companies Act and our Bye-laws at such time and place as our board of
directors appoints. Our board of directors or the chairman may also, whenever in its judgment it is necessary, convene general meetings
other than annual general meetings which are called special general meetings. Bermuda law and the Bye-laws provide that a special general
meeting must be called upon the request of shareholders holding not less than one-tenth of the paid-up capital of the Company carrying
the right to vote at general meetings. Any annual general meeting and special general meeting must be called by, respectively, not less
than twenty-one (21) days and five (5) days&#8217; prior notice in writing. A notice of meeting must include the place, day and time of
the meeting and, in the case of an annual general meeting, that the election of directors will take place thereat and any other business
to be conducted at the meeting, and, in the case of a special general meeting, the general nature of the business to be considered at
the meeting. This notice requirement is subject to the ability to hold such meetings on shorter notice if such notice is agreed: (i) in
the case of an annual general meeting by all of the shareholders entitled to attend and vote at such meeting; or (ii) in the case of a
special general meeting by a majority in number of the shareholders entitled to attend and vote at the meeting holding not less than 95%
in nominal value of the shares entitled to vote at such meeting. A shareholder may appoint a proxy to attend and vote at the general meeting
by providing notice in writing to us at our registered office or at such other place or in such manner as specified in the notice of the
general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chairman, if present,
and if not, the chief executive officer, if present, and if not, the president, if present, and if not, any person appointed by our board
of directors will act as chairman of the meeting. In their absence and if no one is appointed by our board of directors as chairman of
such meeting, a chairman of the meeting will be appointed or elected by those present at the meeting and entitled to vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board and Shareholder Ability to Call Special
Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bye-laws provide that
(a) the president or the chairman of the Company (if any) or any two Directors or any Director and the Secretary or the Board may convene
a special general meeting whenever in their judgment such a meeting is necessary and (b) the board of directors must convene a special
general meeting at the request of shareholders holding not less than one-tenth of the paid-up share capital of the Company with the right
to vote at general meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shareholder Meeting Quorum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bye-laws provide that
at any general meeting of shareholders, At any general meeting two or more persons present throughout the meeting and representing in
person or by proxy in excess of 331/3% of the total voting rights of all issued and outstanding shares in the Company shall form a quorum
for the transaction of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any restrictions
for the time being lawfully attached to any class of shares, every shareholder who is present in person or by proxy at a general meeting
shall be entitled to one vote on a show of hands and be entitled to one vote for every share of which he is a holder on a vote taken by
poll, and any question proposed for the consideration of the shareholders at any general meeting shall be decided by the affirmative votes
of a majority of the votes cast in accordance with the Bye-laws, and in the case of an equality of votes, the resolution will fail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shareholder Action by Written Consent</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bye-laws provide that
no action required to be taken or which may be taken at any general meeting of Members may be taken without a meeting, and the power of
Members to consent in writing, without a meeting, to the taking of any action is specifically denied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Access to Books and Records and Dissemination
of Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of the general public
have a right to inspect the public documents of a company available at the office of the Registrar of Companies in Bermuda. These documents
include the company&#8217;s memorandum of association, including its objects and powers, and certain alterations to the memorandum of
association. The shareholders have the additional right to inspect the bye-laws of the company, minutes of general meetings and the company&#8217;s
audited financial statements, which must be presented to the annual general meeting. The register of members of a company is also open
to inspection by shareholders and by members of the general public without charge. The register of members is required to be open for
inspection for not less than two hours in any business day (subject to the ability of a company to close the register of members for not
more than thirty days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of
the Companies Act, establish a branch register outside of Bermuda. A company is required to keep at its registered office a register of
directors and officers that is open for inspection for not less than two hours in any business day by members of the public without charge.
A company is also required to file with the Registrar of Companies in Bermuda a list of its directors to be maintained on a register,
which register will be available for public inspection subject to such conditions as the Registrar may impose and on payment of such fee
as may be prescribed. Bermuda law does not, however, provide a general right for shareholders to inspect or obtain copies of any other
corporate records.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Removal of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Bye-laws
provide that shareholders entitled to vote for the election of directors may, at any special general meeting convened and held in accordance
with the Amended and Restated Bye-laws, remove a director only with cause, by the affirmative vote of shareholders holding at least a
majority of the total voting rights of all shareholders having the right to vote at such meeting, provided that the notice of any such
meeting convened for the purpose of removing a director must contain a statement of the intention so to do and be served on such director
not less than 14 days before the meeting and at such meeting the director will be entitled to be heard on the motion for such director&#8217;s
removal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proceedings of Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bye-laws provide that
our business is to be managed and conducted by our board of directors. Bermuda law permits individual and corporate directors and there
is no requirement in the Bye-laws or Bermuda law that directors hold any of our shares. There is also no requirement in the Bye-laws or
Bermuda law that our directors must retire at a certain age.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remuneration of our directors
is determined by the board of directors from time to time at a duly authorized meeting. Our directors may also be paid all travel, hotel
and other expenses properly incurred by them in connection with our business or their duties as directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provided a director discloses
a direct or indirect interest in any contract or arrangement or proposed contract or arrangement with us as required by Bermuda law, such
director is entitled to vote in respect of any such contract or arrangement in which he or she is interested and/or be counted in the
quorum for the meeting at which such contract or arrangement is to be voted on.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify; text-indent: -27.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify; text-indent: -27.35pt"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify; text-indent: -27.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Amalgamations, Mergers and Business Combinations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amalgamation or merger
of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the amalgamation or merger
agreement to be approved by the company&#8217;s board of directors and by its shareholders. Unless the company&#8217;s bye-laws provide
otherwise, the approval of 75% of the shareholders voting at such meeting is required to approve the amalgamation or merger agreement,
and the quorum for such meeting must be two persons holding or representing more than one-third of the issued shares of the company. The
Amended and Restated Bye-laws provide that an amalgamation, consolidation or a merger (other than with a wholly owned subsidiary or as
described below) that has been approved by the board must only be approved by a majority of the votes cast at a general meeting of the
shareholders at which the quorum shall be two or more persons present in person and representing in person or by proxy in excess of 50%
of all issued and outstanding common voting shares. Any other amalgamation or merger or other business combination (as defined in the
Amended and Restated Bye-laws) not approved by our board must be approved by the holders of not less than 66 2/3% of all votes attaching
to all shares then in issue entitling the holder to attend and vote on the resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dissenter&#8217;s Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Bermuda law, in the
event of an amalgamation or merger of a Bermuda company with another company or corporation, including a public Bermuda company, a shareholder
of the Bermuda company who did not vote in favor of the amalgamation or merger and is not satisfied that fair value has been offered for
such shareholder&#8217;s shares may, within one month of notice of the shareholders meeting, apply to the Supreme Court of Bermuda to
appraise the fair value of those shares. These approval rights did not apply to the Business Combination because the Company was not a
party to any amalgamation or merger contemplated by the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitations on Director Liability and Indemnification
of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 98 of the Companies
Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any liability which by virtue
of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except
in cases where such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to
the company. Section 98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability
incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they
are acquitted or granted relief by the Supreme Court of Bermuda pursuant to section 281 of the Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bye-laws provide that
the directors, resident representative, secretary and other officers acting in relation to any of the affairs of the Company or any subsidiary
thereof and the liquidator or trustees (if any) acting in relation to any of the affairs of the Company or any subsidiary thereof and
every one of them shall be indemnified and secured harmless out of the assets of the Company from and against all actions, costs, charges,
losses, damages and expenses which they or any of them shall or may incur or sustain by or by reason of any act done, concurred in or
omitted in or about the execution of their duty, or supposed duty, or in their respective offices or trusts, and no indemnified party
shall be answerable to the acts, receipts, neglects or defaults of the others of them or for joining in any receipts for the sake of conformity,
or for any bankers or other persons with whom any moneys or effects belonging to the Company shall or may be lodged or deposited for safe
custody, or for insufficiency or deficiency of any security upon which any moneys of or belonging to the Company shall be placed out on
or invested, or for any other loss, misfortune or damage which may happen in the execution of their respective offices or trusts, or in
relation thereto, provided that this indemnity shall not extend to any matter in respect of any fraud or dishonesty in relation to the
Company which may attach to any of the indemnified parties. We may also enter into an indemnification agreement with any director or officer
of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Bye-laws
provide that the Company may (i) purchase and maintain insurance for the benefit of any director or officer against any liability incurred
by such person under the Companies Act in his or her capacity as a director or officer of the Company or indemnifying such director or
officer in respect of any loss arising or liability attaching to him or her by virtue of any rule of law in respect of any negligence,
default, breach of duty or breach of trust of which the director or officer may be guilty in relation to the Company or any of its subsidiaries
and (ii) advance moneys to a director or officer for the costs, charges and expenses incurred by the director or officer in defending
any civil or criminal proceedings against him or her, on condition that the director or officer shall repay the advance if any allegation
of fraud or dishonesty in relation to the Company is proved against him or her.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Class Actions and Derivative Suits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Class actions and derivative
actions are generally not available to shareholders under Bermuda law. The Bermuda courts, however, would ordinarily be expected to permit
a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to
be beyond the corporate power of the company or illegal, or would result in the violation of the company&#8217;s memorandum of association
or bye-laws. Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority
shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#8217;s shareholders than that
which actually approved it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the affairs of a company
are being conducted in a manner which is oppressive or prejudicial to the interests of some part of the shareholders, one or more shareholders
may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the
company&#8217;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Amendment of Memorandum of Association and
Bye-laws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bermuda law provides that
the memorandum of association of a company may be amended by a resolution passed at a general meeting of shareholders. Our Amended and
Restated Bye-laws provide that no bye-law shall be rescinded, altered or amended, and no new bye-law shall be made, unless it shall have
been approved by a resolution of our board of directors and by a resolution of our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Bermuda law, the holders
of an aggregate of not less than 20% in par value of the company&#8217;s issued share capital or any class thereof have the right to apply
to the Supreme Court of Bermuda for an annulment of any amendment of the memorandum of association adopted by shareholders at any general
meeting, other than an amendment which alters or reduces a company&#8217;s share capital as provided in the Companies Act. Where such
an application is made, the amendment becomes effective only to the extent that it is confirmed by the Bermuda court. An application for
an annulment of an amendment of the memorandum of association must be made within 21 days after the date on which the resolution altering
the company&#8217;s memorandum of association is passed and may be made on behalf of persons entitled to make the application by one or
more of their number as they may appoint in writing for the purpose. No application may be made by shareholders voting in favor of the
amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Capitalization of Profits and Reserves</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Bye-laws,
our board of directors may (i) capitalize any part of the amount of our share premium or other reserve accounts or any amount credited
to our profit and loss account or otherwise available for distribution by applying such sum in paying up unissued shares to be allotted
as fully paid bonus shares pro-rata (except in connection with the conversion of shares) to the shareholders; or (ii) capitalize any sum
standing to the credit of a reserve account or sums otherwise available for dividend or distribution by paying up in full, partly paid
or nil paid shares of those shareholders who would have been entitled to such sums if they were distributed by way of dividend or distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Provisions of Bermuda Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Share Certificates</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Bermuda
law, share certificates are only issued in the names of companies, partnerships or individuals. In the case of a shareholder acting in
a special capacity (for example as a trustee), certificates may, at the request of the shareholder, record the capacity in which the shareholder
is acting. Notwithstanding such recording of any special capacity, we are not bound to investigate or see to the execution of any such
trust.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Membership</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Act, only
those persons who agree to become members of a Bermuda company and whose names are entered on the register of members of such company
are deemed members. A Bermuda company is not bound to see to the execution of any trust, whether express, implied or constructive, to
which any of its shares are subject and whether or not the company had notice of such trust. Accordingly, persons holding shares through
a trustee, nominee or depository will not be recognized as members of a Bermuda company under Bermuda law and may only have the benefit
of rights attaching to the shares or remedies conferred by law on members through or with the assistance of the trustee, nominee or depository.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Composition of Our Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors is
currently composed of three members. Our board of directors has determined that, of our four directors, none have a relationship that
would interfere with the exercise of independent judgment in carrying out the responsibilities of two of the directors, Mr. John Brancaccio
and Mr. Simon, and that each of these directors is &#8220;independent&#8221; as that term is defined under Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with our Articles,
at the first general meeting which is held after the date of adoption of the Bye-laws for the purpose of electing Directors, the Class
I Directors shall be elected for a three year term of office, the Class II Directors shall be elected for a two year term of office and
the Class III Directors shall be elected for a one year term of office. At each succeeding annual general meeting, successors to the class
of Directors whose term expires at that annual general meeting shall be elected for a three-year term. If the number of Directors is changed,
any increase or decrease shall be apportioned among the classes so as to maintain the number of Directors in each class as nearly equal
as possible, and any Director of any class elected to fill a vacancy shall hold office for a term that shall coincide with the remaining
term of the other Directors of that class, but in no case shall a decrease in the number of Directors shorten the term of any Director
then in office. A Director shall hold office until the annual general meeting for the year in which his term expires.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Class of the members of
the Board of Directors is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 64%; font-weight: bold">Name</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Class</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year&#160;Current<br/> Term Began</b></span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Year&#160;Current<br/> Term&#160;Expires</b></span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gabriele Cerrone</td><td>&#160;</td>
    <td style="text-align: center">I</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">John Brancaccio</td><td>&#160;</td>
    <td style="text-align: center">II</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Willy Simon</td><td>&#160;</td>
    <td style="text-align: center">III</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of Our Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
three standing committees: an audit committee, a remuneration committee and a nominating committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee, which
consists of, Mr. Brancaccio and Mr. Simon, assists the board of directors in overseeing our accounting and financial reporting processes.
Mr. Brancaccio serves as chairman of the audit committee. The audit committee consists exclusively of members of our board who are financially
literate, and Mr. Simon is considered an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the
requisite financial sophistication as defined under the applicable Nasdaq rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board has determined that
all of the members of the audit committee satisfy the &#8220;independence&#8221; requirements set forth in Rule 10A-3 under the Exchange
Act. The audit committee will be governed by a charter that complies with Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee&#8217;s
responsibilities include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recommending the appointment
of the independent auditor to the general meeting of shareholders;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the appointment, compensation,
retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit
services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">pre-approving the audit services
and non-audit services to be provided by our independent auditor before the auditor is engaged to render such services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">evaluating the independent auditor&#8217;s
qualifications, performance and independence, and presenting its conclusions to the full board of directors on at least an annual basis;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing and discussing with
management and our independent registered public accounting firm our financial statements and our financial reporting process;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing, approving or ratifying
any related party transactions.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recommending the appointment
of the independent auditor to the general meeting of shareholders; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the appointment, compensation,
retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit
services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Remuneration Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remuneration committee
consists of Mr. Brancaccio and Mr. Simon. Mr. Simon serves as chairman of the remuneration committee. Under SEC and Nasdaq rules, there
are heightened independence standards for members of the remuneration committee, including a prohibition against the receipt of any compensation
from us other than standard board member fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remuneration committee&#8217;s
responsibilities include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">identifying, reviewing and proposing
policies relevant to the compensation and benefits of our directors and executive officers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">evaluating each executive officer&#8217;s
performance in light of such policies and reporting to the board; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">overseeing and administering
our employee share option scheme or equity incentive plans in operation from time to time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nominating Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating committee consists
of Mr. Cerrone and Mr. Simon. Mr. Simon serves as chairman of the nominating committee. The nominating committee&#8217;s responsibilities
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">drawing up selection criteria
and appointment procedures for directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recommending nominees for election
to our board of directors and its corresponding committees;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">assessing the functioning of
individual members of our board of directors and executive officers and reporting the results of such assessment to the board of directors;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">developing corporate governance
guidelines.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our non-employee directors
have any service contracts with Tiziana Life Sciences Ltd or any of our subsidiaries that provide for benefits upon termination of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span><b>Board
Diversity Matrix (As of April 24, 2023)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Country of Principal Executive Offices</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; background-color: #CCEEFF">United Kingdom</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Foreign Private Issuer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; ">Yes</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Disclosure Prohibited Under Home Country Law</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt; background-color: #CCEEFF">No</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 83%"><span style="font-size: 10pt">Total Number of Directors</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">3</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Female</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Male</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Binary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Did Not Disclose Gender</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Part I: Gender Identity</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Part II: Demographic Background</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underrepresented Individual in Home Country Jurisdiction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>LGBTQ+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had 9 full time employees. Three of our employees were engaged in research and development and six employees were engaged in management,
administration and finance. Five are located in England and four are located in the United States. None of our employees are members of
labor unions. None of our employees are covered by a collective bargaining agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Insurance and Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent permitted by
the Companies Act, we are empowered to indemnify our directors against any liability they incur by reason of their directorship. We maintain
directors&#8217; and officers&#8217; insurance to insure such persons against certain liabilities. We expect to enter into a deed of indemnity
with each of our directors and executive officers prior to, or as soon as practicable, following the filing of this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to such indemnification,
we provide our directors and executive officers with directors&#8217; and officers&#8217; liability insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or persons controlling
us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9.8pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7. Major Shareholders
and Related Party Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7: MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Major Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information relating to the beneficial ownership of our ordinary shares as of March 31, 2024 by:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">each person, or group of affiliated
persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -22.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">each member of our board of
directors and each of our executive officers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of ordinary shares
beneficially owned by each entity, person, board member, or executive officer is determined in accordance with the rules of the SEC, and
the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes
any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that
the individual has the right to acquire within 60 days of March 31, 2024 through the exercise of any option, warrant or other right. Except
as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
power with respect to all ordinary shares held by that person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Ordinary<br/> Shares Beneficially<br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name and address of beneficial owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">5% or Greater Shareholders:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-size: 10pt">Gabriele Cerrone<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">40,256,023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">38.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Executive Officers and Directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Gabriele Cerrone<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,256,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38.71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">John Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">All directors and executive officers as a group (3 persons)<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,264,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38.71</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mr. Gabriele Cerrone is the ultimate beneficial owner of ordinary shares through Planwise Group Limited and Panetta Partners Limited.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Includes 915,388 stock options which are currently exercisable or exercisable within 60 days of March 31, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes of 915,388 stock options which are currently exercisable or exercisable within 60 days of March 31, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of related party transactions we have entered into since January 1, 2023, with the beneficial owners of 5% or more of our ordinary shares,
which are our only voting securities, and senior management and members of our board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnity Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into deeds
of indemnity with each of our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Person Transaction Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted a written related person transaction policy, effective as of November 9, 2018, the date on which our registration statement on
Form F-1 was declared effective. This policy covers, any transaction or proposed transactions between us and a related person that are
material to us or the related person, including without limitation, purchases of goods or services by or from the related person or entities
in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person.
In reviewing and approving any such transactions, our audit and risk committee is tasked to consider all relevant facts and circumstances,
including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length
transaction and the extent of the related person&#8217;s interest in the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employment Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into a consultancy
agreement with our Acting Chief Executive Officer, and director agreements with our remaining board members. For further details on these
agreements, see Item 6 entitled &#8220;Directors, Senior Management and Employees.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into certain
related party transactions as disclosed in Note 8 and Note 23 to the Consolidated Financial Statements in Item 18 of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Interests of Experts and Counsel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8: FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Consolidated Statements and Other Financial Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as disclosed in this
paragraph, there are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened
of which the Company is aware), which may have, or have had during the 12 months prior to the date of this registration statement, a significant
effect on the Company&#8217;s and/or our financial position or profitability. In addition to the proceedings set out in this section,
the Company is involved in other legal proceedings and claims in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Note 25 of our consolidated
financial statements at the end of this Annual Report for a description of the significant changes since December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9: THE LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shares are listed
on The Nasdaq Capital Market under the symbol &#8220;TLSA.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Plan of Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shares are listed
on the Nasdaq Capital Market under the symbol &#8220;TLSA.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Selling Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Dilution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Expenses of the Issue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10: ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Memorandum of Association and Bye-laws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incorporate by reference
into this Annual Report the description of our memorandum of association and Bye-laws contained in Form 8-K filed with the SEC on October
21, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Material Contracts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise disclosed
in this Annual Report (including the exhibits hereto), we are not currently, and have not been in the last two years, party to any material
contract, other than contracts entered into in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The permission of the Bermuda
Monetary Authority is required, under the provisions of the Exchange Control Act 1972 of Bermuda and related regulations, for all issuances
and transfers of shares (which includes our common shares) of Bermuda companies to or from a non-resident of Bermuda for exchange control
purposes, other than in cases where the Bermuda Monetary Authority has granted a general permission. The Bermuda Monetary Authority, in
its notice to the public dated June 1, 2005, has granted a general permission for the issue and subsequent transfer of any securities
of a Bermuda company from and/or to a non-resident of Bermuda for exchange control purposes for so long as any &#8220;Equity Securities&#8221;
of the company (which include our common shares) are listed on an &#8220;Appointed Stock Exchange&#8221; (which include Nasdaq). In granting
the general permission the Bermuda Monetary Authority accepts no responsibility for our financial soundness or the correctness of any
of the statements made or opinions expressed in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Company is incorporated
in Bermuda, as an exempted company it is classified as a non-resident of Bermuda for exchange control purposes by the Bermuda Monetary
Authority. Other than transferring Bermuda Dollars out of Bermuda, there are no restrictions on the Company&#8217;s ability to transfer
funds into and out of Bermuda or to pay dividends in currency other than Bermuda Dollars to non-residents of Bermuda who are holders of
our common shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material U.S. Federal Income Tax Considerations for U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. Federal Income Tax Considerations for
U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion describes
the material U.S. federal income tax consequences relating to the ownership and disposition of our Common shares by U.S. Holders. This
discussion applies to U.S. Holders that purchase our Common shares pursuant to this offering and hold such Common shares as capital assets
for tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative
and judicial interpretations thereof, and the income tax treaty between the United Kingdom and the United States, or the Treaty, all as
in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not address
all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances
or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies,
dealers or traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes,
tax-exempt entities or governmental organizations, retirement plans, regulated investment companies, real estate investment trusts, grantor
trusts, brokers, dealers or traders in securities, commodities, currencies or notional principal contracts, certain former citizens or
long-term residents of the United States, persons who hold our Common shares as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221;
&#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons that have a &#8220;functional
currency&#8221; other than the U.S. dollar, persons who are subject to the tax accounting rules of Section 451(b) of the Internal Revenue
Code, persons that own directly, indirectly or through attribution 10% or more (by vote or value) of our equity, corporations that accumulate
earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in such pass-through entities).
This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative
minimum tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this discussion,
the term &#8220;U.S. Holder&#8221; means a beneficial owner of our Common shares that is, for U.S. federal income tax purposes, (1) an
individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income
tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate
the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within
the United States is able to exercise primary supervision over its administration and one or more United States persons have the authority
to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic
trust for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity treated as a
partnership for U.S. federal income tax purposes holds our Common shares, the U.S. federal income tax consequences relating to an investment
in such Common shares will depend upon the status and activities of such entity and the particular partner. Any such entity and a partner
in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it (and, as applicable,
its partners) of the purchase, ownership and disposition of our Common shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not sought, nor will
we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that the IRS will not take a different
position concerning the tax consequences of the purchase, ownership or disposition of the Common shares or that any such position would
not be sustained. Persons considering an investment in our Common shares should consult their own tax advisors as to the particular tax
consequences applicable to them relating to the purchase, ownership and disposition of our Common shares, including the applicability
of U.S. federal, state and local tax laws and non-U.S. tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Passive Foreign Investment Company Rules</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a corporation
organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least 75% of its gross income
is &#8220;passive income,&#8221; or the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis,
are assets that produce passive income or are held for the production of passive income, or the PFIC asset test. Passive income for this
purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property
that give rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if
held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally,
in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which
it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although PFIC status is determined
on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature of our current and expected
income and the current and expected value and composition of our assets, we do not believe we were a PFIC for our 2023 tax year and we
do not expect to be a PFIC for our current taxable year. There can be no assurance that we will not be a PFIC in future taxable years.
Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion
and that the IRS would not successfully challenge our position. Because of the uncertainties involved in establishing our PFIC status,
our U.S. counsel expresses no opinion regarding our PFIC status, and also expresses no opinion with respect to our predictions or past
determinations regarding our PFIC status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC in any taxable
year during which a U.S. Holder owns our Common shares, the U.S. Holder could be liable for additional taxes and interest charges under
the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution paid during a taxable year that is greater than 125% of the
average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for our
Common shares, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a pledge,
of our Common shares, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution
or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for our Common
shares. The amount allocated to the current taxable year (<i>i.e</i>., the year in which the distribution occurs or the gain is recognized)
and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year.
The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as
applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will
be added to the tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any year
during which a U.S. Holder holds our Common shares, we must generally continue to be treated as a PFIC by that U.S. Holder for all succeeding
years during which the U.S. Holder holds such Common shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder
makes a &#8220;deemed sale&#8221; election with respect to our Common shares. If the election is made, the U.S. Holder will be deemed
to sell our Common shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC,
and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election,
the U.S. Holder&#8217;s Common shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any taxable
year during which a U.S. Holder holds our Common shares and one of our non-United States subsidiaries is also a PFIC (<i>i.e</i>., a lower-tier
PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be
taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of
the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Any of our non-United
States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships for U.S. federal income tax purposes
would not be corporations under U.S. federal income tax law and accordingly, cannot be classified as lower-tier PFICs. However, a non-United
States subsidiary that has not made the election may be classified as a lower-tier PFIC if we are a PFIC during your holding period and
the subsidiary meets the PFIC income test or PFIC asset test.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC, a U.S. Holder
will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on our Common shares if a valid
&#8220;mark-to-market&#8221; election is made by the U.S. Holder for our Common shares. An electing U.S. Holder generally would take into
account as ordinary income each year, the excess of the fair market value of our Common shares held at the end of such taxable year over
the adjusted tax basis of such Common shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess
of the adjusted tax basis of such Common shares over their fair market value at the end of the taxable year, but only to the extent of
the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S.
Holder&#8217;s tax basis in our Common shares would be adjusted annually to reflect any income or loss recognized as a result of the mark-to-market
election. Any gain from a sale, exchange or other disposition of our Common shares in any taxable year in which we are a PFIC would be
treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the
extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for
a taxable year, we cease to be classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would
not be required to take into account any latent gain or loss in the manner described above and any gain or loss recognized on the sale
or exchange of the Common shares would be classified as a capital gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A mark-to-market election
is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly
traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable U.S. Treasury regulations. A class of stock is regularly
traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during
each calendar quarter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common shares will be
marketable stock as long as they remain listed on Nasdaq and are regularly traded. A mark-to-market election will not apply to the Common
shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which
we become a PFIC. Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S. Holder may continue to be subject
to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the U.S. Holder&#8217;s mark-to-market
election for our Common shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences that
would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid QEF election.
As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election, prospective investors
should assume that a QEF election will not be available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The U.S. federal income
tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect
to the impact of PFIC status on the purchase, ownership and disposition of our </b>Common shares<b>, the consequences to them of an investment
in a PFIC, any elections available with respect to the </b>Common shares <b>and the IRS information reporting obligations with respect
to the purchase, ownership and disposition of </b>Common shares <b>of a PFIC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
above under &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; a U.S. Holder that receives a distribution with respect to
our Common shares generally will be required to include the gross amount of such distribution in gross income as a dividend when actually
or constructively received by the U.S. Holder to the extent of the U.S. Holder&#8217;s pro rata share of our current and/or accumulated
earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder
is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and profits, it will
be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s Common
shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s Common shares, the remainder will be
taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles,
U.S. Holders should expect all distributions to be reported to them as dividends. The amount of a dividend will include any amounts withheld
by the company in respect of United Kingdom taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distributions on our Common
shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes
and generally will constitute passive category income. Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#8217;s
particular circumstances, any United Kingdom income taxes withheld from dividends on Common shares at a rate not exceeding the rate provided
by the Treaty will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing foreign tax credits
are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances.
In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any United Kingdom income
tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes
instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. The amount of any dividend income
paid in a currency other than the U.S. dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on
the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If
the dividend is converted into U.S. dollars on the date of receipt, a U.S. holder should not be required to recognize foreign currency
gain or loss in respect of the dividend amount. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into
U.S. dollars after the date of receipt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distributions paid on our
Common shares will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with
respect to dividends received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &#8220;qualified foreign corporation&#8217;&#8217;
to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable
to ordinary income provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss,
during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements are met. Each U.S. Holder is advised
to consult its tax advisors regarding the availability of the reduced tax rate on dividends to its particular circumstances. However,
if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion above under &#8220;&#8212;
Passive Foreign Investment Company Rules&#8217;&#8217;), we will not be treated as a qualified foreign corporation, and therefore the
reduced capital gains tax rate described above will not apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-United States corporation
(other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year)
generally will be considered to be a qualified foreign corporation with respect to any dividend it pays on Common shares that are readily
tradable on an established securities market in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any dividend
income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date
of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on
the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency gain or loss in respect
of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the
date of receipt (actual or constructive).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sale, Exchange or Other Taxable Disposition
of Our </i></b>Common shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
above under &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; a U.S. Holder generally will recognize capital gain or loss
for U.S. federal income tax purposes upon the sale, exchange or other disposition of our Common shares in an amount equal to the difference,
if any, between the amount realized (<i>i.e</i>., the amount of cash plus the fair market value of any property received) on the sale,
exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the Common shares. Such capital gain or loss generally
will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale,
exchange or other disposition, the Common shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate
U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations.
Any gain or loss recognized from the sale or other disposition of our Common shares will generally be gain or loss from sources within
the United States for U.S. foreign tax credit purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medicare Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders that
are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion
of their net investment income, which may include their gross dividend income and net gains from the disposition of our Common shares.
If you are a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability
of this Medicare tax to your income and gains in respect of your investment in our Common shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders may be required
to file certain U.S. information reporting returns with the IRS with respect to an investment in our Common shares, including, among others,
IRS Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of a PFIC must file
an annual report containing certain information. U.S. Holders paying more than $100,000 for our Common shares may be required to file
IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties and other
adverse circumstances may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends on and proceeds
from the sale or other disposition of our Common shares generally have to be reported to the IRS unless the U.S. Holder establishes a
basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S.
taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons.
However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a
U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to
the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their own tax advisors regarding the backup withholding tax and information reporting rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>EACH PROSPECTIVE INVESTOR
IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR </b>COMMON SHARES <b>IN LIGHT OF THE
INVESTOR&#8217;S OWN CIRCUMSTANCES. IN ADDITION, SIGNIFICANT CHANGES IN U.S. FEDERAL INCOME TAX LAWS WERE RECENTLY ENACTED. PROSPECTIVE
INVESTORS SHOULD ALSO CONSULT WITH THEIR TAX ADVISORS WITH RESPECT TO SUCH CHANGES IN U.S. TAX LAW AS WELL AS POTENTIAL CONFORMING CHANGES
IN STATE TAX LAWS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Bermuda Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under present Bermuda law,
no Bermuda withholding tax on dividends or other distributions, or any Bermuda tax computed on profits or income or on any capital asset,
gain or appreciation will be payable by us or applicable to our operations, and there is no Bermuda tax in the nature of estate duty or
inheritance tax applicable to our shares, debentures or other obligations held by non-residents of Bermuda.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Assurance</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have obtained an assurance
from the Minister of Finance of Bermuda under the Exempted Undertakings Tax Protection Act 1966 that, in the event that any legislation
is enacted in Bermuda imposing any tax computed on profits or income, or computed on any capital asset, gain or appreciation or any tax
in the nature of estate duty or inheritance tax, such tax shall not, until March 31,2035, be applicable to us or to any of our operations
or to our shares, debentures or other obligations except insofar as such tax applies to persons ordinarily resident in Bermuda or is payable
by us in respect of real property owned or leased by us in Bermuda.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation of Shareholders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders should seek advice
from their tax advisor to determine the taxation to which they may be subject based on the shareholder&#8217;s circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Dividends and Paying Agents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G. Statements by Experts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. Documents on Display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the informational
requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other information filed with the SEC at the public reference
facilities of the SEC located at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of the documents at prescribed
rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, DC 20549. Please call the SEC at 1-800-SEC-0330
for further information on the public reference room. The SEC also maintains a website at http://www.sec.gov from which certain filings
may be accessed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also make available on
our website, free of charge, our Annual Report and the text of our reports on Form 6-K, including any amendments to these reports, as
well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC.
Our website address is &#8220;www.tizianalifesciences.com.&#8221; The information contained on our website is not incorporated by reference
in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of the general public
have a right to inspect the public documents of a company available at the office of the Registrar of Companies in Bermuda. These documents
include the company&#8217;s memorandum of association, including its objects and powers, and certain alterations to the memorandum of
association. The shareholders have the additional right to inspect the bye-laws of the company, minutes of general meetings and the company&#8217;s
audited financial statements, which must be presented to the annual general meeting. The register of members of a company is also open
to inspection by shareholders and by members of the general public without charge. The register of members is required to be open for
inspection for not less than two hours in any business day (subject to the ability of a company to close the register of members for not
more than thirty days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of
the Companies Act, establish a branch register outside of Bermuda. A company is required to keep at its registered office a register of
directors and officers that is open for inspection for not less than two hours in any business day by members of the public without charge.
A company is also required to file with the Registrar of Companies in Bermuda a list of its directors to be maintained on a register,
which register will be available for public inspection subject to such conditions as the Registrar may impose and on payment of such fee
as may be prescribed. Bermuda law does not, however, provide a general right for shareholders to inspect or obtain copies of any other
corporate records.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I. Subsidiary Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information on our subsidiaries,
see &#8220;Item 4C. Organizational Structure.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign currency exchange rate
fluctuations. We maintain significant amounts of cash and cash equivalents that are in excess of federally insured limits in various currencies,
placed with one or more financial institutions for varying periods according to expected liquidity requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interest Rate Risk</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our exposure to interest rate
sensitivity is impacted by changes in the underlying U.S. and U.K. bank interest rates. Our surplus cash and cash equivalents have been
invested in interest-bearing savings and money market accounts from time to time. We have not entered into investments for trading or
speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments
with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect
on the fair market value of our portfolio, and therefore we do not expect our operating results or cash flows to be significantly affected
by changes in market interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign Currency Exchange Risk</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain our consolidated
financial statements in the functional currency US Dollar. Monetary assets and liabilities denominated in currencies other than the functional
currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date
of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income
(loss) for the respective periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The currencies of our subsidiaries
are generally their functional currencies, In translating the financial statements of those subsidiaries or branches whose functional
currency is other than the U.S. dollar, assets and liabilities are converted into U.S. dollars using the rates of exchange in effect at
the balance sheet dates, and revenues and expenses are converted using the average foreign exchange rates for the period. Translation
adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment to accumulate other comprehensive
loss, a component of shareholders&#8217; equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently engage
in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future. Instruments that may
be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage
risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 12: DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Debt Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Warrants and Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Other Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. American Depositary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13: DEFAULTS, DIVIDEND ARREARAGES AN DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 14: MATERIAL MODIF</b>IC<b>ATIONS TO THE RIGHTS OF SECURITY
HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 15: CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Evaluation of Disclosure Controls and Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
management, with the participation of the Company&#8217;s Chief Executive Officer and Finance Director, have evaluated the
effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and&#160;15d-15(e) under
the Securities Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;)) as of&#160;December 31, 2023. Based on that
evaluation, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Finance Director have concluded that as
of&#160;December 31, 2023, due to the existence of the material weaknesses in the Company&#8217;s internal control over financial
reporting described below, the Company&#8217;s disclosure controls and procedures were not effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Annual Report on Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s management
is responsible for establishing and maintaining adequate internal controls over financial reporting as defined in Rules&#160;13a-15(f)
and&#160;15d-15(f) under the Exchange Act. The Company&#8217;s internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB),
and IFRIC interpretations as applicable to companies reporting under IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of their inherent
limitations, internal controls over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of management, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Finance Director, the Company
conducted an evaluation of the effectiveness of its internal control over financial over financial reporting based on the framework described
in Internal Control-Integrated Framework issued by the Commission of Sponsoring Organizations of the Treadway Commission, as revised in&#160;2013.
Based on that evaluation, management has concluded that the Company did not maintain effective internal control over financial reporting
as of the period ended&#160;December 31, 2023&#160;due to the existence of the material weaknesses in internal control over financial
reporting described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Material Weaknesses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A deficiency in internal control
over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course
of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or
a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material
misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has determined
that the Company did not maintain effective internal control over financial reporting as of the period ended&#160;December 31, 2023&#160;due
to the existence of the following material weaknesses identified by management. The material weaknesses identified below did not result
in a material misstatement of our consolidated financial statements, and management believes that our consolidated financial statements
present fairly the consolidated financial position, results of operations and cash flows for the periods covered. However, management
recognizes that the failure of the internal control over financial reporting to operate effectively as described below could have resulted
in a material misstatement which may not have been detected by our controls:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Control Environment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not maintain
an effective control environment. The control environment, which is the responsibility of senior management, sets the tone of the organization,
influences the control consciousness of its people, and is the foundation for all other components of internal control over financial
reporting. Our control environment was ineffective because:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We did not timely develop and
communicate an employee handbook for employees to consult in the event an issue arises</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Remediation efforts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management intends to remediate
this item in the following manner:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">i.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Develop and maintain an Employee
Handbook, for employees to reference.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to complete the
remediation of the material weaknesses discussed above as soon as practicable, but we can give no assurance that we will be able to do
so. Designing and implementing effective disclosure controls and procedures is a continuous effort that requires us to anticipate and
react to changes in our business and the economic and regulatory environments and to devote significant resources to maintain a financial
reporting system that adequately satisfies our reporting obligations. The remedial measures that we have taken and intend to take may
not fully address the material weaknesses that we have identified, and material weaknesses in our disclosure controls and procedures may
be identified in the future. Should we discover such conditions, we intend to remediate them as soon as practicable. We are committed
to taking appropriate steps for remediation, as needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM
16: <span style="text-transform: uppercase">[Reserved] </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16A: AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our audit committee
are Mr John Brancaccio and Mr. Willy Simon. Mr. John Brancaccio is the chair of the audit committee. Each of our audit committee members
satisfies the independence requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Marketplace Rules and the independence requirements
of Rule 10A-3(b)(1) under the Exchange Act. Our board of directors has determined that Mr. John Brancaccio is an &#8220;audit committee
financial expert&#8221; as defined in Item 16A of Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16B: CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Code of Business Conduct
and Ethics is applicable to all of our employees, officers and directors and is available on our website at https://www.tizianalifesciences.com.
Our Code of Business Conduct and Ethics provides that our directors and officers are expected to avoid any action, position or interest
that conflicts with the interests of our company or gives the appearance of a conflict. Our directors and officers have an obligation
under our Code of Business Conduct and Ethics to advance our company&#8217;s interests when the opportunity to do so arises. We expect
that any amendment to this code, or any waivers of its requirements, will be disclosed on our website. Information contained on, or that
can be accessed through, our website is not incorporated by reference into this Annual Report, and you should not consider information
on our website to be part of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16C: PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for each of the years indicated, the aggregate fees billed to us for services rendered by PKF and Mazars, our independent registered public
accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">PKF Littlejohn LLP</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assurance services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">190</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">206</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Mazars LLP</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assurance services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">119</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16D: EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16E: PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED
PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">During the year ended December 31, 2023, we purchased
281,253 of our common shares at an average price of $0.90 (excluding fees).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16F: CHANGE IN REGISTRANTS CERTIFYING ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16G: CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sarbanes-Oxley Act of
2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including our company, to comply
with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may follow home country practice
in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent that such exemptions would
be contrary to U.S. federal securities laws. The home country practices followed by our company in lieu of Nasdaq rules are described
below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not follow Nasdaq&#8217;s
quorum requirements applicable to meetings of shareholders. Such quorum requirements are not required under Bermuda law. In accordance
with generally accepted business practice, our Bye-laws provide alternative quorum requirements that are generally applicable to meetings
of shareholders.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not follow Nasdaq&#8217;s
requirements that non-management directors meet on a regular basis without management present. Our board of directors may choose to meet
in executive session at their discretion.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not follow Nasdaq&#8217;s
requirements to seek shareholder approval for the implementation of certain equity compensation plans, the issuances of ordinary shares
under such plans, or in connection with certain private placements of equity securities. In accordance with Bermuda &#160;law, we are
not required to seek shareholder approval to allot ordinary shares in connection with applicable employee equity compensation plans.
We will follow Bermuda. law with respect to any requirement to obtain shareholder approval prior to any private placements of equity
securities.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take all actions
necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley
Act of 2002, the rules adopted by the SEC and Nasdaq&#8217;s listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are a foreign private
issuer, our directors and senior management are not subject to short-swing profit and insider trading reporting obligations under Section
16 of the U.S. Securities Exchange Act of 1934, as amended, or Exchange Act. They are, however, subject to the obligations to report changes
in share ownership under Section 13 of the Exchange Act and related SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16H: MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16I: DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16J: INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span>Pursuant
to applicable SEC transition guidance, the disclosure required by Item 16J will only be applicable to the Company from the fiscal year
ending on December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16K: CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">We believe cybersecurity
is critical to advancing our technological advancements. As a biopharmaceutical company, we face a multitude of cybersecurity threats
that range from attacks common to most industries, such as ransomware and denial-of service. Our customers, suppliers, subcontractors,
and business partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially
adversely affect our operations, performance, and results of operations. These cybersecurity threats and related risks make it imperative
that we expend resources on cybersecurity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors
oversees management&#8217;s processes for identifying and mitigating risks, including cybersecurity risks, to help align our risk exposure
with our strategic objectives. Senior leadership, including our cybersecurity consultant, regularly briefs the Board of Directors on our
cybersecurity and information security posture and the Board of Directors is apprised of cybersecurity incidents deemed to have a moderate
or higher business impact, even if immaterial to us. The full Board retains oversight of cybersecurity because of its importance. In the
event of an incident, we intend to follow our detailed incident response playbook, which outlines the steps to be followed from incident
detection to mitigation, recovery, and notification, including notifying functional areas (e.g., legal), as well as senior leadership
and the Board, as appropriate. Our Cybersecurity consultant has extensive information technology and program management experience. We
have implemented a governance structure and processes to assess, identify, manage, and report cybersecurity risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">As a biopharmaceutical
company, we must comply with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately
safeguarding patient information and reporting cybersecurity incidents to the SEC. We work with our cybersecurity consultant on assessing
cybersecurity risk and on policies and practices aimed at mitigating these risks. We believe we are positioned to meet the requirements
of the SEC. In addition to following SEC guidance and implementing pre-existing third party frameworks, we have developed our own practices
and frameworks, which we believe enhance our ability to identify and manage cybersecurity risks. Third parties also play a role in our
cybersecurity. We engage third-party services to conduct evaluations of our security controls, whether through penetration testing, independent
audits, or consulting on best practices to address new challenges. Assessing, identifying, and managing cybersecurity related risks are
factored into our overall business approach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely heavily on our
supply chain to deliver our products and services, and a cybersecurity incident at a supplier, subcontractor or business partner could
materially adversely impact us. We require that our subcontractors report cybersecurity incidents to us so that we can assess the impact
of the incident on us. Notwithstanding the extensive approach we take to cybersecurity, we may not be successful in preventing or mitigating
a cybersecurity incident that could have a material adverse effect on us. While we maintain cybersecurity insurance, the costs related
to cybersecurity threats or disruptions may not be fully insured. See &#8220;Risk Factors&#8221; for a discussion of cybersecurity risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 17: FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have elected to furnish financial statements
and related information specified in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 18: FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See the Financial Statements beginning on page
F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 19: EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><span style="font-size: 10pt">Description</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390021053952/ea149115ex3-1_tizianalife.htm"><span style="font-size: 10pt">Memorandum of Association of Tiziana Life Sciences Ltd, adopted as of October 20, 2021 (incorporated by reference to Exhibit 3.1 to Form 8-K12B filed on October 21, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">1.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390021053952/ea149115ex3-2_tizianalife.htm"><span style="font-size: 10pt">Amended and restated bye-laws of Tiziana Life Sciences Ltd, adopted as of October 20, 2021 (incorporated by reference to Exhibit 3.2 to Form 8-K12B filed on October 21, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>2.1*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex2-1_tiziana.htm">Description of Securities</a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-1_tiziana.htm"><span style="font-size: 10pt">License Agreement relating to Milciclib between Nerviano Medical Services S.r.l. and Tiziana Life Sciences PLC, dated January 2015 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-2_tiziana.htm"><span style="font-size: 10pt">License and Sublicence Agreement relating to CD3 (NI-0401) between Novimmune SA and Tiziana Life Sciences PLC, dated December 2014. incorporated by reference to Exhibit 10.2 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-3_tiziana.htm"><span style="font-size: 10pt">License and Sublicence Agreement relating to IL-6r (NI-1201) between Novimmune SA and Tiziana Life Sciences PLC, dated December 2016. (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-4_tiziana.htm"><span style="font-size: 10pt">License Agreement relating to a novel formulation of Foralumab in a medical device for nasal administration between The Brigham and Women&#8217;s Hospital, Inc. and Tiziana Life Sciences plc, dated April 2018. (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1723069/000121390023032763/f20f2022ex4-5_tizianalife.htm">Annual Lease for 14-15 Conduit Street, London W1S 2XJ United Kingdom (incorporated by reference to Exhibit 4.5 to Form 20-F filed on April 26, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1723069/000121390023032763/f20f2022ex4-7_tizianalife.htm">Lease agreement for 601 New Britain Road, Suite 102, Doylestown Old Easton Road, Doylestown, Pennsylvania, 18901, United States, dated August 29, 2022. (incorporated by reference to Exhibit 4.7 to Form 20-F filed on April 26, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390019005736/f20f2018ex4-7_tizianalife.htm"><span style="font-size: 10pt">Tiziana Life Sciences plc Employee Share Option Plan, with Non-Employee Sub-Plan and US Sub-Plan, adopted by the Board on 23 March 2016 and approved by shareholders on June 30, 2016. (Incorporated by reference to Exhibit 4.7 to Form 20-F filed on April 4, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390019014612/ff12019ex10-9_tiziana.htm"><span style="font-size: 10pt">Amended and Restated Service Agreement dated July 11, 2019, between the Registrant and Dr. Kunwar Shailubhai (incorporated by reference to Exhibit 10.9 to Amendment No. 2 to Form F-1 filed on September 20, 2019)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390018011631/ff12018a1ex10-10_tiziana.htm"><span style="font-size: 10pt">Form of Deed of Indemnity for board members. (Incorporated by reference to Exhibit 10.10 to Amendment No. 1 to Form F-1 filed on August 23, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390021053952/ea149115ex10-3_tizianalife.htm"><span style="font-size: 10pt">Tiziana Life Sciences Ltd 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Form 8-K12B filed on October 21, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1723069/000121390022028645/f20f2021ex8-1_tizianalife.htm"><span style="font-size: 10pt">List of Subsidiaries. (Incorporated by reference to Exhibit 8.1 to Form 20-F filed on May 23, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">12.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex12-1_tiziana.htm"><span style="font-size: 10pt">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">12.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea020387201ex12-2_tiziana.htm">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">13.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex13-1_tiziana.htm"><span style="font-size: 10pt">Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">13.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea020387201ex13-2_tiziana.htm">Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">15.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex15-1_tiziana.htm"><span style="font-size: 10pt">Consent of Mazars LLP</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">15.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex15-2_tiziana.htm"><span style="font-size: 10pt">Consent of PKF Littlejohn.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>97*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020387201ex97_tiziana.htm">Clawback policy</a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed Herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Options: NewSection; Value: 124 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
registration statement on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Tiziana Life
    Sciences Ltd</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gabriele
    Cerrone&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acting Chief Executive Officer</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 10, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 124 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TIZIANA LIFE SCIENCES LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 90%; padding-left: 9pt; text-indent: -9pt"><a href="#f_001"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (PKF Littlejohn, London, United Kingdom, PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-24664">2814</ix:nonNumeric>)</span></a></td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 9%; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr> <td style="text-align: justify; vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_007">Report of Independent Registered Public Accounting Firm (Mazars LLP, London, United Kingdom, PCAOB ID 1401)</a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">F-3</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance Sheets</span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr> <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_003"><span style="font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss</span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_004"><span style="font-size: 10pt">Consolidated Statements of Shareholders&#8217; Equity</span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr> <tr> <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_005"><span style="font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#f_006"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-8</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Consolidated Financial Statements and Notes
to Financial Statements to be provided under separate cover.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>To the Board of Directors and Stockholders
of Tiziana Life Sciences Ltd </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying Consolidated
Balance Sheet &#160;of Tiziana Life Sciences Ltd and its subsidiaries (the &#8220;Group&#8221;) as of December 31, 2023 and 2022 and the
related Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Cash Flows and Consolidated Statements
of Shareholders&#8217; Equity &#160;for each of the two years ended December 31, 2023 and the related notes (collectively referred to
as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of the Group as of December 31, 2023 and 2022 and the results of its operations
and its cash flows for each of the two years ended December 31, 2023 and 2022 &#160;in conformity with International Financial Reporting
Standards as issued by the International Accounting Standards Board.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern Uncertainty</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Group will continue as a going concern. As discussed in note 2 to the consolidated financial statements,
the Group are pre-revenue, and its business model requires significant ongoing expenditure on research and development. The forecast prepared
by management indicates that the current cash held will be utilised by July 2024 without additional financing facilities in place. Management
is currently pursuing a number of alternatives in order to raise sufficient funds, including deferred payment of existing liabilities,
working capital cost reductions and arranging short-term funding. These conditions raise substantial doubt about the Group&#8217;s ability
to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for opinion </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Group&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Group is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Group&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical audit matters are matters arising from
the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit
committee and that: 1) relate to accounts or disclosures that are material to the financial statements and 2) involved our especially
challenging, subjective, or complex judgements. We determined that there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-24665">PKF Littlejohn LLP</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Group&#8217;s auditor since 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">London, England</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">May 10, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Opinion on the Consolidated Financial Statements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying Consolidated Statements of Operations
and Comprehensive Loss, Consolidated Statements of Shareholders&#8217; Equity, and Consolidated Statements of Cash Flows of Tiziana Life
Sciences Ltd and it&#8217;s subsidiaries (the Group) for the year ended December 31, 2021, and the related notes (collectively referred
to as &#8220;the consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the results of its operations and its cash flows for the year ended December 31, 2021, in conformity with International
Financial Reporting Standards as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basis for Opinion</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Group&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB. The Group is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Group&#8217;s internal control
over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Mazars LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mazars LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We served as the Group&#8217;s auditor from 2016 until November 17,
2022</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-24666">London, England</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 20, 2022</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>TIZIANA LIFE SCIENCES LTD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended <br/>
December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSETS</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current assets:</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24667">1,183</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24668">18,122</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments and other receivables</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PrepaymentsandOtherReceivablesCurrent" scale="3" unitRef="usd" id="ixv-24669">223</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PrepaymentsandOtherReceivablesCurrent" scale="3" unitRef="usd" id="ixv-24670">300</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:TaxationReceivable" scale="3" unitRef="usd" id="ixv-24671">3,793</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:TaxationReceivable" scale="3" unitRef="usd" id="ixv-24672">4,246</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party receivables</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-24673">2,138</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-24674">1,614</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-24675">7,337</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-24676">24,282</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non &#8211; Current Assets:</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-24677">10</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-24678">17</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-24679">283</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="3" unitRef="usd" id="ixv-24680">372</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in related party</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InvestmentsInRelatedParty" scale="3" unitRef="usd" id="ixv-24681">4,554</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InvestmentsInRelatedParty" scale="3" unitRef="usd" id="ixv-24682">1,806</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total non-current assets</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-24683">4,847</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-24684">2,195</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total assets</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-24685">12,184</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-24686">26,477</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-24687">6,387</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-24688">6,532</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Liability</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-24689">138</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-24690">122</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-24691">14</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-24692">9</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current liabilities</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-24693">6,539</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-24694">6,663</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Liability (Non-Current)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-24695">109</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-24696">243</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total liabilities</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="3" unitRef="usd" id="ixv-24697">6,648</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="3" unitRef="usd" id="ixv-24698">6,906</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217; Equity:</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Called up share capital (<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tlsa:IssuanceOfShareCapital" scale="0" unitRef="shares" id="ixv-24699"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalOutstanding" scale="0" unitRef="shares" id="ixv-24700">103,087,744</ix:nonFraction></ix:nonFraction> shares are issued and outstanding; 2022: <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:IssuanceOfShareCapital" scale="0" unitRef="shares" id="ixv-24701"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalOutstanding" scale="0" unitRef="shares" id="ixv-24702">102,272,614</ix:nonFraction></ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="3" unitRef="usd" id="ixv-24703">103</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="3" unitRef="usd" id="ixv-24704">102</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share premium</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-24705">16,492</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-24706">15,596</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based payment reserve &#8211; Options</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-24707">6,905</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-24708">5,190</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based payment reserve &#8211; warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentReserveWarrants" scale="3" unitRef="usd" id="ixv-24709">697</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger relief reserve</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd" id="ixv-24710">118,697</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd" id="ixv-24711">118,697</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury shares</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TreasuryShares" scale="3" unitRef="usd" id="ixv-24712">1,574</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TreasuryShares" scale="3" unitRef="usd" id="ixv-24713">1,320</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares to be issued reserve</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesToBeIssuedReserve" scale="3" unitRef="usd" id="ixv-24714">225</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation reserve</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" sign="-" unitRef="usd" id="ixv-24715">1,636</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" sign="-" unitRef="usd" id="ixv-24716">3,128</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained earnings</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-24717">133,676</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-24718">116,263</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total shareholders&#8217; equity</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24719">5,536</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24720">19,571</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total liabilities and shareholders&#8217; equity</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-24721">12,184</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-24722">26,477</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>TIZIANA LIFE SCIENCES LTD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Operations and Comprehensive
Loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands, except loss per share)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: center">Notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and Development</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24723">8,113</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24724">12,955</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24725">13,208</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="3" unitRef="usd" id="ixv-24726">9,871</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="3" unitRef="usd" id="ixv-24727">1,631</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="3" unitRef="usd" id="ixv-24728">13,311</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Realization bonus</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RealisationBonus" scale="3" unitRef="usd" id="ixv-24729">855</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-24730">17,984</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-24731">14,586</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OperatingExpense" scale="3" unitRef="usd" id="ixv-24732">27,374</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24733">17,984</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24734">14,586</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24735">27,374</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income/(expense):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance (expense)/ income</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-24736">1,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-24737">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-24738">176</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">FV Loss on Investment</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnDisposalsOfInvestments" scale="3" sign="-" unitRef="usd" id="ixv-24739">402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnDisposalsOfInvestments" scale="3" sign="-" unitRef="usd" id="ixv-24740">869</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income/(losses)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">4</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-24741">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-24742">893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total other income/(expense)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="3" unitRef="usd" id="ixv-24743">742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="3" sign="-" unitRef="usd" id="ixv-24744">811</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="3" unitRef="usd" id="ixv-24745">717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Loss from operations before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24746">17,242</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24747">15,397</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24748">26,657</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax (expense)/credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxSCredit" scale="3" unitRef="usd" id="ixv-24749">449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxSCredit" scale="3" sign="-" unitRef="usd" id="ixv-24750">3,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Loss for the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24751">17,691</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24752">15,397</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24753">23,417</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other Comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain/(Loss) on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-24754">1,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" sign="-" unitRef="usd" id="ixv-24755">3,582</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" sign="-" unitRef="usd" id="ixv-24756">4,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24757">16,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24758">18,979</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24759">27,895</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9">Basic and diluted loss per share attributable to common shareholders</div></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-24760">0.17</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-24761">0.15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-24762">0.24</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>TIZIANA LIFE SCIENCES LTD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Shareholders&#8217;
Equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Based<br/> Payment<br/> Reserve<br/> (Options)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Based<br/> Payment<br/> Reserve<br/> (warrants)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Merger<br/> Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Treasury<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> Earnings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> to be<br/> issued<br/> Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Translation<br/> Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at 1 January 2021</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24763">97</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24764">8,624</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24765">697</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24766">118,697</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24767">84,646</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24768">13,503</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24769">5,414</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24770">62,386</ix:nonFraction></td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Issue of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-24771">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-24772">759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="3" unitRef="usd" id="ixv-24773">761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share based payment charge (options)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24774">5,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24775">5,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in lieu of cash realization bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" scale="3" unitRef="usd" id="ixv-24776">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" scale="3" unitRef="usd" id="ixv-24777">14,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" scale="3" sign="-" unitRef="usd" id="ixv-24778">13,503</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" scale="3" sign="-" unitRef="usd" id="ixv-24779">482</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" scale="3" unitRef="usd" id="ixv-24780">855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total transactions with owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24781">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24782">15,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24783">5,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24784">13,503</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24785">482</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24786">6,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Loss for Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:fixed-zero" name="ifrs-full:ProfitLoss" scale="3" unitRef="usd" id="ixv-24787">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24788">23,417</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24789">23,417</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" sign="-" unitRef="usd" id="ixv-24790">4,478</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" sign="-" unitRef="usd" id="ixv-24791">4,478</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24792">23,417</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24793">4,478</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24794">27,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at 31 December 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24795">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24796">15,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24797">13,797</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24798">697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24799">118,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24800">108,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24801">454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24802">41,280</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Treasury Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" unitRef="usd" id="ixv-24803">1,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" unitRef="usd" id="ixv-24804">1,320</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share based payment charge (options)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24805">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24806">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Options Forfeited/Cancelled in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedcancelled" scale="3" sign="-" unitRef="usd" id="ixv-24807">3,221</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedcancelled" scale="3" sign="-" unitRef="usd" id="ixv-24808">3,221</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reclass of FV for options forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" sign="-" unitRef="usd" id="ixv-24809">7,197</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" unitRef="usd" id="ixv-24810">7,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total transactions with owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24811">8,607</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24812">7,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24813">1,410</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Loss for Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24814">15,397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24815">15,397</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" sign="-" unitRef="usd" id="ixv-24816">3,582</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" sign="-" unitRef="usd" id="ixv-24817">3,582</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24818">15,397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24819">3,582</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24820">18,979</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at 31 December 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24821">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24822">15,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24823">5,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24824">697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24825">118,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24826">1,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24827">116,263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24828">3,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24829">19,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-24830">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-24831">323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-24832">324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share based payment charge (options)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24833">1,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPaymentoptions" scale="3" unitRef="usd" id="ixv-24834">1,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Options forfeited/cancelled in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedcancelled" scale="3" sign="-" unitRef="usd" id="ixv-24835">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedcancelled" scale="3" sign="-" unitRef="usd" id="ixv-24836">39</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reclass of FV for options forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" sign="-" unitRef="usd" id="ixv-24837">19</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" unitRef="usd" id="ixv-24838">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Warrants Exercised in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:WarrantsExercisedInTheYear" scale="3" unitRef="usd" id="ixv-24839">573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:WarrantsExercisedInTheYear" scale="3" sign="-" unitRef="usd" id="ixv-24840">438</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:WarrantsExercisedInTheYear" scale="3" unitRef="usd" id="ixv-24841">135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Warrants Forfeited in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:WarrantsForfeitedInTheYear" scale="3" sign="-" unitRef="usd" id="ixv-24842">259</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:WarrantsForfeitedInTheYear" scale="3" unitRef="usd" id="ixv-24843">259</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Buyback of Treasury Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:BuybackOfTreasuryShares" scale="3" sign="-" unitRef="usd" id="ixv-24844">254</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:BuybackOfTreasuryShares" scale="3" sign="-" unitRef="usd" id="ixv-24845">254</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares to be issued in lieu of directors fees and cash bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" scale="3" unitRef="usd" id="ixv-24846">225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" scale="3" unitRef="usd" id="ixv-24847">225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total transactions with owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24848">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24849">896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24850">1,715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24851">697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" sign="-" unitRef="usd" id="ixv-24852">254</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24853">278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" unitRef="usd" id="ixv-24854">2,164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Loss for Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24855">17,691</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-24856">17,691</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" unitRef="usd" id="ixv-24857">1,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" scale="3" unitRef="usd" id="ixv-24858">1,492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24859">17,691</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" unitRef="usd" id="ixv-24860">1,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-24861">16,199</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at 31 December 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24862">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24863">16,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24864">6,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24865">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24866">118,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24867">1,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24868">133,676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24869">225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-24870">1,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-24871">5,536</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>TIZIANA LIFE SCIENCES LTD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss from operations before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24872">17,242</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24873">15,397</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-24874">26,657</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Convertible loan interest accrued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForInterestExpense" scale="3" unitRef="usd" id="ixv-24875">163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in lieu of directors fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharesIssuedInLieuOfFees" scale="3" unitRef="usd" id="ixv-24876">425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsForSharebasedPaymentsWarrants" scale="3" unitRef="usd" id="ixv-24877">1,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsForSharebasedPaymentsWarrants" scale="3" unitRef="usd" id="ixv-24878">1,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsForSharebasedPaymentsWarrants" scale="3" unitRef="usd" id="ixv-24879">5,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedDuringTheYear" scale="3" unitRef="usd" id="ixv-24880">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedDuringTheYear" scale="3" unitRef="usd" id="ixv-24881">3,221</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Fair value loss on investment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FVLossOnInvestment" scale="3" unitRef="usd" id="ixv-24882">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FVLossOnInvestment" scale="3" unitRef="usd" id="ixv-24883">869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on disposal of asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LossOnDisposalOfAsset" scale="3" unitRef="usd" id="ixv-24884">129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bonus to be settled in equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:BonusToBeSettledInEquity" scale="3" unitRef="usd" id="ixv-24885">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:BonusToBeSettledInEquity" scale="3" unitRef="usd" id="ixv-24886">855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-24887">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-24888">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-24889">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">(Gain)/ loss on foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-24890">1,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-24891">3,183</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-24892">1,899</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DepreciationOfRightofuseAsset" scale="3" unitRef="usd" id="ixv-24893">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DepreciationOfRightofuseAsset" scale="3" unitRef="usd" id="ixv-24894">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DepreciationOfRightofuseAsset" scale="3" unitRef="usd" id="ixv-24895">133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">(Gain)/loss on disposal of right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CapitalDistribution" scale="3" unitRef="usd" id="ixv-24896">28</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from finance lease reclassified as an investing activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable" scale="3" sign="-" unitRef="usd" id="ixv-24897">152</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash inflow from taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CashInflowFromTaxation" scale="3" unitRef="usd" id="ixv-24898">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CashInflowFromTaxation" scale="3" unitRef="usd" id="ixv-24899">1,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest on related party loan conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InterestReceivedFromLoan" scale="3" unitRef="usd" id="ixv-24900">1,150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net (increase) in related party receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetIncreaseInRelatedPartyReceivables" scale="3" unitRef="usd" id="ixv-24901">1,524</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetIncreaseInRelatedPartyReceivables" scale="3" unitRef="usd" id="ixv-24902">1,158</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetIncreaseInRelatedPartyReceivables" scale="3" unitRef="usd" id="ixv-24903">88</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net (decrease)/increase in related party payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetIncreaseInRelatedPartyPayables" scale="3" unitRef="usd" id="ixv-24904">1,355</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetIncreaseInRelatedPartyPayables" scale="3" unitRef="usd" id="ixv-24905">685</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Net (increase)/decrease in operating assets/other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-24906">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-24907">1,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-24908">516</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net increase/(decrease) in operating liabilities /other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-24909">138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="3" unitRef="usd" id="ixv-24910">347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-24911">516</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24912">15,698</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24913">19,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24914">21,762</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Purchase of PPE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-24915">22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from finance lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProceedsFromFinanceLease" scale="3" unitRef="usd" id="ixv-24916">152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Investment in Related Party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InvestmentInRelatedParty" scale="3" unitRef="usd" id="ixv-24917">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InvestmentInRelatedParty" scale="3" unitRef="usd" id="ixv-24918">2,676</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Purchase of Treasury Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PurchaseOfTreasuryAmount" scale="3" unitRef="usd" id="ixv-24919">253</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PurchaseOfTreasuryAmount" scale="3" unitRef="usd" id="ixv-24920">1,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net cash used in Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24921">1,253</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24922">3,996</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-24923">130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FundraisingCost" scale="3" unitRef="usd" id="ixv-24924">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProceedsFromIssuanceOfOptions" scale="3" unitRef="usd" id="ixv-24925">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProceedsFromIssuanceOfOptions" scale="3" unitRef="usd" id="ixv-24926">129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Repayment of leasing liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RepaymentOfLeasingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-24927">119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RepaymentOfLeasingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-24928">55</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RepaymentOfLeasingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-24929">152</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-24930">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24931">55</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24932">23</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-24933">16,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-24934">23,666</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-24935">21,655</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalent, beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24936">18,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24937">42,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24938">65,824</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exchange difference on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-24939">28</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-24940">398</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-24941">1,983</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalent, end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24942">1,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24943">18,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-24944">42,186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TIZIANA LIFE SCIENCES LTD</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="ixv-19731"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. GENERAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana Life Sciences Ltd,
(the &#8220;company&#8221;) is a public limited company incorporated in Bermuda and at the year-end is quoted on the NASDAQ Capital Market
(NASDAQ: TLSA). The previous parent, Tiziana Life Sciences PLC, delisted from the main market of the London Stock Exchange (LSE: TILS)
on October 21, 2021. The address of its registered office is given on page 1. The principal activities of the Company and its subsidiaries
(the Group) are that of a clinical stage biotechnology company that specializes in the development of transformative therapies for neurodegenerative
and lung diseases. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer&#8217;s, Crohn&#8217;s
Disease and KRAS+ NSCLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functional currency for
the Company is also US dollars ($) indicative of the primary economic environment in which the Company operates. These consolidated financial
statements are presented in thousands of dollars ($&#8217;000) which is the presentational currency of the Company.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-19741"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal accounting policies
applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently
to all the years presented unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" id="ixv-19747"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_2" id="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_3" id="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through profit or loss</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through other comprehensive income</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForGoingConcern" id="ixv-19772"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_2" id="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group incurred losses
during the year and has net assets at the year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_3" id="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_4" id="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AccumulatedLoss" scale="3" unitRef="usd" id="ixv-24945">134</ix:nonFraction>m and a net loss
for the year ended December 31, 2023 of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="6" sign="-" unitRef="usd" id="ixv-24946">17.7</ix:nonFraction>m.</p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_5" id="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.&#160;
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next <ix:nonNumeric contextRef="c0" format="ixt-sec:durmonth" name="tlsa:CashSurplus" id="ixv-24947">12</ix:nonNumeric> months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForGoingConcern-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" id="ixv-19792"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New and Revised Standards</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock-c0_cont_2" id="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Standards in effect in 2023</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForBasisofConsolidation" id="ixv-19820"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of consolidation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation-c0_cont_2" id="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor&#8217;s return.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" id="ixv-19830"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business combination</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group&#8217;s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 &#8216;Business combinations&#8217;
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, Tiziana
Life Sciences Ltd. (the &#8216;Company&#8217;) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group&#8217;s immediate parent company.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="ixv-19843"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="tlsa:NumberOfSegment" scale="0" unitRef="pure" id="ixv-24948">one</ix:nonFraction> operating segment being
the research and development of biotechnological and pharmaceutical products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" id="ixv-19865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Taxation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-19878"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign currency translation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items included in the financial
statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentational
currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Assets and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Profit and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForLicenseFees-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForLicenseFees" id="ixv-19913"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License fees</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForLicenseFees-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. &#8220;License
fees expenses&#8221; are recognized as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-19920"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and development</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group&#8217;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#8216;Intangible
Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-19927"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-19957"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial instruments</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Financial assets, initial
recognition and measurement and subsequent measurement</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Financial liabilities,
initial recognition and measurement and subsequent measurement</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial liabilities are
classified as measured at amortized cost or FVTPL.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s financial
liabilities include trade and other payables.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForWarrantsTextBlock" id="ixv-19988"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_2" id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants are issued by the
Group in return for services and as part of a financing transaction.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_3" id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued in return for services.</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_4" id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_5" id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued as part of a financing transaction.</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="ixv-20025"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share capital</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ordinary shares of the Company
are classified as equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-20032"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property, plant and equipment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(i</b>) Recognition and
measurement</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Depreciation</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" id="ixv-24949">The estimated useful lives
for the current period and the comparative period are as follows.</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock-c0_cont_1"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 60%"><span style="font-size: 10pt">Fixtures and fittings</span></td>
    <td style="width: 40%"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="tlsa:EstimatedUsefulLives" id="ixv-24950">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">IT and equipment</span></td>
    <td><span style="font-size: 10pt"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="tlsa:EstimatedUsefulLives" id="ixv-24951">3</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Right of use asset</span></td>
    <td><ix:nonNumeric contextRef="c74" name="tlsa:RightOfUseAssetDescription" id="ixv-20078"><span style="font-size: 10pt">Economic life of contractual relationship</span></ix:nonNumeric></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="ixv-20084"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of financial assets
measured at amortized cost</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General approach</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Simplified approach</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The simplified approach is
applied to the impairment assessment of trade receivables.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of non-financial assets</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" id="ixv-20142"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contingent Liabilities</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-20150"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases of low value assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases with a duration of 12 months or less.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group&#8217;s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-20214"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share &#8211; based payments</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where employees and directors
are rewarded using share-based payments, the fair value of the employees&#8217;, directors&#8217; and/or advisers&#8217; services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share&#8211;based payment reserve.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss.</p></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods and services received
in exchange for the grant of any share &#8211; based payment are measured at their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock-c0_cont_1" escape="true" name="tlsa:DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" id="ixv-20257"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sub license income</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:UpfrontPayment" scale="3" unitRef="usd" id="ixv-24952">750</ix:nonFraction>k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc&#8217;s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="ixv-20264"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other intangible assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset&#8217;s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset&#8217;s cash generating unit is compared
to the carrying amount.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" id="ixv-20276"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Relassification of Prior Year Presentation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-24953">804</ix:nonFraction>k.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" id="ixv-20286"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. CRITICAL ACCOUNTING JUDGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting
Standards as issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities,
income and expenditure and the disclosures made in the consolidated financial statements. Such estimates and judgements must be continually
evaluated based on historical experience and other factors, including expectations of future events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are considered
to be critical accounting estimates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Share-based payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group accounts for share-based
payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement of the cost of employee
services received in exchange for the options on our ordinary shares, based on the fair value of the award on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes the Black-Scholes-Merton
option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market
conditions. For performance-based options that include vesting conditions relating to the market performance of our ordinary shares, a
Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that have to be met as conditions to vesting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company makes estimates
as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest rate for the term
of the award and correlations and volatilities of the shares of peer group companies. The Company also makes estimates as to the vesting
period for awards that have performance &#8211; based criteria.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="ixv-20318"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4 OTHER (EXPENSE)/ INCOME</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherOperatingIncomeExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" id="ixv-24954">The Group&#8217;s other (expense)/
income is made up of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DisclosureOfOtherOperatingIncomeExpenseExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Sublicense income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SublicenseIncome" scale="3" unitRef="usd" id="ixv-24955">750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Income (see note 19)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" scale="3" unitRef="usd" id="ixv-24956">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" scale="3" unitRef="usd" id="ixv-24957">143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other income/(expense)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherIncomelosses" scale="3" unitRef="usd" id="ixv-24958">33</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherIncomelosses" scale="3" unitRef="usd" id="ixv-24959">893</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sublicense income has been classified as other
income as the counterparty is not considered a customer but an entity we are collaborating with.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory" id="ixv-20408"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. OPERATING LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss-c0_cont_1" escape="true" name="tlsa:DisclosureOfDetailedInformationAboutOperatingLoss" id="ixv-24960">The Group&#8217;s operating
losses are stated after charging/(crediting) the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">License fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Licensefee" scale="3" unitRef="usd" id="ixv-24961">563</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Licensefee" scale="3" sign="-" unitRef="usd" id="ixv-24962">1,047</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Realization bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OperatingLoss" scale="3" unitRef="usd" id="ixv-24963">855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-24964">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-24965">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-24966">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation (Right-of-use asset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" unitRef="usd" id="ixv-24967">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" unitRef="usd" id="ixv-24968">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="3" unitRef="usd" id="ixv-24969">133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange (gains)/losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ForeignExchangegainlosses" scale="3" unitRef="usd" id="ixv-24970">1,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ForeignExchangegainlosses" scale="3" sign="-" unitRef="usd" id="ixv-24971">3,183</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ForeignExchangegainlosses" scale="3" sign="-" unitRef="usd" id="ixv-24972">1,899</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">License fees relating to 2020
were waived in 2021 as a result of negotiations by the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A realization bonus of $<ix:nonFraction contextRef="c75" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:BenefitsPaidOrPayable" scale="6" unitRef="usd" id="ixv-24973">13.5</ix:nonFraction>
million became payable during the year ended December 31, 2020 to the chairman of the board upon the Company raising funds in excess of
$<ix:nonFraction contextRef="c76" decimals="-6" format="ixt:num-dot-decimal" name="tlsa:RaisingFunds" scale="6" unitRef="usd" id="ixv-24974">28</ix:nonFraction>m (&#163;<ix:nonFraction contextRef="c76" decimals="-6" format="ixt:num-dot-decimal" name="tlsa:RaisingFunds" scale="6" unitRef="gbp" id="ixv-24975">20</ix:nonFraction>m), which it successfully raised in August 2020. As the bonus was not settled until November 2021, interest of $<ix:nonFraction contextRef="c34" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="6" unitRef="usd" id="ixv-24976">0.9</ix:nonFraction>m was
accrued on the amount due in the year to December 31, 2021. No realization bonus is accounted for in year ended December 31, 2022.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-20515"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>6. SEGMENTAL REPORTING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year under review
Management identified the Group&#8217;s only operating segment as the research and development of biotechnological and pharmaceutical
products. This one segment is monitored and strategic decisions are made based upon it and other non-financial data collated from industry
intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual consolidated financial
statements.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory" id="ixv-20535"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. EMPLOYEES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory" id="ixv-20541"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Staff costs comprised:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Directors&#8217; salaries (including bonus)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-24977">929</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-24978">554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-24979">2,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Employees&#8217; wages, salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-24980">1,777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-24981">2,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-24982">1,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Social security costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SocialSecurityContributions" scale="3" unitRef="usd" id="ixv-24983">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SocialSecurityContributions" scale="3" unitRef="usd" id="ixv-24984">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SocialSecurityContributions" scale="3" unitRef="usd" id="ixv-24985">176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Recruitment fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RecruitmentFees" scale="3" unitRef="usd" id="ixv-24986">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RecruitmentFees" scale="3" unitRef="usd" id="ixv-24987">197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RecruitmentFees" scale="3" unitRef="usd" id="ixv-24988">242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share based payment (credit) / charge</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-24989">1,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" sign="-" unitRef="usd" id="ixv-24990">1,410</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-24991">5,173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-24992">4,596</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-24993">1,490</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-24994">9,973</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The average monthly number of employees, including directors, employed by the group during the year was:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-24995">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-24996">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-24997">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate and administration</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CorporateAndAdministration" scale="3" unitRef="usd" id="ixv-24998">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CorporateAndAdministration" scale="3" unitRef="usd" id="ixv-24999">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CorporateAndAdministration" scale="3" unitRef="usd" id="ixv-25000">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" scale="3" unitRef="usd" id="ixv-25001">9</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" scale="3" unitRef="usd" id="ixv-25002">9</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" scale="3" unitRef="usd" id="ixv-25003">13</ix:nonFraction></td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-20716"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. REMUNERATION OF KEY MANAGEMENT PERSONNEL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" id="ixv-20721"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Director</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217;<br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">G. Cerrone <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="tlsa:DirectorsFees" scale="3" unitRef="usd">717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="tlsa:Bonus" scale="3" unitRef="usd">100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd">562</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="tlsa:DirectorsFees" scale="3" unitRef="usd">296</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="tlsa:Bonus" scale="3" unitRef="usd">148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="tlsa:DirectorsFees" scale="3" unitRef="usd">330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="tlsa:Bonus" scale="3" unitRef="usd">855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd">624</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25012">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25013">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25014">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25015">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25016">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25017">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">J Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25018">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25019">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25020">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25021">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25022">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25023">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">K. Shailubhai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Salary" scale="3" unitRef="usd" id="ixv-25024">379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" sign="-" unitRef="usd" id="ixv-25025">145</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Bonus" scale="3" unitRef="usd" id="ixv-25026">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Salary" scale="3" unitRef="usd" id="ixv-25027">600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25028">492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" sign="-" unitRef="usd" id="ixv-25029">1,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Salary" scale="3" unitRef="usd" id="ixv-25030">413</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25031">2,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25032">829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Bonus" scale="3" unitRef="usd" id="ixv-25033">100</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25034">758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25035">406</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Bonus" scale="3" unitRef="usd" id="ixv-25036">148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Salary" scale="3" unitRef="usd" id="ixv-25037">379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" sign="-" unitRef="usd" id="ixv-25038">1,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:DirectorsFees" scale="3" unitRef="usd" id="ixv-25039">448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Bonus" scale="3" unitRef="usd" id="ixv-25040">1,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:Salary" scale="3" unitRef="usd" id="ixv-25041">1,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareBasedPayments" scale="3" unitRef="usd" id="ixv-25042">3,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">Gabriele Cerrone&#8217;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherLongtermBenefits" scale="6" unitRef="usd" id="ixv-25043">13.2</ix:nonFraction>m realization bonus.</span></ix:footnote></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All bonuses are short term.
No post-employment or termination payments were made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" id="ixv-25044">The following share options
were granted to directors in the following periods:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">W.Simon</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" scale="0" unitRef="shares" id="ixv-25045">75,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">J. Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" scale="0" unitRef="shares" id="ixv-25046">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" scale="0" unitRef="shares" id="ixv-25047">3,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" scale="0" unitRef="shares" id="ixv-25048">150,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" scale="0" unitRef="shares" id="ixv-25049">3,500,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Key management personnel of
the Group are comprised of directors and officers of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No share options were exercised
by directors during the years ended December 31, 2023,2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company made payments
totaling approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-25050">56</ix:nonFraction>K, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-25051">32</ix:nonFraction>K, and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" scale="3" unitRef="usd" id="ixv-25052">24</ix:nonFraction>K to defined contribution pension schemes on behalf of directors and employees during 2023, 2022,
and 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceCostExplanatory" id="ixv-21259"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. FINANCE COSTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" id="ixv-21263"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Finance Income</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Loan Interest Received</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" unitRef="usd" id="ixv-25053">1,154</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" unitRef="usd" id="ixv-25054">32</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-25055">1,154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-25056">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left">Finance Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance charge accrued on convertible loan notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceChargeAccruedOnConvertibleLoanNotes" scale="3" unitRef="usd" id="ixv-25057">163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25058">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25059">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25060">13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fair Value loss on Investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-25061">402</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-25062">869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total finance Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceExpense" scale="3" unitRef="usd" id="ixv-25063">412</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceExpense" scale="3" unitRef="usd" id="ixv-25064">876</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceExpense" scale="3" unitRef="usd" id="ixv-25065">176</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" scale="3" unitRef="usd" id="ixv-25066">742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-25067">844</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-25068">176</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-21454"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. TAXATION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" id="ixv-21459"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current year tax (credit)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" unitRef="usd" id="ixv-25069">449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" sign="-" unitRef="usd" id="ixv-25070">3,255</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsDueToPriorPeriods" scale="3" sign="-" unitRef="usd" id="ixv-25071">15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxExpenseContinuingOperation" scale="3" unitRef="usd" id="ixv-25072">449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxExpenseContinuingOperation" scale="3" sign="-" unitRef="usd" id="ixv-25073">3,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherLossBeforeTaxation" scale="3" sign="-" unitRef="usd" id="ixv-25074">17,242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherLossBeforeTaxation" scale="3" sign="-" unitRef="usd" id="ixv-25075">15,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OtherLossBeforeTaxation" scale="3" sign="-" unitRef="usd" id="ixv-25076">26,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss charged at standard rate of corporation tax <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfTaxLosses" scale="-2" unitRef="pure" id="ixv-25077">23.52</ix:nonFraction>% 2023 <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfTaxLosses" scale="-2" unitRef="pure" id="ixv-25078"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfTaxLosses" scale="-2" unitRef="pure" id="ixv-25079">19</ix:nonFraction></ix:nonFraction>%2021/22</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" scale="3" sign="-" unitRef="usd" id="ixv-25080">4,055</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" scale="3" sign="-" unitRef="usd" id="ixv-25081">2,926</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" scale="3" sign="-" unitRef="usd" id="ixv-25082">5,065</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Movement in unrecognized deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MovementInUnrecognisedDeferredTax" scale="3" unitRef="usd" id="ixv-25083">3,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MovementInUnrecognisedDeferredTax" scale="3" unitRef="usd" id="ixv-25084">2,319</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MovementInUnrecognisedDeferredTax" scale="3" unitRef="usd" id="ixv-25085">1,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation" scale="3" unitRef="usd" id="ixv-25086">3,961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation" scale="3" unitRef="usd" id="ixv-25087">1,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation" scale="3" unitRef="usd" id="ixv-25088">1,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsDueToPriorPeriod" scale="3" unitRef="usd" id="ixv-25089">449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsDueToPriorPeriod" scale="3" sign="-" unitRef="usd" id="ixv-25090">15</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim" scale="3" sign="-" unitRef="usd" id="ixv-25091">1,401</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income not taxable for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeNotTaxableForTaxPurposes" scale="3" sign="-" unitRef="usd" id="ixv-25092">3,113</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeNotTaxableForTaxPurposes" scale="3" sign="-" unitRef="usd" id="ixv-25093">495</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:IncomeNotTaxableForTaxPurposes" scale="3" sign="-" unitRef="usd" id="ixv-25094">61</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FixedAssetDifferences" scale="3" sign="-" unitRef="usd" id="ixv-25095">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current Tax - Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:CurrentTaxOther" scale="3" unitRef="usd" id="ixv-25096">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to brought forward values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdjustmentsToBroughtForwardValues" scale="3" unitRef="usd" id="ixv-25097">67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-25098">449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-25099">3,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Research and Development
claim has been calculated in accordance with the R&amp;D tax relief available to small and medium sized entities, whereby the entity is
able to claim a cash tax credit (if loss making), worth up to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="tlsa:MaximumPercentageOfSurrenderableLosses" scale="-2" unitRef="pure" id="ixv-25100">14.5</ix:nonFraction>% of the surrenderable losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The adjustments due to prior
periods relate to R&amp;D tax relief claims for the prior period. Under UK tax legislation, a <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tlsa:TermOfResearchAndDevelopmentTaxReliefClaims" id="ixv-25101">2</ix:nonNumeric>-year window is available under which R&amp;D
tax relief can be claimed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No deferred tax asset has
been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of tax losses for
which no deferred tax assets have been recognized for the year ended December 31, 2023 is $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfTaxLosses" scale="3" unitRef="usd" id="ixv-25102">18,137</ix:nonFraction>k (2022 is $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfTaxLosses" scale="3" unitRef="usd" id="ixv-25103">15,011</ix:nonFraction>k; 2021; $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfTaxLosses" scale="3" unitRef="usd" id="ixv-25104">11,591</ix:nonFraction>k).</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-21758"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" id="ixv-25105">Basic loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the
year.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">(Loss) attributable to equity holders of the company ($000)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-25106">17,691</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-25107">15,397</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-25108">23,417</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-25109">102,471,016</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-25110">101,526,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-25111">97,932,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="tlsa:BasicLossPerSharecentsPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-25112">17.3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="1" format="ixt:num-dot-decimal" name="tlsa:BasicLossPerSharecentsPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-25113">15.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="1" format="ixt:num-dot-decimal" name="tlsa:BasicLossPerSharecentsPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-25114">23.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the Group is reporting
a loss from continuing operations for the year then, in accordance with IAS 33, share options, warrants and convertible loan notes are
not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per
share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from
continuing and total operations and therefore no earnings per share for discontinued operations are presented. The weighted average number
of ordinary shares in issuance is stated as net excluding Treasury shares.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-21853"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. OTHER RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" id="ixv-21857"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended <br/>
December 31, 2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security deposits receivable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SecurityDepositsReceivable" scale="3" unitRef="usd" id="ixv-25115">121</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SecurityDepositsReceivable" scale="3" unitRef="usd" id="ixv-25116">130</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="3" unitRef="usd" id="ixv-25117">102</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="3" unitRef="usd" id="ixv-25118">170</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation Receivable</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:TaxationReceivable" scale="3" unitRef="usd" id="ixv-25119">3,793</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:TaxationReceivable" scale="3" unitRef="usd" id="ixv-25120">4,246</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-25121">4,016</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-25122">4,546</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no differences between
the carrying amount and fair value of any of the trade and other receivables above.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" id="ixv-21939"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13 SHARE CAPITAL AND SHARE PREMIUM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Group</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, the Company
acquired the entire shareholding of Tiziana Life Sciences Plc and its subsidiaries through a share for share exchange transaction. On
this date Tiziana Life Sciences Ltd became the Group&#8217;s parent company. This transaction does not constitute a business combination
under IFRS 3 &#8220;Business combinations&#8221; and has been accounted for as a group reorganization. Merger accounting has been applied
to account for the insertion of the new company. Due to a share consolidation, the effect of this was a decrease in share capital of the
Company with an offset posted to the merger reserve. As a common control transaction, the Group has elected to present the comparative
information as if this transaction had occurred before the start of the comparative period. <ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureShareCapitalArisingForShareExchangetextBlock" id="ixv-25123">The share capital arising on the share for
share exchange has been presented as share capital in the comparative period.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Nominal<br/>
 Value</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Share <br/>
Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Share<br/>
 Premium</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Merger<br/>
 Reserve</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">&#163;/$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1 2021 per 20-F annual report</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#163;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="tlsa:NominalValueAnnualReport" scale="0" unitRef="gbpPershares" id="ixv-25124">0.03</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesAnnualReport" scale="0" unitRef="shares" id="ixv-25125">194,612,289</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueAnnualReport" scale="3" unitRef="usd" id="ixv-25126">10,794</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumAnnualReport" scale="3" unitRef="usd" id="ixv-25127">111,821</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Group Reorganization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of share capital in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="tlsa:NominalValueEliminationOfShareCapital" scale="0" unitRef="gbpPershares" id="ixv-25128">0.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesEliminationOfShare" scale="0" sign="-" unitRef="shares" id="ixv-25129">194,612,289</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueEliminationOfShareCapital" scale="3" sign="-" unitRef="usd" id="ixv-25130">10,794</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumEliminationOfShareCapitalIn" scale="3" sign="-" unitRef="usd" id="ixv-25131">111,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveEliminationOfShareCapitalIn" scale="3" unitRef="usd" id="ixv-25132">122,615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued pursuant to share for share exchange and consolidation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="tlsa:NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" scale="0" unitRef="usdPershares" id="ixv-25133">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" scale="0" unitRef="shares" id="ixv-25134">97,306,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" scale="3" unitRef="usd" id="ixv-25135">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" scale="3" sign="-" unitRef="usd" id="ixv-25136">97</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of other reserves in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:EliminationOfOtherReserves" scale="3" sign="-" unitRef="usd" id="ixv-25137">3,821</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Restated at 1 January 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="tlsa:NominalValueRestated" scale="0" unitRef="usdPershares" id="ixv-25138">0.001</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesRestated" scale="0" unitRef="shares" id="ixv-25139">97,306,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueRestated" scale="3" unitRef="usd" id="ixv-25140">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveRestated" scale="3" unitRef="usd" id="ixv-25141">118,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="tlsa:NominalValueConversionOfWarrants" scale="0" unitRef="usdPershares" id="ixv-25142">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesConversionOfWarrants" scale="0" unitRef="shares" id="ixv-25143">136,854</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumConversionOfWarrants" scale="3" unitRef="usd" id="ixv-25144">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of Loan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="tlsa:NominalValueConversionOfLoan" scale="0" unitRef="usdPershares" id="ixv-25145">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesConversionOfLoan" scale="0" unitRef="shares" id="ixv-25146">1,866,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueConversionOfLoan" scale="3" unitRef="usd" id="ixv-25147">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumConversionOfLoan" scale="3" unitRef="usd" id="ixv-25148">603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issued in lieu of cash bonus</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="tlsa:NominalValueIssuedInLieuOfCashBonus" scale="0" unitRef="usdPershares" id="ixv-25149">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesIssuedInLieuOfCashBonus" scale="0" unitRef="shares" id="ixv-25150">2,962,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueIssuedInCashBonus" scale="3" unitRef="usd" id="ixv-25151">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumIssuedInCashBonus" scale="3" unitRef="usd" id="ixv-25152">14,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalShares" scale="0" unitRef="shares" id="ixv-25153">102,272,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueAt31December2021" scale="3" unitRef="usd" id="ixv-25154">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumEnding" scale="3" unitRef="usd" id="ixv-25155">15,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveEnding" scale="3" unitRef="usd" id="ixv-25156">118,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalShares" scale="0" unitRef="shares" id="ixv-25157">102,272,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueAt31December2021" scale="3" unitRef="usd" id="ixv-25158">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumEnding" scale="3" unitRef="usd" id="ixv-25159">15,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveEnding" scale="3" unitRef="usd" id="ixv-25160">118,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued in lieu of fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" name="tlsa:NominalValueSharesIssuedInLieuOfFees" scale="0" unitRef="usdPershares" id="ixv-25161">.0001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesIssuedInLieuOfFees" scale="0" unitRef="shares" id="ixv-25162">450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueSharesIssuedInLieuOfFees" scale="3" unitRef="usd" id="ixv-25163">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumSharesIssuedInLieuOfFees" scale="3" unitRef="usd" id="ixv-25164">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants Exercised</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" name="tlsa:NominalValueWarrantsExercised" scale="0" unitRef="usdPershares" id="ixv-25165">.0001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesWarrantsExercised" scale="0" unitRef="shares" id="ixv-25166">337,501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumWarrantsExercised" scale="3" unitRef="usd" id="ixv-25167">573</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of Stock - ATM</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" name="tlsa:NominalValueIssuanceOfStockATM" scale="0" unitRef="usdPershares" id="ixv-25168">.0001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalSharesIssuanceOfStockATM" scale="0" unitRef="shares" id="ixv-25169">27,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumIssuanceOfStockATM" scale="3" unitRef="usd" id="ixv-25170">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalShares" scale="0" unitRef="shares" id="ixv-25171">103,087,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ShareCapitalValueAt31December2021" scale="3" unitRef="usd" id="ixv-25172">103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:SharePremiumEnding" scale="3" unitRef="usd" id="ixv-25173">16,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MergerReserveEnding" scale="3" unitRef="usd" id="ixv-25174">118,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ordinary shares have a par
value of $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-25175">0.001</ix:nonFraction>. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion
to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person
or by proxy is entitled to one vote, and upon a poll each share is entitled to one vote. The Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfSharesIssued1" scale="0" unitRef="shares" id="ixv-25176">103,087,744</ix:nonFraction> shares in issue and
holds <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:TreasuryShares1" scale="0" unitRef="shares" id="ixv-25177">1,573,510</ix:nonFraction> shares in treasury.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-22386"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. SHARE BASED PAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Group and Company Options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates share-based
payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option
is normally equal to the market price of an ordinary share in the Company at the date of grant. The Company is currently operating two
plans (Tiziana Life Sciences PLC) Share Option Plan which is closed for any new issuances and the Tiziana Life Sciences Ltd 2021 Equity
Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-22396"><b><span style="text-decoration:underline">Tiziana Life Sciences PLC Share Option Plan</span></b></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25178">59</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25179">6,724</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25180">90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25181">22,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25182">67</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25183">17,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceGranted" scale="0" unitRef="usdPershares" id="ixv-25184">166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsGranted" scale="0" unitRef="shares" id="ixv-25185">5,210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceForfeitedCancelled" scale="0" sign="-" unitRef="usdPershares" id="ixv-25186">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedCancelled" scale="0" unitRef="shares" id="ixv-25187">103</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceForfeitedCancelled" scale="0" sign="-" unitRef="usdPershares" id="ixv-25188">92</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsForfeitedCancelled" scale="0" unitRef="shares" id="ixv-25189">15,510</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25190">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25191">6,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25192">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25193">6,724</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceOutstanding" scale="0" unitRef="usdPershares" id="ixv-25194">90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsOutstanding" scale="0" unitRef="shares" id="ixv-25195">22,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceExercisable" scale="0" unitRef="usdPershares" id="ixv-25196">60</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsExercisable" scale="0" unitRef="shares" id="ixv-25197">2,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceExercisable" scale="0" unitRef="usdPershares" id="ixv-25198">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsExercisable" scale="0" unitRef="shares" id="ixv-25199">2,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="tlsa:WeightedAverageExercisePriceExercisable" scale="0" unitRef="usdPershares" id="ixv-25200">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="tlsa:OptionsExercisable" scale="0" unitRef="shares" id="ixv-25201">7,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No options were exercised
during 2023, 2022 or 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total outstanding fair
value charge of the share option instruments is deemed to be approximately $<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingFairValueCharges" scale="3" unitRef="usd" id="ixv-25202">2,602</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingFairValueCharges" scale="3" unitRef="usd" id="ixv-25203">3,223</ix:nonFraction>k (restated), 2021: $<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingFairValueCharges" scale="3" unitRef="usd" id="ixv-25204">12,339</ix:nonFraction>k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Tiziana Life Sciences
PLC Share Option Plan, the total expense recognized for the year ending 31 December 2023 arising from share &#8211; based payment transactions
under the Tiziana Life Sciences PLC Share Option Plan is $<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-25205">703</ix:nonFraction>k of which $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-25206">51</ix:nonFraction>k relates to forfeitures during the year (2022 $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-25207">1,199</ix:nonFraction>k, 2021:
$<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" unitRef="usd" id="ixv-25208">5,173</ix:nonFraction>k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock-c0_cont_1" escape="true" name="tlsa:ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" id="ixv-25209">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock-c0_cont_2" id="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Options <br/>
    at<br/> 31 December <br/> 2023<br/> (&#8217;000)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">26 June 2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c100" name="tlsa:ExpiryDate" id="ixv-25210">26 June 2024</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25211">0.47</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25212">1,831</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>30 April 2018</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c101" name="tlsa:ExpiryDate" id="ixv-25213">30 April 2028</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25214">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25215">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6 May 2020</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c102" name="tlsa:ExpiryDate" id="ixv-25216">5 May 2028</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25217">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25218">3,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>23 July 2020</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c103" name="tlsa:ExpiryDate" id="ixv-25219">26 July 2030</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25220">2.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25221">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">25 August 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c104" name="tlsa:ExpiryDate" id="ixv-25222">24&#160;August&#160;2030</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25223">1.98</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25224">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25225">6,621</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value of options granted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors have used the
Black-Scholes-Merton option pricing model to estimate the fair value of all of the options granted during the year to December 31, 2023,
applying the assumptions below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historical volatility is based
on the historical volatility of the Company itself.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has estimated
a forfeiture rate of zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_1" escape="true" name="tlsa:ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" id="ixv-25226">The model inputs for options
granted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_2" id="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4 November<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 August<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction contextRef="c110" decimals="3" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="usdPershares" id="ixv-25227">0.679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="usdPershares" id="ixv-25228">0.741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25229">0.679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25230">0.741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">-<ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25231">0.10</ix:nonFraction>%&#160;to&#160;-<ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25232">0.02</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25233">0.32</ix:nonFraction>%&#160;to&#160;<ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25234">0.65</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25235">99</ix:nonFraction>% to <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25236">122</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25237">90</ix:nonFraction>% to <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25238">126</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c110" format="ixt-sec:duryear" name="tlsa:OptionLifeShareOptionsGranted" id="ixv-25239">10</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c111" format="ixt-sec:duryear" name="tlsa:OptionLifeShareOptionsGranted" id="ixv-25240">10</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-25241">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-25242">0.741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25243">0.690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25244">0.690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the options issued in
August 2020 with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options.
The Company uses the following methods to determine its underlying assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expected volatilities are based on the historical volatilities of the market;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the expected term of the award is <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tlsa:ExpectedTermOfAwards" id="ixv-25245">4</ix:nonNumeric> years and is based on managements&#8217; assessment of when the market condition is likely to be achieved; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Modification of share &#8211; based payments.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2020, the Company reduced
the exercise price for options issued to employees and directors to $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-25246">0.48</ix:nonFraction> (&#163;<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="gbpPershares" id="ixv-25247">0.35</ix:nonFraction>). This was approved by shareholders at a General
Meeting held on May 6, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the modified
options at the date of modification was determined using the option pricing models as described above. The incremental fair value was
recognized as an expense over the period from the modification date to the end of the vesting period. The expense for the original option
grant will continue to be recognized as if the terms had not been modified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the modified
options was determined using the same models and principles as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Tiziana Life Sciences Ltd Share Option Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:ScheduleOfEquityIncentivePlanTableTextBlock" id="ixv-22966"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25248">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsOutstanding" scale="0" unitRef="shares" id="ixv-25249">2,575</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25250">61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsGranted" scale="0" unitRef="shares" id="ixv-25251">1,753</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25252">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsGranted" scale="0" unitRef="shares" id="ixv-25253">2,575</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25254">57</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsForfeited" scale="0" unitRef="shares" id="ixv-25255">60</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25256">73</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsOutstanding" scale="0" unitRef="shares" id="ixv-25257">4,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-25258">69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tlsa:NumberOfShareOptionsOutstanding" scale="0" unitRef="shares" id="ixv-25259">2,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No options were exercised
during 2023, 2022 or 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total outstanding fair
value charge of the share option instruments is deemed to be approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingFairValueCharges" scale="3" unitRef="usd" id="ixv-25260">974</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingFairValueCharges" scale="3" unitRef="usd" id="ixv-25261">1,176</ix:nonFraction>k)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Tiziana Life Sciences
Ltd 2021 Equity Incentive Plan, the total expenses recognized for the year ending 31 December 2023 arising from share - based payment
transactions are $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" unitRef="usd" id="ixv-25262">1,019</ix:nonFraction>k, not including a charge of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ChargeOfForfeitures" scale="3" unitRef="usd" id="ixv-25263">57</ix:nonFraction>k for forfeitures during the year. (2022:$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ChargeOfForfeitures" scale="3" unitRef="usd" id="ixv-25264">332</ix:nonFraction>k)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><ix:continuation continuedAt="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_3" id="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">26 July <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">14 March<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="usdPershares" id="ixv-25265">0.67</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="usdPershares" id="ixv-25266">0.57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25267">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25268">0.57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25269">3.88</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25270">3.88</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25271">118</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25272">119</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c116" format="ixt-sec:duryear" name="tlsa:OptionLifeShareOptionsGranted" id="ixv-25273">10</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="tlsa:OptionLifeShareOptionsGranted" id="ixv-25274">10</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-25275">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" unitRef="usdPershares" id="ixv-25276">0.57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25277">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-25278">0.57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share&#160;Options<br/>
 as at 31 December <br/> 2023<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">01 August 2022</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><ix:nonNumeric contextRef="c106" name="tlsa:ExpiryDate" id="ixv-25279">01 August 2032</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25280">0.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25281">725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>04 November 2022</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c107" name="tlsa:ExpiryDate" id="ixv-25282">04 November 2032</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25283">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25284">1,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>14 March 2023</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c108" name="tlsa:ExpiryDate" id="ixv-25285">14 March 2033</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25286">0.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25287">993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">26 July 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c109" name="tlsa:ExpiryDate" id="ixv-25288">26 July 2033</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ExerciseSharePrice" scale="0" unitRef="usdPershares" id="ixv-25289">0.67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25290">700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:ShareOptions" scale="0" unitRef="shares" id="ixv-25291">4,268</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Group and Company Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were issued in
2022 or 2023. For warrants issued in 2020, the Directors have estimated the fair value of the warrants using the Black-Scholes valuation
model and assumptions below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="gipPershares" id="ixv-25292">0.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="gipPershares" id="ixv-25293">0.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="tlsa:GrantDateSharesPrice" scale="0" unitRef="gipPershares" id="ixv-25294">1.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="gipPershares" id="ixv-25295">0.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="gipPershares" id="ixv-25296">0.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="gipPershares" id="ixv-25297">0.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25298">0.64</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25299">0.40</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25300">0.04</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25301">61.7</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25302">84.7</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-25303">111</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" id="ixv-23466"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding at 1 January</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FairValueOutstanding" scale="3" unitRef="usd" id="ixv-25304">697</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FairValueOutstanding" scale="3" unitRef="usd" id="ixv-25305">697</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FairValueOutstanding" scale="3" unitRef="usd" id="ixv-25306">697</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingExercised" scale="3" sign="-" unitRef="usd" id="ixv-25307">438</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:OutstandingExpired" scale="3" sign="-" unitRef="usd" id="ixv-25308">259</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at 31 December</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FairValueOutstanding" scale="3" unitRef="usd" id="ixv-25309">697</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FairValueOutstanding" scale="3" unitRef="usd" id="ixv-25310">697</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-hidden: hidden-fact-330"><span style="-sec-ix-hidden: hidden-fact-331"><span style="-sec-ix-hidden: hidden-fact-332">No</span></span></span> share-based payment charges
relating to warrants were recorded during 2023, 2022 or 2021. Approximately $<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-25311">26</ix:nonFraction>K of share-based payment charges are included in the consolidated
statement of operations and comprehensive loss for the year ended December 31, 2020.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-23591"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. RESERVES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share-based payment reserve
for warrants represents the cost to issue warrants in the future based on their grant date fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share-based payment reserve
for options represents the cost to issue share-based compensation, primarily share options, based on their grant date fair value.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Retained earnings represent
the cumulative profits/(losses) of the entity which have not been distributed to shareholders. This reserve has been credited as part
of the capital reduction exercise described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The translation reserve represents
the unrealized gains or losses from the foreign currency translation of Companies within the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares to be issued reserve
represents the equity shares that are to be issued to the Chairman in lieu of his bonus and additional salary for his role as acting CEO
for the year ending December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The merger reserve arises
on consolidation as a result of the share for share exchange transaction that took place this year described in note 13. It represents
the difference between the share capital issued and the aggregate carrying value of assets and liabilities and other reserves of the previous
parent on the merger date.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="ixv-23609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The main risks arising from
the Group&#8217;s financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and
agree policies for managing each of these risks which are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk encompasses three
types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair
value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled
&#8220;interest rate risk&#8221; below. The Directors do not consider the Group&#8217;s exposure to price risk to be significant. The
Group&#8217;s risk management is coordinated by the Directors and focuses on actively securing the Group&#8217;s short to medium term
cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative
purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Credit risk is managed on
a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well
as credit exposure to customers including committed transactions and outstanding receivables. The Group reviews its banking arrangements
carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans
between members of the Group as part of their internal reporting and assesses outstanding receivables for ability to be repaid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s policy is
to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity
requirements in the short and long term. The Group ordinarily finances its activities through cash generated from private and public offerings
of equity and debt securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock-c0_cont_1" escape="true" name="tlsa:ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" id="ixv-25312">The table below summarizes
the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock-c0_cont_2" id="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 3 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12 <br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25313">2,223</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25314">1,914</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25315">4,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25316">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25317">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25318">138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25319">2,354</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25320">1,921</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25321">4,275</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Less than <br/>
3 months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3 to 12 <br/>
months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade payables</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25322">1,230</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25323">3,732</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-25324">4,962</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25325">32</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25326">98</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-25327">130</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party payables</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-336; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25328">1,262</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25329">3,830</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinancialInstrumentsNet" scale="3" unitRef="usd" id="ixv-25330">5,092</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest rate risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has limited exposure
to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Bank of America
base rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors do not consider
the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity
position as of year-end for either the year ended 31 December 2023 or 31 December 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign currency risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group operates internationally
although the majority of its operations are based in the United Kingdom and the United States, and the majority of assets and liabilities
are denominated in US Dollars, with a small amount denominated in Pound Sterling. It therefore is exposed to some foreign exchange risk
arising from exposure to various currencies primarily the Pound Sterling. The Group monitors currency exchange rates and makes judgments
as to whether to enter into currency hedging contracts. Currently no such hedging contracts are in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A reasonably possible strengthening
(weakening) of the US dollar or Sterling against all other currencies at 31 December 2023 would have affected the measurement of the financial
instruments denominated in a foreign currency and affected equity and profit and loss by the amounts shown below. <ix:nonNumeric contextRef="c0" continuedAt="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock-c0_cont_1" escape="true" name="tlsa:ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" id="ixv-25331">This analysis assumes
that all other variables remain constant.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit or loss and equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Strengthening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weakening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">USD (<ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="tlsa:MovementPercentageStrengthening" scale="-2" unitRef="pure" id="ixv-25332"><ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="tlsa:MovementPercentageWeakening" scale="-2" unitRef="pure" id="ixv-25333">5</ix:nonFraction></ix:nonFraction>% movement)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProfitOrLossAndEquityStrengthening" scale="3" unitRef="usd" id="ixv-25334">467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ProfitOrLossAndEquityWeakening" scale="3" sign="-" unitRef="usd" id="ixv-25335">467</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="ixv-23892"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. CAPITAL RISK MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purpose of the Group&#8217;s
capital management, capital includes called up share capital, share premium, share &#8211; based payments for options, share - based payments
for warrants, convertible loan note reserve, and all other equity reserves attributable to the equity holders of the parent as reflected
in the consolidated statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s objectives
when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern and to maximize shareholder value through
the optimization of the equity balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group adjusts its capital
structure in light of changes in economic conditions and expected business demands on capital. The Group may also return capital to shareholders
or issue additional shares.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-23904"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. TRADE AND OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock" id="ixv-23908"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-25336">4,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-25337">4,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accruals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-25338">2,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-25339">1,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-25340">6,387</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-25341">6,532</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="tlsa_InvestmentInRelatedPartyTextBlock-c0_cont_1" escape="true" name="tlsa:InvestmentInRelatedPartyTextBlock" id="ixv-23965"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>19. INVESTMENT IN RELATED PARTY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" id="ixv-23970"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Accustem Sciences Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" scale="3" unitRef="usd" id="ixv-25342">1,806</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" scale="3" unitRef="usd" id="ixv-25343">2,675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossOnFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-25344">969</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossOnFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-25345">869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" scale="3" unitRef="usd" id="ixv-25346">837</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" scale="3" unitRef="usd" id="ixv-25347">1,806</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p></ix:nonNumeric></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="tlsa_InvestmentInRelatedPartyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share price of Accustem
as of December 31, 2023 was $.<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="tlsa:SharesPrice" scale="0" unitRef="usdPershares" id="ixv-25348">63</ix:nonFraction>, which has resulted in the recognition of a fair value loss of $<ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-25349">1,049</ix:nonFraction>k. This has been measured using the
Level 1per IFRS 13 fair value hierarchy. Accustem Sciences Inc is listed on the OTC markets and is run by a separate management team which
is independent of the Tiziana management team. Tiziana is therefore not able to assert significant influence over Accustem Sciences Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Okyo Pharma Ltd</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" scale="3" unitRef="usd" id="ixv-25350">3,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossOnFinancialAssets" scale="3" unitRef="usd" id="ixv-25351">567</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" scale="3" unitRef="usd" id="ixv-25352">3,717</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group acquired <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="tlsa:AcquiredShares" scale="6" unitRef="shares" id="ixv-25353">2.1</ix:nonFraction>m shares of Okyo Pharma Ltd. on October 23,
2023 which is a <ix:nonFraction contextRef="c132" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" unitRef="pure" id="ixv-25354">15.57</ix:nonFraction>% ownership.&#160;The share price of Okyo Pharma Ltd as of December 31, 2023 was $<ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="tlsa:SharesPrice" scale="0" unitRef="usdPershares" id="ixv-25355">1.77</ix:nonFraction>, which has resulted in the
recognition of a fair value gain of $<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-25356">567</ix:nonFraction>k. This has been measured using the Level 1per IFRS 13 fair value hierarchy. Okyo Pharma Ltd
is listed on the OTC markets and is run by a separate management team which is independent of the Tiziana management team. Tiziana is
therefore not able to assert significant influence over Okyo Sciences Inc.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTreasurySharesExplanatory" id="ixv-24100"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>20. TREASURY SHARES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company acquired
<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tlsa:SharesPurchases" scale="0" unitRef="shares" id="ixv-25357">1,683,544</ix:nonFraction> of its own shares through purchases on the NASDAQ stock exchange during the year ended December 31, 2022. The amount paid
to acquire the shares totaled $<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TreasuryShares" scale="3" unitRef="usd" id="ixv-25358">1,320</ix:nonFraction>k, and the shares are held as &#8220;treasury shares&#8221;. The Company has the right to
reissue these shares later. All shares issued by the Company are fully paid. In 2023 there was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="3" unitRef="shares" id="ixv-25359">254</ix:nonFraction>k in buybacks.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="ixv-24110"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>21. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ultimate controlling party
of the Group is Planwise Group Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rasna Therapeutics Inc is
a related party as the entity is controlled by a person that has significant influence over the Group. Rasna is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby Rasna is charged for shared services such as the payroll and rent. During 2022,
Tiziana extended a loan to Rasna for $<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InterestAmount" scale="3" unitRef="usd" id="ixv-25360">75,000</ix:nonFraction> at an interest rate of <ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="tlsa:ShortTermLoanFacility1" scale="-2" unitRef="pure" id="ixv-25361">16</ix:nonFraction>% per annum. There were no additional loans to Rasna in 2023. As
of December 31, 2023, $<ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25362">416</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25363">206</ix:nonFraction>k, 2021: $<ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25364">106</ix:nonFraction>k) was owed to Tiziana Life Sciences Ltd in respect of the loan and shared services
agreement. The total charged under the shared services agreement in the year ending 31 December 2023 was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25365">6</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25366">7</ix:nonFraction>k, 2021: $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25367">11</ix:nonFraction>k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above,
on April 16, 2020, Tiziana also acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin
D (Act D; a.k.a. Dactinomycin), from Rasna to expand its pipeline for a consideration of an initial $<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:InitialAmount" scale="3" unitRef="usd" id="ixv-25368">120</ix:nonFraction>k upfront payment and milestone
payments of up to an additional aggregate $<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:AdditionalPayment" scale="3" unitRef="usd" id="ixv-25369">630</ix:nonFraction>k. There were no milestone payments due in the year ending 31 December 2023 (2022: $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MilestonePaymentDue" scale="3" unitRef="usd" id="ixv-25370">0</ix:nonFraction>k,
2021:$<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MilestonePaymentDue" scale="3" unitRef="usd" id="ixv-25371">0</ix:nonFraction>k).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OKYO Pharma Ltd is a related
party as the entity is controlled by a person that has significant influence over the Group. OKYO is also party to a Shared Services agreement&#160;with&#160;Tiziana&#160;whereby
OKYO is charged for shared services such as the payroll and rent. As of December 31, 2023 $<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25372">398</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25373">274</ix:nonFraction>k, 2021: $<ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25374">42</ix:nonFraction>k) was owed to
Tiziana Life Sciences Ltd in respect of this agreement. The total charged under the shared services agreement in the year ending 31 December
2023 was $<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25375">199</ix:nonFraction>k (2022: $<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25376">125</ix:nonFraction>k, 2021: $<ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ServicesAgreementAmount" scale="3" unitRef="usd" id="ixv-25377">98</ix:nonFraction>k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, the Group
issued a short-term credit facility to OKYO Pharma, a related party, for $<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-25378">2,000</ix:nonFraction>k to support short term liquidity. The loan was available
for a period of 6 months upon first draw-down and carries an interest rate of <ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-25379">16</ix:nonFraction>% per annum, with additional default interest of <ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-25380">4</ix:nonFraction>% if
the loan is not repaid after the 6-month period. In October 23 the loan was converted to an investment in OKYO with <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-25381">20</ix:nonFraction>% interest. The
principal of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PrincipalAmount" scale="3" unitRef="usd" id="ixv-25382">2,000</ix:nonFraction>k plus accrued interest of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued" scale="3" unitRef="usd" id="ixv-25383">1,150</ix:nonFraction>k were converted into <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-25384">2,100,000</ix:nonFraction> Ordinary Shares, with no par value, of OKYO Pharma
Ltd. As at December 31, 2022 $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-25385">1,056</ix:nonFraction>k had been drawn down against the loan and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-25386">19</ix:nonFraction>k of interest had been accrued.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gensignia Lifesciences Inc
is a related party as the entity is controlled by a person that has significant influence over the Group. As of December 31, 2023 the
related party balance is $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" scale="3" unitRef="usd" id="ixv-25387">0</ix:nonFraction> (2022, $<ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" scale="3" unitRef="usd" id="ixv-25388">0</ix:nonFraction>k, 2021: $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" scale="3" unitRef="usd" id="ixv-25389">295</ix:nonFraction>k). On December 31, 2022 $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" scale="3" unitRef="usd" id="ixv-25390">295</ix:nonFraction>k was written off to bad debt after management assessment
and deemed the balance to be irrecoverable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accustem Sciences Inc is a
related party as the entity is controlled by a person that has significant influence over the Group. Accustem is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby the Company is charged for shared services such as payroll and rent as of December
31 2023, $<ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25391">1,324</ix:nonFraction>k (2022:$<ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25392">72</ix:nonFraction>K, 2021:$<ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:PayrollAndRentCharged" scale="3" unitRef="usd" id="ixv-25393">1,341</ix:nonFraction>k). The net amount owed from Accustem, including shared service total costs of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-25394">1,324</ix:nonFraction>k.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-24142"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All leases are accounted for by recognizing a right-of-use
asset and a lease liability except for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases of low value assets; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has leases for its
offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have leases of
low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group
sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent
manner to its property, plant and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of 2022,
the Group entered into a new lease agreement for its London office. <ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock-c0_cont_1" escape="true" name="tlsa:DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" id="ixv-25395">Any leases that have a term shorter than 12 months the Group has applied
the exemption allowed by paragraph 5a in IFRS16 in respect of short &#8211; term leases.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock-c0_cont_2" id="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Right-of-use assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetBeginning" scale="3" unitRef="usd" id="ixv-25396">372</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetBeginning" scale="3" unitRef="usd" id="ixv-25397">448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetsDepreciation" scale="3" sign="-" unitRef="usd" id="ixv-25398">104</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetsDepreciation" scale="3" sign="-" unitRef="usd" id="ixv-25399">50</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Disposal of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ExchangeDifferencesRightofUseAssets" scale="3" unitRef="usd" id="ixv-25400">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ExchangeDifferencesRightofUseAssets" scale="3" sign="-" unitRef="usd" id="ixv-25401">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetsTotal" scale="3" unitRef="usd" id="ixv-25402">283</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:RightOfUseAssetsTotal" scale="3" unitRef="usd" id="ixv-25403">372</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesBeginning" scale="3" unitRef="usd" id="ixv-25404">365</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesBeginning" scale="3" unitRef="usd" id="ixv-25405">448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesInterestExpense" scale="3" unitRef="usd" id="ixv-25406">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesInterestExpense" scale="3" unitRef="usd" id="ixv-25407">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesLeasePayments" scale="3" sign="-" unitRef="usd" id="ixv-25408">119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesLeasePayments" scale="3" sign="-" unitRef="usd" id="ixv-25409">61</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ExchangeDifferences" scale="3" sign="-" unitRef="usd" id="ixv-25410">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:ExchangeDifferences" scale="3" sign="-" unitRef="usd" id="ixv-25411">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesTotal" scale="3" unitRef="usd" id="ixv-25412">247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeaseLiabilitiesTotal" scale="3" unitRef="usd" id="ixv-25413">365</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="ixv-25414">Lease liabilities are presented
in the consolidated statement of financial; position as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfFinancialAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25415">138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25416">122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25417">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-25418">243</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" unitRef="usd" id="ixv-25419">247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" unitRef="usd" id="ixv-25420">365</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="tlsa_DisclosureOfFutureMinimumLeasePayments-c0_cont_1" escape="true" name="tlsa:DisclosureOfFutureMinimumLeasePayments" id="ixv-25421">The lease liabilities are
secured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="tlsa_DisclosureOfFutureMinimumLeasePayments-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minimum lease payment due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Within 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-2 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2-5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Over 5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Lease payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeasePayments" scale="3" unitRef="usd" id="ixv-25422">148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeasePayments" scale="3" unitRef="usd" id="ixv-25423">111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:LeasePayments" scale="3" unitRef="usd" id="ixv-25424">259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Finance Charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceCharges" scale="3" sign="-" unitRef="usd" id="ixv-25425">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceCharges" scale="3" sign="-" unitRef="usd" id="ixv-25426">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:FinanceCharges" scale="3" sign="-" unitRef="usd" id="ixv-25427">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Net Present Values</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetPresentValues" scale="3" unitRef="usd" id="ixv-25428">138</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetPresentValues" scale="3" unitRef="usd" id="ixv-25429">109</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:NetPresentValues" scale="3" unitRef="usd" id="ixv-25430">247</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="ixv-24480"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s main financial
commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research
and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical,
clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Milciclib project research future payments relate to the achievement of clinical milestones or the payment of royalties. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay Nerviano
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25431">1,000,000</ix:nonFraction> upon initiation of the first Phase II clinical trial, this is currently being negotiated with BMS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25432">4,000,000</ix:nonFraction> upon FPD of the first Phase 3 registration trial in HCC.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25433">3,600,000</ix:nonFraction> upon first patient enrollment into a Phase II human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Upon the first NDA equivalent in: thymic carcinoma, $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25434">900,000</ix:nonFraction>; HCC, $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25435">9,000,000</ix:nonFraction>; breast cancer, $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25436">15,000,000</ix:nonFraction>.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Foralumab project &#8211; Future payments relate to the achievement of clinical milestones or the payment of royalties. Diligence obligations are payable to BMS/Medarex should the project continue to commercialisation. $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:AccruedOfDiligenceObligations" scale="0" unitRef="usd" id="ixv-25437">750,000</ix:nonFraction> has been recoded as other income in respect of diligence obligations due to Medarex for 2021.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay BMS
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25438">300,000</ix:nonFraction> upon enrollment of first patient in a Phase I human clinical trial of the first Phase II Clinical trial, this is currently being negotiated with BMS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25439">1,500,000</ix:nonFraction> upon initiation of the first Phase III clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25440">2,000,000</ix:nonFraction> upon filing of the first BLA, or equivalent</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:DevelopmentMilestones" scale="0" unitRef="usd" id="ixv-25441">2,000,000</ix:nonFraction> upon approval of the first BLA, or equivalent</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay Brighams
Womens Hospital the following hospital milestone payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="tlsa:MilestonePayments" scale="0" unitRef="usd" id="ixv-25442">300,000</ix:nonFraction> upon first patient enrollment into a Phase I human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="tlsa:MilestonePayments" scale="0" unitRef="usd" id="ixv-25443">300,000</ix:nonFraction> upon first patient enrollment into a Phase II human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="tlsa:MilestonePayments" scale="0" unitRef="usd" id="ixv-25444">1,500,000</ix:nonFraction> upon first patient enrollment into a Phase III human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tlsa:CommercialSaleOfAProduct" scale="0" unitRef="usd" id="ixv-25445">3,000,000</ix:nonFraction> upon first commercial sale of a product</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">ACT D - Tiziana will need to make milestone payments of up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tlsa:MilestonePayments" scale="3" unitRef="usd" id="ixv-25446">630</ix:nonFraction>k depending on the issuance of a US patent from any US patent application in Transferred IP relating to nanoparticle formulations of Act D and upon the successful completion of a Phase II clinical efficacy trial.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-24614"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>24. CONTINGENT LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The group from time to time
is involved in legal proceedings, none of which have given rise to contingent liabilities. Contingencies arising in the ordinary course
of business, for which no security has been given, are not expected to result in any material financial loss.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-29</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>































































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="tlsa:ShareBasedPaymentReserveWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="tlsa:SharesToBeIssuedReserve" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-5" name="tlsa:RealisationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="tlsa:RealisationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="tlsa:IncomeTaxSCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" decimals="INF" id="hidden-fact-9" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">0.15</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-10" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">0.17</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-11" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="usdPershares">0.24</ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-12" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-13" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-14" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-15" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-16" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-17" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-18" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-20" name="ifrs-full:IssueOfEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-21" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-23" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-25" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-27" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-28" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-29" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-30" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-31" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-32" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-33" name="tlsa:SharesIssuedInLieuOfCashRealizationBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-34" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-35" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-36" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-37" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-38" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-39" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-40" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-41" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-42" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-43" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-44" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-45" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-46" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-47" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-48" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-49" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-50" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-51" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-52" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-53" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-54" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-55" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-56" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-57" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-58" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-59" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-60" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-61" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-62" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-63" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-64" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-65" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-66" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-67" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-68" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-69" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-70" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-71" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-72" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-73" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-74" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-75" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-76" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-77" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-78" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-79" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-80" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-81" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-82" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-83" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-84" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-85" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-86" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-87" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-88" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-89" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-90" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-91" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-92" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-93" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-94" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-95" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-96" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-97" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-98" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-99" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-100" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-101" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-102" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-103" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-104" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-105" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-106" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-107" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-108" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-109" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-110" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-111" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-112" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-113" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-114" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-115" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-116" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-117" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-118" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-119" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-120" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-121" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-122" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-123" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-124" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-125" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-126" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-127" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-128" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-129" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-130" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-131" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-132" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-133" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-134" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-135" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-136" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-137" name="tlsa:ShareBasedPaymentoptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-138" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-139" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-140" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-141" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-142" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-143" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-144" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-145" name="tlsa:OptionsForfeitedcancelled" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-146" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-147" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-148" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-149" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-150" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-151" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-152" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-153" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-154" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-155" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-156" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-157" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-158" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-159" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-160" name="tlsa:WarrantsExercisedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-161" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-162" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-163" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-164" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-165" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-166" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-167" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-168" name="tlsa:WarrantsForfeitedInTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-169" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-170" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-171" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-172" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-173" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-174" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-175" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-176" name="tlsa:BuybackOfTreasuryShares" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-177" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-178" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-179" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-180" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-181" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-182" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-183" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-184" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-185" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-186" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c61" id="hidden-fact-187" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-188" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-189" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-190" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-191" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-192" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-193" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-194" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-195" name="tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-196" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-197" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-198" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-199" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-200" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-201" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" id="hidden-fact-202" name="ifrs-full:ComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-203" name="ifrs-full:AdjustmentsForInterestExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-204" name="ifrs-full:AdjustmentsForInterestExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-205" name="tlsa:SharesIssuedInLieuOfFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-206" name="tlsa:SharesIssuedInLieuOfFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-207" name="tlsa:OptionsForfeitedDuringTheYear" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-208" name="tlsa:FVLossOnInvestment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-209" name="tlsa:LossOnDisposalOfAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-210" name="tlsa:LossOnDisposalOfAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-211" name="tlsa:BonusToBeSettledInEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-212" name="tlsa:CapitalDistribution" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-213" name="tlsa:CapitalDistribution" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-214" name="tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-215" name="tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-216" name="tlsa:CashInflowFromTaxation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-217" name="tlsa:InterestReceivedFromLoan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-218" name="tlsa:InterestReceivedFromLoan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-219" name="tlsa:NetIncreaseInRelatedPartyPayables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-220" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-221" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-222" name="tlsa:ProceedsFromFinanceLease" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-223" name="tlsa:ProceedsFromFinanceLease" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-224" name="tlsa:InvestmentInRelatedParty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-225" name="tlsa:PurchaseOfTreasuryAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-226" name="tlsa:FundraisingCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-227" name="tlsa:FundraisingCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-228" name="tlsa:ProceedsFromIssuanceOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-229" name="tlsa:SublicenseIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-230" name="tlsa:SublicenseIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-231" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-232" name="tlsa:OtherIncomelosses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-233" name="tlsa:OperatingLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-234" name="tlsa:OperatingLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-235" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-236" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-237" name="tlsa:ShareBasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c79" id="hidden-fact-238" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-239" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-240" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-241" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-242" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-243" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-244" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-245" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c85" id="hidden-fact-246" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c85" id="hidden-fact-247" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-248" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-249" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-250" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-251" name="tlsa:ShareBasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c87" id="hidden-fact-252" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c87" id="hidden-fact-253" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c88" id="hidden-fact-254" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-255" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-256" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-257" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-258" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-259" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-260" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c91" id="hidden-fact-261" name="tlsa:DirectorsFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c91" id="hidden-fact-262" name="tlsa:Bonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-263" name="tlsa:Salary" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c93" id="hidden-fact-264" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c94" id="hidden-fact-265" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-266" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c85" id="hidden-fact-267" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-268" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-269" name="tlsa:NumberOfShareOptionsWereGrantedToDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-270" name="ifrs-full:InterestExpenseOnBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-271" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-272" name="tlsa:FinanceChargeAccruedOnConvertibleLoanNotes" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-273" name="tlsa:FinanceChargeAccruedOnConvertibleLoanNotes" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-274" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-275" name="ifrs-full:CurrentTaxExpenseIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-276" name="tlsa:AdjustmentsDueToPriorPeriods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-277" name="tlsa:AdjustmentsDueToPriorPeriods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-278" name="tlsa:IncomeTaxExpenseContinuingOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-279" name="tlsa:AdjustmentsDueToPriorPeriod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-280" name="tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-281" name="tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-282" name="tlsa:FixedAssetDifferences" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-283" name="tlsa:FixedAssetDifferences" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-284" name="tlsa:CurrentTaxOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-285" name="tlsa:CurrentTaxOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-286" name="tlsa:AdjustmentsToBroughtForwardValues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-287" name="tlsa:AdjustmentsToBroughtForwardValues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-288" name="tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-289" name="tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-290" name="tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-291" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-292" name="tlsa:MergerReserveAtJanuary12021Per20FAnnualReport" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-293" name="tlsa:SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-294" name="tlsa:SharePremiumRestatedAt1January2021" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-295" name="tlsa:ShareCapitalConversionOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-296" name="tlsa:MergerReserveConversionOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-297" name="tlsa:MergerReserveConversionOfLoan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-298" name="tlsa:MergerReserveIssuedInLieuOfCashBonus" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-299" name="tlsa:ShareCapitalValueWarrantsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-300" name="tlsa:ShareCapitalValueIssuanceOfStockATM" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-301" name="tlsa:WeightedAverageExercisePriceGranted" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-302" name="tlsa:OptionsGranted" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-303" name="tlsa:WeightedAverageExercisePriceGranted" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-304" name="tlsa:OptionsGranted" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-305" name="tlsa:WeightedAverageExercisePriceForfeitedCancelled" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-306" name="tlsa:OptionsForfeitedCancelled" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-307" name="tlsa:WeightedAverageExercisePriceExercised" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-308" name="tlsa:OptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-309" name="tlsa:WeightedAverageExercisePriceExercised" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-310" name="tlsa:OptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-311" name="tlsa:WeightedAverageExercisePriceExercised" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-312" name="tlsa:OptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-313" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-314" name="tlsa:NumberOfShareOptionsOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-315" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-316" name="tlsa:NumberOfShareOptionsForfeited" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-317" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-318" name="tlsa:NumberofOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-319" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-320" name="tlsa:NumberofOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-321" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-322" name="tlsa:NumberOfShareOptionsExercisable" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-323" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-324" name="tlsa:NumberOfShareOptionsExercisable" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-325" name="tlsa:OutstandingExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-326" name="tlsa:OutstandingExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-327" name="tlsa:OutstandingExpired" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-328" name="tlsa:OutstandingExpired" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-329" name="tlsa:FairValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-330" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-331" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-332" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-333" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-334" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-335" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c127" id="hidden-fact-336" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c128" id="hidden-fact-337" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-338" name="tlsa:RelatedPartyPayablesAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c136" id="hidden-fact-339" name="ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c136" id="hidden-fact-340" name="ifrs-full:ImpairmentLossOnFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c136" id="hidden-fact-341" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-342" name="tlsa:DisposalOfLease" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-343" name="tlsa:DisposalOfLease" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c156" id="hidden-fact-344" name="tlsa:LeasePayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c157" id="hidden-fact-345" name="tlsa:LeasePayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c156" id="hidden-fact-346" name="tlsa:FinanceCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c157" id="hidden-fact-347" name="tlsa:FinanceCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c156" id="hidden-fact-348" name="tlsa:NetPresentValues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c157" id="hidden-fact-349" name="tlsa:NetPresentValues" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-25799">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-25800">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentRegistrationStatement" id="ixv-25801">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-25802">0001723069</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-25803">000-00000</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="tlsa-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact hidden-fact-235 ix_2_fact ix_3_fact ix_4_fact hidden-fact-236 hidden-fact-237 ix_5_fact ix_6_fact hidden-fact-238 ix_7_fact" toRefs="ix_0_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbADF7/9uggu7kBB2+svJKo8=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">tlsa:RightOfUseAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TizianaLifeSciencesPLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentySixJuneTwoThousandFourteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ThirtyAprilTwoThousandAndEighteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:SixMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentyThreeJulyTwoThousandAndTwentyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentyFiveAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ShareOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ZeroOneeAugustTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ZeroFourNovemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:FourteenMarchTwoThousandTwentyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentySixJulyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-04</xbrli:startDate>
    <xbrli:endDate>2022-11-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-04</xbrli:startDate>
    <xbrli:endDate>2022-11-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-04</xbrli:startDate>
    <xbrli:endDate>2022-11-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-26</xbrli:startDate>
    <xbrli:endDate>2023-07-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-14</xbrli:startDate>
    <xbrli:endDate>2023-03-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-21</xbrli:startDate>
    <xbrli:endDate>2020-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-21</xbrli:startDate>
    <xbrli:endDate>2020-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">tlsa:USDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:ClassOfWarrantsOrRightAxis">tlsa:NASDAQStockExchangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">tlsa:LaterThanTwoYearsAndNotLaterThanFiveYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIClinicalTrialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:Phase3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIHumanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:CarcinomaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:HCCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:BreastCancerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIHumanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIIHumanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001723069</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:BLAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="gbp">
  <xbrli:measure>iso4217:GBP</xbrli:measure>
</xbrli:unit><xbrli:unit id="gbpPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="gipPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:GIP</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea020387201ex2-1_tiziana.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our share capital comprises
common shares of par value $0.001 each and preference shares of par value $0.001 each. Subject to a resolution of shareholders to the
contrary and any special rights previously conferred on the holders of any existing shares or class of shares, the Board is authorized
to issue any unissued shares on such terms and conditions as it may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of our common
shares is entitled to one vote for each share on all matters submitted to a vote of the shareholders. Under our Bye-laws, at any general
meeting held for the purpose of electing directors at which a quorum is present, the director nominees receiving the most votes (up to
the number of Directors to be elected) shall be elected as Directors, and an absolute majority of the votes cast shall not be a prerequisite
to the election of such Directors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may, subject to
the our Bye-laws and in accordance with Section 54 of the Bermuda Companies Act, declare a dividend to be paid to the shareholders, in
proportion to the number of shares held by them, and such dividend may be paid in cash or in specie. Dividends unclaimed after seven years
from the date when the respective dividend became payable shall, if the Board so resolves, be forfeited and cease to remain owing by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On winding-up the liquidator
may with the authority of a resolution of the members, divide the whole or any part of our the assets among the shareholders, in whole
or part, in specie or vest the whole or any part of the assets upon such trusts as the liquidator shall think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights, preferences and
privileges of the holders of our common shares is subject to and may be adversely affected by the rights of the holders of shares of any
series of preference shares that we may designate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>ea020387201ex12-1_tiziana.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gabriele Cerrone, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Tiziana Life
Sciences plc;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 10, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Gabriele Cerrone</FONT></TD>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gabriele Cerrone</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acting Chief Executive Officer</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>ea020387201ex12-2_tiziana.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Keeren Shah, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Tiziana Life
Sciences plc;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 10, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Keeren Shah</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>ea020387201ex13-1_tiziana.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The certification set forth below is being submitted
in connection with Tiziana Life Sciences plc&rsquo;s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the &ldquo;Report&rdquo;)
for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)
and Section 1350 of Chapter 63 of Title 18 of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gabriele Cerrone, Acting Chief Executive Officer
of Tiziana Life Sciences plc, certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of Tiziana Life Sciences plc</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 10, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Gabriele Cerrone</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Gabriele Cerrone </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acting Chief Executive Officer</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>ea020387201ex13-2_tiziana.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The certification set forth below is being submitted
in connection with Tiziana Life Sciences plc&rsquo;s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the &ldquo;Report&rdquo;)
for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)
and Section 1350 of Chapter 63 of Title 18 of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.75in">Keeren Shah, Chief Financial Officer of Tiziana
Life Sciences plc, certifies that, to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of Tiziana Life Sciences plc</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 10, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah </FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Keeren Shah</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>ea020387201ex15-1_tiziana.htm
<DESCRIPTION>CONSENT OF MAZARS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors of Tiziana Life Sciences Ltd:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in Registration
Statement on Form F-3 (File No. 333-252441) of our report dated May 20, 2022 with respect to the consolidated statement of operations
and comprehensive loss, cash flows and shareholders&rsquo; equity for the year ended December 31, 2021, and the related notes, for Tiziana
Life Sciences Ltd and its subsidiaries (the Group), which report appears in the December 31, 2023 Annual Report on Form 20-F to be filed
on or about May 10, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Mazars LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mazars LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">London, United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 10, 2024</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>8
<FILENAME>ea020387201ex15-2_tiziana.htm
<DESCRIPTION>CONSENT OF PKF LITTLEJOHN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors of Tiziana Life Sciences Ltd:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We consent to the incorporation by reference of our report dated May 10,
2024 with respect to the consolidated balance sheet as of December 31, 2023 and 2022 and the related consolidated statement of operations
and comprehensive loss, cash flows and shareholders&rsquo; equity for each of the two years ended December 31, 2023, and the related notes,
for Tiziana Life Sciences Ltd, which report appears in the December 31, 2023 annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><IMG SRC="ex15-2_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PKF Littlejohn LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PKF Littlejohn LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">London</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 10, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.
<SEQUENCE>9
<FILENAME>ea020387201ex97_tiziana.htm
<DESCRIPTION>CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 97</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tiziana Life Sciences Ltd.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CLAWBACK POLICY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>I.&nbsp;<U>Purpose
and Scope</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes
integrity and accountability and that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore
adopted this Clawback Policy (this &ldquo;<B>Policy</B>&rdquo;), which provides for the recovery of erroneously awarded Incentive Compensation
(as defined below) in the event of a Triggering Event (as defined below). Unless otherwise defined herein, the capitalized terms have
the meanings set forth under &ldquo;XI. Definitions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>II.&nbsp;<U>Administration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy is designed to comply with and shall
be interpreted to be consistent with Section 10D of the Exchange Act, Rule 10D-1 of the Exchange Act, Nasdaq Listing Rule 5608 and other
regulations, rules and guidance of the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) thereunder, and related securities
regulations and regulations of the stock exchange or association on which Company&rsquo;s common shares are listed (collectively, the
&ldquo;<B>Listing Standards</B>&rdquo;). This Policy shall be administered by the Compensation Committee of the Board, or in the absence
of such committee, a majority of the independent directors serving on a subcommittee of the Board (any such committee or subcommittee
of the Board, the &ldquo;<B>Committee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any determinations made by the Committee shall
be final and binding. In addition, the Company shall file all disclosures with respect to this Policy in accordance with the Listing Standards.
The Committee hereby has the power and authority to enforce the terms and conditions of this Policy and to use any and all of the Company&rsquo;s
resources it deems appropriate to recoup any excess Incentive Compensation subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>III.&nbsp;<U>Covered
Executives</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy applies to the Company&rsquo;s current
and former Covered Executives, as determined by the Committee in accordance with the Listing Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IV.&nbsp;<U>Events
That Trigger Recoupment Under This Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board or Committee will be required to recoup
any excess Incentive Compensation received by any Covered Executive during the three (3) completed fiscal years (together with any intermittent
stub fiscal year period(s) of less than nine (9) months resulting from the Company&rsquo;s transition to different fiscal year measurement
dates) immediately preceding the date the Company is deemed (as determined pursuant to the immediately following sentence) to be required
to prepare a Covered Accounting Restatement of its financial statements (the &ldquo;<B>Three-Year Recovery Period</B>&rdquo;) irrespective
of any fault, misconduct or responsibility of such Covered Executive for the Covered Accounting Restatement. For purposes of the immediately
preceding sentence, the Company is deemed to be required to prepare a Covered Accounting Restatement on the earlier of: (A) the date upon
which the Board or applicable committee of the Board, or the officer or officers of the Company authorized to take such action if Board
action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Covered Accounting Restatement;
or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (each,
a &ldquo;<B>Triggering Event</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>V.&nbsp;<U>Excess
Incentive Compensation: Amount Subject to Recovery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of Incentive Compensation to be recovered
shall be the excess of the Incentive Compensation &ldquo;received&rdquo; by the Covered Executive over the amount of Incentive Compensation
which would have been received by the Covered Executive had the amount of such Incentive Compensation been calculated based on the restated
amounts, as determined by the Committee. For purposes of this Policy, Incentive Compensation shall be deemed &ldquo;received&rdquo;, either
wholly or in part, in the fiscal year during which any applicable Financial Reporting Measure is attained, even if the payment, vesting
or grant of such Incentive Compensation occurs after the end of such fiscal year. Amounts required to be recouped under this Policy shall
be calculated on a pre-tax basis. The date of receipt of the Incentive Compensation depends upon the terms of the award of such Incentive
Compensation. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">If the <I>grant</I> of an award of Incentive Compensation is based, either wholly or in part, on the satisfaction
of a Financial Reporting Measure performance goal, then the award would be deemed received in the fiscal period when that measure was
<I>satisfied</I>;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">If the <I>vesting</I> of an equity award of Incentive Compensation occurs only upon the satisfaction of
a Financial Reporting Measure performance condition, then the award would be deemed received in the fiscal period when it <I>vests</I>;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">If the <I>earning</I> of a non-equity incentive plan award of Incentive Compensation is based on the satisfaction
of the relevant Financial Reporting Measure performance goal, then the non-equity incentive plan award will be deemed received in the
fiscal year in which that performance goal is <I>satisfied</I>; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">If the <I>earning</I> of a cash award of Incentive Compensation is based on the satisfaction of a Financial
Reporting Measure performance goal, then the cash award will be deemed received in the fiscal period when that measure is <I>satisfied</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is specifically understood that, to the extent
that the impact of the Covered Accounting Restatement on the amount of Incentive Compensation received cannot be calculated directly from
the information in the Covered Accounting Restatement (e.g., if such restatement&rsquo;s impact on the Company&rsquo;s share price is
not clear), then such excess amount of Incentive Compensation shall be determined based on the Committee&rsquo;s reasonable estimate of
the effect of the Covered Accounting Restatement on the share price or total shareholder return upon which the Incentive Compensation
was received. The Company shall maintain documentation for the determination of such excess amount and provide such documentation to the
Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VI.&nbsp;<U>Method
of Recovery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee will determine, in its sole discretion,
the methods for recovering excess Incentive Compensation hereunder, which methods may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">requiring reimbursement of cash Incentive Compensation previously paid;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition
of any equity-based awards;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">cancelling outstanding vested or unvested equity awards; and/or</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">taking any other remedial and recovery action permitted by law, as determined by the Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything in this Section VI, and
subject to applicable law, the Committee may cause recoupment under this Policy from any amount of Incentive Compensation approved, awarded,
granted, paid or payable to any Covered Executive prior to, on, or following the Effective Date (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VII.&nbsp;<U>Impracticability</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee shall recover any excess Incentive
Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance
with the Listing Standards. It is specifically understood that recovery will only be deemed impractical if: (A) the direct expense paid
to a third party to assist in enforcing the Policy would exceed the amount to be recovered (before concluding that it would be impracticable
to recover any amount of erroneously awarded Incentive Compensation based on the expense of enforcement, the Committee shall make a reasonable
attempt to recover such erroneously awarded Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation
to Nasdaq); (B) recovery would violate home country law where that law was adopted prior to the November 28, 2022 (before concluding that
it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on violation of home country law,
the Committee shall obtain an opinion of home country counsel, acceptable to the applicable national securities exchange or association
on which Company&rsquo;s common shares are trading, that recovery would result in such a violation, and must provide such opinion to the
exchange or association); or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly
available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and the regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VIII.&nbsp;<U>Other
Recoupment Rights; Acknowledgement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee may require that any employment
agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant
of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this
Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant
to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies
available to the Company. The Company shall provide notice and seek written acknowledgement of this Policy from each Covered Executive;
<I>provided</I>, that the failure to provide such notice or obtain such acknowledgement shall have no impact on the applicability or enforceability
of this Policy to, or against, any Covered Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IX.&nbsp;<U>No
Indemnification of Covered Executives</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any right to indemnification under
any plan, policy or agreement of the Company or any of its affiliates, the Company shall not indemnify any Covered Executives against
the loss of any excess Incentive Compensation. In addition, the Company will be prohibited from paying or reimbursing a Covered Executive
for premiums of any third-party insurance purchased to fund any potential recovery obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>X.&nbsp;<U>Indemnification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent allowable pursuant to applicable
law, each member of the Board or the Committee and any officer or other employee to whom authority to administer any component of this
Policy is designated shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed
upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or
she may be a party or in which he or she may be a party or in which he or she may be involved by reason of any action or failure to act
pursuant to this Policy and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit,
or proceeding against him or her; <I>provided</I>, <I>however</I>, that he or she gives the Company an opportunity, at its own expense,
to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification
shall not be exclusive of any other rights of indemnification to which such individuals may be entitled pursuant to the Company&rsquo;s
Articles of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold
them harmless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XI.&nbsp;<U>Effective
Date</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy shall be effective as of the date
the Policy is adopted by the Board (the &ldquo;<B>Board Adoption Date</B>&rdquo;). This Policy shall apply to any Incentive Compensation
that is received by Covered Executives on or after October 2, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;), even if such Incentive Compensation
was approved, awarded, granted, or paid to Covered Executives prior to the Effective Date or the Board Adoption Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XII.&nbsp;<U>Amendment
and Termination; Interpretation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may amend this Policy from time to time
in its sole discretion and shall amend this Policy as it deems necessary to reflect and comply with further regulations, rules and guidance
of the SEC, and Nasdaq Listing Rules. The Board may terminate this Policy at any time. The Committee is authorized to interpret and construe
this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy is
designed and intended be interpreted in a manner that is consistent with the requirements of the Listing Standards. To the extent of any
inconsistency between this Policy and such regulations, rules and guidance, such regulations, rules and guidance shall control and this
Policy shall be deemed amended to incorporate such regulations, rules and guidance until or unless the Board or the Committee expressly
determine otherwise. This Policy shall be applicable, binding and enforceable against all Covered Executives and their beneficiaries,
heirs, executors, administrators or other legal representatives, to the fullest extent of the law. For the avoidance of doubt, this Policy
shall be in addition to (and not in substitution of) any other clawback policy of the Company in effect from time to time or applicable
to any Covered Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XIII.&nbsp;<U>Definitions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Policy, the following terms
shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">&ldquo;<B>Company</B>&rdquo; means <B>Tiziana Life Sciences Ltd.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">A &ldquo;<B>Covered Accounting Restatement</B>&rdquo; is any accounting restatement of the Company&rsquo;s
financial statements due to the Company&rsquo;s material noncompliance with any financial reporting requirement under U.S. securities
laws. A Covered Accounting Restatement includes any required accounting restatement to correct an error in previously issued financial
statements that is material to the previously issued financial statements (commonly referred to as &ldquo;Big R&rdquo; restatements),
or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period
(commonly referred to as &ldquo;little r&rdquo; restatements). A Covered Accounting Restatement does not include (A) an out-of-period
adjustment when the error is immaterial to the previously issued financial statements, and the correction of the error is also immaterial
to the current period; (B) a retrospective application of a change in accounting principle; (C) a retrospective revision to reportable
segment information due to a change in the structure of an issuer&rsquo;s internal organization; (D) a retrospective reclassification
due to a discontinued operation; (E) a retrospective application of a change in reporting entity, such as from a reorganization of entities
under common control; or (F) a retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital
structure.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">&ldquo;<B>Covered Executive</B>&rdquo; means any person who:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify">Has received applicable Incentive Compensation:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify">During the Three-Year Recovery Period; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD STYLE="text-align: justify">After beginning service as an Executive Officer; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Has served as an Executive Officer at any time during the performance period for such Incentive Compensation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">&ldquo;<B>Exchange Act</B>&rdquo; means the Securities and Exchange Act of 1934, as amended.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">&ldquo;<B>Executive Officer(s)</B>&rdquo; means an &ldquo;executive officer&rdquo; as defined in Exchange
Act Rule 10D-1(d) and the Listing Standards, and includes any person who is the Company&rsquo;s president, principal financial officer,
principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the issuer in charge of
a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making
function, or any other person who performs similar policy-making functions for the Company (with any executive officers of the Company&rsquo;s
parent(s) or subsidiaries being deemed Covered Executives of the Company if they perform such policy making functions for the Company),
and such other senior executives/employees who may from time to time be deemed subject to the Policy by the Board in its sole discretion.
All executive officers of the Company identified by the Board pursuant to 17 CFR 229.401(b) shall be deemed &ldquo;Executive Officers.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">&ldquo;<B>Financial Reporting Measure(s)</B>&rdquo; means any measures that are determined and presented
in accordance with the accounting principles used in preparing the Company&rsquo;s financial statements, and any measure that is derived
wholly or in part from such measures, including share price and total shareholder return, including but not limited to, financial reporting
measures including &ldquo;non-GAAP financial measures&rdquo; for purposes of Exchange Act Regulation G and 17 CFR 229.10, as well other
measures, metrics and ratios that are not non-GAAP measures, like same store sales. Financial Reporting Measures may or may not be included
in a filing with the SEC, and may be presented outside the Company&rsquo;s financial statements, such as in Management&rsquo;s Discussion
and Analysis of Financial Conditions and Results of Operations or the performance graph. Financial Reporting Measures include without
limitation, any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Company share price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Total shareholder return.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Revenues.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Net income.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">Earnings before interest, taxes, depreciation, and amortization (EBITDA).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify">Funds from operations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify">Liquidity measures such as working capital or operating cash flow.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">h.</TD><TD STYLE="text-align: justify">Return measures such as return on invested capital or return on assets.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify">Earnings measures such as earnings per share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify">&ldquo;<B>Incentive Compensation</B>&rdquo; means any compensation which was approved, awarded or granted
to, or earned by a Covered Executive (A) while the Company had a class of securities listed on a national securities exchange or a national
securities association, and (B) following on or after the Effective Date (including any award under any long-term or short-term incentive
compensation plan of the Company, including any other short-term or long-term cash or equity incentive award or any other payment) that,
in each case, is granted, earned, or vested based wholly or in part upon the attainment of any Financial Reporting Measure (i.e., any
measures that are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial
statements, and any measure that is derived wholly or in part from such measures, including share price and total shareholder return).
Incentive Compensation may include (but is not limited to) any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Annual bonuses and other short- and long-term cash incentives;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Stock options;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Stock appreciation rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Restricted shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">Restricted share units;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify">Performance shares; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify">Performance units.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>APPENDIX I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Acknowledgment of Clawback Policy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, the undersigned, agree and acknowledge that I am fully bound by,
and subject to, all of the terms and conditions of the Tiziana Life Sciences Ltd. Clawback Policy (as may be amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Policy</B>&rdquo;) of Tiziana Life Sciences Ltd. (the &ldquo;<B>Company</B>&rdquo;)
if I am a &ldquo;Covered Executive&rdquo; or become a &ldquo;Covered Executive.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of any inconsistency between the Policy and the terms
of any agreement to which I am a party, or the terms of any compensation plan, program or agreement under which any compensation has been,
or will be, granted, awarded, earned or paid, the terms of the Policy shall govern. In the event it is determined by the Compensation
Committee of the Board of Directors of the Company (the &ldquo;<B>Committee</B>&rdquo;) that any amounts granted, awarded, earned or paid
to me must be forfeited or reimbursed by the Company, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement.
Any capitalized terms used in this Acknowledgement without definition shall have the meaning set forth in the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ G # 2(  A$! Q$!_\0
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M#^M+W7J4W4A9+7[WU_#0O1>)].FDD56FQ$&+N8SM7;UR:$\06UTD\<"S1SI
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M5%4+]T 8Q]*/)B$IE\M/,(QOVC./K3Z* $VJ"2%&3UXZTQ((8TVI$BKG.%4
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MZ* "BBB@ HHHH **** .4^&?_)-M"_Z]A_,UU=<I\,_^2;:%_P!>P_F:ZN@
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M_P"_[?XT[(5S0HK/_L^S_P">TG_?]O\ &C^S[/\ Y[2?]_V_QHL@N:%%9_\
M9]G_ ,]I/^_[?XT?V?9_\]I/^_[?XT607-"BL_\ L^S_ .>TG_?]O\:/[/L_
M^>TG_?\ ;_&BR"YH451_LJV_OS_]_F_QH_LJW_O3_P#?YO\ &C0-2]15'^RK
M?^]/_P!_F_QH_LJW_O3_ /?YO\:- U+U%4?[*M_[T_\ W^;_ !H_LJW_ +T_
M_?YO\:- U+U%4?[*M_[T_P#W^;_&C^RK?^]/_P!_F_QHT#4O451_LJW_ +T_
M_?YO\:/[*M_[T_\ W^;_ !HT#4O451_LJW_O3_\ ?YO\:/[*M_[T_P#W^;_&
MC0-2]15'^RK?^]/_ -_F_P :/[*M_P"]/_W^;_&C0-2]15'^RK?^]/\ ]_F_
MQH_LJW_O3_\ ?YO\:- U+U%4?[*M_P"]/_W^;_&C^RK?^]/_ -_F_P :- U+
MU%4?[*MO[T__ '^;_&C^RK?^]/\ ]_F_QHT#4O451_LJW_O3_P#?YO\ &C^R
MK?\ O3_]_F_QHT#4O451_LJW_O3_ /?YO\:/[*M_[T__ '^;_&C0-2]15'^R
MK?\ O3_]_F_QH_LJW_O3_P#?YO\ &C0-2]15'^RK?^]/_P!_F_QH_LJW_O3_
M /?YO\:- U+U%4?[*M_[T_\ W^;_ !H_LJW_ +T__?YO\:- U+U%4?[*MO[T
M_P#W^;_&C^RK?^]/_P!_F_QHT#4O451_LJW_ +T__?YO\:/[*M_[T_\ W^;_
M !HT#4O451_LJW_O3_\ ?YO\:/[*M_[T_P#W^;_&C0-2]15'^RK?^]/_ -_F
M_P :/[*M_P"]/_W^;_&C0-2]15'^RK?^]/\ ]_F_QH_LJW_O3_\ ?YO\:- U
M+U%4?[*M_P"]/_W^;_&C^RK?^]/_ -_F_P :- U+U%4?[*M_[T__ '^;_&C^
MRK?^]/\ ]_F_QHT#4O451_LJV_O3_P#?YO\ &C^RK?\ O3_]_F_QHT#4O451
M_LJW_O3_ /?YO\:/[*M_[T__ '^;_&C0-2]15'^RK?\ O3_]_F_QH_LJW_O3
M_P#?YO\ &C0-2]15'^RK?^]/_P!_F_QH_LJW_O3_ /?YO\:- U+U%4?[*M_[
MT_\ W^;_ !H_LJW_ +T__?YO\:- U+U%4?[*M_[T_P#W^;_&C^RK?^]/_P!_
MF_QHT#4O451_LJW_ +T__?YO\:/[*M_[T_\ W^;_ !HT#4O451_LJW_O3_\
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M->5_VWJ?_00G_P"^S1_;>I_]!"?_ +[-5[!]S/\ M"'\K/4^:.:\L_MO4_\
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MG]1^8K,?P;:32F>>[GDG;&]\*-V.!P!CH*6X\&:?<0>4TDH&000!P0$ /O\
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M$)8,88RRDL#M&03U/UJ.U5OL<'S_ /+->WM4VUO[_P"E>:]SZA;(!'&%*B-
M&&"-HP1Z4Q;6W7;M@B&S.W"#Y<\''I3]K?W_ -*-K?W_ -*0Q$ABC"A(D4+G
M 50,?2A8(DB,2Q1K&<Y0* #GKQ2[6_O_ *4;6_O_ *4 )'#%$ (XT0*-HVJ!
M@>GTH$,0((B0$=,*/K_4TNUO[_Z4;6_O_I0 D<,4*E8HTC4G)"* "?7BGTW:
MW]_]*-K?W_TH =13=K?W_P!*-K?W_P!* *UW86EW(KW%M'*P& 77.!5?^QM,
M_P"?"#_OBKSJV1\_Z4W:W]_]*=V2X1>K13_L;3/^?"#_ +XH_L;3/^?"#_OB
MKFUO[_Z4;6_O_I1S/N+V<.R^XI_V-IG_ #X0?]\4?V-IG_/A!_WQ5S:W]_\
M2C:W]_\ 2CF?</9P[+[BG_8VF?\ /A!_WQ1_8VF?\^$'_?%7-K?W_P!*-K?W
M_P!*.9]P]G#LON*BZ+IA/_'A!_WQ3_[$TO\ Y\+?_OBK*JV?O_I4FUO[_P"E
M',^X>SAV12_L32_^?"W_ .^*/[$TO_GPM_\ OBKNUO[_ .E&UO[_ .E',^X>
MSAV12_L32_\ GPM_^^*/[$TO_GPM_P#OBKNUO[_Z4;6_O_I1S/N'LX=D4O[$
MTO\ Y\+?_OBC^Q-+_P"?"W_[XJ[M;^_^E&UO[_Z4<S[A[.'9&>=&TS)_T"#_
M +XI/[&TS_GP@_[XJX5;)^?]*-K?W_THYGW#V<.R*?\ 8VF?\^$'_?%']C:9
M_P ^$'_?%7-K?W_THVM_?_2CF?</9P[+[BG_ &-IG_/A!_WQ1_8VF?\ /A!_
MWQ5S:W]_]*-K?W_THYGW#V<.R^XI_P!C:9_SX0?]\4?V-IG_ #X0?]\5<VM_
M?_2C:W]_]*.9]P]G#LON*PT72\#_ $"W_P"^*7^Q-+_Y\+?_ +XJXJMM'S_I
M2[6_O_I1S/N'LX=D4O[$TO\ Y\+?_OBIK?3K*TD,EO:Q1.1@LBX.*GVM_?\
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M  A6J?\ /2U_[[/^%')2[A[;%_R_A_P3>_X3+2/6X_[]?_7H_P"$RTCUN/\
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M-K%00I Z[<C(K,-AK4%C&+C3KNXU$B 6]S'("+50%#9.<]0Q( .0V.U>@44
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ME_\ OFC?_LO_ -\T[%&* &[_ /9?_OFC?_LO_P!\TZB@!N__ &7_ .^:-_\
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M[@HHHH **** "BBB@"1?NBEI%^Z*6@ HHHH **** "BBB@"-OO&DI6^\:2@
MHHHH **** "I%^Z*CJ1?NB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M 'KTI:1>E+0!RGPS_P"2;:%_U[#^9KJF^Z?I7*_#/_DFVA?]>P_F:ZIONGZ4
M >-F-Y;B147)W,?PS3VLKE;G[.T1$O\ =I8IEBGN0V<2*Z9';G/]*N#6L.9#
M;Y<D\[^Q.<5Z+;Z'S24>K,V6&2%V61""O)XITMM/!(4DB=6'M5J\U 75F(\8
M=GRWLN.%]^<FI?[9W.QDAWJS[\;\8Y4@?^._K1=A:%]S/\B8+N,4FWKG:<4>
M1-G'DR9QG[AZ>M7CK#LW^K^7/W=QQ]PK_7-22:V6*%(-@1LX#=>2<?K1=]@Y
M8=S)HH/6BJ,SUZU0?8X/F;_5K_$?2IO+']Y_^^C65J6K#1= @O#&LF3#$ S[
M0"[*N2?09S4)\56%M';&^=8GG!*F/+IWQ\V!DG::\U[GU$=D;?EC^\__ 'T:
M/+']Y_\ OHUB6OBJQN)9D=)H2CJL8=#F0$)@@?\ ;0<>G-.O/$!M9[LK9-):
M63*MS/Y@!4G!.%[X!!-(9L^6/[S_ /?1H\L?WG_[Z-8G_"7Z0-F9)@7<(@,)
M!?)8 CU'RM^5(/%VERWD5K;-)<2O<"#Y%X&<C=S_  @C% &YY8_O/_WT:/+'
M]Y_^^C6-/KLUIK$]K<VB):0PB=KD2Y(0DJ#MQZCGVH?Q9I$3RB2=TCB.'F,9
M\L'G W=.<''TH V?+']Y_P#OHT>6/[S_ /?1K*/B&UDT&ZU:TCEN4MU8M"@
M?*C)'/ HOM8N()M/@M+(7$UXCR!6E"!0J@GG'7YJ -7RQ_>?_OHT>6/[S_\
M?1KDCX^MOL]_(MC,6MHX'1"X!E,AP0/3:<Y]N:Z^@")T''S-_P!]&F[!_>;_
M +ZK#\0^(Y=&O(H$M4E#INRSD8YK(_X3JX_Z!\/_ '\/^%:*E)JZ.:>*I0DX
MMZG9[!_>;_OJC8/[S?\ ?5<9_P )U<?] ^'_ +^'_"C_ (3JX_Z!\/\ W\/^
M%/V,^Q/UVCW_  .SV#^\W_?5&P?WF_[ZKC/^$ZN/^@?#_P!_#_A1_P )U<?]
M ^'_ +^'_"CV,^P?7:/?\#L]@_O-_P!]4;!_>;_OJN,_X3JX_P"@?#_W\/\
MA1_PG5Q_T#X?^_A_PH]C/L'UVCW_  .T5!G[S?\ ?1J3RQ_>?_OHUPX\=W /
M_(/A_P"_A_PIW_">W'_0/A_[^'_"CV,P^NT>_P"!VWEC^\__ 'T:/+']Y_\
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MY8_O/_WT:5?NBEH ;Y8_O/\ ]]&CRQ_>?_OHTZB@!OEC^\__ 'T:/+']Y_\
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M++_W5_.C+_W5_.DYR:LV7##TX/FBM1IZFDI"7R?E7\Z3+_W5_.H-AU%-R_\
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MU%-R_P#=7\Z,O_=7\Z '44W+_P!U?SHR_P#=7\Z '44W+_W5_.C+_P!U?SH
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M_P#SVE_[]FC_ (2_1_\ GM+_ -^S7-?\(=JWI!_W\_\ K4?\(=JWI!_W\_\
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M[/&=_P 2QX9URXUE[D3QQIY07&SOG/\ A715D:-H=OHSS&"21_- SOQQC/\
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M%244 1T5)10!'14E% $=%244 1T5)10!'14E% "+TI:** .4^&?_ "3;0O\
MKV'\S75URGPS_P"2;:%_U[#^9KJZ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'*?#/_DFVA?]>P_F:ZNN4^&?_)-M"_Z]A_,UU= !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? G # 2(  A$! Q$!_\0
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M<'_PISP1_P! IO\ O\_^-'_"G/!'_0*;_O\ /_C7>44 <'_PISP1_P! IO\
MO\_^-'_"G/!'_0*;_O\ /_C7>44 <'_PISP1_P! IO\ O\_^-'_"G/!'_0*;
M_O\ /_C7>44 <'_PISP1_P! IO\ O\_^-'_"G/!'_0*;_O\ /_C7>44 <'_P
MISP1_P! IO\ O\_^-'_"G/!'_0*;_O\ /_C7>44 <'_PISP1_P! IO\ O\_^
M-'_"G/!'_0*;_O\ /_C7>44 <'_PISP1_P! IO\ O\_^-'_"G/!'_0*;_O\
M/_C7>44 <'_PISP1_P! IO\ O\_^-'_"G/!'_0*;_O\ /_C7;R7$4?WF&?05
M7;4HAT&?QJ7.*ZC46SD/^%.>"/\ H%-_W^?_ !H_X4YX(_Z!3?\ ?Y_\:ZS^
MU(P<%?UJ>.^A? W;3[TE.+ZCY6<9_P *<\$?] IO^_S_ .-'_"G/!'_0*;_O
M\_\ C7> @C(.115DG!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE%
M'!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S
M_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F
M_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\
M*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-
M'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_
MS_XUWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$
M?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-'_"G
M/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XU
MWE% '!_\*<\$?] IO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] I
MO^_S_P"-'_"G/!'_ $"F_P"_S_XUWE% '!_\*<\$?] IO^_S_P"-8'C;X7^$
M]&\%:MJ-CIQCNK> O&_FL<'([$UZW7*_$O\ Y)OKW_7J?YB@#P[PC_R+L/\
MOO\ SK<K#\(_\B[#_OO_ #K<KUJ7P(^?K?Q)>H4445H9!1110 4444 %%%%
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M:Z@(5\A+7RN''R-DGICGKV(J31;">PEOE=%2"27?$-P9^<ELG R.F,Y(YYH
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M=A_WW_G6Y7K4O@1\_6_B2]0HJ2W0274*-]UI%4_0D5UOB'1[73%NQ#H,HA0
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MQW+MP6.?I3C6A)V0.G)%O;1MJ#S7_O&CS'_O&M+HGE9/MHVU7\U_[QI?-?\
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MUO;%%2=I)O,#8 95 VX.5/ /^[Q34G?83A%*Z9G_ -E7GD&4Q$*(UE [LK'
MP*J".1MV(W.W[V%/'U]*W6UA%TPK#=RBX-G'  ,@JROD\^X]*NQZ]8^<[^9L
M/GB5F97_ 'HV*#PI&3D'AN.:.:78?)!]3E%1I&"HK,QZ!1DTX12MD")SMZX4
M\?6M+2KNV@N+R261H3(A$>W<%^]G!*\CCTK3N-?MQ>(]M<2)&;N.63:"-RA
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M *MP6S"V2,R[<-N#Q\@UP5Z]M(G2GRHCLK"!9RLC>9(%^8$<#/I5^.&6.9Y
M^8\?=/52/3VIQC1"70 AA@MW% N$6149OG8<CU]ZX?4R<FQKF5+E"B@HV23W
M%1(\K><NT#!RA]:F"323_*V8]N-OH?6I#;!)!NF0$\]<&M(TISUBB7*,=RJJ
M22QQ[F\MP0Q'\Q3WC$I63 +1=.:+^YT[2X5DO+C&02J]2^/0"F:'J]EK4,A@
MA*-$>4?DX/0UTQP%5QYGL8O$TU+DOJ.CC5'DXP7Y)]?2K MY6<;A@=SFKBQH
MF=J@9IU7#")?$QNJWL1)"B;2!R.]2TGI2UV1BHZ)&3;>X4AI:*H HI"2 2!D
MXZ4P(6^^Q^@.!2 >2 .3BF)\SLXZ'@4HB0'[N?KS3J "EI*6F(****  TR7[
MH_WA3Z1@&7!'!I# =*6HT)!*,<D<@^HJ0=!0##UJ 7EN20954@]&X-3TQFBW
M8<IN]#C--6ZB(WNHT8[@^W^^%)7\ZD58S\ZJAW<[@.M53(;6X,4,?FJPW>6I
MY3_ZQI(X[V)"L:Q*F255CDK[5IR@+=E+66.X11O.58#C<*J-=A[Y)V0[5X [
MBJNJM?&&7:,7(0^6#T_"N3MO[8%U&5^T[BPW>9G;COG-=U.BN6[U9#9Z']L$
MS".V&YR,EF& HJ:.W5'\QF,DG]YNWT':J.F.BO(A(#MC'O6D2%4EB !U)KBJ
MQY)<J+0M%0K<H[*%5R#T;8<?G4QZ5DTUN R/AG7T.?SI],?Y2)!VX/TI_I2&
M%<W\0?\ DGVN?]>Q_F*Z2N;^(/\ R3[7/^O8_P Q5+<E['D7A'_D78?]]_YU
MT=E.L$K*YPK]_0USGA'_ )%V'_??^=;A&:]^G\"/EJZO4DO,ZN6^LCIBP1++
M'@98AUVNWJW&3]*YFZF$]P"G**, ^M0;!3JI1L8VUNS6AUSR5M6%C UQ:Q^7
M%,6;(ZX.,X)YJ&;5YI[=86CCP/+.1G)V9Q^>:NV^CV<R09DE#_9/M4I) &.F
MT?IS1-H]E:HUQ))/+ 3&J)#@L"X)Y/0XQQCK47C<Z+3L1?\ "02-,9Y+."24
M&3RW)8>6'SD#GGJ<9J%M9F80@Q1_NI(Y!UY**%'Z"KTF@6\5KEKAQ.T#3KNP
M, $X4KUSQR>QJ>WT:P&K^4!.ZVUQ$DJR@ 2!_3\?S%%X#Y:CW9#%K%H;=KB=
M5>[\J6-1L;*[B< '.,#/4\UE6>H?9K<V\EM'<1>8)55R1M<<9X_E6A_9-I(Z
M1!IUFN(I)XS@;$"YPI_+KVJK>6-O'J<5C;M)N8HK/(1C+ 'C'89IKEV)ES[D
M-[J,VH(@F"[E9VW#N6.34YUII 4N+2&:(B/]VQ8 %%V@Y'/3J*L_V59,URR?
M;1'9[_-W(/GV\?*>Q]NPIPTBP2%+F1[GR9O)\M!@,-Y8?-]-OXT7B'+/>Y6.
MO7+7D%T\<321,[=" =W7Z8[8ITOB&X=%5844J@16+L[<.'R23R<BK7]B6)>3
M$MR4A::.3@98H,Y'IFI+718+FV"1,56[:!D:4#?&"7!'_COXU-X=BDJFURB^
MON598[*"(,TCMM+'+.I4GD^]01ZM+$(\11G9;K;C(SD!MV36@NA6D]S;Q0SN
M!<;T4DA@C+SEB.-OKZ5CW\*6U]-!&)-L;;/W@P21U.*I<KT1$N=:LU&\33LZ
ML;6(@2-(5=W8$E2I')X&#T%9MW>FY6&-(D@AA4B.-"2!DY)R>22:JT52BEL2
MYR>[-A]?:6;S9+*!V$OG("S823 R>O.< XZ52@OWA>Z9T67[2C)(&)'4YSQW
MS52BCE2$YR9JIKUS%=3W$:1K)-,LQZ\$ C'T.35:_P!1:^$2F,1I'G WLYR>
MO+$FJ=%'*EJ#G)JURT;^;[/:Q(3&;8N4D1B&^8Y/-3+J\A@5+B&.YDCW>7+*
M267=U^OKS6?13Y4',S9;Q)<M(DK0H90ZN[%V(<K[9P/?%9UW=O=M$755\N,1
MC'<#_P#75>BDHI; YR>["BBBJ)#!/ ZUVT4'DVT4?]U /TKE-,@^TZG;Q8X+
M@GZ#FNXE3K7C9G*_+'YGTV10MSU/1?J4",&E5L&GNF*KS2+!&TC\*HR:\9)W
MLCZ=R25WL7$>K2/6+8W\5ZK-%GY3@YK11ZMIQ?++1F*<:D5.#NF:*/67XEU&
M>QTQ3;2^7,\@ /?'?^E7$>N7U?5X]2NA8I"LL D 5\9);VKLPL7*=[72W/-Q
MTE"FXWLWHOZ1LZ?K"QZ5:_;[I#<39(YR<$\9J>>5W8*HW$G&/6N<3PS'%<%I
MKC?&K?NPHYQZ&NATZ RW@(;&P9 ]:C&3A%7IN]QX55E%^U5K;:W?S+T<<%O!
M%&T3!I."P7(SZ&HKG48K$+$R@%>BJ*M#>AE264,QY4#AA]<5S"O))JA)@^T2
M%R!&W<]JX\!A8XB;Y]D<F8XN6'@N7=LUK/55GFD5WQN.4##!^E;,%OYJJ[<#
MT[UR6HF-9853R_/1<2M$N%+9[8XXZ9%=G:N3;([\':"<]N*[:V7TZ4E*.SZ,
MY\%CJE=2C/==43A0HPH 'M7)>(?"MYJNKO>03P!&B";)"PP1]*ZQ'25=T;JX
MQG*G/%*&4R% 06'51U%:4YNF[Q.FI3C47+(\YU_1KO3;'3_.4W BR7D0G;&,
MYVY]_P .E='X;UG39[%A':Q:>01E,X#GIG/?_P"O707+>5;2NR[@J%BI[C%>
M:2R/KWF75K'#:QV4 D,:# 8[LFE7Q7N<K7O?U<VP67.=3G4K06C_ $/3SQ3!
M*N<-E3[UC>&M=;7(9V:)4,)5>.^15,ZIJ["+Y9#(P8M#]B; <.H";O3:2=WM
M6<6I*Z'5IRI3<)K5'3BE[5SLE_>7DPDTN9TMXI(XY5,8<DM)A\>RJ#4$>J:U
M(]J41F!<_:E-L5$(W 8!_BX.>/KTJK&;9U-%85UK=]!+(L>F/+MD=0H5\D+C
M'.,9;.0>G'/-03^(=3M54S:4 7=43;O().#C@9SSC\#18+G245S":_JZ(ZR:
M+-(R#=T(+9?&!QCA?Y>]=,IW(I/< T F+11VH[T %':BD% ".X0<YS5?S6+?
M>.<9]J?.?G&",X_*HS@ ^O8U#9I%*Q,DN2 PQGI4M50/FRO'OZU.CEA@]133
M%)"[?GW9[8I1VI:!3)$ILD,4H_>1JWU%/'2BF(A@C2$-&BA<'MWJ5F"C+, /
M4G%-'^O/^Z*@NF@CDC>='?LHQD9^GK36K&R*Y,=\Z0PNK%?F9QR%%5;BS>!D
M&X,KG:#CH:TK:-D5G=0KR') [#L*AOID!1>2R.K-@<*,]ZWIU)1?+'8FPATN
M+9A9'#C^(GO]*KK$\GDB2<D.Q0A^=I'IZ_C6M598<.\+H'@?+@GL?2H523W8
MR6.$1$[7<C'1FS^-256V36YS%F6/NC-R/H:L*=RAB"I(Z'J*S?<!<9&/6F1<
MQ+[<4YB0I(&3CI2(NU%'?%2/H.KF_B#_ ,D^US_KV/\ ,5TE<W\0?^2?:Y_U
M['^8JEN2]CR+PC_R+L/^^_\ .MRL/PC_ ,B[#_OO_.MLG YKWZ7P(^6K?Q)>
MHM%&URNX1OM]<<4@(/2M#(L)>7,<D<B3NKQKL0@]%]/I4BZG?),\RW<HD< ,
MV>N.GY53R!U-+2LA\S[EC[?>?9VM_M,OE-G*[NN>35B^UF\O;KSC,Z .'1 W
M"$=,5GT460^9[7+3:E?-%)$;J79(267/7/7\Z@DEDFD,DCEG.,L>O%,HHLA-
MM[EMM4OVDCD:[E+QYVG=TSU^OXTR2^NI69I+B1BS*Q)/=>A_"J]%%D',^Y>M
M-6NK6:202,S.'ZGHS#!;ZU"]_=N[.US(68J2<]U^[^635>BBR'S/:Y:EU*]F
MW>9=2-N0H>>JDY(J"::6XD\R9R[X W-UP.!3**+(3;>X4444Q!1110 444F1
MZB@!:*** "BBB@ HHHH U?#PQJT3GH#C\Z[:1/:N+T@>4\+]S(#^M=Y(G6O&
MS"/O)^1]%DE3W)Q[/]#,D2LW4H]UC,NY5RN,L>*VY$KEO$L-[*T*0V\DL&<D
MQ]=W8?3WKSZ,.:HKNQ[N(JN-&32OTMZZ&'!->Q0?9+>/:92&4J.O;%=58>='
M:1K.<R <\TRTM#:6<<3-N<#+'W/6I<XIXC$>T]U);[]Q8/!NC[SD]K6OHO+S
MUZEU'XJA;:596-U)<P1E788"Y^5<]<#WJ=7H=^*PC-I-)[G5.E&33:U6Q'*^
MXXK9TOR%LAGAL\M[US[M\QK;TZ&.XTY4=@PR3@\$'VKGQ#T\R*RLB\8(S-YH
MV&0?Q$<UDO;23W7VJQD:&?.TMC'45MHH2-8P%8*,#+9-,MIHI;G:AY7.1S48
M>I.E43@[7//K485H.,U<SH-%N9KA);^<2[/NJ!Q6U/;^?8SVP;;YL31[L9QD
M$9_6IZ*]F=24W>1QT:$*2:@MSF+/PG-:0+$NJ. HRNQ2H#<X/7GDD\T1^%Y4
MG=GU4[Y!\P0$%CMP&/S9SD9]*TM>U>31K))XH%F8MC:21_(5Q=I"=9U!-3>X
MMX7,VXP MG@]*YY5K2Y5N>G0P3J0=23M'[]34N=3NO"&DW#:CB\O+N7$"ER0
M_')// _+.>@KA9+_ %2=FD%P+96&/+MU"(%Z8QW_ !K6\774E_XR*3*52"-4
M1">F>2?Q_I61KH17CM]VV,1[VP<9Y_\ K5[6%PT:D5W84HNFM33T/Q=J&@2
M3)'=6;D>9A0'P!C((ZX'8UZQ:W4-[:175O()(95#(P[@UX!IT+CSR%(MR.,]
M"?:O4OAK,[^&IHF)*PW3*F>P(!P/Q-9XRA&"O$QJ*_O/<[!$2)0D:*B^BC I
M&C!YY!]0:?0:\TQ&;&_YZM2C&,$[BISSV-*.E,<8_>*.1U]Q0!)G&.:*0$,
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MC@ <DFF,^[G/%>I> /!PM8H]9U&+-PXW6\3#_5C^\1ZGMZ4:R9=>O&C#F?\
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M73R6S;!'YJN!M/  ]<5H&2,2JLIPTARJX_G6%+;$'*\'KD5+%J,BW,?VDJ5
MP7"\@5PU*+CJMC.5.^J-<PQNZ2$G*9/7CG^M-D$AG#EPL2C)4=3]?:G">.51
MY;J1V /3WIRND@>)=C<?.&-8M(QU18M;GSE4A@RG@,!W%6NU932_9S&?GR?E
M146M"&02+R1N!YQ7I8:MS+ED]3"I"VJV)>U&2%QGCTI.U':NLR%K-U./4'N;
M-K$C9'YC2JSE0QP-@X]\^U:5%,1S$DGBBYC$7D)$K8_>X",#N[@,<#'IGMZU
M=L;;55U"5+BYF:W1$P[!0)7 (; [ \'MTJ348]16^$]B\C 0D>6S9CW[E )7
MC^$L>O:L]=8UN/5+6UN[.*..68@LD3MA<XZ]/3GI3$<T)&@NI$;AD<@Y^M4-
M1U.65V27.!PH[8KL?$?AR6ZF:]L #*?]9%TW>X]ZXZ:WO%8QR6<X8=C$37FR
MI-,\^<91=C)@+&X++G9C!/K5.[&ZZ8@XQQ77V7AR_G43W$#PVP/.X8)^@IFH
M^$UED:6QD"$\F-^GX&NBG![L]/*XJ$W.>FECC7+*HV@GUJ>UM3>W%O:QAC-,
MX7ITK5_X1;5=^/*CQZ^8,5TOA[PTUE.)=X>\(PK+TC]ZTY+L]VI6IQ5T[G5:
M+:QHTDD8'E0*+6'_ '5^\?Q;^5:YJ*VMTM;:."/[J+@>_O4M:)61X<Y<TKA0
M.E':@4R"/!B/RC*>GI3U8,,J<TO>FF-6.>A]1Q2&.HI%! P3GW-+3$%%%% !
M7-?$#_DGVN?]>Q_F*Z6N;^(/_)/M<_Z]3_,4+<3V/(O"/_(NP_[[_P ZW*P_
M"/\ R+L/^^_\ZW*^@I? CY:M_$EZA1116AD%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %/BC,LJH.],K1L8=D?F$<MT^E!,G9%I0%4*.@
MX%+114G.%*JEF"CJ3BDJ[I<'FW>XCY8QN_&LZD^2#EV-\/2=:K&FNK+K1A%"
MCL,4P'FK$RU6/!KY*6]S]0@DHI(L1-5V)ZS4;FK<35461.)I(]3AJI1M4ZM7
M0F<<HDK'BH'J7-1M0Q(K.*KN*M/4#BLF=,64W6H&%6W6J[BL6CI@RKYT:S"(
MNOF$9"YY-2QSQ&4Q"1?,'5<\UA:M;2VUZM["&;G.,<*WJ?:C2;::;47O9E91
MU'/#'VKM^KT_9^TY^GSOVL>=]=KNM['V?VK7UMRVWOW.I1JG4U40U80URIG;
M)%A33P:A4U(#5HQ:)*0K0#3JH@@>,$50N(1@\5JMTJE<#@TF7%E&QG^RW0W$
M!&X.16RV8F'DPY,ARQ']:Y^;&XUM6#S/9A9"$&,*PZXK@KQ2=T%6/VC05%)^
M9OHI/6G6/GLQ,P0$=D[5 D(\CR1(P)ZON^8U)',L$X@1R9%49&,\>Y]:BE)1
MFI2.22NFD:7:@=*.]%>T<@4=J** "C)HHI@'>@FD[TIZ4A@>1S5*;3+>4EE!
MC)_N]/RJ[10";6QEC1ESS,V/85>M[6*V4B->3U8]34QI!0-R;%H-,+$2X/0C
MCZT^@D***.] "=*0NH&2:BF)+8/0<X]:B5E8!ATS@CTI7+4;EI65NAS3JJ@L
MN#QNZ?A3P[#^+/UHN#B3T4U'#^Q]*<>E,@*YOX@_\D^US_KV/\Q70!G<_)C'
MJ>]<]\0,_P#"O=<SC/V4]/J*:W!['D?A'_D78?\ ??\ G6Y6'X1_Y%V'_??^
M=;E?04O@1\K6_B2]0HHHK0R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** );>'SI0O\(Y-:_08%0VL/DQ8/WCR:FI,PG*["BBBD0%=#I=MY
M-B'(^:0[OP[5BV=N;FY2/MG+?2NJP H X Z"O,Q]6R5-'T61X:\G7?31?J4I
MEJFXK0E%4I%YKPY(^SILB4X-3"9(D+R,%4=2>U4KI96MY%A.)","N::\NA9R
M:;(C/(6R,-ROM71A\/[5<U]GKZ=SDQF,]@^7E;NG;M?L=[;S)*@>-PRGH5.1
M5M&K!T"%K;2XD=65B2Q#=16RC4I)1DXIW00;G!2DK-HLYI"::#1FBXK#&J%Q
M4S=*C85#-(E9A4#K5IA4+BLVCHBS%UQFBTN5U;;C&?I4>AN9-/)+%@)6 )&.
M*UG4$$$ CT-1X X  'M5^U_<^RMUO<S6'OB?;WZ6L2*:G0U66ID-8HZ)(LJ:
ME4U IJ0-6J,&B8&G9J'S !DFHY+E53(YSTI\R6YG8L,^!5&XE&#S4D:3S[VR
MH7TSR/>I$TZ%YGC99#LQU/!]ZPEB(K8.91*-C:FZE,C@^6I_.M>:2/<L+HQ5
MQC./TI\<"QH8HLA2"!@TL2>7$%>0LP/)Z'%<<Y.3,I3YG<CDA\N"-1<>6N?E
M)/7VJ]"$,RX'..<U4V^8[1R0,4!R"V,'Z5I0H40Y !)[5MAJ;E._1&-25D2=
MZ***]<Y0%% HH .E%%'>@!.]*>E)Z4W>W(\MJ0QYH'6F>8!]Y67ZBGC!Y%
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M*IQ'@5;4\5\W.HZDG)]3]!HT(X>FJ<=D1R#(JG*M7G%595K&1U09288-9.N
MI:+*H4!7^=L<XK8<5"\:2H4D0.AZJPR#2I3]G44GK8O$4O;494T[7&Z#=FZT
MN-V8NRDHS'N0>M;*-5"$*@"JH4#L!BK:-5.2E)M*QG&FX046[M+<M*:?FH5-
M2 U29FT!IC4\TTT,:(6%1,*G85$U0S6+*SBHB*G>J[L!63-XL.E/5JKJ[2-M
M12S'@ =ZM1Z?<NN698SG:%8\L:S<T@E.*W8OFA1DFG"1Y"%A4NQ]*6"Q4S(D
MY;<W)4=,?6M-X/LH*V<:AV ./4>E0Z^]CFG52=D4EMWE@<DJ77K&#S5F&Q1#
M&[(5(P2I/0U,L40WN%Q(Q ;FI0ZA7\U@H Y)K)RDW=LYY3;%\A$=V"_.< GU
M%.# JR*P)7I@_I444?EINWEE=B<'MFFQ6XCDD:(,68\^E)7Z(S]1BM)%"TMQ
MZY!0?KBG6T< #L&.)/FQV^HJU]GEV;3MP3GKTJ:&!(5VJ!^5;PPTY/71"E42
M0V"%5C4E?FZ\U/117IP@HJR.9N[N%'K1258A1TH/2B@]*0 :**:SA>O)/0#O
M0,=14?[UO[J_J:DH .U1[3&24&5[K_A4E!H :&##*G-.IC(&YY!]13E! P3G
M\* &R@F,J.IXI]%% @HH[44P$90RX-5V0J<8 SW'>K--= ^ ?SI-%)V*WS'(
M(P"<"@.&.1V.#4K1$ $<G-,V$ @(>:FQ=T-7<=P<< \&K*YV+GK35BQRQSCM
M4AII$R=R,_+*#V;@_6N>^('_ "3[7?\ KV/\Q712?P_[PKGOB#_R3[7/^O8_
MS%4MR'L>1>$?^1=A_P!]_P"=;E<QX8U.SMM#BBFFVN'8D;2>_L*V/[:T[_GX
M_P#'&_PKWJ<H\BU/F*T).I+3J7Z*H?VUIW_/Q_XXW^%']M:=_P _'_CC?X5I
MSQ[F7LY]B_15#^VM._Y^/_'&_P */[:T[_GX_P#'&_PHYX]P]G/L7Z*H?VUI
MW_/Q_P".-_A1_;6G?\_'_CC?X4<\>X>SGV+]%4/[:T[_ )^/_'&_PH_MK3O^
M?C_QQO\ "CGCW#V<^Q?HJA_;6G?\_'_CC?X4?VUIW_/Q_P".-_A1SQ[A[.?8
MOT50_MK3O^?C_P <;_"C^VM._P"?C_QQO\*.>/</9S[%^BJ']M:=_P _'_CC
M?X4?VUIW_/Q_XXW^%'/'N'LY]B_15#^VM._Y^/\ QQO\*/[:T[_GX_\ '&_P
MHYX]P]G/L7Z55+L%49)Z5G_VUIW_ #\?^.-_A5ZUUK285W-=C>?^F;\?I1SQ
M[DN$TMF;$$(@CVCJ>IJ6LO\ X2+2?^?O_P AO_A1_P )%I/_ #]_^0W_ ,*G
MGCW,'3J/HS4HK+_X2+2?^?O_ ,AO_A1_PD6D_P#/W_Y#?_"CGCW#V4_Y6:JJ
M68 =36C HC4**PX_$6C1K_Q^98]3Y3_X5,OB?1@?^/S_ ,A/_A7@XW$2JRY8
MKW5^)]ME& AA8>TJ-<[_  7;_/[CI835Q#Q7+Q>*]$'6]_\ (3_X5<3Q?H0'
M_'__ .07_P#B:Y(Q?8]2<X]S>:J\@K,/B_0?^?\ _P#(,G_Q-1OXMT(_\O\
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M_P!!'_R!)_\ $TG_  FWAW_H(_\ D"3_ .)HLPNCH.U%<_\ \)MX=Q_R$?\
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&3N#:L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-%UF6W^'_P#PC\6D:E+J4D<D2K]F(3+L>2Q[8-:VH>7H_A^Q\/:UI=W<Z?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F2_ZIOI3Z9+_JF^E #Z0HI8,5!8="1R*6B@"E?Z7:ZBUNUPA)@F692.,LN<
M ^HYZ4ESI%G=R6C21 "T<O$BX"Y((.1W&#5ZB@!BQ1H%"QJNP87 Q@>U AB6
M8RB)!(PP7"C)'UI]% #0B@L0H&[KQUIBVT"PF%8(Q$W5 @VG\*EHH :D:1C"
M(JCT48I@MH%+%88P6))(4<D]:EHH ;Y: Y"+G&WIV]*2.&*$8BB1!TPJ@4^B
M@!GE1YSL7.=V<=_6CRH]NW8N,[L8[^M/HH 8T,3R+(T2-(GW6*@D?0T@@A68
MS")!*1@N%&XCZU)10! ]G T+QK&(PX()C^4C/4@CH?>J&G>'[73[A[@RSW,K
M1>3NN&#83.=O0=^O<UK44 1?9;?RC%Y$7ED %=@P0.G%*T$+QM&T4;(WWE*@
M@_45)10 T1H-N$4;1A>.@]J8;:!MNZ&,[/NY4?+]*EHH :J(A)55!/7 H,:%
MPY12PZ-CD4ZB@"/R(?,\SRDW_P![:,_G2M#$TJRM&AD7[K%1D?0T^B@!DL4<
MT9CEC61#U5AD'\*IS:/93W\%Y)$"\$30HG&S:Q!/'X"K]% $;P0R[/,B1]AR
MNY0=I]O2E,,32K*T2&11@.5&0/K3Z* &"*,8Q&HQG''3/6FM;0.J*T,;!#E0
M5!VGV]*EHH 1E5L;E!P<C(Z&D$4:D$(H(SC Z9ZTZB@"-;>% X2&-0YR^% W
M?7UIWEIDG8N2-IX[>E.HH C6WA2$PI#&L1ZH% 'Y4J0Q1JBI$BJGW0% V_3T
MI]% $:V\*%RL,8,GW\*!N^OK2F*,]8U/R[>G;T^E/HH C6W@10J0QJ!C "@8
MQTI^Q=^_:-V,;L<XI:* &>5&'WA%W]=V.:0V\)V9AC.PY7*CY3[>E244 1-;
M0. &AC8#&,H#C'2G/#%(Z.\2,Z<JS*"5^GI3Z* (V@A:3S&B0OC&XJ,X^M#V
M\,B,CPQLC'+*R@@GU-244 1O;P2;-\,;;.4W*#M^GI4E%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R7
M_5-]*?4%XYCLY77J%R* )Z**BG^Z/K0!+15+/O1GWH NT52S[T9]Z +M%4L^
M]&?>@"[15+/O6;>Z_IVGW1M[BX974!I"J,RQ@]"Y PN?>@#?HK"?7-.1]AN<
MOYQ@"*K,Q<#)  '/!SGI5>/Q3I$HG*W$O[C_ %F;>0;3Q@<KUY''6@5T=+16
M9:7<%]:QW-M+YD,@RK#/-39]Z!EVBJ6?>C/O0!=HJEGWHS[T 7:*I9]Z;(3Y
M9YH OT52S[T9]Z +M%4L^]&?>@"[15+/O1GWH NT52S[T9]Z +M%4L^]&?>@
M"[15+/O1GWH NT52S[T9]Z +M%4L^]&?>@"[15+/O1GWH NT50C)V=>Y_G3L
M^] %VBJ6?>C/O0!=HJEGWHS[T 7:*I9]Z,^] %VBJ6?>C/O0!=HJEGWHS[T
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M"KN8L!DXX7Y2<^XI$W3(+7PM<:?JIU.UF4W(N.CN=KVY4*5]FXSGVK0&FW\
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MC15>VF1[&!G?V:__ #T7\J/[-?\ YZ+^5:-%'MIA[&!G?V:__/1?RH_LU_\
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MR3OT_1GT?1117KGQH4444 %%%% !3)?]6:?3)?\ 5F@!]%%% !1110 4444
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MMVX["O7:*UA6G!6B85,/3J2YI(\IT+X;:JNII_:S0I9Q-N;RWW&7'8>@KU;
M P!@#H!112J5)5'>15*C"DK1"BBBLS4**** "BBB@!T?^L6K558_]8M6JB1I
M#8*9+_JF^E/IDO\ JF^E26/HHI&) X4M]* %HIF]_P#GDWYC_&C>_P#SR;\Q
M_C0 ^BF;W_YY-^8_QHWO_P \F_,?XT /HIF]_P#GDWYC_&C>_P#SR;\Q_C0
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MYR?XN,'CZ5#)KFH0"-IH(HQ)(J(&1LOTZ#/&<Y'ICFM;2[F6[T^.688D)8'
MX."0#^56RJL064'!R,CI0,P[/5-5N+@"2Q6.$288LC D$CISVR<_2F2ZGJ\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO\
MJF^E/IDO^J;Z4 /JO-:":991+)&ZJ5RA'(/U!]*L44 5OLC\_P"F7'7/5?\
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0IDO^J;Z52_M8?\ /C??]^#0-1$Q\O['>)NXW/%@#ZFER2!5(/K_ %]Q5O\
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5BBB@ IDO^J;Z4^F2_P"J;Z4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex15-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y +@# 2(  A$! Q$!_\0
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MWRD_@"2?85^'7_!QGX57Q%_P1Z_;%U%&$>J> =#^'_Q5T"\XQ::K\/\ XJ>
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MK.TN+'P\^H-I;Z'\4_AGH<5LQC*:/;P7DEND4IF.A^%=(#1H6 EMI6_KT?\
MG_3 _H8\"?'7X0_%7Q'X_P#!?@+X@>'/$_BCX6:Y/X3^(FBV=^O]O>%M:TDC
M[1]OM!F19%^T*UO)L"Q7+1R@LR[5\S\=_%GXU^!_VG/A#\.M,_9_OO&GP!^)
M7A3QD?$WQJ\-:\@OOAC\4K&Z.I:9H7B;PA]Z/P9XBT*VG5O$P<+<>+[_ $V
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M^)PRW#%8VB-]I0F7*E6\QH2XA"L&:8QJI!(-?K@W3\0/7!) !_ \_A7Y_?\
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M%X=0N3,SJ@3ZD_8\^+>F_MXZ9\'?V./ASXI\,>-/A3I'_!//XFZW^V?K]GI
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5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>tlsa-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:16 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:tlsa="http://tizianalifesciences.com/20231231" targetNamespace="http://tizianalifesciences.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsa-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsa-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsa-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tlsa-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet" id="tlsa_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals" id="tlsa_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement" id="tlsa_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals" id="tlsa_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareholdersEquityType2or3" id="tlsa_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ConsolidatedCashFlow" id="tlsa_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/GeneralInformation" id="tlsa_r_GeneralInformation">
        <link:definition>007 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/AccountingPolicies" id="tlsa_r_AccountingPolicies">
        <link:definition>008 - Disclosure - Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/CriticalAccountingJudgement" id="tlsa_r_CriticalAccountingJudgement">
        <link:definition>009 - Disclosure - Critical Accounting Judgement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OtherexpenseIncome" id="tlsa_r_OtherexpenseIncome">
        <link:definition>010 - Disclosure - Other (expense)/ Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OperatingLoss" id="tlsa_r_OperatingLoss">
        <link:definition>011 - Disclosure - Operating Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/SegmentalReporting" id="tlsa_r_SegmentalReporting">
        <link:definition>012 - Disclosure - Segmental Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/Employees" id="tlsa_r_Employees">
        <link:definition>013 - Disclosure - Employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel" id="tlsa_r_RemunerationofKeyManagementPersonnel">
        <link:definition>014 - Disclosure - Remuneration of Key Management Personnel</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinanceCosts" id="tlsa_r_FinanceCosts">
        <link:definition>015 - Disclosure - Finance Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/Taxation" id="tlsa_r_Taxation">
        <link:definition>016 - Disclosure - Taxation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/LossPerShare" id="tlsa_r_LossPerShare">
        <link:definition>017 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OtherReceivables" id="tlsa_r_OtherReceivables">
        <link:definition>018 - Disclosure - Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremium" id="tlsa_r_ShareCapitalandSharePremium">
        <link:definition>019 - Disclosure - Share Capital and Share Premium</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareBasedPayments" id="tlsa_r_ShareBasedPayments">
        <link:definition>020 - Disclosure - Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/Reserves" id="tlsa_r_Reserves">
        <link:definition>021 - Disclosure - Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinancialInstruments" id="tlsa_r_FinancialInstruments">
        <link:definition>022 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/CapitalRiskManagement" id="tlsa_r_CapitalRiskManagement">
        <link:definition>023 - Disclosure - Capital Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TradeandOtherPayables" id="tlsa_r_TradeandOtherPayables">
        <link:definition>024 - Disclosure - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedParty" id="tlsa_r_InvestmentinRelatedParty">
        <link:definition>025 - Disclosure - Investment in Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TreasuryShares" id="tlsa_r_TreasuryShares">
        <link:definition>026 - Disclosure - Treasury Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactions" id="tlsa_r_RelatedPartyTransactions">
        <link:definition>027 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/Leases" id="tlsa_r_Leases">
        <link:definition>028 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinancialCommitments" id="tlsa_r_FinancialCommitments">
        <link:definition>029 - Disclosure - Financial Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ContingentLiabilities" id="tlsa_r_ContingentLiabilities">
        <link:definition>030 - Disclosure - Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/AccountingPoliciesByPolicy" id="tlsa_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/AccountingPoliciesTables" id="tlsa_r_AccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OtherexpenseIncomeTables" id="tlsa_r_OtherexpenseIncomeTables">
        <link:definition>996002 - Disclosure - Other (expense)/ Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OperatingLossTables" id="tlsa_r_OperatingLossTables">
        <link:definition>996003 - Disclosure - Operating Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/EmployeesTables" id="tlsa_r_EmployeesTables">
        <link:definition>996004 - Disclosure - Employees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables" id="tlsa_r_RemunerationofKeyManagementPersonnelTables">
        <link:definition>996005 - Disclosure - Remuneration of Key Management Personnel (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinanceCostsTables" id="tlsa_r_FinanceCostsTables">
        <link:definition>996006 - Disclosure - Finance Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TaxationTables" id="tlsa_r_TaxationTables">
        <link:definition>996007 - Disclosure - Taxation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/LossPerShareTables" id="tlsa_r_LossPerShareTables">
        <link:definition>996008 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OtherReceivablesTables" id="tlsa_r_OtherReceivablesTables">
        <link:definition>996009 - Disclosure - Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables" id="tlsa_r_ShareCapitalandSharePremiumTables">
        <link:definition>996010 - Disclosure - Share Capital and Share Premium (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsTables" id="tlsa_r_ShareBasedPaymentsTables">
        <link:definition>996011 - Disclosure - Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinancialInstrumentsTables" id="tlsa_r_FinancialInstrumentsTables">
        <link:definition>996012 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TradeandOtherPayablesTables" id="tlsa_r_TradeandOtherPayablesTables">
        <link:definition>996013 - Disclosure - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables" id="tlsa_r_InvestmentinRelatedPartyTables">
        <link:definition>996014 - Disclosure - Investment in Related Party (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/LeasesTables" id="tlsa_r_LeasesTables">
        <link:definition>996015 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/AccountingPoliciesDetails" id="tlsa_r_AccountingPoliciesDetails">
        <link:definition>996016 - Disclosure - Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" id="tlsa_r_ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable">
        <link:definition>996017 - Disclosure - Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable" id="tlsa_r_ScheduleofOtherExpenseIncomeTable">
        <link:definition>996018 - Disclosure - Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/OperatingLossDetails" id="tlsa_r_OperatingLossDetails">
        <link:definition>996019 - Disclosure - Operating Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable" id="tlsa_r_ScheduleofOperatingLossesTable">
        <link:definition>996020 - Disclosure - Operating Loss (Details) - Schedule of Operating Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofEmployeesTable" id="tlsa_r_ScheduleofEmployeesTable">
        <link:definition>996021 - Disclosure - Employees (Details) - Schedule of Employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails" id="tlsa_r_RemunerationofKeyManagementPersonnelDetails">
        <link:definition>996022 - Disclosure - Remuneration of Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable" id="tlsa_r_ScheduleofRemunerationofKeyManagementPersonnelTable">
        <link:definition>996023 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable" id="tlsa_r_ScheduleofShareOptionswereGrantedtoDirectorsTable">
        <link:definition>996024 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable" id="tlsa_r_ScheduleofFinanceCostsTable">
        <link:definition>996025 - Disclosure - Finance Costs (Details) - Schedule of Finance Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TaxationDetails" id="tlsa_r_TaxationDetails">
        <link:definition>996026 - Disclosure - Taxation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable" id="tlsa_r_ScheduleofTaxationTable">
        <link:definition>996027 - Disclosure - Taxation (Details) - Schedule of Taxation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals" id="tlsa_r_ScheduleofTaxationTable_Parentheticals">
        <link:definition>996028 - Disclosure - Taxation (Details) - Schedule of Taxation (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable" id="tlsa_r_ScheduleofBasicLossPerShareTable">
        <link:definition>996029 - Disclosure - Loss Per Share (Details) - Schedule of Basic Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable" id="tlsa_r_ScheduleofOtherReceivablesTable">
        <link:definition>996030 - Disclosure - Other Receivables (Details) - Schedule of Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails" id="tlsa_r_ShareCapitalandSharePremiumDetails">
        <link:definition>996031 - Disclosure - Share Capital and Share Premium (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable" id="tlsa_r_ScheduleofShareCapitalArisingontheShareforShareExchangeTable">
        <link:definition>996032 - Disclosure - Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsDetails" id="tlsa_r_ShareBasedPaymentsDetails">
        <link:definition>996033 - Disclosure - Share Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable" id="tlsa_r_ScheduleofShareOptionPlanTable">
        <link:definition>996034 - Disclosure - Share Based Payments (Details) - Schedule of Share Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable" id="tlsa_r_ScheduleofShareOptionsExpiryDatesandExercisePriceTable">
        <link:definition>996035 - Disclosure - Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" id="tlsa_r_ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable">
        <link:definition>996036 - Disclosure - Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable" id="tlsa_r_ScheduleofEquityIncentivePlanTable">
        <link:definition>996037 - Disclosure - Share Based Payments (Details) - Schedule of Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable" id="tlsa_r_ScheduleofEstimatedtheFairValueofWarrantsUsingTable">
        <link:definition>996038 - Disclosure - Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" id="tlsa_r_ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable">
        <link:definition>996039 - Disclosure - Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable" id="tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable">
        <link:definition>996040 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals" id="tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals">
        <link:definition>996041 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable" id="tlsa_r_ScheduleofTradeandOtherPayablesTable">
        <link:definition>996042 - Disclosure - Trade and Other Payables (Details) - Schedule of Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails" id="tlsa_r_InvestmentinRelatedPartyDetails">
        <link:definition>996043 - Disclosure - Investment in Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbLtYXaE3OupcvNEUWjciKqs=] CSR-->
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable" id="tlsa_r_ScheduleofInvestmentinRelatedPartyTable">
        <link:definition>996044 - Disclosure - Investment in Related Party (Details) - Schedule of Investment in Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/TreasurySharesDetails" id="tlsa_r_TreasurySharesDetails">
        <link:definition>996045 - Disclosure - Treasury Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails" id="tlsa_r_RelatedPartyTransactionsDetails">
        <link:definition>996046 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable" id="tlsa_r_ScheduleofRightofUseAssetsandLeaseLiabilitiesTable">
        <link:definition>996047 - Disclosure - Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable" id="tlsa_r_ScheduleofConsolidatedStatementofFinancialTable">
        <link:definition>996048 - Disclosure - Leases (Details) - Schedule of Consolidated Statement of Financial</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable" id="tlsa_r_ScheduleofFutureMinimumLeasePaymentsTable">
        <link:definition>996049 - Disclosure - Leases (Details) - Schedule of Future Minimum Lease Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/FinancialCommitmentsDetails" id="tlsa_r_FinancialCommitmentsDetails">
        <link:definition>996050 - Disclosure - Financial Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tizianalifesciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ConsolidatedStatementsOfShareholdersEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract"/>
  <xs:element name="ScheduleOfOtherExpenseIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfOtherExpenseIncomeAbstract"/>
  <xs:element name="ScheduleOfOperatingLossesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfOperatingLossesAbstract"/>
  <xs:element name="ScheduleOfEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEmployeesAbstract"/>
  <xs:element name="ScheduleOfRemunerationOfKeyManagementPersonnelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract"/>
  <xs:element name="ScheduleOfShareOptionsWereGrantedToDirectorsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract"/>
  <xs:element name="ScheduleOfFinanceCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfFinanceCostsAbstract"/>
  <xs:element name="ScheduleOfBasicLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfBasicLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfOtherReceivablesAbstract"/>
  <xs:element name="ScheduleOfAllOtherVariablesRemainConstantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract5"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherIncomeExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract16"/>
  <xs:element name="StaffCostsComprisedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_StaffCostsComprisedAbstract"/>
  <xs:element name="GroupAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GroupAbstract"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract17"/>
  <xs:element name="FinanceExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceExpenseAbstract"/>
  <xs:element name="GroupAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GroupAbstract0"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract18"/>
  <xs:element name="TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract"/>
  <xs:element name="GroupReorganizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GroupReorganizationAbstract"/>
  <xs:element name="SharesIssuedInThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesIssuedInThePeriodAbstract"/>
  <xs:element name="SharesIssuedInThePeriodAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesIssuedInThePeriodAbstract0"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UnlabeledAbstract24"/>
  <xs:element name="PrepaymentsandOtherReceivablesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PrepaymentsandOtherReceivablesCurrent"/>
  <xs:element name="TaxationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TaxationReceivable"/>
  <xs:element name="InvestmentsInRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentsInRelatedParty"/>
  <xs:element name="ShareBasedPaymentReserveWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentReserveWarrants"/>
  <xs:element name="SharesToBeIssuedReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesToBeIssuedReserve"/>
  <xs:element name="IssuanceOfShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IssuanceOfShareCapital"/>
  <xs:element name="ShareCapitalOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalOutstanding"/>
  <xs:element name="RealisationBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RealisationBonus"/>
  <xs:element name="IncomeTaxSCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeTaxSCredit"/>
  <xs:element name="ShareBasedPaymentoptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentoptions"/>
  <xs:element name="SharesIssuedInLieuOfCashRealizationBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesIssuedInLieuOfCashRealizationBonus"/>
  <xs:element name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1"/>
  <xs:element name="OptionsForfeitedcancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsForfeitedcancelled"/>
  <xs:element name="WarrantsExercisedInTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WarrantsExercisedInTheYear"/>
  <xs:element name="WarrantsForfeitedInTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WarrantsForfeitedInTheYear"/>
  <xs:element name="BuybackOfTreasuryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BuybackOfTreasuryShares"/>
  <xs:element name="SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus"/>
  <xs:element name="SharesIssuedInLieuOfFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesIssuedInLieuOfFees"/>
  <xs:element name="AdjustmentsForSharebasedPaymentsWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AdjustmentsForSharebasedPaymentsWarrants"/>
  <xs:element name="OptionsForfeitedDuringTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsForfeitedDuringTheYear"/>
  <xs:element name="FVLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FVLossOnInvestment"/>
  <xs:element name="LossOnDisposalOfAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LossOnDisposalOfAsset"/>
  <xs:element name="BonusToBeSettledInEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BonusToBeSettledInEquity"/>
  <xs:element name="DepreciationOfRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DepreciationOfRightofuseAsset"/>
  <xs:element name="CapitalDistribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CapitalDistribution"/>
  <xs:element name="ProceedsFromSaleAndCollectionOfFinanceReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable"/>
  <xs:element name="CashInflowFromTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CashInflowFromTaxation"/>
  <xs:element name="InterestReceivedFromLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InterestReceivedFromLoan"/>
  <xs:element name="NetIncreaseInRelatedPartyReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NetIncreaseInRelatedPartyReceivables"/>
  <xs:element name="NetIncreaseInRelatedPartyPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NetIncreaseInRelatedPartyPayables"/>
  <xs:element name="ProceedsFromFinanceLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ProceedsFromFinanceLease"/>
  <xs:element name="InvestmentInRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentInRelatedParty"/>
  <xs:element name="PurchaseOfTreasuryAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PurchaseOfTreasuryAmount"/>
  <xs:element name="FundraisingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FundraisingCost"/>
  <xs:element name="ProceedsFromIssuanceOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ProceedsFromIssuanceOfOptions"/>
  <xs:element name="RepaymentOfLeasingLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RepaymentOfLeasingLiabilities"/>
  <xs:element name="GeneralInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_GeneralInformationTable"/>
  <xs:element name="GeneralInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GeneralInformationLineItems"/>
  <xs:element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_AccountingPoliciesTable"/>
  <xs:element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccountingPoliciesLineItems"/>
  <xs:element name="CriticalAccountingJudgementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_CriticalAccountingJudgementTable"/>
  <xs:element name="CriticalAccountingJudgementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CriticalAccountingJudgementLineItems"/>
  <xs:element name="OperatingLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OperatingLossTable"/>
  <xs:element name="OperatingLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingLossLineItems"/>
  <xs:element name="SegmentalReportingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_SegmentalReportingTable"/>
  <xs:element name="SegmentalReportingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SegmentalReportingLineItems"/>
  <xs:element name="RemunerationofKeyManagementPersonnelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RemunerationofKeyManagementPersonnelTable"/>
  <xs:element name="RemunerationofKeyManagementPersonnelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RemunerationofKeyManagementPersonnelLineItems"/>
  <xs:element name="LossPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_LossPerShareTable"/>
  <xs:element name="LossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LossPerShareLineItems"/>
  <xs:element name="DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock"/>
  <xs:element name="InvestmentInRelatedPartyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentInRelatedPartyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForGoingConcern" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForGoingConcern"/>
  <xs:element name="DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForBasisofConsolidation" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation"/>
  <xs:element name="DescriptionOfAccountingPolicyForLicenseFees" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForLicenseFees"/>
  <xs:element name="DescriptionOfAccountingPolicyForWarrantsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock"/>
  <xs:element name="DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutOperatingLoss" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss"/>
  <xs:element name="OperatingLossTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OperatingLossTablesTable"/>
  <xs:element name="OperatingLossTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingLossTablesLineItems"/>
  <xs:element name="DisclosureOfDetailedInformationAboutEmployeesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory"/>
  <xs:element name="DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock"/>
  <xs:element name="DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock"/>
  <xs:element name="RemunerationofKeyManagementPersonnelTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RemunerationofKeyManagementPersonnelTablesTable"/>
  <xs:element name="RemunerationofKeyManagementPersonnelTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems"/>
  <xs:element name="DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock"/>
  <xs:element name="LossPerShareTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_LossPerShareTablesTable"/>
  <xs:element name="LossPerShareTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LossPerShareTablesLineItems"/>
  <xs:element name="DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock"/>
  <xs:element name="OtherReceivablesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OtherReceivablesTablesTable"/>
  <xs:element name="OtherReceivablesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherReceivablesTablesLineItems"/>
  <xs:element name="DisclosureShareCapitalArisingForShareExchangetextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock"/>
  <xs:element name="ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock"/>
  <xs:element name="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock"/>
  <xs:element name="ScheduleOfEquityIncentivePlanTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock"/>
  <xs:element name="ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock"/>
  <xs:element name="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock"/>
  <xs:element name="ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock"/>
  <xs:element name="ScheduleOfTradeAndOtherPayablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock"/>
  <xs:element name="TradeandOtherPayablesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_TradeandOtherPayablesTablesTable"/>
  <xs:element name="TradeandOtherPayablesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TradeandOtherPayablesTablesLineItems"/>
  <xs:element name="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock"/>
  <xs:element name="DisclosureOfFutureMinimumLeasePayments" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisclosureOfFutureMinimumLeasePayments"/>
  <xs:element name="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
  <xs:element name="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems"/>
  <xs:element name="EstimatedUsefulLives" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_EstimatedUsefulLives"/>
  <xs:element name="RightOfUseAssetDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RightOfUseAssetDescription"/>
  <xs:element name="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable"/>
  <xs:element name="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems"/>
  <xs:element name="SublicenseIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SublicenseIncome"/>
  <xs:element name="OtherIncomelosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherIncomelosses"/>
  <xs:element name="OperatingLossDetailsScheduleofOperatingLossesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable"/>
  <xs:element name="OperatingLossDetailsScheduleofOperatingLossesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems"/>
  <xs:element name="Licensefee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_Licensefee"/>
  <xs:element name="OperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingLoss"/>
  <xs:element name="ForeignExchangegainlosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ForeignExchangegainlosses"/>
  <xs:element name="RecruitmentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RecruitmentFees"/>
  <xs:element name="ResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ResearchAndDevelopment"/>
  <xs:element name="CorporateAndAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CorporateAndAdministration"/>
  <xs:element name="AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems"/>
  <xs:element name="DirectorsFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DirectorsFees"/>
  <xs:element name="Bonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_Bonus"/>
  <xs:element name="Salary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_Salary"/>
  <xs:element name="ShareBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPayments"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems"/>
  <xs:element name="NumberOfShareOptionsWereGrantedToDirectors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfShareOptionsWereGrantedToDirectors"/>
  <xs:element name="FinanceChargeAccruedOnConvertibleLoanNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes"/>
  <xs:element name="FinanceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceExpense"/>
  <xs:element name="NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome"/>
  <xs:element name="AdjustmentsDueToPriorPeriods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AdjustmentsDueToPriorPeriods"/>
  <xs:element name="IncomeTaxExpenseContinuingOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeTaxExpenseContinuingOperation"/>
  <xs:element name="OtherLossBeforeTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherLossBeforeTaxation"/>
  <xs:element name="IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax"/>
  <xs:element name="MovementInUnrecognisedDeferredTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MovementInUnrecognisedDeferredTax"/>
  <xs:element name="IncomeTaxReconciliationExpensesNotDeductibleForTaxation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation"/>
  <xs:element name="AdjustmentsDueToPriorPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AdjustmentsDueToPriorPeriod"/>
  <xs:element name="IncomeTaxReconciliationResearchAndDevelopmentClaim" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim"/>
  <xs:element name="IncomeNotTaxableForTaxPurposes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_IncomeNotTaxableForTaxPurposes"/>
  <xs:element name="FixedAssetDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FixedAssetDifferences"/>
  <xs:element name="CurrentTaxOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CurrentTaxOther"/>
  <xs:element name="AdjustmentsToBroughtForwardValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AdjustmentsToBroughtForwardValues"/>
  <xs:element name="ConsolidationAdjustmentInRelationToForeignExchangeMovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements"/>
  <xs:element name="LossPerShareDetailsScheduleofBasicLossPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable"/>
  <xs:element name="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems"/>
  <xs:element name="BasicLossPerSharecentsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BasicLossPerSharecentsPerShare"/>
  <xs:element name="OtherReceivablesDetailsScheduleofOtherReceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable"/>
  <xs:element name="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems"/>
  <xs:element name="SecurityDepositsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SecurityDepositsReceivable"/>
  <xs:element name="NominalValueAnnualReport" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueAnnualReport"/>
  <xs:element name="ShareCapitalSharesAnnualReport" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesAnnualReport"/>
  <xs:element name="ShareCapitalValueAnnualReport" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueAnnualReport"/>
  <xs:element name="SharePremiumAnnualReport" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumAnnualReport"/>
  <xs:element name="MergerReserveAtJanuary12021Per20FAnnualReport" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport"/>
  <xs:element name="NominalValueEliminationOfShareCapital" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueEliminationOfShareCapital"/>
  <xs:element name="ShareCapitalSharesEliminationOfShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesEliminationOfShare"/>
  <xs:element name="ShareCapitalValueEliminationOfShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueEliminationOfShareCapital"/>
  <xs:element name="SharePremiumEliminationOfShareCapitalIn" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumEliminationOfShareCapitalIn"/>
  <xs:element name="MergerReserveEliminationOfShareCapitalIn" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveEliminationOfShareCapitalIn"/>
  <xs:element name="NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
  <xs:element name="ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation"/>
  <xs:element name="ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation"/>
  <xs:element name="SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
  <xs:element name="MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
  <xs:element name="EliminationOfOtherReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_EliminationOfOtherReserves"/>
  <xs:element name="NominalValueRestated" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueRestated"/>
  <xs:element name="ShareCapitalSharesRestated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesRestated"/>
  <xs:element name="ShareCapitalValueRestated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueRestated"/>
  <xs:element name="SharePremiumRestatedAt1January2021" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumRestatedAt1January2021"/>
  <xs:element name="MergerReserveRestated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveRestated"/>
  <xs:element name="NominalValueConversionOfWarrants" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueConversionOfWarrants"/>
  <xs:element name="ShareCapitalSharesConversionOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesConversionOfWarrants"/>
  <xs:element name="ShareCapitalConversionOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalConversionOfWarrants"/>
  <xs:element name="SharePremiumConversionOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumConversionOfWarrants"/>
  <xs:element name="MergerReserveConversionOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveConversionOfWarrants"/>
  <xs:element name="NominalValueConversionOfLoan" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueConversionOfLoan"/>
  <xs:element name="ShareCapitalSharesConversionOfLoan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesConversionOfLoan"/>
  <xs:element name="ShareCapitalValueConversionOfLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueConversionOfLoan"/>
  <xs:element name="SharePremiumConversionOfLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumConversionOfLoan"/>
  <xs:element name="MergerReserveConversionOfLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveConversionOfLoan"/>
  <xs:element name="NominalValueIssuedInLieuOfCashBonus" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueIssuedInLieuOfCashBonus"/>
  <xs:element name="ShareCapitalSharesIssuedInLieuOfCashBonus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus"/>
  <xs:element name="ShareCapitalValueIssuedInCashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueIssuedInCashBonus"/>
  <xs:element name="SharePremiumIssuedInCashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumIssuedInCashBonus"/>
  <xs:element name="MergerReserveIssuedInLieuOfCashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveIssuedInLieuOfCashBonus"/>
  <xs:element name="ShareCapitalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalShares"/>
  <xs:element name="ShareCapitalValueAt31December2021" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueAt31December2021"/>
  <xs:element name="SharePremiumEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumEnding"/>
  <xs:element name="MergerReserveEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MergerReserveEnding"/>
  <xs:element name="NominalValueSharesIssuedInLieuOfFees" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueSharesIssuedInLieuOfFees"/>
  <xs:element name="ShareCapitalSharesIssuedInLieuOfFees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesIssuedInLieuOfFees"/>
  <xs:element name="ShareCapitalValueSharesIssuedInLieuOfFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees"/>
  <xs:element name="SharePremiumSharesIssuedInLieuOfFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumSharesIssuedInLieuOfFees"/>
  <xs:element name="NominalValueWarrantsExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueWarrantsExercised"/>
  <xs:element name="ShareCapitalSharesWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesWarrantsExercised"/>
  <xs:element name="ShareCapitalValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueWarrantsExercised"/>
  <xs:element name="SharePremiumWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumWarrantsExercised"/>
  <xs:element name="NominalValueIssuanceOfStockATM" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NominalValueIssuanceOfStockATM"/>
  <xs:element name="ShareCapitalSharesIssuanceOfStockATM" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalSharesIssuanceOfStockATM"/>
  <xs:element name="ShareCapitalValueIssuanceOfStockATM" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalValueIssuanceOfStockATM"/>
  <xs:element name="SharePremiumIssuanceOfStockATM" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharePremiumIssuanceOfStockATM"/>
  <xs:element name="WeightedAverageExercisePriceOutstanding" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WeightedAverageExercisePriceOutstanding"/>
  <xs:element name="OptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsOutstanding"/>
  <xs:element name="WeightedAverageExercisePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WeightedAverageExercisePriceGranted"/>
  <xs:element name="OptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsGranted"/>
  <xs:element name="WeightedAverageExercisePriceForfeitedCancelled" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WeightedAverageExercisePriceForfeitedCancelled"/>
  <xs:element name="OptionsForfeitedCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsForfeitedCancelled"/>
  <xs:element name="WeightedAverageExercisePriceExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WeightedAverageExercisePriceExercised"/>
  <xs:element name="OptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsExercised"/>
  <xs:element name="WeightedAverageExercisePriceExercisable" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WeightedAverageExercisePriceExercisable"/>
  <xs:element name="OptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionsExercisable"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems"/>
  <xs:element name="ExpiryDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ExpiryDate"/>
  <xs:element name="ExerciseSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ExerciseSharePrice"/>
  <xs:element name="ShareOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareOptions"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems"/>
  <xs:element name="GrantDateSharesPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GrantDateSharesPrice"/>
  <xs:element name="OptionLifeShareOptionsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OptionLifeShareOptionsGranted"/>
  <xs:element name="NumberOfShareOptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfShareOptionsOutstanding"/>
  <xs:element name="NumberOfShareOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfShareOptionsGranted"/>
  <xs:element name="NumberOfShareOptionsForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfShareOptionsForfeited"/>
  <xs:element name="NumberofOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberofOptionsExercised"/>
  <xs:element name="NumberOfShareOptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfShareOptionsExercisable"/>
  <xs:element name="FairValueOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FairValueOutstanding"/>
  <xs:element name="OutstandingExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OutstandingExercised"/>
  <xs:element name="OutstandingExpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OutstandingExpired"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems"/>
  <xs:element name="RelatedPartyPayablesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RelatedPartyPayablesAmount"/>
  <xs:element name="FinancialInstrumentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialInstrumentsNet"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems"/>
  <xs:element name="ProfitOrLossAndEquityStrengthening" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ProfitOrLossAndEquityStrengthening"/>
  <xs:element name="ProfitOrLossAndEquityWeakening" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ProfitOrLossAndEquityWeakening"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems"/>
  <xs:element name="MovementPercentageStrengthening" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MovementPercentageStrengthening"/>
  <xs:element name="MovementPercentageWeakening" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MovementPercentageWeakening"/>
  <xs:element name="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable"/>
  <xs:element name="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems"/>
  <xs:element name="RightOfUseAssetBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RightOfUseAssetBeginning"/>
  <xs:element name="RightOfUseAssetsDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RightOfUseAssetsDepreciation"/>
  <xs:element name="DisposalOfLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DisposalOfLease"/>
  <xs:element name="ExchangeDifferencesRightofUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ExchangeDifferencesRightofUseAssets"/>
  <xs:element name="RightOfUseAssetsTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RightOfUseAssetsTotal"/>
  <xs:element name="LeaseLiabilitiesBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeaseLiabilitiesBeginning"/>
  <xs:element name="LeaseLiabilitiesInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeaseLiabilitiesInterestExpense"/>
  <xs:element name="LeaseLiabilitiesLeasePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeaseLiabilitiesLeasePayments"/>
  <xs:element name="ExchangeDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ExchangeDifferences"/>
  <xs:element name="LeaseLiabilitiesTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeaseLiabilitiesTotal"/>
  <xs:element name="LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable"/>
  <xs:element name="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems"/>
  <xs:element name="LeasePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LeasePayments"/>
  <xs:element name="FinanceCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceCharges"/>
  <xs:element name="NetPresentValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NetPresentValues"/>
  <xs:element name="AccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_AccountingPoliciesDetailsTable"/>
  <xs:element name="AccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccountingPoliciesDetailsLineItems"/>
  <xs:element name="AccumulatedLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccumulatedLoss"/>
  <xs:element name="CashSurplus" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CashSurplus"/>
  <xs:element name="NumberOfSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfSegment"/>
  <xs:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_UpfrontPayment"/>
  <xs:element name="OperatingLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_OperatingLossDetailsTable"/>
  <xs:element name="OperatingLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingLossDetailsLineItems"/>
  <xs:element name="RaisingFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RaisingFunds"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RemunerationofKeyManagementPersonnelDetailsTable"/>
  <xs:element name="RemunerationofKeyManagementPersonnelDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems"/>
  <xs:element name="TaxationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_TaxationDetailsTable"/>
  <xs:element name="TaxationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TaxationDetailsLineItems"/>
  <xs:element name="MaximumPercentageOfSurrenderableLosses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MaximumPercentageOfSurrenderableLosses"/>
  <xs:element name="TermOfResearchAndDevelopmentTaxReliefClaims" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims"/>
  <xs:element name="ShareCapitalandSharePremiumDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_ShareCapitalandSharePremiumDetailsTable"/>
  <xs:element name="ShareCapitalandSharePremiumDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareCapitalandSharePremiumDetailsLineItems"/>
  <xs:element name="NumberOfSharesIssued1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NumberOfSharesIssued1"/>
  <xs:element name="TreasuryShares1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TreasuryShares1"/>
  <xs:element name="ShareBasedPaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_ShareBasedPaymentsDetailsTable"/>
  <xs:element name="ShareBasedPaymentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentsDetailsLineItems"/>
  <xs:element name="OutstandingFairValueCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OutstandingFairValueCharges"/>
  <xs:element name="ExpectedTermOfAwards" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ExpectedTermOfAwards"/>
  <xs:element name="ChargeOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ChargeOfForfeitures"/>
  <xs:element name="InvestmentinRelatedPartyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_InvestmentinRelatedPartyDetailsTable"/>
  <xs:element name="InvestmentinRelatedPartyDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentinRelatedPartyDetailsLineItems"/>
  <xs:element name="SharesPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesPrice"/>
  <xs:element name="AcquiredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AcquiredShares"/>
  <xs:element name="ClassOfWarrantsOrRightDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ClassOfWarrantsOrRightDomainDomain"/>
  <xs:element name="TreasurySharesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_TreasurySharesDetailsTable"/>
  <xs:element name="TreasurySharesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TreasurySharesDetailsLineItems"/>
  <xs:element name="SharesPurchases" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesPurchases"/>
  <xs:element name="RelatedPartyDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RelatedPartyDomainDomain"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="InterestAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InterestAmount"/>
  <xs:element name="ShortTermLoanFacility1" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShortTermLoanFacility1"/>
  <xs:element name="PayrollAndRentCharged" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PayrollAndRentCharged"/>
  <xs:element name="ServicesAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ServicesAgreementAmount"/>
  <xs:element name="InitialAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InitialAmount"/>
  <xs:element name="AdditionalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AdditionalPayment"/>
  <xs:element name="MilestonePaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MilestonePaymentDue"/>
  <xs:element name="PrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PrincipalAmount"/>
  <xs:element name="FinancialCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tlsa_FinancialCommitmentsDetailsTable"/>
  <xs:element name="FinancialCommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialCommitmentsDetailsLineItems"/>
  <xs:element name="DevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DevelopmentMilestones"/>
  <xs:element name="AccruedOfDiligenceObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccruedOfDiligenceObligations"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_MilestonePayments"/>
  <xs:element name="CommercialSaleOfAProduct" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CommercialSaleOfAProduct"/>
  <xs:element name="ClassOfWarrantsOrRightAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="tlsa_ClassOfWarrantsOrRightAxis"/>
  <xs:element name="RelatedPartyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="tlsa_RelatedPartyAxis"/>
  <xs:element name="AccustemSciencesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccustemSciencesIncMember"/>
  <xs:element name="BLAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BLAMember"/>
  <xs:element name="BlackScholesMertonValuationModelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BlackScholesMertonValuationModelMember"/>
  <xs:element name="BreastCancerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_BreastCancerMember"/>
  <xs:element name="CarcinomaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_CarcinomaMember"/>
  <xs:element name="FourteenMarchTwoThousandTwentyThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FourteenMarchTwoThousandTwentyThreeMember"/>
  <xs:element name="GCerroneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GCerroneMember"/>
  <xs:element name="GensigniaLifesceinecsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_GensigniaLifesceinecsIncMember"/>
  <xs:element name="HCCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_HCCMember"/>
  <xs:element name="JBrancaccioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_JBrancaccioMember"/>
  <xs:element name="KShailubhaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_KShailubhaiMember"/>
  <xs:element name="LaterThanTwoYearsAndNotLaterThanFiveYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember"/>
  <xs:element name="LessThanThreeMonthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_LessThanThreeMonthMember"/>
  <xs:element name="NASDAQStockExchangeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_NASDAQStockExchangeMember"/>
  <xs:element name="OKYOPharmaLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OKYOPharmaLtdMember"/>
  <xs:element name="Phase3Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_Phase3Member"/>
  <xs:element name="PhaseIHumanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PhaseIHumanMember"/>
  <xs:element name="PhaseIIClinicalTrialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PhaseIIClinicalTrialMember"/>
  <xs:element name="PhaseIIHumanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PhaseIIHumanMember"/>
  <xs:element name="PhaseIIIHumanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_PhaseIIIHumanMember"/>
  <xs:element name="RasnaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RasnaTherapeuticsIncMember"/>
  <xs:element name="RightOfUseAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_RightOfUseAssetMember"/>
  <xs:element name="ShareBasedPaymentReserveWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareBasedPaymentReserveWarrantsMember"/>
  <xs:element name="ShareOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ShareOptionMember"/>
  <xs:element name="SharesToBeIssuedReserveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SharesToBeIssuedReserveMember"/>
  <xs:element name="SixMayTwoThousandAndTwentyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_SixMayTwoThousandAndTwentyMember"/>
  <xs:element name="TAdamsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TAdamsMember"/>
  <xs:element name="ThirtyAprilTwoThousandAndEighteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ThirtyAprilTwoThousandAndEighteenMember"/>
  <xs:element name="ThreeToTwelveMonthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ThreeToTwelveMonthMember"/>
  <xs:element name="TizianaLifeSciencesPLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TizianaLifeSciencesPLCMember"/>
  <xs:element name="TranslationReserveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TranslationReserveMember"/>
  <xs:element name="TwentyFiveAugustTwoThousandAndTwentyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember"/>
  <xs:element name="TwentySixJulyTwoThousandTwentyThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TwentySixJulyTwoThousandTwentyThreeMember"/>
  <xs:element name="TwentySixJuneTwoThousandFourteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TwentySixJuneTwoThousandFourteenMember"/>
  <xs:element name="TwentyThreeJulyTwoThousandAndTwentyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember"/>
  <xs:element name="USDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_USDMember"/>
  <xs:element name="WSimonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WSimonMember"/>
  <xs:element name="WillySimonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_WillySimonMember"/>
  <xs:element name="ZeroFourNovemberTwoThousandAndTwentyTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember"/>
  <xs:element name="ZeroOneeAugustTwoThousandAndTwentyTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember"/>
  <xs:element name="AccountingPolicieAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_AccountingPolicieAbstract"/>
  <xs:element name="EmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_EmployeesAbstract"/>
  <xs:element name="FinanceCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinanceCostsAbstract"/>
  <xs:element name="FinancialCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_FinancialCommitmentsAbstract"/>
  <xs:element name="InvestmentInRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_InvestmentInRelatedPartyAbstract"/>
  <xs:element name="OperatingExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_OperatingExpenseAbstract"/>
  <xs:element name="ScheduleOfConsolidatedStatementOfFinancialAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract"/>
  <xs:element name="ScheduleOfEquityIncentivePlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEquityIncentivePlanAbstract"/>
  <xs:element name="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract"/>
  <xs:element name="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumLeasePaymentsAbstarct" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct"/>
  <xs:element name="ScheduleOfInvestmentInRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfInvestmentInRelatedPartyAbstract"/>
  <xs:element name="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract"/>
  <xs:element name="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract"/>
  <xs:element name="ScheduleOfShareOptionPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfShareOptionPlanAbstract"/>
  <xs:element name="ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract"/>
  <xs:element name="ScheduleOfTradeAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_ScheduleOfTradeAndOtherPayablesAbstract"/>
  <xs:element name="TaxationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TaxationAbstract"/>
  <xs:element name="TreasurySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_TreasurySharesAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tlsa_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>tlsa-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:16 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedBalanceSheet" roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedIncomeStatement" roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedCashFlow" roleURI="http://tizianalifesciences.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEmployeesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEmployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOtherReceivablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofInvestmentinRelatedPartyTable" roleURI="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:href="tlsa-20231231.xsd#tlsa_PrepaymentsandOtherReceivablesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="tlsa_PrepaymentsandOtherReceivablesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="tlsa_TaxationReceivable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentsInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentsInRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="tlsa_InvestmentsInRelatedParty" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentReserveWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="tlsa_ShareBasedPaymentReserveWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedReserve" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="tlsa_SharesToBeIssuedReserve" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_TreasuryShares" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OtherExpenseByFunction" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_RealisationBonus" xlink:href="tlsa-20231231.xsd#tlsa_RealisationBonus"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="tlsa_RealisationBonus" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OperatingExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_FinanceIncomeCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_GainsLossesOnDisposalsOfInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherOperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_OtherGainsLosses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxSCredit" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxSCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="tlsa_IncomeTaxSCredit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbNmHxcHMnL30+1SXNE8Vh/Y=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForInterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForInterestExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_SharesIssuedInLieuOfFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsForSharebasedPaymentsWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_AdjustmentsForSharebasedPaymentsWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_FVLossOnInvestment" xlink:href="tlsa-20231231.xsd#tlsa_FVLossOnInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_FVLossOnInvestment" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossOnDisposalOfAsset" xlink:href="tlsa-20231231.xsd#tlsa_LossOnDisposalOfAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_LossOnDisposalOfAsset" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_BonusToBeSettledInEquity" xlink:href="tlsa-20231231.xsd#tlsa_BonusToBeSettledInEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_BonusToBeSettledInEquity" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_DepreciationOfRightofuseAsset" xlink:href="tlsa-20231231.xsd#tlsa_DepreciationOfRightofuseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_DepreciationOfRightofuseAsset" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_CashInflowFromTaxation" xlink:href="tlsa-20231231.xsd#tlsa_CashInflowFromTaxation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_CashInflowFromTaxation" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedDuringTheYear" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedDuringTheYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_OptionsForfeitedDuringTheYear" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_CapitalDistribution" xlink:href="tlsa-20231231.xsd#tlsa_CapitalDistribution"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_CapitalDistribution" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_InterestReceivedFromLoan" xlink:href="tlsa-20231231.xsd#tlsa_InterestReceivedFromLoan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_InterestReceivedFromLoan" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_NetIncreaseInRelatedPartyReceivables" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="tlsa_NetIncreaseInRelatedPartyPayables" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromFinanceLease" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromFinanceLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="tlsa_ProceedsFromFinanceLease" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="tlsa_InvestmentInRelatedParty" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tlsa_PurchaseOfTreasuryAmount" xlink:href="tlsa-20231231.xsd#tlsa_PurchaseOfTreasuryAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="tlsa_PurchaseOfTreasuryAmount" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="tlsa_FundraisingCost" xlink:href="tlsa-20231231.xsd#tlsa_FundraisingCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="tlsa_FundraisingCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromIssuanceOfOptions" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromIssuanceOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="tlsa_ProceedsFromIssuanceOfOptions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_RepaymentOfLeasingLiabilities" xlink:href="tlsa-20231231.xsd#tlsa_RepaymentOfLeasingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="tlsa_RepaymentOfLeasingLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEmployeesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_SocialSecurityContributions" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_RecruitmentFees" xlink:href="tlsa-20231231.xsd#tlsa_RecruitmentFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="tlsa_RecruitmentFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:href="tlsa-20231231.xsd#tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup"/>
    <loc xlink:type="locator" xlink:label="tlsa_ResearchAndDevelopment" xlink:href="tlsa-20231231.xsd#tlsa_ResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:to="tlsa_ResearchAndDevelopment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_CorporateAndAdministration" xlink:href="tlsa-20231231.xsd#tlsa_CorporateAndAdministration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:to="tlsa_CorporateAndAdministration" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <loc xlink:type="locator" xlink:label="tlsa_SecurityDepositsReceivable" xlink:href="tlsa-20231231.xsd#tlsa_SecurityDepositsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherReceivables" xlink:to="tlsa_SecurityDepositsReceivable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_Prepayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherReceivables" xlink:to="tlsa_TaxationReceivable" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:to="ifrs-full_ImpairmentLossOnFinancialAssets" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>tlsa-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:16 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedBalanceSheet" roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedIncomeStatement" roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareholdersEquityType2or3" roleURI="http://tizianalifesciences.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedCashFlow" roleURI="http://tizianalifesciences.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_GeneralInformation" roleURI="http://tizianalifesciences.com/role/GeneralInformation"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPolicies" roleURI="http://tizianalifesciences.com/role/AccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_CriticalAccountingJudgement" roleURI="http://tizianalifesciences.com/role/CriticalAccountingJudgement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherexpenseIncome" roleURI="http://tizianalifesciences.com/role/OtherexpenseIncome"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLoss" roleURI="http://tizianalifesciences.com/role/OperatingLoss"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_SegmentalReporting" roleURI="http://tizianalifesciences.com/role/SegmentalReporting"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Employees" roleURI="http://tizianalifesciences.com/role/Employees"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnel" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinanceCosts" roleURI="http://tizianalifesciences.com/role/FinanceCosts"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Taxation" roleURI="http://tizianalifesciences.com/role/Taxation"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LossPerShare" roleURI="http://tizianalifesciences.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherReceivables" roleURI="http://tizianalifesciences.com/role/OtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremium" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremium"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPayments" roleURI="http://tizianalifesciences.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Reserves" roleURI="http://tizianalifesciences.com/role/Reserves"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialInstruments" roleURI="http://tizianalifesciences.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_CapitalRiskManagement" roleURI="http://tizianalifesciences.com/role/CapitalRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TradeandOtherPayables" roleURI="http://tizianalifesciences.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedParty" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TreasuryShares" roleURI="http://tizianalifesciences.com/role/TreasuryShares"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RelatedPartyTransactions" roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Leases" roleURI="http://tizianalifesciences.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialCommitments" roleURI="http://tizianalifesciences.com/role/FinancialCommitments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ContingentLiabilities" roleURI="http://tizianalifesciences.com/role/ContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesByPolicy" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesTables" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherexpenseIncomeTables" roleURI="http://tizianalifesciences.com/role/OtherexpenseIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLossTables" roleURI="http://tizianalifesciences.com/role/OperatingLossTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_EmployeesTables" roleURI="http://tizianalifesciences.com/role/EmployeesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnelTables" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinanceCostsTables" roleURI="http://tizianalifesciences.com/role/FinanceCostsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TaxationTables" roleURI="http://tizianalifesciences.com/role/TaxationTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LossPerShareTables" roleURI="http://tizianalifesciences.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherReceivablesTables" roleURI="http://tizianalifesciences.com/role/OtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremiumTables" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPaymentsTables" roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialInstrumentsTables" roleURI="http://tizianalifesciences.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TradeandOtherPayablesTables" roleURI="http://tizianalifesciences.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedPartyTables" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LeasesTables" roleURI="http://tizianalifesciences.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOtherExpenseIncomeTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOperatingLossesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEmployeesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEmployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofRemunerationofKeyManagementPersonnelTable" roleURI="http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionswereGrantedtoDirectorsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFinanceCostsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTaxationTable" roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTaxationTable_Parentheticals" roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofBasicLossPerShareTable" roleURI="http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOtherReceivablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareCapitalArisingontheShareforShareExchangeTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionPlanTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionsExpiryDatesandExercisePriceTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" roleURI="http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEquityIncentivePlanTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEstimatedtheFairValueofWarrantsUsingTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable" roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals" roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofInvestmentinRelatedPartyTable" roleURI="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofRightofUseAssetsandLeaseLiabilitiesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofConsolidatedStatementofFinancialTable" roleURI="http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFutureMinimumLeasePaymentsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesDetails" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLossDetails" roleURI="http://tizianalifesciences.com/role/OperatingLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnelDetails" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TaxationDetails" roleURI="http://tizianalifesciences.com/role/TaxationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremiumDetails" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPaymentsDetails" roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedPartyDetails" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TreasurySharesDetails" roleURI="http://tizianalifesciences.com/role/TreasurySharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RelatedPartyTransactionsDetails" roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialCommitmentsDetails" roleURI="http://tizianalifesciences.com/role/FinancialCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#DocumentAndEntityInformation" roleURI="http://tizianalifesciences.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:href="tlsa-20231231.xsd#tlsa_PrepaymentsandOtherReceivablesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="tlsa_PrepaymentsandOtherReceivablesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="tlsa_TaxationReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentsInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentsInRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="tlsa_InvestmentsInRelatedParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IssuedCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_SharePremium" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentReserveWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="tlsa_ShareBasedPaymentReserveWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_OtherReserves" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_TreasuryShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedReserve" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="tlsa_SharesToBeIssuedReserve" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_RetainedEarnings" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_Equity" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_EquityAndLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_IssuanceOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_IssuanceOfShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="tlsa_IssuanceOfShareCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="tlsa_ShareCapitalOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OperatingExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="tlsa_OperatingExpenseAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="ifrs-full_OtherExpenseByFunction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RealisationBonus" xlink:href="tlsa-20231231.xsd#tlsa_RealisationBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="tlsa_RealisationBonus" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RealisationBonus" xlink:to="ifrs-full_OperatingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherIncomeExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="tlsa_OtherIncomeExpenseAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_GainsLossesOnDisposalsOfInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxSCredit" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxSCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="tlsa_IncomeTaxSCredit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentReserveWarrantsMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="tlsa_ShareBasedPaymentReserveWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="tlsa_SharesToBeIssuedReserveMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TranslationReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_TranslationReserveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="tlsa_TranslationReserveMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedcancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedcancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="tlsa_OptionsForfeitedcancelled" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WarrantsExercisedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsExercisedInTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="tlsa_WarrantsExercisedInTheYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WarrantsForfeitedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsForfeitedInTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="tlsa_WarrantsForfeitedInTheYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BuybackOfTreasuryShares" xlink:href="tlsa-20231231.xsd#tlsa_BuybackOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="tlsa_BuybackOfTreasuryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentoptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentoptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="tlsa_ShareBasedPaymentoptions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInLieuOfCashRealizationBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfCashRealizationBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="tlsa_SharesIssuedInLieuOfCashRealizationBonus" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" xlink:href="tlsa-20231231.xsd#tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForInterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_SharesIssuedInLieuOfFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsForSharebasedPaymentsWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_AdjustmentsForSharebasedPaymentsWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedDuringTheYear" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_OptionsForfeitedDuringTheYear" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FVLossOnInvestment" xlink:href="tlsa-20231231.xsd#tlsa_FVLossOnInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_FVLossOnInvestment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossOnDisposalOfAsset" xlink:href="tlsa-20231231.xsd#tlsa_LossOnDisposalOfAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_LossOnDisposalOfAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BonusToBeSettledInEquity" xlink:href="tlsa-20231231.xsd#tlsa_BonusToBeSettledInEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_BonusToBeSettledInEquity" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DepreciationOfRightofuseAsset" xlink:href="tlsa-20231231.xsd#tlsa_DepreciationOfRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_DepreciationOfRightofuseAsset" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CapitalDistribution" xlink:href="tlsa-20231231.xsd#tlsa_CapitalDistribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_CapitalDistribution" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CashInflowFromTaxation" xlink:href="tlsa-20231231.xsd#tlsa_CashInflowFromTaxation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_CashInflowFromTaxation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_InterestReceivedFromLoan" xlink:href="tlsa-20231231.xsd#tlsa_InterestReceivedFromLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="tlsa_InterestReceivedFromLoan" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="tlsa_NetIncreaseInRelatedPartyReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="tlsa_NetIncreaseInRelatedPartyPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromFinanceLease" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromFinanceLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="tlsa_ProceedsFromFinanceLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="tlsa_InvestmentInRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PurchaseOfTreasuryAmount" xlink:href="tlsa-20231231.xsd#tlsa_PurchaseOfTreasuryAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="tlsa_PurchaseOfTreasuryAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FundraisingCost" xlink:href="tlsa-20231231.xsd#tlsa_FundraisingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="tlsa_FundraisingCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromIssuanceOfOptions" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromIssuanceOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="tlsa_ProceedsFromIssuanceOfOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RepaymentOfLeasingLiabilities" xlink:href="tlsa-20231231.xsd#tlsa_RepaymentOfLeasingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="tlsa_RepaymentOfLeasingLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/GeneralInformation">
    <loc xlink:type="locator" xlink:label="tlsa_GeneralInformationLineItems" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_GeneralInformationTable" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_GeneralInformationLineItems" xlink:to="tlsa_GeneralInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GeneralInformationLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPolicies">
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_AccountingPoliciesLineItems" xlink:to="tlsa_AccountingPoliciesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/CriticalAccountingJudgement">
    <loc xlink:type="locator" xlink:label="tlsa_CriticalAccountingJudgementLineItems" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_CriticalAccountingJudgementTable" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_CriticalAccountingJudgementLineItems" xlink:to="tlsa_CriticalAccountingJudgementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_CriticalAccountingJudgementLineItems" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherexpenseIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLoss">
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OperatingLossLineItems" xlink:to="tlsa_OperatingLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossLineItems" xlink:to="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/SegmentalReporting">
    <loc xlink:type="locator" xlink:label="tlsa_SegmentalReportingLineItems" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_SegmentalReportingTable" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_SegmentalReportingLineItems" xlink:to="tlsa_SegmentalReportingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_SegmentalReportingLineItems" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Employees">
    <loc xlink:type="locator" xlink:label="tlsa_EmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_EmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_EmployeesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel">
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinanceCosts">
    <loc xlink:type="locator" xlink:label="tlsa_FinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceCostsAbstract" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Taxation">
    <loc xlink:type="locator" xlink:label="tlsa_TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TaxationAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_LossPerShareLineItems" xlink:to="tlsa_LossPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LossPerShareLineItems" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherReceivables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremium">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Reserves">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/CapitalRiskManagement">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TradeandOtherPayables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedParty">
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedPartyTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentInRelatedPartyAbstract" xlink:to="tlsa_InvestmentInRelatedPartyTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TreasuryShares">
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TreasurySharesAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialCommitments">
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ContingentLiabilities">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForGoingConcern" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForGoingConcern"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForGoingConcern" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForLicenseFees" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForLicenseFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPolicieAbstract" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPolicieAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPolicieAbstract" xlink:to="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherexpenseIncomeTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLossTables">
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OperatingLossTablesLineItems" xlink:to="tlsa_OperatingLossTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossTablesLineItems" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/EmployeesTables">
    <loc xlink:type="locator" xlink:label="tlsa_EmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_EmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_EmployeesAbstract" xlink:to="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables">
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinanceCostsTables">
    <loc xlink:type="locator" xlink:label="tlsa_FinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceCostsAbstract" xlink:to="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TaxationTables">
    <loc xlink:type="locator" xlink:label="tlsa_TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TaxationAbstract" xlink:to="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_LossPerShareTablesLineItems" xlink:to="tlsa_LossPerShareTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LossPerShareTablesLineItems" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OtherReceivablesTablesLineItems" xlink:to="tlsa_OtherReceivablesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherReceivablesTablesLineItems" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TradeandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="tlsa_TradeandOtherPayablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_TradeandOtherPayablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_TradeandOtherPayablesTablesLineItems" xlink:to="tlsa_TradeandOtherPayablesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TradeandOtherPayablesTablesLineItems" xlink:to="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables">
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentInRelatedPartyAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfFutureMinimumLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfFutureMinimumLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="tlsa_DisclosureOfFutureMinimumLeasePayments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable">
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_FixturesAndFittingsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetMember" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="tlsa_RightOfUseAssetMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_EstimatedUsefulLives" xlink:href="tlsa-20231231.xsd#tlsa_EstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="tlsa_EstimatedUsefulLives" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetDescription" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="tlsa_RightOfUseAssetDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable">
    <loc xlink:type="locator" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SublicenseIncome" xlink:href="tlsa-20231231.xsd#tlsa_SublicenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="tlsa_SublicenseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherIncomelosses" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomelosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="tlsa_OtherIncomelosses" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable">
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_Licensefee" xlink:href="tlsa-20231231.xsd#tlsa_Licensefee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="tlsa_Licensefee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="tlsa_OperatingLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="ifrs-full_DepreciationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ForeignExchangegainlosses" xlink:href="tlsa-20231231.xsd#tlsa_ForeignExchangegainlosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="tlsa_ForeignExchangegainlosses" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEmployeesTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_StaffCostsComprisedAbstract" xlink:href="tlsa-20231231.xsd#tlsa_StaffCostsComprisedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEmployeesAbstract" xlink:to="tlsa_StaffCostsComprisedAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="ifrs-full_SocialSecurityContributions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RecruitmentFees" xlink:href="tlsa-20231231.xsd#tlsa_RecruitmentFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="tlsa_RecruitmentFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEmployeesAbstract" xlink:to="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ResearchAndDevelopment" xlink:href="tlsa-20231231.xsd#tlsa_ResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="tlsa_ResearchAndDevelopment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CorporateAndAdministration" xlink:href="tlsa-20231231.xsd#tlsa_CorporateAndAdministration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="tlsa_CorporateAndAdministration" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:href="tlsa-20231231.xsd#tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_GCerroneMember" xlink:href="tlsa-20231231.xsd#tlsa_GCerroneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_GCerroneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WillySimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WillySimonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_WillySimonMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_JBrancaccioMember" xlink:href="tlsa-20231231.xsd#tlsa_JBrancaccioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_JBrancaccioMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_KShailubhaiMember" xlink:href="tlsa-20231231.xsd#tlsa_KShailubhaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_KShailubhaiMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TAdamsMember" xlink:href="tlsa-20231231.xsd#tlsa_TAdamsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_TAdamsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DirectorsFees" xlink:href="tlsa-20231231.xsd#tlsa_DirectorsFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_DirectorsFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_Bonus" xlink:href="tlsa-20231231.xsd#tlsa_Bonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_Bonus" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_Salary" xlink:href="tlsa-20231231.xsd#tlsa_Salary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_Salary" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPayments" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_ShareBasedPayments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable">
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WSimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WSimonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_WSimonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_JBrancaccioMember" xlink:href="tlsa-20231231.xsd#tlsa_JBrancaccioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_JBrancaccioMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TAdamsMember" xlink:href="tlsa-20231231.xsd#tlsa_TAdamsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_TAdamsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsWereGrantedToDirectors" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsWereGrantedToDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:to="tlsa_NumberOfShareOptionsWereGrantedToDirectors" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceIncomeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfFinanceCostsAbstract" xlink:to="tlsa_FinanceIncomeAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceIncomeAbstract" xlink:to="ifrs-full_InterestExpenseOnBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfFinanceCostsAbstract" xlink:to="tlsa_FinanceExpenseAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" xlink:href="tlsa-20231231.xsd#tlsa_FinanceChargeAccruedOnConvertibleLoanNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceExpenseAbstract" xlink:to="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceExpenseAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinanceExpenseAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" order="2" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbKagFEQ9IItGu82rkjT1MKQ=] CSR-->
    <loc xlink:type="locator" xlink:label="tlsa_FinanceExpense" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfFinanceCostsAbstract" xlink:to="tlsa_FinanceExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:href="tlsa-20231231.xsd#tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfFinanceCostsAbstract" xlink:to="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTaxationTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_GroupAbstract0" xlink:href="tlsa-20231231.xsd#tlsa_GroupAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_GroupAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupAbstract0" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsDueToPriorPeriods" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupAbstract0" xlink:to="tlsa_AdjustmentsDueToPriorPeriods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxExpenseContinuingOperation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxExpenseContinuingOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_IncomeTaxExpenseContinuingOperation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherLossBeforeTaxation" xlink:href="tlsa-20231231.xsd#tlsa_OtherLossBeforeTaxation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_OtherLossBeforeTaxation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementInUnrecognisedDeferredTax" xlink:href="tlsa-20231231.xsd#tlsa_MovementInUnrecognisedDeferredTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_MovementInUnrecognisedDeferredTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsDueToPriorPeriod" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_AdjustmentsDueToPriorPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeNotTaxableForTaxPurposes" xlink:href="tlsa-20231231.xsd#tlsa_IncomeNotTaxableForTaxPurposes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_IncomeNotTaxableForTaxPurposes" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FixedAssetDifferences" xlink:href="tlsa-20231231.xsd#tlsa_FixedAssetDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_FixedAssetDifferences" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CurrentTaxOther" xlink:href="tlsa-20231231.xsd#tlsa_CurrentTaxOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_CurrentTaxOther" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsToBroughtForwardValues" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsToBroughtForwardValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_AdjustmentsToBroughtForwardValues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements" xlink:href="tlsa-20231231.xsd#tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable">
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="ifrs-full_WeightedAverageShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BasicLossPerSharecentsPerShare" xlink:href="tlsa-20231231.xsd#tlsa_BasicLossPerSharecentsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="tlsa_BasicLossPerSharecentsPerShare" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable">
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SecurityDepositsReceivable" xlink:href="tlsa-20231231.xsd#tlsa_SecurityDepositsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="tlsa_SecurityDepositsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="ifrs-full_Prepayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="tlsa_TaxationReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="ifrs-full_OtherReceivables" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_NominalValueAnnualReport" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalSharesAnnualReport" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalValueAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_SharePremiumAnnualReport" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveAtJanuary12021Per20FAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_GroupReorganizationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_GroupReorganizationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_GroupReorganizationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueEliminationOfShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_NominalValueEliminationOfShareCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesEliminationOfShare" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesEliminationOfShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_ShareCapitalSharesEliminationOfShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueEliminationOfShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_ShareCapitalValueEliminationOfShareCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEliminationOfShareCapitalIn"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_SharePremiumEliminationOfShareCapitalIn" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEliminationOfShareCapitalIn"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_MergerReserveEliminationOfShareCapitalIn" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_EliminationOfOtherReserves" xlink:href="tlsa-20231231.xsd#tlsa_EliminationOfOtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_EliminationOfOtherReserves" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueRestated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_NominalValueRestated" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesRestated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalSharesRestated" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueRestated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalValueRestated" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumRestatedAt1January2021" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumRestatedAt1January2021"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_SharePremiumRestatedAt1January2021" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveRestated" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveRestated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_MergerReserveRestated" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_NominalValueConversionOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalSharesConversionOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalConversionOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalConversionOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_SharePremiumConversionOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveConversionOfWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_NominalValueConversionOfLoan" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalSharesConversionOfLoan" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueConversionOfLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalValueConversionOfLoan" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_SharePremiumConversionOfLoan" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveConversionOfLoan" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuedInLieuOfCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_NominalValueIssuedInLieuOfCashBonus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuedInCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_ShareCapitalValueIssuedInCashBonus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuedInCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_SharePremiumIssuedInCashBonus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveIssuedInLieuOfCashBonus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveIssuedInLieuOfCashBonus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalShares" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueAt31December2021" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAt31December2021"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ShareCapitalValueAt31December2021" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumEnding" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_SharePremiumEnding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveEnding" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_MergerReserveEnding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedInLieuOfFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_NominalValueSharesIssuedInLieuOfFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedInLieuOfFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedInLieuOfFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_SharePremiumSharesIssuedInLieuOfFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_NominalValueWarrantsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalSharesWarrantsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalValueWarrantsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_SharePremiumWarrantsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuanceOfStockATM"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_NominalValueIssuanceOfStockATM" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuanceOfStockATM"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalSharesIssuanceOfStockATM" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuanceOfStockATM"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_ShareCapitalValueIssuanceOfStockATM" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuanceOfStockATM"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_SharePremiumIssuanceOfStockATM" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_WeightedAverageExercisePriceOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_OptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_OptionsOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceGranted" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_WeightedAverageExercisePriceGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_OptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceForfeitedCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_WeightedAverageExercisePriceForfeitedCancelled" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_OptionsForfeitedCancelled" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceExercised" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_WeightedAverageExercisePriceExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_OptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceExercisable" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_WeightedAverageExercisePriceExercisable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_OptionsExercisable" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable">
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:to="ifrs-full_CreationDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentySixJuneTwoThousandFourteenMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJuneTwoThousandFourteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_TwentySixJuneTwoThousandFourteenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ThirtyAprilTwoThousandAndEighteenMember" xlink:href="tlsa-20231231.xsd#tlsa_ThirtyAprilTwoThousandAndEighteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_ThirtyAprilTwoThousandAndEighteenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SixMayTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_SixMayTwoThousandAndTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_SixMayTwoThousandAndTwentyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyThreeJulyTwoThousandAndTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyFiveAugustTwoThousandAndTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareOptionMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_ShareOptionMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FourteenMarchTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_FourteenMarchTwoThousandTwentyThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_FourteenMarchTwoThousandTwentyThreeMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentySixJulyTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJulyTwoThousandTwentyThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="tlsa_TwentySixJulyTwoThousandTwentyThreeMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExpiryDate" xlink:href="tlsa-20231231.xsd#tlsa_ExpiryDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="tlsa_ExpiryDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExerciseSharePrice" xlink:href="tlsa-20231231.xsd#tlsa_ExerciseSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="tlsa_ExerciseSharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareOptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="tlsa_ShareOptions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable">
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:to="ifrs-full_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_GrantDateSharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_GrantDateSharesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="tlsa_GrantDateSharesPrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionLifeShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionLifeShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="tlsa_OptionLifeShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_NumberOfShareOptionsOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_NumberOfShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsForfeited" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_NumberOfShareOptionsForfeited" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberofOptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NumberofOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_NumberofOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_NumberOfShareOptionsExercisable" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_FairValueOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_FairValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="tlsa_FairValueOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingExercised" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="tlsa_OutstandingExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingExpired" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="tlsa_OutstandingExpired" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable">
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LessThanThreeMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_LessThanThreeMonthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:to="tlsa_LessThanThreeMonthMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ThreeToTwelveMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_ThreeToTwelveMonthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:to="tlsa_ThreeToTwelveMonthMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyPayablesAmount" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyPayablesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="tlsa_RelatedPartyPayablesAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsNet" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="tlsa_FinancialInstrumentsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable">
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_USDMember" xlink:href="tlsa-20231231.xsd#tlsa_USDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="tlsa_USDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProfitOrLossAndEquityStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityStrengthening"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="tlsa_ProfitOrLossAndEquityStrengthening" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProfitOrLossAndEquityWeakening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityWeakening"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="tlsa_ProfitOrLossAndEquityWeakening" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_USDMember" xlink:href="tlsa-20231231.xsd#tlsa_USDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="tlsa_USDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementPercentageStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageStrengthening"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="tlsa_MovementPercentageStrengthening" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementPercentageWeakening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageWeakening"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="tlsa_MovementPercentageWeakening" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable">
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccustemSciencesIncMember" xlink:href="tlsa-20231231.xsd#tlsa_AccustemSciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_AccustemSciencesIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_OKYOPharmaLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_ImpairmentLossOnFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetBeginning" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_RightOfUseAssetBeginning" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetsDepreciation" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_RightOfUseAssetsDepreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisposalOfLease" xlink:href="tlsa-20231231.xsd#tlsa_DisposalOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_DisposalOfLease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExchangeDifferencesRightofUseAssets" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferencesRightofUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_ExchangeDifferencesRightofUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetsTotal" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_RightOfUseAssetsTotal" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesBeginning" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_LeaseLiabilitiesBeginning" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesInterestExpense" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_LeaseLiabilitiesInterestExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_LeaseLiabilitiesLeasePayments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExchangeDifferences" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_ExchangeDifferences" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesTotal" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_LeaseLiabilitiesTotal" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable">
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable">
    <loc xlink:type="locator" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:to="ifrs-full_MaturityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember" xlink:href="tlsa-20231231.xsd#tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="tlsa_LeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceCharges" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="tlsa_FinanceCharges" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetPresentValues" xlink:href="tlsa-20231231.xsd#tlsa_NetPresentValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="tlsa_NetPresentValues" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_AccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccumulatedLoss" xlink:href="tlsa-20231231.xsd#tlsa_AccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_AccumulatedLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CashSurplus" xlink:href="tlsa-20231231.xsd#tlsa_CashSurplus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_CashSurplus" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfSegment" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSegment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_NumberOfSegment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_UpfrontPayment" xlink:href="tlsa-20231231.xsd#tlsa_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_UpfrontPayment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLossDetails">
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="tlsa_OperatingLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="ifrs-full_BenefitsPaidOrPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RaisingFunds" xlink:href="tlsa-20231231.xsd#tlsa_RaisingFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="tlsa_RaisingFunds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails">
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="ifrs-full_OtherLongtermBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TaxationDetails">
    <loc xlink:type="locator" xlink:label="tlsa_TaxationDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_TaxationDetailsLineItems" xlink:to="tlsa_TaxationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MaximumPercentageOfSurrenderableLosses" xlink:href="tlsa-20231231.xsd#tlsa_MaximumPercentageOfSurrenderableLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TaxationDetailsLineItems" xlink:to="tlsa_MaximumPercentageOfSurrenderableLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" xlink:href="tlsa-20231231.xsd#tlsa_TermOfResearchAndDevelopmentTaxReliefClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TaxationDetailsLineItems" xlink:to="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TaxationDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails">
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="tlsa_ShareCapitalandSharePremiumDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfSharesIssued1" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="tlsa_NumberOfSharesIssued1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasuryShares1" xlink:href="tlsa-20231231.xsd#tlsa_TreasuryShares1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="tlsa_TreasuryShares1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BlackScholesMertonValuationModelMember" xlink:href="tlsa-20231231.xsd#tlsa_BlackScholesMertonValuationModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="tlsa_BlackScholesMertonValuationModelMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_TizianaLifeSciencesPLCMember" xlink:href="tlsa-20231231.xsd#tlsa_TizianaLifeSciencesPLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_TizianaLifeSciencesPLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingFairValueCharges" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingFairValueCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="tlsa_OutstandingFairValueCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExpectedTermOfAwards" xlink:href="tlsa-20231231.xsd#tlsa_ExpectedTermOfAwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="tlsa_ExpectedTermOfAwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ChargeOfForfeitures" xlink:href="tlsa-20231231.xsd#tlsa_ChargeOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="tlsa_ChargeOfForfeitures" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails">
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="tlsa_InvestmentinRelatedPartyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_InvestmentinRelatedPartyDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccustemSciencesIncMember" xlink:href="tlsa-20231231.xsd#tlsa_AccustemSciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_AccustemSciencesIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_OKYOPharmaLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_SharesPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="tlsa_SharesPrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AcquiredShares" xlink:href="tlsa-20231231.xsd#tlsa_AcquiredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="tlsa_AcquiredShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TreasurySharesDetails">
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_TreasurySharesDetailsLineItems" xlink:to="tlsa_TreasurySharesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ClassOfWarrantsOrRightAxis" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_TreasurySharesDetailsTable" xlink:to="tlsa_ClassOfWarrantsOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ClassOfWarrantsOrRightDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tlsa_ClassOfWarrantsOrRightAxis" xlink:to="tlsa_ClassOfWarrantsOrRightDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ClassOfWarrantsOrRightDomainDomain_0" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tlsa_ClassOfWarrantsOrRightAxis" xlink:to="tlsa_ClassOfWarrantsOrRightDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_NASDAQStockExchangeMember" xlink:href="tlsa-20231231.xsd#tlsa_NASDAQStockExchangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_ClassOfWarrantsOrRightDomainDomain" xlink:to="tlsa_NASDAQStockExchangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesPurchases" xlink:href="tlsa-20231231.xsd#tlsa_SharesPurchases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TreasurySharesDetailsLineItems" xlink:to="tlsa_SharesPurchases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TreasurySharesDetailsLineItems" xlink:to="ifrs-full_TreasuryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_TreasurySharesDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyTransactionsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_RelatedPartyTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyAxis" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_RelatedPartyTransactionsDetailsTable" xlink:to="tlsa_RelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tlsa_RelatedPartyAxis" xlink:to="tlsa_RelatedPartyDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyDomainDomain_0" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tlsa_RelatedPartyAxis" xlink:to="tlsa_RelatedPartyDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_RasnaTherapeuticsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_RasnaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyDomainDomain" xlink:to="tlsa_RasnaTherapeuticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyDomainDomain" xlink:to="tlsa_OKYOPharmaLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_GensigniaLifesceinecsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_GensigniaLifesceinecsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyDomainDomain" xlink:to="tlsa_GensigniaLifesceinecsIncMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_OKYOPharmaLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_InterestAmount" xlink:href="tlsa-20231231.xsd#tlsa_InterestAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_InterestAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShortTermLoanFacility1" xlink:href="tlsa-20231231.xsd#tlsa_ShortTermLoanFacility1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_ShortTermLoanFacility1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PayrollAndRentCharged" xlink:href="tlsa-20231231.xsd#tlsa_PayrollAndRentCharged"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_PayrollAndRentCharged" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_ServicesAgreementAmount" xlink:href="tlsa-20231231.xsd#tlsa_ServicesAgreementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_ServicesAgreementAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_InitialAmount" xlink:href="tlsa-20231231.xsd#tlsa_InitialAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_InitialAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdditionalPayment" xlink:href="tlsa-20231231.xsd#tlsa_AdditionalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_AdditionalPayment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MilestonePaymentDue" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_MilestonePaymentDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PrincipalAmount" xlink:href="tlsa-20231231.xsd#tlsa_PrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_PrincipalAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_LoansReceived" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_OtherEquityInterest" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_FinancialCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tlsa_FinancialCommitmentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIClinicalTrialMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIClinicalTrialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_PhaseIIClinicalTrialMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_Phase3Member" xlink:href="tlsa-20231231.xsd#tlsa_Phase3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_Phase3Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIHumanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_PhaseIIHumanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CarcinomaMember" xlink:href="tlsa-20231231.xsd#tlsa_CarcinomaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_CarcinomaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_HCCMember" xlink:href="tlsa-20231231.xsd#tlsa_HCCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_HCCMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BreastCancerMember" xlink:href="tlsa-20231231.xsd#tlsa_BreastCancerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_BreastCancerMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIHumanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_PhaseIHumanMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIIHumanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_PhaseIIIHumanMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_BLAMember" xlink:href="tlsa-20231231.xsd#tlsa_BLAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="tlsa_BLAMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_DevelopmentMilestones" xlink:href="tlsa-20231231.xsd#tlsa_DevelopmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_DevelopmentMilestones" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccruedOfDiligenceObligations" xlink:href="tlsa-20231231.xsd#tlsa_AccruedOfDiligenceObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_AccruedOfDiligenceObligations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_MilestonePayments" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_MilestonePayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tlsa_CommercialSaleOfAProduct" xlink:href="tlsa-20231231.xsd#tlsa_CommercialSaleOfAProduct"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_CommercialSaleOfAProduct" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="36" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>tlsa-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:16 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherGainsLosses_lbl" xml:lang="en-US">Total other income/(expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss from operations before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Loss from operations before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss for Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">(Loss) attributable to equity holders of the company ($000)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in)/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalent, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalent, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Other (expense)/ Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_EmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_EmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_EmployeesAbstract_lbl" xml:lang="en-US">Employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EmployeesAbstract" xlink:to="tlsa_EmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Employees, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:href="tlsa-20231231.xsd#tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:to="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceCostsAbstract_lbl" xml:lang="en-US">Finance Costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceCostsAbstract" xlink:to="tlsa_FinanceCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TaxationAbstract_lbl" xml:lang="en-US">Taxation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationAbstract" xlink:to="tlsa_TaxationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract_lbl" xml:lang="en-US">Schedule of Taxation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl" xml:lang="en-US">Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Total Other Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US">Share Capital and Share Premium [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract_lbl" xml:lang="en-US">Schedule of Share Capital Arising on the Share for Share Exchange [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">Share Based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfShareOptionPlanAbstract_lbl" xml:lang="en-US">Schedule of Share Option Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfShareOptionPlanAbstract" xlink:to="tlsa_ScheduleOfShareOptionPlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tlsa_WeightedAverageExercisePriceOutstanding_lbl" xml:lang="en-US">Weighted Average exercise price, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceOutstanding" xlink:to="tlsa_WeightedAverageExercisePriceOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tlsa_WeightedAverageExercisePriceOutstanding_lbl0" xml:lang="en-US">Weighted Average exercise price, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceOutstanding" xlink:to="tlsa_WeightedAverageExercisePriceOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_OptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tlsa_OptionsOutstanding_lbl" xml:lang="en-US">Options, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsOutstanding" xlink:to="tlsa_OptionsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tlsa_OptionsOutstanding_lbl0" xml:lang="en-US">Options, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsOutstanding" xlink:to="tlsa_OptionsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract_lbl" xml:lang="en-US">Schedule of Share Options Expiry Dates and Exercise Price [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract" xlink:to="tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract_lbl" xml:lang="en-US">Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract" xlink:to="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEquityIncentivePlanAbstract_lbl" xml:lang="en-US">Schedule of Equity Incentive Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEquityIncentivePlanAbstract" xlink:to="tlsa_ScheduleOfEquityIncentivePlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average exercise price (cents), Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted Average exercise price (cents), Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tlsa_NumberOfShareOptionsOutstanding_lbl" xml:lang="en-US">Options, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsOutstanding" xlink:to="tlsa_NumberOfShareOptionsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tlsa_NumberOfShareOptionsOutstanding_lbl0" xml:lang="en-US">Options, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsOutstanding" xlink:to="tlsa_NumberOfShareOptionsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract_lbl" xml:lang="en-US">Schedule of Estimated the Fair Value of Warrants Using [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FairValueOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_FairValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tlsa_FairValueOutstanding_lbl" xml:lang="en-US">Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FairValueOutstanding" xlink:to="tlsa_FairValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FairValueOutstanding_lbl0" xml:lang="en-US">Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FairValueOutstanding" xlink:to="tlsa_FairValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract_lbl" xml:lang="en-US">Reserves [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract_lbl" xml:lang="en-US">Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract" xlink:to="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_lbl" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract_lbl" xml:lang="en-US">Capital Risk Management [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:to="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="tlsa_ScheduleOfTradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentInRelatedPartyAbstract_lbl" xml:lang="en-US">Investment in Related Party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedPartyAbstract" xlink:to="tlsa_InvestmentInRelatedPartyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfInvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfInvestmentInRelatedPartyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfInvestmentInRelatedPartyAbstract_lbl" xml:lang="en-US">Schedule of Investment in Related Party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfInvestmentInRelatedPartyAbstract" xlink:to="tlsa_ScheduleOfInvestmentInRelatedPartyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TreasurySharesAbstract_lbl" xml:lang="en-US">Treasury Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TreasurySharesAbstract" xlink:to="tlsa_TreasurySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets and Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Statement Of Financial [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments [Abstarct]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct" xlink:to="tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialCommitmentsAbstract_lbl" xml:lang="en-US">Financial Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialCommitmentsAbstract" xlink:to="tlsa_FinancialCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract_lbl" xml:lang="en-US">Contingent Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:href="tlsa-20231231.xsd#tlsa_PrepaymentsandOtherReceivablesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl" xml:lang="en-US">Prepayments and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:to="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TaxationReceivable_lbl" xml:lang="en-US">Taxation receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationReceivable" xlink:to="tlsa_TaxationReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsa_TaxationReceivable_lbl0" xml:lang="en-US">Taxation Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationReceivable" xlink:to="tlsa_TaxationReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl" xml:lang="en-US">Related party receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non &#8211; Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentsInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentsInRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_InvestmentsInRelatedParty_lbl" xml:lang="en-US">Investment in related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentsInRelatedParty" xlink:to="tlsa_InvestmentsInRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract" xlink:to="tlsa_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract0" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract0" xlink:to="tlsa_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract1" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract1" xlink:to="tlsa_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract2" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract2" xlink:to="tlsa_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease Liability (Non-Current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract3" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract3" xlink:to="tlsa_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Called up share capital (103,087,744 shares are issued and outstanding; 2022: 102,272,614)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IssuanceOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_IssuanceOfShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IssuanceOfShareCapital_lbl" xml:lang="en-US">Share capital, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IssuanceOfShareCapital" xlink:to="tlsa_IssuanceOfShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalOutstanding_lbl" xml:lang="en-US">Share capital, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalOutstanding" xlink:to="tlsa_ShareCapitalOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Share based payment reserve &#8211; Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentReserveWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareBasedPaymentReserveWarrants_lbl" xml:lang="en-US">Share based payment reserve &#8211; warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentReserveWarrants" xlink:to="tlsa_ShareBasedPaymentReserveWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Merger relief reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedReserve" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesToBeIssuedReserve_lbl" xml:lang="en-US">Shares to be issued reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedReserve" xlink:to="tlsa_SharesToBeIssuedReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OperatingExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OperatingExpenseAbstract_lbl" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="tlsa_OperatingExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract4" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract4" xlink:to="tlsa_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract5" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract5" xlink:to="tlsa_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherIncomeExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income/(expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="tlsa_OtherIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Finance (expense)/ income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments_lbl" xml:lang="en-US">FV Loss on Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:to="ifrs-full_GainsLossesOnDisposalsOfInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US">Other income/(losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract6" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract6" xlink:to="tlsa_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract7" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract7" xlink:to="tlsa_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract8" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract8" xlink:to="tlsa_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract9" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract9" xlink:to="tlsa_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other Comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Gain/(Loss) on currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract10" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract10" xlink:to="tlsa_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract11" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract11" xlink:to="tlsa_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per share attributable to common shareholders (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per share attributable to common shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Issue of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentoptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentoptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareBasedPaymentoptions_lbl" xml:lang="en-US">Share based payment charge (options)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentoptions" xlink:to="tlsa_ShareBasedPaymentoptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInLieuOfCashRealizationBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfCashRealizationBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl" xml:lang="en-US">Shares issued in lieu of cash realization bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfCashRealizationBonus" xlink:to="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xml:lang="en-US">Total transactions with owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" xlink:href="tlsa-20231231.xsd#tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1_lbl" xml:lang="en-US">Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" xlink:to="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedcancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedcancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OptionsForfeitedcancelled_lbl" xml:lang="en-US">Options forfeited/cancelled in the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedcancelled" xlink:to="tlsa_OptionsForfeitedcancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US">Reclass of FV for options forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract12" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract12" xlink:to="tlsa_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issuance of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Related party cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_WarrantsExercisedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsExercisedInTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WarrantsExercisedInTheYear_lbl" xml:lang="en-US">Warrants Exercised in the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsExercisedInTheYear" xlink:to="tlsa_WarrantsExercisedInTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WarrantsForfeitedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsForfeitedInTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WarrantsForfeitedInTheYear_lbl" xml:lang="en-US">Warrants Forfeited in the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsForfeitedInTheYear" xlink:to="tlsa_WarrantsForfeitedInTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BuybackOfTreasuryShares" xlink:href="tlsa-20231231.xsd#tlsa_BuybackOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BuybackOfTreasuryShares_lbl" xml:lang="en-US">Buyback of Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BuybackOfTreasuryShares" xlink:to="tlsa_BuybackOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl" xml:lang="en-US">Shares to be issued in lieu of directors fees and cash bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:to="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForInterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForInterestExpense_lbl" xml:lang="en-US">Convertible loan interest accrued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForInterestExpense" xlink:to="ifrs-full_AdjustmentsForInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesIssuedInLieuOfFees_lbl" xml:lang="en-US">Shares issued in lieu of directors fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfFees" xlink:to="tlsa_SharesIssuedInLieuOfFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsForSharebasedPaymentsWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl" xml:lang="en-US">Share based payment &#8211; options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:to="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FVLossOnInvestment" xlink:href="tlsa-20231231.xsd#tlsa_FVLossOnInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FVLossOnInvestment_lbl" xml:lang="en-US">Fair value loss on investment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FVLossOnInvestment" xlink:to="tlsa_FVLossOnInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossOnDisposalOfAsset" xlink:href="tlsa-20231231.xsd#tlsa_LossOnDisposalOfAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LossOnDisposalOfAsset_lbl" xml:lang="en-US">Loss on disposal of asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossOnDisposalOfAsset" xlink:to="tlsa_LossOnDisposalOfAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BonusToBeSettledInEquity" xlink:href="tlsa-20231231.xsd#tlsa_BonusToBeSettledInEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BonusToBeSettledInEquity_lbl" xml:lang="en-US">Bonus to be settled in equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BonusToBeSettledInEquity" xlink:to="tlsa_BonusToBeSettledInEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DepreciationOfRightofuseAsset" xlink:href="tlsa-20231231.xsd#tlsa_DepreciationOfRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DepreciationOfRightofuseAsset_lbl" xml:lang="en-US">Depreciation of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DepreciationOfRightofuseAsset" xlink:to="tlsa_DepreciationOfRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl" xml:lang="en-US">Proceeds from finance lease reclassified as an investing activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:to="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CashInflowFromTaxation" xlink:href="tlsa-20231231.xsd#tlsa_CashInflowFromTaxation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CashInflowFromTaxation_lbl" xml:lang="en-US">Cash inflow from taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashInflowFromTaxation" xlink:to="tlsa_CashInflowFromTaxation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US">Net (increase)/decrease in operating assets/other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Net increase/(decrease) in operating liabilities /other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract13" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract13" xlink:to="tlsa_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromFinanceLease" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromFinanceLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ProceedsFromFinanceLease_lbl" xml:lang="en-US">Proceeds from finance lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromFinanceLease" xlink:to="tlsa_ProceedsFromFinanceLease_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract14" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract14" xlink:to="tlsa_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FundraisingCost" xlink:href="tlsa-20231231.xsd#tlsa_FundraisingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FundraisingCost_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FundraisingCost" xlink:to="tlsa_FundraisingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProceedsFromIssuanceOfOptions" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromIssuanceOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ProceedsFromIssuanceOfOptions_lbl" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromIssuanceOfOptions" xlink:to="tlsa_ProceedsFromIssuanceOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RepaymentOfLeasingLiabilities" xlink:href="tlsa-20231231.xsd#tlsa_RepaymentOfLeasingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RepaymentOfLeasingLiabilities_lbl" xml:lang="en-US">Repayment of leasing liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RepaymentOfLeasingLiabilities" xlink:to="tlsa_RepaymentOfLeasingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract15" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract15" xlink:to="tlsa_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract16" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract16" xlink:to="tlsa_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Exchange difference on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US">Treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasuryShares_lbl0" xml:lang="en-US">Total shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherExpenseByFunction_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByFunction" xlink:to="ifrs-full_OtherExpenseByFunction_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RealisationBonus" xlink:href="tlsa-20231231.xsd#tlsa_RealisationBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_RealisationBonus_lbl" xml:lang="en-US">Realization bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RealisationBonus" xlink:to="tlsa_RealisationBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxSCredit" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxSCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_IncomeTaxSCredit_lbl" xml:lang="en-US">Income tax (expense)/credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxSCredit" xlink:to="tlsa_IncomeTaxSCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US">Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedDuringTheYear" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_OptionsForfeitedDuringTheYear_lbl" xml:lang="en-US">Options forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedDuringTheYear" xlink:to="tlsa_OptionsForfeitedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">(Gain)/ loss on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CapitalDistribution" xlink:href="tlsa-20231231.xsd#tlsa_CapitalDistribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_CapitalDistribution_lbl" xml:lang="en-US">(Gain)/loss on disposal of right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CapitalDistribution" xlink:to="tlsa_CapitalDistribution_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InterestReceivedFromLoan" xlink:href="tlsa-20231231.xsd#tlsa_InterestReceivedFromLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_InterestReceivedFromLoan_lbl" xml:lang="en-US">Interest on related party loan conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="tlsa_InterestReceivedFromLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables_lbl" xml:lang="en-US">Net (increase) in related party receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:to="tlsa_NetIncreaseInRelatedPartyReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables_lbl" xml:lang="en-US">Net (decrease)/increase in related party payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyPayables" xlink:to="tlsa_NetIncreaseInRelatedPartyPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of PPE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_InvestmentInRelatedParty_lbl" xml:lang="en-US">Investment in Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedParty" xlink:to="tlsa_InvestmentInRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PurchaseOfTreasuryAmount" xlink:href="tlsa-20231231.xsd#tlsa_PurchaseOfTreasuryAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_PurchaseOfTreasuryAmount_lbl" xml:lang="en-US">Purchase of Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PurchaseOfTreasuryAmount" xlink:to="tlsa_PurchaseOfTreasuryAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Share Based Payment Reserve (Options)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentReserveWarrantsMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareBasedPaymentReserveWarrantsMember_lbl" xml:lang="en-US">Share Based Payment Reserve (warrants)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentReserveWarrantsMember" xlink:to="tlsa_ShareBasedPaymentReserveWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Merger Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US">Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesToBeIssuedReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesToBeIssuedReserveMember_lbl" xml:lang="en-US">Shares to be issued Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedReserveMember" xlink:to="tlsa_SharesToBeIssuedReserveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TranslationReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_TranslationReserveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TranslationReserveMember_lbl" xml:lang="en-US">Translation Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TranslationReserveMember" xlink:to="tlsa_TranslationReserveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">GENERAL INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives for the Current Period and the Comparative Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:to="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_EstimatedUsefulLives" xlink:href="tlsa-20231231.xsd#tlsa_EstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_EstimatedUsefulLives_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EstimatedUsefulLives" xlink:to="tlsa_EstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetDescription" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RightOfUseAssetDescription_lbl" xml:lang="en-US">Right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetDescription" xlink:to="tlsa_RightOfUseAssetDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl" xml:lang="en-US">CRITICAL ACCOUNTING JUDGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US">OTHER (EXPENSE)/ INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl" xml:lang="en-US">Schedule of Other (Expense)/ Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SublicenseIncome" xlink:href="tlsa-20231231.xsd#tlsa_SublicenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SublicenseIncome_lbl" xml:lang="en-US">Sublicense income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SublicenseIncome" xlink:to="tlsa_SublicenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments_lbl" xml:lang="en-US">Other Income (see note 19)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherIncomelosses" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomelosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OtherIncomelosses_lbl" xml:lang="en-US">Total other income/(expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherIncomelosses" xlink:to="tlsa_OtherIncomelosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl" xml:lang="en-US">Schedule of Operating Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_Licensefee" xlink:href="tlsa-20231231.xsd#tlsa_Licensefee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_Licensefee_lbl" xml:lang="en-US">License fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Licensefee" xlink:to="tlsa_Licensefee_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OperatingLoss_lbl" xml:lang="en-US">Realization bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLoss" xlink:to="tlsa_OperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation of Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US">Depreciation (Right-of-use asset)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ForeignExchangegainlosses" xlink:href="tlsa-20231231.xsd#tlsa_ForeignExchangegainlosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ForeignExchangegainlosses_lbl" xml:lang="en-US">Foreign exchange (gains)/losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ForeignExchangegainlosses" xlink:to="tlsa_ForeignExchangegainlosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">SEGMENTAL REPORTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_lbl" xml:lang="en-US">EMPLOYEES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl" xml:lang="en-US">Schedule of Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:to="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_StaffCostsComprisedAbstract" xlink:href="tlsa-20231231.xsd#tlsa_StaffCostsComprisedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_StaffCostsComprisedAbstract_lbl" xml:lang="en-US">Staff costs comprised:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="tlsa_StaffCostsComprisedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US">Directors&#8217; salaries (including bonus)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Employees&#8217; wages, salaries and bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US">Social security costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RecruitmentFees" xlink:href="tlsa-20231231.xsd#tlsa_RecruitmentFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RecruitmentFees_lbl" xml:lang="en-US">Recruitment fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RecruitmentFees" xlink:to="tlsa_RecruitmentFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US">Share based payment (credit) / charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_lbl" xml:lang="en-US">The average monthly number of employees, including directors, employed by the group during the year was:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ResearchAndDevelopment" xlink:href="tlsa-20231231.xsd#tlsa_ResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ResearchAndDevelopment" xlink:to="tlsa_ResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CorporateAndAdministration" xlink:href="tlsa-20231231.xsd#tlsa_CorporateAndAdministration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CorporateAndAdministration_lbl" xml:lang="en-US">Corporate and administration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CorporateAndAdministration" xlink:to="tlsa_CorporateAndAdministration_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">REMUNERATION OF KEY MANAGEMENT PERSONNEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl" xml:lang="en-US">Schedule of Remuneration of Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:to="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DirectorsFees" xlink:href="tlsa-20231231.xsd#tlsa_DirectorsFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DirectorsFees_lbl" xml:lang="en-US">Directors&#8217; fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DirectorsFees" xlink:to="tlsa_DirectorsFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_Bonus" xlink:href="tlsa-20231231.xsd#tlsa_Bonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_Bonus_lbl" xml:lang="en-US">Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Bonus" xlink:to="tlsa_Bonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_Salary" xlink:href="tlsa-20231231.xsd#tlsa_Salary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_Salary_lbl" xml:lang="en-US">Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Salary" xlink:to="tlsa_Salary_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPayments" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareBasedPayments_lbl" xml:lang="en-US">Share based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPayments" xlink:to="tlsa_ShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl" xml:lang="en-US">Schedule of Share Options were Granted to Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:to="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsWereGrantedToDirectors" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsWereGrantedToDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl" xml:lang="en-US">Number of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsWereGrantedToDirectors" xlink:to="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xml:lang="en-US">FINANCE COSTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:to="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GroupAbstract" xlink:href="tlsa-20231231.xsd#tlsa_GroupAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GroupAbstract_lbl" xml:lang="en-US">Group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupAbstract" xlink:to="tlsa_GroupAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceIncomeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceIncomeAbstract" xlink:to="tlsa_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnBorrowings_lbl" xml:lang="en-US">Loan Interest Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBorrowings" xlink:to="ifrs-full_InterestExpenseOnBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Total finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract17" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract17" xlink:to="tlsa_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinanceExpenseAbstract_lbl" xml:lang="en-US">Finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceExpenseAbstract" xlink:to="tlsa_FinanceExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" xlink:href="tlsa-20231231.xsd#tlsa_FinanceChargeAccruedOnConvertibleLoanNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl" xml:lang="en-US">Finance charge accrued on convertible loan notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" xlink:to="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Fair Value loss on Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceExpense" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinanceExpense_lbl" xml:lang="en-US">Total finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceExpense" xlink:to="tlsa_FinanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:href="tlsa-20231231.xsd#tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl" xml:lang="en-US">Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:to="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GroupAbstract0" xlink:href="tlsa-20231231.xsd#tlsa_GroupAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GroupAbstract0_lbl" xml:lang="en-US">Group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupAbstract0" xlink:to="tlsa_GroupAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Current year tax (credit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsDueToPriorPeriods" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AdjustmentsDueToPriorPeriods_lbl" xml:lang="en-US">Adjustments due to prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriods" xlink:to="tlsa_AdjustmentsDueToPriorPeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxExpenseContinuingOperation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxExpenseContinuingOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IncomeTaxExpenseContinuingOperation_lbl" xml:lang="en-US">Total tax (credit) for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxExpenseContinuingOperation" xlink:to="tlsa_IncomeTaxExpenseContinuingOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract18" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract18" xlink:to="tlsa_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract_lbl" xml:lang="en-US">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract" xlink:to="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherLossBeforeTaxation" xlink:href="tlsa-20231231.xsd#tlsa_OtherLossBeforeTaxation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OtherLossBeforeTaxation_lbl" xml:lang="en-US">Loss before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherLossBeforeTaxation" xlink:to="tlsa_OtherLossBeforeTaxation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl" xml:lang="en-US">Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:to="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses_lbl" xml:lang="en-US">Standard rate of corporation tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfTaxLosses" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementInUnrecognisedDeferredTax" xlink:href="tlsa-20231231.xsd#tlsa_MovementInUnrecognisedDeferredTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MovementInUnrecognisedDeferredTax_lbl" xml:lang="en-US">Movement in unrecognized deferred tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementInUnrecognisedDeferredTax" xlink:to="tlsa_MovementInUnrecognisedDeferredTax_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl" xml:lang="en-US">Expenses not deductible for taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:to="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsDueToPriorPeriod" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AdjustmentsDueToPriorPeriod_lbl" xml:lang="en-US">Adjustments due to prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriod" xlink:to="tlsa_AdjustmentsDueToPriorPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl" xml:lang="en-US">Research and development claim</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:to="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_IncomeNotTaxableForTaxPurposes" xlink:href="tlsa-20231231.xsd#tlsa_IncomeNotTaxableForTaxPurposes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_IncomeNotTaxableForTaxPurposes_lbl" xml:lang="en-US">Income not taxable for tax purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeNotTaxableForTaxPurposes" xlink:to="tlsa_IncomeNotTaxableForTaxPurposes_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FixedAssetDifferences" xlink:href="tlsa-20231231.xsd#tlsa_FixedAssetDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FixedAssetDifferences_lbl" xml:lang="en-US">Fixed asset differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FixedAssetDifferences" xlink:to="tlsa_FixedAssetDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CurrentTaxOther" xlink:href="tlsa-20231231.xsd#tlsa_CurrentTaxOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CurrentTaxOther_lbl" xml:lang="en-US">Current Tax - Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CurrentTaxOther" xlink:to="tlsa_CurrentTaxOther_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdjustmentsToBroughtForwardValues" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsToBroughtForwardValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AdjustmentsToBroughtForwardValues_lbl" xml:lang="en-US">Adjustments to brought forward values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsToBroughtForwardValues" xlink:to="tlsa_AdjustmentsToBroughtForwardValues_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements" xlink:href="tlsa-20231231.xsd#tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements_lbl" xml:lang="en-US">Consolidation adjustment in relation to foreign exchange movements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements" xlink:to="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of ordinary shares in issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BasicLossPerSharecentsPerShare" xlink:href="tlsa-20231231.xsd#tlsa_BasicLossPerSharecentsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BasicLossPerSharecentsPerShare_lbl" xml:lang="en-US">Basic loss per share (cents per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BasicLossPerSharecentsPerShare" xlink:to="tlsa_BasicLossPerSharecentsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER RECEIVABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SecurityDepositsReceivable" xlink:href="tlsa-20231231.xsd#tlsa_SecurityDepositsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SecurityDepositsReceivable_lbl" xml:lang="en-US">Security deposits receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SecurityDepositsReceivable" xlink:to="tlsa_SecurityDepositsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl" xml:lang="en-US">SHARE CAPITAL AND SHARE PREMIUM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:to="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl" xml:lang="en-US">Schedule of Share Capital Arising on the Share for Share Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:to="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueAnnualReport_lbl" xml:lang="en-US">Nominal Value At January 1 2021 per 20-F annual report (in Pounds per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueAnnualReport" xlink:to="tlsa_NominalValueAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesAnnualReport_lbl" xml:lang="en-US">Share Capital Shares At January 1 2021 per 20-F annual report (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesAnnualReport" xlink:to="tlsa_ShareCapitalSharesAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueAnnualReport_lbl" xml:lang="en-US">Share Capital value At January 1 2021 per 20-F annual report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAnnualReport" xlink:to="tlsa_ShareCapitalValueAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumAnnualReport_lbl" xml:lang="en-US">Share Premium At January 1 2021 per 20-F annual report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumAnnualReport" xlink:to="tlsa_SharePremiumAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveAtJanuary12021Per20FAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl" xml:lang="en-US">Merger Reserve At January 1 2021 per 20-F annual report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" xlink:to="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GroupReorganizationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_GroupReorganizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GroupReorganizationAbstract_lbl" xml:lang="en-US">Group Reorganization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_GroupReorganizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueEliminationOfShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueEliminationOfShareCapital_lbl" xml:lang="en-US">Nominal Value Elimination of share capital in Tiziana Life Sciences Plc (in Pounds per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueEliminationOfShareCapital" xlink:to="tlsa_NominalValueEliminationOfShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesEliminationOfShare" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesEliminationOfShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesEliminationOfShare_lbl" xml:lang="en-US">Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesEliminationOfShare" xlink:to="tlsa_ShareCapitalSharesEliminationOfShare_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueEliminationOfShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl" xml:lang="en-US">Share Capital value Elimination of share capital in Tiziana Life Sciences Plc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueEliminationOfShareCapital" xlink:to="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEliminationOfShareCapitalIn"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl" xml:lang="en-US">Share Premium Elimination of share capital in Tiziana Life Sciences Plc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumEliminationOfShareCapitalIn" xlink:to="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEliminationOfShareCapitalIn"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl" xml:lang="en-US">Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveEliminationOfShareCapitalIn" xlink:to="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl" xml:lang="en-US">Nominal Value Shares issued pursuant to share for share exchange and consolidation (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl" xml:lang="en-US">Share Capital Shares Shares issued pursuant to share for share exchange and consolidation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl" xml:lang="en-US">Share Capital value Shares issued pursuant to share for share exchange and consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl" xml:lang="en-US">Share Premium Shares issued pursuant to share for share exchange and consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl" xml:lang="en-US">Merger Reserve Shares issued pursuant to share for share exchange and consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_EliminationOfOtherReserves" xlink:href="tlsa-20231231.xsd#tlsa_EliminationOfOtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_EliminationOfOtherReserves_lbl" xml:lang="en-US">Elimination of other reserves in Tiziana Life Sciences Plc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EliminationOfOtherReserves" xlink:to="tlsa_EliminationOfOtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueRestated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueRestated_lbl" xml:lang="en-US">Nominal Value Restated at 1 January 2021 (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueRestated" xlink:to="tlsa_NominalValueRestated_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesRestated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesRestated_lbl" xml:lang="en-US">Share Capital Shares Restated at 1 January 2021 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesRestated" xlink:to="tlsa_ShareCapitalSharesRestated_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueRestated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueRestated_lbl" xml:lang="en-US">Share Capital value Restated at 1 January 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueRestated" xlink:to="tlsa_ShareCapitalValueRestated_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumRestatedAt1January2021" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumRestatedAt1January2021"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumRestatedAt1January2021_lbl" xml:lang="en-US">Share Premium Restated at 1 January 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumRestatedAt1January2021" xlink:to="tlsa_SharePremiumRestatedAt1January2021_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveRestated" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveRestated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveRestated_lbl" xml:lang="en-US">Merger Reserve Restated at 1 January 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveRestated_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInThePeriodAbstract" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesIssuedInThePeriodAbstract_lbl" xml:lang="en-US">Shares issued in the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInThePeriodAbstract" xlink:to="tlsa_SharesIssuedInThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueConversionOfWarrants_lbl" xml:lang="en-US">Nominal Value Conversion of warrants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfWarrants" xlink:to="tlsa_NominalValueConversionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesConversionOfWarrants_lbl" xml:lang="en-US">Share Capital Shares Conversion of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfWarrants" xlink:to="tlsa_ShareCapitalSharesConversionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalConversionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalConversionOfWarrants_lbl" xml:lang="en-US">Share Capital Conversion of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalConversionOfWarrants" xlink:to="tlsa_ShareCapitalConversionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumConversionOfWarrants_lbl" xml:lang="en-US">Share Premium Conversion of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfWarrants" xlink:to="tlsa_SharePremiumConversionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveConversionOfWarrants_lbl" xml:lang="en-US">Merger Reserve Conversion of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfWarrants" xlink:to="tlsa_MergerReserveConversionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueConversionOfLoan_lbl" xml:lang="en-US">Nominal Value Conversion of Loan (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfLoan" xlink:to="tlsa_NominalValueConversionOfLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesConversionOfLoan_lbl" xml:lang="en-US">Share Capital Shares Conversion of Loan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfLoan" xlink:to="tlsa_ShareCapitalSharesConversionOfLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueConversionOfLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueConversionOfLoan_lbl" xml:lang="en-US">Share Capital value Conversion of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueConversionOfLoan" xlink:to="tlsa_ShareCapitalValueConversionOfLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumConversionOfLoan_lbl" xml:lang="en-US">Share Premium Conversion of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfLoan" xlink:to="tlsa_SharePremiumConversionOfLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveConversionOfLoan_lbl" xml:lang="en-US">Merger Reserve Conversion of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfLoan" xlink:to="tlsa_MergerReserveConversionOfLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuedInLieuOfCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl" xml:lang="en-US">Nominal Value Issued in lieu of cash bonus (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuedInLieuOfCashBonus" xlink:to="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl" xml:lang="en-US">Share Capital Shares Issued in lieu of cash bonus (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuedInCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueIssuedInCashBonus_lbl" xml:lang="en-US">Share Capital value Issued in lieu of cash bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuedInCashBonus" xlink:to="tlsa_ShareCapitalValueIssuedInCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuedInCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumIssuedInCashBonus_lbl" xml:lang="en-US">Share Premium Issued in lieu of cash bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuedInCashBonus" xlink:to="tlsa_SharePremiumIssuedInCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveIssuedInLieuOfCashBonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl" xml:lang="en-US">Merger Reserve Issued in lieu of cash bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveIssuedInLieuOfCashBonus" xlink:to="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalShares" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalShares_lbl" xml:lang="en-US">Share Capital Shares At 31 December 2021 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalShares" xlink:to="tlsa_ShareCapitalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueAt31December2021" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAt31December2021"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueAt31December2021_lbl" xml:lang="en-US">Share Capital value At 31 December 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAt31December2021" xlink:to="tlsa_ShareCapitalValueAt31December2021_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumEnding" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumEnding_lbl" xml:lang="en-US">Share Premium At 31 December 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumEnding" xlink:to="tlsa_SharePremiumEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MergerReserveEnding" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MergerReserveEnding_lbl" xml:lang="en-US">Merger Reserve At 31 December 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_MergerReserveEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesIssuedInThePeriodAbstract0" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInThePeriodAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesIssuedInThePeriodAbstract0_lbl" xml:lang="en-US">Shares issued in the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInThePeriodAbstract0" xlink:to="tlsa_SharesIssuedInThePeriodAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedInLieuOfFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl" xml:lang="en-US">Nominal Value Shares issued in lieu of fees (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl" xml:lang="en-US">Share Capital Shares Shares issued in lieu of fees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedInLieuOfFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl" xml:lang="en-US">Share Capital value Shares issued in lieu of fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedInLieuOfFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl" xml:lang="en-US">Share Premium Shares issued in lieu of fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedInLieuOfFees" xlink:to="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueWarrantsExercised_lbl" xml:lang="en-US">Nominal Value Warrants Exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueWarrantsExercised" xlink:to="tlsa_NominalValueWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesWarrantsExercised_lbl" xml:lang="en-US">Share Capital Shares Warrants Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesWarrantsExercised" xlink:to="tlsa_ShareCapitalSharesWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueWarrantsExercised_lbl" xml:lang="en-US">Share Capital value Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueWarrantsExercised" xlink:to="tlsa_ShareCapitalValueWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumWarrantsExercised_lbl" xml:lang="en-US">Share Premium Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumWarrantsExercised" xlink:to="tlsa_SharePremiumWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NominalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuanceOfStockATM"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NominalValueIssuanceOfStockATM_lbl" xml:lang="en-US">Nominal Value Issuance of Stock - ATM (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuanceOfStockATM" xlink:to="tlsa_NominalValueIssuanceOfStockATM_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalSharesIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuanceOfStockATM"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl" xml:lang="en-US">Share Capital Shares Issuance of Stock - ATM (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuanceOfStockATM"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl" xml:lang="en-US">Share Capital value Issuance of Stock - ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharePremiumIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuanceOfStockATM"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharePremiumIssuanceOfStockATM_lbl" xml:lang="en-US">Share Premium Issuance of Stock - ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuanceOfStockATM" xlink:to="tlsa_SharePremiumIssuanceOfStockATM_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE BASED PAYMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Share Option Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceGranted" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted Average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceGranted" xlink:to="tlsa_WeightedAverageExercisePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OptionsGranted_lbl" xml:lang="en-US">Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsGranted" xlink:to="tlsa_OptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceForfeitedCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WeightedAverageExercisePriceForfeitedCancelled_lbl" xml:lang="en-US">Weighted Average exercise price, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceForfeitedCancelled" xlink:to="tlsa_WeightedAverageExercisePriceForfeitedCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract19" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract19" xlink:to="tlsa_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract20" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract20" xlink:to="tlsa_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceExercisable" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted Average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceExercisable" xlink:to="tlsa_WeightedAverageExercisePriceExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OptionsExercisable_lbl" xml:lang="en-US">Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsExercisable" xlink:to="tlsa_OptionsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Options Expiry Dates and Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" xlink:to="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExpiryDate" xlink:href="tlsa-20231231.xsd#tlsa_ExpiryDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ExpiryDate_lbl" xml:lang="en-US">Expiry Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExpiryDate" xlink:to="tlsa_ExpiryDate_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExerciseSharePrice" xlink:href="tlsa-20231231.xsd#tlsa_ExerciseSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ExerciseSharePrice_lbl" xml:lang="en-US">Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExerciseSharePrice" xlink:to="tlsa_ExerciseSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareOptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareOptions_lbl" xml:lang="en-US">ShareOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareOptions" xlink:to="tlsa_ShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock_lbl" xml:lang="en-US">Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" xlink:to="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GrantDateSharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_GrantDateSharesPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GrantDateSharesPrice_lbl" xml:lang="en-US">Grant date share price (in Dollars per share and Pounds per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GrantDateSharesPrice" xlink:to="tlsa_GrantDateSharesPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise share price (in Dollars per share and Pounds per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionLifeShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionLifeShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Option life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionLifeShareOptionsGranted" xlink:to="tlsa_OptionLifeShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US">Weighted average share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Weighted average fair value per share option (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock" xlink:to="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average exercise price (cents), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberOfShareOptionsGranted_lbl" xml:lang="en-US">Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsGranted" xlink:to="tlsa_NumberOfShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average exercise price (cents), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberofOptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NumberofOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberofOptionsExercised_lbl" xml:lang="en-US">Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberofOptionsExercised" xlink:to="tlsa_NumberofOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract21" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract21" xlink:to="tlsa_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract22" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract22" xlink:to="tlsa_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average exercise price (cents), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberOfShareOptionsExercisable_lbl" xml:lang="en-US">Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsExercisable" xlink:to="tlsa_NumberOfShareOptionsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated the Fair Value of Warrants Using</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:to="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract23" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract23" xlink:to="tlsa_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingExercised" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OutstandingExercised_lbl" xml:lang="en-US">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExercised" xlink:to="tlsa_OutstandingExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingExpired" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OutstandingExpired_lbl" xml:lang="en-US">Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExpired" xlink:to="tlsa_OutstandingExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UnlabeledAbstract24" xlink:href="tlsa-20231231.xsd#tlsa_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract24" xlink:to="tlsa_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">RESERVES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liabilities Based on Contractual Undiscounted Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" xlink:to="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyPayablesAmount" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyPayablesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RelatedPartyPayablesAmount_lbl" xml:lang="en-US">Related party payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyPayablesAmount" xlink:to="tlsa_RelatedPartyPayablesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsNet" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinancialInstrumentsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsNet" xlink:to="tlsa_FinancialInstrumentsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of All Other Variables Remain Constant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" xlink:to="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProfitOrLossAndEquityStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityStrengthening"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ProfitOrLossAndEquityStrengthening_lbl" xml:lang="en-US">Profit or loss and equity, Strengthening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityStrengthening" xlink:to="tlsa_ProfitOrLossAndEquityStrengthening_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ProfitOrLossAndEquityWeakening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityWeakening"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ProfitOrLossAndEquityWeakening_lbl" xml:lang="en-US">Profit or loss and equity, Weakening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityWeakening" xlink:to="tlsa_ProfitOrLossAndEquityWeakening_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementPercentageStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageStrengthening"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MovementPercentageStrengthening_lbl" xml:lang="en-US">Movement percentage Strengthening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageStrengthening" xlink:to="tlsa_MovementPercentageStrengthening_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MovementPercentageWeakening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageWeakening"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MovementPercentageWeakening_lbl" xml:lang="en-US">Movement percentage Weakening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageWeakening" xlink:to="tlsa_MovementPercentageWeakening_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US">CAPITAL RISK MANAGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Trade and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock" xlink:to="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentInRelatedPartyTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_InvestmentInRelatedPartyTextBlock_lbl" xml:lang="en-US">INVESTMENT IN RELATED PARTY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedPartyTextBlock" xlink:to="tlsa_InvestmentInRelatedPartyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl" xml:lang="en-US">Schedule of Investment in Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_lbl" xml:lang="en-US">Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets_lbl" xml:lang="en-US">Movement in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:to="ifrs-full_ImpairmentLossOnFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xml:lang="en-US">TREASURY SHARES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets and Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" xlink:to="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetBeginning" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RightOfUseAssetBeginning_lbl" xml:lang="en-US">At 1 January</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetBeginning" xlink:to="tlsa_RightOfUseAssetBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetsDepreciation" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RightOfUseAssetsDepreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetsDepreciation" xlink:to="tlsa_RightOfUseAssetsDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisposalOfLease" xlink:href="tlsa-20231231.xsd#tlsa_DisposalOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisposalOfLease_lbl" xml:lang="en-US">Disposal of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisposalOfLease" xlink:to="tlsa_DisposalOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExchangeDifferencesRightofUseAssets" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferencesRightofUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ExchangeDifferencesRightofUseAssets_lbl" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferencesRightofUseAssets" xlink:to="tlsa_ExchangeDifferencesRightofUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetsTotal" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RightOfUseAssetsTotal_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetsTotal" xlink:to="tlsa_RightOfUseAssetsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesBeginning" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LeaseLiabilitiesBeginning_lbl" xml:lang="en-US">At 1 January</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesBeginning" xlink:to="tlsa_LeaseLiabilitiesBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesInterestExpense" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LeaseLiabilitiesInterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesInterestExpense" xlink:to="tlsa_LeaseLiabilitiesInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LeaseLiabilitiesLeasePayments_lbl" xml:lang="en-US">Lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesLeasePayments" xlink:to="tlsa_LeaseLiabilitiesLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExchangeDifferences" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ExchangeDifferences_lbl" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferences" xlink:to="tlsa_ExchangeDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeaseLiabilitiesTotal" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LeaseLiabilitiesTotal_lbl" xml:lang="en-US">Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesTotal" xlink:to="tlsa_LeaseLiabilitiesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Consolidated Statement of Financial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US">Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DisclosureOfFutureMinimumLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfFutureMinimumLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfFutureMinimumLeasePayments" xlink:to="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LeasePayments_lbl" xml:lang="en-US">Lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeasePayments" xlink:to="tlsa_LeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinanceCharges" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FinanceCharges_lbl" xml:lang="en-US">Finance Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceCharges" xlink:to="tlsa_FinanceCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NetPresentValues" xlink:href="tlsa-20231231.xsd#tlsa_NetPresentValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NetPresentValues_lbl" xml:lang="en-US">Net Present Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetPresentValues" xlink:to="tlsa_NetPresentValues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl" xml:lang="en-US">FINANCIAL COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_OptionsForfeitedCancelled_lbl" xml:lang="en-US">Options, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedCancelled" xlink:to="tlsa_OptionsForfeitedCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WeightedAverageExercisePriceExercised" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_WeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted Average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceExercised" xlink:to="tlsa_WeightedAverageExercisePriceExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_OptionsExercised_lbl" xml:lang="en-US">Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsExercised" xlink:to="tlsa_OptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average exercise price (cents), Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfShareOptionsForfeited" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tlsa_NumberOfShareOptionsForfeited_lbl" xml:lang="en-US">Options, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsForfeited" xlink:to="tlsa_NumberOfShareOptionsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl" xml:lang="en-US">Fixtures and fittings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">IT and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RightOfUseAssetMember" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RightOfUseAssetMember_lbl" xml:lang="en-US">Right of use asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetMember" xlink:to="tlsa_RightOfUseAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GCerroneMember" xlink:href="tlsa-20231231.xsd#tlsa_GCerroneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GCerroneMember_lbl" xml:lang="en-US">G. Cerrone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GCerroneMember" xlink:to="tlsa_GCerroneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WillySimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WillySimonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WillySimonMember_lbl" xml:lang="en-US">Willy Simon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WillySimonMember" xlink:to="tlsa_WillySimonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_JBrancaccioMember" xlink:href="tlsa-20231231.xsd#tlsa_JBrancaccioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_JBrancaccioMember_lbl" xml:lang="en-US">J Brancaccio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_JBrancaccioMember" xlink:to="tlsa_JBrancaccioMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsa_JBrancaccioMember_lbl0" xml:lang="en-US">J. Brancaccio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_JBrancaccioMember" xlink:to="tlsa_JBrancaccioMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_KShailubhaiMember" xlink:href="tlsa-20231231.xsd#tlsa_KShailubhaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_KShailubhaiMember_lbl" xml:lang="en-US">K. Shailubhai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_KShailubhaiMember" xlink:to="tlsa_KShailubhaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TAdamsMember" xlink:href="tlsa-20231231.xsd#tlsa_TAdamsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TAdamsMember_lbl" xml:lang="en-US">T Adams [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TAdamsMember" xlink:to="tlsa_TAdamsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_WSimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WSimonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_WSimonMember_lbl" xml:lang="en-US">W.Simon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WSimonMember" xlink:to="tlsa_WSimonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentySixJuneTwoThousandFourteenMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJuneTwoThousandFourteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TwentySixJuneTwoThousandFourteenMember_lbl" xml:lang="en-US">26 June 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentySixJuneTwoThousandFourteenMember" xlink:to="tlsa_TwentySixJuneTwoThousandFourteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ThirtyAprilTwoThousandAndEighteenMember" xlink:href="tlsa-20231231.xsd#tlsa_ThirtyAprilTwoThousandAndEighteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ThirtyAprilTwoThousandAndEighteenMember_lbl" xml:lang="en-US">30 April 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ThirtyAprilTwoThousandAndEighteenMember" xlink:to="tlsa_ThirtyAprilTwoThousandAndEighteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SixMayTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_SixMayTwoThousandAndTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SixMayTwoThousandAndTwentyMember_lbl" xml:lang="en-US">6 May 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SixMayTwoThousandAndTwentyMember" xlink:to="tlsa_SixMayTwoThousandAndTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyThreeJulyTwoThousandAndTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember_lbl" xml:lang="en-US">23 July 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember" xlink:to="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyFiveAugustTwoThousandAndTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember_lbl" xml:lang="en-US">25 August 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember" xlink:to="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareOptionMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareOptionMember_lbl" xml:lang="en-US">Share Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareOptionMember" xlink:to="tlsa_ShareOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember_lbl" xml:lang="en-US">01 August 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember" xlink:to="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember_lbl" xml:lang="en-US">04 November 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember" xlink:to="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FourteenMarchTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_FourteenMarchTwoThousandTwentyThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_FourteenMarchTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">14 March 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FourteenMarchTwoThousandTwentyThreeMember" xlink:to="tlsa_FourteenMarchTwoThousandTwentyThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TwentySixJulyTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJulyTwoThousandTwentyThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TwentySixJulyTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">26 July 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentySixJulyTwoThousandTwentyThreeMember" xlink:to="tlsa_TwentySixJulyTwoThousandTwentyThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LessThanThreeMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_LessThanThreeMonthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LessThanThreeMonthMember_lbl" xml:lang="en-US">Less than 3 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LessThanThreeMonthMember" xlink:to="tlsa_LessThanThreeMonthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ThreeToTwelveMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_ThreeToTwelveMonthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ThreeToTwelveMonthMember_lbl" xml:lang="en-US">3 to 12 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ThreeToTwelveMonthMember" xlink:to="tlsa_ThreeToTwelveMonthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_USDMember" xlink:href="tlsa-20231231.xsd#tlsa_USDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_USDMember_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_USDMember" xlink:to="tlsa_USDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccustemSciencesIncMember" xlink:href="tlsa-20231231.xsd#tlsa_AccustemSciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AccustemSciencesIncMember_lbl" xml:lang="en-US">Accustem Sciences Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccustemSciencesIncMember" xlink:to="tlsa_AccustemSciencesIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tlsa_AccustemSciencesIncMember_lbl0" xml:lang="en-US">Accustem [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccustemSciencesIncMember" xlink:to="tlsa_AccustemSciencesIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OKYOPharmaLtdMember_lbl" xml:lang="en-US">OKYO Pharma Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OKYOPharmaLtdMember" xlink:to="tlsa_OKYOPharmaLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">Within 1 year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US">1-2 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember" xlink:href="tlsa-20231231.xsd#tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember_lbl" xml:lang="en-US">2-5 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember" xlink:to="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US">Over 5 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ClassOfWarrantsOrRightAxis" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ClassOfWarrantsOrRightAxis_lbl" xml:lang="en-US">Class of Warrants or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ClassOfWarrantsOrRightAxis" xlink:to="tlsa_ClassOfWarrantsOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyAxis" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RelatedPartyAxis_lbl" xml:lang="en-US">Related party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyAxis" xlink:to="tlsa_RelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccumulatedLoss" xlink:href="tlsa-20231231.xsd#tlsa_AccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AccumulatedLoss_lbl" xml:lang="en-US">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccumulatedLoss" xlink:to="tlsa_AccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CashSurplus" xlink:href="tlsa-20231231.xsd#tlsa_CashSurplus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CashSurplus_lbl" xml:lang="en-US">Cash surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashSurplus" xlink:to="tlsa_CashSurplus_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfSegment" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSegment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberOfSegment_lbl" xml:lang="en-US">Number of operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfSegment" xlink:to="tlsa_NumberOfSegment_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_UpfrontPayment" xlink:href="tlsa-20231231.xsd#tlsa_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UpfrontPayment" xlink:to="tlsa_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses_lbl" xml:lang="en-US">Finance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BenefitsPaidOrPayable_lbl" xml:lang="en-US">Realization bonus payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BenefitsPaidOrPayable" xlink:to="ifrs-full_BenefitsPaidOrPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RaisingFunds" xlink:href="tlsa-20231231.xsd#tlsa_RaisingFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RaisingFunds_lbl" xml:lang="en-US">Raising funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RaisingFunds" xlink:to="tlsa_RaisingFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued amount due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLongtermBenefits_lbl" xml:lang="en-US">Realization bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLongtermBenefits" xlink:to="ifrs-full_OtherLongtermBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xml:lang="en-US">Contribution pension schemes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MaximumPercentageOfSurrenderableLosses" xlink:href="tlsa-20231231.xsd#tlsa_MaximumPercentageOfSurrenderableLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MaximumPercentageOfSurrenderableLosses_lbl" xml:lang="en-US">Surrenderable losses percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MaximumPercentageOfSurrenderableLosses" xlink:to="tlsa_MaximumPercentageOfSurrenderableLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" xlink:href="tlsa-20231231.xsd#tlsa_TermOfResearchAndDevelopmentTaxReliefClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl" xml:lang="en-US">Term of R&amp;D tax relief claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" xlink:to="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NumberOfSharesIssued1" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NumberOfSharesIssued1_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfSharesIssued1" xlink:to="tlsa_NumberOfSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasuryShares1" xlink:href="tlsa-20231231.xsd#tlsa_TreasuryShares1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TreasuryShares1_lbl" xml:lang="en-US">Treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TreasuryShares1" xlink:to="tlsa_TreasuryShares1_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OutstandingFairValueCharges" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingFairValueCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OutstandingFairValueCharges_lbl" xml:lang="en-US">Total outstanding fair value charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingFairValueCharges" xlink:to="tlsa_OutstandingFairValueCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ExpectedTermOfAwards" xlink:href="tlsa-20231231.xsd#tlsa_ExpectedTermOfAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ExpectedTermOfAwards_lbl" xml:lang="en-US">Expected term of the award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExpectedTermOfAwards" xlink:to="tlsa_ExpectedTermOfAwards_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price for options issued to employees and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US">Share based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ChargeOfForfeitures" xlink:href="tlsa-20231231.xsd#tlsa_ChargeOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ChargeOfForfeitures_lbl" xml:lang="en-US">Charge of forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ChargeOfForfeitures" xlink:to="tlsa_ChargeOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based payment charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_SharesPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesPrice_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesPrice" xlink:to="tlsa_SharesPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AcquiredShares" xlink:href="tlsa-20231231.xsd#tlsa_AcquiredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AcquiredShares_lbl" xml:lang="en-US">Acquired shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AcquiredShares" xlink:to="tlsa_AcquiredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SharesPurchases" xlink:href="tlsa-20231231.xsd#tlsa_SharesPurchases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_SharesPurchases_lbl" xml:lang="en-US">Shares purchases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesPurchases" xlink:to="tlsa_SharesPurchases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InterestAmount" xlink:href="tlsa-20231231.xsd#tlsa_InterestAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_InterestAmount_lbl" xml:lang="en-US">Interest amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InterestAmount" xlink:to="tlsa_InterestAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShortTermLoanFacility1" xlink:href="tlsa-20231231.xsd#tlsa_ShortTermLoanFacility1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShortTermLoanFacility1_lbl" xml:lang="en-US">Short term loan facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShortTermLoanFacility1" xlink:to="tlsa_ShortTermLoanFacility1_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PayrollAndRentCharged" xlink:href="tlsa-20231231.xsd#tlsa_PayrollAndRentCharged"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PayrollAndRentCharged_lbl" xml:lang="en-US">Payroll and rent charged</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PayrollAndRentCharged" xlink:to="tlsa_PayrollAndRentCharged_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ServicesAgreementAmount" xlink:href="tlsa-20231231.xsd#tlsa_ServicesAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ServicesAgreementAmount_lbl" xml:lang="en-US">Services agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ServicesAgreementAmount" xlink:to="tlsa_ServicesAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InitialAmount" xlink:href="tlsa-20231231.xsd#tlsa_InitialAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_InitialAmount_lbl" xml:lang="en-US">Initial payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InitialAmount" xlink:to="tlsa_InitialAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AdditionalPayment" xlink:href="tlsa-20231231.xsd#tlsa_AdditionalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AdditionalPayment_lbl" xml:lang="en-US">Additional payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdditionalPayment" xlink:to="tlsa_AdditionalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MilestonePaymentDue" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MilestonePaymentDue_lbl" xml:lang="en-US">Milestone payment due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MilestonePaymentDue" xlink:to="tlsa_MilestonePaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Percentage of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PrincipalAmount" xlink:href="tlsa-20231231.xsd#tlsa_PrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PrincipalAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrincipalAmount" xlink:to="tlsa_PrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl" xml:lang="en-US">Bad debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US">Service total costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DevelopmentMilestones" xlink:href="tlsa-20231231.xsd#tlsa_DevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DevelopmentMilestones_lbl" xml:lang="en-US">Development milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DevelopmentMilestones" xlink:to="tlsa_DevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccruedOfDiligenceObligations" xlink:href="tlsa-20231231.xsd#tlsa_AccruedOfDiligenceObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AccruedOfDiligenceObligations_lbl" xml:lang="en-US">Accrued of diligence obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccruedOfDiligenceObligations" xlink:to="tlsa_AccruedOfDiligenceObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_MilestonePayments" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_MilestonePayments_lbl" xml:lang="en-US">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MilestonePayments" xlink:to="tlsa_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CommercialSaleOfAProduct" xlink:href="tlsa-20231231.xsd#tlsa_CommercialSaleOfAProduct"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CommercialSaleOfAProduct_lbl" xml:lang="en-US">Commercial sale of a product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CommercialSaleOfAProduct" xlink:to="tlsa_CommercialSaleOfAProduct_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl" xml:lang="en-US">Basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForGoingConcern" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForGoingConcern"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl" xml:lang="en-US">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForGoingConcern" xlink:to="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl" xml:lang="en-US">New and Revised Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl" xml:lang="en-US">Basis of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_lbl" xml:lang="en-US">Business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForLicenseFees" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl" xml:lang="en-US">License fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForLicenseFees" xlink:to="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_lbl" xml:lang="en-US">Contingent Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share &#8211; based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl" xml:lang="en-US">Sub license income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xml:lang="en-US">Other Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Relassification of Prior Year Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BlackScholesMertonValuationModelMember" xlink:href="tlsa-20231231.xsd#tlsa_BlackScholesMertonValuationModelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BlackScholesMertonValuationModelMember_lbl" xml:lang="en-US">Black-Scholes-Merton Valuation model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BlackScholesMertonValuationModelMember" xlink:to="tlsa_BlackScholesMertonValuationModelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TizianaLifeSciencesPLCMember" xlink:href="tlsa-20231231.xsd#tlsa_TizianaLifeSciencesPLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TizianaLifeSciencesPLCMember_lbl" xml:lang="en-US">Tiziana Life Sciences PLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TizianaLifeSciencesPLCMember" xlink:to="tlsa_TizianaLifeSciencesPLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_NASDAQStockExchangeMember" xlink:href="tlsa-20231231.xsd#tlsa_NASDAQStockExchangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_NASDAQStockExchangeMember_lbl" xml:lang="en-US">NASDAQ Stock Exchange [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NASDAQStockExchangeMember" xlink:to="tlsa_NASDAQStockExchangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RasnaTherapeuticsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_RasnaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RasnaTherapeuticsIncMember_lbl" xml:lang="en-US">Rasna Therapeutics Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RasnaTherapeuticsIncMember" xlink:to="tlsa_RasnaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GensigniaLifesceinecsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_GensigniaLifesceinecsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_GensigniaLifesceinecsIncMember_lbl" xml:lang="en-US">Gensignia Lifesceinecs Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GensigniaLifesceinecsIncMember" xlink:to="tlsa_GensigniaLifesceinecsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIClinicalTrialMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PhaseIIClinicalTrialMember_lbl" xml:lang="en-US">Phase II [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIClinicalTrialMember" xlink:to="tlsa_PhaseIIClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_Phase3Member" xlink:href="tlsa-20231231.xsd#tlsa_Phase3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_Phase3Member_lbl" xml:lang="en-US">Phase 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Phase3Member" xlink:to="tlsa_Phase3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIHumanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PhaseIIHumanMember_lbl" xml:lang="en-US">Phase II human [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIHumanMember" xlink:to="tlsa_PhaseIIHumanMember_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbMz2zEgEUgvHXYEGXly9hWU=] CSR-->
    <loc xlink:type="locator" xlink:label="tlsa_CarcinomaMember" xlink:href="tlsa-20231231.xsd#tlsa_CarcinomaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_CarcinomaMember_lbl" xml:lang="en-US">Carcinoma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CarcinomaMember" xlink:to="tlsa_CarcinomaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_HCCMember" xlink:href="tlsa-20231231.xsd#tlsa_HCCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_HCCMember_lbl" xml:lang="en-US">HCC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_HCCMember" xlink:to="tlsa_HCCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BreastCancerMember" xlink:href="tlsa-20231231.xsd#tlsa_BreastCancerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BreastCancerMember_lbl" xml:lang="en-US">Breast Cancer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BreastCancerMember" xlink:to="tlsa_BreastCancerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIHumanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PhaseIHumanMember_lbl" xml:lang="en-US">Phase I human [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIHumanMember" xlink:to="tlsa_PhaseIHumanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_PhaseIIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIIHumanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_PhaseIIIHumanMember_lbl" xml:lang="en-US">Phase III human [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIIHumanMember" xlink:to="tlsa_PhaseIIIHumanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_BLAMember" xlink:href="tlsa-20231231.xsd#tlsa_BLAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_BLAMember_lbl" xml:lang="en-US">BLA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BLAMember" xlink:to="tlsa_BLAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GeneralInformationTable" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GeneralInformationTable_lbl" xml:lang="en-US">General Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GeneralInformationTable" xlink:to="tlsa_GeneralInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_GeneralInformationLineItems" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GeneralInformationLineItems_lbl" xml:lang="en-US">General Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GeneralInformationLineItems" xlink:to="tlsa_GeneralInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesTable_lbl" xml:lang="en-US">Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesTable" xlink:to="tlsa_AccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AccountingPoliciesLineItems_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesLineItems" xlink:to="tlsa_AccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CriticalAccountingJudgementTable" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CriticalAccountingJudgementTable_lbl" xml:lang="en-US">Critical Accounting Judgement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CriticalAccountingJudgementTable" xlink:to="tlsa_CriticalAccountingJudgementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_CriticalAccountingJudgementLineItems" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CriticalAccountingJudgementLineItems_lbl" xml:lang="en-US">Critical Accounting Judgement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CriticalAccountingJudgementLineItems" xlink:to="tlsa_CriticalAccountingJudgementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossTable_lbl" xml:lang="en-US">Operating Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossTable" xlink:to="tlsa_OperatingLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossLineItems_lbl" xml:lang="en-US">Operating Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossLineItems" xlink:to="tlsa_OperatingLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SegmentalReportingTable" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SegmentalReportingTable_lbl" xml:lang="en-US">Segmental Reporting [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SegmentalReportingTable" xlink:to="tlsa_SegmentalReportingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_SegmentalReportingLineItems" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SegmentalReportingLineItems_lbl" xml:lang="en-US">Segmental Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SegmentalReportingLineItems" xlink:to="tlsa_SegmentalReportingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTable_lbl" xml:lang="en-US">Remuneration of Key Management Personnel [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTable" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelLineItems_lbl" xml:lang="en-US">Remuneration of Key Management Personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareTable_lbl" xml:lang="en-US">Loss Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareTable" xlink:to="tlsa_LossPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareLineItems_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareLineItems" xlink:to="tlsa_LossPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossTablesTable_lbl" xml:lang="en-US">Operating Loss (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossTablesTable" xlink:to="tlsa_OperatingLossTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OperatingLossTablesLineItems_lbl" xml:lang="en-US">Operating Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossTablesLineItems" xlink:to="tlsa_OperatingLossTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesTable_lbl" xml:lang="en-US">Remuneration of Key Management Personnel (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesTable" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems_lbl" xml:lang="en-US">Remuneration of Key Management Personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareTablesTable_lbl" xml:lang="en-US">Loss Per Share (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareTablesTable" xlink:to="tlsa_LossPerShareTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_LossPerShareTablesLineItems_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareTablesLineItems" xlink:to="tlsa_LossPerShareTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherReceivablesTablesTable_lbl" xml:lang="en-US">Other Receivables (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherReceivablesTablesTable" xlink:to="tlsa_OtherReceivablesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OtherReceivablesTablesLineItems_lbl" xml:lang="en-US">Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherReceivablesTablesLineItems" xlink:to="tlsa_OtherReceivablesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TradeandOtherPayablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TradeandOtherPayablesTablesTable_lbl" xml:lang="en-US">Trade and Other Payables (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TradeandOtherPayablesTablesTable" xlink:to="tlsa_TradeandOtherPayablesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TradeandOtherPayablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_TradeandOtherPayablesTablesLineItems_lbl" xml:lang="en-US">Trade and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TradeandOtherPayablesTablesLineItems" xlink:to="tlsa_TradeandOtherPayablesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable_lbl" xml:lang="en-US">Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:to="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable_lbl" xml:lang="en-US">Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:to="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems_lbl" xml:lang="en-US">Schedule of Other Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable_lbl" xml:lang="en-US">Operating Loss (Details) - Schedule of Operating Losses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable" xlink:to="tlsa_OperatingLossDetailsScheduleofOperatingLossesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems_lbl" xml:lang="en-US">Schedule of Operating Losses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable_lbl" xml:lang="en-US">Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems_lbl" xml:lang="en-US">Schedule of Remuneration of Key Management Personnel [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable_lbl" xml:lang="en-US">Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems_lbl" xml:lang="en-US">Schedule of Share Options were Granted to Directors [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable_lbl" xml:lang="en-US">Loss Per Share (Details) - Schedule of Basic Loss Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:to="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems_lbl" xml:lang="en-US">Schedule of Basic Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable_lbl" xml:lang="en-US">Other Receivables (Details) - Schedule of Other Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:to="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems_lbl" xml:lang="en-US">Schedule of Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable_lbl" xml:lang="en-US">Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems_lbl" xml:lang="en-US">Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable_lbl" xml:lang="en-US">Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems_lbl" xml:lang="en-US">Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_lbl" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of All Other Variables Remain Constant [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of All Other Variables Remain Constant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable_lbl" xml:lang="en-US">Investment in Related Party (Details) - Schedule of Investment in Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:to="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems_lbl" xml:lang="en-US">Investment in Related Party (Details) - Schedule of Investment in Related Party [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US">Aggregated time bands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of Future Minimum Lease Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:to="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesDetailsTable" xlink:to="tlsa_AccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPoliciesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_AccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_AccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossDetailsTable_lbl" xml:lang="en-US">Operating Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossDetailsTable" xlink:to="tlsa_OperatingLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_OperatingLossDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_OperatingLossDetailsLineItems_lbl" xml:lang="en-US">Operating Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="tlsa_OperatingLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsTable_lbl" xml:lang="en-US">Remuneration of Key Management Personnel (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsTable" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems_lbl" xml:lang="en-US">Remuneration of Key Management Personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TaxationDetailsTable_lbl" xml:lang="en-US">Taxation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationDetailsTable" xlink:to="tlsa_TaxationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TaxationDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TaxationDetailsLineItems_lbl" xml:lang="en-US">Disclosure of Income Tax Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationDetailsLineItems" xlink:to="tlsa_TaxationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsTable_lbl" xml:lang="en-US">Share Capital and Share Premium (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsTable" xlink:to="tlsa_ShareCapitalandSharePremiumDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsLineItems_lbl" xml:lang="en-US">Share Capital and Share Premium [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="tlsa_ShareCapitalandSharePremiumDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US">Financial instruments, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsTable_lbl" xml:lang="en-US">Share Based Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsTable" xlink:to="tlsa_ShareBasedPaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentsDetailsLineItems_lbl" xml:lang="en-US">Share Based Payments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentsDetailsLineItems" xlink:to="tlsa_ShareBasedPaymentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentinRelatedPartyDetailsTable_lbl" xml:lang="en-US">Investment in Related Party (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentinRelatedPartyDetailsTable" xlink:to="tlsa_InvestmentinRelatedPartyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentinRelatedPartyDetailsLineItems_lbl" xml:lang="en-US">Investment in Related Party (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentinRelatedPartyDetailsLineItems" xlink:to="tlsa_InvestmentinRelatedPartyDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ClassOfWarrantsOrRightDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ClassOfWarrantsOrRightDomainDomain_lbl" xml:lang="en-US">ClassOfWarrantsOrRightDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ClassOfWarrantsOrRightDomainDomain" xlink:to="tlsa_ClassOfWarrantsOrRightDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TreasurySharesDetailsTable_lbl" xml:lang="en-US">Treasury Shares (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TreasurySharesDetailsTable" xlink:to="tlsa_TreasurySharesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_TreasurySharesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TreasurySharesDetailsLineItems_lbl" xml:lang="en-US">Treasury Shares (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TreasurySharesDetailsLineItems" xlink:to="tlsa_TreasurySharesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RelatedPartyDomainDomain_lbl" xml:lang="en-US">RelatedPartyDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyDomainDomain" xlink:to="tlsa_RelatedPartyDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyTransactionsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyTransactionsDetailsTable" xlink:to="tlsa_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyTransactionsDetailsLineItems" xlink:to="tlsa_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialCommitmentsDetailsTable_lbl" xml:lang="en-US">Financial Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialCommitmentsDetailsTable" xlink:to="tlsa_FinancialCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_FinancialCommitmentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialCommitmentsDetailsLineItems_lbl" xml:lang="en-US">Financial Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialCommitmentsDetailsLineItems" xlink:to="tlsa_FinancialCommitmentsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AccruedOfDiligenceObligations_lbl0" xml:lang="en-US">Accrued of diligence obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccruedOfDiligenceObligations" xlink:to="tlsa_AccruedOfDiligenceObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AccumulatedLoss_lbl0" xml:lang="en-US">Accumulated loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccumulatedLoss" xlink:to="tlsa_AccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AcquiredShares_lbl0" xml:lang="en-US">Number of acquired shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AcquiredShares" xlink:to="tlsa_AcquiredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AdditionalPayment_lbl0" xml:lang="en-US">Additional payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdditionalPayment" xlink:to="tlsa_AdditionalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AdjustmentsDueToPriorPeriod_lbl0" xml:lang="en-US">Adjustments due to prior periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriod" xlink:to="tlsa_AdjustmentsDueToPriorPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AdjustmentsDueToPriorPeriods_lbl0" xml:lang="en-US">Adjustments due to prior periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriods" xlink:to="tlsa_AdjustmentsDueToPriorPeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl0" xml:lang="en-US">Adjustments for share-based payments warrants to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:to="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl0" xml:lang="en-US">Average monthly number of employees, including directors, employed by the group.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:to="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_BonusToBeSettledInEquity_lbl0" xml:lang="en-US">Amount of Bonus to be settled in equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BonusToBeSettledInEquity" xlink:to="tlsa_BonusToBeSettledInEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_BuybackOfTreasuryShares_lbl0" xml:lang="en-US">Buyback of Treasury Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BuybackOfTreasuryShares" xlink:to="tlsa_BuybackOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CapitalDistribution_lbl0" xml:lang="en-US">Capital distribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CapitalDistribution" xlink:to="tlsa_CapitalDistribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CashInflowFromTaxation_lbl0" xml:lang="en-US">Represent the amount of cash inflow from taxation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashInflowFromTaxation" xlink:to="tlsa_CashInflowFromTaxation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CashSurplus_lbl0" xml:lang="en-US">The amount of cash surplus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashSurplus" xlink:to="tlsa_CashSurplus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ChargeOfForfeitures_lbl0" xml:lang="en-US">Amount of charge of forfeitures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ChargeOfForfeitures" xlink:to="tlsa_ChargeOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CommercialSaleOfAProduct_lbl0" xml:lang="en-US">The amount of commercial sale of a product.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CommercialSaleOfAProduct" xlink:to="tlsa_CommercialSaleOfAProduct_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CorporateAndAdministration_lbl0" xml:lang="en-US">The amount of corporate and administration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CorporateAndAdministration" xlink:to="tlsa_CorporateAndAdministration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_CurrentTaxOther_lbl0" xml:lang="en-US">Current tax other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CurrentTaxOther" xlink:to="tlsa_CurrentTaxOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DepreciationOfRightofuseAsset_lbl0" xml:lang="en-US">Depreciation of right-of-use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DepreciationOfRightofuseAsset" xlink:to="tlsa_DepreciationOfRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s material accounting policy information for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for basis of consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForGoingConcern" xlink:to="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForLicenseFees" xlink:to="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s material accounting policy information for revised standards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s material accounting policy information for sub license income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s material accounting policy information for derivative instruments and hedging activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DevelopmentMilestones_lbl0" xml:lang="en-US">The amount of development milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DevelopmentMilestones" xlink:to="tlsa_DevelopmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DirectorsFees_lbl0" xml:lang="en-US">The amount of directors fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DirectorsFees" xlink:to="tlsa_DirectorsFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about finance cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:to="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl0" xml:lang="en-US">The disclosure of accounting share capital and share premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:to="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information about employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:to="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about income tax expense (benefit).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl0" xml:lang="en-US">Disclosure of detailed information about of earnings per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl0" xml:lang="en-US">The disclosure of detailed information about operating loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl0" xml:lang="en-US">Disclosure of detailed information about other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl0" xml:lang="en-US">The disclosure of estimated useful lives for the current period and the comparative period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:to="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl0" xml:lang="en-US">Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfFutureMinimumLeasePayments" xlink:to="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl0" xml:lang="en-US">The disclosure of information about key management personnel.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:to="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl0" xml:lang="en-US">The disclosure of share options were granted to directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:to="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl0" xml:lang="en-US">Disclosure share capital arising for share exchange.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:to="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_DisposalOfLease_lbl0" xml:lang="en-US">Disposal of lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisposalOfLease" xlink:to="tlsa_DisposalOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_EliminationOfOtherReserves_lbl0" xml:lang="en-US">Elimination of other reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EliminationOfOtherReserves" xlink:to="tlsa_EliminationOfOtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_EstimatedUsefulLives_lbl0" xml:lang="en-US">The estimated useful lives for the current period and the comparative period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EstimatedUsefulLives" xlink:to="tlsa_EstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ExchangeDifferences_lbl0" xml:lang="en-US">The Amount of Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferences" xlink:to="tlsa_ExchangeDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ExchangeDifferencesRightofUseAssets_lbl0" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferencesRightofUseAssets" xlink:to="tlsa_ExchangeDifferencesRightofUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ExpectedTermOfAwards_lbl0" xml:lang="en-US">The expected term of the awards is based on managements&#8217; assessment of when the market condition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExpectedTermOfAwards" xlink:to="tlsa_ExpectedTermOfAwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FVLossOnInvestment_lbl0" xml:lang="en-US">FV loss on investment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FVLossOnInvestment" xlink:to="tlsa_FVLossOnInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FairValueOutstanding_lbl1" xml:lang="en-US">Representation amount of outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FairValueOutstanding" xlink:to="tlsa_FairValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl0" xml:lang="en-US">Finance charge accrued on convertible loan notes (recognized as debt).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" xlink:to="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FinanceCharges_lbl0" xml:lang="en-US">Amount of finance charges.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceCharges" xlink:to="tlsa_FinanceCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FinanceExpense_lbl0" xml:lang="en-US">Total finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceExpense" xlink:to="tlsa_FinanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FixedAssetDifferences_lbl0" xml:lang="en-US">Fixed asset differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FixedAssetDifferences" xlink:to="tlsa_FixedAssetDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ForeignExchangegainlosses_lbl0" xml:lang="en-US">The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ForeignExchangegainlosses" xlink:to="tlsa_ForeignExchangegainlosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_FundraisingCost_lbl0" xml:lang="en-US">Fundraising cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FundraisingCost" xlink:to="tlsa_FundraisingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeNotTaxableForTaxPurposes_lbl0" xml:lang="en-US">The aggregate amount of income not taxable for tax purpose.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeNotTaxableForTaxPurposes" xlink:to="tlsa_IncomeNotTaxableForTaxPurposes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeTaxExpenseContinuingOperation_lbl0" xml:lang="en-US">The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxExpenseContinuingOperation" xlink:to="tlsa_IncomeTaxExpenseContinuingOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl0" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expenses not deductible for taxation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:to="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl0" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss charged at standard rate of corporation tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:to="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl0" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development claim.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:to="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_IncomeTaxSCredit_lbl0" xml:lang="en-US">Income tax credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxSCredit" xlink:to="tlsa_IncomeTaxSCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_InitialAmount_lbl0" xml:lang="en-US">Initial amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InitialAmount" xlink:to="tlsa_InitialAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_InterestReceivedFromLoan_lbl0" xml:lang="en-US">Interest Received from loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="tlsa_InterestReceivedFromLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_InvestmentInRelatedParty_lbl0" xml:lang="en-US">Investment in related party amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedParty" xlink:to="tlsa_InvestmentInRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_InvestmentsInRelatedParty_lbl0" xml:lang="en-US">Reprersent the amount of investment in related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentsInRelatedParty" xlink:to="tlsa_InvestmentsInRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_LeasePayments_lbl0" xml:lang="en-US">Amount of lease payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeasePayments" xlink:to="tlsa_LeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_Licensefee_lbl0" xml:lang="en-US">Amount of License fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Licensefee" xlink:to="tlsa_Licensefee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_LossOnDisposalOfAsset_lbl0" xml:lang="en-US">Loss on disposal of asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossOnDisposalOfAsset" xlink:to="tlsa_LossOnDisposalOfAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MaximumPercentageOfSurrenderableLosses_lbl0" xml:lang="en-US">Maximum percentage of surrenderable losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MaximumPercentageOfSurrenderableLosses" xlink:to="tlsa_MaximumPercentageOfSurrenderableLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl0" xml:lang="en-US">Merger Reserve At January 1 2021 per 20-F annual report.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" xlink:to="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveConversionOfLoan_lbl0" xml:lang="en-US">Merger Reserve Conversion of Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfLoan" xlink:to="tlsa_MergerReserveConversionOfLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveConversionOfWarrants_lbl0" xml:lang="en-US">Merger Reserve Conversion of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfWarrants" xlink:to="tlsa_MergerReserveConversionOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl0" xml:lang="en-US">Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveEliminationOfShareCapitalIn" xlink:to="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl0" xml:lang="en-US">Merger Reserve Issued in lieu of cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveIssuedInLieuOfCashBonus" xlink:to="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveRestated_lbl0" xml:lang="en-US">Merger Reserve Restated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveRestated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0" xml:lang="en-US">Merger Reserve Shares issued pursuant to share for share exchange and consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MilestonePaymentDue_lbl0" xml:lang="en-US">Milestone payment due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MilestonePaymentDue" xlink:to="tlsa_MilestonePaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MovementInUnrecognisedDeferredTax_lbl0" xml:lang="en-US">The amount of movement in unrecognised deferred tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementInUnrecognisedDeferredTax" xlink:to="tlsa_MovementInUnrecognisedDeferredTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MovementPercentageStrengthening_lbl0" xml:lang="en-US">Movement percentage strengthening.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageStrengthening" xlink:to="tlsa_MovementPercentageStrengthening_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_MovementPercentageWeakening_lbl0" xml:lang="en-US">Movement percentage weakening.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageWeakening" xlink:to="tlsa_MovementPercentageWeakening_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl0" xml:lang="en-US">The amount of income or cost associated with interest and other financing activities of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:to="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables_lbl0" xml:lang="en-US">Net increase in related party payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyPayables" xlink:to="tlsa_NetIncreaseInRelatedPartyPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables_lbl0" xml:lang="en-US">Net increase in related party receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:to="tlsa_NetIncreaseInRelatedPartyReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NetPresentValues_lbl0" xml:lang="en-US">Amount of net present values.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetPresentValues" xlink:to="tlsa_NetPresentValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueAnnualReport_lbl0" xml:lang="en-US">Nominal Value annual report.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueAnnualReport" xlink:to="tlsa_NominalValueAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueConversionOfLoan_lbl0" xml:lang="en-US">Nominal Value Conversion of Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfLoan" xlink:to="tlsa_NominalValueConversionOfLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueConversionOfWarrants_lbl0" xml:lang="en-US">Nominal Value Conversion of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfWarrants" xlink:to="tlsa_NominalValueConversionOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueEliminationOfShareCapital_lbl0" xml:lang="en-US">Nominal Value Elimination of share capital in Tiziana Life Sciences Plc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueEliminationOfShareCapital" xlink:to="tlsa_NominalValueEliminationOfShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueIssuanceOfStockATM_lbl0" xml:lang="en-US">Nominal value issuance of stock - ATM.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuanceOfStockATM" xlink:to="tlsa_NominalValueIssuanceOfStockATM_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl0" xml:lang="en-US">Nominal Value Issued in lieu of cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuedInLieuOfCashBonus" xlink:to="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueRestated_lbl0" xml:lang="en-US">Nominal Value Restated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueRestated" xlink:to="tlsa_NominalValueRestated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl0" xml:lang="en-US">Nominal value shares issued in lieu of fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0" xml:lang="en-US">Nominal Value Shares issued pursuant to share for share exchange and consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NominalValueWarrantsExercised_lbl0" xml:lang="en-US">Nominal value warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueWarrantsExercised" xlink:to="tlsa_NominalValueWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl0" xml:lang="en-US">Number of share options were granted to directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsWereGrantedToDirectors" xlink:to="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OperatingLoss_lbl0" xml:lang="en-US">Amount of operating loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLoss" xlink:to="tlsa_OperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OptionLifeShareOptionsGranted_lbl0" xml:lang="en-US">The option life of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionLifeShareOptionsGranted" xlink:to="tlsa_OptionLifeShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OptionsForfeitedDuringTheYear_lbl0" xml:lang="en-US">Options forfeited during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedDuringTheYear" xlink:to="tlsa_OptionsForfeitedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OtherIncomelosses_lbl0" xml:lang="en-US">Amount of revenue and income classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherIncomelosses" xlink:to="tlsa_OtherIncomelosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OutstandingExercised_lbl0" xml:lang="en-US">Representation amount of exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExercised" xlink:to="tlsa_OutstandingExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OutstandingExpired_lbl0" xml:lang="en-US">Representtion amount of expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExpired" xlink:to="tlsa_OutstandingExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_OutstandingFairValueCharges_lbl0" xml:lang="en-US">Amount of Outstanding fair value charges.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingFairValueCharges" xlink:to="tlsa_OutstandingFairValueCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl0" xml:lang="en-US">The amount of current prepayments and other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:to="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_PrincipalAmount_lbl0" xml:lang="en-US">Repersentation amount of principal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrincipalAmount" xlink:to="tlsa_PrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ProceedsFromFinanceLease_lbl0" xml:lang="en-US">Proceeds from finance lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromFinanceLease" xlink:to="tlsa_ProceedsFromFinanceLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ProceedsFromIssuanceOfOptions_lbl0" xml:lang="en-US">Proceeds from issuance of options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromIssuanceOfOptions" xlink:to="tlsa_ProceedsFromIssuanceOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl0" xml:lang="en-US">The cash inflow associated with the sale or collection of receivables arising from the financing of goods and services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:to="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ProfitOrLossAndEquityStrengthening_lbl0" xml:lang="en-US">Representation amount of profit or loss and equity, strengthening.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityStrengthening" xlink:to="tlsa_ProfitOrLossAndEquityStrengthening_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ProfitOrLossAndEquityWeakening_lbl0" xml:lang="en-US">Representation amount of profit or loss and equity, weakening.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityWeakening" xlink:to="tlsa_ProfitOrLossAndEquityWeakening_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_RaisingFunds_lbl0" xml:lang="en-US">Raising funds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RaisingFunds" xlink:to="tlsa_RaisingFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_RealisationBonus_lbl0" xml:lang="en-US">Realisation bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RealisationBonus" xlink:to="tlsa_RealisationBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_RecruitmentFees_lbl0" xml:lang="en-US">The amount of recruitment fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RecruitmentFees" xlink:to="tlsa_RecruitmentFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_RepaymentOfLeasingLiabilities_lbl0" xml:lang="en-US">Repayment of leasing liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RepaymentOfLeasingLiabilities" xlink:to="tlsa_RepaymentOfLeasingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ResearchAndDevelopment_lbl0" xml:lang="en-US">The amount of research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ResearchAndDevelopment" xlink:to="tlsa_ResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_Salary_lbl0" xml:lang="en-US">The amount of salary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Salary" xlink:to="tlsa_Salary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl0" xml:lang="en-US">The disclosure of estimated the fair value of warrants using.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:to="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SecurityDepositsReceivable_lbl0" xml:lang="en-US">Security deposits receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SecurityDepositsReceivable" xlink:to="tlsa_SecurityDepositsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ServicesAgreementAmount_lbl0" xml:lang="en-US">The amount of services agreement Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ServicesAgreementAmount" xlink:to="tlsa_ServicesAgreementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareBasedPaymentoptions_lbl0" xml:lang="en-US">Amount of Share based payment options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentoptions" xlink:to="tlsa_ShareBasedPaymentoptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalConversionOfWarrants_lbl0" xml:lang="en-US">Share Capital Conversion of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalConversionOfWarrants" xlink:to="tlsa_ShareCapitalConversionOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalShares_lbl0" xml:lang="en-US">Share Capital Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalShares" xlink:to="tlsa_ShareCapitalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesAnnualReport_lbl0" xml:lang="en-US">Share Capital Shares annual report.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesAnnualReport" xlink:to="tlsa_ShareCapitalSharesAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesConversionOfLoan_lbl0" xml:lang="en-US">Share Capital Shares Conversion of Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfLoan" xlink:to="tlsa_ShareCapitalSharesConversionOfLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesConversionOfWarrants_lbl0" xml:lang="en-US">Share Capital Shares Conversion of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfWarrants" xlink:to="tlsa_ShareCapitalSharesConversionOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesEliminationOfShare_lbl0" xml:lang="en-US">Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesEliminationOfShare" xlink:to="tlsa_ShareCapitalSharesEliminationOfShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl0" xml:lang="en-US">Number of share capital shares issuance of stock - ATM.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl0" xml:lang="en-US">Share Capital Shares Issued in lieu of cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl0" xml:lang="en-US">Number of share capital shares issued in lieu of fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesRestated_lbl0" xml:lang="en-US">Share Capital Shares Restated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesRestated" xlink:to="tlsa_ShareCapitalSharesRestated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl0" xml:lang="en-US">Share Capital Shares Shares issued pursuant to share for share exchange and consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalSharesWarrantsExercised_lbl0" xml:lang="en-US">Number of share capital shares warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesWarrantsExercised" xlink:to="tlsa_ShareCapitalSharesWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueAnnualReport_lbl0" xml:lang="en-US">Share Capital value annual report.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAnnualReport" xlink:to="tlsa_ShareCapitalValueAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueAt31December2021_lbl0" xml:lang="en-US">Share Capital value At 31 December 2021.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAt31December2021" xlink:to="tlsa_ShareCapitalValueAt31December2021_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueConversionOfLoan_lbl0" xml:lang="en-US">Share Capital value Conversion of Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueConversionOfLoan" xlink:to="tlsa_ShareCapitalValueConversionOfLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl0" xml:lang="en-US">Share Capital value Elimination of share capital in Tiziana Life Sciences Plc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueEliminationOfShareCapital" xlink:to="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl0" xml:lang="en-US">Representation amount of share capital value issuance of stock - ATM.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueIssuedInCashBonus_lbl0" xml:lang="en-US">Share Capital value Issued in lieu of cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuedInCashBonus" xlink:to="tlsa_ShareCapitalValueIssuedInCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueRestated_lbl0" xml:lang="en-US">Share Capital value Restated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueRestated" xlink:to="tlsa_ShareCapitalValueRestated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl0" xml:lang="en-US">Representation amount of share capital value shares issued in lieu of fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl0" xml:lang="en-US">Share Capital value Shares issued pursuant to share for share exchange and consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareCapitalValueWarrantsExercised_lbl0" xml:lang="en-US">Representation amount of share capital value warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueWarrantsExercised" xlink:to="tlsa_ShareCapitalValueWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShareOptions_lbl0" xml:lang="en-US">Number of share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareOptions" xlink:to="tlsa_ShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumAnnualReport_lbl0" xml:lang="en-US">Share Premium annual report.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumAnnualReport" xlink:to="tlsa_SharePremiumAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumConversionOfLoan_lbl0" xml:lang="en-US">Share Premium Conversion of Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfLoan" xlink:to="tlsa_SharePremiumConversionOfLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumConversionOfWarrants_lbl0" xml:lang="en-US">Share Premium Conversion of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfWarrants" xlink:to="tlsa_SharePremiumConversionOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl0" xml:lang="en-US">Share Premium Elimination of share capital in Tiziana Life Sciences Plc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumEliminationOfShareCapitalIn" xlink:to="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumIssuanceOfStockATM_lbl0" xml:lang="en-US">Representation amount of share ppremium issuance of stock - ATM.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuanceOfStockATM" xlink:to="tlsa_SharePremiumIssuanceOfStockATM_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumIssuedInCashBonus_lbl0" xml:lang="en-US">Share Premium Issued in lieu of cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuedInCashBonus" xlink:to="tlsa_SharePremiumIssuedInCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumRestatedAt1January2021_lbl0" xml:lang="en-US">Share Premium Restated at 1 January 2021.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumRestatedAt1January2021" xlink:to="tlsa_SharePremiumRestatedAt1January2021_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl0" xml:lang="en-US">Representation amount of share premium shares issued in lieu of fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedInLieuOfFees" xlink:to="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0" xml:lang="en-US">Share Premium Shares issued pursuant to share for share exchange and consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharePremiumWarrantsExercised_lbl0" xml:lang="en-US">Representation amount of share premium warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumWarrantsExercised" xlink:to="tlsa_SharePremiumWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl0" xml:lang="en-US">Shares issued in lieu of cash realization bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfCashRealizationBonus" xlink:to="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharesIssuedInLieuOfFees_lbl0" xml:lang="en-US">Shares issued in lieu of fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfFees" xlink:to="tlsa_SharesIssuedInLieuOfFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharesPrice_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesPrice" xlink:to="tlsa_SharesPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl0" xml:lang="en-US">Shares to be issued in lieu of directors fees and cash bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:to="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SharesToBeIssuedReserve_lbl0" xml:lang="en-US">Shares to be issued reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedReserve" xlink:to="tlsa_SharesToBeIssuedReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_ShortTermLoanFacility1_lbl0" xml:lang="en-US">Short term loan facility.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShortTermLoanFacility1" xlink:to="tlsa_ShortTermLoanFacility1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_SublicenseIncome_lbl0" xml:lang="en-US">Sublicense Income means consideration in any form received by Company and/or Company&apos;s Affiliate(s) in connection with or otherwise attributable to a grant of a sublicense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SublicenseIncome" xlink:to="tlsa_SublicenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_TaxationReceivable_lbl1" xml:lang="en-US">Taxation receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationReceivable" xlink:to="tlsa_TaxationReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl0" xml:lang="en-US">Term of research and development tax relief claims.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" xlink:to="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_UpfrontPayment_lbl0" xml:lang="en-US">Upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UpfrontPayment" xlink:to="tlsa_UpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_WarrantsExercisedInTheYear_lbl0" xml:lang="en-US">Warrants exercised in the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsExercisedInTheYear" xlink:to="tlsa_WarrantsExercisedInTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tlsa_WarrantsForfeitedInTheYear_lbl0" xml:lang="en-US">Warrants forfeited in the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsForfeitedInTheYear" xlink:to="tlsa_WarrantsForfeitedInTheYear_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ExpectedTermOfAwards_lbl1" xml:lang="en-US">Expected Term Of Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExpectedTermOfAwards" xlink:to="tlsa_ExpectedTermOfAwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AdjustmentsDueToPriorPeriod_lbl1" xml:lang="en-US">Adjustments Due To Prior Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriod" xlink:to="tlsa_AdjustmentsDueToPriorPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ResearchAndDevelopment_lbl1" xml:lang="en-US">Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ResearchAndDevelopment" xlink:to="tlsa_ResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DepreciationOfRightofuseAsset_lbl1" xml:lang="en-US">Depreciation Of Rightofuse Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DepreciationOfRightofuseAsset" xlink:to="tlsa_DepreciationOfRightofuseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesIssuedInThePeriodAbstract0_lbl0" xml:lang="en-US">Shares Issued In The Period Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInThePeriodAbstract0" xlink:to="tlsa_SharesIssuedInThePeriodAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0" xml:lang="en-US">Expense from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US">Disclosure of changes in accounting estimates [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Model Inputs For Options Granted Under The Black Scholes Valuation Model Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" xlink:to="tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsGranted_lbl0" xml:lang="en-US">Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsGranted" xlink:to="tlsa_OptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Trade And Other Payables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock" xlink:to="tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for contingent liabilities and contingent assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FVLossOnInvestment_lbl1" xml:lang="en-US">FVLoss On Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FVLossOnInvestment" xlink:to="tlsa_FVLossOnInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Estimated The Fair Value Of Warrants Using Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:to="tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RasnaTherapeuticsIncMember_lbl0" xml:lang="en-US">Rasna Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RasnaTherapeuticsIncMember" xlink:to="tlsa_RasnaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CashInflowFromTaxation_lbl1" xml:lang="en-US">Cash Inflow From Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashInflowFromTaxation" xlink:to="tlsa_CashInflowFromTaxation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RightOfUseAssetsDepreciation_lbl0" xml:lang="en-US">Right Of Use Assets Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetsDepreciation" xlink:to="tlsa_RightOfUseAssetsDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CommercialSaleOfAProduct_lbl1" xml:lang="en-US">Commercial Sale Of AProduct</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CommercialSaleOfAProduct" xlink:to="tlsa_CommercialSaleOfAProduct_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of other operating income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherLossBeforeTaxation_lbl0" xml:lang="en-US">Other Loss Before Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherLossBeforeTaxation" xlink:to="tlsa_OtherLossBeforeTaxation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareOptionMember_lbl0" xml:lang="en-US">Share Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareOptionMember" xlink:to="tlsa_ShareOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsForfeitedcancelled_lbl0" xml:lang="en-US">Options Forfeitedcancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedcancelled" xlink:to="tlsa_OptionsForfeitedcancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesIssuedInLieuOfFees_lbl1" xml:lang="en-US">Shares Issued In Lieu Of Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfFees" xlink:to="tlsa_SharesIssuedInLieuOfFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_EstimatedUsefulLives_lbl1" xml:lang="en-US">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EstimatedUsefulLives" xlink:to="tlsa_EstimatedUsefulLives_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl1" xml:lang="en-US">Income Tax Reconciliation Research And Development Claim</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:to="tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets_lbl0" xml:lang="en-US">Impairment loss on financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:to="ifrs-full_ImpairmentLossOnFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl1" xml:lang="en-US">Description Of Accounting Policy For License Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForLicenseFees" xlink:to="tlsa_DescriptionOfAccountingPolicyForLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsExercised_lbl0" xml:lang="en-US">Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsExercised" xlink:to="tlsa_OptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems_lbl0" xml:lang="en-US">Remunerationof Key Management Personnel Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Operating Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOperatingLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccruedOfDiligenceObligations_lbl1" xml:lang="en-US">Accrued Of Diligence Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccruedOfDiligenceObligations" xlink:to="tlsa_AccruedOfDiligenceObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <loc xlink:type="locator" xlink:label="tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Shareholders Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract" xlink:to="tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses_lbl0" xml:lang="en-US">Insurance finance income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingExpenseAbstract_lbl0" xml:lang="en-US">Operating Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingExpenseAbstract" xlink:to="tlsa_OperatingExpenseAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract_lbl" xml:lang="en-US">Schedule Of Share Options Were Granted To Directors Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract" xlink:to="tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueAnnualReport_lbl1" xml:lang="en-US">Nominal Value Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueAnnualReport" xlink:to="tlsa_NominalValueAnnualReport_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueConversionOfWarrants_lbl1" xml:lang="en-US">Nominal Value Conversion Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfWarrants" xlink:to="tlsa_NominalValueConversionOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PrincipalAmount_lbl1" xml:lang="en-US">Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrincipalAmount" xlink:to="tlsa_PrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl1" xml:lang="en-US">Merger Reserve Elimination Of Share Capital In</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveEliminationOfShareCapitalIn" xlink:to="tlsa_MergerReserveEliminationOfShareCapitalIn_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl1" xml:lang="en-US">Disclosure Share Capital Arising For Share Exchangetext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:to="tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShortTermLoanFacility1_lbl1" xml:lang="en-US">Short Term Loan Facility1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShortTermLoanFacility1" xlink:to="tlsa_ShortTermLoanFacility1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Other Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfFinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinanceCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfFinanceCostsAbstract_lbl" xml:lang="en-US">Schedule Of Finance Costs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfFinanceCostsAbstract" xlink:to="tlsa_ScheduleOfFinanceCostsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl1" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl1" xml:lang="en-US">Disclosure Of Remuneration Of Key Management Personnel Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:to="tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for business combinations [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl1" xml:lang="en-US">Share Capital Value Shares Issued In Lieu Of Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalValueSharesIssuedInLieuOfFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Income Tax Expense Benefit Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl0" xml:lang="en-US">Operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl1" xml:lang="en-US">Share Capital Shares Issued In Lieu Of Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GensigniaLifesceinecsIncMember_lbl0" xml:lang="en-US">Gensignia Lifesceinecs Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GensigniaLifesceinecsIncMember" xlink:to="tlsa_GensigniaLifesceinecsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract18" xlink:to="tlsa_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalandSharePremiumDetailsLineItems_lbl0" xml:lang="en-US">Share Capitaland Share Premium Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalandSharePremiumDetailsLineItems" xlink:to="tlsa_ShareCapitalandSharePremiumDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract19" xlink:to="tlsa_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract16" xlink:to="tlsa_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract17" xlink:to="tlsa_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BlackScholesMertonValuationModelMember_lbl0" xml:lang="en-US">Black Scholes Merton Valuation Model Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BlackScholesMertonValuationModelMember" xlink:to="tlsa_BlackScholesMertonValuationModelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Employees Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:to="tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl1" xml:lang="en-US">Description Of Accounting Policy For Basisof Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl1" xml:lang="en-US">Nominal Value Issued In Lieu Of Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuedInLieuOfCashBonus" xlink:to="tlsa_NominalValueIssuedInLieuOfCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PhaseIIClinicalTrialMember_lbl0" xml:lang="en-US">Phase IIClinical Trial Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIClinicalTrialMember" xlink:to="tlsa_PhaseIIClinicalTrialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumConversionOfWarrants_lbl1" xml:lang="en-US">Share Premium Conversion Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfWarrants" xlink:to="tlsa_SharePremiumConversionOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract21" xlink:to="tlsa_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract22" xlink:to="tlsa_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract20" xlink:to="tlsa_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl1" xml:lang="en-US">Share Capital Shares Issuance Of Stock ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalSharesIssuanceOfStockATM_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract23" xlink:to="tlsa_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember_lbl0" xml:lang="en-US">Twenty Five August Two Thousand And Twenty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember" xlink:to="tlsa_TwentyFiveAugustTwoThousandAndTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract24" xlink:to="tlsa_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SixMayTwoThousandAndTwentyMember_lbl0" xml:lang="en-US">Six May Two Thousand And Twenty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SixMayTwoThousandAndTwentyMember" xlink:to="tlsa_SixMayTwoThousandAndTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InterestReceivedFromLoan_lbl1" xml:lang="en-US">Interest Received From Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InterestReceivedFromLoan" xlink:to="tlsa_InterestReceivedFromLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for reclassification of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumEnding_lbl0" xml:lang="en-US">Share Premium Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumEnding" xlink:to="tlsa_SharePremiumEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl0" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisposalOfLease_lbl1" xml:lang="en-US">Disposal Of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisposalOfLease" xlink:to="tlsa_DisposalOfLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveRestated_lbl1" xml:lang="en-US">Merger Reserve Restated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveRestated" xlink:to="tlsa_MergerReserveRestated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TaxationReceivable_lbl2" xml:lang="en-US">Taxation Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TaxationReceivable" xlink:to="tlsa_TaxationReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WarrantsExercisedInTheYear_lbl1" xml:lang="en-US">Warrants Exercised In The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsExercisedInTheYear" xlink:to="tlsa_WarrantsExercisedInTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_USDMember_lbl0" xml:lang="en-US">USDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_USDMember" xlink:to="tlsa_USDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WeightedAverageExercisePriceOutstanding_lbl1" xml:lang="en-US">Weighted Average Exercise Price Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceOutstanding" xlink:to="tlsa_WeightedAverageExercisePriceOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherGainsLosses_lbl0" xml:lang="en-US">Other gains (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Basis Of Preparation Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty_lbl0" xml:lang="en-US">Impairment loss recognised in profit or loss, investment property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeTaxExpenseContinuingOperation_lbl1" xml:lang="en-US">Income Tax Expense Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxExpenseContinuingOperation" xlink:to="tlsa_IncomeTaxExpenseContinuingOperation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ExerciseSharePrice_lbl0" xml:lang="en-US">Exercise Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExerciseSharePrice" xlink:to="tlsa_ExerciseSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OutstandingExercised_lbl1" xml:lang="en-US">Outstanding Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExercised" xlink:to="tlsa_OutstandingExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Warrants Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FundraisingCost_lbl1" xml:lang="en-US">Fundraising Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FundraisingCost" xlink:to="tlsa_FundraisingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl0" xml:lang="en-US">Disclosure of finance cost [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TradeandOtherPayablesTablesLineItems_lbl0" xml:lang="en-US">Tradeand Other Payables Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TradeandOtherPayablesTablesLineItems" xlink:to="tlsa_TradeandOtherPayablesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1" xml:lang="en-US">Merger Reserve Shares Issued Pursuant To Share For Share Exchange And Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossDetailsLineItems_lbl0" xml:lang="en-US">Operating Loss Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossDetailsLineItems" xlink:to="tlsa_OperatingLossDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WeightedAverageExercisePriceExercisable_lbl0" xml:lang="en-US">Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceExercisable" xlink:to="tlsa_WeightedAverageExercisePriceExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember_lbl0" xml:lang="en-US">Later Than Two Years And Not Later Than Five Year Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember" xlink:to="tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PhaseIIIHumanMember_lbl0" xml:lang="en-US">Phase IIIHuman Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIIHumanMember" xlink:to="tlsa_PhaseIIIHumanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ExchangeDifferencesRightofUseAssets_lbl1" xml:lang="en-US">Exchange Differences Rightof Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferencesRightofUseAssets" xlink:to="tlsa_ExchangeDifferencesRightofUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl1" xml:lang="en-US">Nominal Value Shares Issued In Lieu Of Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedInLieuOfFees" xlink:to="tlsa_NominalValueSharesIssuedInLieuOfFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_Licensefee_lbl1" xml:lang="en-US">Licensefee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Licensefee" xlink:to="tlsa_Licensefee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WeightedAverageExercisePriceGranted_lbl0" xml:lang="en-US">Weighted Average Exercise Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceGranted" xlink:to="tlsa_WeightedAverageExercisePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeaseLiabilitiesBeginning_lbl0" xml:lang="en-US">Lease Liabilities Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesBeginning" xlink:to="tlsa_LeaseLiabilitiesBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesAnnualReport_lbl1" xml:lang="en-US">Share Capital Shares Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesAnnualReport" xlink:to="tlsa_ShareCapitalSharesAnnualReport_lbl1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEmployeesAbstract_lbl" xml:lang="en-US">Schedule Of Employees Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEmployeesAbstract" xlink:to="tlsa_ScheduleOfEmployeesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MovementPercentageStrengthening_lbl1" xml:lang="en-US">Movement Percentage Strengthening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageStrengthening" xlink:to="tlsa_MovementPercentageStrengthening_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl1" xml:lang="en-US">Share Capital Shares Issued In Lieu Of Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesIssuedInLieuOfFees" xlink:to="tlsa_ShareCapitalSharesIssuedInLieuOfFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract10" xlink:to="tlsa_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TizianaLifeSciencesPLCMember_lbl0" xml:lang="en-US">Tiziana Life Sciences PLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TizianaLifeSciencesPLCMember" xlink:to="tlsa_TizianaLifeSciencesPLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract11" xlink:to="tlsa_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_KShailubhaiMember_lbl0" xml:lang="en-US">KShailubhai Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_KShailubhaiMember" xlink:to="tlsa_KShailubhaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract14" xlink:to="tlsa_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract15" xlink:to="tlsa_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract12" xlink:to="tlsa_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract13" xlink:to="tlsa_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl1" xml:lang="en-US">Shares To Be Issued In Lieu Of Directors Fees And Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:to="tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueConversionOfLoan_lbl1" xml:lang="en-US">Nominal Value Conversion Of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueConversionOfLoan" xlink:to="tlsa_NominalValueConversionOfLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsExercisable_lbl0" xml:lang="en-US">Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsExercisable" xlink:to="tlsa_OptionsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MovementPercentageWeakening_lbl1" xml:lang="en-US">Movement Percentage Weakening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementPercentageWeakening" xlink:to="tlsa_MovementPercentageWeakening_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl0" xml:lang="en-US">Fixtures and fittings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember_lbl0" xml:lang="en-US">Twenty Three July Two Thousand And Twenty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember" xlink:to="tlsa_TwentyThreeJulyTwoThousandAndTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Income Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherIncomeExpenseAbstract" xlink:to="tlsa_OtherIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BuybackOfTreasuryShares_lbl1" xml:lang="en-US">Buyback Of Treasury Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BuybackOfTreasuryShares" xlink:to="tlsa_BuybackOfTreasuryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_lbl0" xml:lang="en-US">Adjustments for gains (losses) on fair value adjustment, investment property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLongtermBenefits_lbl0" xml:lang="en-US">Other long-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLongtermBenefits" xlink:to="ifrs-full_OtherLongtermBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesIssuedInThePeriodAbstract_lbl0" xml:lang="en-US">Shares Issued In The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInThePeriodAbstract" xlink:to="tlsa_SharesIssuedInThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesConversionOfLoan_lbl1" xml:lang="en-US">Share Capital Shares Conversion Of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfLoan" xlink:to="tlsa_ShareCapitalSharesConversionOfLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OKYOPharmaLtdMember_lbl0" xml:lang="en-US">OKYOPharma Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OKYOPharmaLtdMember" xlink:to="tlsa_OKYOPharmaLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl0" xml:lang="en-US">Not later than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberofOptionsExercised_lbl0" xml:lang="en-US">Numberof Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberofOptionsExercised" xlink:to="tlsa_NumberofOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl0" xml:lang="en-US">Description of nature of change in accounting estimate [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfShareOptionsGranted_lbl0" xml:lang="en-US">Number Of Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsGranted" xlink:to="tlsa_NumberOfShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveConversionOfLoan_lbl1" xml:lang="en-US">Merger Reserve Conversion Of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfLoan" xlink:to="tlsa_MergerReserveConversionOfLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract2" xlink:to="tlsa_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract1" xlink:to="tlsa_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract4" xlink:to="tlsa_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_Salary_lbl1" xml:lang="en-US">Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Salary" xlink:to="tlsa_Salary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract3" xlink:to="tlsa_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueWarrantsExercised_lbl1" xml:lang="en-US">Share Capital Value Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueWarrantsExercised" xlink:to="tlsa_ShareCapitalValueWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract0" xlink:to="tlsa_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract9" xlink:to="tlsa_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumIssuedInCashBonus_lbl1" xml:lang="en-US">Share Premium Issued In Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuedInCashBonus" xlink:to="tlsa_SharePremiumIssuedInCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract6" xlink:to="tlsa_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract5" xlink:to="tlsa_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfSharesIssued1_lbl0" xml:lang="en-US">Number Of Shares Issued1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfSharesIssued1" xlink:to="tlsa_NumberOfSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract8" xlink:to="tlsa_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract7" xlink:to="tlsa_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MilestonePaymentDue_lbl1" xml:lang="en-US">Milestone Payment Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MilestonePaymentDue" xlink:to="tlsa_MilestonePaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceExpense_lbl1" xml:lang="en-US">Finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceExpense" xlink:to="tlsa_FinanceExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember_lbl0" xml:lang="en-US">Zero Onee August Two Thousand And Twenty Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember" xlink:to="tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfShareOptionsExercisable_lbl0" xml:lang="en-US">Number Of Share Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsExercisable" xlink:to="tlsa_NumberOfShareOptionsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsForfeitedDuringTheYear_lbl1" xml:lang="en-US">Options Forfeited During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedDuringTheYear" xlink:to="tlsa_OptionsForfeitedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SocialSecurityContributions_lbl0" xml:lang="en-US">Social security contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FixedAssetDifferences_lbl1" xml:lang="en-US">Fixed Asset Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FixedAssetDifferences" xlink:to="tlsa_FixedAssetDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl1" xml:lang="en-US">Disclosure Of Share Options Were Granted To Director Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:to="tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LessThanThreeMonthMember_lbl0" xml:lang="en-US">Less Than Three Month Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LessThanThreeMonthMember" xlink:to="tlsa_LessThanThreeMonthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossPerShareTablesLineItems_lbl0" xml:lang="en-US">Loss Per Share Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossPerShareTablesLineItems" xlink:to="tlsa_LossPerShareTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FourteenMarchTwoThousandTwentyThreeMember_lbl0" xml:lang="en-US">Fourteen March Two Thousand Twenty Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FourteenMarchTwoThousandTwentyThreeMember" xlink:to="tlsa_FourteenMarchTwoThousandTwentyThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl1" xml:lang="en-US">Description Of Accounting Policy For Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForGoingConcern" xlink:to="tlsa_DescriptionOfAccountingPolicyForGoingConcern_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RecruitmentFees_lbl1" xml:lang="en-US">Recruitment Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RecruitmentFees" xlink:to="tlsa_RecruitmentFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccumulatedLoss_lbl1" xml:lang="en-US">Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccumulatedLoss" xlink:to="tlsa_AccumulatedLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl1" xml:lang="en-US">Number Of Share Options Were Granted To Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsWereGrantedToDirectors" xlink:to="tlsa_NumberOfShareOptionsWereGrantedToDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments_lbl0" xml:lang="en-US">Non-current financial assets at fair value through profit or loss, measured as such in accordance with exemption for reacquisition of own equity instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CapitalDistribution_lbl1" xml:lang="en-US">Capital Distribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CapitalDistribution" xlink:to="tlsa_CapitalDistribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UnlabeledAbstract" xlink:to="tlsa_UnlabeledAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives For The Current Period And The Comparative Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract" xlink:to="tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeaseLiabilitiesInterestExpense_lbl0" xml:lang="en-US">Lease Liabilities Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesInterestExpense" xlink:to="tlsa_LeaseLiabilitiesInterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract_lbl" xml:lang="en-US">Schedule Of Remuneration Of Key Management Personnel Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract" xlink:to="tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses_lbl0" xml:lang="en-US">Tax rate effect of tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfTaxLosses" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_JBrancaccioMember_lbl1" xml:lang="en-US">JBrancaccio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_JBrancaccioMember" xlink:to="tlsa_JBrancaccioMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NetIncreaseInRelatedPartyPayables_lbl1" xml:lang="en-US">Net Increase In Related Party Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyPayables" xlink:to="tlsa_NetIncreaseInRelatedPartyPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Equity Incentive Plan Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock" xlink:to="tlsa_ScheduleOfEquityIncentivePlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AcquiredShares_lbl1" xml:lang="en-US">Acquired Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AcquiredShares" xlink:to="tlsa_AcquiredShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueAt31December2021_lbl1" xml:lang="en-US">Share Capital Value At31 December2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAt31December2021" xlink:to="tlsa_ShareCapitalValueAt31December2021_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesRestated_lbl1" xml:lang="en-US">Share Capital Shares Restated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesRestated" xlink:to="tlsa_ShareCapitalSharesRestated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WillySimonMember_lbl0" xml:lang="en-US">Willy Simon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WillySimonMember" xlink:to="tlsa_WillySimonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NetPresentValues_lbl1" xml:lang="en-US">Net Present Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetPresentValues" xlink:to="tlsa_NetPresentValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_EliminationOfOtherReserves_lbl1" xml:lang="en-US">Elimination Of Other Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_EliminationOfOtherReserves" xlink:to="tlsa_EliminationOfOtherReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentInRelatedPartyTextBlock_lbl0" xml:lang="en-US">Investment In Related Party Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedPartyTextBlock" xlink:to="tlsa_InvestmentInRelatedPartyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember_lbl0" xml:lang="en-US">Zero Four November Two Thousand And Twenty Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember" xlink:to="tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesPurchases_lbl0" xml:lang="en-US">Shares Purchases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesPurchases" xlink:to="tlsa_SharesPurchases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TranslationReserveMember_lbl0" xml:lang="en-US">Translation Reserve Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TranslationReserveMember" xlink:to="tlsa_TranslationReserveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesEliminationOfShare_lbl1" xml:lang="en-US">Share Capital Shares Elimination Of Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesEliminationOfShare" xlink:to="tlsa_ShareCapitalSharesEliminationOfShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0" xml:lang="en-US">Disclosure of financial risk management [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ProceedsFromFinanceLease_lbl1" xml:lang="en-US">Proceeds From Finance Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromFinanceLease" xlink:to="tlsa_ProceedsFromFinanceLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl0" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl0" xml:lang="en-US">Later than five years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasurySharesMember_lbl0" xml:lang="en-US">Treasury shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueEliminationOfShareCapital_lbl1" xml:lang="en-US">Nominal Value Elimination Of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueEliminationOfShareCapital" xlink:to="tlsa_NominalValueEliminationOfShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl0" xml:lang="en-US">Wages and salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLossTablesLineItems_lbl0" xml:lang="en-US">Operating Loss Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLossTablesLineItems" xlink:to="tlsa_OperatingLossTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ProfitOrLossAndEquityWeakening_lbl1" xml:lang="en-US">Profit Or Loss And Equity Weakening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityWeakening" xlink:to="tlsa_ProfitOrLossAndEquityWeakening_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl0" xml:lang="en-US">Current tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumAnnualReport_lbl1" xml:lang="en-US">Share Premium Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumAnnualReport" xlink:to="tlsa_SharePremiumAnnualReport_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl1" xml:lang="en-US">Income Tax Reconciliation Loss Charged At Standard Rate Of Corporation Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:to="tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfShareOptionsOutstanding_lbl1" xml:lang="en-US">Number Of Share Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsOutstanding" xlink:to="tlsa_NumberOfShareOptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl1" xml:lang="en-US">Disclosure Of Estimated Useful Lives For The Current Period And The Comparative Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:to="tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ExpiryDate_lbl0" xml:lang="en-US">Expiry Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExpiryDate" xlink:to="tlsa_ExpiryDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GrantDateSharesPrice_lbl0" xml:lang="en-US">Grant Date Shares Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GrantDateSharesPrice" xlink:to="tlsa_GrantDateSharesPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for issued capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl1" xml:lang="en-US">Share Capital Value Issuance Of Stock ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuanceOfStockATM" xlink:to="tlsa_ShareCapitalValueIssuanceOfStockATM_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl1" xml:lang="en-US">Prepaymentsand Other Receivables Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PrepaymentsandOtherReceivablesCurrent" xlink:to="tlsa_PrepaymentsandOtherReceivablesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherIncomelosses_lbl1" xml:lang="en-US">Other Incomelosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherIncomelosses" xlink:to="tlsa_OtherIncomelosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DevelopmentMilestones_lbl1" xml:lang="en-US">Development Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DevelopmentMilestones" xlink:to="tlsa_DevelopmentMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesDetailsLineItems_lbl0" xml:lang="en-US">Accounting Policies Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesDetailsLineItems" xlink:to="tlsa_AccountingPoliciesDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OutstandingExpired_lbl1" xml:lang="en-US">Outstanding Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingExpired" xlink:to="tlsa_OutstandingExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl1" xml:lang="en-US">Average Monthly Number Of Employees Including Directors Employed By Group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:to="tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1" xml:lang="en-US">Share Premium Shares Issued Pursuant To Share For Share Exchange And Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ChargeOfForfeitures_lbl1" xml:lang="en-US">Charge Of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ChargeOfForfeitures" xlink:to="tlsa_ChargeOfForfeitures_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl0" xml:lang="en-US">Services expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WeightedAverageExercisePriceExercised_lbl0" xml:lang="en-US">Weighted Average Exercise Price Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceExercised" xlink:to="tlsa_WeightedAverageExercisePriceExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule Of Measurement Of The Financial Instruments Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" xlink:to="tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GroupReorganizationAbstract_lbl0" xml:lang="en-US">Group Reorganization Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupReorganizationAbstract" xlink:to="tlsa_GroupReorganizationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl0" xml:lang="en-US">Weighted average share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GroupAbstract0_lbl0" xml:lang="en-US">Group Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupAbstract0" xlink:to="tlsa_GroupAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RelatedPartyAxis_lbl0" xml:lang="en-US">Related Party Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyAxis" xlink:to="tlsa_RelatedPartyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl0" xml:lang="en-US">Disclosure of treasury shares [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl0" xml:lang="en-US">Expense recognised during period for bad and doubtful debts for related party transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LossOnDisposalOfAsset_lbl1" xml:lang="en-US">Loss On Disposal Of Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LossOnDisposalOfAsset" xlink:to="tlsa_LossOnDisposalOfAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl0" xml:lang="en-US">Accruals classified as current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BenefitsPaidOrPayable_lbl0" xml:lang="en-US">Benefits paid or payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BenefitsPaidOrPayable" xlink:to="ifrs-full_BenefitsPaidOrPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RelatedPartyPayablesAmount_lbl0" xml:lang="en-US">Related Party Payables Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RelatedPartyPayablesAmount" xlink:to="tlsa_RelatedPartyPayablesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForInterestExpense_lbl0" xml:lang="en-US">Adjustments for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForInterestExpense" xlink:to="ifrs-full_AdjustmentsForInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl0" xml:lang="en-US">Other reserves [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueRestated_lbl1" xml:lang="en-US">Share Capital Value Restated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueRestated" xlink:to="tlsa_ShareCapitalValueRestated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl1" xml:lang="en-US">Income Tax Reconciliation Expenses Not Deductible For Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:to="tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Financial Liabilities Based On Contractual Undiscounted Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" xlink:to="tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl1" xml:lang="en-US">Disclosure Of Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfFutureMinimumLeasePayments" xlink:to="tlsa_DisclosureOfFutureMinimumLeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueRestated_lbl1" xml:lang="en-US">Nominal Value Restated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueRestated" xlink:to="tlsa_NominalValueRestated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BasicLossPerSharecentsPerShare_lbl0" xml:lang="en-US">Basic Loss Per Sharecents Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BasicLossPerSharecentsPerShare" xlink:to="tlsa_BasicLossPerSharecentsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsOutstanding_lbl1" xml:lang="en-US">Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsOutstanding" xlink:to="tlsa_OptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ThirtyAprilTwoThousandAndEighteenMember_lbl0" xml:lang="en-US">Thirty April Two Thousand And Eighteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ThirtyAprilTwoThousandAndEighteenMember" xlink:to="tlsa_ThirtyAprilTwoThousandAndEighteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl0" xml:lang="en-US">Other operating income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RightOfUseAssetsTotal_lbl0" xml:lang="en-US">Right Of Use Assets Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetsTotal" xlink:to="tlsa_RightOfUseAssetsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl1" xml:lang="en-US">Merger Reserve Issued In Lieu Of Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveIssuedInLieuOfCashBonus" xlink:to="tlsa_MergerReserveIssuedInLieuOfCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl1" xml:lang="en-US">Treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract_lbl0" xml:lang="en-US">The Tax Charge For The Year Is Different From The Standard Rate Of Corporation Tax In The United Kingdom Of19 The Difference Can Be Reconciled As Follows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract" xlink:to="tlsa_TheTaxChargeForTheYearIsDifferentFromTheStandardRateOfCorporationTaxInTheUnitedKingdomOf19TheDifferenceCanBeReconciledAsFollowsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfOtherExpenseIncomeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOtherExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfOtherExpenseIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Other Expense Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfOtherExpenseIncomeAbstract" xlink:to="tlsa_ScheduleOfOtherExpenseIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl1" xml:lang="en-US">Share Premium Elimination Of Share Capital In</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumEliminationOfShareCapitalIn" xlink:to="tlsa_SharePremiumEliminationOfShareCapitalIn_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PurchaseOfTreasuryAmount_lbl0" xml:lang="en-US">Purchase Of Treasury Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PurchaseOfTreasuryAmount" xlink:to="tlsa_PurchaseOfTreasuryAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Sub License Income Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_lbl0" xml:lang="en-US">Disclosure of information about employees [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveConversionOfWarrants_lbl1" xml:lang="en-US">Merger Reserve Conversion Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveConversionOfWarrants" xlink:to="tlsa_MergerReserveConversionOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueIssuedInCashBonus_lbl1" xml:lang="en-US">Share Capital Value Issued In Cash Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueIssuedInCashBonus" xlink:to="tlsa_ShareCapitalValueIssuedInCashBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OutstandingFairValueCharges_lbl1" xml:lang="en-US">Outstanding Fair Value Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OutstandingFairValueCharges" xlink:to="tlsa_OutstandingFairValueCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DirectorsFees_lbl1" xml:lang="en-US">Directors Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DirectorsFees" xlink:to="tlsa_DirectorsFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl1" xml:lang="en-US">Shares Issued In Lieu Of Cash Realization Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesIssuedInLieuOfCashRealizationBonus" xlink:to="tlsa_SharesIssuedInLieuOfCashRealizationBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Weighted average share price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_StaffCostsComprisedAbstract_lbl0" xml:lang="en-US">Staff Costs Comprised Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_StaffCostsComprisedAbstract" xlink:to="tlsa_StaffCostsComprisedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GroupAbstract_lbl0" xml:lang="en-US">Group Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GroupAbstract" xlink:to="tlsa_GroupAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ProceedsFromIssuanceOfOptions_lbl1" xml:lang="en-US">Proceeds From Issuance Of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromIssuanceOfOptions" xlink:to="tlsa_ProceedsFromIssuanceOfOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalConversionOfWarrants_lbl1" xml:lang="en-US">Share Capital Conversion Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalConversionOfWarrants" xlink:to="tlsa_ShareCapitalConversionOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeaseLiabilitiesTotal_lbl0" xml:lang="en-US">Lease Liabilities Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesTotal" xlink:to="tlsa_LeaseLiabilitiesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl1" xml:lang="en-US">Net Finance Expense Recognized In Statement Of Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:to="tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1" xml:lang="en-US">Nominal Value Shares Issued Pursuant To Share For Share Exchange And Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:to="tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionLifeShareOptionsGranted_lbl1" xml:lang="en-US">Option Life Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionLifeShareOptionsGranted" xlink:to="tlsa_OptionLifeShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NetIncreaseInRelatedPartyReceivables_lbl1" xml:lang="en-US">Net Increase In Related Party Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NetIncreaseInRelatedPartyReceivables" xlink:to="tlsa_NetIncreaseInRelatedPartyReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl1" xml:lang="en-US">Share Capital Value Elimination Of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueEliminationOfShareCapital" xlink:to="tlsa_ShareCapitalValueEliminationOfShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl1" xml:lang="en-US">Share Capital Value Shares Issued Pursuant To Share Exchange And Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceExpenseAbstract_lbl0" xml:lang="en-US">Finance Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceExpenseAbstract" xlink:to="tlsa_FinanceExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Quantitative Information About Rightofuse Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" xlink:to="tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PayrollAndRentCharged_lbl0" xml:lang="en-US">Payroll And Rent Charged</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PayrollAndRentCharged" xlink:to="tlsa_PayrollAndRentCharged_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FairValueOutstanding_lbl2" xml:lang="en-US">Fair Value Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FairValueOutstanding" xlink:to="tlsa_FairValueOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl1" xml:lang="en-US">Adjustments For Sharebased Payments Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsForSharebasedPaymentsWarrants" xlink:to="tlsa_AdjustmentsForSharebasedPaymentsWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveEnding_lbl0" xml:lang="en-US">Merger Reserve Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveEnding" xlink:to="tlsa_MergerReserveEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesToBeIssuedReserve_lbl1" xml:lang="en-US">Shares To Be Issued Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedReserve" xlink:to="tlsa_SharesToBeIssuedReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SecurityDepositsReceivable_lbl1" xml:lang="en-US">Security Deposits Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SecurityDepositsReceivable" xlink:to="tlsa_SecurityDepositsReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ClassOfWarrantsOrRightAxis_lbl0" xml:lang="en-US">Class Of Warrants Or Right Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ClassOfWarrantsOrRightAxis" xlink:to="tlsa_ClassOfWarrantsOrRightAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WarrantsForfeitedInTheYear_lbl1" xml:lang="en-US">Warrants Forfeited In The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WarrantsForfeitedInTheYear" xlink:to="tlsa_WarrantsForfeitedInTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ProfitOrLossAndEquityStrengthening_lbl1" xml:lang="en-US">Profit Or Loss And Equity Strengthening</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProfitOrLossAndEquityStrengthening" xlink:to="tlsa_ProfitOrLossAndEquityStrengthening_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ExchangeDifferences_lbl1" xml:lang="en-US">Exchange Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ExchangeDifferences" xlink:to="tlsa_ExchangeDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_Phase3Member_lbl0" xml:lang="en-US">Phase3 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Phase3Member" xlink:to="tlsa_Phase3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BLAMember_lbl0" xml:lang="en-US">BLAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BLAMember" xlink:to="tlsa_BLAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByFunction_lbl0" xml:lang="en-US">Other expense, by function</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByFunction" xlink:to="ifrs-full_OtherExpenseByFunction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl0" xml:lang="en-US">Interest income on impaired financial assets accrued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesConversionOfWarrants_lbl1" xml:lang="en-US">Share Capital Shares Conversion Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesConversionOfWarrants" xlink:to="tlsa_ShareCapitalSharesConversionOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumWarrantsExercised_lbl1" xml:lang="en-US">Share Premium Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumWarrantsExercised" xlink:to="tlsa_SharePremiumWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RightOfUseAssetMember_lbl0" xml:lang="en-US">Right Of Use Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetMember" xlink:to="tlsa_RightOfUseAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments_lbl0" xml:lang="en-US">Gains (losses) on disposals of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:to="ifrs-full_GainsLossesOnDisposalsOfInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MilestonePayments_lbl0" xml:lang="en-US">Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MilestonePayments" xlink:to="tlsa_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PhaseIIHumanMember_lbl0" xml:lang="en-US">Phase IIHuman Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIIHumanMember" xlink:to="tlsa_PhaseIIHumanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl1" xml:lang="en-US">Disclosure Of Accounting Share Capital And Share Premiumtext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:to="tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesPrice_lbl1" xml:lang="en-US">Shares Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesPrice" xlink:to="tlsa_SharesPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RaisingFunds_lbl1" xml:lang="en-US">Raising Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RaisingFunds" xlink:to="tlsa_RaisingFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeaseLiabilitiesLeasePayments_lbl0" xml:lang="en-US">Lease Liabilities Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeaseLiabilitiesLeasePayments" xlink:to="tlsa_LeaseLiabilitiesLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of profit (loss) from operating activities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InterestAmount_lbl0" xml:lang="en-US">Interest Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InterestAmount" xlink:to="tlsa_InterestAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueAnnualReport_lbl1" xml:lang="en-US">Share Capital Value Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueAnnualReport" xlink:to="tlsa_ShareCapitalValueAnnualReport_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinancialInstrumentsNet_lbl0" xml:lang="en-US">Financial Instruments Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinancialInstrumentsNet" xlink:to="tlsa_FinancialInstrumentsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BonusToBeSettledInEquity_lbl1" xml:lang="en-US">Bonus To Be Settled In Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BonusToBeSettledInEquity" xlink:to="tlsa_BonusToBeSettledInEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RightOfUseAssetBeginning_lbl0" xml:lang="en-US">Right Of Use Asset Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetBeginning" xlink:to="tlsa_RightOfUseAssetBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_PhaseIHumanMember_lbl0" xml:lang="en-US">Phase IHuman Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_PhaseIHumanMember" xlink:to="tlsa_PhaseIHumanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OperatingLoss_lbl1" xml:lang="en-US">Operating Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OperatingLoss" xlink:to="tlsa_OperatingLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentoptions_lbl1" xml:lang="en-US">Share Based Paymentoptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentoptions" xlink:to="tlsa_ShareBasedPaymentoptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CarcinomaMember_lbl0" xml:lang="en-US">Carcinoma Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CarcinomaMember" xlink:to="tlsa_CarcinomaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WSimonMember_lbl0" xml:lang="en-US">WSimon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WSimonMember" xlink:to="tlsa_WSimonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements_lbl0" xml:lang="en-US">Consolidation Adjustment In Relation To Foreign Exchange Movements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements" xlink:to="tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalShares_lbl1" xml:lang="en-US">Share Capital Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalShares" xlink:to="tlsa_ShareCapitalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_GCerroneMember_lbl0" xml:lang="en-US">GCerrone Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_GCerroneMember" xlink:to="tlsa_GCerroneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ForeignExchangegainlosses_lbl1" xml:lang="en-US">Foreign Exchangegainlosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ForeignExchangegainlosses" xlink:to="tlsa_ForeignExchangegainlosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl1" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_HCCMember_lbl0" xml:lang="en-US">HCCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_HCCMember" xlink:to="tlsa_HCCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl1" xml:lang="en-US">Term Of Research And Development Tax Relief Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims" xlink:to="tlsa_TermOfResearchAndDevelopmentTaxReliefClaims_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RightOfUseAssetDescription_lbl0" xml:lang="en-US">Right Of Use Asset Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RightOfUseAssetDescription" xlink:to="tlsa_RightOfUseAssetDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MaximumPercentageOfSurrenderableLosses_lbl1" xml:lang="en-US">Maximum Percentage Of Surrenderable Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MaximumPercentageOfSurrenderableLosses" xlink:to="tlsa_MaximumPercentageOfSurrenderableLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceIncomeAbstract" xlink:to="tlsa_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ThreeToTwelveMonthMember_lbl0" xml:lang="en-US">Three To Twelve Month Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ThreeToTwelveMonthMember" xlink:to="tlsa_ThreeToTwelveMonthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AdditionalPayment_lbl1" xml:lang="en-US">Additional Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdditionalPayment" xlink:to="tlsa_AdditionalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NASDAQStockExchangeMember_lbl0" xml:lang="en-US">NASDAQStock Exchange Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NASDAQStockExchangeMember" xlink:to="tlsa_NASDAQStockExchangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPoliciesLineItems_lbl0" xml:lang="en-US">Accounting Policies Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPoliciesLineItems" xlink:to="tlsa_AccountingPoliciesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AdjustmentsToBroughtForwardValues_lbl0" xml:lang="en-US">Adjustments To Brought Forward Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsToBroughtForwardValues" xlink:to="tlsa_AdjustmentsToBroughtForwardValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalOutstanding_lbl0" xml:lang="en-US">Share Capital Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalOutstanding" xlink:to="tlsa_ShareCapitalOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPayments_lbl0" xml:lang="en-US">Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPayments" xlink:to="tlsa_ShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfShareOptionsForfeited_lbl0" xml:lang="en-US">Number Of Share Options Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfShareOptionsForfeited" xlink:to="tlsa_NumberOfShareOptionsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesWarrantsExercised_lbl1" xml:lang="en-US">Share Capital Shares Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesWarrantsExercised" xlink:to="tlsa_ShareCapitalSharesWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_LeasePayments_lbl1" xml:lang="en-US">Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_LeasePayments" xlink:to="tlsa_LeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueIssuanceOfStockATM_lbl1" xml:lang="en-US">Nominal Value Issuance Of Stock ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueIssuanceOfStockATM" xlink:to="tlsa_NominalValueIssuanceOfStockATM_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl0" xml:lang="en-US">Depreciation, right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl0" xml:lang="en-US">Amounts receivable, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NominalValueWarrantsExercised_lbl1" xml:lang="en-US">Nominal Value Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NominalValueWarrantsExercised" xlink:to="tlsa_NominalValueWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl1" xml:lang="en-US">Share Capital Shares Shares Issued Pursuant For Share Exchange And Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:to="tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation_lbl1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfOperatingLossesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOperatingLossesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfOperatingLossesAbstract_lbl" xml:lang="en-US">Schedule Of Operating Losses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfOperatingLossesAbstract" xlink:to="tlsa_ScheduleOfOperatingLossesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TreasuryShares1_lbl0" xml:lang="en-US">Treasury Shares1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TreasuryShares1" xlink:to="tlsa_TreasuryShares1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl1" xml:lang="en-US">Proceeds From Sale And Collection Of Finance Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:to="tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl1" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfBasicLossPerShareAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfBasicLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfBasicLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Basic Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfBasicLossPerShareAbstract" xlink:to="tlsa_ScheduleOfBasicLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CorporateAndAdministration_lbl1" xml:lang="en-US">Corporate And Administration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CorporateAndAdministration" xlink:to="tlsa_CorporateAndAdministration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentReserveWarrants_lbl0" xml:lang="en-US">Share Based Payment Reserve Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentReserveWarrants" xlink:to="tlsa_ShareBasedPaymentReserveWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IssuanceOfShareCapital_lbl0" xml:lang="en-US">Issuance Of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IssuanceOfShareCapital" xlink:to="tlsa_IssuanceOfShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareCapitalValueConversionOfLoan_lbl1" xml:lang="en-US">Share Capital Value Conversion Of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareCapitalValueConversionOfLoan" xlink:to="tlsa_ShareCapitalValueConversionOfLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl0" xml:lang="en-US">Later than one year and not later than two years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MovementInUnrecognisedDeferredTax_lbl1" xml:lang="en-US">Movement In Unrecognised Deferred Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MovementInUnrecognisedDeferredTax" xlink:to="tlsa_MovementInUnrecognisedDeferredTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RealisationBonus_lbl1" xml:lang="en-US">Realisation Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RealisationBonus" xlink:to="tlsa_RealisationBonus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SublicenseIncome_lbl1" xml:lang="en-US">Sublicense Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SublicenseIncome" xlink:to="tlsa_SublicenseIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Other comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl0" xml:lang="en-US">Loans received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumIssuanceOfStockATM_lbl1" xml:lang="en-US">Share Premium Issuance Of Stock ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumIssuanceOfStockATM" xlink:to="tlsa_SharePremiumIssuanceOfStockATM_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl1" xml:lang="en-US">Merger Reserve At January12021 Per20 FAnnual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport" xlink:to="tlsa_MergerReserveAtJanuary12021Per20FAnnualReport_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl0" xml:lang="en-US">Percentage of voting equity interests acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl1" xml:lang="en-US">Disclosure Detailed Information About Of Finance Cost Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:to="tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl1" xml:lang="en-US">Share Premium Shares Issued In Lieu Of Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumSharesIssuedInLieuOfFees" xlink:to="tlsa_SharePremiumSharesIssuedInLieuOfFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl0" xml:lang="en-US">Directors&apos; remuneration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumConversionOfLoan_lbl1" xml:lang="en-US">Share Premium Conversion Of Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumConversionOfLoan" xlink:to="tlsa_SharePremiumConversionOfLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of effect of change of investment entity status on financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharesToBeIssuedReserveMember_lbl0" xml:lang="en-US">Shares To Be Issued Reserve Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharesToBeIssuedReserveMember" xlink:to="tlsa_SharesToBeIssuedReserveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnBorrowings_lbl0" xml:lang="en-US">Interest expense on borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBorrowings" xlink:to="ifrs-full_InterestExpenseOnBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareOptions_lbl1" xml:lang="en-US">Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareOptions" xlink:to="tlsa_ShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CashSurplus_lbl1" xml:lang="en-US">Cash Surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CashSurplus" xlink:to="tlsa_CashSurplus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_lbl0" xml:lang="en-US">Number and average number of employees [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Of Earnings Per Share Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:to="tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract_lbl" xml:lang="en-US">Schedule Of All Other Variables Remain Constant Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:to="tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_WeightedAverageExercisePriceForfeitedCancelled_lbl0" xml:lang="en-US">Weighted Average Exercise Price Forfeited Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_WeightedAverageExercisePriceForfeitedCancelled" xlink:to="tlsa_WeightedAverageExercisePriceForfeitedCancelled_lbl0"/>
    <loc xlink:type="locator" xlink:label="tlsa_AccountingPolicieAbstract" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPolicieAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccountingPolicieAbstract_lbl" xml:lang="en-US">Accounting Policie Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccountingPolicieAbstract" xlink:to="tlsa_AccountingPolicieAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl1" xml:lang="en-US">Finance Charge Accrued On Convertible Loan Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes" xlink:to="tlsa_FinanceChargeAccruedOnConvertibleLoanNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeNotTaxableForTaxPurposes_lbl1" xml:lang="en-US">Income Not Taxable For Tax Purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeNotTaxableForTaxPurposes" xlink:to="tlsa_IncomeNotTaxableForTaxPurposes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_NumberOfSegment_lbl0" xml:lang="en-US">Number Of Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_NumberOfSegment" xlink:to="tlsa_NumberOfSegment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AdjustmentsDueToPriorPeriods_lbl1" xml:lang="en-US">Adjustments Due To Prior Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AdjustmentsDueToPriorPeriods" xlink:to="tlsa_AdjustmentsDueToPriorPeriods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ServicesAgreementAmount_lbl1" xml:lang="en-US">Services Agreement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ServicesAgreementAmount" xlink:to="tlsa_ServicesAgreementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentInRelatedParty_lbl1" xml:lang="en-US">Investment In Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentInRelatedParty" xlink:to="tlsa_InvestmentInRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_IncomeTaxSCredit_lbl1" xml:lang="en-US">Income Tax SCredit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_IncomeTaxSCredit" xlink:to="tlsa_IncomeTaxSCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems_lbl0" xml:lang="en-US">Remunerationof Key Management Personnel Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_SharePremiumRestatedAt1January2021_lbl1" xml:lang="en-US">Share Premium Restated At1 January2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_SharePremiumRestatedAt1January2021" xlink:to="tlsa_SharePremiumRestatedAt1January2021_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1_lbl0" xml:lang="en-US">Other Comprehensive Income Net Of Tax Exchange Differences On Translation1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" xlink:to="tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_CurrentTaxOther_lbl1" xml:lang="en-US">Current Tax Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_CurrentTaxOther" xlink:to="tlsa_CurrentTaxOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl0" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_UpfrontPayment_lbl1" xml:lang="en-US">Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_UpfrontPayment" xlink:to="tlsa_UpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_FinanceCharges_lbl1" xml:lang="en-US">Finance Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_FinanceCharges" xlink:to="tlsa_FinanceCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TAdamsMember_lbl0" xml:lang="en-US">TAdams Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TAdamsMember" xlink:to="tlsa_TAdamsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_BreastCancerMember_lbl0" xml:lang="en-US">Breast Cancer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_BreastCancerMember" xlink:to="tlsa_BreastCancerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ShareBasedPaymentReserveWarrantsMember_lbl0" xml:lang="en-US">Share Based Payment Reserve Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ShareBasedPaymentReserveWarrantsMember" xlink:to="tlsa_ShareBasedPaymentReserveWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_Bonus_lbl0" xml:lang="en-US">Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_Bonus" xlink:to="tlsa_Bonus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_RepaymentOfLeasingLiabilities_lbl1" xml:lang="en-US">Repayment Of Leasing Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_RepaymentOfLeasingLiabilities" xlink:to="tlsa_RepaymentOfLeasingLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InitialAmount_lbl1" xml:lang="en-US">Initial Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InitialAmount" xlink:to="tlsa_InitialAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_InvestmentsInRelatedParty_lbl1" xml:lang="en-US">Investments In Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_InvestmentsInRelatedParty" xlink:to="tlsa_InvestmentsInRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_AccustemSciencesIncMember_lbl1" xml:lang="en-US">Accustem Sciences Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_AccustemSciencesIncMember" xlink:to="tlsa_AccustemSciencesIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OptionsForfeitedCancelled_lbl0" xml:lang="en-US">Options Forfeited Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OptionsForfeitedCancelled" xlink:to="tlsa_OptionsForfeitedCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl0" xml:lang="en-US">Tax effect of tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_OtherReceivablesTablesLineItems_lbl0" xml:lang="en-US">Other Receivables Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_OtherReceivablesTablesLineItems" xlink:to="tlsa_OtherReceivablesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TwentySixJulyTwoThousandTwentyThreeMember_lbl0" xml:lang="en-US">Twenty Six July Two Thousand Twenty Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentySixJulyTwoThousandTwentyThreeMember" xlink:to="tlsa_TwentySixJulyTwoThousandTwentyThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For New And Revised Standards Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:to="tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="tlsa_ScheduleOfOtherReceivablesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfOtherReceivablesAbstract_lbl" xml:lang="en-US">Schedule Of Other Receivables Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfOtherReceivablesAbstract" xlink:to="tlsa_ScheduleOfOtherReceivablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl0" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_TwentySixJuneTwoThousandFourteenMember_lbl0" xml:lang="en-US">Twenty Six June Two Thousand Fourteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_TwentySixJuneTwoThousandFourteenMember" xlink:to="tlsa_TwentySixJuneTwoThousandFourteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Outstanding Fair Value Charge Of The Share Option Instruments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" xlink:to="tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>tlsa-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 10 17:51:16 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedBalanceSheet" roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedIncomeStatement" roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareholdersEquityType2or3" roleURI="http://tizianalifesciences.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ConsolidatedCashFlow" roleURI="http://tizianalifesciences.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_GeneralInformation" roleURI="http://tizianalifesciences.com/role/GeneralInformation"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPolicies" roleURI="http://tizianalifesciences.com/role/AccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_CriticalAccountingJudgement" roleURI="http://tizianalifesciences.com/role/CriticalAccountingJudgement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherexpenseIncome" roleURI="http://tizianalifesciences.com/role/OtherexpenseIncome"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLoss" roleURI="http://tizianalifesciences.com/role/OperatingLoss"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_SegmentalReporting" roleURI="http://tizianalifesciences.com/role/SegmentalReporting"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Employees" roleURI="http://tizianalifesciences.com/role/Employees"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnel" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinanceCosts" roleURI="http://tizianalifesciences.com/role/FinanceCosts"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Taxation" roleURI="http://tizianalifesciences.com/role/Taxation"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LossPerShare" roleURI="http://tizianalifesciences.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherReceivables" roleURI="http://tizianalifesciences.com/role/OtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremium" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremium"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPayments" roleURI="http://tizianalifesciences.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Reserves" roleURI="http://tizianalifesciences.com/role/Reserves"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialInstruments" roleURI="http://tizianalifesciences.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_CapitalRiskManagement" roleURI="http://tizianalifesciences.com/role/CapitalRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TradeandOtherPayables" roleURI="http://tizianalifesciences.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedParty" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TreasuryShares" roleURI="http://tizianalifesciences.com/role/TreasuryShares"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RelatedPartyTransactions" roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_Leases" roleURI="http://tizianalifesciences.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialCommitments" roleURI="http://tizianalifesciences.com/role/FinancialCommitments"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ContingentLiabilities" roleURI="http://tizianalifesciences.com/role/ContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesByPolicy" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesTables" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherexpenseIncomeTables" roleURI="http://tizianalifesciences.com/role/OtherexpenseIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLossTables" roleURI="http://tizianalifesciences.com/role/OperatingLossTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_EmployeesTables" roleURI="http://tizianalifesciences.com/role/EmployeesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnelTables" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinanceCostsTables" roleURI="http://tizianalifesciences.com/role/FinanceCostsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TaxationTables" roleURI="http://tizianalifesciences.com/role/TaxationTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LossPerShareTables" roleURI="http://tizianalifesciences.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OtherReceivablesTables" roleURI="http://tizianalifesciences.com/role/OtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremiumTables" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPaymentsTables" roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialInstrumentsTables" roleURI="http://tizianalifesciences.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TradeandOtherPayablesTables" roleURI="http://tizianalifesciences.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedPartyTables" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_LeasesTables" roleURI="http://tizianalifesciences.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOtherExpenseIncomeTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOperatingLossesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEmployeesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEmployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofRemunerationofKeyManagementPersonnelTable" roleURI="http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionswereGrantedtoDirectorsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFinanceCostsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTaxationTable" roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTaxationTable_Parentheticals" roleURI="http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofBasicLossPerShareTable" roleURI="http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofOtherReceivablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareCapitalArisingontheShareforShareExchangeTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionPlanTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofShareOptionsExpiryDatesandExercisePriceTable" roleURI="http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" roleURI="http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEquityIncentivePlanTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofEstimatedtheFairValueofWarrantsUsingTable" roleURI="http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable" roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals" roleURI="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofInvestmentinRelatedPartyTable" roleURI="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofRightofUseAssetsandLeaseLiabilitiesTable" roleURI="http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofConsolidatedStatementofFinancialTable" roleURI="http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ScheduleofFutureMinimumLeasePaymentsTable" roleURI="http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_AccountingPoliciesDetails" roleURI="http://tizianalifesciences.com/role/AccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_OperatingLossDetails" roleURI="http://tizianalifesciences.com/role/OperatingLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RemunerationofKeyManagementPersonnelDetails" roleURI="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TaxationDetails" roleURI="http://tizianalifesciences.com/role/TaxationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareCapitalandSharePremiumDetails" roleURI="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_ShareBasedPaymentsDetails" roleURI="http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_InvestmentinRelatedPartyDetails" roleURI="http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_TreasurySharesDetails" roleURI="http://tizianalifesciences.com/role/TreasurySharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_RelatedPartyTransactionsDetails" roleURI="http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#tlsa_r_FinancialCommitmentsDetails" roleURI="http://tizianalifesciences.com/role/FinancialCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tlsa-20231231.xsd#DocumentAndEntityInformation" roleURI="http://tizianalifesciences.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsandOtherReceivablesCurrent" xlink:href="tlsa-20231231.xsd#tlsa_PrepaymentsandOtherReceivablesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="PrepaymentsandOtherReceivablesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="TaxationReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentsInRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="InvestmentsInRelatedParty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IssuedCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentReserveWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ShareBasedPaymentReserveWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_OtherReserves" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_TreasuryShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SharesToBeIssuedReserve" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="SharesToBeIssuedReserve" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_RetainedEarnings" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_EquityAndLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_IssuanceOfShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="IssuanceOfShareCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ShareCapitalOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OperatingExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="OperatingExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpenseAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpenseAbstract" xlink:to="ifrs-full_OtherExpenseByFunction" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RealisationBonus" xlink:href="tlsa-20231231.xsd#tlsa_RealisationBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpenseAbstract" xlink:to="RealisationBonus" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RealisationBonus" xlink:to="ifrs-full_OperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpenseAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="OtherIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnDisposalsOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_GainsLossesOnDisposalsOfInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxSCredit" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxSCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="IncomeTaxSCredit" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfShareholdersEquityAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfShareholdersEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentReserveWarrantsMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentReserveWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ShareBasedPaymentReserveWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherReservesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_TreasurySharesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesToBeIssuedReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedReserveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SharesToBeIssuedReserveMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TranslationReserveMember" xlink:href="tlsa-20231231.xsd#tlsa_TranslationReserveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="TranslationReserveMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="9.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsForfeitedcancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedcancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="OptionsForfeitedcancelled" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsExercisedInTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="WarrantsExercisedInTheYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsForfeitedInTheYear" xlink:href="tlsa-20231231.xsd#tlsa_WarrantsForfeitedInTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="WarrantsForfeitedInTheYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BuybackOfTreasuryShares" xlink:href="tlsa-20231231.xsd#tlsa_BuybackOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="BuybackOfTreasuryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentoptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentoptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ShareBasedPaymentoptions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedInLieuOfCashRealizationBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfCashRealizationBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="SharesIssuedInLieuOfCashRealizationBonus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" xlink:href="tlsa-20231231.xsd#tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForInterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharesIssuedInLieuOfFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="SharesIssuedInLieuOfFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForSharebasedPaymentsWarrants" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsForSharebasedPaymentsWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsForSharebasedPaymentsWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsForfeitedDuringTheYear" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="OptionsForfeitedDuringTheYear" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FVLossOnInvestment" xlink:href="tlsa-20231231.xsd#tlsa_FVLossOnInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="FVLossOnInvestment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnDisposalOfAsset" xlink:href="tlsa-20231231.xsd#tlsa_LossOnDisposalOfAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="LossOnDisposalOfAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusToBeSettledInEquity" xlink:href="tlsa-20231231.xsd#tlsa_BonusToBeSettledInEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="BonusToBeSettledInEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationOfRightofuseAsset" xlink:href="tlsa-20231231.xsd#tlsa_DepreciationOfRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="DepreciationOfRightofuseAsset" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalDistribution" xlink:href="tlsa-20231231.xsd#tlsa_CapitalDistribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="CapitalDistribution" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSaleAndCollectionOfFinanceReceivable" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ProceedsFromSaleAndCollectionOfFinanceReceivable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashInflowFromTaxation" xlink:href="tlsa-20231231.xsd#tlsa_CashInflowFromTaxation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="CashInflowFromTaxation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestReceivedFromLoan" xlink:href="tlsa-20231231.xsd#tlsa_InterestReceivedFromLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="InterestReceivedFromLoan" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncreaseInRelatedPartyReceivables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InterestReceivedFromLoan" xlink:to="NetIncreaseInRelatedPartyReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncreaseInRelatedPartyPayables" xlink:href="tlsa-20231231.xsd#tlsa_NetIncreaseInRelatedPartyPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InterestReceivedFromLoan" xlink:to="NetIncreaseInRelatedPartyPayables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InterestReceivedFromLoan" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InterestReceivedFromLoan" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InterestReceivedFromLoan" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromFinanceLease" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromFinanceLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ProceedsFromFinanceLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInRelatedParty" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="InvestmentInRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfTreasuryAmount" xlink:href="tlsa-20231231.xsd#tlsa_PurchaseOfTreasuryAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="PurchaseOfTreasuryAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundraisingCost" xlink:href="tlsa-20231231.xsd#tlsa_FundraisingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="FundraisingCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfOptions" xlink:href="tlsa-20231231.xsd#tlsa_ProceedsFromIssuanceOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfLeasingLiabilities" xlink:href="tlsa-20231231.xsd#tlsa_RepaymentOfLeasingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfLeasingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/GeneralInformation">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralInformationTable" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationTable"/>
    <loc xlink:type="locator" xlink:label="GeneralInformationLineItems" xlink:href="tlsa-20231231.xsd#tlsa_GeneralInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="GeneralInformationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationTable" xlink:to="GeneralInformationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPolicies">
    <loc xlink:type="locator" xlink:label="AccountingPolicieAbstract" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPolicieAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicieAbstract" xlink:to="AccountingPoliciesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesTable" xlink:to="AccountingPoliciesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/CriticalAccountingJudgement">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:label="CriticalAccountingJudgementTable" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementTable"/>
    <loc xlink:type="locator" xlink:label="CriticalAccountingJudgementLineItems" xlink:href="tlsa-20231231.xsd#tlsa_CriticalAccountingJudgementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="CriticalAccountingJudgementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CriticalAccountingJudgementTable" xlink:to="CriticalAccountingJudgementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CriticalAccountingJudgementLineItems" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherexpenseIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLoss">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLossTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTable"/>
    <loc xlink:type="locator" xlink:label="OperatingLossLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="OperatingLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossTable" xlink:to="OperatingLossLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossLineItems" xlink:to="ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/SegmentalReporting">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentalReportingTable" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingTable"/>
    <loc xlink:type="locator" xlink:label="SegmentalReportingLineItems" xlink:href="tlsa-20231231.xsd#tlsa_SegmentalReportingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="SegmentalReportingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentalReportingTable" xlink:to="SegmentalReportingLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentalReportingLineItems" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Employees">
    <loc xlink:type="locator" xlink:label="EmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_EmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTable"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="RemunerationofKeyManagementPersonnelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelTable" xlink:to="RemunerationofKeyManagementPersonnelLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinanceCosts">
    <loc xlink:type="locator" xlink:label="FinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceCostsAbstract" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Taxation">
    <loc xlink:type="locator" xlink:label="TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="LossPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareTable" xlink:to="LossPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareLineItems" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherReceivables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremium">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Reserves">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/CapitalRiskManagement">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TradeandOtherPayables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedParty">
    <loc xlink:type="locator" xlink:label="InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentInRelatedPartyTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentInRelatedPartyAbstract" xlink:to="InvestmentInRelatedPartyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TreasuryShares">
    <loc xlink:type="locator" xlink:label="TreasurySharesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialCommitments">
    <loc xlink:type="locator" xlink:label="FinancialCommitmentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ContingentLiabilities">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForGoingConcern" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForGoingConcern"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForGoingConcern" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForBasisofConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForBasisofConsolidation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForLicenseFees" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForLicenseFees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForWarrantsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForWarrantsTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="AccountingPolicieAbstract" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPolicieAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicieAbstract" xlink:to="DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherexpenseIncomeTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLossTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLossTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingLossTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="OperatingLossTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossTablesTable" xlink:to="OperatingLossTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutOperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutOperatingLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/EmployeesTables">
    <loc xlink:type="locator" xlink:label="EmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_EmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeesAbstract" xlink:to="DisclosureOfDetailedInformationAboutEmployeesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesTable"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="RemunerationofKeyManagementPersonnelTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelTablesTable" xlink:to="RemunerationofKeyManagementPersonnelTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelTablesLineItems" xlink:to="DisclosureOfShareOptionsWereGrantedToDirectorTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinanceCostsTables">
    <loc xlink:type="locator" xlink:label="FinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceCostsAbstract" xlink:to="DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TaxationTables">
    <loc xlink:type="locator" xlink:label="TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationAbstract" xlink:to="DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="LossPerShareTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareTablesTable" xlink:to="LossPerShareTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OtherReceivablesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="OtherReceivablesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesTablesTable" xlink:to="OtherReceivablesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureShareCapitalArisingForShareExchangetextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="DisclosureShareCapitalArisingForShareExchangetextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityIncentivePlanTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfEquityIncentivePlanTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TradeandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="TradeandOtherPayablesTablesTable" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesTable"/>
    <loc xlink:type="locator" xlink:label="TradeandOtherPayablesTablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TradeandOtherPayablesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="TradeandOtherPayablesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeandOtherPayablesTablesTable" xlink:to="TradeandOtherPayablesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherPayablesTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeandOtherPayablesTablesLineItems" xlink:to="ScheduleOfTradeAndOtherPayablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables">
    <loc xlink:type="locator" xlink:label="InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentInRelatedPartyAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFutureMinimumLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_DisclosureOfFutureMinimumLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfFutureMinimumLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract" xlink:to="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_FixturesAndFittingsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetMember" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="RightOfUseAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable" xlink:to="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EstimatedUsefulLives" xlink:href="tlsa-20231231.xsd#tlsa_EstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="EstimatedUsefulLives" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetDescription" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems" xlink:to="RightOfUseAssetDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherExpenseIncomeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOtherExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable"/>
    <loc xlink:type="locator" xlink:label="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpenseIncomeAbstract" xlink:to="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable" xlink:to="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SublicenseIncome" xlink:href="tlsa-20231231.xsd#tlsa_SublicenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="SublicenseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomelosses" xlink:href="tlsa-20231231.xsd#tlsa_OtherIncomelosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems" xlink:to="OtherIncomelosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLossesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOperatingLossesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLossDetailsScheduleofOperatingLossesTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLossesAbstract" xlink:to="OperatingLossDetailsScheduleofOperatingLossesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesTable" xlink:to="OperatingLossDetailsScheduleofOperatingLossesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Licensefee" xlink:href="tlsa-20231231.xsd#tlsa_Licensefee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="Licensefee" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLoss" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="OperatingLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="ifrs-full_DepreciationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangegainlosses" xlink:href="tlsa-20231231.xsd#tlsa_ForeignExchangegainlosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsScheduleofOperatingLossesLineItems" xlink:to="ForeignExchangegainlosses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEmployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="StaffCostsComprisedAbstract" xlink:href="tlsa-20231231.xsd#tlsa_StaffCostsComprisedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeesAbstract" xlink:to="StaffCostsComprisedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="ifrs-full_SocialSecurityContributions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecruitmentFees" xlink:href="tlsa-20231231.xsd#tlsa_RecruitmentFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="RecruitmentFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StaffCostsComprisedAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberAndAverageNumberOfEmployeesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeesAbstract" xlink:to="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopment" xlink:href="tlsa-20231231.xsd#tlsa_ResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="ResearchAndDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateAndAdministration" xlink:href="tlsa-20231231.xsd#tlsa_CorporateAndAdministration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="CorporateAndAdministration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" xlink:href="tlsa-20231231.xsd#tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberAndAverageNumberOfEmployeesAbstract" xlink:to="AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRemunerationOfKeyManagementPersonnelAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRemunerationOfKeyManagementPersonnelAbstract" xlink:to="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GCerroneMember" xlink:href="tlsa-20231231.xsd#tlsa_GCerroneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="GCerroneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WillySimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WillySimonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="WillySimonMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JBrancaccioMember" xlink:href="tlsa-20231231.xsd#tlsa_JBrancaccioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JBrancaccioMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KShailubhaiMember" xlink:href="tlsa-20231231.xsd#tlsa_KShailubhaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="KShailubhaiMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TAdamsMember" xlink:href="tlsa-20231231.xsd#tlsa_TAdamsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="TAdamsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable" xlink:to="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DirectorsFees" xlink:href="tlsa-20231231.xsd#tlsa_DirectorsFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="DirectorsFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Bonus" xlink:href="tlsa-20231231.xsd#tlsa_Bonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="Bonus" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Salary" xlink:href="tlsa-20231231.xsd#tlsa_Salary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="Salary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPayments" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems" xlink:to="ShareBasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionsWereGrantedToDirectorsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsWereGrantedToDirectorsAbstract" xlink:to="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WSimonMember" xlink:href="tlsa-20231231.xsd#tlsa_WSimonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="WSimonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JBrancaccioMember" xlink:href="tlsa-20231231.xsd#tlsa_JBrancaccioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JBrancaccioMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TAdamsMember" xlink:href="tlsa-20231231.xsd#tlsa_TAdamsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="TAdamsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable" xlink:to="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsWereGrantedToDirectors" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsWereGrantedToDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems" xlink:to="NumberOfShareOptionsWereGrantedToDirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceCostsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceCostsAbstract" xlink:to="FinanceIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_InterestExpenseOnBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceCostsAbstract" xlink:to="FinanceExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceChargeAccruedOnConvertibleLoanNotes" xlink:href="tlsa-20231231.xsd#tlsa_FinanceChargeAccruedOnConvertibleLoanNotes"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbxfU1oythJ56ec21DHGPZwpslDaKjyxv/SY+rtv6T6hI6VzbLHUXFHEKKqWRnqbRryxvSZpxP7JLAUo2nNrvGMEOXo1gwjeFFOB6PUBDySJ8mZoFy7QnnIv40v1B9UZHC7MCwIs+wmz8LSihsflhDc6zJF27af/mivqJFf8tjpXcsKExcdSv5uqNLTMgYL1crW7VdSqHWHbJ4NLcEiNOOPvKlOzDXysb8=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseAbstract" xlink:to="FinanceChargeAccruedOnConvertibleLoanNotes" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpenseAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpense" xlink:href="tlsa-20231231.xsd#tlsa_FinanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceCostsAbstract" xlink:to="FinanceExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" xlink:href="tlsa-20231231.xsd#tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceCostsAbstract" xlink:to="NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTaxationTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="GroupAbstract0" xlink:href="tlsa-20231231.xsd#tlsa_GroupAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="GroupAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupAbstract0" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsDueToPriorPeriods" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupAbstract0" xlink:to="AdjustmentsDueToPriorPeriods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxExpenseContinuingOperation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxExpenseContinuingOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="IncomeTaxExpenseContinuingOperation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherLossBeforeTaxation" xlink:href="tlsa-20231231.xsd#tlsa_OtherLossBeforeTaxation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="OtherLossBeforeTaxation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MovementInUnrecognisedDeferredTax" xlink:href="tlsa-20231231.xsd#tlsa_MovementInUnrecognisedDeferredTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="MovementInUnrecognisedDeferredTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationExpensesNotDeductibleForTaxation" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="IncomeTaxReconciliationExpensesNotDeductibleForTaxation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsDueToPriorPeriod" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsDueToPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="AdjustmentsDueToPriorPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationResearchAndDevelopmentClaim" xlink:href="tlsa-20231231.xsd#tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="IncomeTaxReconciliationResearchAndDevelopmentClaim" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeNotTaxableForTaxPurposes" xlink:href="tlsa-20231231.xsd#tlsa_IncomeNotTaxableForTaxPurposes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="IncomeNotTaxableForTaxPurposes" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssetDifferences" xlink:href="tlsa-20231231.xsd#tlsa_FixedAssetDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="FixedAssetDifferences" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxOther" xlink:href="tlsa-20231231.xsd#tlsa_CurrentTaxOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="CurrentTaxOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToBroughtForwardValues" xlink:href="tlsa-20231231.xsd#tlsa_AdjustmentsToBroughtForwardValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="AdjustmentsToBroughtForwardValues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsolidationAdjustmentInRelationToForeignExchangeMovements" xlink:href="tlsa-20231231.xsd#tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ConsolidationAdjustmentInRelationToForeignExchangeMovements" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicLossPerShareAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfBasicLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareAbstract" xlink:to="LossPerShareDetailsScheduleofBasicLossPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsScheduleofBasicLossPerShareTable" xlink:to="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="ifrs-full_WeightedAverageShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BasicLossPerSharecentsPerShare" xlink:href="tlsa-20231231.xsd#tlsa_BasicLossPerSharecentsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsScheduleofBasicLossPerShareLineItems" xlink:to="BasicLossPerSharecentsPerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherReceivablesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherReceivablesAbstract" xlink:to="OtherReceivablesDetailsScheduleofOtherReceivablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesTable" xlink:to="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SecurityDepositsReceivable" xlink:href="tlsa-20231231.xsd#tlsa_SecurityDepositsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="SecurityDepositsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="ifrs-full_Prepayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxationReceivable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="TaxationReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherReceivablesDetailsScheduleofOtherReceivablesLineItems" xlink:to="ifrs-full_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract"/>
    <loc xlink:type="locator" xlink:label="NominalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="NominalValueAnnualReport" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalSharesAnnualReport" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalValueAnnualReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="SharePremiumAnnualReport" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveAtJanuary12021Per20FAnnualReport" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveAtJanuary12021Per20FAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="MergerReserveAtJanuary12021Per20FAnnualReport" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupReorganizationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_GroupReorganizationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="GroupReorganizationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueEliminationOfShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="NominalValueEliminationOfShareCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesEliminationOfShare" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesEliminationOfShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="ShareCapitalSharesEliminationOfShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueEliminationOfShareCapital" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueEliminationOfShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="ShareCapitalValueEliminationOfShareCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEliminationOfShareCapitalIn"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="SharePremiumEliminationOfShareCapitalIn" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveEliminationOfShareCapitalIn" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEliminationOfShareCapitalIn"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="MergerReserveEliminationOfShareCapitalIn" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EliminationOfOtherReserves" xlink:href="tlsa-20231231.xsd#tlsa_EliminationOfOtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GroupReorganizationAbstract" xlink:to="EliminationOfOtherReserves" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueRestated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="NominalValueRestated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesRestated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalSharesRestated" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueRestated" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueRestated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalValueRestated" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumRestatedAt1January2021" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumRestatedAt1January2021"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="SharePremiumRestatedAt1January2021" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveRestated" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveRestated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="MergerReserveRestated" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="NominalValueConversionOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalSharesConversionOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalConversionOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalConversionOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="SharePremiumConversionOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveConversionOfWarrants" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="MergerReserveConversionOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueConversionOfLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="NominalValueConversionOfLoan" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesConversionOfLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalSharesConversionOfLoan" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueConversionOfLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalValueConversionOfLoan" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumConversionOfLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="SharePremiumConversionOfLoan" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveConversionOfLoan" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveConversionOfLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="MergerReserveConversionOfLoan" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuedInLieuOfCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="NominalValueIssuedInLieuOfCashBonus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalSharesIssuedInLieuOfCashBonus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuedInCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="ShareCapitalValueIssuedInCashBonus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumIssuedInCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuedInCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="SharePremiumIssuedInCashBonus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveIssuedInLieuOfCashBonus" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveIssuedInLieuOfCashBonus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveRestated" xlink:to="MergerReserveIssuedInLieuOfCashBonus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalShares" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueAt31December2021" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueAt31December2021"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="ShareCapitalValueAt31December2021" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumEnding" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="SharePremiumEnding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerReserveEnding" xlink:href="tlsa-20231231.xsd#tlsa_MergerReserveEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract" xlink:to="MergerReserveEnding" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueSharesIssuedInLieuOfFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="NominalValueSharesIssuedInLieuOfFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuedInLieuOfFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalSharesIssuedInLieuOfFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueSharesIssuedInLieuOfFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalValueSharesIssuedInLieuOfFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumSharesIssuedInLieuOfFees" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumSharesIssuedInLieuOfFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="SharePremiumSharesIssuedInLieuOfFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="NominalValueWarrantsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalSharesWarrantsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalValueWarrantsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumWarrantsExercised" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="SharePremiumWarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_NominalValueIssuanceOfStockATM"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="NominalValueIssuanceOfStockATM" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalSharesIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalSharesIssuanceOfStockATM"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalSharesIssuanceOfStockATM" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalValueIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalValueIssuanceOfStockATM"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="ShareCapitalValueIssuanceOfStockATM" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePremiumIssuanceOfStockATM" xlink:href="tlsa-20231231.xsd#tlsa_SharePremiumIssuanceOfStockATM"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerReserveEnding" xlink:to="SharePremiumIssuanceOfStockATM" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionPlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_OptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceGranted" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceForfeitedCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceForfeitedCancelled" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsForfeitedCancelled" xlink:href="tlsa-20231231.xsd#tlsa_OptionsForfeitedCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsForfeitedCancelled" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercised" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOutstanding_0" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceOutstanding_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsOutstanding_0" xlink:href="tlsa-20231231.xsd#tlsa_OptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercisable" xlink:href="tlsa-20231231.xsd#tlsa_WeightedAverageExercisePriceExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="WeightedAverageExercisePriceExercisable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_OptionsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionPlanAbstract" xlink:to="OptionsExercisable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract" xlink:to="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:to="ifrs-full_CreationDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwentySixJuneTwoThousandFourteenMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJuneTwoThousandFourteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="TwentySixJuneTwoThousandFourteenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirtyAprilTwoThousandAndEighteenMember" xlink:href="tlsa-20231231.xsd#tlsa_ThirtyAprilTwoThousandAndEighteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ThirtyAprilTwoThousandAndEighteenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SixMayTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_SixMayTwoThousandAndTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="SixMayTwoThousandAndTwentyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentyThreeJulyTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyThreeJulyTwoThousandAndTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="TwentyThreeJulyTwoThousandAndTwentyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentyFiveAugustTwoThousandAndTwentyMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentyFiveAugustTwoThousandAndTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="TwentyFiveAugustTwoThousandAndTwentyMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionMember" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ShareOptionMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZeroOneeAugustTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ZeroOneeAugustTwoThousandAndTwentyTwoMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZeroFourNovemberTwoThousandAndTwentyTwoMember" xlink:href="tlsa-20231231.xsd#tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ZeroFourNovemberTwoThousandAndTwentyTwoMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FourteenMarchTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_FourteenMarchTwoThousandTwentyThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="FourteenMarchTwoThousandTwentyThreeMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentySixJulyTwoThousandTwentyThreeMember" xlink:href="tlsa-20231231.xsd#tlsa_TwentySixJulyTwoThousandTwentyThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="TwentySixJulyTwoThousandTwentyThreeMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable" xlink:to="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExpiryDate" xlink:href="tlsa-20231231.xsd#tlsa_ExpiryDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="ExpiryDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseSharePrice" xlink:href="tlsa-20231231.xsd#tlsa_ExerciseSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="ExerciseSharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptions" xlink:href="tlsa-20231231.xsd#tlsa_ShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems" xlink:to="ShareOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract" xlink:to="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable" xlink:to="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrantDateSharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_GrantDateSharesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="GrantDateSharesPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionLifeShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_OptionLifeShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="OptionLifeShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityIncentivePlanAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEquityIncentivePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberOfShareOptionsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsGranted" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberOfShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsForfeited" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberOfShareOptionsForfeited" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofOptionsExercised" xlink:href="tlsa-20231231.xsd#tlsa_NumberofOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberofOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsOutstanding_0" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberOfShareOptionsOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsExercisable" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfShareOptionsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityIncentivePlanAbstract" xlink:to="NumberOfShareOptionsExercisable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueOutstanding" xlink:href="tlsa-20231231.xsd#tlsa_FairValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="FairValueOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingExercised" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="OutstandingExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingExpired" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="OutstandingExpired" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOutstanding_0" xlink:href="tlsa-20231231.xsd#tlsa_FairValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract" xlink:to="FairValueOutstanding_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LessThanThreeMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_LessThanThreeMonthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="LessThanThreeMonthMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThreeToTwelveMonthMember" xlink:href="tlsa-20231231.xsd#tlsa_ThreeToTwelveMonthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="ThreeToTwelveMonthMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable" xlink:to="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyPayablesAmount" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyPayablesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="RelatedPartyPayablesAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsNet" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems" xlink:to="FinancialInstrumentsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="USDMember" xlink:href="tlsa-20231231.xsd#tlsa_USDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="USDMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable" xlink:to="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProfitOrLossAndEquityStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityStrengthening"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="ProfitOrLossAndEquityStrengthening" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfitOrLossAndEquityWeakening" xlink:href="tlsa-20231231.xsd#tlsa_ProfitOrLossAndEquityWeakening"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems" xlink:to="ProfitOrLossAndEquityWeakening" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllOtherVariablesRemainConstantAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="USDMember" xlink:href="tlsa-20231231.xsd#tlsa_USDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="USDMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable" xlink:to="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MovementPercentageStrengthening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageStrengthening"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="MovementPercentageStrengthening" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MovementPercentageWeakening" xlink:href="tlsa-20231231.xsd#tlsa_MovementPercentageWeakening"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems" xlink:to="MovementPercentageWeakening" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfInvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentInRelatedPartyAbstract" xlink:to="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccustemSciencesIncMember" xlink:href="tlsa-20231231.xsd#tlsa_AccustemSciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AccustemSciencesIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OKYOPharmaLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable" xlink:to="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossOnFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_ImpairmentLossOnFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetBeginning" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="RightOfUseAssetBeginning" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsDepreciation" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="RightOfUseAssetsDepreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalOfLease" xlink:href="tlsa-20231231.xsd#tlsa_DisposalOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="DisposalOfLease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeDifferencesRightofUseAssets" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferencesRightofUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="ExchangeDifferencesRightofUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsTotal" xlink:href="tlsa-20231231.xsd#tlsa_RightOfUseAssetsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="RightOfUseAssetsTotal" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesBeginning" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="LeaseLiabilitiesBeginning" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesInterestExpense" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="LeaseLiabilitiesInterestExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesLeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="LeaseLiabilitiesLeasePayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeDifferences" xlink:href="tlsa-20231231.xsd#tlsa_ExchangeDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="ExchangeDifferences" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesTotal" xlink:href="tlsa-20231231.xsd#tlsa_LeaseLiabilitiesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract" xlink:to="LeaseLiabilitiesTotal" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedStatementOfFinancialAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumLeasePaymentsAbstarct" xlink:href="tlsa-20231231.xsd#tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsAbstarct" xlink:to="LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:to="ifrs-full_MaturityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaterThanTwoYearsAndNotLaterThanFiveYearMember" xlink:href="tlsa-20231231.xsd#tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="LaterThanTwoYearsAndNotLaterThanFiveYearMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanFiveYearsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable" xlink:to="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LeasePayments" xlink:href="tlsa-20231231.xsd#tlsa_LeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="LeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceCharges" xlink:href="tlsa-20231231.xsd#tlsa_FinanceCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="FinanceCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetPresentValues" xlink:href="tlsa-20231231.xsd#tlsa_NetPresentValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems" xlink:to="NetPresentValues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/AccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="AccountingPolicieAbstract" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPolicieAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AccountingPoliciesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_AccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicieAbstract" xlink:to="AccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsTable" xlink:to="AccountingPoliciesDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedLoss" xlink:href="tlsa-20231231.xsd#tlsa_AccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="AccumulatedLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="CashSurplus" xlink:href="tlsa-20231231.xsd#tlsa_CashSurplus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="CashSurplus" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSegment" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSegment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="NumberOfSegment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayment" xlink:href="tlsa-20231231.xsd#tlsa_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="UpfrontPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/OperatingLossDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLossDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OperatingLossDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_OperatingLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="OperatingLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsTable" xlink:to="OperatingLossDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BenefitsPaidOrPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsLineItems" xlink:to="ifrs-full_BenefitsPaidOrPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RaisingFunds" xlink:href="tlsa-20231231.xsd#tlsa_RaisingFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsLineItems" xlink:to="RaisingFunds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossDetailsLineItems" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="RemunerationofKeyManagementPersonnelDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsTable" xlink:to="RemunerationofKeyManagementPersonnelDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="ifrs-full_OtherLongtermBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RemunerationofKeyManagementPersonnelDetailsLineItems" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TaxationDetails">
    <loc xlink:type="locator" xlink:label="TaxationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TaxationAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxationDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxationDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TaxationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationAbstract" xlink:to="TaxationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationDetailsTable" xlink:to="TaxationDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MaximumPercentageOfSurrenderableLosses" xlink:href="tlsa-20231231.xsd#tlsa_MaximumPercentageOfSurrenderableLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationDetailsLineItems" xlink:to="MaximumPercentageOfSurrenderableLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermOfResearchAndDevelopmentTaxReliefClaims" xlink:href="tlsa-20231231.xsd#tlsa_TermOfResearchAndDevelopmentTaxReliefClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationDetailsLineItems" xlink:to="TermOfResearchAndDevelopmentTaxReliefClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxationDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandSharePremiumDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandSharePremiumDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareCapitalandSharePremiumDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ShareCapitalandSharePremiumDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandSharePremiumDetailsTable" xlink:to="ShareCapitalandSharePremiumDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandSharePremiumDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssued1" xlink:href="tlsa-20231231.xsd#tlsa_NumberOfSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandSharePremiumDetailsLineItems" xlink:to="NumberOfSharesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TreasuryShares1" xlink:href="tlsa-20231231.xsd#tlsa_TreasuryShares1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandSharePremiumDetailsLineItems" xlink:to="TreasuryShares1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_ShareBasedPaymentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ShareBasedPaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BlackScholesMertonValuationModelMember" xlink:href="tlsa-20231231.xsd#tlsa_BlackScholesMertonValuationModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="BlackScholesMertonValuationModelMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TizianaLifeSciencesPLCMember" xlink:href="tlsa-20231231.xsd#tlsa_TizianaLifeSciencesPLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="TizianaLifeSciencesPLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ShareBasedPaymentsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OutstandingFairValueCharges" xlink:href="tlsa-20231231.xsd#tlsa_OutstandingFairValueCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="OutstandingFairValueCharges" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedTermOfAwards" xlink:href="tlsa-20231231.xsd#tlsa_ExpectedTermOfAwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ExpectedTermOfAwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChargeOfForfeitures" xlink:href="tlsa-20231231.xsd#tlsa_ChargeOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ChargeOfForfeitures" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails">
    <loc xlink:type="locator" xlink:label="InvestmentInRelatedPartyAbstract" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentInRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinRelatedPartyDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinRelatedPartyDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_InvestmentinRelatedPartyDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentInRelatedPartyAbstract" xlink:to="InvestmentinRelatedPartyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AccustemSciencesIncMember" xlink:href="tlsa-20231231.xsd#tlsa_AccustemSciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AccustemSciencesIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OKYOPharmaLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsTable" xlink:to="InvestmentinRelatedPartyDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SharesPrice" xlink:href="tlsa-20231231.xsd#tlsa_SharesPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsLineItems" xlink:to="SharesPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsLineItems" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiredShares" xlink:href="tlsa-20231231.xsd#tlsa_AcquiredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsLineItems" xlink:to="AcquiredShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinRelatedPartyDetailsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/TreasurySharesDetails">
    <loc xlink:type="locator" xlink:label="TreasurySharesAbstract" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="TreasurySharesDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TreasurySharesDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_TreasurySharesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesAbstract" xlink:to="TreasurySharesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantsOrRightAxis" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesDetailsTable" xlink:to="ClassOfWarrantsOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantsOrRightDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_ClassOfWarrantsOrRightDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantsOrRightAxis" xlink:to="ClassOfWarrantsOrRightDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NASDAQStockExchangeMember" xlink:href="tlsa-20231231.xsd#tlsa_NASDAQStockExchangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantsOrRightAxis" xlink:to="NASDAQStockExchangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesDetailsTable" xlink:to="TreasurySharesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SharesPurchases" xlink:href="tlsa-20231231.xsd#tlsa_SharesPurchases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesDetailsLineItems" xlink:to="SharesPurchases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesDetailsLineItems" xlink:to="ifrs-full_TreasuryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TreasurySharesDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OKYOPharmaLtdMember" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OKYOPharmaLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyAxis" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyDomainDomain" xlink:href="tlsa-20231231.xsd#tlsa_RelatedPartyDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyAxis" xlink:to="RelatedPartyDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RasnaTherapeuticsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_RasnaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyAxis" xlink:to="RasnaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OKYOPharmaLtdMember_0" xlink:href="tlsa-20231231.xsd#tlsa_OKYOPharmaLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyAxis" xlink:to="OKYOPharmaLtdMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GensigniaLifesceinecsIncMember" xlink:href="tlsa-20231231.xsd#tlsa_GensigniaLifesceinecsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyAxis" xlink:to="GensigniaLifesceinecsIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestAmount" xlink:href="tlsa-20231231.xsd#tlsa_InterestAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="InterestAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermLoanFacility1" xlink:href="tlsa-20231231.xsd#tlsa_ShortTermLoanFacility1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ShortTermLoanFacility1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayrollAndRentCharged" xlink:href="tlsa-20231231.xsd#tlsa_PayrollAndRentCharged"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PayrollAndRentCharged" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesAgreementAmount" xlink:href="tlsa-20231231.xsd#tlsa_ServicesAgreementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ServicesAgreementAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialAmount" xlink:href="tlsa-20231231.xsd#tlsa_InitialAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="InitialAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPayment" xlink:href="tlsa-20231231.xsd#tlsa_AdditionalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="AdditionalPayment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentDue" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="MilestonePaymentDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmount" xlink:href="tlsa-20231231.xsd#tlsa_PrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PrincipalAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_LoansReceived" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_OtherEquityInterest" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/FinancialCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="FinancialCommitmentsAbstract" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialCommitmentsDetailsTable" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialCommitmentsDetailsLineItems" xlink:href="tlsa-20231231.xsd#tlsa_FinancialCommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsAbstract" xlink:to="FinancialCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PhaseIIClinicalTrialMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIClinicalTrialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PhaseIIClinicalTrialMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Phase3Member" xlink:href="tlsa-20231231.xsd#tlsa_Phase3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="Phase3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIHumanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PhaseIIHumanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarcinomaMember" xlink:href="tlsa-20231231.xsd#tlsa_CarcinomaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CarcinomaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HCCMember" xlink:href="tlsa-20231231.xsd#tlsa_HCCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="HCCMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BreastCancerMember" xlink:href="tlsa-20231231.xsd#tlsa_BreastCancerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="BreastCancerMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIHumanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PhaseIHumanMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhaseIIIHumanMember" xlink:href="tlsa-20231231.xsd#tlsa_PhaseIIIHumanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PhaseIIIHumanMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BLAMember" xlink:href="tlsa-20231231.xsd#tlsa_BLAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="BLAMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsTable" xlink:to="FinancialCommitmentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DevelopmentMilestones" xlink:href="tlsa-20231231.xsd#tlsa_DevelopmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsLineItems" xlink:to="DevelopmentMilestones" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedOfDiligenceObligations" xlink:href="tlsa-20231231.xsd#tlsa_AccruedOfDiligenceObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsLineItems" xlink:to="AccruedOfDiligenceObligations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="tlsa-20231231.xsd#tlsa_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsLineItems" xlink:to="MilestonePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialSaleOfAProduct" xlink:href="tlsa-20231231.xsd#tlsa_CommercialSaleOfAProduct"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialCommitmentsDetailsLineItems" xlink:to="CommercialSaleOfAProduct" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tizianalifesciences.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="tlsa-20231231.xsd#tlsa_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865895104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tiziana
Life Sciences Ltd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">103,087,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001723069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Clarendon
House<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2
Church Street,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hamilton
HM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">BM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">2814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PKF Littlejohn LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">London, England<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-00000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Chief
Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14-15
Conduit Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">LondonW1S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2XJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Keeren
Shah<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20 7495 2379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865913936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">$ 18,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PrepaymentsandOtherReceivablesCurrent', window );">Prepayments and other receivables</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TaxationReceivable', window );">Taxation receivable</a></td>
<td class="nump">3,793<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Related party receivables</a></td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">7,337<span></span>
</td>
<td class="nump">24,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non &#8211; Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use asset</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentsInRelatedParty', window );">Investment in related party</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">4,847<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">12,184<span></span>
</td>
<td class="nump">26,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,387<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease Liability</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">6,539<span></span>
</td>
<td class="nump">6,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease Liability (Non-Current)</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,648<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Called up share capital (103,087,744 shares are issued and outstanding; 2022: 102,272,614)</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">16,492<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Share based payment reserve &#8211; Options</a></td>
<td class="nump">6,905<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentReserveWarrants', window );">Share based payment reserve &#8211; warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Merger relief reserve</a></td>
<td class="nump">118,697<span></span>
</td>
<td class="nump">118,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(1,574)<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesToBeIssuedReserve', window );">Shares to be issued reserve</a></td>
<td class="nump">225<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Translation reserve</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(3,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="num">(133,676)<span></span>
</td>
<td class="num">(116,263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">5,536<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 12,184<span></span>
</td>
<td class="nump">$ 26,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentsInRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reprersent the amount of investment in related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentsInRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_PrepaymentsandOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_PrepaymentsandOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPaymentReserveWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPaymentReserveWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesToBeIssuedReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares to be issued reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesToBeIssuedReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TaxationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxation receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TaxationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843220512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IssuanceOfShareCapital', window );">Share capital, issued</a></td>
<td class="nump">103,087,744<span></span>
</td>
<td class="nump">102,272,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalOutstanding', window );">Share capital, outstanding</a></td>
<td class="nump">103,087,744<span></span>
</td>
<td class="nump">102,272,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IssuanceOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IssuanceOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865899536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingExpenseAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="num">$ (8,113)<span></span>
</td>
<td class="num">$ (12,955)<span></span>
</td>
<td class="num">$ (13,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Operating expenses</a></td>
<td class="num">(9,871)<span></span>
</td>
<td class="num">(1,631)<span></span>
</td>
<td class="num">(13,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RealisationBonus', window );">Realization bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(855)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(17,984)<span></span>
</td>
<td class="num">(14,586)<span></span>
</td>
<td class="num">(27,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(17,984)<span></span>
</td>
<td class="num">(14,586)<span></span>
</td>
<td class="num">(27,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherIncomeExpenseAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance (expense)/ income</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfInvestments', window );">FV Loss on Investment</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other income/(losses)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Total other income/(expense)</a></td>
<td class="nump">742<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss from operations before income taxes</a></td>
<td class="num">(17,242)<span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
<td class="num">(26,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeTaxSCredit', window );">Income tax (expense)/credit</a></td>
<td class="num">(449)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(17,691)<span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
<td class="num">(23,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Gain/(Loss) on currency translation</a></td>
<td class="nump">1,492<span></span>
</td>
<td class="num">(3,582)<span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="num">$ (16,199)<span></span>
</td>
<td class="num">$ (18,979)<span></span>
</td>
<td class="num">$ (27,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share attributable to common shareholders (in Dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeTaxSCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeTaxSCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RealisationBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realisation bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RealisationBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843136944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share attributable to common shareholders</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519889598528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th"><div>Share Premium</div></th>
<th class="th"><div>Share Based Payment Reserve (Options)</div></th>
<th class="th"><div>Share Based Payment Reserve (warrants)</div></th>
<th class="th"><div>Merger Reserve</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Shares to be issued Reserve</div></th>
<th class="th"><div>Translation Reserve</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,624<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (84,646)<span></span>
</td>
<td class="nump">$ 13,503<span></span>
</td>
<td class="nump">$ 5,414<span></span>
</td>
<td class="nump">$ 62,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of share capital</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentoptions', window );">Share based payment charge (options)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,173<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesIssuedInLieuOfCashRealizationBonus', window );">Shares issued in lieu of cash realization bonus</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">14,837<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,503)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">5,173<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,503)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="nump">6,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,417)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1', window );">Translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,417)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(27,895)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">13,797<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="nump">118,697<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(108,063)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">41,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsForfeitedcancelled', window );">Options forfeited/cancelled in the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Reclass of FV for options forfeited/Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,197)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentoptions', window );">Share based payment charge (options)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,607)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1', window );">Translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,582)<span></span>
</td>
<td class="num">(3,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,582)<span></span>
</td>
<td class="num">(18,979)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="nump">118,697<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
<td class="num">(116,263)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,128)<span></span>
</td>
<td class="nump">19,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsForfeitedcancelled', window );">Options forfeited/cancelled in the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Reclass of FV for options forfeited/Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance of Stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WarrantsExercisedInTheYear', window );">Warrants Exercised in the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WarrantsForfeitedInTheYear', window );">Warrants Forfeited in the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_BuybackOfTreasuryShares', window );">Buyback of Treasury Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus', window );">Shares to be issued in lieu of directors fees and cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentoptions', window );">Share based payment charge (options)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,773<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="num">(697)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,691)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1', window );">Translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,691)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="num">(16,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 16,492<span></span>
</td>
<td class="nump">$ 6,905<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="num">$ (1,574)<span></span>
</td>
<td class="num">$ (133,676)<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="num">$ (1,636)<span></span>
</td>
<td class="nump">$ 5,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_BuybackOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Buyback of Treasury Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_BuybackOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsForfeitedcancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsForfeitedcancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPaymentoptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Share based payment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPaymentoptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesIssuedInLieuOfCashRealizationBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in lieu of cash realization bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesIssuedInLieuOfCashRealizationBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares to be issued in lieu of directors fees and cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WarrantsExercisedInTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised in the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WarrantsExercisedInTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WarrantsForfeitedInTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants forfeited in the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WarrantsForfeitedInTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874714048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss from operations before income taxes</a></td>
<td class="num">$ (17,242)<span></span>
</td>
<td class="num">$ (15,397)<span></span>
</td>
<td class="num">$ (26,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestExpense', window );">Convertible loan interest accrued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesIssuedInLieuOfFees', window );">Shares issued in lieu of directors fees</a></td>
<td class="nump">425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AdjustmentsForSharebasedPaymentsWarrants', window );">Share based payment &#8211; options</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsForfeitedDuringTheYear', window );">Options forfeited during the year</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FVLossOnInvestment', window );">Fair value loss on investment, net</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LossOnDisposalOfAsset', window );">Loss on disposal of asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_BonusToBeSettledInEquity', window );">Bonus to be settled in equity</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">(Gain)/ loss on foreign exchange</a></td>
<td class="nump">1,519<span></span>
</td>
<td class="num">(3,183)<span></span>
</td>
<td class="num">(1,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DepreciationOfRightofuseAsset', window );">Depreciation of right-of-use asset</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CapitalDistribution', window );">(Gain)/loss on disposal of right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable', window );">Proceeds from finance lease reclassified as an investing activity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CashInflowFromTaxation', window );">Cash inflow from taxation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InterestReceivedFromLoan', window );">Interest on related party loan conversion</a></td>
<td class="num">(1,150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetIncreaseInRelatedPartyReceivables', window );">Net (increase) in related party receivables</a></td>
<td class="num">(1,524)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetIncreaseInRelatedPartyPayables', window );">Net (decrease)/increase in related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,355)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Net (increase)/decrease in operating assets/other receivables</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Net increase/(decrease) in operating liabilities /other liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="num">(516)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,698)<span></span>
</td>
<td class="num">(19,615)<span></span>
</td>
<td class="num">(21,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of PPE</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ProceedsFromFinanceLease', window );">Proceeds from finance lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentInRelatedParty', window );">Investment in Related Party</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,676)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PurchaseOfTreasuryAmount', window );">Purchase of Treasury Shares</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in Investing activities</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(3,996)<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FundraisingCost', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ProceedsFromIssuanceOfOptions', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RepaymentOfLeasingLiabilities', window );">Repayment of leasing liabilities</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(16,911)<span></span>
</td>
<td class="num">(23,666)<span></span>
</td>
<td class="num">(21,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalent, beginning of year</a></td>
<td class="nump">18,122<span></span>
</td>
<td class="nump">42,186<span></span>
</td>
<td class="nump">65,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange difference on cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="num">(1,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalent, end of year</a></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">$ 18,122<span></span>
</td>
<td class="nump">$ 42,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AdjustmentsForSharebasedPaymentsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments warrants to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AdjustmentsForSharebasedPaymentsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_BonusToBeSettledInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Bonus to be settled in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_BonusToBeSettledInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CashInflowFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cash inflow from taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CashInflowFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DepreciationOfRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DepreciationOfRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FVLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FV loss on investment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FVLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FundraisingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fundraising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FundraisingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InterestReceivedFromLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Received from loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InterestReceivedFromLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentInRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in related party amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentInRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LossOnDisposalOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on disposal of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LossOnDisposalOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NetIncreaseInRelatedPartyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase in related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NetIncreaseInRelatedPartyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NetIncreaseInRelatedPartyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase in related party receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NetIncreaseInRelatedPartyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsForfeitedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsForfeitedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ProceedsFromFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ProceedsFromFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ProceedsFromIssuanceOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ProceedsFromIssuanceOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or collection of receivables arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_PurchaseOfTreasuryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_PurchaseOfTreasuryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RepaymentOfLeasingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of leasing liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RepaymentOfLeasingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesIssuedInLieuOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in lieu of fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesIssuedInLieuOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843051312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GeneralInformationLineItems', window );"><strong>General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">GENERAL INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. GENERAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tiziana Life Sciences Ltd,
(the &#8220;company&#8221;) is a public limited company incorporated in Bermuda and at the year-end is quoted on the NASDAQ Capital Market
(NASDAQ: TLSA). The previous parent, Tiziana Life Sciences PLC, delisted from the main market of the London Stock Exchange (LSE: TILS)
on October 21, 2021. The address of its registered office is given on page 1. The principal activities of the Company and its subsidiaries
(the Group) are that of a clinical stage biotechnology company that specializes in the development of transformative therapies for neurodegenerative
and lung diseases. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer&#8217;s, Crohn&#8217;s
Disease and KRAS+ NSCLC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functional currency for
the Company is also US dollars ($) indicative of the primary economic environment in which the Company operates. These consolidated financial
statements are presented in thousands of dollars ($&#8217;000) which is the presentational currency of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_GeneralInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_GeneralInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843105280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal accounting policies
applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently
to all the years presented unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through profit or loss</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through other comprehensive income</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group incurred losses
during the year and has net assets at the year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $134m and a net loss
for the year ended December 31, 2023 of $17.7m.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.&#160;
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next 12 months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New and Revised Standards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Standards in effect in 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor&#8217;s return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group&#8217;s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 &#8216;Business combinations&#8217;
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, Tiziana
Life Sciences Ltd. (the &#8216;Company&#8217;) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group&#8217;s immediate parent company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only one operating segment being
the research and development of biotechnological and pharmaceutical products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Taxation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign currency translation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items included in the financial
statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentational
currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Assets and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Profit and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. &#8220;License
fees expenses&#8221; are recognized as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group&#8217;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#8216;Intangible
Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Financial assets, initial
recognition and measurement and subsequent measurement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Financial liabilities,
initial recognition and measurement and subsequent measurement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial liabilities are
classified as measured at amortized cost or FVTPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s financial
liabilities include trade and other payables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants are issued by the
Group in return for services and as part of a financing transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued in return for services.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued as part of a financing transaction.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ordinary shares of the Company
are classified as equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property, plant and equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(i</b>) Recognition and
measurement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Depreciation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated useful lives
for the current period and the comparative period are as follows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 60%"><span style="font-size: 10pt">Fixtures and fittings</span></td>
    <td style="width: 40%"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">IT and equipment</span></td>
    <td><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Right of use asset</span></td>
    <td><span style="font-size: 10pt">Economic life of contractual relationship</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of financial assets
measured at amortized cost</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General approach</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Simplified approach</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The simplified approach is
applied to the impairment assessment of trade receivables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of non-financial assets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contingent Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases of low value assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group&#8217;s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share &#8211; based payments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where employees and directors
are rewarded using share-based payments, the fair value of the employees&#8217;, directors&#8217; and/or advisers&#8217; services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share&#8211;based payment reserve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods and services received
in exchange for the grant of any share &#8211; based payment are measured at their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sub license income</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $750k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc&#8217;s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other intangible assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset&#8217;s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset&#8217;s cash generating unit is compared
to the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Relassification of Prior Year Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $804k.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843133072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Judgement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CriticalAccountingJudgementLineItems', window );"><strong>Critical Accounting Judgement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate', window );">CRITICAL ACCOUNTING JUDGEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. CRITICAL ACCOUNTING JUDGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting
Standards as issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities,
income and expenditure and the disclosures made in the consolidated financial statements. Such estimates and judgements must be continually
evaluated based on historical experience and other factors, including expectations of future events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are considered
to be critical accounting estimates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Share-based payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group accounts for share-based
payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement of the cost of employee
services received in exchange for the options on our ordinary shares, based on the fair value of the award on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes the Black-Scholes-Merton
option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market
conditions. For performance-based options that include vesting conditions relating to the market performance of our ordinary shares, a
Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that have to be met as conditions to vesting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company makes estimates
as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest rate for the term
of the award and correlations and volatilities of the shares of peer group companies. The Company also makes estimates as to the vesting
period for awards that have performance &#8211; based criteria.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CriticalAccountingJudgementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CriticalAccountingJudgementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843033680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (expense)/ Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Other (expense)/ Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">OTHER (EXPENSE)/ INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4 OTHER (EXPENSE)/ INCOME</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s other (expense)/
income is made up of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Sublicense income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Income (see note 19)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other income/(expense)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">893</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sublicense income has been classified as other
income as the counterparty is not considered a customer but an entity we are collaborating with.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843036128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingLossLineItems', window );"><strong>Operating Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory', window );">OPERATING LOSS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. OPERATING LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s operating
losses are stated after charging/(crediting) the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">License fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,047</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Realization bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation (Right-of-use asset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange (gains)/losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,183</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,899</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">License fees relating to 2020
were waived in 2021 as a result of negotiations by the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A realization bonus of $13.5
million became payable during the year ended December 31, 2020 to the chairman of the board upon the Company raising funds in excess of
$28m (&#163;20m), which it successfully raised in August 2020. As the bonus was not settled until November 2021, interest of $0.9m was
accrued on the amount due in the year to December 31, 2021. No realization bonus is accounted for in year ended December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866045552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmental Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SegmentalReportingLineItems', window );"><strong>Segmental Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">SEGMENTAL REPORTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>6. SEGMENTAL REPORTING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year under review
Management identified the Group&#8217;s only operating segment as the research and development of biotechnological and pharmaceutical
products. This one segment is monitored and strategic decisions are made based upon it and other non-financial data collated from industry
intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual consolidated financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SegmentalReportingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SegmentalReportingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843764448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_EmployeesAbstract', window );"><strong>Employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory', window );">EMPLOYEES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. EMPLOYEES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Staff costs comprised:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Directors&#8217; salaries (including bonus)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">929</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">554</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Employees&#8217; wages, salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Social security costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Recruitment fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share based payment (credit) / charge</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,730</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,410</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,173</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">4,596</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">1,490</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9,973</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The average monthly number of employees, including directors, employed by the group during the year was:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate and administration</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">13</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_EmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_EmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843079216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of Key Management Personnel<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelLineItems', window );"><strong>Remuneration of Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">REMUNERATION OF KEY MANAGEMENT PERSONNEL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. REMUNERATION OF KEY MANAGEMENT PERSONNEL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Director</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217;<br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">G. Cerrone <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">562</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">624</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">J Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">K. Shailubhai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,967</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">100</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,946</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Gabriele Cerrone&#8217;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All bonuses are short term.
No post-employment or termination payments were made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following share options
were granted to directors in the following periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">W.Simon</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">75,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">J. Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">150,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,500,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Key management personnel of
the Group are comprised of directors and officers of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No share options were exercised
by directors during the years ended December 31, 2023,2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company made payments
totaling approximately $56K, $32K, and $24K to defined contribution pension schemes on behalf of directors and employees during 2023, 2022,
and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RemunerationofKeyManagementPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RemunerationofKeyManagementPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843015712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCostsAbstract', window );"><strong>Finance Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">FINANCE COSTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. FINANCE COSTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Finance Income</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Loan Interest Received</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">32</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left">Finance Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance charge accrued on convertible loan notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fair Value loss on Investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total finance Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">412</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(844</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(176</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843775168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TaxationAbstract', window );"><strong>Taxation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. TAXATION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current year tax (credit)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,255</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,242</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,397</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,926</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,065</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Movement in unrecognized deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,722</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,961</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,401</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income not taxable for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,113</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current Tax - Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to brought forward values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Research and Development
claim has been calculated in accordance with the R&amp;D tax relief available to small and medium sized entities, whereby the entity is
able to claim a cash tax credit (if loss making), worth up to 14.5% of the surrenderable losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The adjustments due to prior
periods relate to R&amp;D tax relief claims for the prior period. Under UK tax legislation, a 2-year window is available under which R&amp;D
tax relief can be claimed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No deferred tax asset has
been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of tax losses for
which no deferred tax assets have been recognized for the year ended December 31, 2023 is $18,137k (2022 is $15,011k; 2021; $11,591k).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843580496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LossPerShareLineItems', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">(Loss) attributable to equity holders of the company ($000)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(17,691</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(15,397</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(23,417</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,471,016</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,526,389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,932,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17.3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15.2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the Group is reporting
a loss from continuing operations for the year then, in accordance with IAS 33, share options, warrants and convertible loan notes are
not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per
share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from
continuing and total operations and therefore no earnings per share for discontinued operations are presented. The weighted average number
of ordinary shares in issuance is stated as net excluding Treasury shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LossPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LossPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843056752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract', window );"><strong>Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER RECEIVABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. OTHER RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended <br/>
December 31, 2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security deposits receivable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation Receivable</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,793</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,246</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,016</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,546</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no differences between
the carrying amount and fair value of any of the trade and other receivables above.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843024448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Share Premium<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Share Capital and Share Premium [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock', window );">SHARE CAPITAL AND SHARE PREMIUM</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13 SHARE CAPITAL AND SHARE PREMIUM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Group</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, the Company
acquired the entire shareholding of Tiziana Life Sciences Plc and its subsidiaries through a share for share exchange transaction. On
this date Tiziana Life Sciences Ltd became the Group&#8217;s parent company. This transaction does not constitute a business combination
under IFRS 3 &#8220;Business combinations&#8221; and has been accounted for as a group reorganization. Merger accounting has been applied
to account for the insertion of the new company. Due to a share consolidation, the effect of this was a decrease in share capital of the
Company with an offset posted to the merger reserve. As a common control transaction, the Group has elected to present the comparative
information as if this transaction had occurred before the start of the comparative period. The share capital arising on the share for
share exchange has been presented as share capital in the comparative period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Nominal<br/>
 Value</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Share <br/>
Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Share<br/>
 Premium</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Merger<br/>
 Reserve</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">&#163;/$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1 2021 per 20-F annual report</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#163;</td><td style="width: 9%; font-weight: bold; text-align: right">0.03</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">194,612,289</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Group Reorganization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of share capital in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(194,612,289</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,794</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,615</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued pursuant to share for share exchange and consolidation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,306,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of other reserves in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Restated at 1 January 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.001</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,306,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of Loan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,866,907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issued in lieu of cash bonus</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,962,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,272,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,272,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued in lieu of fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants Exercised</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">573</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of Stock - ATM</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,087,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ordinary shares have a par
value of $0.001. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion
to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person
or by proxy is entitled to one vote, and upon a poll each share is entitled to one vote. The Company has 103,087,744 shares in issue and
holds 1,573,510 shares in treasury.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843774240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE BASED PAYMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. SHARE BASED PAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Group and Company Options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates share-based
payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option
is normally equal to the market price of an ordinary share in the Company at the date of grant. The Company is currently operating two
plans (Tiziana Life Sciences PLC) Share Option Plan which is closed for any new issuances and the Tiziana Life Sciences Ltd 2021 Equity
Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Tiziana Life Sciences PLC Share Option Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(103</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,724</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,732</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No options were exercised
during 2023, 2022 or 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total outstanding fair
value charge of the share option instruments is deemed to be approximately $2,602k (2022: $3,223k (restated), 2021: $12,339k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Tiziana Life Sciences
PLC Share Option Plan, the total expense recognized for the year ending 31 December 2023 arising from share &#8211; based payment transactions
under the Tiziana Life Sciences PLC Share Option Plan is $703k of which $51k relates to forfeitures during the year (2022 $1,199k, 2021:
$5,173k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Options <br/>
    at<br/> 31 December <br/> 2023<br/> (&#8217;000)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">26 June 2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">26 June 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,831</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>30 April 2018</td><td>&#160;</td>
    <td style="text-align: center">30 April 2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6 May 2020</td><td>&#160;</td>
    <td style="text-align: center">5 May 2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,690</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>23 July 2020</td><td>&#160;</td>
    <td style="text-align: center">26 July 2030</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">25 August 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">24&#160;August&#160;2030</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,621</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair value of options granted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors have used the
Black-Scholes-Merton option pricing model to estimate the fair value of all of the options granted during the year to December 31, 2023,
applying the assumptions below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historical volatility is based
on the historical volatility of the Company itself.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has estimated
a forfeiture rate of zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The model inputs for options
granted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4 November<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 August<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.741</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.741</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">-0.10%&#160;to&#160;-0.02</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">0.32%&#160;to&#160;0.65%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">99% to 122</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">90% to 126%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.741</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.690</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.690</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the options issued in
August 2020 with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options.
The Company uses the following methods to determine its underlying assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expected volatilities are based on the historical volatilities of the market;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the expected term of the award is 4 years and is based on managements&#8217; assessment of when the market condition is likely to be achieved; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Modification of share &#8211; based payments.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2020, the Company reduced
the exercise price for options issued to employees and directors to $0.48 (&#163;0.35). This was approved by shareholders at a General
Meeting held on May 6, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the modified
options at the date of modification was determined using the option pricing models as described above. The incremental fair value was
recognized as an expense over the period from the modification date to the end of the vesting period. The expense for the original option
grant will continue to be recognized as if the terms had not been modified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the modified
options was determined using the same models and principles as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Tiziana Life Sciences Ltd Share Option Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,575</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No options were exercised
during 2023, 2022 or 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total outstanding fair
value charge of the share option instruments is deemed to be approximately $974k (2022: $1,176k)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Tiziana Life Sciences
Ltd 2021 Equity Incentive Plan, the total expenses recognized for the year ending 31 December 2023 arising from share - based payment
transactions are $1,019k, not including a charge of $57k for forfeitures during the year. (2022:$332k)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">26 July <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">14 March<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.88</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share&#160;Options<br/>
 as at 31 December <br/> 2023<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">01 August 2022</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center">01 August 2032</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>04 November 2022</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">04 November 2032</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>14 March 2023</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">14 March 2033</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">993</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">26 July 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">26 July 2033</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,268</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Group and Company Warrants</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were issued in
2022 or 2023. For warrants issued in 2020, the Directors have estimated the fair value of the warrants using the Black-Scholes valuation
model and assumptions below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">1.15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding at 1 January</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(438</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(259</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at 31 December</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">697</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">697</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-hidden: hidden-fact-330"><span style="-sec-ix-hidden: hidden-fact-331"><span style="-sec-ix-hidden: hidden-fact-332">No</span></span></span> share-based payment charges
relating to warrants were recorded during 2023, 2022 or 2021. Approximately $26K of share-based payment charges are included in the consolidated
statement of operations and comprehensive loss for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843229488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract', window );"><strong>Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">RESERVES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. RESERVES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share-based payment reserve
for warrants represents the cost to issue warrants in the future based on their grant date fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share-based payment reserve
for options represents the cost to issue share-based compensation, primarily share options, based on their grant date fair value.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Retained earnings represent
the cumulative profits/(losses) of the entity which have not been distributed to shareholders. This reserve has been credited as part
of the capital reduction exercise described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The translation reserve represents
the unrealized gains or losses from the foreign currency translation of Companies within the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares to be issued reserve
represents the equity shares that are to be issued to the Chairman in lieu of his bonus and additional salary for his role as acting CEO
for the year ending December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The merger reserve arises
on consolidation as a result of the share for share exchange transaction that took place this year described in note 13. It represents
the difference between the share capital issued and the aggregate carrying value of assets and liabilities and other reserves of the previous
parent on the merger date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843209344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The main risks arising from
the Group&#8217;s financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and
agree policies for managing each of these risks which are summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk encompasses three
types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair
value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled
&#8220;interest rate risk&#8221; below. The Directors do not consider the Group&#8217;s exposure to price risk to be significant. The
Group&#8217;s risk management is coordinated by the Directors and focuses on actively securing the Group&#8217;s short to medium term
cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative
purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Credit risk is managed on
a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well
as credit exposure to customers including committed transactions and outstanding receivables. The Group reviews its banking arrangements
carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans
between members of the Group as part of their internal reporting and assesses outstanding receivables for ability to be repaid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s policy is
to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity
requirements in the short and long term. The Group ordinarily finances its activities through cash generated from private and public offerings
of equity and debt securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarizes
the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 3 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12 <br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,223</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,914</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,354</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,921</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,275</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Less than <br/>
3 months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3 to 12 <br/>
months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade payables</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,230</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,732</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,962</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party payables</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-336; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,262</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,830</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,092</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest rate risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has limited exposure
to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Bank of America
base rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors do not consider
the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity
position as of year-end for either the year ended 31 December 2023 or 31 December 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign currency risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group operates internationally
although the majority of its operations are based in the United Kingdom and the United States, and the majority of assets and liabilities
are denominated in US Dollars, with a small amount denominated in Pound Sterling. It therefore is exposed to some foreign exchange risk
arising from exposure to various currencies primarily the Pound Sterling. The Group monitors currency exchange rates and makes judgments
as to whether to enter into currency hedging contracts. Currently no such hedging contracts are in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A reasonably possible strengthening
(weakening) of the US dollar or Sterling against all other currencies at 31 December 2023 would have affected the measurement of the financial
instruments denominated in a foreign currency and affected equity and profit and loss by the amounts shown below. This analysis assumes
that all other variables remain constant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit or loss and equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Strengthening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weakening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">USD (5% movement)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(467</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866272352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract', window );"><strong>Capital Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">CAPITAL RISK MANAGEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. CAPITAL RISK MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purpose of the Group&#8217;s
capital management, capital includes called up share capital, share premium, share &#8211; based payments for options, share - based payments
for warrants, convertible loan note reserve, and all other equity reserves attributable to the equity holders of the parent as reflected
in the consolidated statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s objectives
when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern and to maximize shareholder value through
the optimization of the equity balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group adjusts its capital
structure in light of changes in economic conditions and expected business demands on capital. The Group may also return capital to shareholders
or issue additional shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842895968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. TRADE AND OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,962</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accruals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,387</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,532</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866093920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentInRelatedPartyAbstract', window );"><strong>Investment in Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentInRelatedPartyTextBlock', window );">INVESTMENT IN RELATED PARTY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>19. INVESTMENT IN RELATED PARTY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Accustem Sciences Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,675</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,806</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share price of Accustem
as of December 31, 2023 was $.63, which has resulted in the recognition of a fair value loss of $1,049k. This has been measured using the
Level 1per IFRS 13 fair value hierarchy. Accustem Sciences Inc is listed on the OTC markets and is run by a separate management team which
is independent of the Tiziana management team. Tiziana is therefore not able to assert significant influence over Accustem Sciences Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Okyo Pharma Ltd</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,717</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group acquired 2.1m shares of Okyo Pharma Ltd. on October 23,
2023 which is a 15.57% ownership.&#160;The share price of Okyo Pharma Ltd as of December 31, 2023 was $1.77, which has resulted in the
recognition of a fair value gain of $567k. This has been measured using the Level 1per IFRS 13 fair value hierarchy. Okyo Pharma Ltd
is listed on the OTC markets and is run by a separate management team which is independent of the Tiziana management team. Tiziana is
therefore not able to assert significant influence over Okyo Sciences Inc.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentInRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentInRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentInRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentInRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843101136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TreasurySharesAbstract', window );"><strong>Treasury Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTreasurySharesExplanatory', window );">TREASURY SHARES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>20. TREASURY SHARES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company acquired
1,683,544 of its own shares through purchases on the NASDAQ stock exchange during the year ended December 31, 2022. The amount paid
to acquire the shares totaled $1,320k, and the shares are held as &#8220;treasury shares&#8221;. The Company has the right to
reissue these shares later. All shares issued by the Company are fully paid. In 2023 there was $254k in buybacks.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TreasurySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TreasurySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843025376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>21. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ultimate controlling party
of the Group is Planwise Group Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rasna Therapeutics Inc is
a related party as the entity is controlled by a person that has significant influence over the Group. Rasna is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby Rasna is charged for shared services such as the payroll and rent. During 2022,
Tiziana extended a loan to Rasna for $75,000 at an interest rate of 16% per annum. There were no additional loans to Rasna in 2023. As
of December 31, 2023, $416k (2022: $206k, 2021: $106k) was owed to Tiziana Life Sciences Ltd in respect of the loan and shared services
agreement. The total charged under the shared services agreement in the year ending 31 December 2023 was $6k (2022: $7k, 2021: $11k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above,
on April 16, 2020, Tiziana also acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin
D (Act D; a.k.a. Dactinomycin), from Rasna to expand its pipeline for a consideration of an initial $120k upfront payment and milestone
payments of up to an additional aggregate $630k. There were no milestone payments due in the year ending 31 December 2023 (2022: $0k,
2021:$0k).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OKYO Pharma Ltd is a related
party as the entity is controlled by a person that has significant influence over the Group. OKYO is also party to a Shared Services agreement&#160;with&#160;Tiziana&#160;whereby
OKYO is charged for shared services such as the payroll and rent. As of December 31, 2023 $398k (2022: $274k, 2021: $42k) was owed to
Tiziana Life Sciences Ltd in respect of this agreement. The total charged under the shared services agreement in the year ending 31 December
2023 was $199k (2022: $125k, 2021: $98k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, the Group
issued a short-term credit facility to OKYO Pharma, a related party, for $2,000k to support short term liquidity. The loan was available
for a period of 6 months upon first draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if
the loan is not repaid after the 6-month period. In October 23 the loan was converted to an investment in OKYO with 20% interest. The
principal of $2,000k plus accrued interest of $1,150k were converted into 2,100,000 Ordinary Shares, with no par value, of OKYO Pharma
Ltd. As at December 31, 2022 $1,056k had been drawn down against the loan and $19k of interest had been accrued.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gensignia Lifesciences Inc
is a related party as the entity is controlled by a person that has significant influence over the Group. As of December 31, 2023 the
related party balance is $0 (2022, $0k, 2021: $295k). On December 31, 2022 $295k was written off to bad debt after management assessment
and deemed the balance to be irrecoverable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accustem Sciences Inc is a
related party as the entity is controlled by a person that has significant influence over the Group. Accustem is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby the Company is charged for shared services such as payroll and rent as of December
31 2023, $1,324k (2022:$72K, 2021:$1,341k). The net amount owed from Accustem, including shared service total costs of $1,324k.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843051312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All leases are accounted for by recognizing a right-of-use
asset and a lease liability except for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases of low value assets; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has leases for its
offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have leases of
low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group
sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent
manner to its property, plant and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of 2022,
the Group entered into a new lease agreement for its London office. Any leases that have a term shorter than 12 months the Group has applied
the exemption allowed by paragraph 5a in IFRS16 in respect of short &#8211; term leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Right-of-use assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Disposal of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">283</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">372</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(119</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lease liabilities are presented
in the consolidated statement of financial; position as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease liabilities are
secured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minimum lease payment due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Within 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-2 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2-5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Over 5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Lease payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Finance Charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Net Present Values</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">138</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">109</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">247</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842868224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsAbstract', window );"><strong>Financial Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">FINANCIAL COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s main financial
commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research
and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical,
clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Milciclib project research future payments relate to the achievement of clinical milestones or the payment of royalties. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay Nerviano
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$1,000,000 upon initiation of the first Phase II clinical trial, this is currently being negotiated with BMS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$4,000,000 upon FPD of the first Phase 3 registration trial in HCC.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$3,600,000 upon first patient enrollment into a Phase II human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Upon the first NDA equivalent in: thymic carcinoma, $900,000; HCC, $9,000,000; breast cancer, $15,000,000.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Foralumab project &#8211; Future payments relate to the achievement of clinical milestones or the payment of royalties. Diligence obligations are payable to BMS/Medarex should the project continue to commercialisation. $750,000 has been recoded as other income in respect of diligence obligations due to Medarex for 2021.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay BMS
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$300,000 upon enrollment of first patient in a Phase I human clinical trial of the first Phase II Clinical trial, this is currently being negotiated with BMS.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$1,500,000 upon initiation of the first Phase III clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$2,000,000 upon filing of the first BLA, or equivalent</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$2,000,000 upon approval of the first BLA, or equivalent</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are obligated to pay Brighams
Womens Hospital the following hospital milestone payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$300,000 upon first patient enrollment into a Phase I human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$300,000 upon first patient enrollment into a Phase II human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$1,500,000 upon first patient enrollment into a Phase III human clinical trial</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">$3,000,000 upon first commercial sale of a product</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">ACT D - Tiziana will need to make milestone payments of up to $630k depending on the issuance of a US patent from any US patent application in Transferred IP relating to nanoparticle formulations of Act D and upon the successful completion of a Phase II clinical efficacy trial.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842871584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract', window );"><strong>Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>24. CONTINGENT LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The group from time to time
is involved in legal proceedings, none of which have given rise to contingent liabilities. Contingencies arising in the ordinary course
of business, for which no security has been given, are not expected to result in any material financial loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866678048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of preparation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through profit or loss</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments &#8211; fair value through other comprehensive income</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForGoingConcern', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group incurred losses
during the year and has net assets at the year end.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $134m and a net loss
for the year ended December 31, 2023 of $17.7m.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.&#160;
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next 12 months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock', window );">New and Revised Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New and Revised Standards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Standards in effect in 2023</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation', window );">Basis of consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor&#8217;s return.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Business combination</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business combination</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group&#8217;s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 &#8216;Business combinations&#8217;
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, Tiziana
Life Sciences Ltd. (the &#8216;Company&#8217;) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group&#8217;s immediate parent company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only one operating segment being
the research and development of biotechnological and pharmaceutical products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Taxation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign currency translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items included in the financial
statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentational
currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Assets and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Profit and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForLicenseFees', window );">License fees</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License fees</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. &#8220;License
fees expenses&#8221; are recognized as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group&#8217;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#8216;Intangible
Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Financial assets, initial
recognition and measurement and subsequent measurement</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Financial liabilities,
initial recognition and measurement and subsequent measurement</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial liabilities are
classified as measured at amortized cost or FVTPL.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s financial
liabilities include trade and other payables.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants are issued by the
Group in return for services and as part of a financing transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued in return for services.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants issued as part of a financing transaction.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share capital</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ordinary shares of the Company
are classified as equity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property, plant and equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>(i</b>) Recognition and
measurement</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Depreciation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated useful lives
for the current period and the comparative period are as follows.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 60%"><span style="font-size: 10pt">Fixtures and fittings</span></td>
    <td style="width: 40%"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">IT and equipment</span></td>
    <td><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Right of use asset</span></td>
    <td><span style="font-size: 10pt">Economic life of contractual relationship</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of financial assets
measured at amortized cost</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General approach</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Simplified approach</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The simplified approach is
applied to the impairment assessment of trade receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impairment of non-financial assets</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory', window );">Contingent Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contingent Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases of low value assets; and</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases with a duration of 12 months or less.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group&#8217;s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share &#8211; based payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share &#8211; based payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where employees and directors
are rewarded using share-based payments, the fair value of the employees&#8217;, directors&#8217; and/or advisers&#8217; services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share&#8211;based payment reserve.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods and services received
in exchange for the grant of any share &#8211; based payment are measured at their fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock', window );">Sub license income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sub license income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $750k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc&#8217;s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Other Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other intangible assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset&#8217;s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset&#8217;s cash generating unit is compared
to the carrying amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory', window );">Relassification of Prior Year Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Relassification of Prior Year Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $804k.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the reclassification of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForGoingConcern">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForGoingConcern</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for revised standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for sub license income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843044912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPolicieAbstract', window );"><strong>Accounting Policie Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock', window );">Schedule of Estimated Useful Lives for the Current Period and the Comparative Period</a></td>
<td class="text">The estimated useful lives
for the current period and the comparative period are as follows.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 60%"><span style="font-size: 10pt">Fixtures and fittings</span></td>
    <td style="width: 40%"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">IT and equipment</span></td>
    <td><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Right of use asset</span></td>
    <td><span style="font-size: 10pt">Economic life of contractual relationship</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccountingPolicieAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccountingPolicieAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of estimated useful lives for the current period and the comparative period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866430624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (expense)/ Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Other (expense)/ Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Schedule of Other (Expense)/ Income</a></td>
<td class="text">The Group&#8217;s other (expense)/
income is made up of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Sublicense income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Income (see note 19)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total other income/(expense)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">893</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843161072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingLossTablesLineItems', window );"><strong>Operating Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfDetailedInformationAboutOperatingLoss', window );">Schedule of Operating Losses</a></td>
<td class="text">The Group&#8217;s operating
losses are stated after charging/(crediting) the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">License fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,047</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Realization bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation (Right-of-use asset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange (gains)/losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,183</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,899</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfDetailedInformationAboutOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfDetailedInformationAboutOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingLossTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingLossTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866498848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_EmployeesAbstract', window );"><strong>Employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory', window );">Schedule of Employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Staff costs comprised:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Directors&#8217; salaries (including bonus)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">929</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">554</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Employees&#8217; wages, salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Social security costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Recruitment fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share based payment (credit) / charge</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,730</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,410</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,173</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">4,596</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">1,490</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9,973</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The average monthly number of employees, including directors, employed by the group during the year was:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate and administration</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 3pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">9</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td><td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: Black 3pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3pt double; text-align: right">13</td><td style="padding-bottom: 3pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_EmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_EmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865817968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of Key Management Personnel (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelTablesLineItems', window );"><strong>Remuneration of Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock', window );">Schedule of Remuneration of Key Management Personnel</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Director</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217;<br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share <br/> based <br/> payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&#8217; <br/> fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">G. Cerrone <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">562</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">624</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Willy Simon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">J Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">K. Shailubhai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,967</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">100</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">379</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,946</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Gabriele Cerrone&#8217;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock', window );">Schedule of Share Options were Granted to Directors</a></td>
<td class="text">The following share options
were granted to directors in the following periods:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">W.Simon</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">75,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">J. Brancaccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">T Adams</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">150,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,500,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share options were granted to directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RemunerationofKeyManagementPersonnelTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RemunerationofKeyManagementPersonnelTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843097648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCostsAbstract', window );"><strong>Finance Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock', window );">Schedule of Finance Costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Finance Income</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Loan Interest Received</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">32</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left">Finance Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance charge accrued on convertible loan notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fair Value loss on Investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total finance Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">412</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(844</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(176</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about finance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865934608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TaxationAbstract', window );"><strong>Taxation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Taxation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021<br/> $&#8217;000</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Group</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current year tax (credit)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,255</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,242</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,397</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,926</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,065</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Movement in unrecognized deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,722</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,961</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments due to prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,401</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income not taxable for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,113</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current Tax - Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to brought forward values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843036128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LossPerShareTablesLineItems', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock', window );">Schedule of Basic Loss Per Share</a></td>
<td class="text">Basic loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the
year.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">(Loss) attributable to equity holders of the company ($000)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(17,691</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(15,397</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(23,417</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102,471,016</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,526,389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,932,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17.3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15.2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LossPerShareTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LossPerShareTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866093920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherReceivablesTablesLineItems', window );"><strong>Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended <br/>
December 31, 2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security deposits receivable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation Receivable</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,793</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,246</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,016</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,546</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherReceivablesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherReceivablesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519869159968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Share Premium (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Share Capital and Share Premium [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock', window );">Schedule of Share Capital Arising on the Share for Share Exchange</a></td>
<td class="text">The share capital arising on the share for
share exchange has been presented as share capital in the comparative period.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Nominal<br/>
 Value</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">Share <br/>
Capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Share<br/>
 Premium</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Merger<br/>
 Reserve</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">&#163;/$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">$000</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1 2021 per 20-F annual report</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#163;</td><td style="width: 9%; font-weight: bold; text-align: right">0.03</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">194,612,289</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Group Reorganization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of share capital in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(194,612,289</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,794</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,615</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued pursuant to share for share exchange and consolidation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,306,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Elimination of other reserves in Tiziana Life Sciences Plc</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Restated at 1 January 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.001</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,306,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Conversion of Loan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,866,907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issued in lieu of cash bonus</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,962,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,272,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Shares issued in the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,272,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued in lieu of fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants Exercised</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">573</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of Stock - ATM</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.0001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At 31 December 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,087,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,697</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure share capital arising for share exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866205488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Share Option Plan</a></td>
<td class="text"><b><span style="text-decoration:underline">Tiziana Life Sciences PLC Share Option Plan</span></b><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(103</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,724</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,732</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock', window );">Schedule of Share Options Expiry Dates and Exercise Price</a></td>
<td class="text">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Options <br/>
    at<br/> 31 December <br/> 2023<br/> (&#8217;000)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">26 June 2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">26 June 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,831</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>30 April 2018</td><td>&#160;</td>
    <td style="text-align: center">30 April 2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6 May 2020</td><td>&#160;</td>
    <td style="text-align: center">5 May 2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,690</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>23 July 2020</td><td>&#160;</td>
    <td style="text-align: center">26 July 2030</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">25 August 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">24&#160;August&#160;2030</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,621</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise<br/>
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share&#160;Options<br/>
 as at 31 December <br/> 2023<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%">01 August 2022</td><td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center">01 August 2032</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>04 November 2022</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">04 November 2032</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>14 March 2023</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">14 March 2033</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">993</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">26 July 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">26 July 2033</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,268</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock', window );">Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model</a></td>
<td class="text">The model inputs for options
granted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4 November<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 August<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.741</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.741</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">-0.10%&#160;to&#160;-0.02</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">0.32%&#160;to&#160;0.65%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">99% to 122</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">90% to 126%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.741</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.690</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.690</td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">26 July <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">14 March<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.88</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average share price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average fair value per share option</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.57</td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">21 January<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">1 June<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Grant date share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#163;</td><td style="width: 9%; text-align: right">1.15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#163;</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfEquityIncentivePlanTableTextBlock', window );">Schedule of Equity Incentive Plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<br/> exercise<br/> price<br/> (cents)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options<br/> (&#8217;000)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,575</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Outstanding at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Exercisable at 31 December</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock', window );">Schedule of Estimated the Fair Value of Warrants Using</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021 <br/>
$000</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding at 1 January</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">697</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(438</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-325">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-326">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(259</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at 31 December</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">697</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">697</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfEquityIncentivePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfEquityIncentivePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of estimated the fair value of warrants using.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843226608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock', window );">Schedule of Financial Liabilities Based on Contractual Undiscounted Payments</a></td>
<td class="text">The table below summarizes
the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted payments:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 3 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12 <br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,223</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,914</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,354</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,921</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,275</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$000</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Less than <br/>
3 months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3 to 12 <br/>
months</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade payables</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,230</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,732</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,962</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party payables</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-336; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,262</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,830</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,092</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock', window );">Schedule of All Other Variables Remain Constant</a></td>
<td class="text">This analysis assumes
that all other variables remain constant.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit or loss and equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Strengthening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weakening</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">USD (5% movement)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(467</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842868224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TradeandOtherPayablesTablesLineItems', window );"><strong>Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock', window );">Schedule of Trade and Other Payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,962</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accruals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,387</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,532</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TradeandOtherPayablesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TradeandOtherPayablesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843008336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentInRelatedPartyAbstract', window );"><strong>Investment in Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory', window );">Schedule of Investment in Related Party</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Accustem Sciences Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,675</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,806</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Investment in Okyo Pharma Ltd</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,150</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Movement in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,717</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the effect of the change of investment entity status on the financial statements. [Refer: Disclosure of investment entities [text block]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 9B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentInRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentInRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865716656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock', window );">Schedule of Right-of-Use Assets and Lease Liabilities</a></td>
<td class="text">Any leases that have a term shorter than 12 months the Group has applied
the exemption allowed by paragraph 5a in IFRS16 in respect of short &#8211; term leases.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Right-of-use assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Disposal of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">283</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">372</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Lease Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">At 1 January</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(119</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Consolidated Statement of Financial</a></td>
<td class="text">Lease liabilities are presented
in the consolidated statement of financial; position as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 Dec <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$000</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">365</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisclosureOfFutureMinimumLeasePayments', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text">The lease liabilities are
secured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minimum lease payment due</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Within 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-2 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2-5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Over 5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Lease payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Finance Charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Net Present Values</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">138</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">109</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">247</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfFutureMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfFutureMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866672352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPoliciesDetailsLineItems', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccumulatedLoss', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,691)<span></span>
</td>
<td class="num">$ (15,397)<span></span>
</td>
<td class="num">$ (23,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CashSurplus', window );">Cash surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfSegment', window );">Number of operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceFinanceIncomeExpenses', window );">Finance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceFinanceIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that comprises the change in the carrying amount of the group of insurance contracts arising from: (a) the effect of the time value of money and changes in the time value of money; and (b) the effect of financial risk and changes in financial risk; but (c) excluding any such changes for groups of insurance contracts with direct participation features that would adjust the contractual service margin but do not do so when applying paragraphs 45(b)(ii), 45(b)(iii), 45(c)(ii) or 45(c)(iii) of IFRS 17.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 110<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_110&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceFinanceIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CashSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CashSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865734192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures and fittings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems', window );"><strong>Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_EstimatedUsefulLives', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">IT and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems', window );"><strong>Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_EstimatedUsefulLives', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=tlsa_RightOfUseAssetMember', window );">Right of use asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems', window );"><strong>Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RightOfUseAssetDescription', window );">Right of use asset</a></td>
<td class="text">Economic life of contractual relationship<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_EstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated useful lives for the current period and the comparative period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_EstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RightOfUseAssetDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RightOfUseAssetDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=tlsa_RightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=tlsa_RightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866220096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems', window );"><strong>Schedule of Other Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SublicenseIncome', window );">Sublicense income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments', window );">Other Income (see note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherIncomelosses', window );">Total other income/(expense)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through profit or loss measured as such in accordance with the exemption for reacquisition of own equity instruments. [Refer: Financial assets at fair value through profit or loss, measured as such in accordance with exemption for reacquisition of own equity instruments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherIncomelosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherIncomelosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SublicenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense Income means consideration in any form received by Company and/or Company's Affiliate(s) in connection with or otherwise attributable to a grant of a sublicense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SublicenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874646928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Loss (Details)<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingLossDetailsLineItems', window );"><strong>Operating Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BenefitsPaidOrPayable', window );">Realization bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RaisingFunds', window );">Raising funds</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">&#163; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BenefitsPaidOrPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefits paid or payable for retirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BenefitsPaidOrPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingLossDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingLossDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RaisingFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Raising funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RaisingFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874955968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Loss (Details) - Schedule of Operating Losses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems', window );"><strong>Schedule of Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Licensefee', window );">License fee</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OperatingLoss', window );">Realization bonus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation of Property, plant and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation (Right-of-use asset)</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ForeignExchangegainlosses', window );">Foreign exchange (gains)/losses</a></td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="num">$ (3,183)<span></span>
</td>
<td class="num">$ (1,899)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ForeignExchangegainlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ForeignExchangegainlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_Licensefee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of License fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_Licensefee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865922816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employees (Details) - Schedule of Employees - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_StaffCostsComprisedAbstract', window );"><strong>Staff costs comprised:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors&#8217; salaries (including bonus)</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 2,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Employees&#8217; wages, salaries and bonus</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RecruitmentFees', window );">Recruitment fees</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based payment (credit) / charge</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employees, total</a></td>
<td class="nump">4,596<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">9,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract', window );"><strong>The average monthly number of employees, including directors, employed by the group during the year was:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CorporateAndAdministration', window );">Corporate and administration</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup', window );">Total</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberAndAverageNumberOfEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberAndAverageNumberOfEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average monthly number of employees, including directors, employed by the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CorporateAndAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of corporate and administration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CorporateAndAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RecruitmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of recruitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RecruitmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_StaffCostsComprisedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_StaffCostsComprisedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866082272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of Key Management Personnel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems', window );"><strong>Remuneration of Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermBenefits', window );">Realization bonus</a></td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Contribution pension schemes</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term employee benefits other than post-employment benefits and termination benefits. Such benefits may include long-term paid absences, jubilee or other long-service benefits, long-term disability benefits, long-term profit-sharing and bonuses and long-term deferred remuneration. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 158<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_158&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866364560">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">758<span></span>
</td>
<td class="num">(1,946)<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_GCerroneMember', window );">G. Cerrone [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">717<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">562<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WillySimonMember', window );">Willy Simon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember', window );">J Brancaccio [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_KShailubhaiMember', window );">K. Shailubhai [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember', window );">T Adams [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems', window );"><strong>Schedule of Remuneration of Key Management Personnel [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DirectorsFees', window );">Directors&#8217; fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Bonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_Salary', window );">Salary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPayments', window );">Share based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,967)<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Gabriele Cerrone&#8217;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_Bonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_Bonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of directors fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_Salary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_Salary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_GCerroneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_GCerroneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WillySimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WillySimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_KShailubhaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_KShailubhaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519871074656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems', window );"><strong>Schedule of Share Options were Granted to Directors [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsWereGrantedToDirectors', window );">Number of share options</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WSimonMember', window );">W.Simon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems', window );"><strong>Schedule of Share Options were Granted to Directors [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsWereGrantedToDirectors', window );">Number of share options</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember', window );">J. Brancaccio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems', window );"><strong>Schedule of Share Options were Granted to Directors [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsWereGrantedToDirectors', window );">Number of share options</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember', window );">T Adams [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems', window );"><strong>Schedule of Share Options were Granted to Directors [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsWereGrantedToDirectors', window );">Number of share options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfShareOptionsWereGrantedToDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options were granted to directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfShareOptionsWereGrantedToDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WSimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_WSimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_JBrancaccioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TAdamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519893266656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Costs (Details) - Schedule of Finance Costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceIncomeAbstract', window );"><strong>Finance Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Loan Interest Received</a></td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total finance income</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceExpenseAbstract', window );"><strong>Finance Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceChargeAccruedOnConvertibleLoanNotes', window );">Finance charge accrued on convertible loan notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss', window );">Fair Value loss on Investment</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceExpense', window );">Total finance Expense</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome', window );">Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="num">$ (844)<span></span>
</td>
<td class="num">$ (176)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceChargeAccruedOnConvertibleLoanNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance charge accrued on convertible loan notes (recognized as debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceChargeAccruedOnConvertibleLoanNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total finance Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842868832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TaxationDetailsLineItems', window );"><strong>Disclosure of Income Tax Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MaximumPercentageOfSurrenderableLosses', window );">Surrenderable losses percentage</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TermOfResearchAndDevelopmentTaxReliefClaims', window );">Term of R&amp;D tax relief claims</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Deferred tax assets</a></td>
<td class="nump">$ 18,137<span></span>
</td>
<td class="nump">$ 15,011<span></span>
</td>
<td class="nump">$ 11,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MaximumPercentageOfSurrenderableLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of surrenderable losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MaximumPercentageOfSurrenderableLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TaxationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TaxationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TermOfResearchAndDevelopmentTaxReliefClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of research and development tax relief claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TermOfResearchAndDevelopmentTaxReliefClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866176432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Details) - Schedule of Taxation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GroupAbstract0', window );"><strong>Group</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current year tax (credit)</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AdjustmentsDueToPriorPeriods', window );">Adjustments due to prior periods</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeTaxExpenseContinuingOperation', window );">Total tax (credit) for the period</a></td>
<td class="nump">449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherLossBeforeTaxation', window );">Loss before taxation</a></td>
<td class="num">(17,242)<span></span>
</td>
<td class="num">(15,397)<span></span>
</td>
<td class="num">(26,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax', window );">Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22</a></td>
<td class="num">(4,055)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
<td class="num">(5,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MovementInUnrecognisedDeferredTax', window );">Movement in unrecognized deferred tax</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation', window );">Expenses not deductible for taxation</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AdjustmentsDueToPriorPeriod', window );">Adjustments due to prior periods</a></td>
<td class="nump">449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim', window );">Research and development claim</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_IncomeNotTaxableForTaxPurposes', window );">Income not taxable for tax purposes</a></td>
<td class="num">(3,113)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FixedAssetDifferences', window );">Fixed asset differences</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CurrentTaxOther', window );">Current Tax - Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AdjustmentsToBroughtForwardValues', window );">Adjustments to brought forward values</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements', window );">Consolidation adjustment in relation to foreign exchange movements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,240)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AdjustmentsDueToPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments due to prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AdjustmentsDueToPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AdjustmentsDueToPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments due to prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AdjustmentsDueToPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AdjustmentsToBroughtForwardValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AdjustmentsToBroughtForwardValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CurrentTaxOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CurrentTaxOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FixedAssetDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FixedAssetDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_GroupAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_GroupAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeNotTaxableForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income not taxable for tax purpose.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeNotTaxableForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeTaxExpenseContinuingOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeTaxExpenseContinuingOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expenses not deductible for taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss charged at standard rate of corporation tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MovementInUnrecognisedDeferredTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of movement in unrecognised deferred tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MovementInUnrecognisedDeferredTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherLossBeforeTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherLossBeforeTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874273648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Details) - Schedule of Taxation (Parentheticals)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Schedule of Taxation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Standard rate of corporation tax</a></td>
<td class="nump">23.52%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866203904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Schedule of Basic Loss Per Share - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems', window );"><strong>Schedule of Basic Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">(Loss) attributable to equity holders of the company ($000)</a></td>
<td class="num">$ (17,691)<span></span>
</td>
<td class="num">$ (15,397)<span></span>
</td>
<td class="num">$ (23,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares in issue</a></td>
<td class="nump">102,471,016<span></span>
</td>
<td class="nump">101,526,389<span></span>
</td>
<td class="nump">97,932,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_BasicLossPerSharecentsPerShare', window );">Basic loss per share (cents per share)</a></td>
<td class="num">$ (17.3)<span></span>
</td>
<td class="num">$ (15.2)<span></span>
</td>
<td class="num">$ (23.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_BasicLossPerSharecentsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_BasicLossPerSharecentsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865745680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables (Details) - Schedule of Other Receivables - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems', window );"><strong>Schedule of Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SecurityDepositsReceivable', window );">Security deposits receivable</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TaxationReceivable', window );">Taxation Receivable</a></td>
<td class="nump">3,793<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Total Other Receivable</a></td>
<td class="nump">$ 4,016<span></span>
</td>
<td class="nump">$ 4,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SecurityDepositsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Security deposits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SecurityDepositsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TaxationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxation receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TaxationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843529216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Share Premium (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalandSharePremiumDetailsLineItems', window );"><strong>Share Capital and Share Premium [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfSharesIssued1', window );">Shares issued</a></td>
<td class="nump">103,087,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TreasuryShares1', window );">Treasury shares</a></td>
<td class="nump">1,573,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalandSharePremiumDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalandSharePremiumDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TreasuryShares1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TreasuryShares1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519867657728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract', window );"><strong>Schedule of Share Capital Arising on the Share for Share Exchange [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueAnnualReport', window );">Nominal Value At January 1 2021 per 20-F annual report (in Pounds per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesAnnualReport', window );">Share Capital Shares At January 1 2021 per 20-F annual report (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,612,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueAnnualReport', window );">Share Capital value At January 1 2021 per 20-F annual report</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumAnnualReport', window );">Share Premium At January 1 2021 per 20-F annual report</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveAtJanuary12021Per20FAnnualReport', window );">Merger Reserve At January 1 2021 per 20-F annual report</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GroupReorganizationAbstract', window );"><strong>Group Reorganization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueEliminationOfShareCapital', window );">Nominal Value Elimination of share capital in Tiziana Life Sciences Plc (in Pounds per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesEliminationOfShare', window );">Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,612,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueEliminationOfShareCapital', window );">Share Capital value Elimination of share capital in Tiziana Life Sciences Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumEliminationOfShareCapitalIn', window );">Share Premium Elimination of share capital in Tiziana Life Sciences Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(111,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveEliminationOfShareCapitalIn', window );">Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation', window );">Nominal Value Shares issued pursuant to share for share exchange and consolidation (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation', window );">Share Capital Shares Shares issued pursuant to share for share exchange and consolidation (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,306,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation', window );">Share Capital value Shares issued pursuant to share for share exchange and consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation', window );">Share Premium Shares issued pursuant to share for share exchange and consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation', window );">Merger Reserve Shares issued pursuant to share for share exchange and consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_EliminationOfOtherReserves', window );">Elimination of other reserves in Tiziana Life Sciences Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueRestated', window );">Nominal Value Restated at 1 January 2021 (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesRestated', window );">Share Capital Shares Restated at 1 January 2021 (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,306,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueRestated', window );">Share Capital value Restated at 1 January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumRestatedAt1January2021', window );">Share Premium Restated at 1 January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveRestated', window );">Merger Reserve Restated at 1 January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueConversionOfWarrants', window );">Nominal Value Conversion of warrants (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesConversionOfWarrants', window );">Share Capital Shares Conversion of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalConversionOfWarrants', window );">Share Capital Conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumConversionOfWarrants', window );">Share Premium Conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveConversionOfWarrants', window );">Merger Reserve Conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueConversionOfLoan', window );">Nominal Value Conversion of Loan (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesConversionOfLoan', window );">Share Capital Shares Conversion of Loan (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,866,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueConversionOfLoan', window );">Share Capital value Conversion of Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumConversionOfLoan', window );">Share Premium Conversion of Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveConversionOfLoan', window );">Merger Reserve Conversion of Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueIssuedInLieuOfCashBonus', window );">Nominal Value Issued in lieu of cash bonus (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus', window );">Share Capital Shares Issued in lieu of cash bonus (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,962,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueIssuedInCashBonus', window );">Share Capital value Issued in lieu of cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumIssuedInCashBonus', window );">Share Premium Issued in lieu of cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveIssuedInLieuOfCashBonus', window );">Merger Reserve Issued in lieu of cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalShares', window );">Share Capital Shares At 31 December 2021 (in Shares) | shares</a></td>
<td class="nump">103,087,744<span></span>
</td>
<td class="nump">102,272,614<span></span>
</td>
<td class="nump">102,272,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueAt31December2021', window );">Share Capital value At 31 December 2021</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumEnding', window );">Share Premium At 31 December 2021</a></td>
<td class="nump">16,492<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="nump">15,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MergerReserveEnding', window );">Merger Reserve At 31 December 2021</a></td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="nump">$ 118,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueSharesIssuedInLieuOfFees', window );">Nominal Value Shares issued in lieu of fees (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesIssuedInLieuOfFees', window );">Share Capital Shares Shares issued in lieu of fees (in Shares) | shares</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueSharesIssuedInLieuOfFees', window );">Share Capital value Shares issued in lieu of fees</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumSharesIssuedInLieuOfFees', window );">Share Premium Shares issued in lieu of fees</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueWarrantsExercised', window );">Nominal Value Warrants Exercised (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesWarrantsExercised', window );">Share Capital Shares Warrants Exercised (in Shares) | shares</a></td>
<td class="nump">337,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueWarrantsExercised', window );">Share Capital value Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumWarrantsExercised', window );">Share Premium Warrants Exercised</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NominalValueIssuanceOfStockATM', window );">Nominal Value Issuance of Stock - ATM (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalSharesIssuanceOfStockATM', window );">Share Capital Shares Issuance of Stock - ATM (in Shares) | shares</a></td>
<td class="nump">27,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareCapitalValueIssuanceOfStockATM', window );">Share Capital value Issuance of Stock - ATM</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharePremiumIssuanceOfStockATM', window );">Share Premium Issuance of Stock - ATM</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_EliminationOfOtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Elimination of other reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_EliminationOfOtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_GroupReorganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_GroupReorganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveAtJanuary12021Per20FAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve At January 1 2021 per 20-F annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveAtJanuary12021Per20FAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveConversionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Conversion of Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveConversionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveEliminationOfShareCapitalIn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveEliminationOfShareCapitalIn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveIssuedInLieuOfCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Issued in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveIssuedInLieuOfCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Reserve Shares issued pursuant to share for share exchange and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueConversionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Conversion of Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueConversionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueEliminationOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Elimination of share capital in Tiziana Life Sciences Plc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueEliminationOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueIssuanceOfStockATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value issuance of stock - ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueIssuanceOfStockATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueIssuedInLieuOfCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Issued in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueIssuedInLieuOfCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Restated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueSharesIssuedInLieuOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value shares issued in lieu of fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueSharesIssuedInLieuOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal Value Shares issued pursuant to share for share exchange and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NominalValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NominalValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesConversionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Conversion of Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesConversionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesEliminationOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesEliminationOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesIssuanceOfStockATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share capital shares issuance of stock - ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesIssuanceOfStockATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Issued in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesIssuedInLieuOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share capital shares issued in lieu of fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesIssuedInLieuOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital Shares Shares issued pursuant to share for share exchange and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share capital shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueAt31December2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value At 31 December 2021.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueAt31December2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueConversionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value Conversion of Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueConversionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueEliminationOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value Elimination of share capital in Tiziana Life Sciences Plc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueEliminationOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueIssuanceOfStockATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share capital value issuance of stock - ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueIssuanceOfStockATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueIssuedInCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value Issued in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueIssuedInCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueRestated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value Restated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueRestated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueSharesIssuedInLieuOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share capital value shares issued in lieu of fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueSharesIssuedInLieuOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital value Shares issued pursuant to share for share exchange and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareCapitalValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share capital value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareCapitalValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumConversionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Conversion of Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumConversionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumEliminationOfShareCapitalIn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Elimination of share capital in Tiziana Life Sciences Plc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumEliminationOfShareCapitalIn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumIssuanceOfStockATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share ppremium issuance of stock - ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumIssuanceOfStockATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumIssuedInCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Issued in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumIssuedInCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumRestatedAt1January2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Restated at 1 January 2021.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumRestatedAt1January2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumSharesIssuedInLieuOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share premium shares issued in lieu of fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumSharesIssuedInLieuOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Premium Shares issued pursuant to share for share exchange and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharePremiumWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of share premium warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharePremiumWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865625440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OutstandingFairValueCharges', window );">Total outstanding fair value charge</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Total expenses</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">$ 5,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpectedTermOfAwards', window );">Expected term of the award</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price for options issued to employees and directors | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="nump">&#163; 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share based payment transactions</a></td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ChargeOfForfeitures', window );">Charge of forfeitures</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment charges</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TizianaLifeSciencesPLCMember', window );">Tiziana Life Sciences PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Total expenses</a></td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=tlsa_BlackScholesMertonValuationModelMember', window );">Black-Scholes-Merton Valuation model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OutstandingFairValueCharges', window );">Total outstanding fair value charge</a></td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="nump">$ 3,223<span></span>
</td>
<td class="nump">$ 12,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ChargeOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of charge of forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ChargeOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ExpectedTermOfAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected term of the awards is based on managements&#8217; assessment of when the market condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ExpectedTermOfAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OutstandingFairValueCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Outstanding fair value charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OutstandingFairValueCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPaymentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPaymentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TizianaLifeSciencesPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_TizianaLifeSciencesPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=tlsa_BlackScholesMertonValuationModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=tlsa_BlackScholesMertonValuationModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519870949104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details) - Schedule of Share Option Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfShareOptionPlanAbstract', window );"><strong>Schedule of Share Option Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceOutstanding', window );">Weighted Average exercise price, Outstanding beginning</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsOutstanding', window );">Options, Outstanding beginning</a></td>
<td class="nump">6,724<span></span>
</td>
<td class="nump">22,234<span></span>
</td>
<td class="nump">17,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceGranted', window );">Weighted Average exercise price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsGranted', window );">Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceForfeitedCancelled', window );">Weighted Average exercise price, Forfeited/Cancelled</a></td>
<td class="num">$ (44)<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsForfeitedCancelled', window );">Options, Forfeited/Cancelled</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(15,510)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceExercised', window );">Weighted Average exercise price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsExercised', window );">Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceOutstanding', window );">Weighted Average exercise price, Outstanding ending</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsOutstanding', window );">Options, Outstanding ending</a></td>
<td class="nump">6,621<span></span>
</td>
<td class="nump">6,724<span></span>
</td>
<td class="nump">22,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_WeightedAverageExercisePriceExercisable', window );">Weighted Average exercise price, Exercisable</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionsExercisable', window );">Options, Exercisable</a></td>
<td class="nump">2,829<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">7,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsForfeitedCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsForfeitedCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfShareOptionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfShareOptionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WeightedAverageExercisePriceForfeitedCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WeightedAverageExercisePriceForfeitedCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_WeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_WeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865468688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">4,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_TwentySixJuneTwoThousandFourteenMember', window );">26 June 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">26 June 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">1,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_ThirtyAprilTwoThousandAndEighteenMember', window );">30 April 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">30 April 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_SixMayTwoThousandAndTwentyMember', window );">6 May 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">5 May 2028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">3,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_TwentyThreeJulyTwoThousandAndTwentyMember', window );">23 July 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">26 July 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_TwentyFiveAugustTwoThousandAndTwentyMember', window );">25 August 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">24&#160;August&#160;2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_ShareOptionMember', window );">Share Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">6,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember', window );">01 August 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">01 August 2032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember', window );">04 November 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">04 November 2032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_FourteenMarchTwoThousandTwentyThreeMember', window );">14 March 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">14 March 2033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=tlsa_TwentySixJulyTwoThousandTwentyThreeMember', window );">26 July 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExpiryDate', window );">Expiry Date</a></td>
<td class="text">26 July 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExerciseSharePrice', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareOptions', window );">ShareOptions</a></td>
<td class="nump">700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ExerciseSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ExerciseSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_TwentySixJuneTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_TwentySixJuneTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_ThirtyAprilTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_ThirtyAprilTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_SixMayTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_SixMayTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_TwentyThreeJulyTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_TwentyThreeJulyTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_TwentyFiveAugustTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_TwentyFiveAugustTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_ShareOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_ShareOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_FourteenMarchTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_FourteenMarchTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=tlsa_TwentySixJulyTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=tlsa_TwentySixJulyTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874673232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model<br></strong></div></th>
<th class="th">
<div>Jul. 26, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Jan. 21, 2020 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GrantDateSharesPrice', window );">Grant date share price (in Dollars per share and Pounds per share) | (per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.679<span></span>
</td>
<td class="nump">$ 0.741<span></span>
</td>
<td class="nump">&#163; 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price (in Dollars per share and Pounds per share) | (per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.679<span></span>
</td>
<td class="nump">$ 0.741<span></span>
</td>
<td class="nump">&#163; 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">118.00%<span></span>
</td>
<td class="nump">119.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OptionLifeShareOptionsGranted', window );">Option life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average fair value per share option (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GrantDateSharesPrice', window );">Grant date share price (in Dollars per share and Pounds per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price (in Dollars per share and Pounds per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems', window );"><strong>Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_GrantDateSharesPrice', window );">Grant date share price (in Dollars per share and Pounds per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price (in Dollars per share and Pounds per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.00%<span></span>
</td>
<td class="nump">126.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_GrantDateSharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_GrantDateSharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519840011728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details) - Schedule of Equity Incentive Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfEquityIncentivePlanAbstract', window );"><strong>Schedule of Equity Incentive Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Outstanding beginning</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsOutstanding', window );">Options, Outstanding beginning</a></td>
<td class="nump">2,575<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Granted</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsGranted', window );">Options, Granted</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Forfeited/Cancelled</a></td>
<td class="num">$ (57)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsForfeited', window );">Options, Forfeited/Cancelled</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberofOptionsExercised', window );">Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Outstanding ending</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsOutstanding', window );">Options, Outstanding ending</a></td>
<td class="nump">4,268<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average exercise price (cents), Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NumberOfShareOptionsExercisable', window );">Options, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfShareOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfShareOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfShareOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfShareOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberOfShareOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberOfShareOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NumberofOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NumberofOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfEquityIncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfEquityIncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866161728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract', window );"><strong>Schedule of Estimated the Fair Value of Warrants Using [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FairValueOutstanding', window );">Outstanding beginning</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OutstandingExercised', window );">Exercised</a></td>
<td class="num">(438)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_OutstandingExpired', window );">Expired</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FairValueOutstanding', window );">Outstanding ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FairValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FairValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OutstandingExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OutstandingExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_OutstandingExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representtion amount of expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_OutstandingExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843441392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems', window );"><strong>Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables</a></td>
<td class="nump">$ 4,137<span></span>
</td>
<td class="nump">$ 4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyPayablesAmount', window );">Related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsNet', window );">Total</a></td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">5,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_LessThanThreeMonthMember', window );">Less than 3 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems', window );"><strong>Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyPayablesAmount', window );">Related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsNet', window );">Total</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_ThreeToTwelveMonthMember', window );">3 to 12 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems', window );"><strong>Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyPayablesAmount', window );">Related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsNet', window );">Total</a></td>
<td class="nump">$ 1,921<span></span>
</td>
<td class="nump">$ 3,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialInstrumentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialInstrumentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RelatedPartyPayablesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RelatedPartyPayablesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_LessThanThreeMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_LessThanThreeMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_ThreeToTwelveMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=tlsa_ThreeToTwelveMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842869296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant - USD [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems', window );"><strong>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ProfitOrLossAndEquityStrengthening', window );">Profit or loss and equity, Strengthening</a></td>
<td class="nump">$ 467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ProfitOrLossAndEquityWeakening', window );">Profit or loss and equity, Weakening</a></td>
<td class="num">$ (467)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ProfitOrLossAndEquityStrengthening">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of profit or loss and equity, strengthening.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ProfitOrLossAndEquityStrengthening</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ProfitOrLossAndEquityWeakening">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Representation amount of profit or loss and equity, weakening.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ProfitOrLossAndEquityWeakening</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=tlsa_USDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=tlsa_USDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519992286352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) - USD [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems', window );"><strong>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MovementPercentageStrengthening', window );">Movement percentage Strengthening</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MovementPercentageWeakening', window );">Movement percentage Weakening</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MovementPercentageStrengthening">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Movement percentage strengthening.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MovementPercentageStrengthening</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MovementPercentageWeakening">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Movement percentage weakening.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MovementPercentageWeakening</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=tlsa_USDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=tlsa_USDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843308624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables (Details) - Schedule of Trade and Other Payables - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfTradeAndOtherPayablesAbstract', window );"><strong>Schedule of Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 4,137<span></span>
</td>
<td class="nump">$ 4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accruals</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total</a></td>
<td class="nump">$ 6,387<span></span>
</td>
<td class="nump">$ 6,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843816688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Related Party (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentinRelatedPartyDetailsLineItems', window );"><strong>Investment in Related Party (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceFinanceIncomeExpenses', window );">Finance expense</a></td>
<td class="nump">$ 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AcquiredShares', window );">Acquired shares</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.57%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember', window );">Accustem [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentinRelatedPartyDetailsLineItems', window );"><strong>Investment in Related Party (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesPrice', window );">Share price</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceFinanceIncomeExpenses', window );">Finance expense</a></td>
<td class="nump">$ 1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember', window );">OKYO Pharma Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentinRelatedPartyDetailsLineItems', window );"><strong>Investment in Related Party (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesPrice', window );">Share price</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceFinanceIncomeExpenses', window );">Finance expense</a></td>
<td class="nump">$ 567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceFinanceIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that comprises the change in the carrying amount of the group of insurance contracts arising from: (a) the effect of the time value of money and changes in the time value of money; and (b) the effect of financial risk and changes in financial risk; but (c) excluding any such changes for groups of insurance contracts with direct participation features that would adjust the contractual service margin but do not do so when applying paragraphs 45(b)(ii), 45(b)(iii), 45(c)(ii) or 45(c)(iii) of IFRS 17.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 110<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_110&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceFinanceIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acquired shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentinRelatedPartyDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentinRelatedPartyDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519843464912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Related Party (Details) - Schedule of Investment in Related Party - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember', window );">Accustem Sciences Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems', window );"><strong>Investment in Related Party (Details) - Schedule of Investment in Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty', window );">Investment</a></td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">$ 2,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossOnFinancialAssets', window );">Movement in fair value</a></td>
<td class="num">(969)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty', window );">Total</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember', window );">OKYO Pharma Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems', window );"><strong>Investment in Related Party (Details) - Schedule of Investment in Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty', window );">Investment</a></td>
<td class="nump">3,150<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossOnFinancialAssets', window );">Movement in fair value</a></td>
<td class="nump">567<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty', window );">Total</a></td>
<td class="nump">$ 3,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) arising from a change in the fair value of investment property to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investment property; Gains (losses) on fair value adjustment, investment property; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossOnFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss on financial assets. [Refer: Financial assets; Impairment loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossOnFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for investment property. [Refer: Impairment loss recognised in profit or loss; Investment property]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2023-01-01<br> -Paragraph 76<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_76_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_d_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_AccustemSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874966112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TreasurySharesDetailsLineItems', window );"><strong>Treasury Shares (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_SharesPurchases', window );">Shares purchases</a></td>
<td class="nump">1,683,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Total shares (in Dollars)</a></td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="nump">$ 1,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Fully paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ClassOfWarrantsOrRightAxis=tlsa_NASDAQStockExchangeMember', window );">NASDAQ Stock Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_TreasurySharesDetailsLineItems', window );"><strong>Treasury Shares (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Total shares (in Dollars)</a></td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_SharesPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_SharesPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_TreasurySharesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_TreasurySharesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ClassOfWarrantsOrRightAxis=tlsa_NASDAQStockExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ClassOfWarrantsOrRightAxis=tlsa_NASDAQStockExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519874329904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ServicesAgreementAmount', window );">Services agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InitialAmount', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AdditionalPayment', window );">Additional payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MilestonePaymentDue', window );">Milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Related party cost</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction', window );">Bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Service total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyAxis=tlsa_RasnaTherapeuticsIncMember', window );">Rasna Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_InterestAmount', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ShortTermLoanFacility1', window );">Short term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PayrollAndRentCharged', window );">Payroll and rent charged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyAxis=tlsa_OKYOPharmaLtdMember', window );">OKYO Pharma Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PayrollAndRentCharged', window );">Payroll and rent charged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyAxis=tlsa_GensigniaLifesceinecsIncMember', window );">Gensignia Lifesceinecs Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_PayrollAndRentCharged', window );">Payroll and rent charged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction', window );">Bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember', window );">OKYO Pharma Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ServicesAgreementAmount', window );">Services agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised during the period in respect of bad or doubtful debts due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest on impaired financial assets accrued after impairment using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InitialAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InitialAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_InterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_InterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MilestonePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MilestonePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_PayrollAndRentCharged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_PayrollAndRentCharged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_PrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repersentation amount of principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_PrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ServicesAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services agreement Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ServicesAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ShortTermLoanFacility1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term loan facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ShortTermLoanFacility1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RelatedPartyAxis=tlsa_RasnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RelatedPartyAxis=tlsa_RasnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RelatedPartyAxis=tlsa_OKYOPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RelatedPartyAxis=tlsa_OKYOPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RelatedPartyAxis=tlsa_GensigniaLifesceinecsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RelatedPartyAxis=tlsa_GensigniaLifesceinecsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_OKYOPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519842970272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract', window );"><strong>Schedule of Right-of-Use Assets and Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RightOfUseAssetBeginning', window );">At 1 January</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RightOfUseAssetsDepreciation', window );">Depreciation</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DisposalOfLease', window );">Disposal of lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExchangeDifferencesRightofUseAssets', window );">Exchange differences</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_RightOfUseAssetsTotal', window );">Right-of-use assets</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeaseLiabilitiesBeginning', window );">At 1 January</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeaseLiabilitiesInterestExpense', window );">Interest expense</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeaseLiabilitiesLeasePayments', window );">Lease payments</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ExchangeDifferences', window );">Exchange differences</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeaseLiabilitiesTotal', window );">Lease Liabilities</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DisposalOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DisposalOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ExchangeDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Amount of Exchange differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ExchangeDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ExchangeDifferencesRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ExchangeDifferencesRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeaseLiabilitiesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeaseLiabilitiesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeaseLiabilitiesInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeaseLiabilitiesInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeaseLiabilitiesLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeaseLiabilitiesLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeaseLiabilitiesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeaseLiabilitiesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RightOfUseAssetBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RightOfUseAssetBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RightOfUseAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RightOfUseAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_RightOfUseAssetsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_RightOfUseAssetsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519865712288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Consolidated Statement of Financial - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract', window );"><strong>Schedule Of Consolidated Statement Of Financial [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Lease Liabilities</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519869123632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems', window );"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasePayments', window );">Lease payments</a></td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCharges', window );">Finance Charges</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetPresentValues', window );">Net Present Values</a></td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems', window );"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasePayments', window );">Lease payments</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCharges', window );">Finance Charges</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetPresentValues', window );">Net Present Values</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">1-2 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems', window );"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasePayments', window );">Lease payments</a></td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCharges', window );">Finance Charges</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetPresentValues', window );">Net Present Values</a></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember', window );">2-5 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems', window );"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasePayments', window );">Lease payments</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCharges', window );">Finance Charges</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetPresentValues', window );">Net Present Values</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Over 5 years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems', window );"><strong>Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_LeasePayments', window );">Lease payments</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinanceCharges', window );">Finance Charges</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_NetPresentValues', window );">Net Present Values</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinanceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of finance charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinanceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_NetPresentValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net present values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_NetPresentValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140519866575168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Commitments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_AccruedOfDiligenceObligations', window );">Accrued of diligence obligations</a></td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_CommercialSaleOfAProduct', window );">Commercial sale of a product</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIClinicalTrialMember', window );">Phase II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_Phase3Member', window );">Phase 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIHumanMember', window );">Phase II human [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_CarcinomaMember', window );">Carcinoma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_HCCMember', window );">HCC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BreastCancerMember', window );">Breast Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIHumanMember', window );">Phase I human [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIIHumanMember', window );">Phase III human [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BLAMember', window );">BLA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_FinancialCommitmentsDetailsLineItems', window );"><strong>Financial Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tlsa_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_AccruedOfDiligenceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued of diligence obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_AccruedOfDiligenceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_CommercialSaleOfAProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial sale of a product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_CommercialSaleOfAProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_DevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_DevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_FinancialCommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_FinancialCommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tlsa_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tlsa_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tlsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_Phase3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_Phase3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIHumanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIHumanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_CarcinomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_CarcinomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_HCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_HCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIHumanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIHumanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIIHumanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_PhaseIIIHumanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BLAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=tlsa_BLAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>102
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  V(JE@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  -B*I8]?G],>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.NF 0]3E N*T24A, G&+$F^+:)HH,6KW]J1EZX3@ 3C&_O/Y
ML^361&E"PN<4(B9RF&]&W_59FKAF1Z(H ;(YHM>Y+HF^-/<A>4WEF0X0M?G0
M!X2&\WOP2-IJTC !J[@0F6JMD2:AII#.>&L6?/Q,W0RS!K!#CSUE$+4 IJ:)
M\31V+5P!$XPP^?Q=0+L0Y^J?V+D#[)P<LUM2PS#4PVK.E1T$O&TW+_.ZE>LS
MZ=Y@^96=I%/$-;M,?ET]/.Z>F&IX<UOQNTKP72,DYU+P]\GUA]]5V ?K]NX?
M&U\$50N_[D)] 5!+ P04    "  -B*I8F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  V(JECT0H_;<08  "T>   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MK9E+<]LV%(7W_A48=::;6A%?MNS4UHPL1XD:Q]%8;M*TTP5,0B)K$E !T(K[
MZWL!2H22H2Z9M%G$)$4<?L3C' "\V CYJ%+&-/E<Y%Q=]E*MUR\' Q6GK*#J
MA5@S#K\LA2RHAE.Y&JBU9#2QA8I\$'C>Z:"@&>^-+NRUN1Q=B%+G&6=S2519
M%%0^7[%<;"Y[?F]WX2Y;I=I<&(PNUG3%%DS_NIY+.!O4*DE6,*XRP8EDR\O>
MV']Y%9V: O:.#QG;J+UC8E[E08A'<S)++GN>(6(YB[61H/#GB4U8GALEX/A[
M*]JKGVD*[A_OU*?VY>%E'JAB$Y%_S!*=7O;.>B1A2UKF^DYLWK#M"YT8O5CD
MROY/-M6])V&/Q*72HM@6!H(BX]5?^GE;$7L%HNA @6!;(+#<U8,LY375='0A
MQ89(<S>HF0/[JK8TP&7<M,I"2_@U@W)Z="WB$BI9DS%/R"NN,_U,9KQJ;:BU
MBX&&AYA;!_%6\*H2# X(^@%Y)[A.%:@E+/E28 !T-6*P0[P*4,5K%K\@H7],
M B\(B4JI9 J1#>LW#ZULV/;F>Z]+;N F,M.L4$UO7@E&S8)F_+Q4:QJSRQX,
M$,7D$^N-?OS!/_5^1G"C&C?"U$?;MKECJTQI28'[EA:LB1+7N<_^R2BG1S?9
MDI%%G#$>,T5N--92)S7C":I=5^G]\[H1#2\>>/TI0G%:4YRB,I-22@,QS51,
M<_*)46GZ(H'QT0B%J_7[?M /?81K6',-N[3@1!0%]+2%%O'C,5G8[DS>EUII
MRI.,KYH0*^$3*VQ\]FGD>Z%W-AQ&T<7@J8'IK&8Z0YG&T%R);;)I3AL?C9=?
MTEPQI&[.:X[S3G4#)!+:; ;6\9F\9<]-1+B2YWG^, B]TW,$R_></7J=P+9]
MZHZMA=302M!^5)>-+M&B>"LPL#W?]KN ?1!YR37D*73WG,EF(%SI$VJG?N"(
M@BY$EH-,8+"MA&QLP!:=6\'[-(XAN"6())4@1N@<WT<=>D?X$>8 _4<N-C *
M&56"PT-F2I5?/V5+BVOBS>G<W<=MN;;..9.92%##:I/:Y:4-3(S.^;K?T=CW
M/74*%YO[6YO-XU3.YWW<FK^FVE;=82Y<;OH)HW(N[W>R^5<%DRMC%*]!0:?&
M]M>4-X\'7+#-8WUG]C[NUENT10H#  7Z;Z;O.]?W<;.>3:9W9%PFF1:2C+5F
M$()V'G8HC5KTVL@"Y_L![M)[\V)>0M^JC+\)J45(RQ(E<H8?X#;M)E<P^U.9
MK2:$"A=KK2CG^@'NUC76%[T*(\/U6LF<VP>=W'[&8R$!QG:L8YO;C$!WFP@(
M3FGF8TFCR[:H7WL8I//]H-.T?IPD, U4Q[N#:B'RGC>3X9*3'*:4/!'\Z(TH
M\;IT 1#@GHUBWF]$(V9+#!Q-TE+&*;2(A-7K,<;I(B' /?QKSHDY@\:^A[!O
M9,3EWM BR[6IR7<8GLN&H%,VU'AS 8:7D]^S]>%NB"OZV,HD<,D0=$H&5V_5
MX&@$PI6NT)IRR1!T6A#,N(99H-VY,=,ANIN(-X+ABNA$+73!$'8,AFG&*8\S
M:#YK*?;:*RFMLP!CM>GTAPFR/QOW$O#'M-E@Z'(C[)@;XS@VK;I=O/"$RJ01
M#)>S+<*MF<*KNTKX8F5DQ=%-&I<O(9X'N]G!-),%F5TW$N,*P9D?82A[&T:X
MY>]0#FV\M!2?OYV"7VJ=L[]$RLG-S1RC<@D2XG:_H[H1\<$MNQ:)&V'BXA@6
M':L<V@[#<HD1=EPR[':L['BHATHC):[8.B1<2H2=4L(L+,EM63PT+_Q:1#S/
MZWOF'X;DDB'$??RJ5' %$G4B8#D?-]</*O&=^X^ARXCP['_?,$6SXGN)78B$
MG4+DFR97+9*3-&/+(V=[[Y?++$:W)R(7+5&GO:9OFF2U2/I1WS\Y@CZ5E)G>
MSK0P5I<J4:?MI\X3K1:YRH$^^@L,SF5&U&DGZENF62V*P6^_8&0N0J).:Y(N
M\ZP6I==7&-#>5X66Q4)E-V;O1 G.67[XLP(N])8QF)@=+5*:8F N/R+<[6V'
M&DM&#S<9+O!3A*5^Y,(BPGW>Y&I.YJG@6%BTB 0>&4;G)R0(AXW[TH.]+WAF
MX\A^IU3$3MBJCWGUU?I;Z+CZ NANKSZDOJ-FWTF1G"VAJ/=B"-4DJV^3U8D6
M:_L]\$%H+0I[F#*:,&EN@-^70NC=B7E _85X]"]02P,$%     @ #8BJ6 L_
MS5?>!0  @!D  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RM6=MNVS@0
M_17"+8H42&J1U,VY&$A=++9 NPV2=O>9D6E;J"2J)&4G?[^D)$NV2-'I;EX2
M76:&9SC#.3/R]8[QGV)#J01/>5:(F\E&RO)R.A7)AN9$?& E+=2;%>,YD>J6
MKZ>BY)0L:Z4\FR+/"Z<Y28O)_+I^=L?GUZR265K0.PY$E>>$/W^D&=O=3.!D
M_^ ^76^D?C"=7Y=D31^H_%'><74W[:PLTYP6(F4%X'1U,[F%EPN,M$(M\7=*
M=^+@&FA7'AG[J6\^+V\FGD9$,YI(;8*H?UNZH%FF+2D<OUJCDVY-K7AXO;?^
M1^V\<N:1"+I@V3_I4FYN)O$$+.F*5)F\9[L_:>M0H.TE+!/U7[!K9;T)2"HA
M6=XJ*P1Y6C3_R5.[$0<*T!]10*T">JD";A5P[6B#K';K$Y%D?LW9#G MK:SI
MBWIO:FWE35KH,#Y(KMZF2D_.%ZP0+$N71-(E^$@R4B04/&AS ER 'P^?P-G;
M]^ M2 OP?<,J08JEN)Y*M;+6GR;M*A^;5=#(*I]H\@%@> Z0A[!%??%R=72L
M/E7^=DZCSFE4V\-C3E><TT("(H3R\]+F3V/ MQO09^M2E"2A-Q-U> 3E6SJ9
MOWL#0^_*YMTK&3OR%7>^8I?U^8*(#5!1 XF^H+^J=$LRY;PUBHVIL#:E"\!V
M#F&L K8]],8B%$,=EZT%IM_!])TP[S@MR7.N@=5HF=Q0KNI$0A7>QXQ:X38F
M@P,D" W1FC+8\^Q8@PYKX,3ZG3P1V92Q/3P;NL!<.9H-X9E"/O)#.[ZPPQ<Z
M\=W3K#[.)>'R^=0>AN8>0AP/4)I",(2^'674H8S<N\@DR52).SR*-H"1L7:$
M<30 : HA'\4C.1EW"&-GF?A+A?C=FQA!> 7V)>-VO&3$KUDR7LG8D=^SSN_9
MB;.HN@2=.OH@ZHI1ZG-Y#@HJ;7[/S.3P!N&QB$3VV$"O)R[/G>6:H %;@4K0
M)GVLO.29F6%4-(L0CD:2!QXP*W0"_%Q(4JQ3=? <\)PF['$&5@+]_X:.W>RY
M%#KI2[FYI4+J#-%- C^L/5:/D5GQ@L ?1L24@K$W4A=ASX70389-S2E8<7&Z
M[K2FCH#&_K#P6*00G 4C0'LVA&XZ;( ZP)FT!A&,C6VT,&3H1V-GKR= &+RH
M@<I2\IAFJ4RIO21")Y'^;DU\+6O'3O>L"MVT>ILDK-+]B6I42'VJ57DD2<(K
ME>_T20U6PDZQT*3/$,=&)EFD CQ6A7J6A6Z:_4+5D .^M(&R'TF3/<T6P"8T
MUO3!GF&AD\CFW^HV[R"-K/AB<VDCTTV9V0BXG@:AFP>/.Y13($V.4^&;#6%:
MI,(0VY&BG@N1FPL'009GJG6Y: _I>^MX8S(>](9@+4+('\/:TR)RTV*SJR=V
ML[5QO$_^,"=M4K,QED 'TZ&;T18DR]21KDH@-H13-3F5J<9\!CU\[L71>>3[
MS2LUJZCWJ1"Z!-1C2R6%8OUE6JROZFGU$D /G:,(G:N&V1X*"]5YPP[%*C1R
M^E!/A\A-AP^U>ZI8YFF56[&9[ 9#?X:&Z"QB03 ;"T3/@LC-@@T^_95&-Q3U
M= C:RMXUYM]*/8K9D\AD/Y4>P1"\*17 V<B(B'J*1.XA\278=X1S,C**N\W_
M1F>(S!$SG(UT *@G0^0FPZ^4K^L!/4OI:N^8U0_+[ CC0P0MS)-RQTA[ D0G
MYDRNBF/%G]L3:\5H<ML%#*(AQUC%,!I+E9X$D9L$'YI2(AEX[(J):T=-JD/(
MR.K_,$"ZY@'4LR8ZP9HJI46V_T R[H7)A!<PQ.'0#XL8ABBV[SGN&1.?F!ZI
M).J1:MP(+U2UMG\.,PE0!1R'T1"E51"&:(S9<<^6^"5L6:?NAF5+RD5=/**K
M>C"W]W/8I,4@,';6(J4&EPB.(.[9$[O9T^#WFAA_TP-D?F.TC#<6,=MX,SWX
M/*Y_F_A*^#HM!,CH2NEY'R*U![SYW-_<2%;67\P?F90LKR\WE"CH6D"]7S$F
M]S?Z(WSWH\O\7U!+ P04    "  -B*I8QAZT"4@"  #&!0  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;*U476O;,!3]*\*#L4$7?Z8IG6-84\;V, @-
MVQ[&'A3[.A:5)4^Z2=I_ORO9]1)P1P=[L72E>X[.D75O?M3FWC8 R!Y:J>PR
M:!"[ZS"T90,MMS/=@:*=6IN6(X5F%]K. *\\J)5A$D678<N%"HK<KZU-D>L]
M2J%@;9C=MRTWCS<@]7$9Q,'3PIW8->@6PB+O^ XV@%^[M:$H'%DJT8*R0BMF
MH%X&'^+K5>;R?<(W 4=[,F?.R5;K>Q=\KI9!Y 2!A!(= Z?A "N0TA&1C%\#
M9S >Z8"G\R?VC]X[>=ER"RLMOXL*FV5P%; *:KZ7>*>/GV#P,W=\I9;6?]FQ
MSYUG 2OW%G4[@$E!*U0_\H?A'DX \7. 9  D+P6D R#U1GMEWM8M1U[D1A^9
M<=G$YB;^;CR:W CE_N(&#>T*PF&QTLIJ*2J.4+$;+KDJ@6T<G65OUMR P@90
ME%S:M^P=LPTMV3Q$.MH1A.5PS$U_3/+,,;=0SE@:7[ D2M()^.KE\.0<'I+A
MT74RNDX\7_H,WP;)+[U%9+IFM5#D6G#).FV%?UP_^-:BH2?V<\IJSYU-<[NR
MN[8=+V$94%U9, <(BM>OXLOH_93Q_T1V=@WI> WIW]B+C?N;K.2=0"XOF+!V
M#]64XYYF[FE<7S@4<91&5XM%EN7AX=3.5&:2+)++^$_FF=9LU)K]BU9J2!:Y
MJH3:30G.7BQX*G-:<'A29:[#?>%F)Y1E$FK"1K,%D9B^:_0!ZLX7WE8CE;&?
M-M1HP;@$VJ^UQJ? U?+8NHO?4$L#!!0    (  V(JEC?@)%ZZ 0  "P4   8
M    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5AMCZ,V$/XK%CU5NU)WP4!X
MV2:1;I>[=J6>NKJ]NWYVP GH *>VD^SVU]<&0@@,=*_*EX279Q[[F1F/!\\/
MC'\7*:42O11Y*19&*N7VSC1%G-*"B%NVI:5ZLV:\(%+=\HTIMIR2I#(J<M.V
M+,\L2%8:RWGU[(DOYVPG\ZRD3QR)75$0_GI/<W98&-@X/OB<;5*I'YC+^99L
MZ#.57[=/7-V9+4N2%;04&2L1I^N%\1[?13C4!A7B6T8/HG.-M)058]_US6.R
M,"P](YK36&H*HO[V]('FN692\_B[(37:,;5A]_K(_K$2K\2LB* /+/\K2V2Z
M, (#)71-=KG\S Z_TT;03//%+!?5+SHT6,M \4Y(5C3&:@9%5M;_Y*5Q1,<
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M2E94ERDERGL:H-ZO&9/'&SU >T"X_!=02P,$%     @ #8BJ6/E9/W*9 @
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M8K"/I]MUYD&XTR.2'=!;W._#BQZ3&C0)@DZXZ7::E:4=Q$B\7@<N0M_$7=V
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M>5LJT%531:2U#*7A4\E=DGRWR9+O.TLIUEEJ;IY>-\KA[91)_>/%GELF 1L
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M RT+T'MNJ*:[ QO8_F>9_@M02P,$%     @ #8BJ6)\R*L-*(0  =64  !@
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MX#BO  >*=0W2B_1=A@N,M8=4\E1>X ??D@2S7U_>Y$^_\Z'T-3B1AO!#QD9
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M'?S2TX\W8'3N@7C_Q&D-!ATV?W%^2EV$@<:W9&61^_FJ-W2VPY%)7:N"FD_
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M_==T X2<&Y:<DD_^^?0_QX ^H\?G#F7%JORUI\-84G7B[<++.I-6$.YT2Y+
M%*11,M,GO=6P!W'@[T*"BJB3S2C[T31@<#A3'9",AI2?5 NQ5$C7)1HWRAIV
M(VN3A9:GHXFW="]4&)6>/S<93'8S$[YPAX,$)WRSDW$^&QEU*#FX0!KZ.>Z5
M+BL(UI!+/V' DXB031,[M?BQTT4\M3Z#"@1)9'CRBI3YZ/DLJN3*"5LURKGE
MFUY1(9!M9-+ART>@B,-VQSFQN;RIY3+HX.2W]#'0;5@3R\_&+5+(']*ABU?8
MO(],5X#P,=/G3V:A,X_7O"37_S7^.(:<MTF[[_FK3*R!J#)-PMVOY$3IR+(*
M"5=3A [VT Q@_8DHO".4>^ZKJ6-(0.8-9JTY6RQX!PA7(]S&*XRXS?2;F:IC
M3&A6<J)]V/7-K!T_=;S $3KVIXJ=C?+[M-@AU.$BH[]FC@4R<.$#A?0<VXZ:
M;+/@GKC.>"9GP;@\><8#X<5+93A)EQP?D5./8E#^2DM])N$L74_3UR+;+,@U
MYW(VBNY.&862U+;##:$!OH5^A'2L]!(N&>+6(D&26F$VOH>'SQA3K^O<F%R+
M3.Z4I![!A+TQ^*QMJ2NZYZPM&9*';,.XX<&N21N9ZE2#Q.V"<[4'[9N\!C?=
MM!H?#7@A99V7@<5T$K;>?MC0@!Z&EF]POL<8&95XP4S\.K:2M-A7GQ8*!PV_
M\_,R8<6&/0Y]$XHW0K1.:^Z8IU-TO\UL-P@?CR3^<M0OU\((T&ML(R*"C6ER
MB8Z("IWOAY<5$ +L-2MC&H=13(=9[3U")93W#L_17\_<T$E]"HM,A=/ 8@K^
M!OW@G",8Y3GF)CF= 5TS?JS?^=SPA U),VI/GN(2YF[Q"+/E1) D*I.=Q!Y>
MN8IV$;HD%=\1->9J)ERE0SE>WA)!6P392D\"X<UI%1I[S(^N ^?8\KM0G\UF
M6$JG8UGB?2O8H"05#.EPT-$]42MT)_&4J@>HX8Q33S>,X#DDI'DVD>74Y>-$
MG"[-CTNBG#X-QS 'EH924\-Y)S.&BXJ&:(,:GI(+9I;YC[*7:1->UO(]4@OL
M,^S(\B#I*%HJI1DU@O,1#:8K&M- \+" U' 3EZ<MWF=E!5Q3S#;2(,_-</L#
MM1?Y.^*&3M7 0UY88"]KC1<4#9:9HQ>KI:N\30!33@<=?%H #VC[X&29?]RE
M=\\<W3D#JM C$8[I#A$37CTUZ [B-%W#*3_G<]"^39MZ1,0CZ=KT]51?2[T:
MJ&L6C*U@@X'E\"KLG<R0/+PP,&\5  +<$,9XCN]NC8>="OA=#VYL'JF5_U:&
M9="7 KQXLW(2YJT820:>INV&62!GT&3&>V4,9T9K&!:LPHT?>(@^G@WZ:R=)
M,?F+62VY^M2[1[]63,Y-SEF&9D:ZE/ XAIMT;7$R+!ITPO@ :_D0HMP?##[J
M1N\ZO@H);R^177*K&=8"<3#83 4FS@H/U:;5'#W) R23[S <I;OQ7QKK[\!<
M4$^W(%W.,WWQ[==//E$3X>187+\#I:?3-8?IT9AL< TJG;^8H1$[>7:*LE6Y
M]@L>!C+4:L4YYNI0[[: N,"GRZ9D1AC]5VD2NV]C&6PL7L8(^HK%7P@WKB[?
MYQ_(+LJUOBXLD]3"1YVD-JTCKHR88H9G[=G;R6\S&?0_W@SQ5D;T)PQ]7>[8
M]\%KA/M\AK?7M?[&\^/=@C,-@;Z;8GJ9139;W^0&&7\P<.Z$4>*-9IW1("M!
M'P('J6S']7NY6]QTF5R2Z4N5A#+"')S_'TTT6YA,FQ6I@O#@S%1JI!:AV.(P
M*I'B&=O! 1"ZUXM\VO_@O17ODHL(\BL)^]GG\0W@]?BF=%AY/$_ #6Q2)B@.
M2=.>-#31(.EM!S[ZB<,4(H9X$V-CPZ5XGDY\M5"XJ&L@NMA1GWKY<!(S]?7S
M/7+<X#1S5_KX*F>DY?@:N N^"E5V<!#=(W@-GM+G(3S(H'N <)@OOGORU:?E
MW+^T\#CYIS!JO+,+_\$/1]7%CO]5C/!M^#=%+OF?THB/\S](\A-$#-BY6>DU
MO/ID^>W7CSA/YC]T=D?_L,;*=IVMZ<^M!GJU^ #\OK:V\Q]P@O OK;SX?U!+
M P04    "  -B*I8>LD1!CD%  "J"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6R=5LMRVS84W>LK,,I,5HY>=M*,8VO&5AY5)DX]EM,N.EU X*6(
M&B08 )2L?GW/!4A:3ATONI$(X#[./?<!G.VLN_,%41#WI:G\^; (H3X=C[TJ
MJ)1^9&NJ<));5\J I=N,?>U(9E&I-./99/)F7$I=#>=G<>_:S<]L$XRNZ-H)
MWY2E=/M+,G9W/IP.NXT;O2D";XSG9[7<T(K"M_K:837NK62ZI,IK6PE'^?GP
M8GIZ><+R4>!W33M_\"TXDK6U=[Q89N?#"0,B0RJP!8F_+2W(&#8$&-];F\/>
M)2L>?G?6/\;8$<M:>EI8\X?.0G$^?#L4&>6R,>'&[GZE-I[7;$]9X^.OV"79
M$WA4C0^V;)6Q+G65_N5]R\.!PMO)3Q1FK<(LXDZ.(LKW,LCYF;,[X5@:UO@C
MAAJU 4Y7G)15<#C5T OSA=-!*VG$A5*VJ8*N-N)SDVT(Q(>S<8 +%ARKUMQE
M,C?[B;GI3%S9*A1>?*@RRAX;& -;#W#6 ;R</6OQ/:F1.)X>B=ED=OR,O>,^
MX.-H[_C_!"S^O%C[X% J?ST5>[)\\K1E;I]37TM%YT/TAR>WI>'\Y8OIF\F[
M9W"?]+A/GK,^7]PL;Y>+BR_B8K'X[=O7V^773^+SM_>?/EQ]^'K[%-CGS1V/
MQ+,6Q6U! F'4TLG8/C87N:YDI;0T UVE<< 'FEM+69?AC%"]H1 ;JLA)8_9\
M0G6@+(JT;-?,KU9TQ*H!;A2ZBNWS]R=GFUJLB06752!712_(U\?.N[BAVCHV
M-5@%667295Y(+[3W#3RM]]'0\F)U>82Q\;W12$;<RO"E@G586?30'0GR02,,
MG,..^+LK Q:70<@\AWQ4==$EQU%R&(Q6>D_!'PFCY5H;%!7Y(Q"C;$G1&MUC
M<&8Z-"ZM$P*OC/4-(RIE1CT#MO+6Z$RRBYYFX0,V(J"16#6J^#G>$I,"K+$A
M$-,P]P/:2M-$BSRV,H%<%1H#Q<7R9WA.$^>,;5G <"*7D1_.C#)-QDE@.15B
M$GPL@B9&1-L$B\LDMP:SG86E2['HC!QE ]#,F+J..ZB!/I!3L2J@]2I!K.4^
MQ7/;ET*KY.$%=\F#[*"5%6C7RDN5 +(0E;6Q>P))3Y3F\N/-2LP>.;U.AH[$
MKM#@^%')E"0Y6]%16Z'*^OC=N1EPIZ.</305X8K)V"_=JT)6&XJ(6,W6+85H
MI<8)@$*:W3Z%!,;['+%P+K43G+Z^+^0.9=X=;Q!R$%PM*0$+6]:RVHLFH!#_
M::%?&JGN7JU480WY5U?D@JT&"05:4"M.0VDS,MP[,58.3-:ULSB&;00?"IO%
M"#)"*^+Z8266[?*7_0"50SM(4H+M(_5X$:#FW1V% 4H$C<%TC 3N5H%*C/,$
M66KU.K9B'Z9B)+%EKP#PH [*C8Q[*+480W1P:+!#]1_"Y8!O*I GG;$_,+(#
M)8U/F80B.@/V\5PPW3Q(K17''ZA7L2#8!(FB<9FA%GDAMR12%X!,)OH ._;;
MB!YGD2>3?^B0@?1==("4-P83)X]AR:KE*=%\E#(3^Y5[*<+96B8(XVG?55*#
MB]F9/0<;J<"0U/Y.Y(YX'"'-\"P<Y[\K74[]X%$=\L1 7R7V.1;>Z%UA$G;.
M$MF1'0*+F]C2*@8*J<=Q2^/MC\&+A^!;K@8\MMJJ;*OK@>K#O+]\\78VG;YK
M&XN'$!3EZ*FK>'SP?BK);>(KD7.%P9.>4OUN_Q"]2.^O!_'TBKV2;J-!B*$<
MJI/1+Z^'X#>^#-,BV#J^QM8VX&T7/PL\ILFQ ,YS:T.W8 ?]\WS^+U!+ P04
M    "  -B*I8QSK@\\\"   :!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6R5E6U/VS 0Q]_W4YR"A$#:FB8I4$I;B8=N\ *H*'O2M!=.<FTL'#NS
M'0K??N<DS;JM5)HJ);9S]_/_?+[K:*7TD\D0+;SD0IJQEUE;#'W?)!GFS'15
M@9*^+)3.F:6I7OJFT,C2RBD7?MCK'?LYX]*;C*JUF9Z,5&D%ESC38,H\9_KU
M H5:C;W 6R\\\&5FW8(_&15LB7.TGXJ9IIG?4E*>HS1<2="X&'OGP?"B[^PK
M@\\<5V9C#"Z26*DG-[E)QU[/"4*!B74$1J]GO$0A'(AD_&R87KNE<]P<K^D?
MJM@IEI@9O%3B"T]M-O8&'J2X8*6P#VIUC4T\1XZ7*&&J)ZQJV^C(@Z0T5N6-
M,RG(N:S?[*4YAPV'0>\-A[!Q""O=]4:5RBMFV62DU0JTLR::&U2A5MXDCDN7
ME+G5])63GYW<VPPU'. +9=G@H0\W,E$YCGQ+<&?B)PWHH@:%;X""$&Z5M)F!
MJ4PQ_1/@DZI66KB6=A'N)%YATH4H> =A+XQV\*(VU*CB1?\7*GP_CXW5=#U^
M;(NZ9O:W,UW)#$W!$AQ[5!,&]3-ZD_V]X+AWMD-QOU7<WT6?W#]>3Q_@8/IU
M-KV;3YWBN\O[V^DVF;M!?7@#!8\9PD>MRF)_;Q &)V<&U%_'U.'U,7%#]RY%
M* M0"R C6"A!-<WE<MCYADS7B0=*&^8Q(2AU'9<ZE[_0/8+.O(P%3QP7&NI[
M^IT<]3IU<IJ,'!A$D,HB!*>'9!!%$/2CSJ.R3#3Z:G>_E5E;#4XC^'>/C!F(
M$24D@AG#%YQ4LB;0=70T=R$EJI06=<&T?741DPA:HQ:4HG9>34F2@+BTP"2@
MM)Q,5T30SET(%BO-+)T*5;+-NMNN@;]1K\1:5EW)U)O7I=NNMHWOO*[WW^9U
MU[QE>LFE 8$+<NUU3ZC/Z+H3U1.KBJKZ8V5)>#7,J'FC=@;T?:'HG)N)VZ#]
M.YC\ E!+ P04    "  -B*I8NY]L7=,#  #L!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6R-5=MNVS@0?==7#-2@L ''NL6)D]@&G*3M%D@;(^GN
M8K'8!UH:640I4B6I.-ZO[Y!R7*>;&OMB\S+G\,P9<3A9*_W55(@6GFHAS32L
MK&TNHLCD%=;,#%6#DG9*I6MF::I7D6DTLL*#:A&E<7P:U8S+<#;Q:PL]FZC6
M"BYQH<&T=<WTY@J%6D_#)'Q>N.>KRKJ%:#9IV H?T/[>+#3-HAU+P6N4ABL)
M&LMI.$\NKDY<O _X@^/:[(W!9;)4ZJN;?"RF8>P$H<#<.@9&?X]XC4(X(I+Q
M;<L9[HYTP/WQ,_M[GSOELF0&KY7XDQ>VFH;C$ HL62OLO5K_AMM\1HXO5\+X
M7UAWL>EI"'EKK*JW8%)0<]G]LZ>M#WN <?P+0+H%I%YW=Y!7><,LFTVT6H-V
MT<3F!CY5CR9Q7+JB/%A-NYQP=G;7H&:6RQ7<*F,FD25.MQ/E6_Q5AT]_@4]2
M^*2DK0R\DP46+PDB$K-3E#XKNDH/,MY@/H0L&4 :I]D!OFR78>;YLO^5(?P]
M7QJKZ6/XY[5D.ZJ3UZG<!;DP#<MQ&M(-,*@?,9R]?9.<QI<'A)[LA)X<8I_=
M+=[=S[]\_/P!;N\>'EY3=Q@_&L)+"OA2(7S0JFW>OAFGR=FE ?5L1B#(##3
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M 4XJ2LIG9W JH>>F=WS#B9Z+@8,UVAL4G>9UT,R^HIEF[+U6;FG9:U6*\M#
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MPQ/++Y=XTPI# CB?:^VV'^1@]TJ>_@M02P,$%     @ #8BJ6#YW'LD)!
MZ0@  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULG59M;]M&#/ZN7T%H
MPY "FJT7VXDSVX"3IFN!%@OB;L4P[,-9HJU#I3OU[A0G_W[D25$=P F* 8+$
M>^'#ASSRJ,5!FZ^V1'3P4%?*+L/2N>9R/+9YB;6P(]V@HI6=-K5P-#3[L6T,
MBL(KU=4XC>/9N!92A:N%G[LUJX5N7245WAJP;5T+\WB%E3XLPR1\FKB3^]+Q
MQ'BU:,0>-^C^;&X-C<8#2B%K5%9J!09WRW"=7%Y->+_?\)?$@SV2@3W9:OV5
M!Q^*91@S(:PP=XP@Z'./UUA5#$0TOO68X6"2%8_E)_1WWG?R92LL7NOJBRQ<
MN0PO0BAP)]K*W>G#>^S]F3)>KBOKWW#H]J:S$/+6.EWWRL2@EJK[BH<^#D<*
M%_$+"FFOD'K>G2'/\JUP8K4P^@"&=Q,:"]Y5KTWDI.)#V3A#JY+TW.JCMA9N
MT<"F% 878T>8O#+.>_VK3C]]03])X9-6KK1PHPHLG@.,B<S *'UB=)6^BO@6
M\Q%D201IG&:OX&6#AYG'RW[(0_AGO;7.4#+\>\K9#FIR&HH+Y-(V(L=E2!5@
MT=QCN/KEIV06__8*T<E =/(:^NKC'YL-W-[<P>;]^N[F%+O7]9-D!,\QX$I8
MF4/%$6@H M9'0%K(196WE7!8!-M'*.2]+*3:@RNQVRR<,W+;.K&M$)P&_-9*
M]PBEK@HT%O3.;[W6=2/4(Q $#P^^ K  <8^&"AI46V_)*NW6AO"IYCL&%J0B
M%K9%*%K3&PX>49A1\#>] 3F5@!(!/0 E0\#)P!F1\BL)SOA4W_P@S[SG>?9S
M',=OX"PYCV;S!%B:1MG\G*4TBR8)2<&7_^%%$J?1Y#R)XF1&<A)-TUF47<QA
M?A[-LS2*I]/@Y$F<Y:C<T83G-LHZ9J.TXS6:TW=MO2>_&]TV?( &&VT<A2X0
M'>C.Z)H<5337<D3IUC:"[SU:TL8K<X!94!$S%WE._@B5T\%)5\*']0:R+.J9
MZ<;K1G 0Q@@F*53!^!04)SG:E18*E'84!U((2.)E*RGP%+Q"5BU?M[#%7+06
M/0%\0)-+&O3G\LP4W=YM54!)82=;]#CYZX""NQW=XB/X3%I;'TFFXY?)&/FE
MR&<?R* #%33@"E6\3I<_F]M1X3Z9EHJ2@A@XJ@%J,8Y]X 5J"9I+I* Y254R
M@G55/3/0L][)?<LY\-V*V&JF;MA!/HW@Z#28K=-.5,?GXB<'DTJ?-$-G5TC;
M0[$O1_JT/ICO8O-""08O)Z]/ $HH'XF"XZ;H3P ?\JKU5\)GZO2V'=1&I^ZY
M\5'[J='L?9.E2T:WRG6=:)@=^OBZ:U_?MW<_ 9^$V4ORK<(=J<:C\VD(IFNL
MW<#IQC>SK7;4&KU8TK\(&MY ZSM-*=D/V,#P=[/Z#U!+ P04    "  -B*I8
MKPZ(F*$"  "6!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R-5&UO
MVD ,_LZOL+)IGRKR1NG+(!*T3*VTJ@BZ3M.T#T?BD%.3N^SN@/+OY[M RC2*
M]@'.]MG//;9C#S92O>@"T<!K50H]] ICZFO?UVF!%=-=6:.@FURJBAE2U=+7
MM4*6N:"J]*,@Z/L5X\)+!LXV5<E KDS)!4X5Z%55,;4=8RDW0R_T]H897Q;&
M&OQD4+,ESM%\JZ>*-+]%R7B%0G,I0&$^]$;A];AG_9W#,\>-/I#!9K*0\L4J
M]]G0"RPA+#$U%H'1L<8;+$L+1#1^[S"]]DD;>"COT;^XW"F7!=-X(\OO/#/%
MT+OT(,.<K4HSDYL[W.5S;O%266KW#YO&-[KR(%UI(ZM=,#&HN&A.]KJKPT'
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M<PH-NA?G'JAF"S2*D;6;O(4T-,=.+&AQHK(.=)]+:?:*?:!=Q<D?4$L#!!0
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M#7A.X[#!]PLY-L!^9:'O,.$#IB^BS?]02P,$%     @ #8BJ6'?X>_Y0"
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M!B'-@7E=%X^8GM0%X*P]8#*'I+YJ<#3". >+*@A,7JT)1O/EZX[+D;-,<L9
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MQF?\++CVX6@#;^O8K'/KN?7'SY+?6G0!P/,;RX>["\("P^N]_!=02P,$%
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MGS<7W-WTYM\$/R% :$4JY!)+X_'1P8!L<_5N7KRIPG5W83PNS^%Q+07V)IZ
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M[N_,XC=NXQD)7FIR%_[2HK&-89S6SINB=0:#0I?-KWIJ==AP..C_Q"%I'9+
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M=-,9_W.,11HZL0H 'A#!B37,:A1W_X8^BPT'V#JTP5)OJRFDK]L/D1P/'/5
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M*"_!(3%-@VF%R?<UG>33TKG#"I1 JUA#'M1@,XIWD 2>T?9=[6RY0LG&#?C
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MK-&XI:C9DME@KE,Q&Y<+** Y&M_:.;B"L#7X:  VJ>B\#JRF@[";\63#*9U
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MXU^ZYD!_3F[3=%U3T8][ _QJ\0'X?MLTG?\%!PA_8/#Y_P-02P,$%     @
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M+0L:Q*AL IWG4II-8"_8CO;97U!+ P04    "  -B*I8?5>832\#  "1!@
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M0\J%:H=PNS%RXP;?0AH:HVZYIN\65%: [I=2FOW&.NB^A*9_ U!+ P04
M"  -B*I85TZB./D"  !/!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6R-56UKVS 0_IY?<7@P4FCKUR99EP2:OFR%=92VZQAC'Q3[$HO*DB?)2;=?
MOY/M>"E+PPA8.NGNN><DW9/Q6NDGDR-:>"Z$-!,OM[8\]7V3YE@P<ZQ*E+2S
M4+I@EDR]]$VID65U4"'\* @&?L&X]*;C>NU63\>JLH)+O-5@JJ)@^M<,A5I/
MO-#;+-SQ96[=@C\=EVR)]VB_E+>:++]#R7B!TG E0>-BXIV%I[/$^=<.CQS7
M9FL.KI*Y4D_.N,XF7N (H<#4.@1&PPK/40@'1#1^MIA>E](%;L\WZ%=U[53+
MG!D\5^(KSVP^\48>9+A@E;!W:OT1VWI.'%ZJA*F_L&Y\HX$':66L*MI@8E!P
MV8SLN3V'K8!1\$I U 9$->\F4<WR@EDV'6NU!NV\"<U-ZE+K:"+'I;N4>ZMI
MEU.<G5YQR62*<*Z,-=!_8'.!YF#L6\)V'G[:XLP:G.@5G#""&R5M;N!29IB]
M!/")5,<LVC";17L1+S ]AC@\A"B(XCUX<5=I7./%_U7I][.YL9K>Q(]=M39(
MR6XDUR>GIF0I3CQJ!(-ZA=[T[9MP$+S?PS/I>";[T*?WU'=9)1#4 EYPWD5T
M/]0W9!K0W0?0:6(Q1^U.M.=.U!UKY#YA[X-65=G;Y+J6J2JP]TDQ27.+5*&%
M.PJG[LD@/ Q/$H@C..H]*,L$+-HP7H=M[V\ +Y])00QV=IHSO43JQU17A$BM
MF2JY0FTYO3T0+J]4%@T<T2\<Q+V.!39(+D0@M2((SN9<<,O).PQ@"&'<NV)<
MPR,3E<,RQCE?$[RQ)"46DB""T>#=/_1;DI#00QX-!Q .![W/I(DOR_.AWW(X
M($5*U5+RWU0"EW1#TBC!,V;)-I8&E\ZX2R0!U<Q)D $F,RJVH%>3.UU;M12'
M203]49+  ?0I,1SL>D;^5I,72"?HI,P07"5MT^_=:J>69XU(_'5OI/:&+H 3
M'8$+"@V.AR<>Z$:^&L.JLI:,N;(D0/4T)\5'[1QH?Z'H@EK#)>C^0Z9_ %!+
M P04    "  -B*I8@(YUF=H#   O"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6R%5FUOVS80_NY?06CHD "*]6J[SFP#2=INQ18L2-(-P[ /M'2V
MN%*D2E*VNU^_.TI6'2!-OEA\N7ONN5=ZL=?FLZT '#O44MEE4#G77$:1+2JH
MN1WK!A3>;+2IN<.MV4:V,<!+KU3+*(WC:51SH8+5PI_=F=5"MTX*!7>&V;:N
MN?EZ#5+OET$2' _NQ;9R=!"M%@W?P@.X3\V=P5TTH)2B!F6%5LS 9AE<)9?7
M.<E[@3\$[.W)FI$G:ZT_T^9CN0QB(@02"D<('#\[N $I"0AI?.DQ@\$D*9ZN
MC^@?O._HRYI;N-'R3U&Z:AF\#5@)&]Y*=Z_WOT#OSX3P"BVM_V7[3C9%BT5K
MG:Y[9=S70G5??NCC<*+P-OZ.0MHKI)YW9\BS?,<=7RV,WC-#THA&"^^JUT9R
M0E%2'IS!6X%Z;O7(#]R'Y^R1KR78\T7D$)8NHZ*'N.X@TN] )"F[U<I5EKU7
M)91/ 2+D,Y!*CZ2NTQ<1WT$Q9ED2LC1.LQ?PLL')S.-EKSGY]]7:.H.5\,]S
M;G8@^?,@U!V7MN$%+ ,L?PMF!\'JQQ^2:?S3"Q3S@6+^$OKJ ;NM;"4PO6%'
MNL]Q?!GE+^"FRP+#&$*]!D-Q'%$<*9@I_22CGXUNF]%-:PPHQ[Z2DN,'=E88
M*(4[9WD^9Q?L+ O3R82=CZ[*?[$0L1.=964+S&G6&*$-:P _I459E$Y(]%$[
M+I^"X>!@KH)>^ 0[CTD!;TB\J+C9PB#L.0DT)S8;\"PW1M?^RCJN2FY*9KCS
MX2JT:;3I$DQ00GFY3THXC,.O0FU+5$7!9/YFS,C@$;4 5G#%UH#CI="J$!(5
MN$46$H>5O1S]IJW%:V3E6?:=DLR0?,K.R><PF\]HE4[#Z017G4KG#6*YU^FF
MV7B2OO&E3@PI01$FZBP/8XH^0H?S=$J+21A/*<BW>@>4#?*T541]J\1_: ZG
M$6!.2X^;A<D\9VF8)7.6A+,T';T_X"BW8)G2#F7+%B<B]GP7]*-W63B?)J@0
M9U/\G4SBU]/?I]07P#UV!C=%Q=!KM+'#J=]XKH7DHNXK)<SC!&4_JD+7X-F0
M^1,JK&DQ2$05"R5),O(^G_MH3$GS@SCX3%E\M;XETWIP%+H8:AM;"0]_QWHP
M#&'0_!-WT)4U]@(.;K*\IS3MN&P]TG1&.%I9+479Q88/JA1Z [+/HB9MG/^*
MP0%3K["0ZSY'77-<C)Z6_7,#(SH9XC5@^=!3A:6D6^6Z>3Z<#J_A5?<(?!/O
MGM);K#ZA+).P0=5X/)L$S'3/4[=QNO%/PEH[?&#\LL(7'0P)X/U&:W?<D('A
M/\+J?U!+ P04    "  -B*I8U4<[KN("  !G!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6R=E6UKVS 0Q]_G4QS>&"F8^"D/39<$FG9C@Q5*NZV,
ML1>*?8E%9<F5Y*;Y]CO):99"&LK>V"?Y[J?_V7?GR5KI>U,B6GBJA#33H+2V
M/HLBDY=8,=-3-4IZLE2Z8I:6>A696B,K?% EHC2.AU'%N QF$[]WK6<3U5C!
M)5YK,$U5,;V9HU#K:9 $SQLW?%5:MQ'-)C5;X2W:'_6UIE6THQ2\0FFXDJ!Q
M.0W.D[-YW_E[AY\<UV;/!I?)0JE[M_A:3(/8"4*!N74$1K='O$ A'(AD/&R9
MP>Y(%[AO/],_^]PIEP4S>*'$'2]L.0U. RAPR1IA;]3Z"V[S&3A>KH3Q5UBW
MOED60-X8JZIM,"FHN&SO[&G['O8"3N-7 M)M0.IUMP=YE9?,LME$JS5HYTTT
M9_A4?32)X])]E%NKZ2FG.#O[IHR!:]1P6S*-T/W.%@+-R22R!'<N4;X%S5M0
M^@HH2>%*25L:^"0++%X"(E*UDY8^2YNG1XF7F/<@2T)(XS0[PLMVJ6:>E[TM
MU=_G"V,U5<6?0\FVJ/YAE.N4,U.S'*<!M8)!_8C![,.[9!A_/"*TOQ/:/T:?
MW5+G%8U 4$N8,\-S>"G]D-[CQ)8B'*4FBO$O@!O(F<@;P2P6G<4&"O[("RY7
M8$MLG9FUFB\:ZXH"K )\:+C=0*E$@=HX?<[U0E4UDQL@A%NN?2=@ >P1-34V
MR*9:T*GDK33QJ?=;!0:X)!6F02@:O3VXLT&F>YU?= 5TE014!^@!5 L=5PNN
M(%)W23I=]V9.WJ@SW^KLOH_C^ 2ZR2@<CA-PUB#,QB-GI5G83\CJW/U'%DF<
MAOU1$L;)D.PD'*3#,#L=PW@4CK,TC >#SL$OT<U1VKT-KZV7M<IZ::NK-X:3
M0\45[35_A7KE1QQ]6M5(V\Z!W>YNBIZWP^.?>SN"KYA><6E X))"X]YH$(!N
MQUJ[L*KVHV2A+ TF;Y;T)T#M'.CY4BG[O' '[/XML[]02P,$%     @ #8BJ
M6&]0XM=; @  -@4  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULC531
M;M,P%'WO5UP9A$"J%L?)NC':2.O&! \3U3I "/'@)K>--2<.MM-N?X_MM%D1
M7<5+?*]]S_&YCH_'&Z4?3(EHX;&2M9F0TMKF(HI,7F+%S8EJL'8K2Z4K;EVJ
M5Y%I-/(B@"H9,4I'4<5%3;)QF)OI;*Q:*T6-,PVFK2JNGZ8HU69"8K*;N!.K
MTOJ)*!LW?(5SM%^;F799U+,4HL+:"%6#QN6$7,87T]37AX)O C=F+P;?R4*I
M!Y]\+B:$>D$H,;>>@;MAC5<HI2=R,GYO.4F_I0?NQSOVF]"[ZV7!#5XI^5T4
MMIR0<P(%+GDK[9W:?,)M/Z>>+U?2A"]LNMJ$$LA;8U6U!3L%E:B[D3]NSV$/
M</X2@&T!+.CN-@HJK[GEV5BK#6A?[=A\$%H-:"=.U/ZGS*UVJ\+A;/;%EJCA
M#G,4:[Z0:.#M?1C?C2/K^'U5E&^YIAT7>X$K9G"K:EL:^%@76/Q-$#EAO3JV
M4S=E1QFO,3^!)!X"HRPYPI?TW2:!+_GO;G]>+HS5[F[\.M1OQY8>9O-^N3 -
MSW%"G"$,ZC62[,VK>$0_'-&:]EK38^S9W/FO:"6"6L(_N@^)/4IW6.QK2BG\
M0*X!_1\;^&/V9\T&<\Q;+>R3N^&-,L(:Y\#=[A"S&.*$#F8:&_[D+.J68\H@
M/J.#>_[(@]^>U4(R/'N?0#IDZ6B0#FD\<O%I.H)#IQ3MW>4*]2HXUD"NVMIV
MU[J?[1^%R\X+S^7=BW++]4K4!B0N'92>G)T2T)U+N\2J)CACH:SS60A+]["A
M]@5N?:F4W25^@_ZIS/X 4$L#!!0    (  V(JEA+VI@L%@0  %<)   9
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M?_E?)Q0@Q*S?\X@L)40V['M2[+=(I5V6)9!UAQDCB,L!.T:*P>6(."6_PHD
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M$IX)H&T ];J;C;S*&V98,E-R#\IY6YH;^%1]M!57"'<I:Z/L:F'C3'*O6(;
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MM5M \RNE[*[C-M@_Z.;_ %!+ P04    "  -B*I8<<NE95,#  #0#@  &0
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MG4H07A1214>RS%0**R95W6&:6U5[ M<3U/LU8_+0T0M4U6SP&U!+ P04
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MF\6[(;BD:<ID2;F]HO&*ILJBH@7I6U1,@GF&P&KDN25Y[H^OWZY)JDV">8;
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MQVZS1_4M.N(YCF!DR8\-![8&*WCYPNT[[YK4- D+#<%J2G<KI;MM].#;BLR
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MXQ)P#$P-D._GE(J;AG)072 %_P!02P,$%     @ #8BJ6 WT%;*X P  G@T
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M\Z6JRT U,')=ML<+:;#9+E\SO$"!L@;X_U)B8:P'=H'F2C;[#5!+ P04
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MU)<(<!V@GJ>,R5U'3]!^VX3_ 5!+ P04    "  -B*I8#@.W'/ $  "O%
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MR6[;,!#]%8(%BA9HK<UVF]06$$<MTD, (^YR*'J@I;%%A!)5<KST[\M%5NQ
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MCL78^>B0'%:TX3@7VZ_0^1D9ODQP9;]DV\5Z#LD:A:+LP%I!R:JVI4]='O8
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MZ]<JTBT8LZ4VU0^N.K(HML84)XIO\NTH=UPIGN2':Q8NF,ANT-\O.5=/)UF
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MF 7(SY>,B9>-[,'5ZF'KZ;]02P,$%     @ #8BJ6)P]J]B3 P  30\  !D
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M3:05,.]70NB7@5V@NGV*_P%02P,$%     @ #8BJ6/]ICP%X @  R@4  !D
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MUK6RU/M^6]&P1>T<Z'ZCE-T;+L$POK-?4$L#!!0    (  V(JE@E_$<S7P(
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M:.Y9)NN(*.(/!5\@879K-C/(8I.AM1K*S#%>*J&_4HU3_@F;@U3Z7!2B#%U
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M@$ D-0-6KQ5,@!!-I-+X77%:=4@-W!YOV"^,=J5EC@5,&/F9QC(967T+Q;#
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MV> M3=8:;U\U]M9QF@%?FEN&0!$KJ"Q/UGJVOLB,S?EM/[N7MZ KS)<I%8C
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M<VAE971S+W-H965T.#$N>&ULQ5A=3]LP%/TK5H8FD%82N]^LK32HT)!@J^B
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MARL0,2CW@+V_D-+L3ER"YC>-R7]02P,$%     @ #8BJ6!2'R-1[ P  *1@
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M!D=NT_Y&8[9,H_JJ&TA$=573_@K#\\/Z#4K'8B*F*QI/JJZ<3\NFHQLZ:G6
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ #8BJ6!Y/I=2N!0  =C4   \
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M4@C2^8,,@FS^H Q!>?X@AR"?/R@@*.8/:B"HF3_H$8(>YP]*2Y1Q29 TP9I
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M>@>!WH%Z!X'>@7H'@=Z!>@>!WC'Y69! [T"]@T#O0+V#0.\&]6X(]&Y0[X9
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M8_SU;U!+ 0(4 Q0    (  V(JE@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #8BJ6/7Y_3'N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ #8BJ6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  -B*I8]$*/VW$&   M'@  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ #8BJ6 L_S5?>!0  @!D  !@              ("!M X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  V(JEC&'K0)2 (  ,8%
M   8              " @<@4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  -B*I8WX"1>N@$   L%   &               @(%&%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ #8BJ6/E9/W*9
M @  S@8  !@              ("!9!P  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    (  V(JE@4VC$+\0D  &5<   8              "
M@3,?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  -B*I8
M@IH]=28(  !/*   &               @(%:*0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ #8BJ6+S(IM%)!   OP@  !@
M     ("!MC$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M  V(JEB?,BK#2B$  '5E   8              " @34V  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  -B*I8>LD1!CD%  "J"P  &0
M            @(&U5P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    (  V(JEC'.N#SSP(  !H&   9              " @25=  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ #8BJ6+N?;%W3 P
M[ <  !D              ("!*V   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  -B*I8RZOIP P#  !O!@  &0              @($U
M9   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  V(JE@O
MC+3M+ ,  (D&   9              " @7AG  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ #8BJ6-FA<^&J!   + H  !D
M     ("!VVH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V(JEAO1\?S0@8  $\.   9              "
M@6M_  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ #8BJ
M6 3O;844"@  SQL  !D              ("!Y(4  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  -B*I81^ M& T$   ="0  &0
M        @($OD   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   (  V(JEAW^'O^4 @  +<3   9              " @7.4  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ #8BJ6,E51V.? P  R0<
M !D              ("!^IP  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  -B*I8(61D=UL"   U!0  &0              @('0H
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  V(JEB^^211
MU ,  (<)   9              " @6*C  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ #8BJ6!>YR7/A @  .08  !D
M ("!;:<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  -
MB*I8_MQ"QJX&   +$0  &0              @(&%J@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  V(JEBE5Y($C04  !(,   9
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M970S,RYX;6Q02P$"% ,4    "  -B*I8<V=@188"  ";!0  &0
M    @(%[Y0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M  V(JE@H[U.7U@(  .8%   9              " @3CH  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ #8BJ6'U7F$TO P  D08  !D
M             ("!1>L  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  -B*I8P1#^9-<#   5"0  &0              @(&K[@  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  V(JEA73J(X^0(
M $\&   9              " @;GR  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ #8BJ6(".=9G: P  +P@  !D              ("!
MZ?4  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  -B*I8
MU4<[KN("  !G!@  &0              @('Z^0  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    (  V(JEAO4.+76P(  #8%   9
M      " @1/]  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ #8BJ6$O:F"P6!   5PD  !D              ("!I?\  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  -B*I80]?E8,P%  ##$
M&0              @('R P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    (  V(JE@\IH>#; ,  .('   9              " @?4) 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ #8BJ6#O5E^-/
M @  +04  !D              ("!F T! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  -B*I8KI 7!8 "  "^!0  &0
M@($>$ $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  V(
MJEC&E.!W* 0  -P)   9              " @=42 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ #8BJ6''+I653 P  T X  !D
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M=#4R+GAM;%!+ 0(4 Q0    (  V(JEA+NUIY$00  '4.   9
M  " @5XG 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M#8BJ6!&XZS.; @  Q@<  !D              ("!IBL! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    "  -B*I8YH[-<74&  "2+   &0
M            @(%X+@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    (  V(JE@+[Y#W< ,  $P2   9              " @20U 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ #8BJ6 WT%;*X P
MG@T  !D              ("!RS@! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    "  -B*I8).LFZN$"  #G"   &0              @(&Z
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  V(JE@.
M [<<\ 0  *\4   9              " @=(_ 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ #8BJ6!ZWO7QK @  G 8  !D
M     ("!^40! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V(JEAE0:-_-@4  + B   9              "
M@5%: 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ #8BJ
M6!C!,;7A P  D!$  !D              ("!OE\! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    "  -B*I8?7C/@C,%  "L)   &0
M        @('68P$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   (  V(JEA';*[1SP4  '@M   9              " @4!I 0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ #8BJ6)P]J]B3 P  30\
M !D              ("!1F\! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    "  -B*I8K7!6&>H"  #&"0  &0              @($0<P$
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  V(JEC 'KTT
M\0,  (D2   9              " @3%V 0!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ #8BJ6/]ICP%X @  R@4  !D
M ("!67H! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  -
MB*I8$]OA,6<"  #*!0  &0              @($(?0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (  V(JE@E_$<S7P(  %T&   9
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M970W."YX;6Q02P$"% ,4    "  -B*I8=,!B_7 #  "S"P  &0
M    @(%XDP$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (
M  V(JEBSJE;8<0(  &,&   9              " @1^7 0!X;"]W;W)K<VAE
M971S+W-H965T.# N>&UL4$L! A0#%     @ #8BJ6 4Q(E5> P  V!$  !D
M             ("!QYD! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"
M% ,4    "  -B*I81]ZU$2D$  #?&   &0              @(%<G0$ >&PO
M=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (  V(JE@4A\C4>P,
M "D8   -              "  ;RA 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !: %H K1@  "2Q 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/GeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/AccountingPolicies</Role>
      <ShortName>Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Critical Accounting Judgement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/CriticalAccountingJudgement</Role>
      <ShortName>Critical Accounting Judgement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other (expense)/ Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OtherexpenseIncome</Role>
      <ShortName>Other (expense)/ Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Operating Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OperatingLoss</Role>
      <ShortName>Operating Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Segmental Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/SegmentalReporting</Role>
      <ShortName>Segmental Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/Employees</Role>
      <ShortName>Employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Remuneration of Key Management Personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel</Role>
      <ShortName>Remuneration of Key Management Personnel</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Finance Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinanceCosts</Role>
      <ShortName>Finance Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/Taxation</Role>
      <ShortName>Taxation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OtherReceivables</Role>
      <ShortName>Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Share Capital and Share Premium</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareCapitalandSharePremium</Role>
      <ShortName>Share Capital and Share Premium</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareBasedPayments</Role>
      <ShortName>Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/Reserves</Role>
      <ShortName>Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Capital Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/CapitalRiskManagement</Role>
      <ShortName>Capital Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TradeandOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Investment in Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/InvestmentinRelatedParty</Role>
      <ShortName>Investment in Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Treasury Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TreasuryShares</Role>
      <ShortName>Treasury Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Financial Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinancialCommitments</Role>
      <ShortName>Financial Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ContingentLiabilities</Role>
      <ShortName>Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/AccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/AccountingPoliciesTables</Role>
      <ShortName>Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/AccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Other (expense)/ Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OtherexpenseIncomeTables</Role>
      <ShortName>Other (expense)/ Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OtherexpenseIncome</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Operating Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OperatingLossTables</Role>
      <ShortName>Operating Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OperatingLoss</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/EmployeesTables</Role>
      <ShortName>Employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/Employees</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Remuneration of Key Management Personnel (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables</Role>
      <ShortName>Remuneration of Key Management Personnel (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Finance Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinanceCostsTables</Role>
      <ShortName>Finance Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinanceCosts</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Taxation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TaxationTables</Role>
      <ShortName>Taxation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/Taxation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/LossPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OtherReceivables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Share Capital and Share Premium (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables</Role>
      <ShortName>Share Capital and Share Premium (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareCapitalandSharePremium</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPayments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinancialInstruments</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TradeandOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TradeandOtherPayables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Investment in Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables</Role>
      <ShortName>Investment in Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/InvestmentinRelatedParty</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/Leases</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/AccountingPoliciesDetails</Role>
      <ShortName>Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/AccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable</Role>
      <ShortName>Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/AccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable</Role>
      <ShortName>Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OtherexpenseIncomeTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Operating Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/OperatingLossDetails</Role>
      <ShortName>Operating Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OperatingLossTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Operating Loss (Details) - Schedule of Operating Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable</Role>
      <ShortName>Operating Loss (Details) - Schedule of Operating Losses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OperatingLossTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Employees (Details) - Schedule of Employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofEmployeesTable</Role>
      <ShortName>Employees (Details) - Schedule of Employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/EmployeesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Remuneration of Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails</Role>
      <ShortName>Remuneration of Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable</Role>
      <ShortName>Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable</Role>
      <ShortName>Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Finance Costs (Details) - Schedule of Finance Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable</Role>
      <ShortName>Finance Costs (Details) - Schedule of Finance Costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinanceCostsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Taxation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TaxationDetails</Role>
      <ShortName>Taxation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TaxationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Taxation (Details) - Schedule of Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofTaxationTable</Role>
      <ShortName>Taxation (Details) - Schedule of Taxation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TaxationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Taxation (Details) - Schedule of Taxation (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals</Role>
      <ShortName>Taxation (Details) - Schedule of Taxation (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TaxationTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Loss Per Share (Details) - Schedule of Basic Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable</Role>
      <ShortName>Loss Per Share (Details) - Schedule of Basic Loss Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/LossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Other Receivables (Details) - Schedule of Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable</Role>
      <ShortName>Other Receivables (Details) - Schedule of Other Receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/OtherReceivablesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Share Capital and Share Premium (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails</Role>
      <ShortName>Share Capital and Share Premium (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable</Role>
      <ShortName>Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Share Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Share Based Payments (Details) - Schedule of Share Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable</Role>
      <ShortName>Share Based Payments (Details) - Schedule of Share Option Plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable</Role>
      <ShortName>Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable</Role>
      <ShortName>Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Share Based Payments (Details) - Schedule of Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable</Role>
      <ShortName>Share Based Payments (Details) - Schedule of Equity Incentive Plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable</Role>
      <ShortName>Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals</Role>
      <ShortName>Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Trade and Other Payables (Details) - Schedule of Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable</Role>
      <ShortName>Trade and Other Payables (Details) - Schedule of Trade and Other Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TradeandOtherPayablesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Investment in Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails</Role>
      <ShortName>Investment in Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Investment in Related Party (Details) - Schedule of Investment in Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable</Role>
      <ShortName>Investment in Related Party (Details) - Schedule of Investment in Related Party</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Treasury Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/TreasurySharesDetails</Role>
      <ShortName>Treasury Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/TreasuryShares</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/RelatedPartyTransactions</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/LeasesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Leases (Details) - Schedule of Consolidated Statement of Financial</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable</Role>
      <ShortName>Leases (Details) - Schedule of Consolidated Statement of Financial</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/LeasesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Leases (Details) - Schedule of Future Minimum Lease Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable</Role>
      <ShortName>Leases (Details) - Schedule of Future Minimum Lease Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0203872-20f_tiziana.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Financial Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tizianalifesciences.com/role/FinancialCommitmentsDetails</Role>
      <ShortName>Financial Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tizianalifesciences.com/role/FinancialCommitments</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentAccountingStandard, dei:DocumentRegistrationStatement, dei:EntityFileNumber, ifrs-full:DilutedEarningsLossPerShare -  ea0203872-20f_tiziana.htm 20197, 20206, 20207, 20208, 20549, 20551</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0203872-20f_tiziana.htm">ea0203872-20f_tiziana.htm</File>
    <File>tlsa-20231231.xsd</File>
    <File>tlsa-20231231_cal.xml</File>
    <File>tlsa-20231231_def.xml</File>
    <File>tlsa-20231231_lab.xml</File>
    <File>tlsa-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="526">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0203872-20f_tiziana.htm": {
   "nsprefix": "tlsa",
   "nsuri": "http://tizianalifesciences.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0203872-20f_tiziana.htm"
     ]
    },
    "schema": {
     "local": [
      "tlsa-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tlsa-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tlsa-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tlsa-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tlsa-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 187,
   "keyCustom": 219,
   "axisStandard": 10,
   "axisCustom": 2,
   "memberStandard": 14,
   "memberCustom": 40,
   "hidden": {
    "total": 355,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 128,
    "http://tizianalifesciences.com/20231231": 221,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 167,
   "entityCount": 1,
   "segmentCount": 55,
   "elementCount": 623,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 526,
    "http://xbrl.sec.gov/dei/2023": 41
   },
   "report": {
    "R1": {
     "role": "http://tizianalifesciences.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "tlsa:PrepaymentsandOtherReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "tlsa:IssuanceOfShareCapital",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "tlsa:IssuanceOfShareCapital",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://tizianalifesciences.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://tizianalifesciences.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:AdjustmentsForInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://tizianalifesciences.com/role/GeneralInformation",
     "longName": "007 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://tizianalifesciences.com/role/AccountingPolicies",
     "longName": "008 - Disclosure - Accounting Policies",
     "shortName": "Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://tizianalifesciences.com/role/CriticalAccountingJudgement",
     "longName": "009 - Disclosure - Critical Accounting Judgement",
     "shortName": "Critical Accounting Judgement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tizianalifesciences.com/role/OtherexpenseIncome",
     "longName": "010 - Disclosure - Other (expense)/ Income",
     "shortName": "Other (expense)/ Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://tizianalifesciences.com/role/OperatingLoss",
     "longName": "011 - Disclosure - Operating Loss",
     "shortName": "Operating Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tizianalifesciences.com/role/SegmentalReporting",
     "longName": "012 - Disclosure - Segmental Reporting",
     "shortName": "Segmental Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://tizianalifesciences.com/role/Employees",
     "longName": "013 - Disclosure - Employees",
     "shortName": "Employees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel",
     "longName": "014 - Disclosure - Remuneration of Key Management Personnel",
     "shortName": "Remuneration of Key Management Personnel",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tizianalifesciences.com/role/FinanceCosts",
     "longName": "015 - Disclosure - Finance Costs",
     "shortName": "Finance Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://tizianalifesciences.com/role/Taxation",
     "longName": "016 - Disclosure - Taxation",
     "shortName": "Taxation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tizianalifesciences.com/role/LossPerShare",
     "longName": "017 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://tizianalifesciences.com/role/OtherReceivables",
     "longName": "018 - Disclosure - Other Receivables",
     "shortName": "Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://tizianalifesciences.com/role/ShareCapitalandSharePremium",
     "longName": "019 - Disclosure - Share Capital and Share Premium",
     "shortName": "Share Capital and Share Premium",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tizianalifesciences.com/role/ShareBasedPayments",
     "longName": "020 - Disclosure - Share Based Payments",
     "shortName": "Share Based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tizianalifesciences.com/role/Reserves",
     "longName": "021 - Disclosure - Reserves",
     "shortName": "Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tizianalifesciences.com/role/FinancialInstruments",
     "longName": "022 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tizianalifesciences.com/role/CapitalRiskManagement",
     "longName": "023 - Disclosure - Capital Risk Management",
     "shortName": "Capital Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tizianalifesciences.com/role/TradeandOtherPayables",
     "longName": "024 - Disclosure - Trade and Other Payables",
     "shortName": "Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://tizianalifesciences.com/role/InvestmentinRelatedParty",
     "longName": "025 - Disclosure - Investment in Related Party",
     "shortName": "Investment in Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:InvestmentInRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:InvestmentInRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://tizianalifesciences.com/role/TreasuryShares",
     "longName": "026 - Disclosure - Treasury Shares",
     "shortName": "Treasury Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tizianalifesciences.com/role/RelatedPartyTransactions",
     "longName": "027 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://tizianalifesciences.com/role/Leases",
     "longName": "028 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://tizianalifesciences.com/role/FinancialCommitments",
     "longName": "029 - Disclosure - Financial Commitments",
     "shortName": "Financial Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://tizianalifesciences.com/role/ContingentLiabilities",
     "longName": "030 - Disclosure - Contingent Liabilities",
     "shortName": "Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://tizianalifesciences.com/role/AccountingPoliciesTables",
     "longName": "996001 - Disclosure - Accounting Policies (Tables)",
     "shortName": "Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://tizianalifesciences.com/role/OtherexpenseIncomeTables",
     "longName": "996002 - Disclosure - Other (expense)/ Income (Tables)",
     "shortName": "Other (expense)/ Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://tizianalifesciences.com/role/OperatingLossTables",
     "longName": "996003 - Disclosure - Operating Loss (Tables)",
     "shortName": "Operating Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOperatingLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOperatingLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://tizianalifesciences.com/role/EmployeesTables",
     "longName": "996004 - Disclosure - Employees (Tables)",
     "shortName": "Employees (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables",
     "longName": "996005 - Disclosure - Remuneration of Key Management Personnel (Tables)",
     "shortName": "Remuneration of Key Management Personnel (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://tizianalifesciences.com/role/FinanceCostsTables",
     "longName": "996006 - Disclosure - Finance Costs (Tables)",
     "shortName": "Finance Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://tizianalifesciences.com/role/TaxationTables",
     "longName": "996007 - Disclosure - Taxation (Tables)",
     "shortName": "Taxation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://tizianalifesciences.com/role/LossPerShareTables",
     "longName": "996008 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://tizianalifesciences.com/role/OtherReceivablesTables",
     "longName": "996009 - Disclosure - Other Receivables (Tables)",
     "shortName": "Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables",
     "longName": "996010 - Disclosure - Share Capital and Share Premium (Tables)",
     "shortName": "Share Capital and Share Premium (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureShareCapitalArisingForShareExchangetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureShareCapitalArisingForShareExchangetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://tizianalifesciences.com/role/ShareBasedPaymentsTables",
     "longName": "996011 - Disclosure - Share Based Payments (Tables)",
     "shortName": "Share Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://tizianalifesciences.com/role/FinancialInstrumentsTables",
     "longName": "996012 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://tizianalifesciences.com/role/TradeandOtherPayablesTables",
     "longName": "996013 - Disclosure - Trade and Other Payables (Tables)",
     "shortName": "Trade and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables",
     "longName": "996014 - Disclosure - Investment in Related Party (Tables)",
     "shortName": "Investment in Related Party (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsa:InvestmentInRelatedPartyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "tlsa:InvestmentInRelatedPartyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://tizianalifesciences.com/role/LeasesTables",
     "longName": "996015 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://tizianalifesciences.com/role/AccountingPoliciesDetails",
     "longName": "996016 - Disclosure - Accounting Policies (Details)",
     "shortName": "Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "tlsa:AccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "tlsa:AccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable",
     "longName": "996017 - Disclosure - Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period",
     "shortName": "Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c72",
      "name": "tlsa:EstimatedUsefulLives",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c72",
      "name": "tlsa:EstimatedUsefulLives",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable",
     "longName": "996018 - Disclosure - Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income",
     "shortName": "Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "tlsa:SublicenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "tlsa:SublicenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://tizianalifesciences.com/role/OperatingLossDetails",
     "longName": "996019 - Disclosure - Operating Loss (Details)",
     "shortName": "Operating Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c75",
      "name": "ifrs-full:BenefitsPaidOrPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "ifrs-full:BenefitsPaidOrPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable",
     "longName": "996020 - Disclosure - Operating Loss (Details) - Schedule of Operating Losses",
     "shortName": "Operating Loss (Details) - Schedule of Operating Losses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:Licensefee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:Licensefee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://tizianalifesciences.com/role/ScheduleofEmployeesTable",
     "longName": "996021 - Disclosure - Employees (Details) - Schedule of Employees",
     "shortName": "Employees (Details) - Schedule of Employees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DirectorsRemunerationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DirectorsRemunerationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails",
     "longName": "996022 - Disclosure - Remuneration of Key Management Personnel (Details)",
     "shortName": "Remuneration of Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherLongtermBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherLongtermBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable",
     "longName": "996023 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel",
     "shortName": "Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DirectorsFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DirectorsFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable",
     "longName": "996024 - Disclosure - Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors",
     "shortName": "Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:NumberOfShareOptionsWereGrantedToDirectors",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:NumberOfShareOptionsWereGrantedToDirectors",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable",
     "longName": "996025 - Disclosure - Finance Costs (Details) - Schedule of Finance Costs",
     "shortName": "Finance Costs (Details) - Schedule of Finance Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://tizianalifesciences.com/role/TaxationDetails",
     "longName": "996026 - Disclosure - Taxation (Details)",
     "shortName": "Taxation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:MaximumPercentageOfSurrenderableLosses",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:MaximumPercentageOfSurrenderableLosses",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://tizianalifesciences.com/role/ScheduleofTaxationTable",
     "longName": "996027 - Disclosure - Taxation (Details) - Schedule of Taxation",
     "shortName": "Taxation (Details) - Schedule of Taxation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals",
     "longName": "996028 - Disclosure - Taxation (Details) - Schedule of Taxation (Parentheticals)",
     "shortName": "Taxation (Details) - Schedule of Taxation (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxRateEffectOfTaxLosses",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxRateEffectOfTaxLosses",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable",
     "longName": "996029 - Disclosure - Loss Per Share (Details) - Schedule of Basic Loss Per Share",
     "shortName": "Loss Per Share (Details) - Schedule of Basic Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable",
     "longName": "996030 - Disclosure - Other Receivables (Details) - Schedule of Other Receivables",
     "shortName": "Other Receivables (Details) - Schedule of Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "tlsa:SecurityDepositsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "tlsa:SecurityDepositsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails",
     "longName": "996031 - Disclosure - Share Capital and Share Premium (Details)",
     "shortName": "Share Capital and Share Premium (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable",
     "longName": "996032 - Disclosure - Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange",
     "shortName": "Share Capital and Share Premium (Details) - Schedule of Share Capital Arising on the Share for Share Exchange",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "tlsa:NominalValueAnnualReport",
      "unitRef": "gbpPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "tlsa:NominalValueAnnualReport",
      "unitRef": "gbpPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails",
     "longName": "996033 - Disclosure - Share Based Payments (Details)",
     "shortName": "Share Based Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:OutstandingFairValueCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:OutstandingFairValueCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable",
     "longName": "996034 - Disclosure - Share Based Payments (Details) - Schedule of Share Option Plan",
     "shortName": "Share Based Payments (Details) - Schedule of Share Option Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "tlsa:WeightedAverageExercisePriceOutstanding",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c15",
      "name": "tlsa:WeightedAverageExercisePriceOutstanding",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable",
     "longName": "996035 - Disclosure - Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price",
     "shortName": "Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable",
     "longName": "996036 - Disclosure - Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model",
     "shortName": "Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c116",
      "name": "tlsa:GrantDateSharesPrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c116",
      "name": "tlsa:GrantDateSharesPrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable",
     "longName": "996037 - Disclosure - Share Based Payments (Details) - Schedule of Equity Incentive Plan",
     "shortName": "Share Based Payments (Details) - Schedule of Equity Incentive Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfEquityIncentivePlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfEquityIncentivePlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable",
     "longName": "996038 - Disclosure - Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using",
     "shortName": "Share Based Payments (Details) - Schedule of Estimated the Fair Value of Warrants Using",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "tlsa:FairValueOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c15",
      "name": "tlsa:FairValueOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable",
     "longName": "996039 - Disclosure - Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments",
     "shortName": "Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable",
     "longName": "996040 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant",
     "shortName": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c129",
      "name": "tlsa:ProfitOrLossAndEquityStrengthening",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c129",
      "name": "tlsa:ProfitOrLossAndEquityStrengthening",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals",
     "longName": "996041 - Disclosure - Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals)",
     "shortName": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c129",
      "name": "tlsa:MovementPercentageStrengthening",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c129",
      "name": "tlsa:MovementPercentageStrengthening",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable",
     "longName": "996042 - Disclosure - Trade and Other Payables (Details) - Schedule of Trade and Other Payables",
     "shortName": "Trade and Other Payables (Details) - Schedule of Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails",
     "longName": "996043 - Disclosure - Investment in Related Party (Details)",
     "shortName": "Investment in Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InsuranceFinanceIncomeExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:AcquiredShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable",
     "longName": "996044 - Disclosure - Investment in Related Party (Details) - Schedule of Investment in Related Party",
     "shortName": "Investment in Related Party (Details) - Schedule of Investment in Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c131",
      "name": "ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
       "tlsa:InvestmentInRelatedPartyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c131",
      "name": "ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
       "tlsa:InvestmentInRelatedPartyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://tizianalifesciences.com/role/TreasurySharesDetails",
     "longName": "996045 - Disclosure - Treasury Shares (Details)",
     "shortName": "Treasury Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "tlsa:SharesPurchases",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "tlsa:SharesPurchases",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails",
     "longName": "996046 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ServicesAgreementAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:ServicesAgreementAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable",
     "longName": "996047 - Disclosure - Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities",
     "shortName": "Leases (Details) - Schedule of Right-of-Use Assets and Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:RightOfUseAssetBeginning",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:RightOfUseAssetBeginning",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable",
     "longName": "996048 - Disclosure - Leases (Details) - Schedule of Consolidated Statement of Financial",
     "shortName": "Leases (Details) - Schedule of Consolidated Statement of Financial",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable",
     "longName": "996049 - Disclosure - Leases (Details) - Schedule of Future Minimum Lease Payments",
     "shortName": "Leases (Details) - Schedule of Future Minimum Lease Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "tlsa:LeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "tlsa:LeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://tizianalifesciences.com/role/FinancialCommitmentsDetails",
     "longName": "996050 - Disclosure - Financial Commitments (Details)",
     "shortName": "Financial Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DevelopmentMilestones",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "tlsa:DevelopmentMilestones",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0203872-20f_tiziana.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "tlsa_AccountingPolicieAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPolicieAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policie Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesDetailsScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies (Details) - Schedule of Estimated Useful Lives for the Current Period and the Comparative Period [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "tlsa_AccruedOfDiligenceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccruedOfDiligenceObligations",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued of diligence obligations",
        "documentation": "Accrued of diligence obligations.",
        "label": "Accrued Of Diligence Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccumulatedLoss",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated loss",
        "documentation": "Accumulated loss.",
        "label": "Accumulated Loss"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AccustemSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AccustemSciencesIncMember",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails",
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accustem Sciences Inc [Member]",
        "verboseLabel": "Accustem [Member]",
        "label": "Accustem Sciences Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AcquiredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AcquiredShares",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired shares",
        "documentation": "Number of acquired shares.",
        "label": "Acquired Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AdditionalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AdditionalPayment",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payment",
        "documentation": "Additional payment.",
        "label": "Additional Payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AdjustmentsDueToPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AdjustmentsDueToPriorPeriod",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments due to prior periods",
        "documentation": "Adjustments due to prior periods.",
        "label": "Adjustments Due To Prior Period"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AdjustmentsDueToPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AdjustmentsDueToPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments due to prior periods",
        "documentation": "Adjustments due to prior periods.",
        "label": "Adjustments Due To Prior Periods"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (increase)/decrease in operating assets/other receivables",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable": {
       "parentTag": "ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment",
        "label": "Adjustments for gains (losses) on fair value adjustment, investment property"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gains (losses) arising from a change in the fair value of investment property to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investment property; Gains (losses) on fair value adjustment, investment property; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net increase/(decrease) in operating liabilities /other liabilities",
        "label": "Adjustments for increase (decrease) in other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_AdjustmentsForInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible loan interest accrued",
        "label": "Adjustments for interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment charges",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "tlsa_AdjustmentsForSharebasedPaymentsWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AdjustmentsForSharebasedPaymentsWarrants",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment \u2013 options",
        "documentation": "Adjustments for share-based payments warrants to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Sharebased Payments Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_AdjustmentsToBroughtForwardValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AdjustmentsToBroughtForwardValues",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to brought forward values",
        "label": "Adjustments To Brought Forward Values"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r90",
      "r91",
      "r94",
      "r95",
      "r97",
      "r98",
      "r113",
      "r141",
      "r149",
      "r151"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r40"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r80",
      "r81",
      "r124",
      "r126"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ]
    },
    "tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "documentation": "Average monthly number of employees, including directors, employed by the group.",
        "label": "Average Monthly Number Of Employees Including Directors Employed By Group"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_BLAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BLAMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BLA [Member]",
        "label": "BLAMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share attributable to common shareholders (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "tlsa_BasicLossPerSharecentsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BasicLossPerSharecentsPerShare",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share (cents per share)",
        "label": "Basic Loss Per Sharecents Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BenefitsPaidOrPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BenefitsPaidOrPayable",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realization bonus payable",
        "label": "Benefits paid or payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefits paid or payable for retirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "tlsa_BlackScholesMertonValuationModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BlackScholesMertonValuationModelMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes-Merton Valuation model [Member]",
        "label": "Black Scholes Merton Valuation Model Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_Bonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "Bonus",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus",
        "label": "Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_BonusToBeSettledInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BonusToBeSettledInEquity",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus to be settled in equity",
        "documentation": "Amount of Bonus to be settled in equity.",
        "label": "Bonus To Be Settled In Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r97",
      "r108",
      "r145",
      "r146",
      "r180"
     ]
    },
    "tlsa_BreastCancerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BreastCancerMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Breast Cancer [Member]",
        "label": "Breast Cancer Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159"
     ]
    },
    "tlsa_BuybackOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "BuybackOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buyback of Treasury Shares",
        "documentation": "Buyback of Treasury Shares.",
        "label": "Buyback Of Treasury Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CapitalDistribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CapitalDistribution",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain)/loss on disposal of right of use asset",
        "documentation": "Capital distribution.",
        "label": "Capital Distribution"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CarcinomaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CarcinomaMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carcinoma [Member]",
        "label": "Carcinoma Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalent, beginning of year",
        "periodEndLabel": "Cash and cash equivalent, end of year",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r77"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in Investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CashInflowFromTaxation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CashInflowFromTaxation",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash inflow from taxation",
        "documentation": "Represent the amount of cash inflow from taxation.",
        "label": "Cash Inflow From Taxation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CashSurplus": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CashSurplus",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash surplus",
        "documentation": "The amount of cash surplus.",
        "label": "Cash Surplus"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails",
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails",
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails",
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable",
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable",
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable",
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "tlsa_ChargeOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ChargeOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge of forfeitures",
        "documentation": "Amount of charge of forfeitures.",
        "label": "Charge Of Forfeitures"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ClassOfWarrantsOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ClassOfWarrantsOrRightAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrants or Right [Axis]",
        "label": "Class Of Warrants Or Right Axis"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ClassOfWarrantsOrRightDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ClassOfWarrantsOrRightDomainDomain",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ClassOfWarrantsOrRightDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "tlsa_CommercialSaleOfAProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CommercialSaleOfAProduct",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial sale of a product",
        "documentation": "The amount of commercial sale of a product.",
        "label": "Commercial Sale Of AProduct"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IT and equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement",
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "terseLabel": "Total comprehensive loss",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r23",
      "r68",
      "r70",
      "r76",
      "r144"
     ]
    },
    "tlsa_ConsolidatedStatementsOfShareholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ConsolidatedStatementsOfShareholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Shareholders Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ConsolidationAdjustmentInRelationToForeignExchangeMovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ConsolidationAdjustmentInRelationToForeignExchangeMovements",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation adjustment in relation to foreign exchange movements",
        "label": "Consolidation Adjustment In Relation To Foreign Exchange Movements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CorporateAndAdministration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CorporateAndAdministration",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate and administration",
        "documentation": "The amount of corporate and administration.",
        "label": "Corporate And Administration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66"
     ]
    },
    "tlsa_CriticalAccountingJudgementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CriticalAccountingJudgementLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/CriticalAccountingJudgement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Judgement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_CriticalAccountingJudgementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CriticalAccountingJudgementTable",
     "presentation": [
      "http://tizianalifesciences.com/role/CriticalAccountingJudgement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Judgement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable",
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued amount due",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r144"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liability",
        "verboseLabel": "Current",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r75",
      "r144"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year tax (credit)",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "tlsa_CurrentTaxOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "CurrentTaxOther",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Tax - Other",
        "documentation": "Current tax other.",
        "label": "Current Tax Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of Property, plant and equipment",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "tlsa_DepreciationOfRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DepreciationOfRightofuseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of right-of-use asset",
        "documentation": "Depreciation of right-of-use asset.",
        "label": "Depreciation Of Rightofuse Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation (Right-of-use asset)",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "tlsa_DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "documentation": "The description of the entity's material accounting policy information for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Description Of Accounting Policy For Basis Of Preparation Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DescriptionOfAccountingPolicyForBasisofConsolidation": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForBasisofConsolidation",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "documentation": "The description of the entity's accounting policy for basis of consolidation.",
        "label": "Description Of Accounting Policy For Basisof Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination",
        "label": "Description of accounting policy for business combinations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Liabilities",
        "label": "Description of accounting policy for contingent liabilities and contingent assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "tlsa_DescriptionOfAccountingPolicyForGoingConcern": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForGoingConcern",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern",
        "documentation": "The description of the entity's accounting policy for going concern.",
        "label": "Description Of Accounting Policy For Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "tlsa_DescriptionOfAccountingPolicyForLicenseFees": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForLicenseFees",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fees",
        "documentation": "The description of the entity's accounting policy for license fees.",
        "label": "Description Of Accounting Policy For License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New and Revised Standards",
        "documentation": "The description of the entity's material accounting policy information for revised standards.",
        "label": "Description Of Accounting Policy For New And Revised Standards Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relassification of Prior Year Presentation",
        "label": "Description of accounting policy for reclassification of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the reclassification of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Description of accounting policy for segment reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share \u2013 based payments",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "tlsa_DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sub license income",
        "documentation": "The description of the entity's material accounting policy information for sub license income.",
        "label": "Description Of Accounting Policy For Sub License Income Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxation",
        "label": "Description of accounting policy for taxes other than income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "tlsa_DescriptionOfAccountingPolicyForWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForWarrantsTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "The description of the entity's material accounting policy information for derivative instruments and hedging activities.",
        "label": "Description Of Accounting Policy For Warrants Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
     "presentation": [
      "http://tizianalifesciences.com/role/CriticalAccountingJudgement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CRITICAL ACCOUNTING JUDGEMENT",
        "label": "Description of nature of change in accounting estimate [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "tlsa_DevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones",
        "documentation": "The amount of development milestones.",
        "label": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share attributable to common shareholders",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "tlsa_DirectorsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DirectorsFees",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 fee",
        "documentation": "The amount of directors fees.",
        "label": "Directors Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DirectorsRemunerationExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 salaries (including bonus)",
        "label": "Directors' remuneration expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "tlsa_DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/FinanceCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Costs",
        "documentation": "The disclosure of detailed information about finance cost.",
        "label": "Disclosure Detailed Information About Of Finance Cost Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremium"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL AND SHARE PREMIUM",
        "documentation": "The disclosure of accounting share capital and share premium.",
        "label": "Disclosure Of Accounting Share Capital And Share Premiumtext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL INFORMATION",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Share Premium [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/ContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL COMMITMENTS",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfDetailedInformationAboutEmployeesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEmployeesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/EmployeesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employees",
        "documentation": "The disclosure of detailed information about employees.",
        "label": "Disclosure Of Detailed Information About Employees Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Taxation",
        "documentation": "The disclosure of detailed information about income tax expense (benefit).",
        "label": "Disclosure Of Detailed Information About Income Tax Expense Benefit Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic Loss Per Share",
        "documentation": "Disclosure of detailed information about of earnings per share.",
        "label": "Disclosure Of Detailed Information About Of Earnings Per Share Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfDetailedInformationAboutOperatingLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOperatingLoss",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Losses",
        "documentation": "The disclosure of detailed information about operating loss.",
        "label": "Disclosure Of Detailed Information About Operating Loss"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivables",
        "documentation": "Disclosure of detailed information about other receivables.",
        "label": "Disclosure Of Detailed Information About Other Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment in Related Party",
        "label": "Disclosure of effect of change of investment entity status on financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the effect of the change of investment entity status on the financial statements. [Refer: Disclosure of investment entities [text block]]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/SegmentalReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENTAL REPORTING",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "tlsa_DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives for the Current Period and the Comparative Period",
        "documentation": "The disclosure of estimated useful lives for the current period and the comparative period.",
        "label": "Disclosure Of Estimated Useful Lives For The Current Period And The Comparative Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceCostExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/FinanceCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCE COSTS",
        "label": "Disclosure of finance cost [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Statement of Financial",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/CapitalRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CAPITAL RISK MANAGEMENT",
        "label": "Disclosure of financial risk management [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "tlsa_DisclosureOfFutureMinimumLeasePayments": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfFutureMinimumLeasePayments",
     "presentation": [
      "http://tizianalifesciences.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Disclosure Of Future Minimum Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/Taxation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXATION",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutEmployeesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/Employees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEES",
        "label": "Disclosure of information about employees [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about employees."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REMUNERATION OF KEY MANAGEMENT PERSONNEL",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Option Plan",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherexpenseIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other (Expense)/ Income",
        "label": "Disclosure of other operating income (expense) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherexpenseIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER (EXPENSE)/ INCOME",
        "label": "Disclosure of other operating income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING LOSS",
        "label": "Disclosure of profit (loss) from operating activities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "tlsa_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Right-of-Use Assets and Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Rightofuse Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "tlsa_DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Remuneration of Key Management Personnel",
        "documentation": "The disclosure of information about key management personnel.",
        "label": "Disclosure Of Remuneration Of Key Management Personnel Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReservesWithinEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReservesWithinEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Risk Management [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/Reserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESERVES",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "tlsa_DisclosureOfShareOptionsWereGrantedToDirectorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureOfShareOptionsWereGrantedToDirectorTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Options were Granted to Directors",
        "documentation": "The disclosure of share options were granted to directors.",
        "label": "Disclosure Of Share Options Were Granted To Director Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE BASED PAYMENTS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/TradeandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE AND OTHER PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER RECEIVABLES",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasuryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TREASURY SHARES",
        "label": "Disclosure of treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "tlsa_DisclosureShareCapitalArisingForShareExchangetextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisclosureShareCapitalArisingForShareExchangetextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital Arising on the Share for Share Exchange",
        "documentation": "Disclosure share capital arising for share exchange.",
        "label": "Disclosure Share Capital Arising For Share Exchangetext Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_DisposalOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DisposalOfLease",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of lease",
        "documentation": "Disposal of lease.",
        "label": "Disposal Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "tlsa_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange difference on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "tlsa_EliminationOfOtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "EliminationOfOtherReserves",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of other reserves in Tiziana Life Sciences Plc",
        "documentation": "Elimination of other reserves.",
        "label": "Elimination Of Other Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employees, total",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r27",
      "r132"
     ]
    },
    "tlsa_EmployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "EmployeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails",
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails",
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails",
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable",
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable",
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r17",
      "r67",
      "r69",
      "r79",
      "r80",
      "r81"
     ]
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tlsa_EstimatedUsefulLives": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "EstimatedUsefulLives",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "documentation": "The estimated useful lives for the current period and the comparative period.",
        "label": "Estimated Useful Lives"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ExchangeDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ExchangeDifferences",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "documentation": "The Amount of Exchange differences",
        "label": "Exchange Differences"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ExchangeDifferencesRightofUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ExchangeDifferencesRightofUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "documentation": "Exchange differences",
        "label": "Exchange Differences Rightof Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price for options issued to employees and directors",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise share price (in Dollars per share and Pounds per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "tlsa_ExerciseSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ExerciseSharePrice",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price (in Dollars per share)",
        "label": "Exercise Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ExpectedTermOfAwards": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ExpectedTermOfAwards",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of the award",
        "documentation": "The expected term of the awards is based on managements\u2019 assessment of when the market condition.",
        "label": "Expected Term Of Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment transactions",
        "label": "Expense from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment (credit) / charge",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses",
        "label": "Expense from share-based payment transactions with parties other than employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debts",
        "label": "Expense recognised during period for bad and doubtful debts for related party transaction"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised during the period in respect of bad or doubtful debts due from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "tlsa_ExpiryDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ExpiryDate",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry Date",
        "label": "Expiry Date"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FVLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FVLossOnInvestment",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value loss on investment, net",
        "documentation": "FV loss on investment amount.",
        "label": "FVLoss On Investment"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FairValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FairValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning",
        "terseLabel": "Outstanding ending",
        "documentation": "Representation amount of outstanding.",
        "label": "Fair Value Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinanceChargeAccruedOnConvertibleLoanNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceChargeAccruedOnConvertibleLoanNotes",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance charge accrued on convertible loan notes",
        "documentation": "Finance charge accrued on convertible loan notes (recognized as debt).",
        "label": "Finance Charge Accrued On Convertible Loan Notes"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinanceCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceCharges",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Charges",
        "documentation": "Amount of finance charges.",
        "label": "Finance Charges"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinanceCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total finance Expense",
        "documentation": "Total finance Expense",
        "label": "Finance Expense"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinanceExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceExpenseAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Expense",
        "label": "Finance Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "tlsa_FinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinanceIncomeAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income",
        "label": "Finance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance (expense)/ income",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value loss on Investment",
        "label": "Financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "tlsa_FinancialCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialCommitmentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialCommitmentsDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Commitments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialCommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialCommitmentsDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantParentheticalsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant (Parentheticals) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofAllOtherVariablesRemainConstantTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of All Other Variables Remain Constant [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments measured at fair value through profit or loss, because a credit derivative is used to manage the credit risk of these instruments. It also represents the standard value for the 'Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk' axis if no other member is used. [Refer: Financial instruments, class [member]; Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "tlsa_FinancialInstrumentsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FinancialInstrumentsNet",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Financial Instruments Net"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FixedAssetDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FixedAssetDifferences",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed asset differences",
        "documentation": "Fixed asset differences.",
        "label": "Fixed Asset Differences"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixtures and fittings [Member]",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "tlsa_ForeignExchangegainlosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ForeignExchangegainlosses",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange (gains)/losses",
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]",
        "label": "Foreign Exchangegainlosses"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FourteenMarchTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FourteenMarchTwoThousandTwentyThreeMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "14 March 2023 [Member]",
        "label": "Fourteen March Two Thousand Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_FundraisingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "FundraisingCost",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ordinary shares",
        "documentation": "Fundraising cost.",
        "label": "Fundraising Cost"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GCerroneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GCerroneMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G. Cerrone [Member]",
        "label": "GCerrone Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnDisposalsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FV Loss on Investment",
        "label": "Gains (losses) on disposals of investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of investments."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain)/ loss on foreign exchange",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35"
     ]
    },
    "tlsa_GeneralInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GeneralInformationLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GeneralInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GeneralInformationTable",
     "presentation": [
      "http://tizianalifesciences.com/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GensigniaLifesceinecsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GensigniaLifesceinecsIncMember",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gensignia Lifesceinecs Inc [Member]",
        "label": "Gensignia Lifesceinecs Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GrantDateSharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GrantDateSharesPrice",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date share price (in Dollars per share and Pounds per share)",
        "label": "Grant Date Shares Price"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GroupAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GroupAbstract0",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group",
        "label": "Group Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_GroupReorganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "GroupReorganizationAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group Reorganization",
        "label": "Group Reorganization Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_HCCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "HCCMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HCC [Member]",
        "label": "HCCMember"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ]
    },
    "ifrs-full_ImpairmentLossOnFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossOnFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable": {
       "parentTag": "ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in fair value",
        "label": "Impairment loss on financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss on financial assets. [Refer: Financial assets; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossInvestmentProperty",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Impairment loss recognised in profit or loss, investment property"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for investment property. [Refer: Impairment loss recognised in profit or loss; Investment property]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "tlsa_IncomeNotTaxableForTaxPurposes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeNotTaxableForTaxPurposes",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income not taxable for tax purposes",
        "documentation": "The aggregate amount of income not taxable for tax purpose.",
        "label": "Income Not Taxable For Tax Purposes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_IncomeTaxExpenseContinuingOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeTaxExpenseContinuingOperation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total tax (credit) for the period",
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense income",
        "label": "Income Tax Expense Continuing Operation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r30",
      "r44",
      "r78",
      "r123"
     ]
    },
    "tlsa_IncomeTaxReconciliationExpensesNotDeductibleForTaxation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeTaxReconciliationExpensesNotDeductibleForTaxation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses not deductible for taxation",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expenses not deductible for taxation.",
        "label": "Income Tax Reconciliation Expenses Not Deductible For Taxation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to loss charged at standard rate of corporation tax.",
        "label": "Income Tax Reconciliation Loss Charged At Standard Rate Of Corporation Tax"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_IncomeTaxReconciliationResearchAndDevelopmentClaim": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeTaxReconciliationResearchAndDevelopmentClaim",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development claim",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development claim.",
        "label": "Income Tax Reconciliation Research And Development Claim"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_IncomeTaxSCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IncomeTaxSCredit",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax (expense)/credit",
        "documentation": "Income tax credit.",
        "label": "Income Tax SCredit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Taxation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclass of FV for options forfeited/Cancelled",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transactions with owners",
        "label": "Increase (decrease) through transactions with owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury Shares",
        "label": "Increase (decrease) through treasury share transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "tlsa_InitialAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InitialAmount",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment",
        "documentation": "Initial amount.",
        "label": "Initial Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InsuranceFinanceIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InsuranceFinanceIncomeExpenses",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails",
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense",
        "label": "Insurance finance income (expenses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that comprises the change in the carrying amount of the group of insurance contracts arising from: (a) the effect of the time value of money and changes in the time value of money; and (b) the effect of financial risk and changes in financial risk; but (c) excluding any such changes for groups of insurance contracts with direct participation features that would adjust the contractual service margin but do not do so when applying paragraphs 45(b)(ii), 45(b)(iii), 45(c)(ii) or 45(c)(iii) of IFRS 17."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53"
     ]
    },
    "tlsa_InterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InterestAmount",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest amount",
        "label": "Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Interest Received",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnImpairedFinancialAssetsAccrued",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest income on impaired financial assets accrued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest on impaired financial assets accrued after impairment using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "tlsa_InterestReceivedFromLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InterestReceivedFromLoan",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest on related party loan conversion",
        "documentation": "Interest Received from loan",
        "label": "Interest Received From Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentInRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentInRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in Related Party",
        "documentation": "Investment in related party amount.",
        "label": "Investment In Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentInRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentInRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentInRelatedPartyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentInRelatedPartyTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN RELATED PARTY",
        "label": "Investment In Related Party Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentinRelatedPartyDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentinRelatedPartyDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Related Party (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Related Party (Details) - Schedule of Investment in Related Party [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentinRelatedPartyDetailsScheduleofInvestmentinRelatedPartyTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Related Party (Details) - Schedule of Investment in Related Party [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentinRelatedPartyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentinRelatedPartyDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Related Party (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_InvestmentsInRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "InvestmentsInRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in related party",
        "documentation": "Reprersent the amount of investment in related party.",
        "label": "Investments In Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_IssuanceOfShareCapital": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "IssuanceOfShareCapital",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital, issued",
        "label": "Issuance Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share capital",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Called up share capital (103,087,744 shares are issued and outstanding; 2022: 102,272,614)",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tlsa_JBrancaccioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "JBrancaccioMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable",
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "J Brancaccio [Member]",
        "verboseLabel": "J. Brancaccio [Member]",
        "label": "JBrancaccio Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_KShailubhaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "KShailubhaiMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "K. Shailubhai [Member]",
        "label": "KShailubhai Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over 5 years [Member]",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r98",
      "r149",
      "r150",
      "r152"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1-2 years [Member]",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r98",
      "r149",
      "r152",
      "r168"
     ]
    },
    "tlsa_LaterThanTwoYearsAndNotLaterThanFiveYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2-5 years [Member]",
        "label": "Later Than Two Years And Not Later Than Five Year Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "tlsa_LeaseLiabilitiesBeginning": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeaseLiabilitiesBeginning",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At 1 January",
        "label": "Lease Liabilities Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeaseLiabilitiesInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeaseLiabilitiesInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Lease Liabilities Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeaseLiabilitiesLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeaseLiabilitiesLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments",
        "label": "Lease Liabilities Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeaseLiabilitiesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeaseLiabilitiesTotal",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities",
        "label": "Lease Liabilities Total"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments",
        "documentation": "Amount of lease payments.",
        "label": "Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeasesDetailsScheduleofFutureMinimumLeasePaymentsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of Future Minimum Lease Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LeasesDetailsScheduleofFutureMinimumLeasePaymentsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of Future Minimum Lease Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LessThanThreeMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LessThanThreeMonthMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 3 months [Member]",
        "label": "Less Than Three Month Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r80",
      "r81",
      "r124",
      "r127"
     ]
    },
    "tlsa_Licensefee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "Licensefee",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee",
        "documentation": "Amount of License fee.",
        "label": "Licensefee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tizianalifesciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossOnDisposalOfAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossOnDisposalOfAsset",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of asset",
        "documentation": "Loss on disposal of asset.",
        "label": "Loss On Disposal Of Asset"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareDetailsScheduleofBasicLossPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareDetailsScheduleofBasicLossPerShareLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareDetailsScheduleofBasicLossPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareDetailsScheduleofBasicLossPerShareTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share (Details) - Schedule of Basic Loss Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareTable",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareTablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share [Abstract]",
        "label": "Loss Per Share Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_LossPerShareTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "LossPerShareTablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r90",
      "r91",
      "r94",
      "r95",
      "r97",
      "r98",
      "r113",
      "r119",
      "r141",
      "r149"
     ]
    },
    "tlsa_MaximumPercentageOfSurrenderableLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MaximumPercentageOfSurrenderableLosses",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surrenderable losses percentage",
        "documentation": "Maximum percentage of surrenderable losses.",
        "label": "Maximum Percentage Of Surrenderable Losses"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveAtJanuary12021Per20FAnnualReport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveAtJanuary12021Per20FAnnualReport",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve At January 1 2021 per 20-F annual report",
        "documentation": "Merger Reserve At January 1 2021 per 20-F annual report.",
        "label": "Merger Reserve At January12021 Per20 FAnnual Report"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveConversionOfLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveConversionOfLoan",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Conversion of Loan",
        "documentation": "Merger Reserve Conversion of Loan.",
        "label": "Merger Reserve Conversion Of Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveConversionOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveConversionOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Conversion of warrants",
        "documentation": "Merger Reserve Conversion of warrants.",
        "label": "Merger Reserve Conversion Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveEliminationOfShareCapitalIn": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveEliminationOfShareCapitalIn",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc",
        "documentation": "Merger Reserve Elimination of share capital in Tiziana Life Sciences Plc.",
        "label": "Merger Reserve Elimination Of Share Capital In"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveEnding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveEnding",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve At 31 December 2021",
        "label": "Merger Reserve Ending"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveIssuedInLieuOfCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveIssuedInLieuOfCashBonus",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Issued in lieu of cash bonus",
        "documentation": "Merger Reserve Issued in lieu of cash bonus.",
        "label": "Merger Reserve Issued In Lieu Of Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveRestated",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Restated at 1 January 2021",
        "documentation": "Merger Reserve Restated.",
        "label": "Merger Reserve Restated"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve Shares issued pursuant to share for share exchange and consolidation",
        "documentation": "Merger Reserve Shares issued pursuant to share for share exchange and consolidation.",
        "label": "Merger Reserve Shares Issued Pursuant To Share For Share Exchange And Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MilestonePaymentDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MilestonePaymentDue",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment due",
        "documentation": "Milestone payment due.",
        "label": "Milestone Payment Due"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MovementInUnrecognisedDeferredTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MovementInUnrecognisedDeferredTax",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in unrecognized deferred tax",
        "documentation": "The amount of movement in unrecognised deferred tax.",
        "label": "Movement In Unrecognised Deferred Tax"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MovementPercentageStrengthening": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MovementPercentageStrengthening",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement percentage Strengthening",
        "documentation": "Movement percentage strengthening.",
        "label": "Movement Percentage Strengthening"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_MovementPercentageWeakening": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "MovementPercentageWeakening",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement percentage Weakening",
        "documentation": "Movement percentage weakening.",
        "label": "Movement Percentage Weakening"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NASDAQStockExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NASDAQStockExchangeMember",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ Stock Exchange [Member]",
        "label": "NASDAQStock Exchange Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinanceCostsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss",
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity.",
        "label": "Net Finance Expense Recognized In Statement Of Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NetIncreaseInRelatedPartyPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NetIncreaseInRelatedPartyPayables",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net (decrease)/increase in related party payables",
        "documentation": "Net increase in related party payables.",
        "label": "Net Increase In Related Party Payables"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NetIncreaseInRelatedPartyReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NetIncreaseInRelatedPartyReceivables",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net (increase) in related party receivables",
        "documentation": "Net increase in related party receivables.",
        "label": "Net Increase In Related Party Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NetPresentValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NetPresentValues",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Present Values",
        "documentation": "Amount of net present values.",
        "label": "Net Present Values"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueAnnualReport": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueAnnualReport",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value At January 1 2021 per 20-F annual report (in Pounds per share)",
        "documentation": "Nominal Value annual report.",
        "label": "Nominal Value Annual Report"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueConversionOfLoan": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueConversionOfLoan",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Conversion of Loan (in Dollars per share)",
        "documentation": "Nominal Value Conversion of Loan.",
        "label": "Nominal Value Conversion Of Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueConversionOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueConversionOfWarrants",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Conversion of warrants (in Dollars per share)",
        "documentation": "Nominal Value Conversion of warrants.",
        "label": "Nominal Value Conversion Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueEliminationOfShareCapital": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueEliminationOfShareCapital",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Elimination of share capital in Tiziana Life Sciences Plc (in Pounds per share)",
        "documentation": "Nominal Value Elimination of share capital in Tiziana Life Sciences Plc.",
        "label": "Nominal Value Elimination Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueIssuanceOfStockATM": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueIssuanceOfStockATM",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Issuance of Stock - ATM (in Dollars per share)",
        "documentation": "Nominal value issuance of stock - ATM.",
        "label": "Nominal Value Issuance Of Stock ATM"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueIssuedInLieuOfCashBonus": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueIssuedInLieuOfCashBonus",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Issued in lieu of cash bonus (in Dollars per share)",
        "documentation": "Nominal Value Issued in lieu of cash bonus.",
        "label": "Nominal Value Issued In Lieu Of Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueRestated": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueRestated",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Restated at 1 January 2021 (in Dollars per share)",
        "documentation": "Nominal Value Restated",
        "label": "Nominal Value Restated"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueSharesIssuedInLieuOfFees": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueSharesIssuedInLieuOfFees",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Shares issued in lieu of fees (in Dollars per share)",
        "documentation": "Nominal value shares issued in lieu of fees.",
        "label": "Nominal Value Shares Issued In Lieu Of Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Shares issued pursuant to share for share exchange and consolidation (in Dollars per share)",
        "documentation": "Nominal Value Shares issued pursuant to share for share exchange and consolidation.",
        "label": "Nominal Value Shares Issued Pursuant To Share For Share Exchange And Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NominalValueWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NominalValueWarrantsExercised",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal Value Warrants Exercised (in Dollars per share)",
        "documentation": "Nominal value warrants exercised.",
        "label": "Nominal Value Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r144"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non \u2013 Current Assets:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income (see note 19)",
        "label": "Non-current financial assets at fair value through profit or loss, measured as such in accordance with exemption for reacquisition of own equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through profit or loss measured as such in accordance with the exemption for reacquisition of own equity instruments. [Refer: Financial assets at fair value through profit or loss, measured as such in accordance with exemption for reacquisition of own equity instruments]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liability (Non-Current)",
        "verboseLabel": "Non-current",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year [Member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r90",
      "r91",
      "r98",
      "r149",
      "r152"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense)/ Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberAndAverageNumberOfEmployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberAndAverageNumberOfEmployeesAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The average monthly number of employees, including directors, employed by the group during the year was:",
        "label": "Number and average number of employees [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfSegment",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number Of Segment"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfShareOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfShareOptionsExercisable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable",
        "label": "Number Of Share Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfShareOptionsForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfShareOptionsForfeited",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited/Cancelled",
        "label": "Number Of Share Options Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfShareOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfShareOptionsGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted",
        "label": "Number Of Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfShareOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfShareOptionsOutstanding",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding beginning",
        "periodEndLabel": "Options, Outstanding ending",
        "label": "Number Of Share Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_NumberOfShareOptionsWereGrantedToDirectors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfShareOptionsWereGrantedToDirectors",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options",
        "documentation": "Number of share options were granted to directors.",
        "label": "Number Of Share Options Were Granted To Directors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "tlsa_NumberOfSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberOfSharesIssued1",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Number Of Shares Issued1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fully paid",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "tlsa_NumberofOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "NumberofOptionsExercised",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised",
        "label": "Numberof Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OKYOPharmaLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OKYOPharmaLtdMember",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails",
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails",
      "http://tizianalifesciences.com/role/ScheduleofInvestmentinRelatedPartyTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OKYO Pharma Ltd [Member]",
        "label": "OKYOPharma Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "tlsa_OperatingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingExpenseAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses",
        "label": "Operating Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLoss",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realization bonus",
        "documentation": "Amount of operating loss.",
        "label": "Operating Loss"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss [Abstract]",
        "label": "Operating Loss Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossDetailsScheduleofOperatingLossesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossDetailsScheduleofOperatingLossesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Losses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossDetailsScheduleofOperatingLossesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossDetailsScheduleofOperatingLossesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss (Details) - Schedule of Operating Losses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossTable",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossTablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss [Abstract]",
        "label": "Operating Loss Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OperatingLossTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OperatingLossTablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionLifeShareOptionsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionLifeShareOptionsGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option life",
        "documentation": "The option life of share options granted.",
        "label": "Option Life Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsExercisable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable",
        "label": "Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsExercised",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Exercised",
        "label": "Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsForfeitedCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsForfeitedCancelled",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited/Cancelled",
        "label": "Options Forfeited Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsForfeitedDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsForfeitedDuringTheYear",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited during the year",
        "documentation": "Options forfeited during the year.",
        "label": "Options Forfeited During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsForfeitedcancelled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsForfeitedcancelled",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited/cancelled in the year",
        "label": "Options Forfeitedcancelled"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted",
        "label": "Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OptionsOutstanding",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding beginning",
        "periodEndLabel": "Options, Outstanding ending",
        "label": "Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/(Loss) on currency translation",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r25"
     ]
    },
    "tlsa_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation",
        "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_OtherExpenseByFunction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherExpenseByFunction",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating expenses",
        "label": "Other expense, by function"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r43",
      "r133"
     ]
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income/(expense)",
        "label": "Other gains (losses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166"
     ]
    },
    "tlsa_OtherIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherIncomeExpenseAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(expense):",
        "label": "Other Income Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OtherIncomelosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherIncomelosses",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other income/(expense)",
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Incomelosses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLongtermBenefits",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realization bonus",
        "label": "Other long-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term employee benefits other than post-employment benefits and termination benefits. Such benefits may include long-term paid absences, jubilee or other long-service benefits, long-term disability benefits, long-term profit-sharing and bonuses and long-term deferred remuneration. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "tlsa_OtherLossBeforeTaxation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherLossBeforeTaxation",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before taxation",
        "label": "Other Loss Before Taxation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofConsolidatedStatementofFinancialTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(losses)",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Receivable",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherReceivablesDetailsScheduleofOtherReceivablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OtherReceivablesDetailsScheduleofOtherReceivablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherReceivablesDetailsScheduleofOtherReceivablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables (Details) - Schedule of Other Receivables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OtherReceivablesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherReceivablesTablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables [Abstract]",
        "label": "Other Receivables Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OtherReceivablesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherReceivablesTablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger relief reserve",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Reserve",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r20"
     ]
    },
    "tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OtherexpenseIncomeDetailsScheduleofOtherExpenseIncomeTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense)/ Income (Details) - Schedule of Other (Expense)/ Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OutstandingExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OutstandingExercised",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "documentation": "Representation amount of exercised.",
        "label": "Outstanding Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OutstandingExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OutstandingExpired",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedtheFairValueofWarrantsUsingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "documentation": "Representtion amount of expired.",
        "label": "Outstanding Expired"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_OutstandingFairValueCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "OutstandingFairValueCharges",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total outstanding fair value charge",
        "documentation": "Amount of Outstanding fair value charges.",
        "label": "Outstanding Fair Value Charges"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "tlsa_PayrollAndRentCharged": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PayrollAndRentCharged",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and rent charged",
        "label": "Payroll And Rent Charged"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "tlsa_Phase3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "Phase3Member",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 [Member]",
        "label": "Phase3 Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_PhaseIHumanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PhaseIHumanMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase I human [Member]",
        "label": "Phase IHuman Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_PhaseIIClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PhaseIIClinicalTrialMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase II [Member]",
        "label": "Phase IIClinical Trial Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_PhaseIIHumanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PhaseIIHumanMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase II human [Member]",
        "label": "Phase IIHuman Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_PhaseIIIHumanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PhaseIIIHumanMember",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase III human [Member]",
        "label": "Phase IIIHuman Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution pension schemes",
        "label": "Post-employment benefit expense, defined contribution plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "ifrs-full_OtherReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "tlsa_PrepaymentsandOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PrepaymentsandOtherReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments and other receivables",
        "documentation": "The amount of current prepayments and other receivables.",
        "label": "Prepaymentsand Other Receivables Current"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_PrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "documentation": "Repersentation amount of principal.",
        "label": "Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ProceedsFromFinanceLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ProceedsFromFinanceLease",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from finance lease",
        "documentation": "Proceeds from finance lease.",
        "label": "Proceeds From Finance Lease"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ProceedsFromIssuanceOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ProceedsFromIssuanceOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants",
        "documentation": "Proceeds from issuance of options.",
        "label": "Proceeds From Issuance Of Options"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ProceedsFromSaleAndCollectionOfFinanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ProceedsFromSaleAndCollectionOfFinanceReceivable",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from finance lease reclassified as an investing activity",
        "documentation": "The cash inflow associated with the sale or collection of receivables arising from the financing of goods and services.",
        "label": "Proceeds From Sale And Collection Of Finance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails",
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement",
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable",
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss for the year",
        "terseLabel": "Loss for Period",
        "verboseLabel": "(Loss) attributable to equity holders of the company ($000)",
        "netLabel": "Net loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r22",
      "r58",
      "r68",
      "r70",
      "r124",
      "r125",
      "r144",
      "r147"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow",
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before income taxes",
        "terseLabel": "Loss from operations before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r132",
      "r133",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r173"
     ]
    },
    "tlsa_ProfitOrLossAndEquityStrengthening": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ProfitOrLossAndEquityStrengthening",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss and equity, Strengthening",
        "documentation": "Representation amount of profit or loss and equity, strengthening.",
        "label": "Profit Or Loss And Equity Strengthening"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ProfitOrLossAndEquityWeakening": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ProfitOrLossAndEquityWeakening",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss and equity, Weakening",
        "documentation": "Representation amount of profit or loss and equity, weakening.",
        "label": "Profit Or Loss And Equity Weakening"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of interest",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r71"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of PPE",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "tlsa_PurchaseOfTreasuryAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "PurchaseOfTreasuryAmount",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of Treasury Shares",
        "label": "Purchase Of Treasury Amount"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RaisingFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RaisingFunds",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/OperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raising funds",
        "documentation": "Raising funds.",
        "label": "Raising Funds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r97",
      "r108",
      "r145",
      "r146",
      "r180"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r97",
      "r108",
      "r145",
      "r146",
      "r180"
     ]
    },
    "tlsa_RasnaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RasnaTherapeuticsIncMember",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rasna Therapeutics Inc [Member]",
        "label": "Rasna Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RealisationBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RealisationBonus",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realization bonus",
        "documentation": "Realisation bonus.",
        "label": "Realisation Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RecruitmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RecruitmentFees",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recruitment fees",
        "documentation": "The amount of recruitment fees.",
        "label": "Recruitment Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RelatedPartyAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party [Axis]",
        "label": "Related Party Axis"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RelatedPartyDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RelatedPartyDomainDomain",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RelatedPartyDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RelatedPartyPayablesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RelatedPartyPayablesAmount",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party payables",
        "label": "Related Party Payables Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RelatedPartyTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remuneration of Key Management Personnel [Abstract]",
        "label": "Remunerationof Key Management Personnel Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Remuneration of Key Management Personnel [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsScheduleofRemunerationofKeyManagementPersonnelTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel (Details) - Schedule of Remuneration of Key Management Personnel [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Options were Granted to Directors [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsScheduleofShareOptionswereGrantedtoDirectorsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel (Details) - Schedule of Share Options were Granted to Directors [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelTable",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnel"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelTablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remuneration of Key Management Personnel [Abstract]",
        "label": "Remunerationof Key Management Personnel Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RemunerationofKeyManagementPersonnelTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RemunerationofKeyManagementPersonnelTablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/RemunerationofKeyManagementPersonnelTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration of Key Management Personnel (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RepaymentOfLeasingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RepaymentOfLeasingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of leasing liabilities",
        "documentation": "Repayment of leasing liabilities.",
        "label": "Repayment Of Leasing Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "tlsa_AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "documentation": "The amount of research and development.",
        "label": "Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and Development",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment reserve \u2013 Options",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Payment Reserve (Options)",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r134"
     ]
    },
    "tlsa_RightOfUseAssetBeginning": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RightOfUseAssetBeginning",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At 1 January",
        "label": "Right Of Use Asset Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RightOfUseAssetDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RightOfUseAssetDescription",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset",
        "label": "Right Of Use Asset Description"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RightOfUseAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RightOfUseAssetMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEstimatedUsefulLivesfortheCurrentPeriodandtheComparativePeriodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset [Member]",
        "label": "Right Of Use Asset Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RightOfUseAssetsDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RightOfUseAssetsDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Right Of Use Assets Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_RightOfUseAssetsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "RightOfUseAssetsTotal",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRightofUseAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right Of Use Assets Total"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r89"
     ]
    },
    "tlsa_Salary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "Salary",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary",
        "documentation": "The amount of salary.",
        "label": "Salary"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfAllOtherVariablesRemainConstantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfAllOtherVariablesRemainConstantAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of All Other Variables Remain Constant Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfBasicLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfBasicLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Basic Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfConsolidatedStatementOfFinancialAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfConsolidatedStatementOfFinancialAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Statement Of Financial [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEmployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEmployeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employees Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEquityIncentivePlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEquityIncentivePlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Incentive Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEquityIncentivePlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEquityIncentivePlanTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Incentive Plan",
        "label": "Schedule Of Equity Incentive Plan Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEstimatedTheFairValueOfWarrantsUsingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated the Fair Value of Warrants Using [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated the Fair Value of Warrants Using",
        "documentation": "The disclosure of estimated the fair value of warrants using.",
        "label": "Schedule Of Estimated The Fair Value Of Warrants Using Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives For The Current Period And The Comparative Period Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfFinanceCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfFinanceCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Finance Costs Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Liabilities Based on Contractual Undiscounted Payments",
        "label": "Schedule Of Financial Liabilities Based On Contractual Undiscounted Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfFutureMinimumLeasePaymentsAbstarct": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfFutureMinimumLeasePaymentsAbstarct",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Payments [Abstarct]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfInvestmentInRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfInvestmentInRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment in Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of All Other Variables Remain Constant",
        "label": "Schedule Of Measurement Of The Financial Instruments Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model",
        "label": "Schedule Of Model Inputs For Options Granted Under The Black Scholes Valuation Model Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfOperatingLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfOperatingLossesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Losses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfOtherExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfOtherExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Expense Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Receivables Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Options Expiry Dates and Exercise Price",
        "label": "Schedule Of Outstanding Fair Value Charge Of The Share Option Instruments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfRemunerationOfKeyManagementPersonnelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfRemunerationOfKeyManagementPersonnelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Remuneration Of Key Management Personnel Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfRightofUseAssetsAndLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of-Use Assets and Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfShareCapitalArisingOnTheShareForShareExchangeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital Arising on the Share for Share Exchange [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfShareOptionPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfShareOptionPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Option Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfShareOptionsExpiryDatesAndExercisePriceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Options Expiry Dates and Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfShareOptionsWereGrantedToDirectorsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfShareOptionsWereGrantedToDirectorsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Options Were Granted To Directors Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfTradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfTradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ScheduleOfTradeAndOtherPayablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ScheduleOfTradeAndOtherPayablesTableTextBlock",
     "presentation": [
      "http://tizianalifesciences.com/role/TradeandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Payables",
        "label": "Schedule Of Trade And Other Payables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SecurityDepositsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SecurityDepositsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "ifrs-full_OtherReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits receivable",
        "documentation": "Security deposits receivable.",
        "label": "Security Deposits Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SegmentalReportingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SegmentalReportingLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/SegmentalReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segmental Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SegmentalReportingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SegmentalReportingTable",
     "presentation": [
      "http://tizianalifesciences.com/role/SegmentalReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segmental Reporting [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable",
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable",
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable",
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r83",
      "r124",
      "r140",
      "r148"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable",
      "http://tizianalifesciences.com/role/ScheduleofOperatingLossesTable",
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable",
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r83",
      "r128",
      "r140",
      "r148"
     ]
    },
    "tlsa_ServicesAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ServicesAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services agreement amount",
        "documentation": "The amount of services agreement Amount.",
        "label": "Services Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service total costs",
        "label": "Services expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "tlsa_ShareBasedPaymentReserveWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentReserveWarrants",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment reserve \u2013 warrants",
        "label": "Share Based Payment Reserve Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentReserveWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentReserveWarrantsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Payment Reserve (warrants)",
        "label": "Share Based Payment Reserve Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentoptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentoptions",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment charge (options)",
        "documentation": "Amount of Share based payment options.",
        "label": "Share Based Paymentoptions"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPayments",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payments",
        "label": "Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) - Schedule of Model Inputs for Options Granted Under the Black Scholes Valuation Model [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsScheduleofShareOptionsExpiryDatesandExercisePriceTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) - Schedule of Share Options Expiry Dates and Exercise Price [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareBasedPaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareBasedPaymentsDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalConversionOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalConversionOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Conversion of warrants",
        "documentation": "Share Capital Conversion of warrants.",
        "label": "Share Capital Conversion Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalOutstanding",
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital, outstanding",
        "label": "Share Capital Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalShares",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares At 31 December 2021 (in Shares)",
        "documentation": "Share Capital Shares.",
        "label": "Share Capital Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesAnnualReport": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesAnnualReport",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares At January 1 2021 per 20-F annual report (in Shares)",
        "documentation": "Share Capital Shares annual report.",
        "label": "Share Capital Shares Annual Report"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesConversionOfLoan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesConversionOfLoan",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Conversion of Loan (in Shares)",
        "documentation": "Share Capital Shares Conversion of Loan.",
        "label": "Share Capital Shares Conversion Of Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesConversionOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesConversionOfWarrants",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Conversion of warrants (in Shares)",
        "documentation": "Share Capital Shares Conversion of warrants.",
        "label": "Share Capital Shares Conversion Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesEliminationOfShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesEliminationOfShare",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc (in Shares)",
        "documentation": "Share Capital Shares Elimination of share capital in Tiziana Life Sciences Plc.",
        "label": "Share Capital Shares Elimination Of Share"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesIssuanceOfStockATM": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesIssuanceOfStockATM",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Issuance of Stock - ATM (in Shares)",
        "documentation": "Number of share capital shares issuance of stock - ATM.",
        "label": "Share Capital Shares Issuance Of Stock ATM"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesIssuedInLieuOfCashBonus": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesIssuedInLieuOfCashBonus",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Issued in lieu of cash bonus (in Shares)",
        "documentation": "Share Capital Shares Issued in lieu of cash bonus.",
        "label": "Share Capital Shares Issued In Lieu Of Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesIssuedInLieuOfFees": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesIssuedInLieuOfFees",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Shares issued in lieu of fees (in Shares)",
        "documentation": "Number of share capital shares issued in lieu of fees.",
        "label": "Share Capital Shares Issued In Lieu Of Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesRestated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesRestated",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Restated at 1 January 2021 (in Shares)",
        "documentation": "Share Capital Shares Restated.",
        "label": "Share Capital Shares Restated"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Shares issued pursuant to share for share exchange and consolidation (in Shares)",
        "documentation": "Share Capital Shares Shares issued pursuant to share for share exchange and consolidation.",
        "label": "Share Capital Shares Shares Issued Pursuant For Share Exchange And Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalSharesWarrantsExercised",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital Shares Warrants Exercised (in Shares)",
        "documentation": "Number of share capital shares warrants exercised.",
        "label": "Share Capital Shares Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueAnnualReport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueAnnualReport",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value At January 1 2021 per 20-F annual report",
        "documentation": "Share Capital value annual report.",
        "label": "Share Capital Value Annual Report"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueAt31December2021": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueAt31December2021",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value At 31 December 2021",
        "documentation": "Share Capital value At 31 December 2021.",
        "label": "Share Capital Value At31 December2021"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueConversionOfLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueConversionOfLoan",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Conversion of Loan",
        "documentation": "Share Capital value Conversion of Loan.",
        "label": "Share Capital Value Conversion Of Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueEliminationOfShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueEliminationOfShareCapital",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Elimination of share capital in Tiziana Life Sciences Plc",
        "documentation": "Share Capital value Elimination of share capital in Tiziana Life Sciences Plc.",
        "label": "Share Capital Value Elimination Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueIssuanceOfStockATM": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueIssuanceOfStockATM",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Issuance of Stock - ATM",
        "documentation": "Representation amount of share capital value issuance of stock - ATM.",
        "label": "Share Capital Value Issuance Of Stock ATM"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueIssuedInCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueIssuedInCashBonus",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Issued in lieu of cash bonus",
        "documentation": "Share Capital value Issued in lieu of cash bonus.",
        "label": "Share Capital Value Issued In Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueRestated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueRestated",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Restated at 1 January 2021",
        "documentation": "Share Capital value Restated.",
        "label": "Share Capital Value Restated"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueSharesIssuedInLieuOfFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueSharesIssuedInLieuOfFees",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Shares issued in lieu of fees",
        "documentation": "Representation amount of share capital value shares issued in lieu of fees.",
        "label": "Share Capital Value Shares Issued In Lieu Of Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Shares issued pursuant to share for share exchange and consolidation",
        "documentation": "Share Capital value Shares issued pursuant to share for share exchange and consolidation.",
        "label": "Share Capital Value Shares Issued Pursuant To Share Exchange And Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalValueWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital value Warrants Exercised",
        "documentation": "Representation amount of share capital value warrants exercised.",
        "label": "Share Capital Value Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalandSharePremiumDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalandSharePremiumDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital and Share Premium [Abstract]",
        "label": "Share Capitaland Share Premium Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareCapitalandSharePremiumDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareCapitalandSharePremiumDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Share Premium (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails",
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Stock",
        "verboseLabel": "Related party cost",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "tlsa_ShareOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareOptionMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Option [Member]",
        "label": "Share Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShareOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShareOptions",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ShareOptions",
        "documentation": "Number of share options.",
        "label": "Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "tlsa_SharePremiumAnnualReport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumAnnualReport",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium At January 1 2021 per 20-F annual report",
        "documentation": "Share Premium annual report.",
        "label": "Share Premium Annual Report"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumConversionOfLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumConversionOfLoan",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Conversion of Loan",
        "documentation": "Share Premium Conversion of Loan.",
        "label": "Share Premium Conversion Of Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumConversionOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumConversionOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Conversion of warrants",
        "documentation": "Share Premium Conversion of warrants.",
        "label": "Share Premium Conversion Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumEliminationOfShareCapitalIn": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumEliminationOfShareCapitalIn",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Elimination of share capital in Tiziana Life Sciences Plc",
        "documentation": "Share Premium Elimination of share capital in Tiziana Life Sciences Plc.",
        "label": "Share Premium Elimination Of Share Capital In"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumEnding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumEnding",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium At 31 December 2021",
        "label": "Share Premium Ending"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumIssuanceOfStockATM": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumIssuanceOfStockATM",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Issuance of Stock - ATM",
        "documentation": "Representation amount of share ppremium issuance of stock - ATM.",
        "label": "Share Premium Issuance Of Stock ATM"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumIssuedInCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumIssuedInCashBonus",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Issued in lieu of cash bonus",
        "documentation": "Share Premium Issued in lieu of cash bonus.",
        "label": "Share Premium Issued In Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tlsa_SharePremiumRestatedAt1January2021": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumRestatedAt1January2021",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Restated at 1 January 2021",
        "documentation": "Share Premium Restated at 1 January 2021.",
        "label": "Share Premium Restated At1 January2021"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumSharesIssuedInLieuOfFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumSharesIssuedInLieuOfFees",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Shares issued in lieu of fees",
        "documentation": "Representation amount of share premium shares issued in lieu of fees.",
        "label": "Share Premium Shares Issued In Lieu Of Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Shares issued pursuant to share for share exchange and consolidation",
        "documentation": "Share Premium Shares issued pursuant to share for share exchange and consolidation.",
        "label": "Share Premium Shares Issued Pursuant To Share For Share Exchange And Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharePremiumWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharePremiumWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareCapitalArisingontheShareforShareExchangeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium Warrants Exercised",
        "documentation": "Representation amount of share premium warrants exercised.",
        "label": "Share Premium Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesIssuedInLieuOfCashRealizationBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesIssuedInLieuOfCashRealizationBonus",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in lieu of cash realization bonus",
        "documentation": "Shares issued in lieu of cash realization bonus.",
        "label": "Shares Issued In Lieu Of Cash Realization Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesIssuedInLieuOfFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesIssuedInLieuOfFees",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in lieu of directors fees",
        "documentation": "Shares issued in lieu of fees.",
        "label": "Shares Issued In Lieu Of Fees"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesPrice",
     "presentation": [
      "http://tizianalifesciences.com/role/InvestmentinRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Shares Price"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesPurchases": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesPurchases",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares purchases",
        "label": "Shares Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares to be issued in lieu of directors fees and cash bonus",
        "documentation": "Shares to be issued in lieu of directors fees and cash bonus.",
        "label": "Shares To Be Issued In Lieu Of Directors Fees And Cash Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesToBeIssuedReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesToBeIssuedReserve",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares to be issued reserve",
        "documentation": "Shares to be issued reserve.",
        "label": "Shares To Be Issued Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SharesToBeIssuedReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SharesToBeIssuedReserveMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares to be issued Reserve",
        "label": "Shares To Be Issued Reserve Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ShortTermLoanFacility1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ShortTermLoanFacility1",
     "presentation": [
      "http://tizianalifesciences.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term loan facility",
        "documentation": "Short term loan facility.",
        "label": "Short Term Loan Facility1"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SixMayTwoThousandAndTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SixMayTwoThousandAndTwentyMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6 May 2020 [Member]",
        "label": "Six May Two Thousand And Twenty Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SocialSecurityContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SocialSecurityContributions",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security costs",
        "label": "Social security contributions"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "tlsa_StaffCostsComprisedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "StaffCostsComprisedAbstract",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Staff costs comprised:",
        "label": "Staff Costs Comprised Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_SublicenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "SublicenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofOtherExpenseIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense income",
        "documentation": "Sublicense Income means consideration in any form received by Company and/or Company's Affiliate(s) in connection with or otherwise attributable to a grant of a sublicense.",
        "label": "Sublicense Income"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TAdamsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TAdamsMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable",
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "T Adams [Member]",
        "label": "TAdams Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Tax effect of tax losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_TaxRateEffectOfTaxLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfTaxLosses",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTaxationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard rate of corporation tax",
        "label": "Tax rate effect of tax losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "tlsa_TaxationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TaxationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TaxationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TaxationDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Income Tax Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TaxationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TaxationDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TaxationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TaxationReceivable",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "ifrs-full_OtherReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxation receivable",
        "verboseLabel": "Taxation Receivable",
        "documentation": "Taxation receivable.",
        "label": "Taxation Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TermOfResearchAndDevelopmentTaxReliefClaims": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TermOfResearchAndDevelopmentTaxReliefClaims",
     "presentation": [
      "http://tizianalifesciences.com/role/TaxationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of R&amp;D tax relief claims",
        "documentation": "Term of research and development tax relief claims.",
        "label": "Term Of Research And Development Tax Relief Claims"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ThirtyAprilTwoThousandAndEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ThirtyAprilTwoThousandAndEighteenMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "30 April 2018 [Member]",
        "label": "Thirty April Two Thousand And Eighteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ThreeToTwelveMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ThreeToTwelveMonthMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3 to 12 months [Member]",
        "label": "Three To Twelve Month Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TizianaLifeSciencesPLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TizianaLifeSciencesPLCMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiziana Life Sciences PLC [Member]",
        "label": "Tiziana Life Sciences PLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r97",
      "r108",
      "r145",
      "r146",
      "r180"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "tlsa_TradeandOtherPayablesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TradeandOtherPayablesTablesLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/TradeandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Payables [Abstract]",
        "label": "Tradeand Other Payables Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TradeandOtherPayablesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TradeandOtherPayablesTablesTable",
     "presentation": [
      "http://tizianalifesciences.com/role/TradeandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Payables (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TranslationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TranslationReserveMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation Reserve",
        "label": "Translation Reserve Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ConsolidatedBalanceSheet",
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury shares",
        "terseLabel": "Total shares (in Dollars)",
        "label": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r136"
     ]
    },
    "tlsa_TreasuryShares1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TreasuryShares1",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury Shares1"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TreasurySharesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TreasurySharesDetailsLineItems",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TreasurySharesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TreasurySharesDetailsTable",
     "presentation": [
      "http://tizianalifesciences.com/role/TreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tlsa_TwentyFiveAugustTwoThousandAndTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TwentyFiveAugustTwoThousandAndTwentyMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "25 August 2020 [Member]",
        "label": "Twenty Five August Two Thousand And Twenty Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TwentySixJulyTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TwentySixJulyTwoThousandTwentyThreeMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "26 July 2023 [Member]",
        "label": "Twenty Six July Two Thousand Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TwentySixJuneTwoThousandFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TwentySixJuneTwoThousandFourteenMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "26 June 2014 [Member]",
        "label": "Twenty Six June Two Thousand Fourteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_TwentyThreeJulyTwoThousandAndTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "TwentyThreeJulyTwoThousandAndTwentyMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "23 July 2020 [Member]",
        "label": "Twenty Three July Two Thousand And Twenty Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_USDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "USDMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable",
      "http://tizianalifesciences.com/role/ScheduleofAllOtherVariablesRemainConstantTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "USDMember"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://tizianalifesciences.com/role/AccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "documentation": "Upfront payment.",
        "label": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WSimonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WSimonMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionswereGrantedtoDirectorsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "W.Simon [Member]",
        "label": "WSimon Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEmployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees\u2019 wages, salaries and bonus",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "tlsa_WarrantsExercisedInTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WarrantsExercisedInTheYear",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Exercised in the year",
        "documentation": "Warrants exercised in the year.",
        "label": "Warrants Exercised In The Year"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WarrantsForfeitedInTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WarrantsForfeitedInTheYear",
     "crdr": "credit",
     "presentation": [
      "http://tizianalifesciences.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Forfeited in the year",
        "documentation": "Warrants forfeited in the year.",
        "label": "Warrants Forfeited In The Year"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price, Exercisable",
        "label": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WeightedAverageExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WeightedAverageExercisePriceExercised",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average exercise price, Exercised",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WeightedAverageExercisePriceForfeitedCancelled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WeightedAverageExercisePriceForfeitedCancelled",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price, Forfeited/Cancelled",
        "label": "Weighted Average Exercise Price Forfeited Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_WeightedAverageExercisePriceGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WeightedAverageExercisePriceGranted",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price, Granted",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price (cents), Exercisable",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price (cents), Exercised",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average exercise price (cents), Forfeited/Cancelled",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average exercise price (cents), Granted",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofEquityIncentivePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average exercise price (cents), Outstanding beginning",
        "periodEndLabel": "Weighted Average exercise price (cents), Outstanding ending",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104"
     ]
    },
    "tlsa_WeightedAverageExercisePriceOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WeightedAverageExercisePriceOutstanding",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average exercise price, Outstanding beginning",
        "periodEndLabel": "Weighted Average exercise price, Outstanding ending",
        "label": "Weighted Average Exercise Price Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price (in Dollars per share)",
        "label": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofModelInputsforOptionsGrantedUndertheBlackScholesValuationModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value per share option (in Dollars per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofBasicLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares in issue",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "tlsa_WillySimonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "WillySimonMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofRemunerationofKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Willy Simon [Member]",
        "label": "Willy Simon Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ZeroFourNovemberTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ZeroFourNovemberTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "04 November 2022 [Member]",
        "label": "Zero Four November Two Thousand And Twenty Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "tlsa_ZeroOneeAugustTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tizianalifesciences.com/20231231",
     "localname": "ZeroOneeAugustTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://tizianalifesciences.com/role/ScheduleofShareOptionsExpiryDatesandExercisePriceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "01 August 2022 [Member]",
        "label": "Zero Onee August Two Thousand And Twenty Two Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "9B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_9B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "110",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_110&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24G&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_d&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_e&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "158",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_158&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001213900-24-041808-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-041808-xbrl.zip
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M!0DS7T5_>Z&^7V[V=U_O[+]X#SKGAY]>U1[UOCL)3V-2<!+.3GXY/;\X.[P
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M/RAO4YN]W@Z^M;?G.]JSPTA.C#L%. I^C=6S'6=9-<[R@]SCO]*X3 J1S3[
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MMISA^T\'6PU9N_IZZ-!;K.ZQ00I6[)2B_6B #RV208[H9NRT4Z2 @LC''H#
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MHZF.ICJ:NILAF0FLX*J*%VDTH9B"T15W--/13$<SFF9<(X@=K=KS@I*',O1
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MPV2R";"WP%/#&TY8;9=!V=#['.@,.?X[G)G" G.XM_S3Q(^QXLB$-G.8(Z&
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M%=C8 1/;'!$^-Q8PC=,8@<17GC;13G_]L#)F1==A+]@Y>-!\L-5<A_Y.L+M
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M(F]5[OX1>ODMQ4S1E:A"26[#7XZ^TL\J?=F5D*-2@4Y*#G]X-(<!R%-BTL)
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MB1I($8/=;%.!$"/P45_!4Z9I(;E08B 3.52=9Z0CM([0:H367CK$Y1(3='\
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MJ@( ZCO.05 'MM*6[Q(.OP:H3Z* RGDUQ&.4.NV1\%$6-=&B)3*(95;+>B7
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M/4_0;G/DN=4%=_&4XF.:T>6;W:;^84Y*-[I^ A/L)Q0A/*I5QEY=RCBRB'7
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MP4'H?!+8^, 3K *A"]]2NNN/L96)!K8_&7);-8H161>*Z\%J,@IMHD\H@D&
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MUUSP?ZW7:5J",XPY^SJWUAEX9-*AYB!J$"XROJSE(G4=H#J@U><(M ID0#G
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MN*!;_M<TM:!GCABAU'PS20_(W0IGF@)>;BXCL5GDH(Z!L5;/:"*<?;3\=""
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MB5M>%=3&9]HD1Q:@!:J@YM4FA=()!]32TQJP3+DR;;Y!!NKVW"-%JVK1#.J
MQP&NRA5Y(32$-"9X-G7C>@C#+U*J8ZL\'/#@H%7S<"JI&K '$XD[P=4Q]-)<
M@Y5I)>,NRC[K#:84#AUC; Q6CA<+3H",E7J[8'=U3IN;P)F2F<<A3A.OT<>4
MB_><%+B4,*?+A.LT=:J7@1U%FS-6NF<MNMU<Y<98KLW6Y+)>^T.YB;D LR#0
M\1ICQ6I2&,HK!EZ+,7:;PU,I'S<R5^9!90W#A&$QE.Y.@1_3355J(!G&K1Y
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M"0GYMN'-[,>OQ1:\]?W(X,)+AI4J;&_=3./=E7N];,+\3?/I=X2E*/9 C[O
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M9DB%A?&2NU+E C:M#Q4H&QF^3E V?)<;[JF+";PN,_N4-AL;.KGKA,'Z3AC
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M:<;N1,GQ@/4PHR5Y";7$CD%+:Z3X*_",*(7H2I2;%'PY=8_4JY<2'H<.?H?
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M8U>"DU1H;,,&U!W)GF22"5\AO;^Z9_KZX/::(@9OR[R15) '@"Z1<$I%*5M
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M>"S5T.BG\ /\KM;;IMUF_"7KT9AGDTRP?ZJ;LHK5$AWX3LO(7>'\VR]OR_T
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M 2X@2TUURL_H<)@41V2BP<-!%)R3.N&TC^45-(;B40'(V(G59#$?2:F*9J"
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MAE#B$@"]?+O(VZJDV/^'^-8"ZU;M#9?$51:79EX0ZW*,:0BD.#[9LH),.$\
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MZ0XS\L]F9^^+(^F!MD)(3C(#_M-ZH/KO"ATXSCNVHO0>A!!\HTJK7WWYZED
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M;< EP3CK<1CI_8&/OA/.$"T2YXIX.NGF!@0QD5XPJX(+<"Y2)2M>>FVP9%L
M.HYP.!S@#] X^NV@_BQ4I55-IHW=Z[J-XG=!JP2BR[8GFH4<R-&,#1_W&M5K
M8"])A2E $N8=)_4W3-05[*%2Q9Y3,"7P%-#[ $I''H.$AQ#0XR:4ND&[1ET=
M*:ZXA$((\F#*T^HS0 @'ST5"P ]4MJIC&#:DHNHV+<)8-I?Y8F!=E5=Y7<7
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M7G!.EL.+#4HEG><519XROSI?J !_* 3U: M!'4)0O]I"4.^D<-^B5V6H3\W
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MQNG76NK]^**95RNJ$;(/G&=2!TD:S>L8@J04Q2!1P0V,F*N&+):"B)(\B4R
M'&2T K G^O5HE&I?(H*;2F3X&E;33V(M@]'-L#1RQ:;8N?[ !Y9_U%]3>J[2
M6>I*4#*7#*EC^WY.B]MH+%9+N1V+'+XE714\W8F)NC.&W1 #B+X]E%W>PAO.
M['G1&K,TC%UOJ!GPA9N.K@:NAFN,+*001@/I48V7HR'1SE*QR\Z\#N*R6T5S
MQ3/F8C'UY!G7-)%2:WUE9)^$Q:&_=4*\W]*4G.!<'>P;>'),>@-/CF?:':')
M23X238[Y,)J<Y./0Y)A?19.3_-8T.>;7T>3THCM<K#S21AJB0J:"$L790X2
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M\^G"*UN9N$LRT6\UR#:Q7$KHNJRM#;GI(GTP;))(7'/7*.P"*9=/TU=ULJQ
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MI9'=4U+SY2ALP4-_C5,:"[(]0,DO*.UH;JPB8$AXTPK:E+HAS]:ADNV/MD4
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M?D5MI6DK34H/U3!OM\J2*"3$-\SX;4EI8%RG[+IINX3 ?_!WLP-&<,B-TY,
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M"33'LM<2IV7Y1*;5:2%WI/Y6IXLV :*\(Q71ZJB3G;]=???$ZN"NF*D2FU5
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MF?X2('3]^AXF^!O2FAR:0 '* ?U.FJZT0:0!B$,"HL#8ZOM"R/:'5]1$N4E
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M>+'UJ+CB,J>&..1]7U#F8&;O*:OC^'(DZ^#TY.W>NTE(*:HT\EY)]C0@[@-
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ME*I$]61ID4*OV]RF=" X29^69D&P]W#))$M59(_9'.%!7&7IE4>QXOA#R.%
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MMK=1N[FOLTJ)Q;L,A[+N!#59+\Q:M\>RR!E#X2<BJ3:[#"+S&JI02S_;IA!
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MX@SIJF6>4;-9P01D\OUB_N+)'XNQ3J+Y*U:_[*F8U<OH01MOHC3Z(Z+/SSK
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MTTGWMHY%&)8 /?6]=1XP_6TV3"Z0]']-*V<TCR$$3]M#>%*"QMO7)V=-HZG
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M_].CKEM9NA+O,3X/E..-KK(@O]!ZY/\>5,#::P@M4T10JR0@%_4AVIY,0A1
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MM5BV)V9^9'6V:DL;#U<^O6,(_$#=W_>@0)]ETY4,OSL'TT]WX17M[>!SRUP
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M5RX>=Z?!BG#\FP)&W&.6A=IG?VMK;W<O[.Z$QSC?O8E6U;IC!3<^5P_@0SP
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M T+SWUI A0@H3+7L3UF<@\LDOI(:'0YILX5?AL>:+2YF#, 2!<\"Q>(+KH<
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MR4(LPX(_XSIA&)>>:*!;P]EAFB;RTY/.&ZLMKTH[ 5DY_H0F-D:ZYN>=8MH
MR<,?/DY;DOU2@>XT!YZRHO>'1OOT:;JT0LYB[RNAPI97S9H45+\)6 C$**^Y
M?FW<6()B<)$%@VNBE523! (;B.OAWRW3@U!&,N5\-=JJY1N?G2<9&>*_<R>=
MQ)+PE $RP_ IC%&"^I$+ *+LD?V,F@GP.:>LD)(A$O2Q4)-ID@>?%=^R7CC
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MZE\C$&/R?5DZVC?^]*4!Z/[JNKX!F)IP,3I^SH"N-*QR%"36H*2 WDF+!,=
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M61-\ 0R'V768 =M,LRT!,H#!_&_*'2/2(J45JFBT5W:01UB1ELJM-RH*\9#
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M;+!Q&*;%)"!++$(T<XJH8WKF)Y"B;+@!'_W=CPLT#WK[W6,-.%=RJ8.3&%,
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MRQ@+U#$"N'DE<Q& A_L&Y*:E?79 8JA)ZL.:C@]>>3#+8*QV*[>2:)2FD2I
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MB"@^#S)K04PD1$%XI)DO.,/WYK[@8><)G(8E&__G+[V_//B</Q5D%X$XY5X
MIB,(_N1<<BNH^G):YWX7!/V*,0B;YT..9;_WUR;OY<D43L6;WS_O=7N'_MX^
M&,^B/NIK-8#TM_)0*U:2?O7DK^VT-Y+U?M_4ZSN:,_P%,H*;%Y,DS7[H"]W6
M9B7VUC9>.:V]@O7)\$[_>.Y$5@GS>B>2%7_.YH>>,2=^UF6">NI+\\%">[\L
M/-M'^AF3[:XBK#-S=V3"NW*2?X5?#R(_RZT_]G:7_=QM>]VRP4>]VQY:-RYI
M4R;<*0?Z=3FP&;O==I97M(7]_55MX8-LT,%J-\C]_]PK-0E"+)R+U1/8KN[1
M$S]QAS_#?XZZ^-_C[J;+VB^1*C ;AD7L1Y5A-@/)7T':P@5I"7PYGN'E2N"G
MX':@%*9<>C-6#G\FV4SKIS\2#58MH[L'CWK"YQB/=_%)=[_.&[=:H\M;:VUW
MR'.&GFNX+3^5);[ZV_DYW8S(K=B/?WMYIW,>ERTWDE8T#5M[#FL\ 8%6)<N#
M2*UV2J\$;OB20FH&!N\M ]NM]-.W<=,=KQKV:6B^>_>.N!V&^)ZQK(T(\UTD
M18J9/&^LZPB^/G/^(" T]ZNBNYY/2<<]\:R[)X)F0S@679;Y 4%!35S\RX?S
M5^Y[<TV<I.[K- G&1:H\]Q\JI=RP[@&/T7%-MT\7&\ ]+EUZFQ*"9:S83#!5
M,BOT[>#ME9V9.%"UDDC.A1P+%!=?EG':7&9NV,G^E+SECOLE#?%^*2FO14#4
MVN%V_*8N!$S2Z=B/G:&B,1G&A7,O&!70IPBQKKBFTG"I>KL+N=3=D;2_=V_.
M)$=OMSV9PUA*CK:4."O?]:\,(('.9<SKII:-R6/U$)?>YGQ_&(P1N9BU*2/W
MWB0E)I#>%-M6/:*"-?R-_.+8)J!L!Y*,JUTD3Z<M;9*64D)^"L+G1@;4UWXB
M) UH[$<CK,[ 9'TJP7)_!>4]M>[2_=INN3L5@W&7X)?-]@#KJ^_3"*LWF-Q>
M$VD5STUY;!B6&CC1G$M.S8)-C90I"L,;_22%$>-PL ?[&V942%I-M2IB!*T,
M>+<Q%TSE/K:Y!J9%NPZ_?86GAI)D3.)6IX.YB-P V^.2RFDRE;I4QTXRX(3=
M6!),U- Z&28EBF<R30AH*+F*#4@EO@>?Q<1 S-W&VEM37H9XUP'F$Q E^GN'
M+G4FESHWJNH$@\KAY!:K% A^1@!A:?AN 4PQ7B(!R6"1^OZ^.[GZ&1&44 @<
M4/*0"@J&PZ3R=2J(Y[N_ RXH#V8!0CA)?7L2_]R7?XU&SG?WWP?NS;=L5U(1
MS'5A[X KZWGB-<;!Z5=R,"2SH7LJHL(DPW/JB:!RIZ0[]1O1C-_ Q!F%-=9^
MH)_,*H_:"2"H'7%"E+NA2]_=JIPO<;> ;<JY:&BN55QF\G\[#:S^VY3JIF<.
M7(14+PT<#DQM8>2 T,A(L ]GF57VC2KDZVM3F[ C?U(99ZD':3CEM T0%5C?
M&& )2B U$)SJ3WQJB?U=2EV 7\!!X42N6DZ+P\*'WM:BA!&< _ ;?*PA*)46
M5ZU0S82G"RUE2::.!M?&B"B8:JHXJY[R*7TLI"HK8PU7P6>G> 8SO :68M<:
MZAD"=J>TZAE+5<GV:TOS-'%T//%[*@LD68KY@8'W*F*ZI=S/L4)R3;0]:S*9
M%7?#9@1($55BXI1"W1Z$8><XH1:E4G5QUJ<[3E779V5UZTP* H'05[!+H+W,
M#M!>8FZN3%<G@7#U)-<0_MKMO7%W$#8PFZ#TY7<P]\E8-+L>/-6'I^A@H4B.
M'-X=^DOO'SN"HI23'21_0*Z&/YZ[S;_^3VF'#RI)TE2.@KDR\9"RP02,2I5J
ML+9'G*UH[U%+NN4"*3!N.UA0^=G GV98CMPBKCD;QZE@ HU"XO;JPXF5#::Q
M3NZ=$78;-I#SA#+ [F4>+E(_TMW6CS3K1PZW]2,;&BQA X$ 1] U$RN $H/1
M#3GPN&J>>C=<)RA.)-L6_6\4YXA:4V"57D9Q%Y*?4@)(=8[-LLH*:)MQ.I/T
M"DM*.%T7XUM4C'B%@SL"->ZY \SG)=S2R(]C\N93/Z0<7Y"4B/K-[7D0!1*Q
M:62 .7F0:)Z.X @EA.DR3-PXR;5;,=-UQE;!"E6B^((Z1\_A"P)F3X8K&K_7
M*L::6LRQE"'HI8P^0F^!KX.5RCBQA-L?H';(.1W0@O5GYP63E-6P[-?CT!2P
MK#0%%8Z!JVP,-A99^6"(7HU+:2]@"#U/0Q]@\4&( 988K6H_LX:' 7_J=D\Z
MAQ-4/Q')9OPBS9T^A].M?M)S;$P>@OM(\Q#]O2CQL2Z"M(5+VH)^P\7*F'B_
M><)](PZ?.6Y@BE+MPU"S"'!RE&0$M_*9P/1S^MGU1X@&E?O??8,<^%/WN'-8
M[J)$FJ@+BV*$X1J#]#UXY[!ST/J.T_X.&QT_]8XZQY-%OM$E,YL1)"+L[$),
MU3(3857B3I(4^ _0&.B;HTW@$*=V>GJR+YZ-_E02LA#1"[Q2* Y[ @LY5A<L
M>@X=';-AJ% SI2A&([4/Y)#KJ IQIQ9C,,0PY%8BN8@:6[Q7Q'JE@@++:C"*
M(?XDP8T(3"@#KK)]B<W.%!C_OF[3QW'=F9' +3.A*&8)$1>.</+)@!Q'@J+.
MC?L'7R,1CB.*/&N.1_Q7DI-(:#<2:YFD(:H&-T*+60:NF/9>.2//8;E*/CA:
MP^& 0$&?)S.#&08.5ZH0N3O&,)VDC [6U#ICQ2O[G_ 70>&QN#[[GY_#7]:Y
M1)Z(7NBJODW?^:"NV(Y"TP&X.5OS.DLO_E&/R[MZ,T02'A-_Y@P484NE5$CH
M1J&N*W49\O=?6EA'?CBA<$R( VM #V-E!2"C.&BL#5_0FU$^)M'+D(T<:H4G
MK(^P(,:A,5Z"-BIUBR*@?7,3Q,&UG-$6RS++"HP,WTQ@#9[T3Y/P>M:<(Z,;
M"NQ_:4>;5G@.*!2%#W+4B! *0;*6Z_I* #Z10-41&?B;GKTT;.MH!?YI1&GL
M2.B=,/_ %[RNH1I1%T]NZ)?G$75-!6<BPZ8)0[QVT/%08 KP\4A9E8Y,B7<G
M\4ZRX+DY4&Z1S-II5"UZQ6Y4/R7/6+B_ SL"IB!4"68<,.:XYPN5#N]S-3$=
M/DSW*#Q.,5H/#MZ%$<MQPRG3)X-+5JG-B":F!HW7#4K R$OP\E?%UV&:Q,2W
M,'X)%89%>7B11ZX#%I+;0/ (32HC[W)[.;R!PE 262]FAFYMAM*$CM="M]Y#
M+ A*;519-JJL9G7Z2\^3]Y=1%JTGA%,5,@?IJX\,HVHD[IP]$P91WZ4+#>\P
MWOC['/W5]XVZYQ_?I94?PVP%GHL9@R+X9*>SCUG'1Z/(KQ&AU&?WMN5P(UW3
M7[@4!3@W]!'WT!2LK0#%<!(3F*V#Y><Y#Q.%?%N-@2,@*-XCZ:KRVAPHM)12
M^\/D2J.32!DL*2_#SR^>&2]M262?\V3D)*15_8P"?>$P1(F# 2NP%Q"YC&E<
MYU5;'&CT6FZ<ASPT\+/P9=5.6@62MQ12WE4[28F6<TJ4#DZFWQ<I9>H=X'.5
M1F*4-)C! >&UX"BG1\>GKTR?)&NT.]X\:S^H(H(T5$]YT@M;0AE)@**J8W]]
M@137"FW:Z'#7[Q[D&ZNBZQ?L;\(H]ASE"\#.1BU/1H703V>P-,ALA^/:Z5I)
M_UR50;8Q:8=O-6$T2"V9]RE='#BM>DHWUE:Y  -I&TOK'+*P"",23G=*8L[V
M&(Q:Q)OQM&#AJG,+)5=(#04F%Z% G?(SB.F)(M;_AA>R"<4^P9C;X;[A==UF
MA#>'X"=@"""(/-ZQL]K;=1F*6RR\E0:9UNERG.MN;T1#C(E_+;WAS^9>Y7E%
MF>AR:?6AI;M2GS;D7!L$#7U'6;F/<VZ_CY/VQ/1.&?#5;S<O\^BPR=6;N1N4
M0QCCO0?'SSON>XXM6[% S(U+4H'^F1-1QR-?=I9AO%].N0OCML"YCC65,]:S
MU9XFA_/MA3MR$7F&,?6A.TX"-/),:K0>P>Z^J=.',3N;)!L+E4>SH%?*>OJ<
ME4WIWTIL?]W!W!6N$,4(V/>(_$4)Z]9%376U:PK85&/6CRA-OOZW/YF^>E/>
MYPBJ7WDC[Y"*S3B#CF]G*2\LCG7?-@U2I\>:>\_$6<BITE^C$Z9'I?S83#5G
MDHRV7M13]*+::NM*?.);1S4\8%B.G''7OTJ5..V,X_CU,Y9N?,3_6G#[%JPE
M-H,)->LA1X%RP3P,CO5+S@ZQ:R,Y9UX6#ZN$#"ND<FI^8E_[8BT/-F]]M>F>
MW:V[LV EZX*[N1H>J2:08L*QVBNFI?C0&?4HN[@A K@4J4ZUJKZMKR\RW9YY
M@?2M\J7VO5Z%M[E2';D48GAOF_'9S/@\VF9\+L&R6_VY.OTYF4;)3*D]G9VC
MI:)GE4& 7^2G%,W13TDO8>REEOK8&8>K3\%BD_HN#+7 .)44(!*9^H.9J^(K
MX".R$;4]J.]S-E\IKC7<R4:UE3]%U0LA8_IRQ8MQ@%.,AZ5L^JQ/W6SMX37>
M*H UHF\2=+:&0DLD+/-;V/(LS[+<0/-MNYM*VJ%;Y#+0*_QQ>^9L(BO) YU@
M'A#\3R?+Y^,P'>YQ3DL9&RK]C>V- N7<FE \<"$84W$UZ973C,K6\[ 14E5F
M72_H.DDC\93^J^DFF?O9-PWY;^5.NM0K<\C"$M.>9K1UXG+IOZ;/-.5HF9X0
M&(GE?@SU^(Y.N@B^R1;I<KB]P6Q/5\;1U?6M<5MQIBN!(KZ-$ZX0$:8;OM&Y
MF_HA;5U2Y!ELE&.YXQZY\C0N>O-M$2;)LFE+MO9J[MS\I&P#:\\%!4PDIQ$$
M&\Q,E:"42;*(I6748A(X+\$?M^6%55WC1U&"+;>,E23QM(22[!B5P AUIS30
M*O(?-T-BT;*U0F($\M<'1R9=9@1RWB)_CN'4:08(2I'B%:LI7S5O NTPEN+@
MSGDF\2]3(!IA"=C\/?*S#+Z&$3M88Y$QXCKM>IE'6'(%;CAE5ZA*D- *U[ \
MCOTK+8RM;78JVZR;%_SHWDNDT1BM-TGZ[7:2.$A[<LSH#D)VE@X2+BM,A<@E
MYSSY"\<E4VO8_!L O6_@V$]P]_\#\@;WLW&^S!$JR;6Z&.]S!!1?'%+K/@#4
MW8.'1Z#^9WN5U'HQI]=%P!4@>&.=V,,0ZXFL=C$ R.>RVD5!$I_':AO(I(]T
M[!<6@VWKV*&<@Z3(P#[(6M%<[S/!-VS<I?9UM6W&Z*A;17/^^&I^OO?<[P>X
M*;KOL/=7RA)GG(PZ5SP ?/U/<\:<@UQ_[!T>-YCS_OCX:YSYB7?:1&5_$C/O
M>_WCISGSKM<_:*"3KK35P?U!KI=$CSY9$CQZ91/I=ANJ\;%FXG6/#S=D+OVC
M@^5FLAII_HON2;CJY1YN#.&]XY--F<N)=WBX9%N E<WEP.L>-;J^K$#^G9U?
M[KU9\5H.ESQ;JYO(I@CAXTVAR&8TGOGE_.SKWN5+X<*#)<_UZF3OIE@">ZL7
M=+<ZQG_YY2)7DR]I&.=OOR[D2F]R@X@&->_5'V)+@"T!GBP!FK+^"?1(T0U%
MAHM%K.XGDQL>>:L=W.TV8N,/JQH6F4:WYYVNVD]9:!Y]K[=_\OCS./1.3Y?<
MEC6TH.+^K4MQ[),5*TM(QV<L7+=4V%+A82V-=?<BJT_R8&J4[X_*L-[]=@QF
MX Z38A"IA<+H2XUQFU9OH<3]N75SU]YN2KR4Q;?:+R]D\:U&TSW6OM*6=QN;
MAV:2"TVN'V4PXAUWZD<.Y9Z6^(ON)!FJ"%NF-1)<P]C%L@R4[[X EK0F%3(.
M 6+"$WK &#9155 0)"TP'_NQ]!T)8P<D=A3>.;AG)5$.&=Q8<+U211G6F-C.
M<K](38HU37N/1JZ7M J^ M>;:'2$:O:DSM CJ&I?P!@J\,!8-MN:TT<@F'IR
M-<!\3  5S(COF$Q*W:<(J2?C1%#'O#A5:8:9OY'.6D6HY!333[G2R"J*X<8?
ME1*:]GQEQK#$1-XZR+$&498.6)0A;0TW"2.5Y4FL/#=-9GZ$^/G^3- !J8J4
M&JA0R8ZD.,\HC9#V*DR'A)(9ZIXP-^-D8F [*.]"0XDU$XB16;EDE?-F23XL
MLM:7GOR.N:@6IHA=GL!IZRUXVW/2W,.,3G2$6'""'0L'(^<.;0;[5N!FD7V!
MD0;P-!:?3PB?*G6_Q<D-L[Z?4]=,^!,B,/%<LMR@%6JX%#IA=)@&>%YP'3[W
M*-+=;:2,8@$0<H$2G[M"!R9X,U:,(8ZGTBN17$VWA# >1=@%"7%7B'K$[8BP
M<NO8TFW'4 [;,66V((L+V(BD )X.LV_<F:M\F$1WM6E6'5Z]N95V=2-^P?[V
M%D7B:5;-M7E%"U;!$GA1D$R59XJ./ /J7#E_M]266+:$UZI0N2JC:7F\6G?%
MV!U<>'L9V98-5\:&E<8\W* O3<"T0P4A?2:GB'P82=GO^T]O]K@2ZO)L3Z%&
MH6IM!J+8<M66JVA4R\21QG%@4::P= %M] P BC32-2#Y=LUE0Z1M^6O+7T9Y
MLJGJ<0>M*1M=V-<JTX9EL]F,M.R"'\&EH=VQ8?P*<('3K7;<\MD<[5A:]+6J
MSL"?ED#+5"[ZC;@.FZI=V8A@=AU_.81*MPRW93@>M>Y%HA^/$39%/=EG@B@L
M;+AWE?I#Z=J-. 32-%K#Q\%G!E0"37@W+2ARW!0 6SV7G!WYX)>.GQ8_KG,.
MRP&1];= 9$T@LN,M$-E6+#\ML<SM"Z5AH,'F\;BAU5 C.RA$@PFHQRZXSWB]
MPMW$RD!,>]=;CIX_+9F[9;;5.<]AV=N2?&+LE(!<=84W5;'T1+L2;;]EFRW;
MT*ALN=4<E4JOZ+;>JN&(.T"/56R:NB)VFR)YY4=)3!=%!'D$5 3:^A;J$3YT
M"Y#;E@M?'!?:T'6^Z7V,D$[83YOH7@LKE\AK]1O.LEV5#N"L'>CN"?@E&OT.
M;T!CO";E"V;V^GR0".H:KW3;.CW?V7N9<A-P8.G?7,2<HZ"&IM$I1=1:G$OS
MJHHDJ6$89IH?/ <\6APVQ3076%7C[<<&7'J0M@Z_<@(.2=BSX016F.4IX[Z_
M[,8.-F'\"F&<^;T>"(7Q 6&!RV2>$/^@@@(GX$D;/N4T)U>"!7?<^4NP4-YM
M>#Z4=RK+.)_'0'U22UI/@_^34R&=Q<2K</QB&);0_2LX&)LBP# A*PC1=2H3
MN22%K6TOYN1V57OM4/Y6^4<<<JS\(;=N0W#"8CI-4NFQ8)15F;=LI>K!5M2R
M5^[*YZHOZ$:9N1:IE2I7;CAL/NZVI]FB%-J>!< ,TI-J1$AZ@VLY F>!G,NL
M2"G;2\ 7&TTGY(4I=1CB$T3QPI)A:TDM \5Z7-[ *8"^Z&P O\@45BO12&2^
MAS6':9FQY%(KU)<IMREI*LP(._<['$33<UPXR,%NB"37$$>+F$W$7\9I9)K1
M=#_$L$I<-T[B/>GCS73>(%Y;#7N]";-IDF%#]Y'[W@X/?9'PT);3?HC3K)Q4
MZL%LD;L]&C?D2SVK6^=S9;W/Y.._YU;,.V*1[KY,?OMLH]=KVY.Z+Q-^L,(V
M/3%[M.2PHR,;)<"=<9(KS7Y(1TI'N%;2;=NG'&NP8;)Q."T3J)\Q4UWZW\FJ
M>)ELQ%C#WS4SD(.-CD:8#,$#GZ)AR?V],-$X9S&D]5TNE)-JN9$B$&+]6\*%
MQEAP>L4E(# 6E0NTC@"FKP&Z)W$H2=]#!Y\9,( T]C/6BAC$I+K&B#/)//>R
M_2G\(TKERMCR#/8G'R<W\;P6[V2/^D,D'TP#1^36R22(Z=%$#B!8P&B[<P,)
M#?(]5&AGT[G#&VNB TV1Y@8DGQ8I2'8!T+9)8OI@S^KK< (_"@K6#PSHCX^G
M%'SBKW,Q1$C"@;IOJMBG\$>2EE4DUWA%K_^@&VUK>@[ 8T6;/!LKE>N^VL_P
M\"\QA3\(FOZ/WWESU%4H/9X])YOX$;O4$S4,BPDW=9Z9!&:@:JA&A%E_@ST8
MJ/  +]FHEM4MIOB+[D'G\*_:/\N(#^![/DOLC-T<.)7X<2HA #<,..[%[\IR
MF0T'V\R&9F;#R3:S81,/ 341/NL\?C=RF(9>X^.U"C=V2EJ2(S'D<"A2Q3<O
M\,2(@_=CK![%^!&V\2!K)I,&(ZFZ#F%R''1-BFA(RGJ 5M WO%+,J"5(P"$[
M^)+$Y6 0ZIP#Q^,%"5[B@',,HJ5AQL5]_Z0RT[>-U@/HUO8I[,EH\X_,+QN@
MGY!ERQM!NO++ZKT\6EFZ8O5E+6T>B-:NIO6+JL1;30.0MOMC#4S?<GG=>J%=
M0L/OST/Y']R.JJ*_V+RP'OF3,)K][2[B-"ZWX?3.[12"![2EX]M]D%E61,BY
MW1(>@X[<,>1NHCW-I?6>Z=+.,15-/05FMZ3&:JE2;[3QX&1YV!T4PQ<T:)F!
ML#BKMK'E[7!>#\'XF_B%%<-LB?(].OCK0_+J5QN/ZTUYF7U;#MB2C2L6>6I.
MPXH'/),"S[70JA[NLZVG_TG344-];0GY8PLZ\$X.>LLO:@DALQ)]42H+993%
M#]@T\X7M [+LJ7=RW%VP^?*#\N=FD:'K'?5/MF0 _=IO502K(L.*[(('-0)*
M=*E!$A<+G^E%_9!EH OO<&(>G"'V'H)EMP1XS@2XE]+53VHP3,2\!+MB^J!3
M9U#=Y DJY>ZQ=WIRL%5'W0/O\'2M^F@SZ=#W^J=K-=)6I99_) ZQDNC&4_W2
M8[LZ'Y),US)95\.;?HZV<G4K5[=R]>E)NY<C5S\+[@4F>/Z\(Q;K[M]6=)0V
MANP;N<&/%'!XQ_644FA0,L&*>*#K=0\.UK$Q#RBWCU^\ZH)=.VS77#\LS-[]
MPR7K+HF!!;$,DJ^\'I@2;0F8F/FS:"X.<,'!?H]3->UI[&[B3$^.3I_&3 ^P
M[W-]HD]*>MH*=!NIW?A Y='A$YOP VJQH]:;X@UP/59R,"4:VVK?;KRZ/6Z_
MCMY\2^FDN[W<[7J'A^W!CC5HMF?N3FVDXW9WY_6#A[UI:HN&NER7I(LU<_][
M^\W3K5-<7'O5&](]7$.\E81A>[?G][02PUU3QM1+VHE#[V"_-2"^II.SW0B=
M?W32GG_T&/NPU84;_J7'MN7?&YTFU> OR=/>.3@XW12;^CG0\XE&+IXN0VW%
M^X9_:?-=':M">&O :9_FJ#V78&M);UV:E[@1/:]WTGI1NW5IGHPFVG"=]^#W
MA@@VDJJQBC/$7T'XJVWJS::GWLP3)V3 /Z1 ^=4/XY]WT #:Q>0(ALP+9@BD
M'@LDVS+B3N9W"XF7?^,N5+ 5R_RN=W"Z5%QW%31X<E3;Z7N')_<AVR/9+,]P
M"PZ]_>.E;,;FBNZGP)ZYR'^VRN6!;=6FW;%U(MB;._*ZIZW1L:TWM]Z-./%.
M3XZV&_'8&]'SCN_A5;<)RDH;L V"[GL06/5YT#TOO)%4A2R5YMFF<X]SHU+E
M_G32Z;K H1'"'E1@P.?A05*SFY0[1_S4[75.EWF]Y_HP'=UU:.3^=- Y<>1]
M!B@W?Z76BEE.S2X$P)* 4I. 6G?;B.@)@JO#HGQN#N5^&>, />Z91M."__E1
M,?$'..P4GBN;SV-K%:**<C(5)/$0NVE,T^0JQ:Y4H*4GV(!JB@WZ@DBE219F
M-E5UDUMK DB#!&;G1OY 13A3GXB!O?ZRC,?V)QH//O,GRH#!(MAW,AIE*G<'
M,_JS/\@(+!F6#OQ1C&"JW(B#FAGATB__[X>+O</][K-O";-M&S>O24<#^L#E
MPWU:GJ[%#K>?U<YWYVBIX^UA8YJRK=@(Y4M/C]!Q+L>JTI&LB=E0/^Y^Y7EZ
MA1!:=/L:\QY^JS=QAP5VD(#7(FR$X,8%38_D1CI2)"XR!X9I3A8%0[4!F)QK
MZ1#6: M&G^QV]B>-<:3C7F5N^YU^]4&<A>Y7EG'C.SUY4.RYU0^/FKPQ)HUN
MUQ.,L3V4'\O0L'!^".3I\<2-07R@;Z$'+.*1?YVDNBV$ HZ"R5'_9.5,DFOJ
M0V&WT'M6@F/U38+*!'</:;]6(;1)T.G8G 0DB#2*U!FQW#C*,:*#6?;X8+*0
M2"*K0 ;VW2OLMLH#')G#+@<"F!D/WPA.AGN-/1AT"UUIS_??_W72ZQZ_PN.O
MJ]WP^<_?9@E:#'"<W _YT"/QP\(%>Q3-V"RASIG8<S/@SBJ]3G?"OP3*@:AH
MS-NC&8-\.#ZNB%1N :,GX/"(+$D.]\UB\3],1A2.1@J8GDME-R682VT%'1RK
MVV>1\-7/8I]&]:>JR,,@0YYM+-)S@*+[O<ZD2FX2(C0Y2[(N06JW2NJS(, N
M-Q/W(@C1J*&Y=*S).+=0O L"5"A^&\&!,?H(HR_OSR>]6Y*^5[X@ZW=PK$CD
MN=!\ZH=#X;W][N3)=^)]B&XGA]MN)\UN)Z?;;B>/S-K<GY2USZ7_W3V7W-67
MZ!N<F291F,6K35<0;P[HD.0J#O\C6F01WT#:FEV'F6D@ 7_JZAX1?59<NID9
M-UH/X$B3.4#>]F\?OYX__5[-2S8LZ>F&)=U'M](V($:PVH8EW34T+'F.O4DJ
MH>,RRDQQZ1N%T6U\)QJ^<I>X]%V@64G+#7#+-]MZ%5#+D>:!JZ^@=;HM'[G?
M)>^Z"#BWW<7]Z<?].!Z"6$]DM=V7LUK=D&0CCL+"HJ%M)?4^(LTA[S/!9KN/
MORTVVT5[8RQ+A4T;=UUM/*KLB_# \R^OZNR\9,>#MD_]-&?,.9T/3..'.1-I
M^\3N)DR[[_7V3Y[:M'N(YK#$E!^JLJ8YLGWSY%=NGFX]A7/':Q"B==.X5<'\
M!VL;M8HI]+U^MZ$VUSJ'+I#AN,$'#[7Y]Q%>;0++K[<.N \YVHV,%IKL+4>.
ME<UCYZ0I"Q^,.1:>Q4*3^.$$SO?@[(<I!8[Q6C++5/Y"=OF)SF.]0F"NY?\F
MS*9)AHA8(_<]F+01=@XNX.<O*48V\ME"1OH#YE3?1O5[96<W]F6.F['H)+8$
M>)D$>$B3;>YQ9'2ZMFZ/C[$'#0/H7N0W,._WW(2&J?^D%M\[]OK'!R]S\5W,
M$EXTK/48ZG(]EL'=#Z[13'GRDWE8U[F2)^7NO#5(H"M==W])CW%U+E+W^.CQ
M7:3>_NDF&\]-+/PUL<G.R4%#<SR" ]O4W8_&K=YQ_WAABJS'8K/ Q[9V\M,F
M0-_K'>R_="+L_!@5ECY[6WOM>4]F+5+XD\JI6\A3]I8,9-1+=!5W>GWOH-O0
M[2]C\2?>?O?^\9&MF[R=S'K<Y* -EFKC5KZ=S&:XS7.5]3NI\6M#KI+L[+9\
MFJ=H21.@TM-2:0])@ /OX+B1(_*""'!RVHBNK>WN:7/%T'8RFRJ@#\H[R"H4
M%,,-WL7+O?N=QWF@-<N8V'< WQC<H 46<"]1M,%+[QU[)Z>-'*27L'38\^;-
M0@O/+RI^5PE5M-["^2TXT4. $W7[G?WEX(6JZ"7]$GQDD=>[=72B_4[_ =")
M1K#0/-Q[_V'OZ*L[2>(DB C< W\[2(:P7'=G<C;(=FGVJ'*XVA]G6\'\<6"H
M=P;)"!^)$% HHV_%5U@6_S&,@C"(PL%ZT8"VR#\;AOS3[1PM@_S3JR#_X,'I
M+W5PO/K)Z78[QU7<'_OH+(+[4WU^/NC/4:<_,>@4_&!FH_T(,HX>SC'#P>M%
MGN4^GQU&*3$+Q05E_C6=*D2(Z!P08%?D@YH4Z"T#B $D*P*8UECYPP".+V%=
M", 0_Y%FCZ^K*^!B>MT1S \+6".)D78C>"5)K_Q89Y3S8-UR1AE#(65%Z@LR
M& BJ<J )=B,L 7^ M;ZIW$5DL[ LHWU#1>&?/><GPM5 Q"#"5I$QYN,%N08O
MB C+?5ZOY'SJ^6G H]6!9*Q5_-CY_:\)ADFDSLL4.F? H7ZUX('//*A;(W0&
M*D!@NZD_(S:J':\Y<F2_#=\*?QXD?CI$%1QF]9&+:<) >N>,/>.F?IBALAR1
M(@V)=97@V/1.)NX.DK'_JK<_V?7<FW$(ADB8NUE!Z'RC(HIX",8O."NN@!0T
MMXY[ELED<,6($!,G\*+*\P@>AG,?1NXG/!VX(CZR&CS&X1-Q.F%@G2!("WA%
M)NY/2&C@T1-,0"(1D*(A9SOP 7=4I'3JFKN @Q-,S>WD=K34?R;GT^X%;S>;
M?HF'LPG#)?1PZCS!+'FRE'TM1Q".)Z+K:7W\PQA<K<!0&G#$!H+"PY.W6"^"
MM=4_7 [ZR:E /U4.%R]1S"E@+0RE#ROG<XXIM#9@J/5 O_T0/M31%A^J@0]U
MNK_%A]H,#M_"1)4S:71Z97O)MNA($BX'&L7V2E@?F\3U<B/U'-$&0>2'$XT\
MM8]N(]]RYF"V@<%'9M%U".09S ALRK/5#WF9-WYH8)HMG*$<%9M^EUNZ3],D
M4(K<0P*O\OGK#G[]5BWY+"&>Z#R^[K@?PG\7(>SBC!S <W\:XG7&5Y4E11I@
M(&:-VF@M*G 1HE^$Y(H79(8JBB^ <Z'<L7^M''03V$5&:XE\%'6M8K".D(+X
M2&EAE*$13/^0\$6LKCC:%?C9V!U%R0V8=VDRH0^6 %D=]T_^HHN^#PY6^;,#
MAM 0IH#F#X)MP8DAMA8VER$9DSPBRPVT+1B1Z<P@G9Y-@$R!C_";TR0+\P3^
M=J%14%/W[,U%YM&,@R2FFS7TT*($7@ :J.QY'HQE7&<2-6W8I<H9^T/>7Z(?
M_@-,@Q"L: JV<+BH:\SU5<=WUPG5>(Z+?8=<_3*5;PLB7AT0SS[X<-"4'XRU
M:P7G.TR&V%= 96B\#E<'?/<CI^S)HN'=VL=J 82[.]J,:Z"KAVL= UKQG^W6
M":O)V_M<+IPC\2/4F@MY]AC$0@F\"&6>YM)ZSW=IW0?EY[:<G_\Z/W_[]MV[
MVQ#,'G)96&5!DKZ0\'-I#99WX[<UA5H2I.LAY_[3 O.: _3UL%W!CTY/%B31
MFIJ6;3?EU#OJ'FXW9:,VI=?UCH]N[4:[^DVY7][M"N4MWQ'<+6\7UIWSTU<?
M\GQY!)78,LT5'Z;-(D/?.SUM[5SYLLC06RLK/*QYM8JSO2.'>]?]F9L7H%<T
MF%G]=9[06<?"\?M/\?&8\K!5_;^H@]GMW[EWCZT/WXY&*J#\.Y/NA3%KN=FG
MODMS(Y2+TG]1%W*9A/<[_,\5R-A6%^,QV/E9D+/?[K)MZ7EO@_#TY"E; :M1
M9S\PZE/]TF,K%#3"=G3J]>[/=I/4U2J2 SILNLO[FGSW.V>R\G-_Y)TB7OL3
M$*4O<X-Z?>_H:&-\U.T&M47%CM;KJZRE^/&1\X9"4@1TS?^'1-K*RJ4SR_M>
MW^W_!B2#?"Y2##RBNT4Z$$L5K'O]V[K<]3W3YLYS.(D-6_F:O!Z3'*1;@>-T
M35]&S""(DWB/OJH3G4D5BY]'U8V3:1+KU).;)/V&>Q5PME?'G7]3Y931%$Y:
M.2PKP18L ^F;:BT*U/S4[YR:$>I9W7.&<5:;A_>4F,FYBYEZAIG@YQ4SD[,<
M,[EU9CKM'"W)3+T:,_4Z73V"LR S2>O.#4RJ68UL?F]N0=8DFY](]MZ;A:JJ
M*)N/61E+4@R[6B>S[9J)"\QU$1O6=.?4=[U\%MOIUMJV-WN_WW#[<N5.BQ1.
M(,ZBYW7W][W]_7W=/AV/+-:>8D4I_H;//U5L8HA/?NL.BADZZVX6C-5$6<)T
MN_GS2^JLS3_XH:WO=8[OVOQ&V93S/@X\9@&WP@)=K]\_]DZ/JRS0JS% ]^4Q
MP+(53<?;BJ9F15-W6]&TQH[D59UM;C=_QHY2YG+SG;G<?!SW:G.2JQ=4VJC^
M]HUE2!5*VAKE0J&I/]/=WR**86H4"I+>4G/[4Z=[8+DJ<1:R](:7T'@N*RVD
MXDE]5VD09HK,8C]-?3"1.^[M4[;,]KAB.,^YT^:)5597G9E9F]-<VY,O$']X
M#?\CG++8SG:MG6W-6'"6V%U[)&8^F_%<F_&>_&:3W'E7,*++5[Q32!FKY-&E
MT :P]Y_,B'B_#[Z\P=#)$\=<RV3%  %Q\M!'% QRW.-8,7P-E8I105E\E50E
MC$<&:1@4D9_">SY6S;O^\)K@!ZA$)55!%,9X[51YK8IN14$#_5B>PB3(Z<=O
M N\BC XP,NPMUK )K ]^:77E+H];V6*5K]Q2YG)790L84'.SUP].IM\727_M
M'>!SS?BW'=/^[_\Z/3H^?75;<+]5%-P^:J;4-Y"H5\!95&OH3U$>(F.@!D5O
MJ84S\K%?PW/!.$^D,)&EREZO[@[$;SGJ>7$4N-- W!#OGJG,E:00(F212$-
M0L26"P>%8&^-4A]^+@*"\D,G'*1C$$[]7/OUR62"JA2A>'B(5IY$=F6LH1N$
MY)JYR2!'O"WKV\+:- G$#8HI+&F/K] Y)Q%\$V.Y[;] #N?1;,O%+XZ+QV#8
MN$A49$.$E!.Y!LRLAJQF:]B:4Y5FJ,RC+;>\.&X!6X^P^@B=H"+0\-=@@(41
M^Q((0QB@Q$D()P!?N$JY*EF!!DUF2KD#'VMKX<4M'[TT/IJ QD*MY;G"4?@_
MT%JY=BI"N\'Y5!J<N],DS4<)N*:==;/,XI[9!OAGRP6B3[:!Z&8@NK<-1#_]
M(,5 12$8+NS&<:B"HUD.AK$\D,11Y*J8P3])9R':C8UU8^,*<X8I8Q39J-RI
M%1TRX=AP@N83JKY1@4^5@#H#ND:#9S+EX(W<A*QZO"O+LF(B>,(T8S3NT9(G
M'-V!<F_2)+[B"[8;!*(JHJ$+S@6;\S!G_]H/(]99,LU40RG!P4MBA5/S$7Y+
MPC<=]_T(\6)2%2C$!&IQCVE!1!#",FSZ(UXY'$Z3T(?<#+8G'"&\3UYQ.]C7
M,12U4!]E8*<2Q_'N]JM>/ [0:Q7XDJV#?!<70.P$F#D-LV\9!<(*$%PI*ELR
MS(#+DB DLE,<+A4(?:^*GT_ 2_6-@V],*4$@4 49(_/X :]\"SY7L+>:RQT.
M%\/N:J!:B<G5TG@J)ZKC8CX2'R(ZGOA@Y<C1*1XJ/)!TC&CJ>#;*8&3)CM$,
MX=]L?/ )^MG(<DF:(<QN$!7XC6TL\/E:GP1,%H"(]Y"!KX 7$'2LR E<D/DG
MRZV(<1ER;N\QX36"S26@>7IWBXJM'_TB.9"8S'-!-I*J(R4\9=$+QNTDXW8?
MLY; GN#KP8\1D 0WR=;<13Y.TBUCO7#&HAXRK#5M067TFU'==1.K=I?6L+@\
M<V$R_T:M$J/6UF63C[?\^2+Y4R!+@1E)P'F:0X8LUDJ[LT0/+=D,R)F-R;R[
MG06W7+?ENA:I2-J5-"[RSC@D$1<#[714FL( 63'%4"/Q5@"#A3$VV<  =C[>
MLL\+9A_T@#$MBZ,3HS#2&A)$2Z:"@@3-% 00&OALGE% !Y4J1[SU"RH&)4GY
M=?/#W524F(GG,)+6;*V/[NE0"L&*9]M;E1?+I_ 6,A\(,6. ^0%%2V"7@G&<
M1,E52.F8&\D=:XR<_4%MEK("B 0:@<T1L$Q2SZ'H*X98@=8:;=W8&!IP/2M&
MHQ"K)7*^[!Q3J!F>&H5 1;P'G=5BH[J-CD%ACB6),DV**P8NR-&D&2D4+UG'
MN4Q<>TME5M12JG)E+V$S/9"-N\Z#>NY,DCU4FHW#J>DFQ<&S@0(+/RI ?DA$
MN/$-:8&EO\"AC1S4YW"/*DAT9,[CDP;GCR.&_E6J.$P'9ALV6E178>#Z410B
M)>"7("&Q;S$*14P=O9*8'O@/\V.^COVHI]-@*+@.5 9)&,:P:J O]@UB]Y@%
M*;;U S+8Y\#33I+9UCQ5_B3SRL -A8C\"4VJ:6@Z"=YL8Z";E\*Q?';@310?
M8?L'=BL]F$F1:6)7HZ6-[:V27KC$)/!F6*03.\A*:FB(,3#7$A1='X)VF"&Q
M)V'N29=!7 Y.$P:2"WJ].#M*E9C8:TL<?P0JC#>+*<!DIN8 / 1MG;0-U/9[
M.QD-=]^0;4\,=H.$ '4[4JG;/B;,.E/1]2JSRYM](FH%"2OJ)S/XY;SCWMGV
MUW._D+'!1L('X4#/57G066?[C T0YQ=*N=@4K+?_ZCU6LAUT7G>H25COU7O+
M9'*^B,GDT</=5_->FD=[\Q[^WG[WL&-!$> ?I7*&6II0,QC\)7P^0X60=62<
MI[Y%Q*MO.NYEBA<P[]&LG9!\>$;\=P>KW;GS3F7GA<$:!'LN'/$022FGVZ24
M9E)*?YN4L@G"[BT<]]%H[[4?D3E_,59@BIQ9-NDSDGP+9MJ %4=&+AGA%II&
MHZ,,I:\@J, PH1?*EFOXJB=!W='>0(B;$7&K!K^?83@DC*U*N2*2!!VY"..F
MW)P2<?'V_,G#MQ#?O0,EZP^P-,I]$V9!E&1HE\,JSV'0U.>(T.<![!@3X&GW
M3VMEOP5F<GL+)!/2%7HA< LX158;\I)^R&AM/;8,8-*CL]73ZH1TUMIRM\\A
MJ#FX<F57I(-*[.UA6PVM_^N5&-Z-0L<9'XJ&BU@J.R3VDB(#1LQV]8QN&5*X
MHU3J.%I[++.E14_+@&UVS]WSODQR/ZI/MW5N G5G?[2^ 9N_W _8*YXR+O]G
MD/[\"UBRV$SKH=?_8XN]W\H>V+HP79T&O[Q6^8U2L=MEDJ&D/=0JQ5W=9W%C
M2GVY-(6?!#M^Q$:TR(Y,VD-7%OT0['@/\?LZ2;D@*%M,!+?SK.!V_K37*I=?
M\I@_@J.=7@UV>OL'7J]_XO4.#W?GWHD=]FK=A2(URN=R?!DD832+Q+95JVQH
M.@8M=7R:+]]U+)JSGW>PK79*RPTJV]0[/%UVD4M/[AF1JWMPLB77$N1"L.XM
MN18EU]Y#$^L^Z/CS5.X!4G0A6_G@#MJWT@9>:H7 YD7]5/_F4F/,EW4M4U]\
MNY_*NEN$ULM8=U/ZO(AU-\3(/5;=#MJ^C2?=-Y[4>]'QI+NU88LGM^9XTCWF
MV.ZX/XUXTH,M]RG$DY:SQDP$9AM/>GKLN GQI.6"%XO&G%IB+7.,AD5L@KN,
MGNT45C,%&XYED?\N.>4?\?@V.GIVMX"PAE_4HE]XT#GMROLGO647N:;XQD:2
MJ]O?U&#C1I*K=]#?DFMQ<CUB].P^=Q7U*?68Z@MY#[W[[= :8@\M$O%!8RZ;
MN_(6X?9"5MXBIU[(RE<7:7N1J%%?V(0TM356-KN#-1#NZR(+8XPW? 9)C"GL
M\ZH>NON=\X[[T0>7$//==2IBII\?40512@5C0Y7[8;2^8IV59F/^VG$O_)%R
M?_-38.@7EO)[.0XS]RR."RIQX%KYV'V7I!.>7&]_[QW_"W,M_3#.'&"$&S\=
M[D5)0F!?60X\HQ&\\K%D\DZ4'TMQ_@6W"Y !C\],/J\*"L:WP8XTQ)#51[MO
M]:-OOW/K0/.@GSFUU.$O:7B-!7#6J!_@_]BQ@K5A=0:]#D-V3T\/._P1+ &A
M.DOI:9"'>:3,R3CWJ5#13V?NA5XFC'4%Z\?%O1-2?&!2..89?6H>_830?WPW
M'/Z?O_C_;W__!,LW_%\>\OB\OWS[T3WZF_OF_=>WYY>?OU[ LV\_O?_\U?UX
M]NGLU[<?WWZZ=,\^O7'??OSRX?,_W[Z]6,L1VP-YUB,E^/ 9S4TBG'7<-V&J
M"'M.&#D.06!^]&.?T]U?G%QI2=Y6C*N9CYVP+);"3'\Y3IC2/2S)2$G;'ZET
M3ZZ$#A[]/&TTZ,&"=TF#ECS06^$(@,&QA(E9^ 'ZB-]]C7#7=,ZN5C*;!;[\
M)<G"LBBR!7KA/J[O?YV?OWW[[MW<^&+_\*]W3>U7?Y"&"G@3#TP"*CU/0 *Y
MYRI-DQA^^_J,Z;+3:^T%WP@ +)(*=/+7^VS?8>_!)G!X-UW>?B<TEVOEGH_]
M$&0. XLBE!I(G/-QJ$9N^<QGA()0Z3TWUKJ@N'U2?X;8@N8BG&A39Z?K];Q^
MZ\XL&D]?C/C'K<1O^\8= WU*XKV2;EKYK>Y$W#&=OR?CV'V=^G'@!P'P_4YW
MUW-WUD+1H_53]/'A75:O!W\$X6<1Y![@D =&[?FJ)@5AS*!5<T[E:+E"3PBS
M6I8\&975+<JPC69Z]_G6'52[77W<@VJ?$D(N(6G\3&G6+H9^@&9GQ3#,%R/7
MXXN*#4 A 'FRA2%HPA <;&$(-H.W5^I19QR*F% H8HY?O07)OU_^Q]WNK<8<
M/+W34[G#RZZ;.+<[2 \\L95XO;?D=]T^H8]^GH]AR]_XUV'V0-8W>X(?I56>
M^('D*O)?RJ2=-?F(ORN5JMB]&/OC!UUB"6GT8PMYP/U$=SCT)^YY1*'2\$'7
M:Z.MK6GK_DXH)A<=]^]^D P>:#5-U]!SSS^>N__M3Z:@V\%Y/->]*ZPE/V^;
ML&$U#^Z*@Q%D5_>5^S]A25!'1X96AP.X3,^WM0 3+C&ACVG';:>J(U3UW)!;
MR+]#<0!B4V[ML,<RX@"A%!V#V3' !.X03):6H%P6HNEY-DW#""R2[D''Q>_J
M;<.W1S0X]M2(W4&8&/#/F</?P1N_,':3.*#?8HN$$5WJ%1FBCN(].=_-3))(
M46-R^+5_%2>P]B#SS"RC,$, Y@QQ1&4EF5Y+R*B@G_QLZ/_;S6\2O'/'I7[T
MP]CYR&"6.-#9^X^N_ AS^I#$PR2N+BE(]O2*SM%:&X&.,5-_'P<=G)%93866
MF4H19!_FBL0\3_8T%5^Y8^7<4%\D,WQ:>\50')8&DFWL7LQBE<(7OE0Z0F4\
M"=: B/.:P4KG/\(?U9()QB:DO(@;I"$$J_07U5?"X97O7E;@6VDHFT#P@<2F
MTCL%W_Y'F-XRB^8J'6'%UPG0V"T(*1B)-H$E*X3KAM,QS;GNJ+>_?\R]M-['
MXW 0PF%HF5;Y#=]<5N&2ZN^4W_KCXJ=>YW 0.X3E"V1\G2(U(_?C#.WQBW\7
MX6  VXBS =;O5;\G1VM.'-LZ<9?A?T*P\=T/X4BY%PAHC/WB/N3#*B.-DJ#(
MU!![>*7^E(B8:>YZA<QD#?G5SV# 2_M)X4S#CS(<8>7"-"N0LT3Z\E7,((E4
M\<U7D]#/[&_A+OVFINB[M&[NJWG+KT[W5T0@OHK#&@W,<6H_^?6E.(E%K8(@
MC2=AD"9?/YV5B,,S5KEW[\I9 (-B?DVY(PC>JX:<@3,JGWP=)O\(<^1=AH%V
M8.NJK'"5^L."T.&IOP9*^G\FZ3?WCQAFD(*%/B/U=OP*F"I7*?!V,$Z SW!P
MG09$_ V4\&%2J7E\J!#?&1EPH!_TAQ,P)PCK&:&:=SZ^/MM]W"9]CZ@9Z>/6
MK8UM1\R+VV^ ZMXX6X))*/8Q$1(U+HM4[N?73LVZ1<'6PJ?D6DON[F$') @*
M2Q\\D_B;J#UL2(C".G=_3\&U4SG^S?W4^8<H-G!JZ3>LH%T.93DX'T* 17O!
M568V'&9U*RJ%Q0Y(.1#MKVGP#WPZNZ>GQRCLX?]/)66)ET!>23DH#/ N 8<#
M1>LUZ$D2G67>B*,'.\7!0$7U:*%^D+,2"BQU3M__/ ,I*%[!-?S^K;H:@R%#
MP^#K,LP!#7-3&P',ECTX\:AN_P%R_'O?G4:!NX.A)95&,Z=W\/,Q&(/4=N57
M</ZF[F])-"3T<GAP5Y0>VF]B3@W9Z*NJRB^1/T.U'[AO,<2):66T:BVFQ;SZ
M?'FNC3'9]XY+#.24K$.C,UDM.B#ZOYF9K:UD.)!S9Q,4@$-_X@DS 4V.Q-\O
M1WI3!#[N!B:4391YDKG-06Y#(\5W8^#:<DOMM7[^_9^?1:FA+NZLV2-:OP-6
MOXG=2LI[3:A&1H]:G>;8!\ Y_W+F67*S:8HR-*8M*4'BSC#0N]]QWZ$@T'[6
M_H$<V8\^_KU[[)'!86W?C8BM.<$CATT<< U3,DR:-CU9G]A->(!M#<D(G$B4
M#8Q%&*-TK3KUC\];X%R'Q"'3>]2Z1,OL)R/H=K\'1,3?_;C S$^@2]]R<NR)
M7((H3-%R*PU#?M\Q,M,]BT8^!K+!6$VGTD_#DI2GA(-[@P\TAK_-)I:=-:@)
M.$NOQ6(7FO#3MK/3/?+F>)Y,0&OD_4.9[]^+6!$V ]'C\[=98LDVPVO\S'Y]
M.YUYVZEW@CXKK+I_(I\T(8'3=5F?1FJN-G%TO@BU0K^V^)P;O]T <;5Q\M.F
M(?$=7WP5J3.'C,"M((#H^1++FM1[^3H)PG>?V_TZ.#E>7=W3,9GG13MC_YH;
M>((<3(H,OE>>$/P46UCE3*DF(XE UNKV])DR#IO*]/FAX]<]0D//DOM?4KP%
MA-_]*^'F9;08UA*>8]:>3=$2Z^Z[,P0!0,OY'V'FZQ@+GEQ);?Z@_"%'4%"P
MZI9(N?(GV,@F)<1ODIBIRJ8)..9XP8?3_J9,UQOL>52NR6IOZI0/3",_-LW6
MP"R.9EDHT;H @0NF:1+P\BTQ&L'D3$<W'\/YX91O;V"^. $P<N.LO#&5UD 3
MB1#BDFG%VD%V@&0YS:881&"WZMY.(-[(93!$96(9:J*6)AX:*VQT"09Y"DX(
MM;O4%)O*U1K1FOLQZ=G;<4WI]NJ<I?D8U/L91@TRQ>&&UZ_/W3^3-!K>A$.%
M7U;N&(Q?W*S7?@"?9C'KIU*B 7^-L>,.$N,M;$ R09[$D<A_JKHY8 ZGV&,*
M.US ><L+;#(T<DH/!8\"-H'WL<G[.L7DXPAG??GX)U\_NGNE:*[='CJWWAZN
M/WZQ=GJU2^8W(&J9='@Z%/9$R_ 6!ONKI21+D2^QE><P+:[L[HL>MISZ].:,
M3_\@3-B)E'Y=C2=??X GW[TYL]IM2^]VLCKAE*74O*SC?DHX_X ?!!-[D/K<
MJPMQJ2KSE8A"$LN95.Z'<)C 8<2"J>.#5T">H(BF(%_TS^=)%*2SC'^4"X@L
MI[ZVI&/^]\_/_+>.]:E2)SAV4!MYB10.D!=6WKRF;EQ@Y^!C#QN&LHCH2FA>
M8O5?*73P!LB$@I,[W,=#IVP'QYW(D@&Z[4AC0UZ2[M9JSDSKLP@,RW)M-V8I
M]=GB !^**8QK0OI_?/T@DQ?#VLP<-)6?CA4%*_(QAB\_-?9:>R]A? T+03$8
M8],ZMWOL?J9.%.[K)/FFPP)3:<&%TZCL&H=<4([C@!SJ=DI_GY0>\4H&8M>:
M,A+JT@=^\6L;H!4OM^#&*7\/014I8(>?3O;W/Z+H'U!U&\GK!.,9/W5?X\&
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M\V"(GHL]-:>=R<.M\+A[_-R6! ;4<UO2WG9!&[Z@D_N<HX>"Y+GOI*TZ[]7
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M0]#AV3CW"W9?I5Z3&Y3K*36M5;KC17OZ2CYCY! B74B?/#3DM56O_#0*^;X
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M+KCAAVNMW"Q=]F*=+FM+E^VMTV7W5;X'KW\7U_F]8'/7MOB3U]U,PP%J@85
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M;$(\[;P(YE^2)(+DX@8D#B&A,7*&."8963ZZ@;#32/.$+*!77U(>R8S%LM5
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M@HY-OW<<HL0BGRL_6H)DQ(T&?7&N-&QI+YTRTH3M E' Z*4[<<!100RP@ ]
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M&(8\_RSJE(MREKC7/+>7VWNF&\P%QNEA)>P^M^0':Q;N"QQ4)9K#F(,.KLZ
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MK;_*V5U_&"X3P,+-#PBU"^B[6IN9AHXG%K&LRXP=E$0K(MB17]<$2*,K!XP
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MW65"'1#?SRJ^F/1>H(V+X?5KF7T0J?DQ?Z*&I9;&"#< >$!,![%.%-F3*09
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MDDV&%IFFZLV2$BHUW[%U:[JIHU(]E\3>BZ+M@@B]M.YQ *H=4^\W9Z;(RZ@
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MJ=]K;S-GJ?SQ.6I,XP/J^:U<]<WP7E3[S:*!9Q6S6T-A6&N(?;CL@O$_GUX
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M$&/0S.FE$Y7:]9?XV"E5L+(P6?A:_D#.DZ'FMZ4==OXN\+6WP*9Y_%J@;[&
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M+ 5'0J.:XHOK0#KRZ^K/#N/U6.(#9-_?8T6QB[__;M@NL !.):NI<-$345'
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M&XK#UK*PN:7]3B<74S4OV)#[=$VMAGY= Y_MW^!=&.U4F^+9BFP+D+E#S_8
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MAE0@]_6BK8R4GRX'MS6\VJ .*@FO;21%!O#J@- H3&1L+! .'Q:V>!]]#"%
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M Q\ 0JF+A67^ *WC$/TC5;*36!+B*MGIWK2=5;: E^UT]6-!#)M<PI\-,KV
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M< &43E'M%S0/14O[!O+)>5\I$',SDY>@U9%NS;=EKJLB8K=S13F]^/9%Q'>
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MF71Q=_MT<_OKU>V3].UF]/7FV\W3S561E2IT))^<Y=:_Q->F(%S @HD"K>[
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MWKL6!O6=)Y/^"AM(_^OO(,U/"VQ[2<3CP!]Z<P42.IA0,G)DCXA(PU*XG9.
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M@<84+/D;@_[#.) 1,,)S^)E>-9069MNG(&"FM21'P0(3%E/$&3B:XV@5IV@
MS*I >F9817*L;#G58HXTGIKDM7<1IV4 '[ R6G)7P8NHF;-,(IZ-)3D5S/4F
M(V\52JM",G+R)]N\"IC49,12HH)U98:5*(G2'9AN$6</;Q*YCIYMD9.[DN2#
MIUAR<L4C F*Q.NE27(0S&"Z1^IM2QN6NMQ\_[D*S!$;-L-9!N6-R935LM"\C
MQWQ3ICC70IN3XA"&'UB3NI)B_&U>24X%4^%Q0/O_MW>FS8GC6AC^*[GY.L7$
M-HNA:RY50)IL)&0"Z>[TU-0MQ1:@CK%IV6;)K[^266(<=[/$PI+,U%17\"+)
MYY&.K-='4LRJ% <H2K +V/O"K.L><9-6MYQWMRGW6"J%P^0>6SF+2>6]A>EC
MPH3SD3DW#$T?$SF<CTS"899[+/;RX4P?M^=C/A_S-KO>!"\ LMU6,'VM;:\<
M9OC;V')F['+:,JNR%N+BQ(8C4B2:^WREBTAPT$<K3'PYXK[*K96#QCOT[?EK
M?C@::0];[=Z<"]$H_^7:'UO.E=ZC&D<F#26=I1JWE%0^,GDHR&J'7F)3EG&.
M*C*)*.DL8Y\R,B,[')*7P#>A7SRGSCC3V">-C.PA:230):9-)'#B%P_Z;MF*
M_?(DHQ1(AE7O&N<\;1.B3S5224Q:49H6Z,]+@J9C.M6B4CFM]H#EPK_.UA(+
MUYC-Z9\[1C"UN8E< UCSV+,F.>:&\RHKRFFU^?0^H]WS>8!]NM!-\,6\0S]?
MSU=2"N>E_OJY=LCPL^TA;]8@J6-@7=DFG-[ V7I&VFE54115U_)*J?(NMUVS
M:B(+SD>=Z[GD@UQR"OTO[I%(1O3HO'ZMX&&X#/2J_F4A^^63:PS@$)#<3Z;!
M[P&F!:'5CR[3EB<OI^J?TZ"R!:>]V8B4SD7#D45K7)!%*,UE)J[CXR"/X-<\
M5L4=H-%)#SM#DIE+G^-_RO]HM3\A?ZGSOR+SK.D9;75-?O57(>[J4N2W3J\L
MKNXIQ=U3IF?TX,SIB>>$"^8XGNUX*T\Y?<86^K1@%7 @K.95Y^1D<18&O*K!
MH=5!9-+#/03Q26!J8KV!YXT^G9U-)I,_76C\V7?&9XVKF_5*$[UYE=59)*]0
M_J.@E47R)^-([)V3!E&E.'.*2OY?)O)V[F21?.A9S+>;5"V75]]RGI\)EV:5
M,ZUT:Z:JQEE./5UE>$#3O9D$]JEW"#WTXI1)"C(=6<A WBVD+>[$1$.Z(*%C
MAUMDS31)#2<OH(L_NJ1-U*;(/:W2:^J^BVQRE 9"D7HU3VA>JG?I5Q?E.HL4
M3!;06BJ@=S8=&5%X@-C]O0V69SY@@[QP-M 2MT%!#!NL-2%MGR:D)=Z$B@*:
M3MW'=&KBIBN)V,VL+XCKV'0LU^[-5PR:=S*A47X0FK<(3=O0T2S+ED17$_(5
M2N*^0I>=6CC6=A,T09B596>VB(5=?/=;^P(@"<**G CCUS-9X%Q&$TN"4*4C
M4LGXO5T13-M:@-M(3!ADJLS(UO=WV\A,&&B:S- >H >0#<W/ -MT?8.#"1AL
MF>7E8Q;:.H$N;#\?#2P\I#0.LB IM]">0K(A*QX<&6<&*,E79],7'7A4F%1=
M9M+I"!5<<B[+S)D+<8-+[!7YL',FB/"(73OJ*!GIO[6C_,)$?N&2]5&U81YV
MP@OJH]B3*2]^U(BR0OKPTE(&E)60&*8F+H9I4HMAJ<=R,  FM:;%A=;!EI^$
M6A5GH@5;?A**3NFK#TR1Y:46C+B(XF  36KMAX<H#@;,)-1P.!G8L^4FJR##
M2Q0' V2'%U4X,\!1:V"M*G$RQ2I_E"C8?M?EA?-1V<@D]J,@DDGL1QTE(_UW
MX2B_L(_BX(7U4;5A'L7!"^JCV),I+W[4B+)"6L)XG?25%;8+^$@MAJ4>Q<$
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M>;"9#XR=E<@"&<?4^/12(@M9@O5,O P+\B++5:(T<&Y@BZ=&!0B#E9+:O:\
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MG A^3QJAT*X 0V6OT-W^*?KL,>$/H;DX$Y:/C#;D71YAH!/SM+NY?,RD.@8
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M\@3-=& ;?^F=;FVWTV?<8'^QF>&<W4=ZIH0W$4Z^X<5.>QK!1SIE+E:$RPA
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MOUN>)]J3+G]H7']FJ>;![GAEG1 )A2(![C'-I8 4-012Z1!<C.06>$I_N-A
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M+XGS-U7;O&$6KYSFS?0O4$L#!!0    (  V(JEBMI?_GS ,  ) .   =
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MFT;AO2D?TCTB>*!5HM41 7>GF]M\Y_]R5=\;L./N2]L+E+MG_0!02P,$%
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MUHW4U=X/,@ %2BGL>(R- H]I>_ HVX@2>PLN%5 <\KQB0QM6#OU.X6R=2*Y
ML'7)J8= #(WLPHIW/A><J5I\;M2BXL0X)%3L=0_>IN9F)0>YB,I7L([$ENZ
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M#:7T=]Q=Q#QR%IW72>6+-K3N@->R1V=U(E]#I>^EY.NKOP!02P,$%     @
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M,9)V^I?.@6CJ-/W>G8@_FOYV.E^KV'30]GY$US%A?-5&_"7EO:&O6X^1DE"
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M?E.35H]P=;#!V88*2'_,M@R.-S&4!./-Q)9X] 7N+G4=Q%%:6:I*'\?&8#
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M+2#XA%'?]'HZO-+EV6 -5A<NV#'2LM# (?H]_-!20C4\:_#7B,:P772SG1P
M W? P7%JI>KDQKA*4[S@H,8[.5'DG!O)$/'>F+IW>&*J(:4%A U'79R:01!L
M11V"(+8: LF5E:/_W4C_'?D[!KSOJ.DNPNP*KF)<XF7-'H.<H_&->]"_WWK0
MG0?]^ZT'_3-I99%:%MV&<;_TKEO;KA%CK;,J,2KKN22;QXWO_:TB7V9=W7\O
MSZ]_^M<#3)A^\*'+^B1YTP>;)$X_WBQQNG'[ 4J=R)@C_%B!S5)ON4?J]'A=
M=O0&H-@\(_V;1.;!9L@\:5QF<5O'@QC+:".0NS4\6#2[2G>ZU3K;3"=5._DA
MY+=A<X8"'\],1O:2KC-JR4<>QBM"JY-(@7?))YC U;AG!=UW^^)D78,'5]3+
M.PT=#U=LF2Z[*0JV[B@=D3O0U<6DVMJ*6IR'_BP1$+Q)$G;L('++^XU6W9P)
MF.(ZQZIPG1EEN'OJ5,/6/.ZB9=M==DG3].TD05FO!B^YJ>'"V.4]SA5E<-+.
MZQ8Q[H8"WR/&H%X]1GRL>;+?6[>35&,EI"@Z-[,!4A.CK-.R";N4QHP.\ZK<
M,^,]OPR9X &A-^:^0XY#*G8X^3 TU<F##@S!NHT&EZDUT0PA6ZD)*,[1Q:QB
ML/Q\NW6OW=?-@%RVILL2=^  VQM6EJ>@JV'*9GL0W(IU-@D?*S87K/*!C;II
MC#N[\4040BB+:D17MW$K/())47>(05T6DU]-,0%A_J=S/.V<=RT&[!UKHQA!
MF#*A9O*P(P2W ;#X82[N!)B:<U!X8.$L;Z XC@3! _$R.>6[=)R$&8Q+PW5F
M..?"OK@%L.CGX(N<+"P+Z:+ Z(Y5K4_Y+PIC4*/38*3RZBF-SEW ALS$P7QM
MX=%6M/Y5T?KD[GI2R\9>UI@H4 1$0,G>YOG7@,2ONDCPZ,7K5]<QZ>WAY9*\
M=&XQ@0\LC=*)Z)^BIDUQEO^*-N=;W/X%W/ZP"7+U9@?TO+Z-9O7M)NV^C%N4
M?1J4;8BS$XHU#A6L+>.;7(H;2H=&%AKEK[_FW)XM]O[>-BC$"Q$GR F[41+'
MGN(+H>+FE,YP($UI=4QXJ^I\<E7G^[NJ.O$=K,M:#D4O5URF>L*M%Q__^.1[
M3J[A:-5G1O('>Q?7X6R#\,33;7C"A2>>?F/AB8UO+?IF&-'3NS.BEMS9L;M=
M9I?W+*GZ%AQ^WC\8]73066!7_1[RJ_H.ZIUD-[AWEA(&!BXW(7(HUK8>>GVZ
MO)\8@D;+OQQXEXU,([^26^4 JT_]MY&7Q^<V[Z!;:<QE?WS+F\]+;3_J;G1G
M+T:JBEVNL$+M:B^L)=RK1RX=\D!,@1"4NZ6@7LJPL@ R:P4FH0[(BV&U[Z%1
M9>S\VO&^%FQJUHS*AV=IPVHW+@CT>T/@.:T!<S$Y(KXWH[XN_9Z?)>1A\LL1
MX,.[S>H_-T)8IHUN(.0H^TYP02]13?LFOMK[C??.9527SS=, T Y00&T69S.
M)6ET9=FU8OSTY\(OG_'IT@'6+1T=OB$)A0%B5:8IF]S/][ NIT8H81+1<C)!
MG572N(<XY"\VDA:[DZCVX0REZ7H0"J(\SIMO#!OG\3[^09R]>",.#G[<QQ+N
MX>ZJ>YN6^(+==R=]JTU^:B;^[*Y,_):;'%:P\X7O0^^"*M@T(.J@PFTP*+<'
MJR16W('<Y2VW>,=WXH(Z<):]V=)FVZL]_]'B0L '%#/T&G7<&L9GSM5I\(X&
M3H20W1OU'>?DN^[&X_$[PZJDV =UIZ7(RJ KAM;O!1#6[SJ<X!T9_SXYN8K>
M\P][3(Q;P?Z&@O\FI)F)?].ZHW/[^!'I_7.%C3:XQT"]\YDJ8:]L,I!XB/"+
M>PH+JU_![A-<SF!+K&8@(;-_V^T@7"H Z\<?K@[!26U'+'A?/=W;YDDEY&*Z
M(H- 7-3/CKNM;$HD7AK"1#_+3$Z:C?7/@7%6UE(4!"<\R62ZL)I@7._IK+ZI
M'A]Z0^$\>N:UCY%8G[+7N ZBD/ET#7!\S,QU.>[WZC;' U^EV,C6V+HZOY!>
MR%&=J.<:7X7SY*O&S8;-@:]7<.XM@KZ0QKMOL#RE4G:+D"^D:>PK1?D;9O:Y
MF=CG= X^VSH'G7/PV=8Y^)>=@U\UV]BPX>\%7[EF?74SY2$IK*LOY7O<38)E
M'ZZGG3/99J@#N]2?G8O3R^OSD]VM'/C4"!UOAM 7%:9%D9T<$L"V4OJ38V>R
M&79>ZC\JG6#OC.!.\ ;NW!3DIG39:Y39Q@BD#^U4C,& W&+R4V-RNJD"3%?8
M+:'176U'+8]=E_X(H_6WTEI5;@_F)T?GABDT00XN(53Y;W*,"Z!%^E4@[>MV
MBO]P5Z=X=S),MS.\<1D,MT?I[*. !]9U4L"4<^XO!-3 (9>N!J&8. \#I@T'
MIYC*!-.K,6F;KI^L<SU2S5=ZH!-U;?OC\ 3FG=?I(G7+85;/, F^+@U;TRQU
MIW9F4^T*M>_D#&[NLY1-]C!.P"UO0._CO\)5T/U> YAT,70S4!7[VNN 8S06
M%D*$:4C.(9C;5TZ[2X ;04M)74AWR><](%<TM;N",?"V.UMWP6"D$?X<2^:&
MU\OQA7#;O"RQ?Z>OW,%);[M >T?OJ_T!%[QO'FKI;HK_D2(M<2G-VE!+!R0^
M3J1E=Q\[(';V'(_N"!0[&(71MA6(V=WZS[]D__E)EE68U&"RRKJ\M?APTP>M
MDQW.L_TJ LM?-18W]+3S7<;<WF>+E2_%O<Y808W$^UY<D[<MAKX0?SL64(+X
M<\TLBRU'^V)<FFW,4+;=%CU?BH/R*DJP<"=G6X_RY7@H8_30P?F&PXD_;,.)
M+ISXPS:<>$LX\>-VVV%D4BLD;$MY=77QZOSR?^+R$[<_\M/^+7NK+T7R+I8S
MW\.-<Z6_KDT^.+[D2@&^/9!:+P[<74'D>JEO@&'7RZ60,^J<MP#N@!W[AXN0
MA.XSQP?4T\^Y/_AB'M=KTB<SNN]6=Q5J0Y4NX_1=Q;F4;.#;A228:YGG?*4Z
M>CSCOLUB9A).-E_*>N>-UYY8C[^ZERVN\Y8UMGKB+O=/VNWW])A!)OV#2[Y7
M[^8U6 B+:3"W/%LGMW\T_']\@G(-5FXB%^2J7IJJT7'44TNXYJJ^1R.T W?
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M<I+1\@GRLC]BX>!DOR2"@(J&=N?V'?R[=_'9*8@IV/_E#ZP.P$1%$$!\@X1
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MOEJW.W&^O_U(9%ES3%N=IY-YU$N$4B^H''_C5>\'KMN!'%+[FY]4'S.DJQL
M,B_K/[_"'&V\+8ST()D65(6RV*I]G)>(-=J;N2I]H^K%3(\X@R0Q4O=]O[ ;
M#$%8EBX4,793[5%/6>S,B-Y3B?90X#-NR65H1@TTJ>)%LS4D6!/8+'&&1FJ
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M]"%Z'M_G#VD:A-3LK.(,["!"-QQ@C#)(F9Z2,0MZGP '65X<YVX*4I!7O!C
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M/7+]@;SGR1X$B\W+!(]2IYU+^L)/!F2*[@3XH'9\G101\7)[I4F'4(E]GC-
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MTP5:R([)W@-XZL .GKE9'7UM1@S.=4(Y A_7(K54?:A="4@\KD]IBX4ZML,
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M5Z]#:;A?8$1:)S^8,/O_FP!02P,$%     @ #8BJ6'O'/UD-;@  87<   T
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M@9DV7-HV.083#\7 G4.71;.(C>9&=;/0KF'[0FZ85X#T(58#RERBY79]T38
M$<$^EW#=N5*Z:NU6LG7L5Y7MG\WP<=!/':G.N70)FC$M%P8(Y@<Y0-E1Z2SI
M=UZUA^FY&F(@B9+&%=5UQR&:F+UR1KU$,<*!8[6 D4G8-=^TNVX(_/.B!RD
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M3 6! UP%9IG6\D%M(5=B+5DB^IC7WZFRAJ9EF:C!&!.5_WY&!;BR_WZ2>05
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M.EK,MC#HE-71M+4NF-<K\R=O"Z'M%NY61FU2.TYS34-+;(5-'F2\,OT#\W)
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M,;B]N_F!@^"+)%,-IP 6 E0&)G[A$D&)#+E))U#J.2S*96YB)_A]>S<6++6
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M@F9Z]NM=,.)"##?I=O0)1.+/Z4F!EF1\QRCTOIQ -P!Y]=1W=O7 0.E!]W-
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M$G(/@,[1ZJ>Y/F&/1V29Y_#@#M7W&#7S5I'Z[Q'A[/.4:!APE]6NO\'A#X#
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M    :6UA9V5?,# S+FIP9\R[=5Q<S98NW+A#2'!W" 1W#R&XNT-"0W!W")I
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M:NI!4.-L& ';2*9$)#I)8A<.WE?..%G $^RDHP2O)+V_8CEV<K3&#X-=3U)
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M*JU[]F? =L:32I[@W>K3\66.VD=:2>9R[GREH&Q'(\\O+0\7>OVA!]//@)3
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M,)2.T'C6!?PK'-(Q"L@/\5$X_:<#I]GJ$6<6SJ(HP9[H/7![\P: RDUH?3T
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M?57B'R?<M[0%0DT/7#VX3S_SPQ/]8.D8 ,QA"5C=0IP6/B;1+(R8\342:6L
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MA\= 4P8#]V#N:+V2DPCNB-<"&I01W:BN>E >;$"9SM.T)]AFU*W:#[A^OH0
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MO()T!"W+X'I%';T10"U\N:*N70R&W-K+H,,ZAVR!J"*G5\6&1U&:%+X]+"]
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M4?PZ0*XI;,4]9@T1Y>0_U;D0GL'DS_P74$L#!!0    (  V(JEA$P!.6L4L
M ,FP!  5    =&QS82TR,#(S,3(S,5]D968N>&UL[7WID]PVDN_W_2NT>E_>
MBPV-#J_/&+^-ZDMNJUO5TUVRQK.QX6"S4%6T6&09)/OP7[\ 2%;Q , $"!!D
MNR,FQE*KD4C^$D=F(H^__]?#-GQQAW 2Q-&/+]_^[<W+%RCRXV40K7]\^>GF
MU>SF^/S\Y7_]_Q<O_NWO__[JU8OW*$+82]'RQ>WCB^-XN[OQ@Q<+[$7)*L;;
M%_\WW?Z_%Z]>;-)T]\/KU_?W]W_SR>\D?H!1$F?81PG]P8M7KPC!DN0Q1I3@
M#R_.</#BTGM\\?;-B[??_O#UVQ_>?O/BT^+XQ;LW[_XS'_)O?P^#Z,NMEZ 7
MA.\H^?%E9::'6QS^+<;KU^_>O/GJ=?F++_/?_.&!_J#V^_=?L=]^^_WWW[]F
M_[K_U23@_2(A^_;U/R\O;OP-VGJO@BA)O<BG$R3!#PG[X47L>RE#LI.O%\+?
MH'][5?[:*_JC5V_?O?KJ[=\>DN6>1?([RW0_397 UZ_S?WQ)\7KQXN\X#M$U
M6KU@G_A#^KA#/[Y,@NTNI)RSGVTP6OWX,@T3C\SV[JNW[_*Y_@_]R6_XM^,X
M2N(P6%(A'7DA_>:;#4+IRQ>4]*?K\ST;:?!GX$5>&*P0$3E91[FX7]/?>RTD
M\]HVH[]=>1A%Z0:E@>^%B2&^FU2M?,8YV8M;=).2/V_)9#U8;U*B[%KGUQSR
M'83-?<W-AE#>Q.&2G(FG?V1!^K@@1-[%^"M%[B6$"+?&D3_VDLU9&-_WP'A/
MXG5^.IM@,;\OPO.(7@_L;%1DD$,@9\\,?S/?C[,H)=?=%8&!S*ZZ2#D$3/)W
MC .VQ _3_)PMUUJ'@822N>TS)WL2HX<=BA*4[UE%-CD$3.(YWU'UA7S\19RH
MBKH^UB17-VA-Y>"%UV@78SJ%ZF'3)F"2OU/RN_$C4MX<AW'&;L=KM,V8"DI.
M@GCU 3U>DMGS97Q%3MHXBE"HR"6(I*DS^RR(J IQ'">I*IJUH>:V[,)[T#F8
M]\-,+C2ZLPCF[.Y4Y*<VU/"!=HU\%-QYMZ'R#F@--[6.V'<>>[L@I3KIDOWU
M"J-MD&UU%!4!)<-ZU1&Q:)97WB/=6JI(<@B87'G7*$'X3EF^^V$F><DW>D"U
MGB3%F0Y:7!(&];IBO5P'R9?#::FJD7!IF-H@"^PM$5G/; >2):.S>_DT3'%X
M'I&%D]*/#J)K%%(5G)@UZ:,BDT(RQN[<!49>DN%'M@75,:P--J@('#Z5.: \
MGUY'ZAM80,88HQ?D^Y51*P:9U3K(<7 <;[=!VNM$J9(P>:+$S"@A9"\"[S8(
MB;6BC!J?ABD0VZ;>T2/[D^J.E1"RQ^M"YP 4DC&V.]KVGA:C0C+F&*U:?WH\
M<B@88V]O:FFQUAQM<%]#K"LMGA4(FU-CJS:8%M<< B95Q](JT^*M,=C<#5@Q
MS;08XQ PZA1J&&GZ)U";B&$+BF^G:3'<3<^HBZMEONDSS2-C;+'R+*<>.YU+
MR*J-H[?U)93,+6&1J:+%<@<Q@U=8KHSKG5S5H0;/ G^#EEF(XM5ID@9;^NV?
M$K3*PHN @+**,1'C<89Q?A<&\9*(EOXHWNX\>F/>H?S'C#'5+6AT;AN8L$5\
MVE(&M;]31,_H^7B8K:HF%FM'GW4>,8-;H[(8:BJD_IJJDS%VK!]F .N-VM\
MG\&8-W@_-[L@YSOFP[@G)M%[[$5DAZ;Q28"1G\:XIWR@]"T(KJ4Z:W]$FY*-
M8ZBF3FOS6J=BY\BIS=$O: -(U,YW$,4P\%O&@O87",A9N[*:UD._"ZM%S=)A
M4Y@0,QPDY)Z)J9#9SXDFP/Y[^N!OO&C=4Q8:4UFYYBKGWQ4QFXP=I@=BMME.
MB"83X,<3HK@E1#4[?4#8#Q)B^@6^"1E!)[%P05S&2T2LK5V64C6T8*2XH#Y%
M2T0UTZ/0\[^0(636Y!<OS-@1Q0;V^W83<UNQ#UCH&=%:J9U$5._>:U9(T()
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M&&_7-%O^GA4%><YB?!ZEY&Y-!J\8*N?B*0BU V=;G9T:%BSUO6F;]FRP4[-
M7Q =B%@(1ZX+O!T)K=1@"TS,\3W64T!PS&R\$39#"DXR3-A6>;F24YCRUNG
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M45^>1W,(V.OGW5NL=DKNWO@;M,Q"&BR5I0FM+DK/K[*,QS%A9DUAV: *7Y5
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MVZ/<NG-T\.5\N97*'1]N-D1%R6[)_RL@W!XU/80Y7V[Z)8G-LY@MO2U72Q*
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M_0QW-Q4(Z^!#F(CGL1Z'KW#:Y_4/UN+LW7(HU;1XKCV,NO3)')S2GH:QN02
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M^C33F1>GKW_)7S]J]S.M6SD\B#'F<^[RL_N3] ?>_4GSEY% :51N(O%GK0F
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MIPT(^AL^\!&P B&)]D N[4+^/^OS@[6<5@E9E*D%'9/M>0Y$'!72@.SKFUV
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MPVT_1$7U;Q05Y,D?$3%^XM#W5NSQN[AX?):>.X3;+&LQO7/M5L=G6LQJP'D
M )5GMSU%,-1KU2G)I?-L^R27RXC=%Z=Y+$$Z=?+/QD/2UH]N19(5)< #<];/
M$.ZNQ5,=E'X+ISC 9//N=8;;=S2KC^3V8EWB?)=0J%]0LJ%.!T>&4OTG^:74
MBN36CA^/U ]]CPR;!/7!I<Y\K9[W'K6$SIE!GTTR>^^X!(CA QMH?!N!$X 7
MZ$9D]K VNS=-UJ*H+V#_)*=#J/5M431K+9TP6?UGE[K?\1GQ4\/KR NC].5L
MN6"PD(#Q#4O$#0"-2A>TVF&:]KNEO= V[6;/"Y613:%J.F>N!8_FCD1+ZWC!
MS@L>%KE;)(42&3JF+^](\"2,5E35""(;.2O,D(+&J@VC(+,"/;)KH1.P:I]?
M?J]Y@/R]]0/D[\=_@/Q]2[C0-#1C5LM'"I3T].@\C,@_?R6[ZCP^\]9KS-["
M(^R1W]XF3K!RHM6-DV :-$CO]!,DD=[S@#2X"[P$KWXF(%N%F\7Z^#WY74[$
MQ5,G.&41B,"EMO(D/@]]/_P,5*H!,#067DWKMI',6U <AVK/[)0UUYW,.//(
M+IPSB2C0V9_BC$_$JEJ$M+!KP2HCY06L7<HNROBE#8_?_Z^O$1UP57"-7"=
M]YB% %/&D1,3+ACK/]A,$1B)V%H:9"1\Z3_N1-]3I*<NIYB #>>A!BD5 O4U
M_^ 3GQ$PZ3&."<AI2_J!V ^M=,B@_O8E,,U^-FR.K/29%CI$BNC5)!$!5\W
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MF-VBA+SHV,0-33(>BY@+D>[I#U!Y+X]L7WAXMUA/G?CQ- QVZL%GB([-+!N
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M.5P^AKN8N.+G9/43C%6$*TG*>*ZI'%\ )$Z^0[0;.CDZ_L:^CE:35OG!RZ^
M5AAB^>A%R<MD&WE^A3I]4X^=**BA2)*660]6DBL 1&^/$.M*4?3]&#PA18&5
M0%)8!MWW=KSG2^>E3CW%KP*(.HD8WGNZ^ %P\QTBO0AH3H[& !I9R90OY<C,
MNM_&M20PP#_M_+Z D:=F-,XBS1:T>[U%M!\((4L;F(+4&GN8[%+H!6U2,N?>
M$Y[L'G9Q,@BHI,B9=F>D.8. ]2U*>T+0L@,L%=$UD"6]&+H*JW("KK*3M7J9
MWKJ:#$!W]V@[E#8<AP,%+GBY07'GIBO@?^$H7 18@"+R.P71J] S[E0I, <
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M7WTIF_\X9-M\_<(>ONSWY4.10\]9S1>=4X.5$Q E[7ATS-L^('BCS0+' H#
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M?=[/-&WAV;5\PK%8L)SD)_4W=*[:-BG'_2C2'-#D7F0?L>-J*K[HEH"04WI
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ME)Z2D)<6D K*=8=GX2GH$04T)P<DO1$QLRZ.8( I[J.YF,JEJ>>^C31S]9,
M(^U;N&F9L;:M:*XD2X6ZV8 C_/J"_2%?9MM%E8>JNO >I.M">!_\$D9N2@PQ
MA(A.;126CZTQF;+]Q^C$,F5#1-E?H$$N3"J BT_YGJVCU4WV C["!9MIS13@
M4T9R\4*4;_E7R%Y\AC3:=WY+05VQ##O.N39.' E64A<A/%NMV*"U_ ^84LX"
M<=*RZ1OU#V%DFA<4Z?WAI4675P31J"_O]T[.FR_O]V<3>GF_-Y,\G<0EXK!/
MUN^/6N"+IW*""_Q][ )_/X4%[N2\98&_G]("?Q^QP--RN),U>(FJ?:GE%5S
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M JHZ-8CMS$IT)GOH[8B8PJJ1$"31<>O%\B:9Z_B*#=506GQF#-AH%A@-S2L
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M#M>?KB6DP:0FY05M %W.F@]GEW3)+S6FZ)^-P?V$OD3OC'B'!PDSUWP<*W!
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M,EZ#95\F[&=0F/V>&ZX@] J,#<G>5'0MNKU]_^[]AS/VO]\_UZO?Q0^4'O;
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M^-)0-55'VQL;&(57%Q!;<*^JRSK 'M#-CB&RP[;'.,8EVED0J#([K'+VX4\
M>BB]0E88,M&,J'8X4K%,>!AX8Z4GY4G%ZYEWH<7SBILS9L^YNU8F]- #J\F\
M$O8A MU0GSMN:HSS*D1XPC>FF@-3[=<4L$(Y;"B@C;INBY;U;1<%"0N],+V.
M;EH,"83(3BB!FZI<Y\V\@IH<@&O/K5AW346+!W;R%9Z:&*(G; %>FX3C_?/>
MI-<=+8@S3)EI>(ED1LIC2H4%=+BY3E- &UBAM<73H"P3-QCN) [!L^<']>)Y
M$E&:4PRJ'J\W/C'U:2P#(KSQ\7Q,N:-N $OS@Q_?1[0QZI:D/\2TN9K'E4%(
MJI"R\T\S/__:!FC'?SL#@VV#R:>ORY[5FRL .H>W_5=>\%B6+BT>9NQ1_\@3
ML4*!5QR@9,W![+DIY;N#J#S]/5FKP4C6CD9^R>1XR !5XXBWGS'',##U(UP'
M(S]_N3H42]^K3:0RR2B1-^2>W1*R!ZZT[%38I>*C.&DXW771,%VB;D0&V[RX
MWNVSO**KMCZP\%:SRZGR( 6H450..KO.<SF0VF'95J8XPRU?H<,(C*/;Y?P=
MSSND4'1A,3\^5UKZ"X*8EZB1R&XB[1Z$2-[@U$)0<_CX3*LEX.'$54!HG_QM
M/W3IN BR"\5/?DK5=U"]*X!Q:50I,_7AY.RW4F"PW4-GZK3)6_J0@R)2-%^R
MG3-:5"9.=HT)M$9BM&OR0Q.NF\#D.O5YV3108BBB+(%HZJE,@')Y6PBPW]!.
M2I/S?  ]IXXUCCXG\YUDW+W\$_A0K@O#FSFKN"#@GZ,0_JC\H #Y:S&=VDP'
MVGV5*7%67W/6?1H_(>(;\=.^C+ZI\!*H^W#^7+#39U;1[*)<.0]6:$.@$8%6
M>-XP?:[#<]2D ]-EK.N1"JI".4*%15P]$D;[D<7^7(JQW[30'9IG6431LNTJ
M'U^N:@+H'N:CN!1V.[^"^6DCK7_*\J(&/PFMYP6C8%_6V;:&\@ALQB)>SPDU
M"5W)=UO>^7MX6*]4?U%<HAT!_TR.(-,NU&C^I M9S+?LRV5!5>BD,V!1-6P#
M2#&C%8>S-G1]!UV)[J 9^^0*/GNUS9PAH&TC JT0M?K>;(V(#).45/X$[LFX
MOO[WPRX+%)SG+8EL.GR/HGAG>M.V^V@LE.'D4G4..?VB81>,;J=H@E6@>OE3
M6A&HOH$-(@)ZEIQF8BE3X[AAB/:UC$V-DL]U^T#T-&^#BQ<IYFFWI.DT)#0[
MWV9Y#74Z#L7*:5R6;0AOA'AAZG,U[6(&(4D],_IF<**_2]Q^W@@[*$*?L%W/
M,TG"0B?E/X=T.Q.E5/S&HNFA Y;V"#*6<@3YZ8.(M!M!Q)+!"P"\U"VF<^>?
M'OUZWHN ._YP^EXX_3ND;-W5/]D*?&-X$GXKC^=PPBM#/=/]E8E;)_.P&G'J
MO=>?KK'9;-0D3P73<91F17$ "XFJ.12+327ZD6&5)2P_HHLDKW/7P8"4\FC#
M :Z+NJEX):CZ"PV 1.6\8'W;GK .:)JF@P"#[UY"TRGPO#P3) ?>T:;90L"3
M, :ZECYO+U,A91<(D__8QRA('I+GH,+@NI]<1(?Y.7W(B\*3[&OQF;=]4(\;
M%R$AU_F X@D[&;5DBF0NQG6;A#+"P3AQY^((/K[6M3A:9.F 1KC9+MX>:35'
M(FQS8]X.@Z3-'IDN)F:V6K%!ZPM0)MVO'QD3(QN_(;(Y/IYX?_I#,[J;Q)07
M5_L<@O>1&T=</1^A%3)HN#9?8]%:J$E6U57(\X*=0Q6H@2OZ_'<:6K.R->'-
M"6N/5M#5.GO[DK62F.S$Y1? N78!E/ZJ>N)U=ZX#W91&.3V41YV%"/M[SDDM
M0O%S'FH ^*E&0MZ\X' 36V_:N4*W 7!2E86XZL8 )W_3C8)OE8HFV*[BC.17
M0KO3!6-#7I2[S*^VM,TFH+,,IFSL%2M)R<ZEG^_R71E0 D4;_&Q!?:X&&TU"
M4GDJ>G#F':"7+"3!?K<HV4N O1H*M9T^EX_4Z\?H#4FZ,=NR&_#K14GDN!WF
M?#LRHIA>P0]S<[R6MUAF7.'/'9.J,XDRAF(J7ONL3EDZ$^%/%[2JRB(0_*Y:
M&6=5:I[VIVOPTT9-<JU(\RZ&LG%UCZHEU19+S;%08%=HG*0F]2KT#ZJ'+"]$
MD*CKE!B>[ET/U/(3+C),[X*?X+01O?S8XN"#LKX3U*[WG\^\>#:I9)FK)6L_
MB8"-(1'V)>^A-Z&^_N\7%_X3NVV =OVU,S#6[V#R*<^*!:T@"8J]PQ@9FUFQ
MNJ2/=%ON.3QB]LQ$FM/UQ3;+=\[3 X8 5XT:A <L:L,0-@X1 Q$Q$IH(1E!K
M"&DTI]+I+ -?DX8=,\*_IO6:4&*J-JN0B\T@.^'Q\SE[SG>'W0UE Q9-]@ .
M&EX'?44KR/CZY+U_96_2=>>EW/0!R*?A?9P\@R"*1$-(8SB3O#B7@&>(K<TE
M6EM*<^%$70QF;VI%;AH3[HS%IJ)T42Z>Z/:1O9F+9N._IWE[,#F('H1WL5C7
MTM\=#D+,B\)+<<K+?;9:Y7 <9EMI'7>#WZN&R@> >- 8LS8X[* KE1WNR^SN
M<O8?=TVY_+4U!GG7M-9!LZ#A+VDG(0;' R2GJ_+01\*#>.6\H-<-W3E-G%I>
MC>I#H!/AO5#Y[Z'&7/,ARE.M?JV2Q*(\YS5M&O8 ?\JJ%8^H= M"J[ !(76B
M*Y%]16 IIH(3),QR#D6Q(G79 8E:?TX+NLX!)\=;8$\U)_>RO5%E#Z<D@)T*
MNPW"2W+B_#!IO1Y4PG&GZ"CCO*W@#Z:%WE?OQTMH8G[KWG_GV6.)<D#V@_2F
M;6>PA;)TO/UR@.O=$6?H5'1XIZX.N>S7@8SCJCL^DDR5)\R R:$K"YA!6"_L
MSQQA\%1(RWD[,F\CX!JGA2KR&M[8KY43L#LU DT/+R,457-+E^5#D7/D5QVS
MW6D(D7ZB-C0)/"TRD0X_%NDDI-L7P@FY.@689$N.W_$PR?;<R>G")'N(MPO_
M& :B8KF.Q <= +GZ8$+Q(T8BH4)C^)',:&&D5-MDX<X?QTD@]R>,]ZE)J)66
MN[R0J9O@<P8#-U/1P"XU6WQV\5;VDKFKJA]74[E-CG5%M#OX:3+UT@@6I(UX
M&&0F:0]"77?V)8Q]-/+#RFZ0?JX8=F1$/+$.4\5(9B4%%@DIO'?T ;:]2)=F
M?SC5ZZ(6XY)*#?S;>EIXV'+<PR+(9X27Y[ZBRUPHN(-Z]6[1=WW>D IZO2W7
M;UD_^8"<@&#=5+DD%^)#8FNOCN0A3!:S8N5+':V'L+0CX5,*8>,!K-$G?YYO
M;2;Z3A=3Y96\<ZR64PLG[<4N8$JT0JPRP@_JY+[HQ7/=@(U\ ':NJQ'>M&&.
M4(WXI5>E&']!1!-L%_=(?B5\).I*8_3SL*\V3ZM\A)<@K\X\@?(1YA-5_+\H
M67YSJ$"K!T\B_[6R-[&CHY>E,NI5+_\CZ[FK3X!A7IKJV[@$B-[L?0<[#_35
MC(HP$1S/?^U$+OL<V4))WK*R+H#EAJX.6]#_]8QLTQ*UJ>A:]'G[_MW[#V?L
M?[]_KE>_BQPEZ:(.S0;X95NNLA\\Q_N)]&R]XL?:18NJ6UU1C$AF?5I4-&,:
MR(M8XF?.N#O93)X49YB'^V#*!H>M)*5@*"3Y7R_7E2RZ/6L:RE[O<!CX8*NO
M+ZYNB2HHKO49H%@G1C1PTZ'S.X;B=&@R5;FD=,4-\7?95IS(VRU=BH>T#'CM
MU"_7#:G&(3 0@9'DK:?&@K-(1?UVPV&68!Y%M[%ACF-<XI?L!0\+;X: I"XA
MRN:B!C#9=AV0/4YV*ARN)1_).ON/42W.LSI?PLUS0X4B<Z1RX1XGI9<K/)T(
M_8+W%77666^I^9HZ!J*2$12:1<WP<R2I ?D+(U2L:5G@,N!69NW?R@YM4,E$
M7,<N4NP[V4]X2CW\HJSV)5,[X9"?K=B[EU>5\ST8VQ[\%NSWP5.\W7086R%$
M<FIOO!ZX)R%N]+JAD0&*1($!&<54T0,6!T39']A!+J2*6->\I-K#WZFMZ^YA
MW92"ZI.WTV PWD=J*G8;&,MZ_=Q/919IN!)6QWY98>B-7K361YK7U.1A1F)5
M^Q,[*ZO%)BOF!?U/FH%7XDO9M+]=/)7PV]J?U<2;DX:U)X"$\L)Z<*]043*E
MO/M;\U3RO]5FA5 T._\H^NT7_A$L3%>B3$(371=?BZJ-1KRD:\HTE-4B>W8F
M(LN. /^D=R6J+^3R8^8@AP@S]E\D*Q+FZM-LF]=<.>'PW,XZ.%T[PANBW?[#
M&1L\MI.44NDZW&_S)63\B&1GYP73MI.YW'@:U6#&YKUA)2EU-#FOEWE1[O85
MW;"YY(^1&?.\'UGJ'4DNLN=MJ$XH=T"(-ONQ'\>1I&]NT"*DS]F=F<,;23\\
M7AJ.8]*.&]:D*W%JF:Q'%1]HVBO3-[E 4S]-=M4UP(*T\2AZ.(W 6JY%B!S8
MK&7,W/B )LI'^K=L7]9_K;5T!AF4..6@I1@FV#?7<:Q,M_\^T^J!5M)L,&O^
MEA6'K'HY>__N_=D-K=Z_NXJI7"0&:>THLX;HXQ ^$+ERUC)*KMV.H=G4=,=S
M+.WNU2& _E'RL-9>)>YZMF0_5^X[3(-'8MOVD0\QK'1>DTR.@K]3HPFV;]&1
M_$JH;W>'QR5MLIQ7%EJ7U4Z Y]Z7AZ;U*0(8X +.E,6(:KAJ5*(-2_BXNF,6
MAB9\;+*P5,3%K(E[!%N,_7P")J>V>TME00^FNBX^Y?3 9DI#(,5*:^I'JET7
M! ;@<J<Z/ BF\N0BT*M"^;F2^F5WR0Z.);O8V:V_.Q14>$L"2"%M'Z$KL==$
MU]4 #<%2CMQDN12A$"-P'AWCC.9J\WC-Y9A;)LY0[J4=,;'BXWK-%LE\?<$#
M0>?K:S8_ ?PC=.>[)FL.];QHRQS"+^B1SQ'^+?B7#,AE_\K;[\G7"JGY%Z$>
MR+HM"EFW'YWRD^4DK(QXU)Q09)TY)RH.1\-&5F.JJYI]YZ:L<W&%VZ)Q@.$U
MXSCG-@S$6=YDSV51[E[^ '$Z;]]]>/O^PQ_X!Z!%]Z^WR[+ZGZX)#^89.9G4
M]U#,I%R!/:HK[)!N%^QE;P=^/!*>]HB%,(#7CF50XN-Q464KB+?@!M&;[ 74
M3V=T V_,G8,EMPSO97OL9%XK$78Y>.A-K6;SDJY"D93/?;^C5FK4HHRMU*N5
M3009$]U+CUU'\%.?/#%6O<:ERC@OSLNJ*I_8:]VY&]IJY5)GAEO\ONV%?UAY
M2++OC2 /DOI#+'@MXO+OX;6,![K)U2 :T WR<R>.5+O0QK I69'(RW+)BX-?
M,4TNVT($Q17[C3O#7#8GHCV!#H3WP#C1/ 3H(@C2F310:QY3'G(^C8J0<U\5
MR/F@\F.:8%NVB>X.U7[K#N3@!XIL@W;/:O,TN&?0D/H-T&;&RXQXA;RH4%W#
M4>0=)(%"(I H!?">5J/8'P0XL>6Q%-N/[I$,2R-/K0"N"(1OT4O$4]N)_2-+
M_<HL@+87$=VP#G(?*</3/$QV6@5(9A7%EUUK<ZFF67[-39!#M0DP ,55-E^[
M_3@?LZH ;5DE\(SVF,W7 :>9^H*6]^1SG2'ZSH[GD\>%]EKFOS87;[;=<L/!
M/[(JYY:#6[K+\@+P!)JL:([,S(L=-5WQ\;%3B\C98R,1$4_8CD7$8$2--BF8
M@)&BMN3SC>%=ZKO]XXY6#VRW_,3>]\T& B&SPNG8D%>[ZD-$)R)[(5TK 5KL
M=[N'[(27B0\YJH4FOX"(@.W6'4:C1B%RF!;0A_"!.K!VT@Z%>C6,H]K85\<P
MK2?3^//>J-$RZEQW]TZXQ)R3<)S49G4=6SXU?F4=Y['K)SB5'4$%\C#]XX&R
M*54'NIH7P@_>Y+Q,7E9\*1M/#5\5%<6'('(,,B^(-@J/""!\'$1;3CRQAK3&
M\BE9BBE/ F ?7F3/<&6S@X7]Z^90[4M/W4=94)!U([(?!^2">JFJ*Z*8_#09
MHHEA03)%M"W>(2*9(^J5B(;3J$\BYF)PV$I4*M@C"0!TE5>[:Z=JH4".H!6Y
MOL3BIC'?H5)G(0;#0A.'D7$1Q,= MLO$X&-X*$ZIW70%VRX/=%$R);"LV+L_
M+U?.0UHO6\<Z@1N==R.RWS0JUAGDF(I.D';$ +M>=$6'0S4^>JX91)ITR+-3
M*U<TCGK[KCJ*A<G<B[1Z!$CCV4-%>023@,=U>AIE<]*V)Z(#7G"*G0#3<N,C
M-%WT<!?A>%WHP,-N[;,-*KTNB.Q!>!?,IYN+#(O"Z:,W)>224'V9MGMW45&F
M603T?=#O94L\@^5PS@Y]?DA4PLM:#\@OUW^G+Y_9,?; -QB[MNJR*.A66/7#
M18#[8Q$V&.E&(^UPTHGB*!"<'GAA/ ,,,1[/Q:1A*#+R_Y:CB]+5K#F3"8R0
MOQB7^Z#Z$M:9:+U1WW1AXLSK))(?*4\X%^S!%]HPS2-[#M7$<\(."\].;V2B
MS"*4>R[AM&S!R;7QP;2E?P'O*'TU<XPE<")V)S.WR-<=FQF?>0BR%43*&Z)N
MS<&D#2%8B<(#/&#+89<WQ^44+;N^$TX-LE,8?OGX.),\'ORFK!L1<@83D@7)
M96#T)?MW0:&*0%/E]P?8J3=LNDZM!<9ZVPVF*K2KN/$W9"4&9/+M1B3  ?S2
M2L?PP2[JXSF:2H/YNF?4,WU*8%VZ3C_92L%[XMU7_>D:YYZ-FI2Z1L_'$^GO
M0DP,[T_7[[&JDW)33]!80LD$MEW$?Q>;JCP\;)0O'"I5>.LXJ?[DNY4<X7O2
MB#&ZFE]0M5$,\T:B<F"'V<:2;3]WQC$MK6+@"VKHEQ#["0!W(>R-__)>P^2=
M 1:O> GZ:G/^["_R9M9X>Q!?)'DA_O"6?Q1R_O@EEG6?1<Z>^09,M*^D;R:M
M=,;%Q6R5[0* L*+-,*40H7R,-E?C/#8)2:4EG,,ITO!(H\K/2-%2A%]5V"F:
MYK0-GKHH2XR<X0$<CTB0#8"OF\MZ<C#LOJS92-ZDDUB+%&O= #W V_2<MN/<
M:E-.9EFYI?+>G*^A2@S4$@N7QFD[<1 8T8U\LE3(03%J>PBR6*^#Y*=U]+ /
M9UN_(U,V&GHO<7QIVGPM'AZ#&@QO93W675F[_95XSLHZVEMII3?9@3);+@]@
M3[E;YMQNS%XYW05@C7^1'8CJ ?9Y;*7$287!]P"]:9]MEIS[MD;D:Z ).M#:
M*4,36$BUOY?&L"G=B26?:/&)%K+#Y!(JG(28?B@_R6DW#_B])*@7^Z<HJ>I\
MBF;/&I!:PW[:\O;(F\)&@GT+N(E-=E,, \EX7F0XU$)X=+5^(M'4$5.!XZQU
M4V5WQ8:XD!HQ00 !AP*'1:LI!0SWYVU?^3;:4NKXBR>FH[W<Y<]_.VQ?%D_E
M8E,>ZJQ8B=\O-A4-P&V)AH2-0& (PL8@:A B_\B',4P*R0UEL:2:5K1Q3$J9
M<$_K997O16';07+7"[O(OM"G6;&ZI8]0!^BN87/.JE4=SK7OAN5)R8.TMQ>>
MN,/&YB44Y>BD'7XJ -6OXXVQ"D["Z]>FU@\/Z"-SZ9W#("3/N^82D2UOWKY3
M2,>,EY8E'=[+C=0WKZU4L[7>SK2J4L>5H[83EYK%#K_K GXX5"\"HP-BW;+E
MT4[K1@XF79>--IS%>3TI[[63#Z.\V %N)G0L=II$035-XHI]HJ&T&*%KL>=%
M3]=20UA<-YBJEH=,GYX5Y$Y";UMW-A\:P"19L5O_*LLK4>&4A[JP=^N&:J[M
MZX*=VASSL#8!=JQ..?U6ZSY#X#NJ.*S(=8<@X0TE.E0AT3XW+:"CD_+.=VN>
M2C+"/2YYQMZ]OTJ^L=^P'R!$ 12D_P]02P,$%     @ #8BJ6&+@#B&$3@
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M.I@Y. TV&QIWLBA%$I 6)1!!"2-[29T[ZK%HQ5AJ<AI00JR'>B<[\2?3%=M
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MW"'&/DI\($K/F-?*XR3F>G?6627!(P"Z#S"8\"X<&G*AL1]_=D(NV.@3MP)
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M&VP5L/Z&!586%Q6J>[#RY#(6T$&U/PMI$BR<XV,+NRB]FV1YQOQ.W[Z53D_
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M<A7=&.D_/%&-CUNCB12J2#6R_YJCY[C%W&(<+8IY#F*^ZB"F1>6.N@7T_);
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M04A)-%L6>&-_[_7R7@L;*%H!:RC*>TR;V$%TPD0CF)^31&P%WF8[QM1W#1*
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M5?B\H/?*I:_RGLQ(8FRG[4":R@7C,%BB;#E;:(NWR@"6/VRU5&O2 SM21I!
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M=_?XQVO.PIT3$?ZW_P]02P$"% ,4    "  -B*I8&9[ B,D;! #Y92$ &0
M            @ $     96$P,C S.#<R+3(P9E]T:7II86YA+FAT;5!+ 0(4
M Q0    (  V(JEAG>;0SXP8  #$E   =              "  0 <! !E83 R
M,#,X-S(P,65X,3(M,5]T:7II86YA+FAT;5!+ 0(4 Q0    (  V(JE@'%;?%
MV08  !LE   =              "  1XC! !E83 R,#,X-S(P,65X,3(M,E]T
M:7II86YA+FAT;5!+ 0(4 Q0    (  V(JE@<L]"[R@,  * .   =
M      "  3(J! !E83 R,#,X-S(P,65X,3,M,5]T:7II86YA+FAT;5!+ 0(4
M Q0    (  V(JEBMI?_GS ,  ) .   =              "  3<N! !E83 R
M,#,X-S(P,65X,3,M,E]T:7II86YA+FAT;5!+ 0(4 Q0    (  V(JEC=1/PH
M5 (  .$'   =              "  3XR! !E83 R,#,X-S(P,65X,34M,5]T
M:7II86YA+FAT;5!+ 0(4 Q0    (  V(JE@#%*RI:@(  &X)   =
M      "  <TT! !E83 R,#,X-S(P,65X,34M,E]T:7II86YA+FAT;5!+ 0(4
M Q0    (  V(JE@.<=1+KP0  ,42   <              "  7(W! !E83 R
M,#,X-S(P,65X,BTQ7W1I>FEA;F$N:'1M4$L! A0#%     @ #8BJ6&I8UT_C
M'@  -;X  !L              ( !6SP$ &5A,#(P,S@W,C Q97@Y-U]T:7II
M86YA+FAT;5!+ 0(4 Q0    (  V(JEA2(400?T0  !58   -
M  "  7=;! !I;6%G95\P,#$N:G!G4$L! A0#%     @ #8BJ6'O'/UD-;@
M87<   T              ( !(: $ &EM86=E7S P,BYJ<&=02P$"% ,4
M"  -B*I8[ (E9U%0  #V6@  #0              @ %9#@4 :6UA9V5?,# S
M+FIP9U!+ 0(4 Q0    (  V(JEA90G99C"<  &4/ @ 1              "
M =5>!0!T;'-A+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    (  V(JE@O@M^=80T
M %J9   5              "  9"&!0!T;'-A+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  -B*I81, 3EK%+  #)L 0 %0              @ $DE 4
M=&QS82TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ #8BJ6"[OTIGAUP
M_Y<* !4              ( !". % '1L<V$M,C R,S$R,S%?;&%B+GAM;%!+
M 0(4 Q0    (  V(JEABX XAA$X  (T2!0 5              "  1RX!@!T
J;'-A+3(P,C,Q,C,Q7W!R92YX;6Q02P4&     !$ $0"8!   TP8'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>ea0203872-20f_tiziana_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tlsa="http://tizianalifesciences.com/20231231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tlsa-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:ShareBasedPaymentReserveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:SharesToBeIssuedReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">tlsa:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">tlsa:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:GCerroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WillySimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:JBrancaccioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TAdamsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">tlsa:BlackScholesMertonValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:TizianaLifeSciencesPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentySixJuneTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ThirtyAprilTwoThousandAndEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:SixMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentyThreeJulyTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentyFiveAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ShareOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ZeroOneeAugustTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:ZeroFourNovemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:FourteenMarchTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">tlsa:TwentySixJulyTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:LessThanThreeMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">tlsa:ThreeToTwelveMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">tlsa:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2023-10-23</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:AccustemSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:ClassOfWarrantsOrRightAxis">tlsa:NASDAQStockExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:RasnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:OKYOPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tlsa:RelatedPartyAxis">tlsa:GensigniaLifesceinecsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">tlsa:LaterThanTwoYearsAndNotLaterThanFiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:Phase3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIHumanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:CarcinomaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:HCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:BreastCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIHumanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:PhaseIIIHumanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001723069</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">tlsa:BLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="gbpPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gipPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:GIP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-24637">20-F</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-24638">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-24639">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-24640">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-24641">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-24642">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-24643">false</dei:DocumentShellCompanyReport>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-109">Tiziana Life Sciences Ltd</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-120">D0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-24644">Clarendon House</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-134">2 Church Street,</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-24645">Hamilton HM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-24646">11</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-24647">BM</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-150">Keeren Shah</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-155">Chief Financial Officer</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-24648">14-15 Conduit Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-24649">LondonW1S</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-24650">2XJ</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-24651">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-24652">+44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-24653">20 7495 2379</dei:LocalPhoneNumber>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-24654"
      unitRef="shares">103087744</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-24655">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-24656">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-24657">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-24658">No</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-24659">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-24660">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-24661">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-24662">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-24663">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0" id="ixv-24664">2814</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-24665">PKF Littlejohn LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-24666">London, England</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-24667" unitRef="usd">1183000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-24668" unitRef="usd">18122000</ifrs-full:CashAndCashEquivalents>
    <tlsa:PrepaymentsandOtherReceivablesCurrent contextRef="c2" decimals="-3" id="ixv-24669" unitRef="usd">223000</tlsa:PrepaymentsandOtherReceivablesCurrent>
    <tlsa:PrepaymentsandOtherReceivablesCurrent contextRef="c3" decimals="-3" id="ixv-24670" unitRef="usd">300000</tlsa:PrepaymentsandOtherReceivablesCurrent>
    <tlsa:TaxationReceivable contextRef="c2" decimals="-3" id="ixv-24671" unitRef="usd">3793000</tlsa:TaxationReceivable>
    <tlsa:TaxationReceivable contextRef="c3" decimals="-3" id="ixv-24672" unitRef="usd">4246000</tlsa:TaxationReceivable>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c2" decimals="-3" id="ixv-24673" unitRef="usd">2138000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c3" decimals="-3" id="ixv-24674" unitRef="usd">1614000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-24675" unitRef="usd">7337000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-24676" unitRef="usd">24282000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-24677" unitRef="usd">10000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-24678" unitRef="usd">17000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="-3" id="ixv-24679" unitRef="usd">283000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c3" decimals="-3" id="ixv-24680" unitRef="usd">372000</ifrs-full:RightofuseAssets>
    <tlsa:InvestmentsInRelatedParty contextRef="c2" decimals="-3" id="ixv-24681" unitRef="usd">4554000</tlsa:InvestmentsInRelatedParty>
    <tlsa:InvestmentsInRelatedParty contextRef="c3" decimals="-3" id="ixv-24682" unitRef="usd">1806000</tlsa:InvestmentsInRelatedParty>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-24683" unitRef="usd">4847000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-24684" unitRef="usd">2195000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-24685" unitRef="usd">12184000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-24686" unitRef="usd">26477000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-24687" unitRef="usd">6387000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-24688" unitRef="usd">6532000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-24689" unitRef="usd">138000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-24690" unitRef="usd">122000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="-3" id="ixv-24691" unitRef="usd">14000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c3" decimals="-3" id="ixv-24692" unitRef="usd">9000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-24693" unitRef="usd">6539000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-24694" unitRef="usd">6663000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-24695" unitRef="usd">109000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-24696" unitRef="usd">243000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities contextRef="c2" decimals="-3" id="ixv-24697" unitRef="usd">6648000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c3" decimals="-3" id="ixv-24698" unitRef="usd">6906000</ifrs-full:Liabilities>
    <tlsa:IssuanceOfShareCapital
      contextRef="c2"
      decimals="0"
      id="ixv-24699"
      unitRef="shares">103087744</tlsa:IssuanceOfShareCapital>
    <tlsa:ShareCapitalOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-24700"
      unitRef="shares">103087744</tlsa:ShareCapitalOutstanding>
    <tlsa:IssuanceOfShareCapital
      contextRef="c3"
      decimals="0"
      id="ixv-24701"
      unitRef="shares">102272614</tlsa:IssuanceOfShareCapital>
    <tlsa:ShareCapitalOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-24702"
      unitRef="shares">102272614</tlsa:ShareCapitalOutstanding>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="-3" id="ixv-24703" unitRef="usd">103000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c3" decimals="-3" id="ixv-24704" unitRef="usd">102000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-24705" unitRef="usd">16492000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-24706" unitRef="usd">15596000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-24707" unitRef="usd">6905000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-24708" unitRef="usd">5190000</ifrs-full:ReserveOfSharebasedPayments>
    <tlsa:ShareBasedPaymentReserveWarrants contextRef="c3" decimals="-3" id="ixv-24709" unitRef="usd">697000</tlsa:ShareBasedPaymentReserveWarrants>
    <ifrs-full:OtherReserves contextRef="c2" decimals="-3" id="ixv-24710" unitRef="usd">118697000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c3" decimals="-3" id="ixv-24711" unitRef="usd">118697000</ifrs-full:OtherReserves>
    <ifrs-full:TreasuryShares contextRef="c2" decimals="-3" id="ixv-24712" unitRef="usd">1574000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares contextRef="c3" decimals="-3" id="ixv-24713" unitRef="usd">1320000</ifrs-full:TreasuryShares>
    <tlsa:SharesToBeIssuedReserve contextRef="c2" decimals="-3" id="ixv-24714" unitRef="usd">225000</tlsa:SharesToBeIssuedReserve>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-24715" unitRef="usd">-1636000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c3" decimals="-3" id="ixv-24716" unitRef="usd">-3128000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-24717" unitRef="usd">-133676000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-24718" unitRef="usd">-116263000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-24719" unitRef="usd">5536000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-24720" unitRef="usd">19571000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-24721" unitRef="usd">12184000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-24722" unitRef="usd">26477000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-24723" unitRef="usd">8113000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-24724" unitRef="usd">12955000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-24725" unitRef="usd">13208000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherExpenseByFunction contextRef="c0" decimals="-3" id="ixv-24726" unitRef="usd">9871000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="c4" decimals="-3" id="ixv-24727" unitRef="usd">1631000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="c5" decimals="-3" id="ixv-24728" unitRef="usd">13311000</ifrs-full:OtherExpenseByFunction>
    <tlsa:RealisationBonus contextRef="c5" decimals="-3" id="ixv-24729" unitRef="usd">855000</tlsa:RealisationBonus>
    <ifrs-full:OperatingExpense contextRef="c0" decimals="-3" id="ixv-24730" unitRef="usd">17984000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c4" decimals="-3" id="ixv-24731" unitRef="usd">14586000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c5" decimals="-3" id="ixv-24732" unitRef="usd">27374000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-24733" unitRef="usd">-17984000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="-3" id="ixv-24734" unitRef="usd">-14586000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c5" decimals="-3" id="ixv-24735" unitRef="usd">-27374000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-24736" unitRef="usd">1144000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c4" decimals="-3" id="ixv-24737" unitRef="usd">-7000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c5" decimals="-3" id="ixv-24738" unitRef="usd">-176000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:GainsLossesOnDisposalsOfInvestments contextRef="c0" decimals="-3" id="ixv-24739" unitRef="usd">-402000</ifrs-full:GainsLossesOnDisposalsOfInvestments>
    <ifrs-full:GainsLossesOnDisposalsOfInvestments contextRef="c4" decimals="-3" id="ixv-24740" unitRef="usd">-869000</ifrs-full:GainsLossesOnDisposalsOfInvestments>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c4" decimals="-3" id="ixv-24741" unitRef="usd">65000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c5" decimals="-3" id="ixv-24742" unitRef="usd">893000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherGainsLosses contextRef="c0" decimals="-3" id="ixv-24743" unitRef="usd">742000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c4" decimals="-3" id="ixv-24744" unitRef="usd">-811000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c5" decimals="-3" id="ixv-24745" unitRef="usd">717000</ifrs-full:OtherGainsLosses>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-24746" unitRef="usd">-17242000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="-3" id="ixv-24747" unitRef="usd">-15397000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="-3" id="ixv-24748" unitRef="usd">-26657000</ifrs-full:ProfitLossBeforeTax>
    <tlsa:IncomeTaxSCredit contextRef="c0" decimals="-3" id="ixv-24749" unitRef="usd">449000</tlsa:IncomeTaxSCredit>
    <tlsa:IncomeTaxSCredit contextRef="c5" decimals="-3" id="ixv-24750" unitRef="usd">-3240000</tlsa:IncomeTaxSCredit>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-24751" unitRef="usd">-17691000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-24752" unitRef="usd">-15397000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-24753" unitRef="usd">-23417000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c0" decimals="-3" id="ixv-24754" unitRef="usd">1492000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c4" decimals="-3" id="ixv-24755" unitRef="usd">-3582000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c5" decimals="-3" id="ixv-24756" unitRef="usd">-4478000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-24757" unitRef="usd">-16199000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-24758" unitRef="usd">-18979000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-24759" unitRef="usd">-27895000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="INF"
      id="ixv-24760"
      unitRef="usdPershares">-0.17</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="INF"
      id="ixv-24761"
      unitRef="usdPershares">-0.15</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-24762"
      unitRef="usdPershares">-0.24</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c6" decimals="-3" id="ixv-24763" unitRef="usd">97000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-24764" unitRef="usd">8624000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-24765" unitRef="usd">697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-24766" unitRef="usd">118697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-24767" unitRef="usd">-84646000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-24768" unitRef="usd">13503000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-24769" unitRef="usd">5414000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-24770" unitRef="usd">62386000</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity contextRef="c16" decimals="-3" id="ixv-24771" unitRef="usd">2000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c17" decimals="-3" id="ixv-24772" unitRef="usd">759000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c5" decimals="-3" id="ixv-24773" unitRef="usd">761000</ifrs-full:IssueOfEquity>
    <tlsa:ShareBasedPaymentoptions contextRef="c18" decimals="-3" id="ixv-24774" unitRef="usd">5173000</tlsa:ShareBasedPaymentoptions>
    <tlsa:ShareBasedPaymentoptions contextRef="c5" decimals="-3" id="ixv-24775" unitRef="usd">5173000</tlsa:ShareBasedPaymentoptions>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus contextRef="c16" decimals="-3" id="ixv-24776" unitRef="usd">3000</tlsa:SharesIssuedInLieuOfCashRealizationBonus>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus contextRef="c17" decimals="-3" id="ixv-24777" unitRef="usd">14837000</tlsa:SharesIssuedInLieuOfCashRealizationBonus>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus contextRef="c23" decimals="-3" id="ixv-24778" unitRef="usd">-13503000</tlsa:SharesIssuedInLieuOfCashRealizationBonus>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus contextRef="c24" decimals="-3" id="ixv-24779" unitRef="usd">-482000</tlsa:SharesIssuedInLieuOfCashRealizationBonus>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus contextRef="c5" decimals="-3" id="ixv-24780" unitRef="usd">855000</tlsa:SharesIssuedInLieuOfCashRealizationBonus>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c16" decimals="-3" id="ixv-24781" unitRef="usd">5000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c17" decimals="-3" id="ixv-24782" unitRef="usd">15596000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c18" decimals="-3" id="ixv-24783" unitRef="usd">5173000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c23" decimals="-3" id="ixv-24784" unitRef="usd">-13503000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c24" decimals="-3" id="ixv-24785" unitRef="usd">-482000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c5" decimals="-3" id="ixv-24786" unitRef="usd">6789000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c16" decimals="-3" id="ixv-24787" unitRef="usd">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c22" decimals="-3" id="ixv-24788" unitRef="usd">-23417000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-24789" unitRef="usd">-23417000</ifrs-full:ProfitLoss>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c24" decimals="-3" id="ixv-24790" unitRef="usd">-4478000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c5" decimals="-3" id="ixv-24791" unitRef="usd">-4478000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <ifrs-full:ComprehensiveIncome contextRef="c22" decimals="-3" id="ixv-24792" unitRef="usd">-23417000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c24" decimals="-3" id="ixv-24793" unitRef="usd">-4478000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-24794" unitRef="usd">-27895000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Equity contextRef="c25" decimals="-3" id="ixv-24795" unitRef="usd">102000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c26" decimals="-3" id="ixv-24796" unitRef="usd">15596000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-24797" unitRef="usd">13797000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-24798" unitRef="usd">697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-24799" unitRef="usd">118697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-24800" unitRef="usd">-108063000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c33" decimals="-3" id="ixv-24801" unitRef="usd">454000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c34" decimals="-3" id="ixv-24802" unitRef="usd">41280000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c40" decimals="-3" id="ixv-24803" unitRef="usd">1320000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions contextRef="c4" decimals="-3" id="ixv-24804" unitRef="usd">1320000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <tlsa:ShareBasedPaymentoptions contextRef="c37" decimals="-3" id="ixv-24805" unitRef="usd">1811000</tlsa:ShareBasedPaymentoptions>
    <tlsa:ShareBasedPaymentoptions contextRef="c4" decimals="-3" id="ixv-24806" unitRef="usd">1811000</tlsa:ShareBasedPaymentoptions>
    <tlsa:OptionsForfeitedcancelled contextRef="c37" decimals="-3" id="ixv-24807" unitRef="usd">-3221000</tlsa:OptionsForfeitedcancelled>
    <tlsa:OptionsForfeitedcancelled contextRef="c4" decimals="-3" id="ixv-24808" unitRef="usd">-3221000</tlsa:OptionsForfeitedcancelled>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c37" decimals="-3" id="ixv-24809" unitRef="usd">-7197000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c41" decimals="-3" id="ixv-24810" unitRef="usd">7197000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c37" decimals="-3" id="ixv-24811" unitRef="usd">-8607000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c41" decimals="-3" id="ixv-24812" unitRef="usd">7197000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c4" decimals="-3" id="ixv-24813" unitRef="usd">-1410000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c41" decimals="-3" id="ixv-24814" unitRef="usd">-15397000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-24815" unitRef="usd">-15397000</ifrs-full:ProfitLoss>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c43" decimals="-3" id="ixv-24816" unitRef="usd">-3582000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c4" decimals="-3" id="ixv-24817" unitRef="usd">-3582000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <ifrs-full:ComprehensiveIncome contextRef="c41" decimals="-3" id="ixv-24818" unitRef="usd">-15397000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c43" decimals="-3" id="ixv-24819" unitRef="usd">-3582000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-24820" unitRef="usd">-18979000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-24821" unitRef="usd">102000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-24822" unitRef="usd">15596000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-24823" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c47" decimals="-3" id="ixv-24824" unitRef="usd">697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c48" decimals="-3" id="ixv-24825" unitRef="usd">118697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c49" decimals="-3" id="ixv-24826" unitRef="usd">-1320000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c50" decimals="-3" id="ixv-24827" unitRef="usd">-116263000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c52" decimals="-3" id="ixv-24828" unitRef="usd">-3128000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-24829" unitRef="usd">19571000</ifrs-full:Equity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c53" decimals="-3" id="ixv-24830" unitRef="usd">1000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c54" decimals="-3" id="ixv-24831" unitRef="usd">323000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c0" decimals="-3" id="ixv-24832" unitRef="usd">324000</ifrs-full:ShareIssueRelatedCost>
    <tlsa:ShareBasedPaymentoptions contextRef="c55" decimals="-3" id="ixv-24833" unitRef="usd">1773000</tlsa:ShareBasedPaymentoptions>
    <tlsa:ShareBasedPaymentoptions contextRef="c0" decimals="-3" id="ixv-24834" unitRef="usd">1773000</tlsa:ShareBasedPaymentoptions>
    <tlsa:OptionsForfeitedcancelled contextRef="c55" decimals="-3" id="ixv-24835" unitRef="usd">-39000</tlsa:OptionsForfeitedcancelled>
    <tlsa:OptionsForfeitedcancelled contextRef="c0" decimals="-3" id="ixv-24836" unitRef="usd">-39000</tlsa:OptionsForfeitedcancelled>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c55" decimals="-3" id="ixv-24837" unitRef="usd">-19000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c59" decimals="-3" id="ixv-24838" unitRef="usd">19000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <tlsa:WarrantsExercisedInTheYear contextRef="c54" decimals="-3" id="ixv-24839" unitRef="usd">573000</tlsa:WarrantsExercisedInTheYear>
    <tlsa:WarrantsExercisedInTheYear contextRef="c56" decimals="-3" id="ixv-24840" unitRef="usd">-438000</tlsa:WarrantsExercisedInTheYear>
    <tlsa:WarrantsExercisedInTheYear contextRef="c0" decimals="-3" id="ixv-24841" unitRef="usd">135000</tlsa:WarrantsExercisedInTheYear>
    <tlsa:WarrantsForfeitedInTheYear contextRef="c56" decimals="-3" id="ixv-24842" unitRef="usd">-259000</tlsa:WarrantsForfeitedInTheYear>
    <tlsa:WarrantsForfeitedInTheYear contextRef="c59" decimals="-3" id="ixv-24843" unitRef="usd">259000</tlsa:WarrantsForfeitedInTheYear>
    <tlsa:BuybackOfTreasuryShares contextRef="c58" decimals="-3" id="ixv-24844" unitRef="usd">-254000</tlsa:BuybackOfTreasuryShares>
    <tlsa:BuybackOfTreasuryShares contextRef="c0" decimals="-3" id="ixv-24845" unitRef="usd">-254000</tlsa:BuybackOfTreasuryShares>
    <tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus contextRef="c60" decimals="-3" id="ixv-24846" unitRef="usd">225000</tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus>
    <tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus contextRef="c0" decimals="-3" id="ixv-24847" unitRef="usd">225000</tlsa:SharesToBeIssuedInLieuOfDirectorsFeesAndCashBonus>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c53" decimals="-3" id="ixv-24848" unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c54" decimals="-3" id="ixv-24849" unitRef="usd">896000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c55" decimals="-3" id="ixv-24850" unitRef="usd">1715000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c56" decimals="-3" id="ixv-24851" unitRef="usd">-697000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c58" decimals="-3" id="ixv-24852" unitRef="usd">-254000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c59" decimals="-3" id="ixv-24853" unitRef="usd">278000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c0" decimals="-3" id="ixv-24854" unitRef="usd">2164000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c59" decimals="-3" id="ixv-24855" unitRef="usd">-17691000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-24856" unitRef="usd">-17691000</ifrs-full:ProfitLoss>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c61" decimals="-3" id="ixv-24857" unitRef="usd">1492000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1 contextRef="c0" decimals="-3" id="ixv-24858" unitRef="usd">1492000</tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1>
    <ifrs-full:ComprehensiveIncome contextRef="c59" decimals="-3" id="ixv-24859" unitRef="usd">-17691000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c61" decimals="-3" id="ixv-24860" unitRef="usd">1492000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-24861" unitRef="usd">-16199000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Equity contextRef="c62" decimals="-3" id="ixv-24862" unitRef="usd">103000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c63" decimals="-3" id="ixv-24863" unitRef="usd">16492000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c64" decimals="-3" id="ixv-24864" unitRef="usd">6905000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c65" decimals="-3" id="ixv-24865" unitRef="usd">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c66" decimals="-3" id="ixv-24866" unitRef="usd">118697000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c67" decimals="-3" id="ixv-24867" unitRef="usd">-1574000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c68" decimals="-3" id="ixv-24868" unitRef="usd">-133676000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c69" decimals="-3" id="ixv-24869" unitRef="usd">225000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c70" decimals="-3" id="ixv-24870" unitRef="usd">-1636000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-24871" unitRef="usd">5536000</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-24872" unitRef="usd">-17242000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="-3" id="ixv-24873" unitRef="usd">-15397000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="-3" id="ixv-24874" unitRef="usd">-26657000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForInterestExpense contextRef="c5" decimals="-3" id="ixv-24875" unitRef="usd">163000</ifrs-full:AdjustmentsForInterestExpense>
    <tlsa:SharesIssuedInLieuOfFees contextRef="c0" decimals="-3" id="ixv-24876" unitRef="usd">425000</tlsa:SharesIssuedInLieuOfFees>
    <tlsa:AdjustmentsForSharebasedPaymentsWarrants contextRef="c0" decimals="-3" id="ixv-24877" unitRef="usd">1773000</tlsa:AdjustmentsForSharebasedPaymentsWarrants>
    <tlsa:AdjustmentsForSharebasedPaymentsWarrants contextRef="c4" decimals="-3" id="ixv-24878" unitRef="usd">1811000</tlsa:AdjustmentsForSharebasedPaymentsWarrants>
    <tlsa:AdjustmentsForSharebasedPaymentsWarrants contextRef="c5" decimals="-3" id="ixv-24879" unitRef="usd">5173000</tlsa:AdjustmentsForSharebasedPaymentsWarrants>
    <tlsa:OptionsForfeitedDuringTheYear contextRef="c0" decimals="-3" id="ixv-24880" unitRef="usd">39000</tlsa:OptionsForfeitedDuringTheYear>
    <tlsa:OptionsForfeitedDuringTheYear contextRef="c4" decimals="-3" id="ixv-24881" unitRef="usd">3221000</tlsa:OptionsForfeitedDuringTheYear>
    <tlsa:FVLossOnInvestment contextRef="c0" decimals="-3" id="ixv-24882" unitRef="usd">402000</tlsa:FVLossOnInvestment>
    <tlsa:FVLossOnInvestment contextRef="c4" decimals="-3" id="ixv-24883" unitRef="usd">869000</tlsa:FVLossOnInvestment>
    <tlsa:LossOnDisposalOfAsset contextRef="c4" decimals="-3" id="ixv-24884" unitRef="usd">129000</tlsa:LossOnDisposalOfAsset>
    <tlsa:BonusToBeSettledInEquity contextRef="c0" decimals="-3" id="ixv-24885" unitRef="usd">100000</tlsa:BonusToBeSettledInEquity>
    <tlsa:BonusToBeSettledInEquity contextRef="c5" decimals="-3" id="ixv-24886" unitRef="usd">855000</tlsa:BonusToBeSettledInEquity>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c0" decimals="-3" id="ixv-24887" unitRef="usd">7000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c4" decimals="-3" id="ixv-24888" unitRef="usd">1000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c5" decimals="-3" id="ixv-24889" unitRef="usd">8000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-24890" unitRef="usd">-1519000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-24891" unitRef="usd">3183000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c5" decimals="-3" id="ixv-24892" unitRef="usd">1899000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <tlsa:DepreciationOfRightofuseAsset contextRef="c0" decimals="-3" id="ixv-24893" unitRef="usd">89000</tlsa:DepreciationOfRightofuseAsset>
    <tlsa:DepreciationOfRightofuseAsset contextRef="c4" decimals="-3" id="ixv-24894" unitRef="usd">50000</tlsa:DepreciationOfRightofuseAsset>
    <tlsa:DepreciationOfRightofuseAsset contextRef="c5" decimals="-3" id="ixv-24895" unitRef="usd">133000</tlsa:DepreciationOfRightofuseAsset>
    <tlsa:CapitalDistribution contextRef="c5" decimals="-3" id="ixv-24896" unitRef="usd">28000</tlsa:CapitalDistribution>
    <tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable contextRef="c5" decimals="-3" id="ixv-24897" unitRef="usd">-152000</tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable>
    <tlsa:CashInflowFromTaxation contextRef="c4" decimals="-3" id="ixv-24898" unitRef="usd">490000</tlsa:CashInflowFromTaxation>
    <tlsa:CashInflowFromTaxation contextRef="c5" decimals="-3" id="ixv-24899" unitRef="usd">1415000</tlsa:CashInflowFromTaxation>
    <tlsa:InterestReceivedFromLoan contextRef="c0" decimals="-3" id="ixv-24900" unitRef="usd">1150000</tlsa:InterestReceivedFromLoan>
    <tlsa:NetIncreaseInRelatedPartyReceivables contextRef="c0" decimals="-3" id="ixv-24901" unitRef="usd">1524000</tlsa:NetIncreaseInRelatedPartyReceivables>
    <tlsa:NetIncreaseInRelatedPartyReceivables contextRef="c4" decimals="-3" id="ixv-24902" unitRef="usd">1158000</tlsa:NetIncreaseInRelatedPartyReceivables>
    <tlsa:NetIncreaseInRelatedPartyReceivables contextRef="c5" decimals="-3" id="ixv-24903" unitRef="usd">88000</tlsa:NetIncreaseInRelatedPartyReceivables>
    <tlsa:NetIncreaseInRelatedPartyPayables contextRef="c4" decimals="-3" id="ixv-24904" unitRef="usd">1355000</tlsa:NetIncreaseInRelatedPartyPayables>
    <tlsa:NetIncreaseInRelatedPartyPayables contextRef="c5" decimals="-3" id="ixv-24905" unitRef="usd">685000</tlsa:NetIncreaseInRelatedPartyPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c0" decimals="-3" id="ixv-24906" unitRef="usd">80000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c4" decimals="-3" id="ixv-24907" unitRef="usd">1002000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c5" decimals="-3" id="ixv-24908" unitRef="usd">516000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c0" decimals="-3" id="ixv-24909" unitRef="usd">-138000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c4" decimals="-3" id="ixv-24910" unitRef="usd">347000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c5" decimals="-3" id="ixv-24911" unitRef="usd">-516000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-24912" unitRef="usd">-15698000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-24913" unitRef="usd">-19615000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-24914" unitRef="usd">-21762000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-24915" unitRef="usd">22000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <tlsa:ProceedsFromFinanceLease contextRef="c5" decimals="-3" id="ixv-24916" unitRef="usd">152000</tlsa:ProceedsFromFinanceLease>
    <tlsa:InvestmentInRelatedParty contextRef="c0" decimals="-3" id="ixv-24917" unitRef="usd">1000000</tlsa:InvestmentInRelatedParty>
    <tlsa:InvestmentInRelatedParty contextRef="c4" decimals="-3" id="ixv-24918" unitRef="usd">2676000</tlsa:InvestmentInRelatedParty>
    <tlsa:PurchaseOfTreasuryAmount contextRef="c0" decimals="-3" id="ixv-24919" unitRef="usd">253000</tlsa:PurchaseOfTreasuryAmount>
    <tlsa:PurchaseOfTreasuryAmount contextRef="c4" decimals="-3" id="ixv-24920" unitRef="usd">1320000</tlsa:PurchaseOfTreasuryAmount>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-24921" unitRef="usd">-1253000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-24922" unitRef="usd">-3996000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-24923" unitRef="usd">130000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <tlsa:FundraisingCost contextRef="c0" decimals="-3" id="ixv-24924" unitRef="usd">24000</tlsa:FundraisingCost>
    <tlsa:ProceedsFromIssuanceOfOptions contextRef="c0" decimals="-3" id="ixv-24925" unitRef="usd">135000</tlsa:ProceedsFromIssuanceOfOptions>
    <tlsa:ProceedsFromIssuanceOfOptions contextRef="c5" decimals="-3" id="ixv-24926" unitRef="usd">129000</tlsa:ProceedsFromIssuanceOfOptions>
    <tlsa:RepaymentOfLeasingLiabilities contextRef="c0" decimals="-3" id="ixv-24927" unitRef="usd">-119000</tlsa:RepaymentOfLeasingLiabilities>
    <tlsa:RepaymentOfLeasingLiabilities contextRef="c4" decimals="-3" id="ixv-24928" unitRef="usd">-55000</tlsa:RepaymentOfLeasingLiabilities>
    <tlsa:RepaymentOfLeasingLiabilities contextRef="c5" decimals="-3" id="ixv-24929" unitRef="usd">-152000</tlsa:RepaymentOfLeasingLiabilities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-24930" unitRef="usd">40000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="-3" id="ixv-24931" unitRef="usd">-55000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-24932" unitRef="usd">-23000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c0" decimals="-3" id="ixv-24933" unitRef="usd">-16911000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c4" decimals="-3" id="ixv-24934" unitRef="usd">-23666000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c5" decimals="-3" id="ixv-24935" unitRef="usd">-21655000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-24936" unitRef="usd">18122000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c34" decimals="-3" id="ixv-24937" unitRef="usd">42186000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c15" decimals="-3" id="ixv-24938" unitRef="usd">65824000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-24939" unitRef="usd">-28000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-24940" unitRef="usd">-398000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-24941" unitRef="usd">-1983000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-24942" unitRef="usd">1183000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-24943" unitRef="usd">18122000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c34" decimals="-3" id="ixv-24944" unitRef="usd">42186000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-19731">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;1. GENERAL INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Tiziana Life Sciences Ltd,
(the &#x201c;company&#x201d;) is a public limited company incorporated in Bermuda and at the year-end is quoted on the NASDAQ Capital Market
(NASDAQ: TLSA). The previous parent, Tiziana Life Sciences PLC, delisted from the main market of the London Stock Exchange (LSE: TILS)
on October 21, 2021. The address of its registered office is given on page 1. The principal activities of the Company and its subsidiaries
(the Group) are that of a clinical stage biotechnology company that specializes in the development of transformative therapies for neurodegenerative
and lung diseases. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer&#x2019;s, Crohn&#x2019;s
Disease and KRAS+ NSCLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The functional currency for
the Company is also US dollars ($) indicative of the primary economic environment in which the Company operates. These consolidated financial
statements are presented in thousands of dollars ($&#x2019;000) which is the presentational currency of the Company.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-19741">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2. ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The principal accounting policies
applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently
to all the years presented unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments &#x2013; fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments &#x2013; fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group incurred losses
during the year and has net assets at the year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $134m and a net loss
for the year ended December 31, 2023 of $17.7m.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.&#160;
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next 12 months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company&#x2019;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;New and Revised Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Standards in effect in 2023&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor&#x2019;s return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Business combination&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group&#x2019;s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 &#x2018;Business combinations&#x2019;
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On 21 October 2021, Tiziana
Life Sciences Ltd. (the &#x2018;Company&#x2019;) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group&#x2019;s immediate parent company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only one operating segment being
the research and development of biotechnological and pharmaceutical products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Taxation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Items included in the financial
statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#x2019;s presentational
currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Assets and liabilities at the rate of exchange ruling at the year-end date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Profit and loss account items at the average rate of exchange for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License fees&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. &#x201c;License
fees expenses&#x201d; are recognized as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and development&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group&#x2019;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#x2018;Intangible
Assets&#x2019;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1 - valued using quoted prices in active
markets for identical assets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(a) Financial assets, initial
recognition and measurement and subsequent measurement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(b) Financial liabilities,
initial recognition and measurement and subsequent measurement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial liabilities are
classified as measured at amortized cost or FVTPL.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s financial
liabilities include trade and other payables.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrants are issued by the
Group in return for services and as part of a financing transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants issued in return for services.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants issued as part of a financing transaction.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Ordinary shares of the Company
are classified as equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;(i&lt;/b&gt;) Recognition and
measurement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(ii) Depreciation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The estimated useful lives
for the current period and the comparative period are as follows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-size: 10pt"&gt;Fixtures and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;IT and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Economic life of contractual relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Impairment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Impairment of financial assets
measured at amortized cost&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;General approach&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Simplified approach&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The simplified approach is
applied to the impairment assessment of trade receivables.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Impairment of non-financial assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Contingent Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group&#x2019;s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share &#x2013; based payments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#x2019;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Where employees and directors
are rewarded using share-based payments, the fair value of the employees&#x2019;, directors&#x2019; and/or advisers&#x2019; services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share&#x2013;based payment reserve.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All goods and services received
in exchange for the grant of any share &#x2013; based payment are measured at their fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sub license income&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $750k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc&#x2019;s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Other intangible assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset&#x2019;s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset&#x2019;s cash generating unit is compared
to the carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Relassification of Prior Year Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $804k.&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <tlsa:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock contextRef="c0" id="ixv-19747">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of preparation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB), and International Financial Reporting Interpretations Committee IFRIC interpretations as applicable
to companies reporting under IFRS. These accounts have been prepared under the historical cost convention except for the following items:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments &#x2013; fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments &#x2013; fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DescriptionOfAccountingPolicyForBasisOfPreparationTextBlock>
    <tlsa:DescriptionOfAccountingPolicyForGoingConcern contextRef="c0" id="ixv-19772">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group incurred losses
during the year and has net assets at the year end.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group is in the early
stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and
immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure
in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully
funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has experienced net losses and significant cash outflows
from cash used in operating activities over the past years, and as December 31, 2023, had an accumulated loss of $134m and a net loss
for the year ended December 31, 2023 of $17.7m.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Directors have prepared
cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation.&#160;
Based on those projections, that the company will not be able to meet its liabilities as they fall due within the next 12 months from
the date when these financial statements are issued. The Directors are however aware, through their own extensive experience in the sector,
that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research
and development activity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The top line data for the
clinical trial is expected in 2025 and the Directors are taking steps to put engagements and plans into place to ensure that sufficient
funds will be forthcoming. These steps include possible deferred payments of existing liabilities, working capital cost reductions and
raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there
is a material uncertainty that may cast significant doubt on the Group and Company&#x2019;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material
uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors
are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be
forthcoming and accordingly they have prepared these financial statements on a going concern basis.&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForGoingConcern>
    <tlsa:AccumulatedLoss contextRef="c2" decimals="-3" id="ixv-24945" unitRef="usd">134000</tlsa:AccumulatedLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-5" id="ixv-24946" unitRef="usd">-17700000</ifrs-full:ProfitLoss>
    <tlsa:CashSurplus contextRef="c0" id="ixv-24947">P12M</tlsa:CashSurplus>
    <tlsa:DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock contextRef="c0" id="ixv-19792">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;New and Revised Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Standards in effect in 2023&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There are no new IFRS standards,
amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2023, that are relevant to
the Group and that have had any impact in the year to December 31, 2023. New standards, amendments to standards and interpretations that
are not yet effective, which have been deemed by the Group as currently not relevant and are not listed here.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForNewAndRevisedStandardsTextBlock>
    <tlsa:DescriptionOfAccountingPolicyForBasisofConsolidation contextRef="c0" id="ixv-19820">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsidiary undertakings are
all entities over which the Group exercises control. The Group has control when it can demonstrate all, of the following: (a) power over
the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power
over the investee to affect the amount of the investor&#x2019;s return.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The existence and effect of
both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether
control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated
from the date at which control ceases.&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForBasisofConsolidation>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="c0" id="ixv-19830">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Business combination&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group undertook a group
reorganization exercise during the year to December 31, 2021. As part of this process, Tiziana Life Sciences Ltd (a Bermudan entity) was
inserted above Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) in the Group&#x2019;s structure. As both entities were
under common control of Planwise Ltd, the transaction does not constitute a business combination under IFRS 3 &#x2018;Business combinations&#x2019;
and instead has been accounted for as a group reorganization, using the pooling of interest method. This results in assets and liabilities
being measured at their carrying amount in Tiziana Life Sciences Limited (formerly Tiziana Life Sciences Plc) but share capital being
that of Tiziana Life Sciences Ltd (a Bermudan entity). Merger accounting has been used to account for this transaction (See note 15 for
details).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On 21 October 2021, Tiziana
Life Sciences Ltd. (the &#x2018;Company&#x2019;) acquired the entire shareholding of the former Tiziana Life Sciences Plc and its related
subsidiaries, by a way of a share for share exchange with Tiziana Life Sciences Ltd becoming the Group&#x2019;s immediate parent company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On 21 October 2021, the Company
was admitted for listing on the NASDAQ Capital Market Exchange and the former Tiziana Life Sciences Plc was delisted from the London Stock
Exchange.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c0" id="ixv-19843">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Operating segments are reported
in a manner consistent with the internal reporting provided to the Board. The Board considers there to be only one operating segment being
the research and development of biotechnological and pharmaceutical products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <tlsa:NumberOfSegment contextRef="c0" decimals="0" id="ixv-24948" unitRef="pure">1</tlsa:NumberOfSegment>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c0" id="ixv-19865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Taxation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The tax expense for the year
represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable
profit for the year. Current tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred tax is provided in
full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially
enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled.
Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the
temporary differences can be utilized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and Development tax
credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure.
Any differences that are rebated are recognized in the following year, when the cash is received from the UK tax authorities.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-19878">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Items included in the financial
statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity
operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group&#x2019;s presentational
currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the Consolidated statements of operations and comprehensive
loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The financial statements of
overseas subsidiary undertakings are translated into US dollars on the following basis:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Assets and liabilities at the rate of exchange ruling at the year-end date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Profit and loss account items at the average rate of exchange for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the Consolidated statements of operations and comprehensive loss) on consolidation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <tlsa:DescriptionOfAccountingPolicyForLicenseFees contextRef="c0" id="ixv-19913">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License fees&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Payments made which provide
the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. &#x201c;License
fees expenses&#x201d; are recognized as incurred.&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForLicenseFees>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-19920">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All on-going research and
development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the
development of the Group&#x2019;s products, the criteria for development costs to be recognized as an asset, as set out in IAS 38 &#x2018;Intangible
Assets&#x2019;, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow
to the Group. The Group currently has no qualifying expenditure.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0" id="ixv-19927">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management have assessed the
categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined
on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1 - valued using quoted prices in active
markets for identical assets&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2 - valued by reference to valuation techniques
using observable inputs other than quoted prices included within&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3 - valued by reference to valuation techniques
using inputs that are not based on observable market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-19957">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group classifies a financial
instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance
of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group evaluates the terms
of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified
separately as financial assets, financial liabilities or equity instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A financial instrument is
any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(a) Financial assets, initial
recognition and measurement and subsequent measurement&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All financial assets not recorded
at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs.
Financial assets carried at fair value through profit or loss (FVTPL) are initially recognized at fair value, and transaction costs are
expensed in the consolidated statements of operations and comprehensive loss. The measurement of financial assets depends on their classification.
Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less
loss allowance. The Group holds an investment in Accustem Inc.as a financial asset at fair value through profit or loss or fair value
through other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(b) Financial liabilities,
initial recognition and measurement and subsequent measurement&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial liabilities are
classified as measured at amortized cost or FVTPL.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A financial liability is classified
as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest
expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective
interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition
is also recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s financial
liabilities include trade and other payables.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <tlsa:DescriptionOfAccountingPolicyForWarrantsTextBlock contextRef="c0" id="ixv-19988">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrants are issued by the
Group in return for services and as part of a financing transaction.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants issued in return for services.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;These warrants fall within
the scope of IFRS 2. The Company recognizes that the fair value at the date of grant of these warrants should be expensed to the Statement
of Income and recognized over the life of the service for which the warrant was provided. These warrants have been valued by reference
to the equity instruments granted as they are all tied to Convertible loan notes. The measurement date is therefore the date that the
Convertible loan note was entered into.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants issued as part of a financing transaction.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrants issued as part of
a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is
exchanged for a fixed amount of equity. The fair value is recognized within equity and is not remeasured.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForWarrantsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="c0" id="ixv-20025">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Ordinary shares of the Company
are classified as equity.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-20032">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;(i&lt;/b&gt;) Recognition and
measurement&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Items of property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly
attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized
as part of that equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When parts of an item of property,
plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Gains and losses on disposal
of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property,
plant and equipment, and are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;(ii) Depreciation&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation is calculated
on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation is recognized
in consolidated statements of operations and comprehensive loss on a straight-line basis over the estimated useful life of each part of
an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless
it is reasonably certain that the Group will obtain ownership by the end of the lease term in which case they are depreciated over their
useful lives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The estimated useful lives
for the current period and the comparative period are as follows.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-size: 10pt"&gt;Fixtures and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;IT and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Economic life of contractual relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation methods, useful
lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the Consolidated
statements of operations and comprehensive loss.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <tlsa:DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock contextRef="c0" id="ixv-24949">The estimated useful lives
for the current period and the comparative period are as follows.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-size: 10pt"&gt;Fixtures and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;IT and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Economic life of contractual relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfEstimatedUsefulLivesForTheCurrentPeriodAndTheComparativePeriodTextBlock>
    <tlsa:EstimatedUsefulLives contextRef="c72" id="ixv-24950">P5Y</tlsa:EstimatedUsefulLives>
    <tlsa:EstimatedUsefulLives contextRef="c73" id="ixv-24951">P3Y</tlsa:EstimatedUsefulLives>
    <tlsa:RightOfUseAssetDescription contextRef="c74" id="ixv-20078">Economic life of contractual relationship</tlsa:RightOfUseAssetDescription>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c0" id="ixv-20084">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Impairment of financial assets
measured at amortized cost&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At each reporting date the
Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In establishing the appropriate
amount of loss allowance to be recognized, the Group applies either the general approach or the simplified approach, depending on the
nature of the underlying group of financial assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;General approach&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The general approach is applied
to the impairment assessment of refundable lease deposits and other refundable lease contributions, and cash and cash equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the general approach
the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit
risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognized at an
amount equal to the lifetime expected credit losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Simplified approach&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The simplified approach is
applied to the impairment assessment of trade receivables.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the simplified approach
the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Impairment of non-financial assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Non-financial assets are tested
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Non-financial assets are impaired
when carrying amounts exceed recoverable amounts. The recoverable amount is measured as the higher of fair value less cost of disposal
and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present
value at a pre-tax discount rate.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory contextRef="c0" id="ixv-20142">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Contingent Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is required to
make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their
nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers
the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-20150">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All leases are accounted for
by recognizing a right-of-use asset and a lease liability except for:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has leases for its
offices. Each lease is reflected on the consolidated balance sheet as a right-of-use asset and a lease liability. The Group does not have
any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage
of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets
in a consistent manner to its property, plant and equipment (see Note 21).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease. The expected costs of returning to its original condition are considered negligible.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At the lease commencement
date, the Group recognizes a right-of-use asset and a lease liability in its consolidated balance sheets. The right-of-use asset is measured
at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate
of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement
date (net of any incentives received).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At the commencement date,
the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group&#x2019;s
incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest
rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the
same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee
entity have a different risk profile to that of the Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group depreciates the
right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use
asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Lease payments included in
the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index
or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Subsequent to initial measurement,
the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost
is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Short term leases exempt from
IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and loss on a straight-line
basis over the term of the lease.&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-20214">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Share &#x2013; based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the Consolidated statements of operations and comprehensive loss
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#x2019;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of
the awards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Where employees and directors
are rewarded using share-based payments, the fair value of the employees&#x2019;, directors&#x2019; and/or advisers&#x2019; services are
determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes
the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with IFRS 2,
a charge is made to the Consolidated statements of operations and comprehensive loss for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to an equity reserve, in the case of options/warrants
awarded to employees, directors, advisers and other consultants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options/warrants expected to vest. Non- market vesting conditions are included in assumptions about the number of options/warrants that
are expected to become exercisable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Estimates are subsequently
revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon exercise of share options/warrants,
the proceeds received are allocated to share capital with any excess being recorded as share premium. A corresponding debit is made to
the share&#x2013;based payment reserve.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the remainder of the vesting period is recognized immediately within the Consolidated statements of operations and comprehensive
loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All goods and services received
in exchange for the grant of any share &#x2013; based payment are measured at their fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <tlsa:DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock contextRef="c0" id="ixv-20257">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sub license income&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2021 the Company
signed a collaboration agreement signed with Precision Biosciences, Inc. under which $750k was recognized as an upfront payment in accordance
with the contract for the grant of an exclusive license to use foralumab as a lymphodepletion agent in conjunction with Precision Biosciences,
Inc&#x2019;s allogeneic CAR T therapeutics for the treatment of cancers. Sublicense income is included in other income on the consolidated
statements of operations and comprehensive loss.&lt;/p&gt;</tlsa:DescriptionOfAccountingPolicyForSubLicenseIncomeTextBlock>
    <tlsa:UpfrontPayment contextRef="c71" decimals="-3" id="ixv-24952" unitRef="usd">750000</tlsa:UpfrontPayment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c0" id="ixv-20264">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Other intangible assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Other intangible assets that
are acquired by the Group are stated at cost less accumulated impairment losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At each balance sheet date
non-financial assets are assessed to determine whether there is an indication that the asset or the asset&#x2019;s cash generating unit
may be impaired. If there is such an indication the recoverable amount of the asset or asset&#x2019;s cash generating unit is compared
to the carrying amount.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-20276">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Relassification of Prior Year Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment
has been made to the consolidated statement of comprehensive income for the year ending December 31, 2022 to reclassify other loss to
finance expense totaling $804k.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory>
    <ifrs-full:InsuranceFinanceIncomeExpenses contextRef="c0" decimals="-3" id="ixv-24953" unitRef="usd">804000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate contextRef="c0" id="ixv-20286">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;3. CRITICAL ACCOUNTING JUDGEMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial
information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting
Standards as issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities,
income and expenditure and the disclosures made in the consolidated financial statements. Such estimates and judgements must be continually
evaluated based on historical experience and other factors, including expectations of future events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following are considered
to be critical accounting estimates:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-based payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group accounts for share-based
payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement of the cost of employee
services received in exchange for the options on our ordinary shares, based on the fair value of the award on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company utilizes the Black-Scholes-Merton
option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market
conditions. For performance-based options that include vesting conditions relating to the market performance of our ordinary shares, a
Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that have to be met as conditions to vesting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company makes estimates
as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest rate for the term
of the award and correlations and volatilities of the shares of peer group companies. The Company also makes estimates as to the vesting
period for awards that have performance &#x2013; based criteria.&lt;/p&gt;</ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory contextRef="c0" id="ixv-20318">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;4 OTHER (EXPENSE)/ INCOME&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s other (expense)/
income is made up of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Sublicense income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Income (see note 19)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total other income/(expense)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;893&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Sublicense income has been classified as other
income as the counterparty is not considered a customer but an entity we are collaborating with.&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c0" id="ixv-24954">The Group&#x2019;s other (expense)/
income is made up of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Sublicense income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Income (see note 19)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total other income/(expense)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;893&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <tlsa:SublicenseIncome contextRef="c5" decimals="-3" id="ixv-24955" unitRef="usd">750000</tlsa:SublicenseIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments contextRef="c3" decimals="-3" id="ixv-24956" unitRef="usd">33000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments contextRef="c34" decimals="-3" id="ixv-24957" unitRef="usd">143000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments>
    <tlsa:OtherIncomelosses contextRef="c4" decimals="-3" id="ixv-24958" unitRef="usd">33000</tlsa:OtherIncomelosses>
    <tlsa:OtherIncomelosses contextRef="c5" decimals="-3" id="ixv-24959" unitRef="usd">893000</tlsa:OtherIncomelosses>
    <ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory contextRef="c0" id="ixv-20408">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;5. OPERATING LOSS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s operating
losses are stated after charging/(crediting) the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;License fee&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Realization bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of Property, plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation (Right-of-use asset)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange (gains)/losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,183&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,899&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;License fees relating to 2020
were waived in 2021 as a result of negotiations by the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A realization bonus of $13.5
million became payable during the year ended December 31, 2020 to the chairman of the board upon the Company raising funds in excess of
$28m (&#xa3;20m), which it successfully raised in August 2020. As the bonus was not settled until November 2021, interest of $0.9m was
accrued on the amount due in the year to December 31, 2021. No realization bonus is accounted for in year ended December 31, 2022.&lt;/p&gt;</ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory>
    <tlsa:DisclosureOfDetailedInformationAboutOperatingLoss contextRef="c0" id="ixv-24960">The Group&#x2019;s operating
losses are stated after charging/(crediting) the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;License fee&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Realization bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of Property, plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation (Right-of-use asset)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange (gains)/losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,183&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,899&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfDetailedInformationAboutOperatingLoss>
    <tlsa:Licensefee contextRef="c0" decimals="-3" id="ixv-24961" unitRef="usd">563000</tlsa:Licensefee>
    <tlsa:Licensefee contextRef="c5" decimals="-3" id="ixv-24962" unitRef="usd">-1047000</tlsa:Licensefee>
    <tlsa:OperatingLoss contextRef="c5" decimals="-3" id="ixv-24963" unitRef="usd">855000</tlsa:OperatingLoss>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="-3" id="ixv-24964" unitRef="usd">7000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="-3" id="ixv-24965" unitRef="usd">1000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="-3" id="ixv-24966" unitRef="usd">8000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c0" decimals="-3" id="ixv-24967" unitRef="usd">89000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c4" decimals="-3" id="ixv-24968" unitRef="usd">50000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c5" decimals="-3" id="ixv-24969" unitRef="usd">133000</ifrs-full:DepreciationRightofuseAssets>
    <tlsa:ForeignExchangegainlosses contextRef="c0" decimals="-3" id="ixv-24970" unitRef="usd">1519000</tlsa:ForeignExchangegainlosses>
    <tlsa:ForeignExchangegainlosses contextRef="c4" decimals="-3" id="ixv-24971" unitRef="usd">-3183000</tlsa:ForeignExchangegainlosses>
    <tlsa:ForeignExchangegainlosses contextRef="c5" decimals="-3" id="ixv-24972" unitRef="usd">-1899000</tlsa:ForeignExchangegainlosses>
    <ifrs-full:BenefitsPaidOrPayable contextRef="c75" decimals="-5" id="ixv-24973" unitRef="usd">13500000</ifrs-full:BenefitsPaidOrPayable>
    <tlsa:RaisingFunds contextRef="c76" decimals="-6" id="ixv-24974" unitRef="usd">28000000</tlsa:RaisingFunds>
    <tlsa:RaisingFunds contextRef="c76" decimals="-6" id="ixv-24975" unitRef="gbp">20000000</tlsa:RaisingFunds>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c34" decimals="-5" id="ixv-24976" unitRef="usd">900000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-20515">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;6. SEGMENTAL REPORTING&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year under review
Management identified the Group&#x2019;s only operating segment as the research and development of biotechnological and pharmaceutical
products. This one segment is monitored and strategic decisions are made based upon it and other non-financial data collated from industry
intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual consolidated financial
statements.&lt;/p&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory contextRef="c0" id="ixv-20535">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;7. EMPLOYEES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Staff costs comprised:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Directors&#x2019; salaries (including bonus)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;554&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees&#x2019; wages, salaries and bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Social security costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Recruitment fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share based payment (credit) / charge&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,730&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,410&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;4,596&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;1,490&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9,973&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The average monthly number of employees, including directors, employed by the group during the year was:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate and administration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 3pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory>
    <tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory contextRef="c0" id="ixv-20541">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Staff costs comprised:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Directors&#x2019; salaries (including bonus)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;554&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees&#x2019; wages, salaries and bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Social security costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Recruitment fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share based payment (credit) / charge&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,730&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,410&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;4,596&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;1,490&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9,973&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The average monthly number of employees, including directors, employed by the group during the year was:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate and administration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 3pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3pt double; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfDetailedInformationAboutEmployeesExplanatory>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c0" decimals="-3" id="ixv-24977" unitRef="usd">929000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c4" decimals="-3" id="ixv-24978" unitRef="usd">554000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c5" decimals="-3" id="ixv-24979" unitRef="usd">2526000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:WagesAndSalaries contextRef="c0" decimals="-3" id="ixv-24980" unitRef="usd">1777000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c4" decimals="-3" id="ixv-24981" unitRef="usd">2014000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c5" decimals="-3" id="ixv-24982" unitRef="usd">1856000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions contextRef="c0" decimals="-3" id="ixv-24983" unitRef="usd">136000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c4" decimals="-3" id="ixv-24984" unitRef="usd">135000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c5" decimals="-3" id="ixv-24985" unitRef="usd">176000</ifrs-full:SocialSecurityContributions>
    <tlsa:RecruitmentFees contextRef="c0" decimals="-3" id="ixv-24986" unitRef="usd">24000</tlsa:RecruitmentFees>
    <tlsa:RecruitmentFees contextRef="c4" decimals="-3" id="ixv-24987" unitRef="usd">197000</tlsa:RecruitmentFees>
    <tlsa:RecruitmentFees contextRef="c5" decimals="-3" id="ixv-24988" unitRef="usd">242000</tlsa:RecruitmentFees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c0" decimals="-3" id="ixv-24989" unitRef="usd">1730000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c4" decimals="-3" id="ixv-24990" unitRef="usd">-1410000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c5" decimals="-3" id="ixv-24991" unitRef="usd">5173000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-24992" unitRef="usd">4596000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c4" decimals="-3" id="ixv-24993" unitRef="usd">1490000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c5" decimals="-3" id="ixv-24994" unitRef="usd">9973000</ifrs-full:EmployeeBenefitsExpense>
    <tlsa:ResearchAndDevelopment contextRef="c0" decimals="-3" id="ixv-24995" unitRef="usd">3000</tlsa:ResearchAndDevelopment>
    <tlsa:ResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-24996" unitRef="usd">3000</tlsa:ResearchAndDevelopment>
    <tlsa:ResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-24997" unitRef="usd">8000</tlsa:ResearchAndDevelopment>
    <tlsa:CorporateAndAdministration contextRef="c0" decimals="-3" id="ixv-24998" unitRef="usd">6000</tlsa:CorporateAndAdministration>
    <tlsa:CorporateAndAdministration contextRef="c4" decimals="-3" id="ixv-24999" unitRef="usd">6000</tlsa:CorporateAndAdministration>
    <tlsa:CorporateAndAdministration contextRef="c5" decimals="-3" id="ixv-25000" unitRef="usd">5000</tlsa:CorporateAndAdministration>
    <tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup contextRef="c0" decimals="-3" id="ixv-25001" unitRef="usd">9000</tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup>
    <tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup contextRef="c4" decimals="-3" id="ixv-25002" unitRef="usd">9000</tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup>
    <tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup contextRef="c5" decimals="-3" id="ixv-25003" unitRef="usd">13000</tlsa:AverageMonthlyNumberOfEmployeesIncludingDirectorsEmployedByGroup>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-20716">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;8. REMUNERATION OF KEY MANAGEMENT PERSONNEL&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;$&#x2019;000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Director&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019;&lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share &lt;br/&gt; based &lt;br/&gt; payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019; &lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share &lt;br/&gt; based &lt;br/&gt; payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019; &lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;G. Cerrone &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;562&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;624&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Willy Simon&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;J Brancaccio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;K. Shailubhai&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(145&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;T Adams&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,065&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Gabriele Cerrone&#x2019;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All bonuses are short term.
No post-employment or termination payments were made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following share options
were granted to directors in the following periods:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;W.Simon&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;J. Brancaccio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;T Adams&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Key management personnel of
the Group are comprised of directors and officers of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No share options were exercised
by directors during the years ended December 31, 2023,2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company made payments
totaling approximately $56K, $32K, and $24K to defined contribution pension schemes on behalf of directors and employees during 2023, 2022,
and 2021, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock contextRef="c0" id="ixv-20721">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;$&#x2019;000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Director&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019;&lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share &lt;br/&gt; based &lt;br/&gt; payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019; &lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share &lt;br/&gt; based &lt;br/&gt; payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&#x2019; &lt;br/&gt; fee&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;G. Cerrone &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;562&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;624&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Willy Simon&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;J Brancaccio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;K. Shailubhai&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(145&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;T Adams&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;758&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;379&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,065&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Gabriele Cerrone&#x2019;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</tlsa:DisclosureOfRemunerationOfKeyManagementPersonnelTextBlock>
    <tlsa:DirectorsFees contextRef="c77" decimals="-3" id="ix_0_fact" unitRef="usd">717000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c77" decimals="-3" id="ix_1_fact" unitRef="usd">100000</tlsa:Bonus>
    <tlsa:ShareBasedPayments contextRef="c77" decimals="-3" id="ix_2_fact" unitRef="usd">562000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c78" decimals="-3" id="ix_3_fact" unitRef="usd">296000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c78" decimals="-3" id="ix_4_fact" unitRef="usd">148000</tlsa:Bonus>
    <tlsa:DirectorsFees contextRef="c79" decimals="-3" id="ix_5_fact" unitRef="usd">330000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c79" decimals="-3" id="ix_6_fact" unitRef="usd">855000</tlsa:Bonus>
    <tlsa:ShareBasedPayments contextRef="c79" decimals="-3" id="ix_7_fact" unitRef="usd">624000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c80" decimals="-3" id="ixv-25012" unitRef="usd">56000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c80" decimals="-3" id="ixv-25013" unitRef="usd">98000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c81" decimals="-3" id="ixv-25014" unitRef="usd">55000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c81" decimals="-3" id="ixv-25015" unitRef="usd">83000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c82" decimals="-3" id="ixv-25016" unitRef="usd">59000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c82" decimals="-3" id="ixv-25017" unitRef="usd">93000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c83" decimals="-3" id="ixv-25018" unitRef="usd">56000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c83" decimals="-3" id="ixv-25019" unitRef="usd">98000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c84" decimals="-3" id="ixv-25020" unitRef="usd">55000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c84" decimals="-3" id="ixv-25021" unitRef="usd">83000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c85" decimals="-3" id="ixv-25022" unitRef="usd">59000</tlsa:DirectorsFees>
    <tlsa:ShareBasedPayments contextRef="c85" decimals="-3" id="ixv-25023" unitRef="usd">93000</tlsa:ShareBasedPayments>
    <tlsa:Salary contextRef="c87" decimals="-3" id="ixv-25024" unitRef="usd">379000</tlsa:Salary>
    <tlsa:ShareBasedPayments contextRef="c87" decimals="-3" id="ixv-25025" unitRef="usd">-145000</tlsa:ShareBasedPayments>
    <tlsa:Bonus contextRef="c88" decimals="-3" id="ixv-25026" unitRef="usd">210000</tlsa:Bonus>
    <tlsa:Salary contextRef="c88" decimals="-3" id="ixv-25027" unitRef="usd">600000</tlsa:Salary>
    <tlsa:ShareBasedPayments contextRef="c88" decimals="-3" id="ixv-25028" unitRef="usd">492000</tlsa:ShareBasedPayments>
    <tlsa:ShareBasedPayments contextRef="c90" decimals="-3" id="ixv-25029" unitRef="usd">-1967000</tlsa:ShareBasedPayments>
    <tlsa:Salary contextRef="c91" decimals="-3" id="ixv-25030" unitRef="usd">413000</tlsa:Salary>
    <tlsa:ShareBasedPayments contextRef="c91" decimals="-3" id="ixv-25031" unitRef="usd">2197000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c0" decimals="-3" id="ixv-25032" unitRef="usd">829000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c0" decimals="-3" id="ixv-25033" unitRef="usd">100000</tlsa:Bonus>
    <tlsa:ShareBasedPayments contextRef="c0" decimals="-3" id="ixv-25034" unitRef="usd">758000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c4" decimals="-3" id="ixv-25035" unitRef="usd">406000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c4" decimals="-3" id="ixv-25036" unitRef="usd">148000</tlsa:Bonus>
    <tlsa:Salary contextRef="c4" decimals="-3" id="ixv-25037" unitRef="usd">379000</tlsa:Salary>
    <tlsa:ShareBasedPayments contextRef="c4" decimals="-3" id="ixv-25038" unitRef="usd">-1946000</tlsa:ShareBasedPayments>
    <tlsa:DirectorsFees contextRef="c5" decimals="-3" id="ixv-25039" unitRef="usd">448000</tlsa:DirectorsFees>
    <tlsa:Bonus contextRef="c5" decimals="-3" id="ixv-25040" unitRef="usd">1065000</tlsa:Bonus>
    <tlsa:Salary contextRef="c5" decimals="-3" id="ixv-25041" unitRef="usd">1013000</tlsa:Salary>
    <tlsa:ShareBasedPayments contextRef="c5" decimals="-3" id="ixv-25042" unitRef="usd">3499000</tlsa:ShareBasedPayments>
    <ifrs-full:OtherLongtermBenefits contextRef="c0" decimals="-5" id="ixv-25043" unitRef="usd">13200000</ifrs-full:OtherLongtermBenefits>
    <tlsa:DisclosureOfShareOptionsWereGrantedToDirectorTextBlock contextRef="c0" id="ixv-25044">The following share options
were granted to directors in the following periods:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;W.Simon&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;J. Brancaccio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;T Adams&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfShareOptionsWereGrantedToDirectorTextBlock>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c92"
      decimals="0"
      id="ixv-25045"
      unitRef="shares">75000</tlsa:NumberOfShareOptionsWereGrantedToDirectors>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c83"
      decimals="0"
      id="ixv-25046"
      unitRef="shares">75000</tlsa:NumberOfShareOptionsWereGrantedToDirectors>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c91"
      decimals="0"
      id="ixv-25047"
      unitRef="shares">3500000</tlsa:NumberOfShareOptionsWereGrantedToDirectors>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c0"
      decimals="0"
      id="ixv-25048"
      unitRef="shares">150000</tlsa:NumberOfShareOptionsWereGrantedToDirectors>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c5"
      decimals="0"
      id="ixv-25049"
      unitRef="shares">3500000</tlsa:NumberOfShareOptionsWereGrantedToDirectors>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c0" decimals="-3" id="ixv-25050" unitRef="usd">56000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c4" decimals="-3" id="ixv-25051" unitRef="usd">32000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans contextRef="c5" decimals="-3" id="ixv-25052" unitRef="usd">24000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="c0" id="ixv-21259">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;9. FINANCE COSTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="text-decoration:underline"&gt;Finance Income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Loan Interest Received&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;32&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Finance Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance charge accrued on convertible loan notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fair Value loss on Investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total finance Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;412&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock contextRef="c0" id="ixv-21263">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="text-decoration:underline"&gt;Finance Income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Loan Interest Received&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;32&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total finance income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Finance Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance charge accrued on convertible loan notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fair Value loss on Investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total finance Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;412&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net finance income/ (expense) recognized in Consolidated statements of operations and comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureDetailedInformationAboutOfFinanceCostTableTextBlock>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c0" decimals="-3" id="ixv-25053" unitRef="usd">1154000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c4" decimals="-3" id="ixv-25054" unitRef="usd">32000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-25055" unitRef="usd">1154000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-25056" unitRef="usd">32000</ifrs-full:FinanceIncome>
    <tlsa:FinanceChargeAccruedOnConvertibleLoanNotes contextRef="c5" decimals="-3" id="ixv-25057" unitRef="usd">163000</tlsa:FinanceChargeAccruedOnConvertibleLoanNotes>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="-3" id="ixv-25058" unitRef="usd">10000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-25059" unitRef="usd">7000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c5" decimals="-3" id="ixv-25060" unitRef="usd">13000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c2" decimals="-3" id="ixv-25061" unitRef="usd">402000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c3" decimals="-3" id="ixv-25062" unitRef="usd">869000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <tlsa:FinanceExpense contextRef="c0" decimals="-3" id="ixv-25063" unitRef="usd">412000</tlsa:FinanceExpense>
    <tlsa:FinanceExpense contextRef="c4" decimals="-3" id="ixv-25064" unitRef="usd">876000</tlsa:FinanceExpense>
    <tlsa:FinanceExpense contextRef="c5" decimals="-3" id="ixv-25065" unitRef="usd">176000</tlsa:FinanceExpense>
    <tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-25066" unitRef="usd">742000</tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome>
    <tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-25067" unitRef="usd">-844000</tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome>
    <tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-25068" unitRef="usd">-176000</tlsa:NetFinanceExpenseRecognizedInStatementOfComprehensiveIncome>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-21454">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;10. TAXATION &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current year tax (credit)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments due to prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,926&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,065&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Movement in unrecognized deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,319&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses not deductible for taxation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments due to prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development claim&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,401&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income not taxable for tax purposes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Fixed asset differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current Tax - Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments to brought forward values&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Consolidation adjustment in relation to foreign exchange movements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Research and Development
claim has been calculated in accordance with the R&amp;amp;D tax relief available to small and medium sized entities, whereby the entity is
able to claim a cash tax credit (if loss making), worth up to 14.5% of the surrenderable losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The adjustments due to prior
periods relate to R&amp;amp;D tax relief claims for the prior period. Under UK tax legislation, a 2-year window is available under which R&amp;amp;D
tax relief can be claimed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No deferred tax asset has
been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The amount of tax losses for
which no deferred tax assets have been recognized for the year ended December 31, 2023 is $18,137k (2022 is $15,011k; 2021; $11,591k).&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-21459">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt; $&#x2019;000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration:underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current year tax (credit)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,255&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments due to prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Loss charged at standard rate of corporation tax 23.52% 2023 19%2021/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,055&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,926&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,065&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Movement in unrecognized deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,319&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses not deductible for taxation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,961&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments due to prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development claim&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,401&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income not taxable for tax purposes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Fixed asset differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current Tax - Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustments to brought forward values&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Consolidation adjustment in relation to foreign exchange movements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;449&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfDetailedInformationAboutIncomeTaxExpenseBenefitTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c0" decimals="-3" id="ixv-25069" unitRef="usd">449000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c5" decimals="-3" id="ixv-25070" unitRef="usd">-3255000</ifrs-full:CurrentTaxExpenseIncome>
    <tlsa:AdjustmentsDueToPriorPeriods contextRef="c5" decimals="-3" id="ixv-25071" unitRef="usd">-15000</tlsa:AdjustmentsDueToPriorPeriods>
    <tlsa:IncomeTaxExpenseContinuingOperation contextRef="c0" decimals="-3" id="ixv-25072" unitRef="usd">449000</tlsa:IncomeTaxExpenseContinuingOperation>
    <tlsa:IncomeTaxExpenseContinuingOperation contextRef="c5" decimals="-3" id="ixv-25073" unitRef="usd">-3240000</tlsa:IncomeTaxExpenseContinuingOperation>
    <tlsa:OtherLossBeforeTaxation contextRef="c0" decimals="-3" id="ixv-25074" unitRef="usd">-17242000</tlsa:OtherLossBeforeTaxation>
    <tlsa:OtherLossBeforeTaxation contextRef="c4" decimals="-3" id="ixv-25075" unitRef="usd">-15397000</tlsa:OtherLossBeforeTaxation>
    <tlsa:OtherLossBeforeTaxation contextRef="c5" decimals="-3" id="ixv-25076" unitRef="usd">-26657000</tlsa:OtherLossBeforeTaxation>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="c0" decimals="4" id="ixv-25077" unitRef="pure">0.2352</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="c4" decimals="2" id="ixv-25078" unitRef="pure">0.19</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="c5" decimals="2" id="ixv-25079" unitRef="pure">0.19</ifrs-full:TaxRateEffectOfTaxLosses>
    <tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax contextRef="c0" decimals="-3" id="ixv-25080" unitRef="usd">-4055000</tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax>
    <tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax contextRef="c4" decimals="-3" id="ixv-25081" unitRef="usd">-2926000</tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax>
    <tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax contextRef="c5" decimals="-3" id="ixv-25082" unitRef="usd">-5065000</tlsa:IncomeTaxReconciliationLossChargedAtStandardRateOfCorporationTax>
    <tlsa:MovementInUnrecognisedDeferredTax contextRef="c0" decimals="-3" id="ixv-25083" unitRef="usd">3194000</tlsa:MovementInUnrecognisedDeferredTax>
    <tlsa:MovementInUnrecognisedDeferredTax contextRef="c4" decimals="-3" id="ixv-25084" unitRef="usd">2319000</tlsa:MovementInUnrecognisedDeferredTax>
    <tlsa:MovementInUnrecognisedDeferredTax contextRef="c5" decimals="-3" id="ixv-25085" unitRef="usd">1722000</tlsa:MovementInUnrecognisedDeferredTax>
    <tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation contextRef="c0" decimals="-3" id="ixv-25086" unitRef="usd">3961000</tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation>
    <tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation contextRef="c4" decimals="-3" id="ixv-25087" unitRef="usd">1036000</tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation>
    <tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation contextRef="c5" decimals="-3" id="ixv-25088" unitRef="usd">1550000</tlsa:IncomeTaxReconciliationExpensesNotDeductibleForTaxation>
    <tlsa:AdjustmentsDueToPriorPeriod contextRef="c0" decimals="-3" id="ixv-25089" unitRef="usd">449000</tlsa:AdjustmentsDueToPriorPeriod>
    <tlsa:AdjustmentsDueToPriorPeriod contextRef="c5" decimals="-3" id="ixv-25090" unitRef="usd">-15000</tlsa:AdjustmentsDueToPriorPeriod>
    <tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim contextRef="c5" decimals="-3" id="ixv-25091" unitRef="usd">-1401000</tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim>
    <tlsa:IncomeNotTaxableForTaxPurposes contextRef="c0" decimals="-3" id="ixv-25092" unitRef="usd">-3113000</tlsa:IncomeNotTaxableForTaxPurposes>
    <tlsa:IncomeNotTaxableForTaxPurposes contextRef="c4" decimals="-3" id="ixv-25093" unitRef="usd">-495000</tlsa:IncomeNotTaxableForTaxPurposes>
    <tlsa:IncomeNotTaxableForTaxPurposes contextRef="c5" decimals="-3" id="ixv-25094" unitRef="usd">-61000</tlsa:IncomeNotTaxableForTaxPurposes>
    <tlsa:FixedAssetDifferences contextRef="c4" decimals="-3" id="ixv-25095" unitRef="usd">-1000</tlsa:FixedAssetDifferences>
    <tlsa:CurrentTaxOther contextRef="c0" decimals="-3" id="ixv-25096" unitRef="usd">13000</tlsa:CurrentTaxOther>
    <tlsa:AdjustmentsToBroughtForwardValues contextRef="c4" decimals="-3" id="ixv-25097" unitRef="usd">67000</tlsa:AdjustmentsToBroughtForwardValues>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-25098" unitRef="usd">449000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="-3" id="ixv-25099" unitRef="usd">-3240000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <tlsa:MaximumPercentageOfSurrenderableLosses contextRef="c0" decimals="3" id="ixv-25100" unitRef="pure">0.145</tlsa:MaximumPercentageOfSurrenderableLosses>
    <tlsa:TermOfResearchAndDevelopmentTaxReliefClaims contextRef="c0" id="ixv-25101">P2Y</tlsa:TermOfResearchAndDevelopmentTaxReliefClaims>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c0" decimals="-3" id="ixv-25102" unitRef="usd">18137000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c4" decimals="-3" id="ixv-25103" unitRef="usd">15011000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c5" decimals="-3" id="ixv-25104" unitRef="usd">11591000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-21758">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;11. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Basic loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the
year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($000)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,691&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(15,397&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23,417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,471,016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,526,389&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;97,932,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Basic loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the Group is reporting
a loss from continuing operations for the year then, in accordance with IAS 33, share options, warrants and convertible loan notes are
not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per
share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from
continuing and total operations and therefore no earnings per share for discontinued operations are presented. The weighted average number
of ordinary shares in issuance is stated as net excluding Treasury shares.&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <tlsa:DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock contextRef="c0" id="ixv-25105">Basic loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the
year.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($000)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,691&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(15,397&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23,417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102,471,016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,526,389&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;97,932,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Basic loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfDetailedInformationAboutOfEarningsPerShareTableTextBlock>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-25106" unitRef="usd">-17691000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-25107" unitRef="usd">-15397000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-25108" unitRef="usd">-23417000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-25109"
      unitRef="shares">102471016</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-25110"
      unitRef="shares">101526389</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-25111"
      unitRef="shares">97932055</ifrs-full:WeightedAverageShares>
    <tlsa:BasicLossPerSharecentsPerShare
      contextRef="c0"
      decimals="1"
      id="ixv-25112"
      unitRef="usdPershares">-17.3</tlsa:BasicLossPerSharecentsPerShare>
    <tlsa:BasicLossPerSharecentsPerShare
      contextRef="c4"
      decimals="1"
      id="ixv-25113"
      unitRef="usdPershares">-15.2</tlsa:BasicLossPerSharecentsPerShare>
    <tlsa:BasicLossPerSharecentsPerShare
      contextRef="c5"
      decimals="1"
      id="ixv-25114"
      unitRef="usdPershares">-23.9</tlsa:BasicLossPerSharecentsPerShare>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-21853">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. OTHER RECEIVABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Security deposits receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;121&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;102&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxation Receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,793&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,246&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,546&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There are no differences between
the carrying amount and fair value of any of the trade and other receivables above.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock contextRef="c0" id="ixv-21857">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Security deposits receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;121&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;102&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxation Receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,793&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,246&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,016&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,546&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfDetailedInformationAboutOtherReceivablesTableTextBlock>
    <tlsa:SecurityDepositsReceivable contextRef="c2" decimals="-3" id="ixv-25115" unitRef="usd">121000</tlsa:SecurityDepositsReceivable>
    <tlsa:SecurityDepositsReceivable contextRef="c3" decimals="-3" id="ixv-25116" unitRef="usd">130000</tlsa:SecurityDepositsReceivable>
    <ifrs-full:Prepayments contextRef="c2" decimals="-3" id="ixv-25117" unitRef="usd">102000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="c3" decimals="-3" id="ixv-25118" unitRef="usd">170000</ifrs-full:Prepayments>
    <tlsa:TaxationReceivable contextRef="c2" decimals="-3" id="ixv-25119" unitRef="usd">3793000</tlsa:TaxationReceivable>
    <tlsa:TaxationReceivable contextRef="c3" decimals="-3" id="ixv-25120" unitRef="usd">4246000</tlsa:TaxationReceivable>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-25121" unitRef="usd">4016000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-25122" unitRef="usd">4546000</ifrs-full:OtherReceivables>
    <tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock contextRef="c0" id="ixv-21939">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;13 SHARE CAPITAL AND SHARE PREMIUM&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Group&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On 21 October 2021, the Company
acquired the entire shareholding of Tiziana Life Sciences Plc and its subsidiaries through a share for share exchange transaction. On
this date Tiziana Life Sciences Ltd became the Group&#x2019;s parent company. This transaction does not constitute a business combination
under IFRS 3 &#x201c;Business combinations&#x201d; and has been accounted for as a group reorganization. Merger accounting has been applied
to account for the insertion of the new company. Due to a share consolidation, the effect of this was a decrease in share capital of the
Company with an offset posted to the merger reserve. As a common control transaction, the Group has elected to present the comparative
information as if this transaction had occurred before the start of the comparative period. The share capital arising on the share for
share exchange has been presented as share capital in the comparative period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Nominal&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;Share &lt;br/&gt;
Capital&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Share&lt;br/&gt;
 Premium&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Merger&lt;br/&gt;
 Reserve&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&#xa3;/$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt; Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1 2021 per 20-F annual report&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;194,612,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Group Reorganization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Elimination of share capital in Tiziana Life Sciences Plc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(194,612,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,794&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Shares issued pursuant to share for share exchange and consolidation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,306,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Elimination of other reserves in Tiziana Life Sciences Plc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Restated at 1 January 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,306,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Shares issued in the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Conversion of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Conversion of Loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,866,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issued in lieu of cash bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,962,709&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,272,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Shares issued in the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,272,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Shares issued in lieu of fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Warrants Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;573&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issuance of Stock - ATM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,087,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary Shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Ordinary shares have a par
value of $0.001. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion
to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person
or by proxy is entitled to one vote, and upon a poll each share is entitled to one vote. The Company has 103,087,744 shares in issue and
holds 1,573,510 shares in treasury.&lt;/p&gt;</tlsa:DisclosureOfAccountingShareCapitalAndSharePremiumtextBlock>
    <tlsa:DisclosureShareCapitalArisingForShareExchangetextBlock contextRef="c0" id="ixv-25123">The share capital arising on the share for
share exchange has been presented as share capital in the comparative period.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Nominal&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;Share &lt;br/&gt;
Capital&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Share&lt;br/&gt;
 Premium&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Merger&lt;br/&gt;
 Reserve&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&#xa3;/$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt; Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1 2021 per 20-F annual report&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;194,612,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Group Reorganization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Elimination of share capital in Tiziana Life Sciences Plc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(194,612,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,794&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Shares issued pursuant to share for share exchange and consolidation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,306,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Elimination of other reserves in Tiziana Life Sciences Plc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Restated at 1 January 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,306,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Shares issued in the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Conversion of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Conversion of Loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,866,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issued in lieu of cash bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,962,709&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,272,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Shares issued in the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,272,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Shares issued in lieu of fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Warrants Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;573&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issuance of Stock - ATM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.0001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At 31 December 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,087,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureShareCapitalArisingForShareExchangetextBlock>
    <tlsa:NominalValueAnnualReport
      contextRef="c5"
      decimals="2"
      id="ixv-25124"
      unitRef="gbpPershares">0.03</tlsa:NominalValueAnnualReport>
    <tlsa:ShareCapitalSharesAnnualReport
      contextRef="c5"
      decimals="INF"
      id="ixv-25125"
      unitRef="shares">194612289</tlsa:ShareCapitalSharesAnnualReport>
    <tlsa:ShareCapitalValueAnnualReport contextRef="c5" decimals="-3" id="ixv-25126" unitRef="usd">10794000</tlsa:ShareCapitalValueAnnualReport>
    <tlsa:SharePremiumAnnualReport contextRef="c5" decimals="-3" id="ixv-25127" unitRef="usd">111821000</tlsa:SharePremiumAnnualReport>
    <tlsa:NominalValueEliminationOfShareCapital
      contextRef="c5"
      decimals="2"
      id="ixv-25128"
      unitRef="gbpPershares">0.03</tlsa:NominalValueEliminationOfShareCapital>
    <tlsa:ShareCapitalSharesEliminationOfShare
      contextRef="c5"
      decimals="INF"
      id="ixv-25129"
      unitRef="shares">-194612289</tlsa:ShareCapitalSharesEliminationOfShare>
    <tlsa:ShareCapitalValueEliminationOfShareCapital contextRef="c5" decimals="-3" id="ixv-25130" unitRef="usd">-10794000</tlsa:ShareCapitalValueEliminationOfShareCapital>
    <tlsa:SharePremiumEliminationOfShareCapitalIn contextRef="c5" decimals="-3" id="ixv-25131" unitRef="usd">-111821000</tlsa:SharePremiumEliminationOfShareCapitalIn>
    <tlsa:MergerReserveEliminationOfShareCapitalIn contextRef="c5" decimals="-3" id="ixv-25132" unitRef="usd">122615000</tlsa:MergerReserveEliminationOfShareCapitalIn>
    <tlsa:NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation
      contextRef="c5"
      decimals="3"
      id="ixv-25133"
      unitRef="usdPershares">0.001</tlsa:NominalValueSharesIssuedPursuantToShareForShareExchangeAndConsolidation>
    <tlsa:ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation
      contextRef="c5"
      decimals="INF"
      id="ixv-25134"
      unitRef="shares">97306144</tlsa:ShareCapitalSharesSharesIssuedPursuantForShareExchangeAndConsolidation>
    <tlsa:ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation contextRef="c5" decimals="-3" id="ixv-25135" unitRef="usd">97000</tlsa:ShareCapitalValueSharesIssuedPursuantToShareExchangeAndConsolidation>
    <tlsa:MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation contextRef="c5" decimals="-3" id="ixv-25136" unitRef="usd">-97000</tlsa:MergerReserveSharesIssuedPursuantToShareForShareExchangeAndConsolidation>
    <tlsa:EliminationOfOtherReserves contextRef="c5" decimals="-3" id="ixv-25137" unitRef="usd">-3821000</tlsa:EliminationOfOtherReserves>
    <tlsa:NominalValueRestated
      contextRef="c5"
      decimals="3"
      id="ixv-25138"
      unitRef="usdPershares">0.001</tlsa:NominalValueRestated>
    <tlsa:ShareCapitalSharesRestated
      contextRef="c5"
      decimals="INF"
      id="ixv-25139"
      unitRef="shares">97306144</tlsa:ShareCapitalSharesRestated>
    <tlsa:ShareCapitalValueRestated contextRef="c5" decimals="-3" id="ixv-25140" unitRef="usd">97000</tlsa:ShareCapitalValueRestated>
    <tlsa:MergerReserveRestated contextRef="c5" decimals="-3" id="ixv-25141" unitRef="usd">118697000</tlsa:MergerReserveRestated>
    <tlsa:NominalValueConversionOfWarrants
      contextRef="c5"
      decimals="3"
      id="ixv-25142"
      unitRef="usdPershares">0.001</tlsa:NominalValueConversionOfWarrants>
    <tlsa:ShareCapitalSharesConversionOfWarrants
      contextRef="c5"
      decimals="INF"
      id="ixv-25143"
      unitRef="shares">136854</tlsa:ShareCapitalSharesConversionOfWarrants>
    <tlsa:SharePremiumConversionOfWarrants contextRef="c5" decimals="-3" id="ixv-25144" unitRef="usd">156000</tlsa:SharePremiumConversionOfWarrants>
    <tlsa:NominalValueConversionOfLoan
      contextRef="c5"
      decimals="3"
      id="ixv-25145"
      unitRef="usdPershares">0.001</tlsa:NominalValueConversionOfLoan>
    <tlsa:ShareCapitalSharesConversionOfLoan
      contextRef="c5"
      decimals="INF"
      id="ixv-25146"
      unitRef="shares">1866907</tlsa:ShareCapitalSharesConversionOfLoan>
    <tlsa:ShareCapitalValueConversionOfLoan contextRef="c5" decimals="-3" id="ixv-25147" unitRef="usd">2000</tlsa:ShareCapitalValueConversionOfLoan>
    <tlsa:SharePremiumConversionOfLoan contextRef="c5" decimals="-3" id="ixv-25148" unitRef="usd">603000</tlsa:SharePremiumConversionOfLoan>
    <tlsa:NominalValueIssuedInLieuOfCashBonus
      contextRef="c5"
      decimals="3"
      id="ixv-25149"
      unitRef="usdPershares">0.001</tlsa:NominalValueIssuedInLieuOfCashBonus>
    <tlsa:ShareCapitalSharesIssuedInLieuOfCashBonus
      contextRef="c5"
      decimals="INF"
      id="ixv-25150"
      unitRef="shares">2962709</tlsa:ShareCapitalSharesIssuedInLieuOfCashBonus>
    <tlsa:ShareCapitalValueIssuedInCashBonus contextRef="c5" decimals="-3" id="ixv-25151" unitRef="usd">3000</tlsa:ShareCapitalValueIssuedInCashBonus>
    <tlsa:SharePremiumIssuedInCashBonus contextRef="c5" decimals="-3" id="ixv-25152" unitRef="usd">14837000</tlsa:SharePremiumIssuedInCashBonus>
    <tlsa:ShareCapitalShares
      contextRef="c5"
      decimals="INF"
      id="ixv-25153"
      unitRef="shares">102272614</tlsa:ShareCapitalShares>
    <tlsa:ShareCapitalValueAt31December2021 contextRef="c5" decimals="-3" id="ixv-25154" unitRef="usd">102000</tlsa:ShareCapitalValueAt31December2021>
    <tlsa:SharePremiumEnding contextRef="c5" decimals="-3" id="ixv-25155" unitRef="usd">15596000</tlsa:SharePremiumEnding>
    <tlsa:MergerReserveEnding contextRef="c5" decimals="-3" id="ixv-25156" unitRef="usd">118697000</tlsa:MergerReserveEnding>
    <tlsa:ShareCapitalShares
      contextRef="c4"
      decimals="INF"
      id="ixv-25157"
      unitRef="shares">102272614</tlsa:ShareCapitalShares>
    <tlsa:ShareCapitalValueAt31December2021 contextRef="c4" decimals="-3" id="ixv-25158" unitRef="usd">102000</tlsa:ShareCapitalValueAt31December2021>
    <tlsa:SharePremiumEnding contextRef="c4" decimals="-3" id="ixv-25159" unitRef="usd">15596000</tlsa:SharePremiumEnding>
    <tlsa:MergerReserveEnding contextRef="c4" decimals="-3" id="ixv-25160" unitRef="usd">118697000</tlsa:MergerReserveEnding>
    <tlsa:NominalValueSharesIssuedInLieuOfFees
      contextRef="c0"
      decimals="4"
      id="ixv-25161"
      unitRef="usdPershares">0.0001</tlsa:NominalValueSharesIssuedInLieuOfFees>
    <tlsa:ShareCapitalSharesIssuedInLieuOfFees
      contextRef="c0"
      decimals="INF"
      id="ixv-25162"
      unitRef="shares">450000</tlsa:ShareCapitalSharesIssuedInLieuOfFees>
    <tlsa:ShareCapitalValueSharesIssuedInLieuOfFees contextRef="c0" decimals="-3" id="ixv-25163" unitRef="usd">1000</tlsa:ShareCapitalValueSharesIssuedInLieuOfFees>
    <tlsa:SharePremiumSharesIssuedInLieuOfFees contextRef="c0" decimals="-3" id="ixv-25164" unitRef="usd">300000</tlsa:SharePremiumSharesIssuedInLieuOfFees>
    <tlsa:NominalValueWarrantsExercised
      contextRef="c0"
      decimals="4"
      id="ixv-25165"
      unitRef="usdPershares">0.0001</tlsa:NominalValueWarrantsExercised>
    <tlsa:ShareCapitalSharesWarrantsExercised
      contextRef="c0"
      decimals="INF"
      id="ixv-25166"
      unitRef="shares">337501</tlsa:ShareCapitalSharesWarrantsExercised>
    <tlsa:SharePremiumWarrantsExercised contextRef="c0" decimals="-3" id="ixv-25167" unitRef="usd">573000</tlsa:SharePremiumWarrantsExercised>
    <tlsa:NominalValueIssuanceOfStockATM
      contextRef="c0"
      decimals="4"
      id="ixv-25168"
      unitRef="usdPershares">0.0001</tlsa:NominalValueIssuanceOfStockATM>
    <tlsa:ShareCapitalSharesIssuanceOfStockATM
      contextRef="c0"
      decimals="INF"
      id="ixv-25169"
      unitRef="shares">27629</tlsa:ShareCapitalSharesIssuanceOfStockATM>
    <tlsa:SharePremiumIssuanceOfStockATM contextRef="c0" decimals="-3" id="ixv-25170" unitRef="usd">23000</tlsa:SharePremiumIssuanceOfStockATM>
    <tlsa:ShareCapitalShares
      contextRef="c0"
      decimals="INF"
      id="ixv-25171"
      unitRef="shares">103087744</tlsa:ShareCapitalShares>
    <tlsa:ShareCapitalValueAt31December2021 contextRef="c0" decimals="-3" id="ixv-25172" unitRef="usd">103000</tlsa:ShareCapitalValueAt31December2021>
    <tlsa:SharePremiumEnding contextRef="c0" decimals="-3" id="ixv-25173" unitRef="usd">16492000</tlsa:SharePremiumEnding>
    <tlsa:MergerReserveEnding contextRef="c0" decimals="-3" id="ixv-25174" unitRef="usd">118697000</tlsa:MergerReserveEnding>
    <ifrs-full:ParValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-25175"
      unitRef="usdPershares">0.001</ifrs-full:ParValuePerShare>
    <tlsa:NumberOfSharesIssued1
      contextRef="c0"
      decimals="0"
      id="ixv-25176"
      unitRef="shares">103087744</tlsa:NumberOfSharesIssued1>
    <tlsa:TreasuryShares1
      contextRef="c0"
      decimals="0"
      id="ixv-25177"
      unitRef="shares">1573510</tlsa:TreasuryShares1>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-22386">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;14. SHARE BASED PAYMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Group and Company Options&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company operates share-based
payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option
is normally equal to the market price of an ordinary share in the Company at the date of grant. The Company is currently operating two
plans (Tiziana Life Sciences PLC) Share Option Plan which is closed for any new issuances and the Tiziana Life Sciences Ltd 2021 Equity
Incentive Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Tiziana Life Sciences PLC Share Option Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Outstanding at 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(103&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-309"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-310"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,732&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No options were exercised
during 2023, 2022 or 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The total outstanding fair
value charge of the share option instruments is deemed to be approximately $2,602k (2022: $3,223k (restated), 2021: $12,339k).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the Tiziana Life Sciences
PLC Share Option Plan, the total expense recognized for the year ending 31 December 2023 arising from share &#x2013; based payment transactions
under the Tiziana Life Sciences PLC Share Option Plan is $703k of which $51k relates to forfeitures during the year (2022 $1,199k, 2021:
$5,173k).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Share options outstanding
at the end of the year have the following expiry dates and exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share Options &lt;br/&gt;
    at&lt;br/&gt; 31 December &lt;br/&gt; 2023&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%"&gt;26 June 2014&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;26 June 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;30 April 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;30 April 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;6 May 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 May 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;23 July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;26 July 2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;25 August 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;24&#160;August&#160;2030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.98&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,621&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fair value of options granted&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Directors have used the
Black-Scholes-Merton option pricing model to estimate the fair value of all of the options granted during the year to December 31, 2023,
applying the assumptions below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Historical volatility is based
on the historical volatility of the Company itself.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has estimated
a forfeiture rate of zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The model inputs for options
granted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;4 November&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1 August&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;-0.10%&#160;to&#160;-0.02&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.32%&#160;to&#160;0.65%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;99% to 122&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;90% to 126%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average fair value per share option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the options issued in
August 2020 with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options.
The Company uses the following methods to determine its underlying assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected volatilities are based on the historical volatilities of the market;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;the expected term of the award is 4 years and is based on managements&#x2019; assessment of when the market condition is likely to be achieved; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Modification of share &#x2013; based payments.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2020, the Company reduced
the exercise price for options issued to employees and directors to $0.48 (&#xa3;0.35). This was approved by shareholders at a General
Meeting held on May 6, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the modified
options at the date of modification was determined using the option pricing models as described above. The incremental fair value was
recognized as an expense over the period from the modification date to the end of the vesting period. The expense for the original option
grant will continue to be recognized as if the terms had not been modified.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the modified
options was determined using the same models and principles as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Tiziana Life Sciences Ltd Share Option Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No options were exercised
during 2023, 2022 or 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The total outstanding fair
value charge of the share option instruments is deemed to be approximately $974k (2022: $1,176k)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the Tiziana Life Sciences
Ltd 2021 Equity Incentive Plan, the total expenses recognized for the year ending 31 December 2023 arising from share - based payment
transactions are $1,019k, not including a charge of $57k for forfeitures during the year. (2022:$332k)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;26 July &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;14 March&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average fair value per share option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Share options outstanding
at the end of the year have the following expiry dates and exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share&#160;Options&lt;br/&gt;
 as at 31 December &lt;br/&gt; 2023&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%"&gt;01 August 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;01 August 2032&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;04 November 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;04 November 2032&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;14 March 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;14 March 2033&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;993&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;26 July 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;26 July 2033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,268&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Group and Company Warrants&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No warrants were issued in
2022 or 2023. For warrants issued in 2020, the Directors have estimated the fair value of the warrants using the Black-Scholes valuation
model and assumptions below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;21 January&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;21 January&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2021 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding at 1 January&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(438&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(259&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at 31 December&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-330"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-332"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; share-based payment charges
relating to warrants were recorded during 2023, 2022 or 2021. Approximately $26K of share-based payment charges are included in the consolidated
statement of operations and comprehensive loss for the year ended December 31, 2020.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-22396">&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Tiziana Life Sciences PLC Share Option Plan&lt;/span&gt;&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Outstanding at 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(103&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-309"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-310"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,732&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-25178"
      unitRef="usdPershares">59</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-25179"
      unitRef="shares">6724</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c34"
      decimals="0"
      id="ixv-25180"
      unitRef="usdPershares">90</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-25181"
      unitRef="shares">22234</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c15"
      decimals="0"
      id="ixv-25182"
      unitRef="usdPershares">67</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-25183"
      unitRef="shares">17024</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceGranted
      contextRef="c5"
      decimals="0"
      id="ixv-25184"
      unitRef="usdPershares">166</tlsa:WeightedAverageExercisePriceGranted>
    <tlsa:OptionsGranted
      contextRef="c5"
      decimals="INF"
      id="ixv-25185"
      unitRef="shares">5210</tlsa:OptionsGranted>
    <tlsa:WeightedAverageExercisePriceForfeitedCancelled
      contextRef="c0"
      decimals="0"
      id="ixv-25186"
      unitRef="usdPershares">-44</tlsa:WeightedAverageExercisePriceForfeitedCancelled>
    <tlsa:OptionsForfeitedCancelled
      contextRef="c0"
      decimals="INF"
      id="ixv-25187"
      unitRef="shares">103</tlsa:OptionsForfeitedCancelled>
    <tlsa:WeightedAverageExercisePriceForfeitedCancelled
      contextRef="c4"
      decimals="0"
      id="ixv-25188"
      unitRef="usdPershares">-92</tlsa:WeightedAverageExercisePriceForfeitedCancelled>
    <tlsa:OptionsForfeitedCancelled
      contextRef="c4"
      decimals="INF"
      id="ixv-25189"
      unitRef="shares">15510</tlsa:OptionsForfeitedCancelled>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-25190"
      unitRef="usdPershares">62</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-25191"
      unitRef="shares">6621</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-25192"
      unitRef="usdPershares">59</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-25193"
      unitRef="shares">6724</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceOutstanding
      contextRef="c34"
      decimals="0"
      id="ixv-25194"
      unitRef="usdPershares">90</tlsa:WeightedAverageExercisePriceOutstanding>
    <tlsa:OptionsOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-25195"
      unitRef="shares">22234</tlsa:OptionsOutstanding>
    <tlsa:WeightedAverageExercisePriceExercisable
      contextRef="c2"
      decimals="0"
      id="ixv-25196"
      unitRef="usdPershares">60</tlsa:WeightedAverageExercisePriceExercisable>
    <tlsa:OptionsExercisable
      contextRef="c0"
      decimals="INF"
      id="ixv-25197"
      unitRef="shares">2829</tlsa:OptionsExercisable>
    <tlsa:WeightedAverageExercisePriceExercisable
      contextRef="c3"
      decimals="0"
      id="ixv-25198"
      unitRef="usdPershares">58</tlsa:WeightedAverageExercisePriceExercisable>
    <tlsa:OptionsExercisable
      contextRef="c4"
      decimals="INF"
      id="ixv-25199"
      unitRef="shares">2732</tlsa:OptionsExercisable>
    <tlsa:WeightedAverageExercisePriceExercisable
      contextRef="c34"
      decimals="0"
      id="ixv-25200"
      unitRef="usdPershares">54</tlsa:WeightedAverageExercisePriceExercisable>
    <tlsa:OptionsExercisable
      contextRef="c5"
      decimals="INF"
      id="ixv-25201"
      unitRef="shares">7616</tlsa:OptionsExercisable>
    <tlsa:OutstandingFairValueCharges contextRef="c95" decimals="-3" id="ixv-25202" unitRef="usd">2602000</tlsa:OutstandingFairValueCharges>
    <tlsa:OutstandingFairValueCharges contextRef="c96" decimals="-3" id="ixv-25203" unitRef="usd">3223000</tlsa:OutstandingFairValueCharges>
    <tlsa:OutstandingFairValueCharges contextRef="c97" decimals="-3" id="ixv-25204" unitRef="usd">12339000</tlsa:OutstandingFairValueCharges>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c98" decimals="-3" id="ixv-25205" unitRef="usd">703000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c0" decimals="-3" id="ixv-25206" unitRef="usd">51000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c4" decimals="-3" id="ixv-25207" unitRef="usd">1199000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c5" decimals="-3" id="ixv-25208" unitRef="usd">5173000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <tlsa:ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock contextRef="c0" id="ixv-25209">Share options outstanding
at the end of the year have the following expiry dates and exercise prices:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share Options &lt;br/&gt;
    at&lt;br/&gt; 31 December &lt;br/&gt; 2023&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%"&gt;26 June 2014&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;26 June 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;30 April 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;30 April 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;6 May 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 May 2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;23 July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;26 July 2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;25 August 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;24&#160;August&#160;2030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.98&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,621&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grant Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise&lt;br/&gt;
 Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share&#160;Options&lt;br/&gt;
 as at 31 December &lt;br/&gt; 2023&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 63%"&gt;01 August 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;01 August 2032&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;04 November 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;04 November 2032&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;14 March 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;14 March 2033&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;993&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;26 July 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;26 July 2033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,268&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfOutstandingFairValueChargeOfTheShareOptionInstrumentsTableTextBlock>
    <tlsa:ExpiryDate contextRef="c100" id="ixv-25210">26 June 2024</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c100"
      decimals="2"
      id="ixv-25211"
      unitRef="usdPershares">0.47</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c100"
      decimals="0"
      id="ixv-25212"
      unitRef="shares">1831</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c101" id="ixv-25213">30 April 2028</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c101"
      decimals="2"
      id="ixv-25214"
      unitRef="usdPershares">1.1</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c101"
      decimals="0"
      id="ixv-25215"
      unitRef="shares">500</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c102" id="ixv-25216">5 May 2028</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c102"
      decimals="2"
      id="ixv-25217"
      unitRef="usdPershares">0.47</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c102"
      decimals="0"
      id="ixv-25218"
      unitRef="shares">3690</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c103" id="ixv-25219">26 July 2030</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c103"
      decimals="2"
      id="ixv-25220"
      unitRef="usdPershares">2.11</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c103"
      decimals="0"
      id="ixv-25221"
      unitRef="shares">100</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c104" id="ixv-25222">24&#160;August&#160;2030</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c104"
      decimals="2"
      id="ixv-25223"
      unitRef="usdPershares">1.98</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c104"
      decimals="0"
      id="ixv-25224"
      unitRef="shares">500</tlsa:ShareOptions>
    <tlsa:ShareOptions
      contextRef="c105"
      decimals="0"
      id="ixv-25225"
      unitRef="shares">6621</tlsa:ShareOptions>
    <tlsa:ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock contextRef="c0" id="ixv-25226">The model inputs for options
granted during the year ended 31 December 2022 valued under the Black-Scholes-Merton model included:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;4 November&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1 August&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;-0.10%&#160;to&#160;-0.02&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.32%&#160;to&#160;0.65%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;99% to 122&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;90% to 126%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average fair value per share option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;26 July &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;14 March&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average fair value per share option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;21 January&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;21 January&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;1 June&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#xa3;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfModelInputsForOptionsGrantedUnderTheBlackScholesValuationModelTableTextBlock>
    <tlsa:GrantDateSharesPrice
      contextRef="c110"
      decimals="3"
      id="ixv-25227"
      unitRef="usdPershares">0.679</tlsa:GrantDateSharesPrice>
    <tlsa:GrantDateSharesPrice
      contextRef="c111"
      decimals="3"
      id="ixv-25228"
      unitRef="usdPershares">0.741</tlsa:GrantDateSharesPrice>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c110"
      decimals="3"
      id="ixv-25229"
      unitRef="usdPershares">0.679</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c111"
      decimals="3"
      id="ixv-25230"
      unitRef="usdPershares">0.741</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c112"
      decimals="4"
      id="ixv-25231"
      unitRef="pure">0.001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c113"
      decimals="4"
      id="ixv-25232"
      unitRef="pure">0.0002</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c114"
      decimals="4"
      id="ixv-25233"
      unitRef="pure">0.0032</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c115"
      decimals="4"
      id="ixv-25234"
      unitRef="pure">0.0065</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c112"
      decimals="2"
      id="ixv-25235"
      unitRef="pure">0.99</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c113"
      decimals="2"
      id="ixv-25236"
      unitRef="pure">1.22</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c114"
      decimals="2"
      id="ixv-25237"
      unitRef="pure">0.90</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c115"
      decimals="2"
      id="ixv-25238"
      unitRef="pure">1.26</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <tlsa:OptionLifeShareOptionsGranted contextRef="c110" id="ixv-25239">P10Y</tlsa:OptionLifeShareOptionsGranted>
    <tlsa:OptionLifeShareOptionsGranted contextRef="c111" id="ixv-25240">P10Y</tlsa:OptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c110"
      decimals="2"
      id="ixv-25241"
      unitRef="usdPershares">0.67</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c111"
      decimals="3"
      id="ixv-25242"
      unitRef="usdPershares">0.741</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c110"
      decimals="3"
      id="ixv-25243"
      unitRef="usdPershares">0.69</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c111"
      decimals="3"
      id="ixv-25244"
      unitRef="usdPershares">0.69</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <tlsa:ExpectedTermOfAwards contextRef="c0" id="ixv-25245">P4Y</tlsa:ExpectedTermOfAwards>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c99"
      decimals="2"
      id="ixv-25246"
      unitRef="usdPershares">0.48</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c99"
      decimals="2"
      id="ixv-25247"
      unitRef="gbpPershares">0.35</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <tlsa:ScheduleOfEquityIncentivePlanTableTextBlock contextRef="c0" id="ixv-22966">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt; (&#x2019;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable at 31 December&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfEquityIncentivePlanTableTextBlock>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="0"
      id="ixv-25248"
      unitRef="usdPershares">69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-25249"
      unitRef="shares">2575</tlsa:NumberOfShareOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c0"
      decimals="0"
      id="ixv-25250"
      unitRef="usdPershares">61</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsGranted
      contextRef="c0"
      decimals="0"
      id="ixv-25251"
      unitRef="shares">1753</tlsa:NumberOfShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="0"
      id="ixv-25252"
      unitRef="usdPershares">69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsGranted
      contextRef="c4"
      decimals="0"
      id="ixv-25253"
      unitRef="shares">2575</tlsa:NumberOfShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c0"
      decimals="0"
      id="ixv-25254"
      unitRef="usdPershares">57</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsForfeited
      contextRef="c0"
      decimals="0"
      id="ixv-25255"
      unitRef="shares">60</tlsa:NumberOfShareOptionsForfeited>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="0"
      id="ixv-25256"
      unitRef="usdPershares">73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-25257"
      unitRef="shares">4268</tlsa:NumberOfShareOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="0"
      id="ixv-25258"
      unitRef="usdPershares">69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <tlsa:NumberOfShareOptionsOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-25259"
      unitRef="shares">2575</tlsa:NumberOfShareOptionsOutstanding>
    <tlsa:OutstandingFairValueCharges contextRef="c0" decimals="-3" id="ixv-25260" unitRef="usd">974000</tlsa:OutstandingFairValueCharges>
    <tlsa:OutstandingFairValueCharges contextRef="c4" decimals="-3" id="ixv-25261" unitRef="usd">1176000</tlsa:OutstandingFairValueCharges>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c0" decimals="-3" id="ixv-25262" unitRef="usd">1019000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <tlsa:ChargeOfForfeitures contextRef="c0" decimals="-3" id="ixv-25263" unitRef="usd">57000</tlsa:ChargeOfForfeitures>
    <tlsa:ChargeOfForfeitures contextRef="c4" decimals="-3" id="ixv-25264" unitRef="usd">332000</tlsa:ChargeOfForfeitures>
    <tlsa:GrantDateSharesPrice
      contextRef="c116"
      decimals="2"
      id="ixv-25265"
      unitRef="usdPershares">0.67</tlsa:GrantDateSharesPrice>
    <tlsa:GrantDateSharesPrice
      contextRef="c117"
      decimals="2"
      id="ixv-25266"
      unitRef="usdPershares">0.57</tlsa:GrantDateSharesPrice>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c116"
      decimals="2"
      id="ixv-25267"
      unitRef="usdPershares">0.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c117"
      decimals="2"
      id="ixv-25268"
      unitRef="usdPershares">0.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c116"
      decimals="4"
      id="ixv-25269"
      unitRef="pure">0.0388</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c117"
      decimals="4"
      id="ixv-25270"
      unitRef="pure">0.0388</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c116"
      decimals="2"
      id="ixv-25271"
      unitRef="pure">1.18</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c117"
      decimals="2"
      id="ixv-25272"
      unitRef="pure">1.19</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <tlsa:OptionLifeShareOptionsGranted contextRef="c116" id="ixv-25273">P10Y</tlsa:OptionLifeShareOptionsGranted>
    <tlsa:OptionLifeShareOptionsGranted contextRef="c117" id="ixv-25274">P10Y</tlsa:OptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c116"
      decimals="2"
      id="ixv-25275"
      unitRef="usdPershares">0.67</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c117"
      decimals="2"
      id="ixv-25276"
      unitRef="usdPershares">0.57</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c116"
      decimals="2"
      id="ixv-25277"
      unitRef="usdPershares">0.67</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c117"
      decimals="2"
      id="ixv-25278"
      unitRef="usdPershares">0.57</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <tlsa:ExpiryDate contextRef="c106" id="ixv-25279">01 August 2032</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c106"
      decimals="2"
      id="ixv-25280"
      unitRef="usdPershares">0.74</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c106"
      decimals="0"
      id="ixv-25281"
      unitRef="shares">725</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c107" id="ixv-25282">04 November 2032</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c107"
      decimals="2"
      id="ixv-25283"
      unitRef="usdPershares">0.67</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c107"
      decimals="0"
      id="ixv-25284"
      unitRef="shares">1850</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c108" id="ixv-25285">14 March 2033</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c108"
      decimals="2"
      id="ixv-25286"
      unitRef="usdPershares">0.57</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c108"
      decimals="0"
      id="ixv-25287"
      unitRef="shares">993</tlsa:ShareOptions>
    <tlsa:ExpiryDate contextRef="c109" id="ixv-25288">26 July 2033</tlsa:ExpiryDate>
    <tlsa:ExerciseSharePrice
      contextRef="c109"
      decimals="2"
      id="ixv-25289"
      unitRef="usdPershares">0.67</tlsa:ExerciseSharePrice>
    <tlsa:ShareOptions
      contextRef="c109"
      decimals="0"
      id="ixv-25290"
      unitRef="shares">700</tlsa:ShareOptions>
    <tlsa:ShareOptions
      contextRef="c0"
      decimals="0"
      id="ixv-25291"
      unitRef="shares">4268</tlsa:ShareOptions>
    <tlsa:GrantDateSharesPrice
      contextRef="c118"
      decimals="2"
      id="ixv-25292"
      unitRef="gipPershares">0.43</tlsa:GrantDateSharesPrice>
    <tlsa:GrantDateSharesPrice
      contextRef="c119"
      decimals="2"
      id="ixv-25293"
      unitRef="gipPershares">0.43</tlsa:GrantDateSharesPrice>
    <tlsa:GrantDateSharesPrice
      contextRef="c120"
      decimals="2"
      id="ixv-25294"
      unitRef="gipPershares">1.15</tlsa:GrantDateSharesPrice>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c118"
      decimals="2"
      id="ixv-25295"
      unitRef="gipPershares">0.42</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c119"
      decimals="2"
      id="ixv-25296"
      unitRef="gipPershares">0.35</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c120"
      decimals="2"
      id="ixv-25297"
      unitRef="gipPershares">0.7</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c118"
      decimals="4"
      id="ixv-25298"
      unitRef="pure">0.0064</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c119"
      decimals="4"
      id="ixv-25299"
      unitRef="pure">0.004</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c120"
      decimals="4"
      id="ixv-25300"
      unitRef="pure">0.0004</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c118"
      decimals="3"
      id="ixv-25301"
      unitRef="pure">0.617</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c119"
      decimals="3"
      id="ixv-25302"
      unitRef="pure">0.847</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c120"
      decimals="2"
      id="ixv-25303"
      unitRef="pure">1.11</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <tlsa:ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock contextRef="c0" id="ixv-23466">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2021 &lt;br/&gt;
$000&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding at 1 January&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(438&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(259&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at 31 December&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;697&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfEstimatedTheFairValueOfWarrantsUsingTableTextBlock>
    <tlsa:FairValueOutstanding contextRef="c3" decimals="-3" id="ixv-25304" unitRef="usd">697000</tlsa:FairValueOutstanding>
    <tlsa:FairValueOutstanding contextRef="c34" decimals="-3" id="ixv-25305" unitRef="usd">697000</tlsa:FairValueOutstanding>
    <tlsa:FairValueOutstanding contextRef="c15" decimals="-3" id="ixv-25306" unitRef="usd">697000</tlsa:FairValueOutstanding>
    <tlsa:OutstandingExercised contextRef="c0" decimals="-3" id="ixv-25307" unitRef="usd">-438000</tlsa:OutstandingExercised>
    <tlsa:OutstandingExpired contextRef="c0" decimals="-3" id="ixv-25308" unitRef="usd">-259000</tlsa:OutstandingExpired>
    <tlsa:FairValueOutstanding contextRef="c3" decimals="-3" id="ixv-25309" unitRef="usd">697000</tlsa:FairValueOutstanding>
    <tlsa:FairValueOutstanding contextRef="c34" decimals="-3" id="ixv-25310" unitRef="usd">697000</tlsa:FairValueOutstanding>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c75" decimals="-3" id="ixv-25311" unitRef="usd">26000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-23591">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;15. RESERVES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The share-based payment reserve
for warrants represents the cost to issue warrants in the future based on their grant date fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The share-based payment reserve
for options represents the cost to issue share-based compensation, primarily share options, based on their grant date fair value.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Retained earnings represent
the cumulative profits/(losses) of the entity which have not been distributed to shareholders. This reserve has been credited as part
of the capital reduction exercise described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The translation reserve represents
the unrealized gains or losses from the foreign currency translation of Companies within the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The shares to be issued reserve
represents the equity shares that are to be issued to the Chairman in lieu of his bonus and additional salary for his role as acting CEO
for the year ending December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The merger reserve arises
on consolidation as a result of the share for share exchange transaction that took place this year described in note 13. It represents
the difference between the share capital issued and the aggregate carrying value of assets and liabilities and other reserves of the previous
parent on the merger date.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-23609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;16. FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The main risks arising from
the Group&#x2019;s financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and
agree policies for managing each of these risks which are summarized below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Market risk encompasses three
types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair
value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled
&#x201c;interest rate risk&#x201d; below. The Directors do not consider the Group&#x2019;s exposure to price risk to be significant. The
Group&#x2019;s risk management is coordinated by the Directors and focuses on actively securing the Group&#x2019;s short to medium term
cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative
purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Credit risk is managed on
a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well
as credit exposure to customers including committed transactions and outstanding receivables. The Group reviews its banking arrangements
carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans
between members of the Group as part of their internal reporting and assesses outstanding receivables for ability to be repaid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Liquidity risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s policy is
to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity
requirements in the short and long term. The Group ordinarily finances its activities through cash generated from private and public offerings
of equity and debt securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The table below summarizes
the maturity profile of the Group&#x2019;s financial liabilities based on contractual undiscounted payments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than &lt;br/&gt; 3 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12 &lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,921&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,275&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Less than &lt;br/&gt;
3 months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3 to 12 &lt;br/&gt;
months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,732&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,962&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related party payables&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-336; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,262&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,830&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,092&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Interest rate risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has limited exposure
to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Bank of America
base rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Directors do not consider
the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity
position as of year-end for either the year ended 31 December 2023 or 31 December 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Foreign currency risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group operates internationally
although the majority of its operations are based in the United Kingdom and the United States, and the majority of assets and liabilities
are denominated in US Dollars, with a small amount denominated in Pound Sterling. It therefore is exposed to some foreign exchange risk
arising from exposure to various currencies primarily the Pound Sterling. The Group monitors currency exchange rates and makes judgments
as to whether to enter into currency hedging contracts. Currently no such hedging contracts are in place.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Sensitivity analysis &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A reasonably possible strengthening
(weakening) of the US dollar or Sterling against all other currencies at 31 December 2023 would have affected the measurement of the financial
instruments denominated in a foreign currency and affected equity and profit and loss by the amounts shown below. This analysis assumes
that all other variables remain constant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Profit or loss and equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Strengthening&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weakening&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;USD (5% movement)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <tlsa:ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock contextRef="c0" id="ixv-25312">The table below summarizes
the maturity profile of the Group&#x2019;s financial liabilities based on contractual undiscounted payments:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than &lt;br/&gt; 3 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12 &lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,921&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,275&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Less than &lt;br/&gt;
3 months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3 to 12 &lt;br/&gt;
months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,732&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,962&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related party payables&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-336; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,262&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,830&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,092&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsTableTextBlock>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c121"
      decimals="-3"
      id="ixv-25313"
      unitRef="usd">2223000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c122"
      decimals="-3"
      id="ixv-25314"
      unitRef="usd">1914000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c2" decimals="-3" id="ixv-25315" unitRef="usd">4137000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:LeaseLiabilities
      contextRef="c121"
      decimals="-3"
      id="ixv-25316"
      unitRef="usd">34000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c122"
      decimals="-3"
      id="ixv-25317"
      unitRef="usd">104000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-25318" unitRef="usd">138000</ifrs-full:LeaseLiabilities>
    <tlsa:FinancialInstrumentsNet
      contextRef="c121"
      decimals="-3"
      id="ixv-25319"
      unitRef="usd">2354000</tlsa:FinancialInstrumentsNet>
    <tlsa:FinancialInstrumentsNet
      contextRef="c122"
      decimals="-3"
      id="ixv-25320"
      unitRef="usd">1921000</tlsa:FinancialInstrumentsNet>
    <tlsa:FinancialInstrumentsNet contextRef="c2" decimals="-3" id="ixv-25321" unitRef="usd">4275000</tlsa:FinancialInstrumentsNet>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c125"
      decimals="-3"
      id="ixv-25322"
      unitRef="usd">1230000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c126"
      decimals="-3"
      id="ixv-25323"
      unitRef="usd">3732000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c3" decimals="-3" id="ixv-25324" unitRef="usd">4962000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:LeaseLiabilities
      contextRef="c125"
      decimals="-3"
      id="ixv-25325"
      unitRef="usd">32000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c126"
      decimals="-3"
      id="ixv-25326"
      unitRef="usd">98000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-25327" unitRef="usd">130000</ifrs-full:LeaseLiabilities>
    <tlsa:FinancialInstrumentsNet
      contextRef="c125"
      decimals="-3"
      id="ixv-25328"
      unitRef="usd">1262000</tlsa:FinancialInstrumentsNet>
    <tlsa:FinancialInstrumentsNet
      contextRef="c126"
      decimals="-3"
      id="ixv-25329"
      unitRef="usd">3830000</tlsa:FinancialInstrumentsNet>
    <tlsa:FinancialInstrumentsNet contextRef="c3" decimals="-3" id="ixv-25330" unitRef="usd">5092000</tlsa:FinancialInstrumentsNet>
    <tlsa:ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock contextRef="c0" id="ixv-25331">This analysis assumes
that all other variables remain constant.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Profit or loss and equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Strengthening&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weakening&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;USD (5% movement)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfMeasurementOfTheFinancialInstrumentsTextBlock>
    <tlsa:MovementPercentageStrengthening
      contextRef="c129"
      decimals="2"
      id="ixv-25332"
      unitRef="pure">0.05</tlsa:MovementPercentageStrengthening>
    <tlsa:MovementPercentageWeakening
      contextRef="c129"
      decimals="2"
      id="ixv-25333"
      unitRef="pure">0.05</tlsa:MovementPercentageWeakening>
    <tlsa:ProfitOrLossAndEquityStrengthening
      contextRef="c129"
      decimals="-3"
      id="ixv-25334"
      unitRef="usd">467000</tlsa:ProfitOrLossAndEquityStrengthening>
    <tlsa:ProfitOrLossAndEquityWeakening
      contextRef="c129"
      decimals="-3"
      id="ixv-25335"
      unitRef="usd">-467000</tlsa:ProfitOrLossAndEquityWeakening>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="c0" id="ixv-23892">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;17. CAPITAL RISK MANAGEMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the purpose of the Group&#x2019;s
capital management, capital includes called up share capital, share premium, share &#x2013; based payments for options, share - based payments
for warrants, convertible loan note reserve, and all other equity reserves attributable to the equity holders of the parent as reflected
in the consolidated statement of financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s objectives
when managing capital are to safeguard the Company&#x2019;s ability to continue as a going concern and to maximize shareholder value through
the optimization of the equity balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group adjusts its capital
structure in light of changes in economic conditions and expected business demands on capital. The Group may also return capital to shareholders
or issue additional shares.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-23904">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;18. TRADE AND OTHER PAYABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Accruals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,387&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,532&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock contextRef="c0" id="ixv-23908">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Accruals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,387&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,532&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:ScheduleOfTradeAndOtherPayablesTableTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-25336" unitRef="usd">4137000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-25337" unitRef="usd">4962000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c2" decimals="-3" id="ixv-25338" unitRef="usd">2250000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c3" decimals="-3" id="ixv-25339" unitRef="usd">1570000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-25340" unitRef="usd">6387000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-25341" unitRef="usd">6532000</ifrs-full:TradeAndOtherCurrentPayables>
    <tlsa:InvestmentInRelatedPartyTextBlock contextRef="c0" id="ixv-23965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;19. INVESTMENT IN RELATED PARTY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Investment in Accustem Sciences Inc&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Movement in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(969&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The share price of Accustem
as of December 31, 2023 was $.63, which has resulted in the recognition of a fair value loss of $1,049k. This has been measured using the
Level 1per IFRS 13 fair value hierarchy. Accustem Sciences Inc is listed on the OTC markets and is run by a separate management team which
is independent of the Tiziana management team. Tiziana is therefore not able to assert significant influence over Accustem Sciences Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Investment in Okyo Pharma Ltd&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-339"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Movement in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-340"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,717&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group acquired 2.1m shares of Okyo Pharma Ltd. on October 23,
2023 which is a 15.57% ownership.&#160;The share price of Okyo Pharma Ltd as of December 31, 2023 was $1.77, which has resulted in the
recognition of a fair value gain of $567k. This has been measured using the Level 1per IFRS 13 fair value hierarchy. Okyo Pharma Ltd
is listed on the OTC markets and is run by a separate management team which is independent of the Tiziana management team. Tiziana is
therefore not able to assert significant influence over Okyo Sciences Inc.&lt;/p&gt;</tlsa:InvestmentInRelatedPartyTextBlock>
    <ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory contextRef="c0" id="ixv-23970">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Investment in Accustem Sciences Inc&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Movement in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(969&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Investment in Okyo Pharma Ltd&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-339"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Movement in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-340"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,717&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory>
    <ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty
      contextRef="c131"
      decimals="-3"
      id="ixv-25342"
      unitRef="usd">1806000</ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty>
    <ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty
      contextRef="c135"
      decimals="-3"
      id="ixv-25343"
      unitRef="usd">2675000</ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty>
    <ifrs-full:ImpairmentLossOnFinancialAssets
      contextRef="c131"
      decimals="-3"
      id="ixv-25344"
      unitRef="usd">-969000</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossOnFinancialAssets
      contextRef="c135"
      decimals="-3"
      id="ixv-25345"
      unitRef="usd">-869000</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty
      contextRef="c131"
      decimals="-3"
      id="ixv-25346"
      unitRef="usd">837000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty
      contextRef="c135"
      decimals="-3"
      id="ixv-25347"
      unitRef="usd">1806000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty>
    <tlsa:SharesPrice
      contextRef="c130"
      decimals="0"
      id="ixv-25348"
      unitRef="usdPershares">63</tlsa:SharesPrice>
    <ifrs-full:InsuranceFinanceIncomeExpenses
      contextRef="c131"
      decimals="-3"
      id="ixv-25349"
      unitRef="usd">1049000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty
      contextRef="c134"
      decimals="-3"
      id="ixv-25350"
      unitRef="usd">3150000</ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty>
    <ifrs-full:ImpairmentLossOnFinancialAssets
      contextRef="c134"
      decimals="-3"
      id="ixv-25351"
      unitRef="usd">567000</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty
      contextRef="c134"
      decimals="-3"
      id="ixv-25352"
      unitRef="usd">3717000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty>
    <tlsa:AcquiredShares
      contextRef="c0"
      decimals="-5"
      id="ixv-25353"
      unitRef="shares">2100000</tlsa:AcquiredShares>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c132"
      decimals="4"
      id="ixv-25354"
      unitRef="pure">0.1557</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <tlsa:SharesPrice
      contextRef="c133"
      decimals="2"
      id="ixv-25355"
      unitRef="usdPershares">1.77</tlsa:SharesPrice>
    <ifrs-full:InsuranceFinanceIncomeExpenses
      contextRef="c134"
      decimals="-3"
      id="ixv-25356"
      unitRef="usd">567000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:DisclosureOfTreasurySharesExplanatory contextRef="c0" id="ixv-24100">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;20. TREASURY SHARES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The company acquired
1,683,544 of its own shares through purchases on the NASDAQ stock exchange during the year ended December 31, 2022. The amount paid
to acquire the shares totaled $1,320k, and the shares are held as &#x201c;treasury shares&#x201d;. The Company has the right to
reissue these shares later. All shares issued by the Company are fully paid. In 2023 there was $254k in buybacks.&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfTreasurySharesExplanatory>
    <tlsa:SharesPurchases
      contextRef="c4"
      decimals="0"
      id="ixv-25357"
      unitRef="shares">1683544</tlsa:SharesPurchases>
    <ifrs-full:TreasuryShares
      contextRef="c137"
      decimals="-3"
      id="ixv-25358"
      unitRef="usd">1320000</ifrs-full:TreasuryShares>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c2"
      decimals="-3"
      id="ixv-25359"
      unitRef="shares">254000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0" id="ixv-24110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;21. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The ultimate controlling party
of the Group is Planwise Group Ltd.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Rasna Therapeutics Inc is
a related party as the entity is controlled by a person that has significant influence over the Group. Rasna is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby Rasna is charged for shared services such as the payroll and rent. During 2022,
Tiziana extended a loan to Rasna for $75,000 at an interest rate of 16% per annum. There were no additional loans to Rasna in 2023. As
of December 31, 2023, $416k (2022: $206k, 2021: $106k) was owed to Tiziana Life Sciences Ltd in respect of the loan and shared services
agreement. The total charged under the shared services agreement in the year ending 31 December 2023 was $6k (2022: $7k, 2021: $11k).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In addition to the above,
on April 16, 2020, Tiziana also acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin
D (Act D; a.k.a. Dactinomycin), from Rasna to expand its pipeline for a consideration of an initial $120k upfront payment and milestone
payments of up to an additional aggregate $630k. There were no milestone payments due in the year ending 31 December 2023 (2022: $0k,
2021:$0k).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;OKYO Pharma Ltd is a related
party as the entity is controlled by a person that has significant influence over the Group. OKYO is also party to a Shared Services agreement&#160;with&#160;Tiziana&#160;whereby
OKYO is charged for shared services such as the payroll and rent. As of December 31, 2023 $398k (2022: $274k, 2021: $42k) was owed to
Tiziana Life Sciences Ltd in respect of this agreement. The total charged under the shared services agreement in the year ending 31 December
2023 was $199k (2022: $125k, 2021: $98k).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2022, the Group
issued a short-term credit facility to OKYO Pharma, a related party, for $2,000k to support short term liquidity. The loan was available
for a period of 6 months upon first draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if
the loan is not repaid after the 6-month period. In October 23 the loan was converted to an investment in OKYO with 20% interest. The
principal of $2,000k plus accrued interest of $1,150k were converted into 2,100,000 Ordinary Shares, with no par value, of OKYO Pharma
Ltd. As at December 31, 2022 $1,056k had been drawn down against the loan and $19k of interest had been accrued.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Gensignia Lifesciences Inc
is a related party as the entity is controlled by a person that has significant influence over the Group. As of December 31, 2023 the
related party balance is $0 (2022, $0k, 2021: $295k). On December 31, 2022 $295k was written off to bad debt after management assessment
and deemed the balance to be irrecoverable.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Accustem Sciences Inc is a
related party as the entity is controlled by a person that has significant influence over the Group. Accustem is also party to a Shared
Services agreement&#160;with&#160;Tiziana&#160;whereby the Company is charged for shared services such as payroll and rent as of December
31 2023, $1,324k (2022:$72K, 2021:$1,341k). The net amount owed from Accustem, including shared service total costs of $1,324k.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <tlsa:InterestAmount
      contextRef="c138"
      decimals="-3"
      id="ixv-25360"
      unitRef="usd">75000000</tlsa:InterestAmount>
    <tlsa:ShortTermLoanFacility1
      contextRef="c138"
      decimals="2"
      id="ixv-25361"
      unitRef="pure">0.16</tlsa:ShortTermLoanFacility1>
    <tlsa:PayrollAndRentCharged
      contextRef="c139"
      decimals="-3"
      id="ixv-25362"
      unitRef="usd">416000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c140"
      decimals="-3"
      id="ixv-25363"
      unitRef="usd">206000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c141"
      decimals="-3"
      id="ixv-25364"
      unitRef="usd">106000</tlsa:PayrollAndRentCharged>
    <tlsa:ServicesAgreementAmount contextRef="c0" decimals="-3" id="ixv-25365" unitRef="usd">6000</tlsa:ServicesAgreementAmount>
    <tlsa:ServicesAgreementAmount contextRef="c4" decimals="-3" id="ixv-25366" unitRef="usd">7000</tlsa:ServicesAgreementAmount>
    <tlsa:ServicesAgreementAmount contextRef="c5" decimals="-3" id="ixv-25367" unitRef="usd">11000</tlsa:ServicesAgreementAmount>
    <tlsa:InitialAmount
      contextRef="c142"
      decimals="-3"
      id="ixv-25368"
      unitRef="usd">120000</tlsa:InitialAmount>
    <tlsa:AdditionalPayment
      contextRef="c142"
      decimals="-3"
      id="ixv-25369"
      unitRef="usd">630000</tlsa:AdditionalPayment>
    <tlsa:MilestonePaymentDue contextRef="c4" decimals="-3" id="ixv-25370" unitRef="usd">0</tlsa:MilestonePaymentDue>
    <tlsa:MilestonePaymentDue contextRef="c5" decimals="-3" id="ixv-25371" unitRef="usd">0</tlsa:MilestonePaymentDue>
    <tlsa:PayrollAndRentCharged
      contextRef="c143"
      decimals="-3"
      id="ixv-25372"
      unitRef="usd">398000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c144"
      decimals="-3"
      id="ixv-25373"
      unitRef="usd">274000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c145"
      decimals="-3"
      id="ixv-25374"
      unitRef="usd">42000</tlsa:PayrollAndRentCharged>
    <tlsa:ServicesAgreementAmount
      contextRef="c134"
      decimals="-3"
      id="ixv-25375"
      unitRef="usd">199000</tlsa:ServicesAgreementAmount>
    <tlsa:ServicesAgreementAmount
      contextRef="c136"
      decimals="-3"
      id="ixv-25376"
      unitRef="usd">125000</tlsa:ServicesAgreementAmount>
    <tlsa:ServicesAgreementAmount
      contextRef="c146"
      decimals="-3"
      id="ixv-25377"
      unitRef="usd">98000</tlsa:ServicesAgreementAmount>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c147"
      decimals="-3"
      id="ixv-25378"
      unitRef="usd">2000000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c148"
      decimals="2"
      id="ixv-25379"
      unitRef="pure">0.16</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c149"
      decimals="2"
      id="ixv-25380"
      unitRef="pure">0.04</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c0" decimals="2" id="ixv-25381" unitRef="pure">0.20</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <tlsa:PrincipalAmount contextRef="c2" decimals="-3" id="ixv-25382" unitRef="usd">2000000</tlsa:PrincipalAmount>
    <ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued contextRef="c0" decimals="-3" id="ixv-25383" unitRef="usd">1150000</ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-25384"
      unitRef="shares">2100000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:LoansReceived contextRef="c3" decimals="-3" id="ixv-25385" unitRef="usd">1056000</ifrs-full:LoansReceived>
    <ifrs-full:OtherEquityInterest contextRef="c3" decimals="-3" id="ixv-25386" unitRef="usd">19000</ifrs-full:OtherEquityInterest>
    <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction contextRef="c0" decimals="-3" id="ixv-25387" unitRef="usd">0</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
    <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction
      contextRef="c150"
      decimals="-3"
      id="ixv-25388"
      unitRef="usd">0</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
    <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction contextRef="c5" decimals="-3" id="ixv-25389" unitRef="usd">295000</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
    <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction contextRef="c4" decimals="-3" id="ixv-25390" unitRef="usd">295000</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
    <tlsa:PayrollAndRentCharged
      contextRef="c151"
      decimals="-3"
      id="ixv-25391"
      unitRef="usd">1324000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c152"
      decimals="-3"
      id="ixv-25392"
      unitRef="usd">72000</tlsa:PayrollAndRentCharged>
    <tlsa:PayrollAndRentCharged
      contextRef="c153"
      decimals="-3"
      id="ixv-25393"
      unitRef="usd">1341000</tlsa:PayrollAndRentCharged>
    <ifrs-full:ServicesExpense contextRef="c0" decimals="-3" id="ixv-25394" unitRef="usd">1324000</ifrs-full:ServicesExpense>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-24142">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;22. LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;All leases are accounted for by recognizing a right-of-use
asset and a lease liability except for:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group has leases for its
offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have leases of
low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group
sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent
manner to its property, plant and equipment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For leases over office buildings
and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition
at the end of the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the course of 2022,
the Group entered into a new lease agreement for its London office. Any leases that have a term shorter than 12 months the Group has applied
the exemption allowed by paragraph 5a in IFRS16 in respect of short &#x2013; term leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;At 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(50&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Disposal of lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;372&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Lease Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;At 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(119&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Lease liabilities are presented
in the consolidated statement of financial; position as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease liabilities are
secured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Minimum lease payment due&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Within 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;1-2 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Over 5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Lease payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Finance Charges&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Net Present Values&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <tlsa:DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock contextRef="c0" id="ixv-25395">Any leases that have a term shorter than 12 months the Group has applied
the exemption allowed by paragraph 5a in IFRS16 in respect of short &#x2013; term leases.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;At 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(50&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Disposal of lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;372&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Lease Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;At 1 January&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(119&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfQuantitativeInformationAboutRightofuseAssetsTableTextBlock>
    <tlsa:RightOfUseAssetBeginning contextRef="c0" decimals="-3" id="ixv-25396" unitRef="usd">372000</tlsa:RightOfUseAssetBeginning>
    <tlsa:RightOfUseAssetBeginning contextRef="c4" decimals="-3" id="ixv-25397" unitRef="usd">448000</tlsa:RightOfUseAssetBeginning>
    <tlsa:RightOfUseAssetsDepreciation contextRef="c0" decimals="-3" id="ixv-25398" unitRef="usd">-104000</tlsa:RightOfUseAssetsDepreciation>
    <tlsa:RightOfUseAssetsDepreciation contextRef="c4" decimals="-3" id="ixv-25399" unitRef="usd">-50000</tlsa:RightOfUseAssetsDepreciation>
    <tlsa:ExchangeDifferencesRightofUseAssets contextRef="c0" decimals="-3" id="ixv-25400" unitRef="usd">15000</tlsa:ExchangeDifferencesRightofUseAssets>
    <tlsa:ExchangeDifferencesRightofUseAssets contextRef="c4" decimals="-3" id="ixv-25401" unitRef="usd">-26000</tlsa:ExchangeDifferencesRightofUseAssets>
    <tlsa:RightOfUseAssetsTotal contextRef="c0" decimals="-3" id="ixv-25402" unitRef="usd">283000</tlsa:RightOfUseAssetsTotal>
    <tlsa:RightOfUseAssetsTotal contextRef="c4" decimals="-3" id="ixv-25403" unitRef="usd">372000</tlsa:RightOfUseAssetsTotal>
    <tlsa:LeaseLiabilitiesBeginning contextRef="c0" decimals="-3" id="ixv-25404" unitRef="usd">365000</tlsa:LeaseLiabilitiesBeginning>
    <tlsa:LeaseLiabilitiesBeginning contextRef="c4" decimals="-3" id="ixv-25405" unitRef="usd">448000</tlsa:LeaseLiabilitiesBeginning>
    <tlsa:LeaseLiabilitiesInterestExpense contextRef="c0" decimals="-3" id="ixv-25406" unitRef="usd">10000</tlsa:LeaseLiabilitiesInterestExpense>
    <tlsa:LeaseLiabilitiesInterestExpense contextRef="c4" decimals="-3" id="ixv-25407" unitRef="usd">6000</tlsa:LeaseLiabilitiesInterestExpense>
    <tlsa:LeaseLiabilitiesLeasePayments contextRef="c0" decimals="-3" id="ixv-25408" unitRef="usd">-119000</tlsa:LeaseLiabilitiesLeasePayments>
    <tlsa:LeaseLiabilitiesLeasePayments contextRef="c4" decimals="-3" id="ixv-25409" unitRef="usd">-61000</tlsa:LeaseLiabilitiesLeasePayments>
    <tlsa:ExchangeDifferences contextRef="c0" decimals="-3" id="ixv-25410" unitRef="usd">-9000</tlsa:ExchangeDifferences>
    <tlsa:ExchangeDifferences contextRef="c4" decimals="-3" id="ixv-25411" unitRef="usd">-28000</tlsa:ExchangeDifferences>
    <tlsa:LeaseLiabilitiesTotal contextRef="c0" decimals="-3" id="ixv-25412" unitRef="usd">247000</tlsa:LeaseLiabilitiesTotal>
    <tlsa:LeaseLiabilitiesTotal contextRef="c4" decimals="-3" id="ixv-25413" unitRef="usd">365000</tlsa:LeaseLiabilitiesTotal>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c0" id="ixv-25414">Lease liabilities are presented
in the consolidated statement of financial; position as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31 Dec &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;$000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;365&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-25415" unitRef="usd">138000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-25416" unitRef="usd">122000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-25417" unitRef="usd">109000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-25418" unitRef="usd">243000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c2" decimals="-3" id="ixv-25419" unitRef="usd">247000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c3" decimals="-3" id="ixv-25420" unitRef="usd">365000</ifrs-full:OtherNoncurrentLiabilities>
    <tlsa:DisclosureOfFutureMinimumLeasePayments contextRef="c0" id="ixv-25421">The lease liabilities are
secured by the related underlying assets. Future minimum lease payments as of 31 December 2023 were as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Minimum lease payment due&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Within 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;1-2 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Over 5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Lease payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Finance Charges&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Net Present Values&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tlsa:DisclosureOfFutureMinimumLeasePayments>
    <tlsa:LeasePayments
      contextRef="c154"
      decimals="-3"
      id="ixv-25422"
      unitRef="usd">148000</tlsa:LeasePayments>
    <tlsa:LeasePayments
      contextRef="c155"
      decimals="-3"
      id="ixv-25423"
      unitRef="usd">111000</tlsa:LeasePayments>
    <tlsa:LeasePayments contextRef="c2" decimals="-3" id="ixv-25424" unitRef="usd">259000</tlsa:LeasePayments>
    <tlsa:FinanceCharges
      contextRef="c154"
      decimals="-3"
      id="ixv-25425"
      unitRef="usd">-10000</tlsa:FinanceCharges>
    <tlsa:FinanceCharges
      contextRef="c155"
      decimals="-3"
      id="ixv-25426"
      unitRef="usd">-2000</tlsa:FinanceCharges>
    <tlsa:FinanceCharges contextRef="c2" decimals="-3" id="ixv-25427" unitRef="usd">-12000</tlsa:FinanceCharges>
    <tlsa:NetPresentValues
      contextRef="c154"
      decimals="-3"
      id="ixv-25428"
      unitRef="usd">138000</tlsa:NetPresentValues>
    <tlsa:NetPresentValues
      contextRef="c155"
      decimals="-3"
      id="ixv-25429"
      unitRef="usd">109000</tlsa:NetPresentValues>
    <tlsa:NetPresentValues contextRef="c2" decimals="-3" id="ixv-25430" unitRef="usd">247000</tlsa:NetPresentValues>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="c0" id="ixv-24480">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;23. FINANCIAL COMMITMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Group&#x2019;s main financial
commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research
and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical,
clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Milciclib project research future payments relate to the achievement of clinical milestones or the payment of royalties. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are obligated to pay Nerviano
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$1,000,000 upon initiation of the first Phase II clinical trial, this is currently being negotiated with BMS.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$4,000,000 upon FPD of the first Phase 3 registration trial in HCC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$3,600,000 upon first patient enrollment into a Phase II human clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon the first NDA equivalent in: thymic carcinoma, $900,000; HCC, $9,000,000; breast cancer, $15,000,000.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Foralumab project &#x2013; Future payments relate to the achievement of clinical milestones or the payment of royalties. Diligence obligations are payable to BMS/Medarex should the project continue to commercialisation. $750,000 has been recoded as other income in respect of diligence obligations due to Medarex for 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are obligated to pay BMS
the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$300,000 upon enrollment of first patient in a Phase I human clinical trial of the first Phase II Clinical trial, this is currently being negotiated with BMS.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$1,500,000 upon initiation of the first Phase III clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$2,000,000 upon filing of the first BLA, or equivalent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$2,000,000 upon approval of the first BLA, or equivalent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are obligated to pay Brighams
Womens Hospital the following hospital milestone payments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$300,000 upon first patient enrollment into a Phase I human clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$300,000 upon first patient enrollment into a Phase II human clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$1,500,000 upon first patient enrollment into a Phase III human clinical trial&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;$3,000,000 upon first commercial sale of a product&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ACT D - Tiziana will need to make milestone payments of up to $630k depending on the issuance of a US patent from any US patent application in Transferred IP relating to nanoparticle formulations of Act D and upon the successful completion of a Phase II clinical efficacy trial.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <tlsa:DevelopmentMilestones contextRef="c158" decimals="0" id="ixv-25431" unitRef="usd">1000000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c159" decimals="0" id="ixv-25432" unitRef="usd">4000000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c160" decimals="0" id="ixv-25433" unitRef="usd">3600000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c161" decimals="0" id="ixv-25434" unitRef="usd">900000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c162" decimals="0" id="ixv-25435" unitRef="usd">9000000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c163" decimals="0" id="ixv-25436" unitRef="usd">15000000</tlsa:DevelopmentMilestones>
    <tlsa:AccruedOfDiligenceObligations contextRef="c0" decimals="0" id="ixv-25437" unitRef="usd">750000</tlsa:AccruedOfDiligenceObligations>
    <tlsa:DevelopmentMilestones contextRef="c164" decimals="0" id="ixv-25438" unitRef="usd">300000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c165" decimals="0" id="ixv-25439" unitRef="usd">1500000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c166" decimals="0" id="ixv-25440" unitRef="usd">2000000</tlsa:DevelopmentMilestones>
    <tlsa:DevelopmentMilestones contextRef="c0" decimals="0" id="ixv-25441" unitRef="usd">2000000</tlsa:DevelopmentMilestones>
    <tlsa:MilestonePayments contextRef="c164" decimals="0" id="ixv-25442" unitRef="usd">300000</tlsa:MilestonePayments>
    <tlsa:MilestonePayments contextRef="c160" decimals="0" id="ixv-25443" unitRef="usd">300000</tlsa:MilestonePayments>
    <tlsa:MilestonePayments contextRef="c165" decimals="0" id="ixv-25444" unitRef="usd">1500000</tlsa:MilestonePayments>
    <tlsa:CommercialSaleOfAProduct contextRef="c0" decimals="0" id="ixv-25445" unitRef="usd">3000000</tlsa:CommercialSaleOfAProduct>
    <tlsa:MilestonePayments contextRef="c0" decimals="-3" id="ixv-25446" unitRef="usd">630000</tlsa:MilestonePayments>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-24614">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;24. CONTINGENT LIABILITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The group from time to time
is involved in legal proceedings, none of which have given rise to contingent liabilities. Contingencies arising in the ordinary course
of business, for which no security has been given, are not expected to result in any material financial loss.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentReserveWarrants
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesToBeIssuedReserve
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RealisationBonus
      contextRef="c0"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RealisationBonus
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:IncomeTaxSCredit
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="INF"
      id="hidden-fact-9"
      unitRef="usdPershares">-0.15</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-10"
      unitRef="usdPershares">-0.17</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.24</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity
      contextRef="c7"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c11"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c18"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c19"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c20"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c21"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c22"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c24"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c16"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c19"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c21"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c23"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c24"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus
      contextRef="c18"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus
      contextRef="c19"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus
      contextRef="c20"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus
      contextRef="c21"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfCashRealizationBonus
      contextRef="c22"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c19"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c20"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c21"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c22"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c20"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c23"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c16"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c17"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c18"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c19"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c20"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c21"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c22"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c23"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c16"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c17"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c18"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c19"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c20"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c21"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c23"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c30"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c32"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c35"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c36"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c37"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c38"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c39"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c41"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c42"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="c43"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c35"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c36"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c38"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c39"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c40"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c41"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c42"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c43"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c35"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c36"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c38"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c39"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c40"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c41"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c42"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c43"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c35"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c36"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c38"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c39"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c40"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c42"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c43"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c4"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c35"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c36"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c38"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c39"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c40"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c42"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c43"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c36"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c37"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c38"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c39"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c40"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c42"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c43"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c35"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c36"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c37"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c38"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c39"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c41"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c42"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c35"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c36"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c37"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c38"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c39"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c42"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c51"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c55"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c56"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c57"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c58"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c59"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c60"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c61"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c53"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c54"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c56"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c57"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c58"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c59"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c60"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPaymentoptions
      contextRef="c61"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c53"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c54"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c56"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c57"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c58"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c59"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c60"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedcancelled
      contextRef="c61"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c53"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c54"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c56"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c57"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c58"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c60"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c61"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c0"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c53"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c55"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c57"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c58"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c59"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c60"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsExercisedInTheYear
      contextRef="c61"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c53"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c54"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c55"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c57"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c58"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c60"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c61"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WarrantsForfeitedInTheYear
      contextRef="c0"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c53"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c54"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c55"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c56"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c57"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c59"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c60"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BuybackOfTreasuryShares
      contextRef="c61"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c57"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c60"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="c61"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c53"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c54"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c55"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c56"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c57"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c58"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c60"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c61"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c53"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c54"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c55"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c56"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c57"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c58"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c59"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation1
      contextRef="c60"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c53"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c54"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c55"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c56"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c57"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c58"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c60"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="c0"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="c4"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfFees
      contextRef="c4"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharesIssuedInLieuOfFees
      contextRef="c5"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedDuringTheYear
      contextRef="c5"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FVLossOnInvestment
      contextRef="c5"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:LossOnDisposalOfAsset
      contextRef="c0"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:LossOnDisposalOfAsset
      contextRef="c5"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:BonusToBeSettledInEquity
      contextRef="c4"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:CapitalDistribution
      contextRef="c0"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:CapitalDistribution
      contextRef="c4"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable
      contextRef="c0"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ProceedsFromSaleAndCollectionOfFinanceReceivable
      contextRef="c4"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:CashInflowFromTaxation
      contextRef="c0"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:InterestReceivedFromLoan
      contextRef="c4"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:InterestReceivedFromLoan
      contextRef="c5"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:NetIncreaseInRelatedPartyPayables
      contextRef="c0"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c4"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ProceedsFromFinanceLease
      contextRef="c0"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ProceedsFromFinanceLease
      contextRef="c4"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:InvestmentInRelatedParty
      contextRef="c5"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:PurchaseOfTreasuryAmount
      contextRef="c5"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FundraisingCost
      contextRef="c4"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FundraisingCost
      contextRef="c5"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ProceedsFromIssuanceOfOptions
      contextRef="c4"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SublicenseIncome
      contextRef="c0"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SublicenseIncome
      contextRef="c4"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLossMeasuredAsSuchInAccordanceWithExemptionForReacquisitionOfOwnEquityInstruments
      contextRef="c2"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OtherIncomelosses
      contextRef="c0"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OperatingLoss
      contextRef="c0"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OperatingLoss
      contextRef="c4"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c77"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c78"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPayments
      contextRef="c78"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c79"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c81"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c81"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c82"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c83"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c83"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c84"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c84"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c85"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c85"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c86"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c86"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c86"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareBasedPayments
      contextRef="c86"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c87"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c87"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c88"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c89"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c89"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c89"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c90"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c90"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c90"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DirectorsFees
      contextRef="c91"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Bonus
      contextRef="c91"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:Salary
      contextRef="c0"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c93"
      id="hidden-fact-264"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c94"
      id="hidden-fact-265"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c84"
      id="hidden-fact-266"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c85"
      id="hidden-fact-267"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c89"
      id="hidden-fact-268"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsWereGrantedToDirectors
      contextRef="c90"
      id="hidden-fact-269"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="c5"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c5"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FinanceChargeAccruedOnConvertibleLoanNotes
      contextRef="c0"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FinanceChargeAccruedOnConvertibleLoanNotes
      contextRef="c4"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c34"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="c4"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:AdjustmentsDueToPriorPeriods
      contextRef="c0"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:AdjustmentsDueToPriorPeriods
      contextRef="c4"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:IncomeTaxExpenseContinuingOperation
      contextRef="c4"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:AdjustmentsDueToPriorPeriod
      contextRef="c4"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim
      contextRef="c0"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:IncomeTaxReconciliationResearchAndDevelopmentClaim
      contextRef="c4"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FixedAssetDifferences
      contextRef="c0"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FixedAssetDifferences
      contextRef="c5"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:CurrentTaxOther
      contextRef="c4"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:CurrentTaxOther
      contextRef="c5"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:AdjustmentsToBroughtForwardValues
      contextRef="c0"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:AdjustmentsToBroughtForwardValues
      contextRef="c5"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements
      contextRef="c0"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements
      contextRef="c4"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ConsolidationAdjustmentInRelationToForeignExchangeMovements
      contextRef="c5"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:MergerReserveAtJanuary12021Per20FAnnualReport
      contextRef="c5"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharePremiumSharesIssuedPursuantToShareForShareExchangeAndConsolidation
      contextRef="c5"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:SharePremiumRestatedAt1January2021
      contextRef="c5"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareCapitalConversionOfWarrants
      contextRef="c5"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:MergerReserveConversionOfWarrants
      contextRef="c5"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:MergerReserveConversionOfLoan
      contextRef="c5"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:MergerReserveIssuedInLieuOfCashBonus
      contextRef="c5"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareCapitalValueWarrantsExercised
      contextRef="c0"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:ShareCapitalValueIssuanceOfStockATM
      contextRef="c0"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceGranted
      contextRef="c0"
      id="hidden-fact-301"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsGranted
      contextRef="c0"
      id="hidden-fact-302"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceGranted
      contextRef="c4"
      id="hidden-fact-303"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsGranted
      contextRef="c4"
      id="hidden-fact-304"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceForfeitedCancelled
      contextRef="c5"
      id="hidden-fact-305"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsForfeitedCancelled
      contextRef="c5"
      id="hidden-fact-306"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceExercised
      contextRef="c0"
      id="hidden-fact-307"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsExercised
      contextRef="c0"
      id="hidden-fact-308"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceExercised
      contextRef="c4"
      id="hidden-fact-309"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsExercised
      contextRef="c4"
      id="hidden-fact-310"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:WeightedAverageExercisePriceExercised
      contextRef="c5"
      id="hidden-fact-311"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:OptionsExercised
      contextRef="c5"
      id="hidden-fact-312"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c34"
      id="hidden-fact-313"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsOutstanding
      contextRef="c34"
      id="hidden-fact-314"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c4"
      id="hidden-fact-315"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsForfeited
      contextRef="c4"
      id="hidden-fact-316"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c0"
      id="hidden-fact-317"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberofOptionsExercised
      contextRef="c0"
      id="hidden-fact-318"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c4"
      id="hidden-fact-319"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberofOptionsExercised
      contextRef="c4"
      id="hidden-fact-320"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c2"
      id="hidden-fact-321"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsExercisable
      contextRef="c2"
      id="hidden-fact-322"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c3"
      id="hidden-fact-323"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tlsa:NumberOfShareOptionsExercisable
      contextRef="c3"
      id="hidden-fact-324"
      unitRef="shares"
      xsi:nil="true"/>
    <tlsa:OutstandingExercised
      contextRef="c4"
      id="hidden-fact-325"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OutstandingExercised
      contextRef="c5"
      id="hidden-fact-326"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OutstandingExpired
      contextRef="c4"
      id="hidden-fact-327"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:OutstandingExpired
      contextRef="c5"
      id="hidden-fact-328"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FairValueOutstanding
      contextRef="c2"
      id="hidden-fact-329"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c0"
      id="hidden-fact-330"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c4"
      id="hidden-fact-331"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c5"
      id="hidden-fact-332"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c123"
      id="hidden-fact-333"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c124"
      id="hidden-fact-334"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c0"
      id="hidden-fact-335"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c127"
      id="hidden-fact-336"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c128"
      id="hidden-fact-337"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:RelatedPartyPayablesAmount
      contextRef="c4"
      id="hidden-fact-338"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty
      contextRef="c136"
      id="hidden-fact-339"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossOnFinancialAssets
      contextRef="c136"
      id="hidden-fact-340"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossInvestmentProperty
      contextRef="c136"
      id="hidden-fact-341"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DisposalOfLease
      contextRef="c0"
      id="hidden-fact-342"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:DisposalOfLease
      contextRef="c4"
      id="hidden-fact-343"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:LeasePayments
      contextRef="c156"
      id="hidden-fact-344"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:LeasePayments
      contextRef="c157"
      id="hidden-fact-345"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FinanceCharges
      contextRef="c156"
      id="hidden-fact-346"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:FinanceCharges
      contextRef="c157"
      id="hidden-fact-347"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:NetPresentValues
      contextRef="c156"
      id="hidden-fact-348"
      unitRef="usd"
      xsi:nil="true"/>
    <tlsa:NetPresentValues
      contextRef="c157"
      id="hidden-fact-349"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-25799">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-25800">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-25801">false</dei:DocumentRegistrationStatement>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-25802">0001723069</dei:EntityCentralIndexKey>
    <dei:EntityFileNumber contextRef="c0" id="ixv-25803">000-00000</dei:EntityFileNumber>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-235"
          xlink:label="hidden-fact-235"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-236"
          xlink:label="hidden-fact-236"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-237"
          xlink:label="hidden-fact-237"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-238"
          xlink:label="hidden-fact-238"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Gabriele Cerrone&#x2019;s 2021 bonus is the interest charged on his 2020 bonus due to delayed issuance of shares; his 2020 bonus includes a $13.2m realization bonus.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-235"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-236"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-237"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-238"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
